<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18596154</PMID><DateCompleted><Year>2008</Year><Month>08</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>27</Issue><PubDate><Year>2008</Year><Month>Jul</Month><Day>02</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Immunotherapy reduces vascular amyloid-beta in PDAPP mice.</ArticleTitle><Pagination><StartPage>6787</StartPage><EndPage>6793</EndPage><MedlinePgn>6787-93</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.2377-07.2008</ELocationID><Abstract><AbstractText>In addition to parenchymal amyloid-beta (Abeta) plaques, Alzheimer's disease (AD) is characterized by Abeta in the cerebral vasculature [cerebral amyloid angiopathy (CAA)] in the majority of patients. Recent studies investigating vascular Abeta (VAbeta) in amyloid precursor protein transgenic mice have suggested that passive immunization with anti-Abeta antibodies may clear parenchymal amyloid but increase VAbeta and the incidence of microhemorrhage. However, the influences of antibody specificity and exposure levels on VAbeta and microhemorrhage rates have not been well established, nor has any clear causal relationship been identified. This report examines the effects of chronic, passive immunization on VAbeta and microhemorrhage in PDAPP mice by comparing antibodies with different Abeta epitopes (3D6, Abeta(1-5); 266, Abeta(16-23)) and performing a 3D6 dose-response study. VAbeta and microhemorrhage were assessed using concomitant Abeta immunohistochemistry and hemosiderin detection. 3D6 prevented or cleared VAbeta in a dose-dependent manner, whereas 266 was without effect. Essentially complete absence of VAbeta was observed at the highest 3D6 dose, whereas altered morphology suggestive of ongoing clearance was seen at lower doses. The incidence of microhemorrhage was increased in the high-dose 3D6 group and limited to focal, perivascular sites. These colocalized with Abeta deposits having altered morphology and apparent clearance in the lower-dose 3D6 group. Our results suggest that passive immunization can reduce VAbeta levels, and modulating antibody dose can significantly mitigate the incidence of microhemorrhage while still preventing or reducing VAbeta. These observations raise the possibility that Abeta immunotherapy can potentially slow or halt the course of CAA development in AD that is implicated in vascular dysfunction.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schroeter</LastName><ForeName>Sally</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Elan Pharmaceuticals, South San Francisco, California 94080, and Wyeth Pharmaceuticals, Cambridge, Massachusetts 02140, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Barbour</LastName><ForeName>Robin</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Doan</LastName><ForeName>Minhtam</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Ming</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Guido</LastName><ForeName>Terry</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Gill</LastName><ForeName>Davinder</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Basi</LastName><ForeName>Guriqbal</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Schenk</LastName><ForeName>Dale</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Seubert</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Games</LastName><ForeName>Dora</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016657" MajorTopicYN="N">Cerebral Amyloid Angiopathy</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002536" MajorTopicYN="N">Cerebral Arteries</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002543" MajorTopicYN="N">Cerebral Hemorrhage</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007116" MajorTopicYN="N">Immunization, Passive</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008657" MajorTopicYN="N">Metabolic Clearance Rate</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>7</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>7</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>1</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18596154</ArticleId><ArticleId IdType="pmc">PMC6670967</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2377-07.2008</ArticleId><ArticleId IdType="pii">28/27/6787</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6:916&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932230</ArticleId></ArticleIdList></Reference><Reference><Citation>Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, Guido T, Hoenow K, Hu K, Johnson-Wood K, Khan K, Kholodenko D, Lee C, Lee M, Motter R, Nguyen M, Reed A, Schenk D, Tang P, Vasquez N, et al. Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci U S A. 2003;100:2023&#x2013;2028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC149952</ArticleId><ArticleId IdType="pubmed">12566568</ArticleId></ArticleIdList></Reference><Reference><Citation>Boche D, DeBeer S, Cox A, Wilkinson D, Holmes C, Neal J, Love S, Esiri M, Bridges L, Weller R, Nicoll J. Evidence of a transient increase in cerebral amyloid angiopathy after Abeta42 immunization in human Alzheimer's disease. Neurodegenerative Dis. 2007;4(Suppl 1):273.</Citation></Reference><Reference><Citation>Burbach GJ, Vlachos A, Ghebremedhin E, Del Turco D, Coomaraswamy J, Staufenbiel M, Jucker M, Deller T. Vessel ultrastructure in APP23 transgenic mice after passive anti-Abeta immunotherapy and subsequent intracerebral hemorrhage. Neurobiol Aging. 2007;28:202&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">16427722</ArticleId></ArticleIdList></Reference><Reference><Citation>Buttini M, Masliah E, Barbour R, Grajeda H, Motter R, Johnson-Wood K, Khan K, Seubert P, Freedman S, Schenk D, Games D. Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. J Neurosci. 2005;25:9096&#x2013;9101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725749</ArticleId><ArticleId IdType="pubmed">16207868</ArticleId></ArticleIdList></Reference><Reference><Citation>Christie R, Yamada M, Moskowitz M, Hyman B. Structural and functional disruption of vascular smooth muscle cells in a transgenic mouse model of amyloid angiopathy. Am J Pathol. 2001;158:1065&#x2013;1071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850363</ArticleId><ArticleId IdType="pubmed">11238054</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickstein DL, Biron KE, Ujiie M, Pfeifer CG, Jeffries AR, Jefferies WA. Abeta peptide immunization restores blood-brain barrier integrity in Alzheimer disease. FASEB J. 2006;20:426&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">16507760</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis RJ, Olichney JM, Thal LJ, Mirra SS, Morris JC, Beekly D, Heyman A. Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, part XV. Neurology. 1996;46:1592&#x2013;1596.</Citation><ArticleIdList><ArticleId IdType="pubmed">8649554</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer I, Boada Rovira M, S&#xe1;nchez Guerra ML, Rey MJ, Costa-Juss&#xe1; F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 2004;14:11&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095815</ArticleId><ArticleId IdType="pubmed">14997933</ArticleId></ArticleIdList></Reference><Reference><Citation>Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, Guido T, Hagopian S, Johnson-Wood K, Khan K, Lee M, Leibowitz P, Lieberburg I, Little S, Masliah E, McConlogue L, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 1995;373:523&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">7845465</ArticleId></ArticleIdList></Reference><Reference><Citation>Games D, Buttini M, Kobayashi D, Schenk D, Seubert P. Mice as models: transgenic approaches and Alzheimer's disease. J Alzheimers Dis. 2006;9:133&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">16914852</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tz J, Streffer JR, David D, Schild A, Hoerndli F, Pennanen L, Kurosinski P, Chen F. Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy. Mol Psychiatry. 2004;9:664&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pubmed">15052274</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg SM, Gurol ME, Rosand J, Smith EE. Amyloid angiopathy-related vascular cognitive impairment. Stroke. 2004;35:2616&#x2013;2619.</Citation><ArticleIdList><ArticleId IdType="pubmed">15459438</ArticleId></ArticleIdList></Reference><Reference><Citation>Herzig MC, Winkler DT, Burgermeister P, Pfeifer M, Kohler E, Schmidt SD, Danner S, Abramowski D, St&#xfc;rchler-Pierrat C, B&#xfc;rki K, van Duinen SG, Maat-Schieman ML, Staufenbiel M, Mathews PM, Jucker M. Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat Neurosci. 2004;7:954&#x2013;960.</Citation><ArticleIdList><ArticleId IdType="pubmed">15311281</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988;75:800&#x2013;802.</Citation></Reference><Reference><Citation>Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, M&#xfc;ller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, Wollmer MA, Umbricht D, de Quervain DJ, Hofmann M, Maddalena A, Papassotiropoulos A, Nitsch RM. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron. 2003;38:547&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pubmed">12765607</ArticleId></ArticleIdList></Reference><Reference><Citation>Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, St George-Hyslop P, Westaway D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 2000;408:979&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pubmed">11140685</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, Khan K, Gordon M, Tan H, Games D, Lieberburg I, Schenk D, Seubert P, McConlogue L. Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci U S A. 1997;94:1550&#x2013;1555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19829</ArticleId><ArticleId IdType="pubmed">9037091</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, Seubert P, Games D, Kirby L, Schenk D. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology. 2005;64:129&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">15642916</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 2000;408:982&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pubmed">11140686</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med. 2003;9:448&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">12640446</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll JA, Barton E, Boche D, Neal JW, Ferrer I, Thompson P, Vlachouli C, Wilkinson D, Bayer A, Games D, Seubert P, Schenk D, Holmes C. Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol. 2006;65:1040&#x2013;1048.</Citation><ArticleIdList><ArticleId IdType="pubmed">17086100</ArticleId></ArticleIdList></Reference><Reference><Citation>Patton RL, Kalback WM, Esh CL, Kokjohn TA, Van Vickle GD, Luehrs DC, Kuo YM, Lopez J, Brune D, Ferrer I, Masliah E, Newel AJ, Beach TG, Casta&#xf1;o EM, Roher AE. Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol. 2006:1048&#x2013;1063.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1698828</ArticleId><ArticleId IdType="pubmed">16936277</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, Mathews PM, Jucker M. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science. 2002;298:1379.</Citation><ArticleIdList><ArticleId IdType="pubmed">12434053</ArticleId></ArticleIdList></Reference><Reference><Citation>Prada CM, Garcia-Alloza M, Betensky RA, Zhang-Nunes SX, Greenberg SM, Bacskai BJ, Frosch MP. Antibody-mediated clearance of amyloid-&#x3b2; peptide from cerebral amyloid angiopathy revealed by quantitative in vivo imaging. J Neurosci. 2007;27:1973&#x2013;1980.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673561</ArticleId><ArticleId IdType="pubmed">17314293</ArticleId></ArticleIdList></Reference><Reference><Citation>Preston SD, Steart PV, Wilkinson A, Nicoll JA, Weller RO. Capillary and arterial cerebral amyloid angiopathy in Alzheimer's disease: defining the perivascular route for the elimination of amyloid beta from the human brain. Neuropathol Appl Neurobiol. 2003;29:106&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">12662319</ArticleId></ArticleIdList></Reference><Reference><Citation>Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, Piroozi KS, Jordan WH, Brown DD, Hoffman WP, Holtzman DM, Bales KR, Gitter BD, May PC, Paul SM, DeMattos RB. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid &#x3b2;. J Neurosci. 2005;25:629&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725332</ArticleId><ArticleId IdType="pubmed">15659599</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadowski MJ, Pankiewicz J, Scholtzova H, Mehta PD, Prelli F, Quartermain D, Wisniewski T. Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease. Proc Natl Acad Sci U S A. 2006;103:18787&#x2013;18792.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1654132</ArticleId><ArticleId IdType="pubmed">17116874</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">10408445</ArticleId></ArticleIdList></Reference><Reference><Citation>Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, Sinha S, Schlossmacher M, Whaley J, Swindlehurst C, McCormack R, Wolfert R, Selkoe D, Lieberburg I, Schenk D. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature. 1992;359:325&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">1406936</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation. 2004;1:24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC539292</ArticleId><ArticleId IdType="pubmed">15588287</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, Alamed J, Gottschall PE, Grimm J, Rosenthal A, Pons J, Ronan V, Symmonds K, Gordon MN, Morgan D. Deglycosylated anti-amyloid-&#x3b2; antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J Neurosci. 2006;26:5340&#x2013;5346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675288</ArticleId><ArticleId IdType="pubmed">16707786</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler DT, Bondolfi L, Herzig MC, Jann L, Calhoun ME, Wiederhold KH, Tolnay M, Staufenbiel M, Jucker M. Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy. J Neurosci. 2001;21:1619&#x2013;1627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762950</ArticleId><ArticleId IdType="pubmed">11222652</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18596919</PMID><DateCompleted><Year>2008</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0021-9738</ISSN><JournalIssue CitedMedium="Print"><Volume>118</Volume><Issue>8</Issue><PubDate><Year>2008</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The Journal of clinical investigation</Title><ISOAbbreviation>J Clin Invest</ISOAbbreviation></Journal><ArticleTitle>Inhibition of calpains improves memory and synaptic transmission in a mouse model of Alzheimer disease.</ArticleTitle><Pagination><StartPage>2796</StartPage><EndPage>2807</EndPage><MedlinePgn>2796-807</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1172/JCI34254</ELocationID><Abstract><AbstractText>Calpains are calcium-dependent enzymes that determine the fate of proteins through regulated proteolytic activity. Calpains have been linked to the modulation of memory and are key to the pathogenesis of Alzheimer disease (AD). When abnormally activated, calpains can also initiate degradation of proteins essential for neuronal survival. Here we show that calpain inhibition through E64, a cysteine protease inhibitor, and the highly specific calpain inhibitor BDA-410 restored normal synaptic function both in hippocampal cultures and in hippocampal slices from the APP/PS1 mouse, an animal model of AD. Calpain inhibition also improved spatial-working memory and associative fear memory in APP/PS1 mice. These beneficial effects of the calpain inhibitors were associated with restoration of normal phosphorylation levels of the transcription factor CREB and involved redistribution of the synaptic protein synapsin I. Thus, calpain inhibition may prove useful in the alleviation of memory loss in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Trinchese</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Pathology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fa'</LastName><ForeName>Mauro</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Shumin</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Hong</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Hidalgo</LastName><ForeName>Ariel</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Stephen D</ForeName><Initials>SD</Initials></Author><Author ValidYN="Y"><LastName>Yamaguchi</LastName><ForeName>Hisako</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Yoshii</LastName><ForeName>Narihiko</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Mathews</LastName><ForeName>Paul M</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><LastName>Nixon</LastName><ForeName>Ralph A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Arancio</LastName><ForeName>Ottavio</ForeName><Initials>O</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS049442</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS049442</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Invest</MedlineTA><NlmUniqueID>7802877</NlmUniqueID><ISSNLinking>0021-9738</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006023">Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C039304">calpain inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D002154">Calpain</NameOfSubstance></Chemical><Chemical><RegistryNumber>GMW67QNF9C</RegistryNumber><NameOfSubstance UI="D007930">Leucine</NameOfSubstance></Chemical><Chemical><RegistryNumber>L5W337AOUR</RegistryNumber><NameOfSubstance UI="C108192">aloxistatin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002154" MajorTopicYN="N">Calpain</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006023" MajorTopicYN="N">Glycoproteins</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006720" MajorTopicYN="N">Homozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007930" MajorTopicYN="N">Leucine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008959" MajorTopicYN="N">Models, Neurological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>7</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>9</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>7</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18596919</ArticleId><ArticleId IdType="pmc">PMC2441853</ArticleId><ArticleId IdType="doi">10.1172/JCI34254</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Huang Y., Wang K.K. The calpain family and human disease. Trends Mol. Med. 2001;7:355&#x2013;362. doi: 10.1016/S1471-4914(01)02049-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1471-4914(01)02049-4</ArticleId><ArticleId IdType="pubmed">11516996</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon R.A. The calpains in aging and aging-related diseases. Ageing Res. Rev. 2003;2:407&#x2013;418. doi: 10.1016/S1568-1637(03)00029-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1568-1637(03)00029-1</ArticleId><ArticleId IdType="pubmed">14522243</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlmutter L.S., et al. The ultrastructural localization of calcium-activated protease &#x201c;calpain&#x201d; in rat brain. Synapse. 1988;2:79&#x2013;88. doi: 10.1002/syn.890020111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/syn.890020111</ArticleId><ArticleId IdType="pubmed">2843999</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito K., Elce J.S., Hamos J.E., Nixon R.A. Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. Proc. Natl. Acad. Sci. U. S. A. 1993;90:2628&#x2013;2632. doi: 10.1073/pnas.90.7.2628.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.90.7.2628</ArticleId><ArticleId IdType="pmc">PMC46148</ArticleId><ArticleId IdType="pubmed">8464868</ArticleId></ArticleIdList></Reference><Reference><Citation>Grynspan F., Griffin W.R., Cataldo A., Katayama S., Nixon R.A. Active site-directed antibodies identify calpain II as an early-appearing and pervasive component of neurofibrillary pathology in Alzheimer&#x2019;s disease. Brain Res. 1997;763:145&#x2013;158. doi: 10.1016/S0006-8993(97)00384-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-8993(97)00384-3</ArticleId><ArticleId IdType="pubmed">9296555</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K.K. Calpain and caspase: can you tell the difference? Trends Neurosci. 2000;23:20&#x2013;26. doi: 10.1016/S0166-2236(99)01479-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0166-2236(99)01479-4</ArticleId><ArticleId IdType="pubmed">10652545</ArticleId></ArticleIdList></Reference><Reference><Citation>Siman R., Card J.P., Davis L.G. Proteolytic processing of beta-amyloid precursor by calpain I. J. Neurosci. 1990;10:2400&#x2013;2411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6570374</ArticleId><ArticleId IdType="pubmed">2115911</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M., Durr J., Fernandez H.L. Possible role of calpain in normal processing of beta-amyloid precursor protein in human platelets. Biochem. Biophys. Res. Commun. 2000;273:170&#x2013;175. doi: 10.1006/bbrc.2000.2919.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/bbrc.2000.2919</ArticleId><ArticleId IdType="pubmed">10873581</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathews P.M., et al. Calpain activity regulates the cell surface distribution of amyloid precursor protein. Inhibition of clapains enhances endosomal generation of beta-cleaved C-terminal APP fragments. J. Biol. Chem. 2002;277:36415&#x2013;36424. doi: 10.1074/jbc.M205208200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M205208200</ArticleId><ArticleId IdType="pubmed">12087104</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner H., et al. Expression of Alzheimer&#x2019;s disease-associated presenilin-1 is controlled by proteolytic degradation and complex formation. J. Biol. Chem. 1998;273:32322&#x2013;32331. doi: 10.1074/jbc.273.48.32322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.273.48.32322</ArticleId><ArticleId IdType="pubmed">9822712</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Song L., Parker E.M. Calpain inhibitor I increases beta-amyloid peptide production by inhibiting the degradation of the substrate of gamma-secretase. Evidence that substrate availability limits beta-amyloid peptide production. . J. Biol. Chem. 1999;274:8966&#x2013;8972. doi: 10.1074/jbc.274.13.8966.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.274.13.8966</ArticleId><ArticleId IdType="pubmed">10085142</ArticleId></ArticleIdList></Reference><Reference><Citation>Pontremoli S., et al. Phosphorylation and proteolytic modification of specific cytoskeletal proteins in human neutrophils stimulated by phorbol 12-myristate 13-acetate. Proc. Natl. Acad. Sci. U. S. A. 1987;84:3604&#x2013;3608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC304923</ArticleId><ArticleId IdType="pubmed">3473471</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandy S., Czernik A.J., Greengard P. Phosphorylation of Alzheimer disease amyloid precursor peptide by protein kinase C and Ca2+/calmodulin-dependent protein kinase II. Proc. Natl. Acad. Sci. U. S. A. 1988;85:6218&#x2013;6221. doi: 10.1073/pnas.85.16.6218.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.85.16.6218</ArticleId><ArticleId IdType="pmc">PMC281937</ArticleId><ArticleId IdType="pubmed">3137567</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K.K., Yuen P.W. Development and therapeutic potential of calpain inhibitors. Adv. Pharmacol. 1997;37:117&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pubmed">8891101</ArticleId></ArticleIdList></Reference><Reference><Citation>Banno Y., Nakashima S., Hachiya T., Nozawa Y. Endogenous cleavage of phospholipase C-beta 3 by agonist-induced activation of calpain in human platelets. J. Biol. Chem. 1995;270:4318&#x2013;4324. doi: 10.1074/jbc.270.9.4318.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.270.9.4318</ArticleId><ArticleId IdType="pubmed">7876193</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M.S., et al. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature. 2000;405:360&#x2013;364. doi: 10.1038/35012636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35012636</ArticleId><ArticleId IdType="pubmed">10830966</ArticleId></ArticleIdList></Reference><Reference><Citation>Carillo S., et al. Differential sensitivity of FOS and JUN family members to calpains. Oncogene. 1994;9:1679&#x2013;1689.</Citation><ArticleIdList><ArticleId IdType="pubmed">8183563</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y.C., Brown K., Siebenlist U. Activation of NF-kappa B requires proteolysis of the inhibitor I kappa B-alpha: signal-induced phosphorylation of I kappa B-alpha alone does not release active NF-kappa B. Proc. Natl. Acad. Sci. U. S. A. 1995;92:552&#x2013;556. doi: 10.1073/pnas.92.2.552.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.92.2.552</ArticleId><ArticleId IdType="pmc">PMC42779</ArticleId><ArticleId IdType="pubmed">7831327</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitolo O.V., et al. Amyloid beta -peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc. Natl. Acad. Sci. U. S. A. 2002;99:13217&#x2013;13221. doi: 10.1073/pnas.172504199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.172504199</ArticleId><ArticleId IdType="pmc">PMC130613</ArticleId><ArticleId IdType="pubmed">12244210</ArticleId></ArticleIdList></Reference><Reference><Citation>Puzzo D., et al. Amyloid-beta peptide inhibits activation of the nitric oxide/cGMP/cAMP-responsive element-binding protein pathway during hippocampal synaptic plasticity. J. Neurosci. 2005;25:6887&#x2013;6897. doi: 10.1523/JNEUROSCI.5291-04.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5291-04.2005</ArticleId><ArticleId IdType="pmc">PMC6725343</ArticleId><ArticleId IdType="pubmed">16033898</ArticleId></ArticleIdList></Reference><Reference><Citation>Mbebi C., et al. Amyloid precursor protein family-induced neuronal death is mediated by impairment of the neuroprotective calcium/calmodulin protein kinase IV-dependent signaling pathway. J. Biol. Chem. 2002;277:20979&#x2013;20990. doi: 10.1074/jbc.M107948200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M107948200</ArticleId><ArticleId IdType="pubmed">11877414</ArticleId></ArticleIdList></Reference><Reference><Citation>Siman R., Baudry M., Lynch G. Brain fodrin: substrate for calpain I, an endogenous calcium-activated protease. Proc. Natl. Acad. Sci. U. S. A. 1984;81:3572&#x2013;3576. doi: 10.1073/pnas.81.11.3572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.81.11.3572</ArticleId><ArticleId IdType="pmc">PMC345551</ArticleId><ArticleId IdType="pubmed">6328521</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson G.V., Litersky J.M., Jope R.S. Degradation of microtubule-associated protein 2 and brain spectrin by calpain: a comparative study. J. Neurochem. 1991;56:1630&#x2013;1638. doi: 10.1111/j.1471-4159.1991.tb02061.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.1991.tb02061.x</ArticleId><ArticleId IdType="pubmed">2013758</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuen E.Y., Liu W., Yan Z. The phosphorylation state of GluR1 subunits determines the susceptibility of AMPA receptors to calpain cleavage. J. Biol. Chem. 2007;282:16434&#x2013;16440. doi: 10.1074/jbc.M701283200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M701283200</ArticleId><ArticleId IdType="pubmed">17428797</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y., et al. Truncations of amphiphysin I by calpain inhibit vesicle endocytosis during neural hyperexcitation. EMBO J. 2007;26:2981&#x2013;2990. doi: 10.1038/sj.emboj.7601741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.emboj.7601741</ArticleId><ArticleId IdType="pmc">PMC1894779</ArticleId><ArticleId IdType="pubmed">17541403</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu K., Phan T., Mansuy I.M., Storm D.R. Proteolytic degradation of SCOP in the hippocampus contributes to activation of MAP kinase and memory. Cell. 2007;128:1219&#x2013;1229. doi: 10.1016/j.cell.2006.12.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2006.12.047</ArticleId><ArticleId IdType="pmc">PMC1899088</ArticleId><ArticleId IdType="pubmed">17382888</ArticleId></ArticleIdList></Reference><Reference><Citation>Sant&#x2019;Angelo A., Trinchese F., Arancio O. Usefulness of behavioral and electrophysiological studies in transgenic models of Alzheimer&#x2019;s disease. Neurochem. Res. 2003;28:1009&#x2013;1015. doi: 10.1023/A:1023251005197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1023251005197</ArticleId><ArticleId IdType="pubmed">12737525</ArticleId></ArticleIdList></Reference><Reference><Citation>Bliss T.V., Collingridge G.L. A synaptic model of memory: long-term potentiation in the hippocampus. Nature. 1993;361:31&#x2013;39. doi: 10.1038/361031a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/361031a0</ArticleId><ArticleId IdType="pubmed">8421494</ArticleId></ArticleIdList></Reference><Reference><Citation>Arancio O., Kandel E.R., Hawkins R.D. Activity-dependent long-term enhancement of transmitter release by presynaptic 3&#x2032;,5&#x2032;-cyclic GMP in cultured hippocampal neurons. Nature. 1995;376:74&#x2013;80. doi: 10.1038/376074a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/376074a0</ArticleId><ArticleId IdType="pubmed">7596438</ArticleId></ArticleIdList></Reference><Reference><Citation>Malgaroli A., Tsien R.W. Glutamate-induced long-term potentiation of the frequency of miniature synaptic currents in cultured hippocampal neurons. Nature. 1992;357:134&#x2013;139. doi: 10.1038/357134a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/357134a0</ArticleId><ArticleId IdType="pubmed">1349728</ArticleId></ArticleIdList></Reference><Reference><Citation>Arancio O., et al. Nitric oxide acts directly in the presynaptic neuron to produce long-term potentiation in cultured hippocampal neurons. Cell. 1996;87:1025&#x2013;1035. doi: 10.1016/S0092-8674(00)81797-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(00)81797-3</ArticleId><ArticleId IdType="pubmed">8978607</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinchese F., et al. Cell cultures from animal models of Alzheimer&#x2019;s disease as a tool for faster screening and testing of drug efficacy. J. Mol. Neurosci. 2004;24:15&#x2013;21. doi: 10.1385/JMN:24:1:015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1385/JMN:24:1:015</ArticleId><ArticleId IdType="pubmed">15314245</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi R.H., et al. Oligomerization of Alzheimer&#x2019;s beta-amyloid within processes and synapses of cultured neurons and brain. J. Neurosci. 2004;24:3592&#x2013;3599. doi: 10.1523/JNEUROSCI.5167-03.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5167-03.2004</ArticleId><ArticleId IdType="pmc">PMC6729733</ArticleId><ArticleId IdType="pubmed">15071107</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb L., et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 1998;4:97&#x2013;100. doi: 10.1038/nm0198-097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0198-097</ArticleId><ArticleId IdType="pubmed">9427614</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, K.K.W., and Yuen, P.-W. 1999. Calpain: pharmacology and toxicology of a calcium-dependent protease. K.K.W. Wang and P.-W. Yuen, editors. CRC Press/Taylor &amp; Francis Group. Philadephia, Pennsylvania, USA. 448 pp.</Citation></Reference><Reference><Citation>Hashida S., Towatari T., Kominami E., Katunuma N. Inhibitions by E-64 derivatives of rat liver cathepsin B and cathepsin L in vitro and in vivo. J. Biochem. 1980;88:1805&#x2013;1811.</Citation><ArticleIdList><ArticleId IdType="pubmed">7462205</ArticleId></ArticleIdList></Reference><Reference><Citation>Chard P.S., Bleakman D., Savidge J.R., Miller R.J. Capsaicin-induced neurotoxicity in cultured dorsal root ganglion neurons: involvement of calcium-activated proteases. Neuroscience. 1995;65:1099&#x2013;1108. doi: 10.1016/0306-4522(94)00548-J.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0306-4522(94)00548-J</ArticleId><ArticleId IdType="pubmed">7617165</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinchese F., et al. Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice. Ann. Neurol. 2004;55:801&#x2013;814. doi: 10.1002/ana.20101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20101</ArticleId><ArticleId IdType="pubmed">15174014</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman P.F., et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat. Neurosci. 1999;2:271&#x2013;276. doi: 10.1038/6374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/6374</ArticleId><ArticleId IdType="pubmed">10195221</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S., et al. Triple-transgenic model of Alzheimer&#x2019;s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409&#x2013;421. doi: 10.1016/S0896-6273(03)00434-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(03)00434-3</ArticleId><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Chen H., Jeong J.J., Chishti A.H. BDA-410: a novel synthetic calpain inhibitor active against blood stage malaria. Mol. Biochem. Parasitol. 2007;155:26&#x2013;32. doi: 10.1016/j.molbiopara.2007.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molbiopara.2007.05.004</ArticleId><ArticleId IdType="pmc">PMC1993804</ArticleId><ArticleId IdType="pubmed">17583361</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshii, N., et al. 1999. Neuroprotective effects of a novel orally active reversible calpain inhibitor BDA-410 [abstract]. Presented at the Society for Neuroscience 28th Annual Meeting. October 23&#x2013;28. Miami Beach, Florida, USA. 344.</Citation></Reference><Reference><Citation>Chan S.L., Culmsee C., Haughey N., Klapper W., Mattson M.P. Presenilin-1 mutations sensitize neurons to DNA damage-induced death by a mechanism involving perturbed calcium homeostasis and activation of calpains and caspase-12. Neurobiol. Dis. 2002;11:2&#x2013;19. doi: 10.1006/nbdi.2002.0542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nbdi.2002.0542</ArticleId><ArticleId IdType="pubmed">12460542</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao X., Sudhof T.C. A transcriptionally [correction of transcriptively] active complex of APP with Fe65 and histone acetyltransferase Tip60. Science. 2001;293:115&#x2013;120. doi: 10.1126/science.1058783.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1058783</ArticleId><ArticleId IdType="pubmed">11441186</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamal A., Almenar-Queralt A., LeBlanc J.F., Roberts E.A., Goldstein L.S. Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP. Nature. 2001;414:643&#x2013;648. doi: 10.1038/414643a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/414643a</ArticleId><ArticleId IdType="pubmed">11740561</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh D.M., et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539. doi: 10.1038/416535a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/416535a</ArticleId><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Dineley K.T., et al. Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer&#x2019;s disease. J. Neurosci. 2001;21:4125&#x2013;4133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762764</ArticleId><ArticleId IdType="pubmed">11404397</ArticleId></ArticleIdList></Reference><Reference><Citation>Dineley K.T., Xia X., Bui D., Sweatt J.D., Zheng H. Accelerated plaque accumulation, associative learning deficits, and up-regulation of alpha 7 nicotinic receptor protein in transgenic mice co-expressing mutant human presenilin 1 and amyloid precursor proteins. J. Biol. Chem. 2002;277:22768&#x2013;22780. doi: 10.1074/jbc.M200164200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M200164200</ArticleId><ArticleId IdType="pubmed">11912199</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong B., et al. Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model following rolipram treatment. J. Clin. Invest. 2004;114:1624&#x2013;1634.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC529285</ArticleId><ArticleId IdType="pubmed">15578094</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva A.J., Kogan J.H., Frankland P.W., Kida S. CREB and memory. Annu. Rev. Neurosci. 1998;21:127&#x2013;148. doi: 10.1146/annurev.neuro.21.1.127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.21.1.127</ArticleId><ArticleId IdType="pubmed">9530494</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S., et al. alpha-Synuclein produces a long-lasting increase in neurotransmitter release. EMBO J. 2004;23:4506&#x2013;4516. doi: 10.1038/sj.emboj.7600451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.emboj.7600451</ArticleId><ArticleId IdType="pmc">PMC526467</ArticleId><ArticleId IdType="pubmed">15510220</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonova I., et al. Rapid increase in clusters of presynaptic proteins at onset of long-lasting potentiation. Science. 2001;294:1547&#x2013;1550. doi: 10.1126/science.1066273.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1066273</ArticleId><ArticleId IdType="pubmed">11641465</ArticleId></ArticleIdList></Reference><Reference><Citation>Goll D.E., Thompson V.F., Li H., Wei W., Cong J. The calpain system. Physiol. Rev. 2003;83:731&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pubmed">12843408</ArticleId></ArticleIdList></Reference><Reference><Citation>Leissring M.A., et al. Capacitative calcium entry deficits and elevated luminal calcium content in mutant presenilin-1 knockin mice. J. Cell Biol. 2000;149:793&#x2013;798. doi: 10.1083/jcb.149.4.793.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.149.4.793</ArticleId><ArticleId IdType="pmc">PMC2174559</ArticleId><ArticleId IdType="pubmed">10811821</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuji T., Shimohama S., Kimura J., Shimizu K. m-Calpain (calcium-activated neutral proteinase) in Alzheimer&#x2019;s disease brains. Neurosci. Lett. 1998;248:109&#x2013;112. doi: 10.1016/S0304-3940(98)00348-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(98)00348-6</ArticleId><ArticleId IdType="pubmed">9654354</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon R.A. Niemann-Pick Type C disease and Alzheimer&#x2019;s disease: the APP-endosome connection fattens up. Am. J. Pathol. 2004;164:757&#x2013;761.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1613265</ArticleId><ArticleId IdType="pubmed">14982829</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Rosa G., Odrijin T., Nixon R.A., Arancio O. Calpain inhibitors: a treatment for Alzheimer&#x2019;s disease. J. Mol. Neurosci. 2002;19:135&#x2013;141. doi: 10.1007/s12031-002-0024-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-002-0024-4</ArticleId><ArticleId IdType="pubmed">12212771</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly B.L., Ferreira A. beta-Amyloid-induced dynamin 1 degradation is mediated by N-methyl-D-aspartate receptors in hippocampal neurons. J. Biol. Chem. 2006;281:28079&#x2013;28089. doi: 10.1074/jbc.M605081200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M605081200</ArticleId><ArticleId IdType="pubmed">16864575</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E. Mechanisms of synaptic dysfunction in Alzheimer&#x2019;s disease. Histol. Histopathol. 1995;10:509&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">7599445</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan D., et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer&#x2019;s disease. Nature. 2000;408:982&#x2013;985. doi: 10.1038/35050116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35050116</ArticleId><ArticleId IdType="pubmed">11140686</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla F.M., Troncoso J.C., Strickland D.K., Kawas C.H., Jay G. Neuronal cell death in Alzheimer&#x2019;s disease correlates with apoE uptake and intracellular Abeta stabilization. J. Clin. Invest. 1997;100:310&#x2013;320. doi: 10.1172/JCI119536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI119536</ArticleId><ArticleId IdType="pmc">PMC508193</ArticleId><ArticleId IdType="pubmed">9218507</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouras G.K., et al. Intraneuronal Abeta42 accumulation in human brain. Am. J. Pathol. 2000;156:15&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1868613</ArticleId><ArticleId IdType="pubmed">10623648</ArticleId></ArticleIdList></Reference><Reference><Citation>Higuchi M., et al. Distinct mechanistic roles of calpain and caspase activation in neurodegeneration as revealed in mice overexpressing their specific inhibitors. J. Biol. Chem. 2005;280:15229&#x2013;15237. doi: 10.1074/jbc.M500939200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M500939200</ArticleId><ArticleId IdType="pubmed">15699033</ArticleId></ArticleIdList></Reference><Reference><Citation>Veeranna, et al. Calpain mediates calcium-induced activation of the erk1,2 MAPK pathway and cytoskeletal phosphorylation in neurons: relevance to Alzheimer&#x2019;s disease. Am. J. Pathol. 2004;165:795&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618589</ArticleId><ArticleId IdType="pubmed">15331404</ArticleId></ArticleIdList></Reference><Reference><Citation>Duff K., et al. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature. 1996;383:710&#x2013;713. doi: 10.1038/383710a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/383710a0</ArticleId><ArticleId IdType="pubmed">8878479</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K., et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102. doi: 10.1126/science.274.5284.99.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.274.5284.99</ArticleId><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Ninan I., Arancio O. Presynaptic CaMKII is necessary for synaptic plasticity in cultured hippocampal neurons. Neuron. 2004;42:129&#x2013;141. doi: 10.1016/S0896-6273(04)00143-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(04)00143-6</ArticleId><ArticleId IdType="pubmed">15066270</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong B., et al. Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory. Cell. 2006;126:775&#x2013;788. doi: 10.1016/j.cell.2006.06.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2006.06.046</ArticleId><ArticleId IdType="pubmed">16923396</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer&#x2019;s amyloid beta-peptide. Nat. Rev. Mol. Cell. Biol. 2007;8:101&#x2013;112. doi: 10.1038/nrm2101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm2101</ArticleId><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt S.D., Jiang Y., Nixon R.A., Mathews P.M.2005. .T issue processing prior to protein analysis and amyloid-beta quantitation. Methods Mol. Biol. 299267&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pubmed">15980611</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt S.D., Nixon R.A., Mathews P.M. ELISA method for measurement of amyloid-beta levels. Methods Mol. Biol. 2005;299:279&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pubmed">15980612</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18614028</PMID><DateCompleted><Year>2008</Year><Month>08</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>59</Volume><Issue>1</Issue><PubDate><Year>2008</Year><Month>Jul</Month><Day>10</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta.</ArticleTitle><Pagination><StartPage>43</StartPage><EndPage>55</EndPage><MedlinePgn>43-55</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2008.06.018</ELocationID><Abstract><AbstractText>As a disease-modifying approach for Alzheimer's disease (AD), clioquinol (CQ) targets beta-amyloid (Abeta) reactions with synaptic Zn and Cu yet promotes metal uptake. Here we characterize the second-generation 8-hydroxy quinoline analog PBT2, which also targets metal-induced aggregation of Abeta, but is more effective as a Zn/Cu ionophore and has greater blood-brain barrier permeability. Given orally to two types of amyloid-bearing transgenic mouse models of AD, PBT2 outperformed CQ by markedly decreasing soluble interstitial brain Abeta within hours and improving cognitive performance to exceed that of normal littermate controls within days. Nontransgenic mice were unaffected by PBT2. The current data demonstrate that ionophore activity, inhibition of in vitro metal-mediated Abeta reactions, and blood-brain barrier permeability are indices that predict a potential disease-modifying drug for AD. The speed of recovery of the animals underscores the acutely reversible nature of the cognitive deficits associated with transgenic models of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Adlard</LastName><ForeName>Paul A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Oxidation Biology Laboratory, The Mental Health Research Institute of Victoria, Parkville, Victoria 3052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cherny</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Finkelstein</LastName><ForeName>David I</ForeName><Initials>DI</Initials></Author><Author ValidYN="Y"><LastName>Gautier</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Robb</LastName><ForeName>Elysia</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Cortes</LastName><ForeName>Mikhalina</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Volitakis</LastName><ForeName>Irene</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xiang</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Jeffrey P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Perez</LastName><ForeName>Keyla</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Laughton</LastName><ForeName>Katrina</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qiao-Xin</ForeName><Initials>QX</Initials></Author><Author ValidYN="Y"><LastName>Charman</LastName><ForeName>Susan A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Nicolazzo</LastName><ForeName>Joseph A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Wilkins</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Deleva</LastName><ForeName>Karolina</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Lynch</LastName><ForeName>Toni</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Kok</LastName><ForeName>Gaik</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Ritchie</LastName><ForeName>Craig W</ForeName><Initials>CW</Initials></Author><Author ValidYN="Y"><LastName>Tanzi</LastName><ForeName>Rudolph E</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>Cappai</LastName><ForeName>Roberto</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>Colin L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Barnham</LastName><ForeName>Kevin J</ForeName><Initials>KJ</Initials></Author><Author ValidYN="Y"><LastName>Bush</LastName><ForeName>Ashley I</ForeName><Initials>AI</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006912">Hydroxyquinolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>789U1901C5</RegistryNumber><NameOfSubstance UI="D003300">Copper</NameOfSubstance></Chemical><Chemical><RegistryNumber>7BHQ856EJ5</RegistryNumber><NameOfSubstance UI="D007464">Clioquinol</NameOfSubstance></Chemical><Chemical><RegistryNumber>J41CSQ7QDS</RegistryNumber><NameOfSubstance UI="D015032">Zinc</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007464" MajorTopicYN="N">Clioquinol</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003300" MajorTopicYN="N">Copper</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006912" MajorTopicYN="N">Hydroxyquinolines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009447" MajorTopicYN="N">Neuroblastoma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015032" MajorTopicYN="N">Zinc</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2008</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>7</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>7</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18614028</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2008.06.018</ArticleId><ArticleId IdType="pii">S0896-6273(08)00536-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18628954</PMID><DateCompleted><Year>2008</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>7</Issue><PubDate><Year>2008</Year><Month>Jul</Month><Day>16</Day></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Age-specific epigenetic drift in late-onset Alzheimer's disease.</ArticleTitle><Pagination><StartPage>e2698</StartPage><MedlinePgn>e2698</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2698</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0002698</ELocationID><Abstract><AbstractText>Despite an enormous research effort, most cases of late-onset Alzheimer's disease (LOAD) still remain unexplained and the current biomedical science is still a long way from the ultimate goal of revealing clear risk factors that can help in the diagnosis, prevention and treatment of the disease. Current theories about the development of LOAD hinge on the premise that Alzheimer's arises mainly from heritable causes. Yet, the complex, non-Mendelian disease etiology suggests that an epigenetic component could be involved. Using MALDI-TOF mass spectrometry in post-mortem brain samples and lymphocytes, we have performed an analysis of DNA methylation across 12 potential Alzheimer's susceptibility loci. In the LOAD brain samples we identified a notably age-specific epigenetic drift, supporting a potential role of epigenetic effects in the development of the disease. Additionally, we found that some genes that participate in amyloid-beta processing (PSEN1, APOE) and methylation homeostasis (MTHFR, DNMT1) show a significant interindividual epigenetic variability, which may contribute to LOAD predisposition. The APOE gene was found to be of bimodal structure, with a hypomethylated CpG-poor promoter and a fully methylated 3'-CpG-island, that contains the sequences for the epsilon4-haplotype, which is the only undisputed genetic risk factor for LOAD. Aberrant epigenetic control in this CpG-island may contribute to LOAD pathology. We propose that epigenetic drift is likely to be a substantial mechanism predisposing individuals to LOAD and contributing to the course of disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Sun-Chong</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Institute of Systems Biology and Bioinformatics, National Central University, Jhongli City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oelze</LastName><ForeName>Beatrice</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Schumacher</LastName><ForeName>Axel</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>07</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018899" MajorTopicYN="N">CpG Islands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019175" MajorTopicYN="N">DNA Methylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044127" MajorTopicYN="Y">Epigenesis, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008957" MajorTopicYN="N">Models, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019032" MajorTopicYN="N">Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>4</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>7</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>9</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>7</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>7</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18628954</ArticleId><ArticleId IdType="pmc">PMC2444024</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0002698</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bird TD. Genetic factors in Alzheimer's disease. N Engl J Med. 2005;352:862&#x2013;864.</Citation><ArticleIdList><ArticleId IdType="pubmed">15745976</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddell MB, Lovestone S, Owen MJ. Genetic risk of Alzheimer's disease: advising relatives. Br J Psychiatry. 2001;178:7&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">11136203</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaminsky Z, Wang S-C, Petronis P. Complex disease, gender and epigenetics. Ann Med. 2006;38:530&#x2013;544.</Citation><ArticleIdList><ArticleId IdType="pubmed">17438668</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeman MV. Psychopathology in women and men: focus on female hormones. Am J Psychiatry. 1997;154:1641&#x2013;1647.</Citation><ArticleIdList><ArticleId IdType="pubmed">9396940</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassett SS, Avramopoulos D, Perry RT, Wiener H, Watson B, Jr., et al. Further evidence of a maternal parent-of-origin effect on chromosome 10 in late-onset Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet. 2006;141:537&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2586169</ArticleId><ArticleId IdType="pubmed">16741936</ArticleId></ArticleIdList></Reference><Reference><Citation>Gimelbrant A, Hutchinson JN, Thompson BR, Chess A. Widespread monoallelic expression on human autosomes. Science. 2007;318:1136&#x2013;1140.</Citation><ArticleIdList><ArticleId IdType="pubmed">18006746</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolinoy DC, Das R, Weidman JR, Jirtle RL. Metastable Epialleles, Imprinting, and the Fetal Origins of Adult Diseases. Pediatr Res 2007</Citation><ArticleIdList><ArticleId IdType="pubmed">17413847</ArticleId></ArticleIdList></Reference><Reference><Citation>Milici A, Salbaum JM, Beyereuther K. Study of the Alzheimer's A4 precursor gene promoter region by genomic sequencing using Taq polymerase. Biochem Biophys Res Commun. 1990;169:46&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">1972017</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwob NG, Nalbantoglu J, Hastings KE, Mikkelsen T, Cashman NR. DNA cytosine methylation in brain of patients with Alzheimer's disease. Ann Neurol. 1990;28:91&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">2375641</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrich M, Field JK, Liloglou T, Xinarianos G, Oeth P, et al. Cytosine methylation profiles as a molecular marker in non-small cell lung cancer. Cancer Res. 2006;66:10911&#x2013;10918.</Citation><ArticleIdList><ArticleId IdType="pubmed">17108128</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrich M, Nelson MR, Stanssens P, Zabeau M, Liloglou T, et al. Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci U S A. 2005;102:15785&#x2013;15790.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1276092</ArticleId><ArticleId IdType="pubmed">16243968</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckhardt F, Lewin J, Cortese R, Rakyan VK, Attwood J, et al. DNA methylation profiling of human chromosomes 6, 20 and 22. Nat Genet. 2006;38:1378&#x2013;1385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3082778</ArticleId><ArticleId IdType="pubmed">17072317</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuks F. DNA methylation and histone modifications: teaming up to silence genes. Curr Opin Genet Dev. 2005;15:490&#x2013;495.</Citation><ArticleIdList><ArticleId IdType="pubmed">16098738</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiota K, Kogo Y, Ohgane J, Imamura T, Urano A, et al. Epigenetic marks by DNA methylation specific to stem, germ and somatic cells in mice. Genes Cells. 2002;7:961&#x2013;969.</Citation><ArticleIdList><ArticleId IdType="pubmed">12296826</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaev EI, Lukiw WJ, Lavrushina O, Rogaeva EA, St George-Hyslop PH. The upstream promoter of the beta-amyloid precursor protein gene (APP) shows differential patterns of methylation in human brain. Genomics. 1994;22:340&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">7528717</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuso A, Seminara L, Cavallaro RA, D'Anselmi F, Scarpa S. S-adenosylmethionine/homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta-amyloid production. Mol Cell Neurosci. 2005;28:195&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">15607954</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber M, Hellmann I, Stadler MB, Ramos L, Paabo S, et al. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet. 2007;39:457&#x2013;466.</Citation><ArticleIdList><ArticleId IdType="pubmed">17334365</ArticleId></ArticleIdList></Reference><Reference><Citation>Bray NJ, Jehu L, Moskvina V, Buxbaum JD, Dracheva S, et al. Allelic expression of APOE in human brain: effects of epsilon status and promoter haplotypes. Hum Mol Genet. 2004;13:2885&#x2013;2892.</Citation><ArticleIdList><ArticleId IdType="pubmed">15385439</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Perez-Tur J, Dupire MJ, Galasko D, Mann D, et al. Distortion of allelic expression of apolipoprotein E in Alzheimer's disease. Hum Mol Genet. 1997;6:2151&#x2013;2154.</Citation><ArticleIdList><ArticleId IdType="pubmed">9328480</ArticleId></ArticleIdList></Reference><Reference><Citation>Mill J, Tang T, Kaminsky Z, Khare T, Yazdanpanah S, et al. Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. Am J Hum Genet. 2008;82:696&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2427301</ArticleId><ArticleId IdType="pubmed">18319075</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook RH, Schneck SA, Clark DB. Twins with Alzheimer's disease. Arch Neurol. 1981;38:300&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">7224917</ArticleId></ArticleIdList></Reference><Reference><Citation>Nee LE, Lippa CF. Alzheimer's disease in 22 twin pairs&#x2013;13-year follow-up: hormonal, infectious and traumatic factors. Dement Geriatr Cogn Disord. 1999;10:148&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pubmed">10026389</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraga MF, Ballestar E, Paz MF, Ropero S, Setien F, et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A. 2005;102:10604&#x2013;10609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1174919</ArticleId><ArticleId IdType="pubmed">16009939</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin GM. Epigenetic drift in aging identical twins. Proc Natl Acad Sci U S A. 2005;102:10413&#x2013;10414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1180801</ArticleId><ArticleId IdType="pubmed">16027353</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmann M, Gottfries CG, Regland B. Identification of cognitive impairment in the elderly: homocysteine is an early marker. Dement Geriatr Cogn Disord. 1999;10:12&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">9844033</ArticleId></ArticleIdList></Reference><Reference><Citation>Quadri P, Fragiacomo C, Pezzati R, Zanda E, Forloni G, et al. Homocysteine, folate, and vitamin B-12 in mild cognitive impairment, Alzheimer disease, and vascular dementia. Am J Clin Nutr. 2004;80:114&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">15213037</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med. 2002;346:476&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pubmed">11844848</ArticleId></ArticleIdList></Reference><Reference><Citation>Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, et al. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science. 2005;307:1282&#x2013;1288.</Citation><ArticleIdList><ArticleId IdType="pubmed">15731448</ArticleId></ArticleIdList></Reference><Reference><Citation>Theuns J, Van Broeckhoven C. Transcriptional regulation of Alzheimer's disease genes: implications for susceptibility. Hum Mol Genet. 2000;9:2383&#x2013;2394.</Citation><ArticleIdList><ArticleId IdType="pubmed">11005793</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell. 2005;120:545&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">15734686</ArticleId></ArticleIdList></Reference><Reference><Citation>Flanagan JM, Popendikyte V, Pozdniakovaite N, Sobolev M, Assadzadeh A, et al. Intra- and interindividual epigenetic variation in human germ cells. Am J Hum Genet. 2006;79:67&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1474120</ArticleId><ArticleId IdType="pubmed">16773567</ArticleId></ArticleIdList></Reference><Reference><Citation>Coon KD, Myers AJ, Craig DW, Webster JA, Pearson JV, et al. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry. 2007;68:613&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pubmed">17474819</ArticleId></ArticleIdList></Reference><Reference><Citation>Laws SM, Hone E, Gandy S, Martins RN. Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription. J Neurochem. 2003;84:1215&#x2013;1236.</Citation><ArticleIdList><ArticleId IdType="pubmed">12614323</ArticleId></ArticleIdList></Reference><Reference><Citation>Petronis A. Epigenetics and twins: three variations on the theme. Trends in Genetics. 2006;22:347&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pubmed">16697072</ArticleId></ArticleIdList></Reference><Reference><Citation>Tohgi H, Utsugisawa K, Nagane Y, Yoshimura M, Genda Y, et al. Reduction with age in methylcytosine in the promoter region -224 approximately -101 of the amyloid precursor protein gene in autopsy human cortex. Brain Res Mol Brain Res. 1999;70:288&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">10407177</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohlsson R. Genetics. Widespread monoallelic expression. Science. 2007;318:1077&#x2013;1078.</Citation><ArticleIdList><ArticleId IdType="pubmed">18006729</ArticleId></ArticleIdList></Reference><Reference><Citation>Kristiansen M, Knudsen GP, Bathum L, Naumova AK, Sorensen TI, et al. Twin study of genetic and aging effects on X chromosome inactivation. Eur J Hum Genet. 2005;13:599&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pubmed">15756296</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson B. Impact of aging on DNA methylation. Ageing Res Rev. 2003;2:245&#x2013;261.</Citation><ArticleIdList><ArticleId IdType="pubmed">12726774</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett-Baker PE, Wilkowski J, Burke DT. Age-associated activation of epigenetically repressed genes in the mouse. Genetics. 2003;165:2055&#x2013;2062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1462878</ArticleId><ArticleId IdType="pubmed">14704185</ArticleId></ArticleIdList></Reference><Reference><Citation>Feil R. Environmental and nutritional effects on the epigenetic regulation of genes. Mutat Res. 2006;600:46&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">16854438</ArticleId></ArticleIdList></Reference><Reference><Citation>Basha MR, Wei W, Bakheet SA, Benitez N, Siddiqi HK, et al. The fetal basis of amyloidogenesis: exposure to lead and latent overexpression of amyloid precursor protein and beta-amyloid in the aging brain. J Neurosci. 2005;25:823&#x2013;829.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725614</ArticleId><ArticleId IdType="pubmed">15673661</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Basha MR, Brock B, Cox DP, Cardozo-Pelaez F, et al. Alzheimer's disease (AD)-like pathology in aged monkeys after infantile exposure to environmental metal lead (Pb): evidence for a developmental origin and environmental link for AD. Journal of Neuroscience. 2008;28:3&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2486412</ArticleId><ArticleId IdType="pubmed">18171917</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller JA, Oldham MC, Geschwind DH. A systems level analysis of transcriptional changes in Alzheimer's disease and normal aging. J Neurosci. 2008;28:1410&#x2013;1420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2902235</ArticleId><ArticleId IdType="pubmed">18256261</ArticleId></ArticleIdList></Reference><Reference><Citation>Bottiglieri T, Godfrey P, Flynn T, Carney MW, Toone BK, et al. Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. J Neurol Neurosurg Psychiatry. 1990;53:1096&#x2013;1098.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC488323</ArticleId><ArticleId IdType="pubmed">2292704</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison LD, Smith DD, Kish SJ. Brain S-adenosylmethionine levels are severely decreased in Alzheimer's disease. J Neurochem. 1996;67:1328&#x2013;1331.</Citation><ArticleIdList><ArticleId IdType="pubmed">8752143</ArticleId></ArticleIdList></Reference><Reference><Citation>Guidi I, Galimberti D, Venturelli E, Lovati C, Del Bo R, et al. Influence of the Glu298Asp polymorphism of NOS3 on age at onset and homocysteine levels in AD patients. Neurobiol Aging. 2005;26:789&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pubmed">15718036</ArticleId></ArticleIdList></Reference><Reference><Citation>Payao SL, Smith MD, Bertolucci PH. Differential chromosome sensitivity to 5-azacytidine in Alzheimer's disease. Gerontology. 1998;44:267&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pubmed">9693257</ArticleId></ArticleIdList></Reference><Reference><Citation>Levenson JM, Sweatt JD. Epigenetic mechanisms: a common theme in vertebrate and invertebrate memory formation. Cell Mol Life Sci. 2006;63:1009&#x2013;1016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11136205</ArticleId><ArticleId IdType="pubmed">16596331</ArticleId></ArticleIdList></Reference><Reference><Citation>Raina AK, Pardo P, Rottkamp CA, Zhu X, Pereira-Smith OM, et al. Neurons in Alzheimer disease emerge from senescence. Mech Ageing Dev. 2001;123:3&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11640946</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark SJ, Harrison J, Paul CL, Frommer M. High sensitivity mapping of methylated cytosines. Nucleic Acids Res. 1994;22:2990&#x2013;2997.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC310266</ArticleId><ArticleId IdType="pubmed">8065911</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18632739</PMID><DateCompleted><Year>2009</Year><Month>12</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2199</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>3</Issue><PubDate><Year>2009</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Cerebral cortex (New York, N.Y. : 1991)</Title><ISOAbbreviation>Cereb Cortex</ISOAbbreviation></Journal><ArticleTitle>The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals.</ArticleTitle><Pagination><StartPage>497</StartPage><EndPage>510</EndPage><MedlinePgn>497-510</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/cercor/bhn113</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is associated with neurodegeneration in vulnerable limbic and heteromodal regions of the cerebral cortex, detectable in vivo using magnetic resonance imaging. It is not clear whether abnormalities of cortical anatomy in AD can be reliably measured across different subject samples, how closely they track symptoms, and whether they are detectable prior to symptoms. An exploratory map of cortical thinning in mild AD was used to define regions of interest that were applied in a hypothesis-driven fashion to other subject samples. Results demonstrate a reliably quantifiable in vivo signature of abnormal cortical anatomy in AD, which parallels known regional vulnerability to AD neuropathology. Thinning in vulnerable cortical regions relates to symptom severity even in the earliest stages of clinical symptoms. Furthermore, subtle thinning is present in asymptomatic older controls with brain amyloid binding as detected with amyloid imaging. The reliability and clinical validity of AD-related cortical thinning suggests potential utility as an imaging biomarker. This "disease signature" approach to cortical morphometry, in which disease effects are mapped across the cortical mantle and then used to define ROIs for hypothesis-driven analyses, may provide a powerful methodological framework for studies of neuropsychiatric diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dickerson</LastName><ForeName>Bradford C</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02129, USA. bradd@nmr.mgh.harvard.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bakkour</LastName><ForeName>Akram</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Salat</LastName><ForeName>David H</ForeName><Initials>DH</Initials></Author><Author ValidYN="Y"><LastName>Feczko</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Pacheco</LastName><ForeName>Jenni</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Greve</LastName><ForeName>Douglas N</ForeName><Initials>DN</Initials></Author><Author ValidYN="Y"><LastName>Grodstein</LastName><ForeName>Fran</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Wright</LastName><ForeName>Christopher I</ForeName><Initials>CI</Initials></Author><Author ValidYN="Y"><LastName>Blacker</LastName><ForeName>Deborah</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Rosas</LastName><ForeName>H Diana</ForeName><Initials>HD</Initials></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Atri</LastName><ForeName>Alireza</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Growdon</LastName><ForeName>John H</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Fischl</LastName><ForeName>Bruce</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Buckner</LastName><ForeName>Randy L</ForeName><Initials>RL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01-AG03991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41-RR14075</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50-AG05134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-NS042861</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG29411</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21-AG29840</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021910</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50-AG05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24-RR021382</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG034556</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23-AG22509</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>07</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cereb Cortex</MedlineTA><NlmUniqueID>9110718</NlmUniqueID><ISSNLinking>1047-3211</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>7</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>7</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>7</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18632739</ArticleId><ArticleId IdType="pmc">PMC2638813</ArticleId><ArticleId IdType="doi">10.1093/cercor/bhn113</ArticleId><ArticleId IdType="pii">bhn113</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Apostolova LG, Steiner CA, Akopyan GG, Dutton RA, Hayashi KM, Toga AW, Cummings JL, Thompson PM. Three-dimensional gray matter atrophy mapping in mild cognitive impairment and mild Alzheimer disease. Arch Neurol. 2007;64:1489&#x2013;1495.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3197839</ArticleId><ArticleId IdType="pubmed">17923632</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb Cortex. 1991;1:103&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">1822725</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology. 1992;42:631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">1549228</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriagada PV, Marzloff K, Hyman BT. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology. 1992;42:1681&#x2013;1688.</Citation><ArticleIdList><ArticleId IdType="pubmed">1307688</ArticleId></ArticleIdList></Reference><Reference><Citation>Atri A, Locascio JJ, Lin JM, Yap L, Dickerson BC, Grodstein F, Irizarry MC, Growdon JH, Greenberg SM. Prevalence and effects of lobar microhemorrhages in early-stage dementia. Neurodegener Dis. 2005;2:305&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">16909013</ArticleId></ArticleIdList></Reference><Reference><Citation>Baron JC, Chetelat G, Desgranges B, Perchey G, Landeau B, de la Sayette V, Eustache F. In vivo mapping of gray matter loss with voxel-based morphometry in mild Alzheimer's disease. Neuroimage. 2001;14:298&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">11467904</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, Wilson RS. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66:1837&#x2013;1844.</Citation><ArticleIdList><ArticleId IdType="pubmed">16801647</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg L, McKeel DW, Jr, Miller JP, Storandt M, Rubin EH, Morris JC, Baty J, Coats M, Norton J, Goate AM, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol. 1998;55:326&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">9520006</ArticleId></ArticleIdList></Reference><Reference><Citation>Bobinski M, de Leon MJ, Convit A, De Santi S, Wegiel J, Tarshish CY, Saint Louis LA, Wisniewski HM. MRI of entorhinal cortex in mild Alzheimer's disease. Lancet. 1999;353:38&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">10023955</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozzali M, Filippi M, Magnani G, Cercignani M, Franceschi M, Schiatti E, Castiglioni S, Mossini R, Falautano M, Scotti G, et al. The contribution of voxel-based morphometry in staging patients with mild cognitive impairment. Neurology. 2006;67:453&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894107</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl). 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E, Bohl J, Bratzke H. Evolution of Alzheimer's disease related cortical lesions. J Neural Transm Suppl. 1998;54:97&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">9850918</ArticleId></ArticleIdList></Reference><Reference><Citation>Brun A, Gustafson L. Distribution of cerebral degeneration in Alzheimer's disease. A clinico-pathological study. Arch Psychiatr Nervenkr. 1976;223:15&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">828039</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Head D, Parker J, Fotenos AF, Marcus D, Morris JC, Snyder AZ. A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume. Neuroimage. 2004;23:724&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pubmed">15488422</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardenas VA, Du AT, Hardin D, Ezekiel F, Weber P, Jagust WJ, Chui HC, Schuff N, Weiner MW. Comparison of methods for measuring longitudinal brain change in cognitive impairment and dementia. Neurobiol Aging. 2003;24:537&#x2013;544.</Citation><ArticleIdList><ArticleId IdType="pubmed">12714110</ArticleId></ArticleIdList></Reference><Reference><Citation>Celone K, Calhoun V, Dickerson BC, Atri A, Chua E, Miller S, Depeau K, Rentz DM, Selkoe DJ, Blacker D, et al. Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis. J Neurosci. 2006;26:10222&#x2013;10231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674636</ArticleId><ArticleId IdType="pubmed">17021177</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleman P, Federoff H, Kurlan R. A focus on the synapse for neuroprotection in Alzheimer disease and other dementias. Neurology. 2004;63:1155&#x2013;1162.</Citation><ArticleIdList><ArticleId IdType="pubmed">15477531</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleman PD, Flood DG. Neuron numbers and dendritic extent in normal aging and Alzheimer's disease. Neurobiol Aging. 1987;8:521&#x2013;545.</Citation><ArticleIdList><ArticleId IdType="pubmed">3323927</ArticleId></ArticleIdList></Reference><Reference><Citation>Csernansky JG, Hamstra J, Wang L, McKeel D, Price JL, Gado M, Morris JC. Correlations between antemortem hippocampal volume and postmortem neuropathology in AD subjects. Alzheimer Dis Assoc Disord. 2004;18:190&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">15592129</ArticleId></ArticleIdList></Reference><Reference><Citation>Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis. I. Segmentation and surface reconstruction. Neuroimage. 1999;9:179&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">9931268</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol. 1990;27:457&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">2360787</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky ST, Scheff SW, Styren SD. Structural correlates of cognition in dementia: quantification and assessment of synapse change. Neurodegeneration. 1996;5:417&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">9117556</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Fenstermacher E, Salat DH, Wolk DA, Maguire RP, Desikan R, Pacheco J, Quinn BT, Van der Kouwe A, Greve DN, et al. Detection of cortical thickness correlates of cognitive performance: reliability across MRI scan sessions, scanners, and field strengths. Neuroimage. 2008;39:10&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2141650</ArticleId><ArticleId IdType="pubmed">17942325</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Goncharova I, Sullivan MP, Forchetti C, Wilson RS, Bennett DA, Beckett LA, deToledo-Morrell L. MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease. Neurobiol Aging. 2001;22:747&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">11705634</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Salat DH, Greve DN, Chua EF, Rand-Giovannetti E, Rentz DM, Bertram L, Mullin K, Tanzi RE, Blacker D, et al. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology. 2005;65:404&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4335677</ArticleId><ArticleId IdType="pubmed">16087905</ArticleId></ArticleIdList></Reference><Reference><Citation>Du AT, Schuff N, Kramer JH, Rosen HJ, Gorno-Tempini ML, Rankin K, Miller BL, Weiner MW. Different regional patterns of cortical thinning in Alzheimer's disease and frontotemporal dementia. Brain. 2007;130:1159&#x2013;1166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1853284</ArticleId><ArticleId IdType="pubmed">17353226</ArticleId></ArticleIdList></Reference><Reference><Citation>Eickhoff SB, Heim S, Zilles K, Amunts K. Testing anatomically specified hypotheses in functional imaging using cytoarchitectonic maps. Neuroimage. 2006;32:570&#x2013;582.</Citation><ArticleIdList><ArticleId IdType="pubmed">16781166</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59:512&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, Dale AM. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci USA. 2000;97:11050&#x2013;11055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27146</ArticleId><ArticleId IdType="pubmed">10984517</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, Liu A, Dale AM. Automated manifold surgery: constructing geometrically accurate and topologically correct models of the human cerebral cortex. IEEE Trans Med Imaging. 2001;20:70&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">11293693</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, Sereno MI, Dale AM. Cortical surface-based analysis. II: Inflation, flattening, and a surface-based coordinate system. Neuroimage. 1999;9:195&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">9931269</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, Sereno MI, Tootell RB, Dale AM. High-resolution intersubject averaging and a coordinate system for the cortical surface. Hum Brain Mapp. 1999;8:272&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6873338</ArticleId><ArticleId IdType="pubmed">10619420</ArticleId></ArticleIdList></Reference><Reference><Citation>Fotenos AF, Mintun MA, Snyder AZ, Morris JC, Buckner RL. Brain volume decline in aging: evidence for a relation between socioeconomic status, preclinical Alzheimer disease, and reserve. Arch Neurol. 2008;65:113&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">18195148</ArticleId></ArticleIdList></Reference><Reference><Citation>Fotenos AF, Snyder AZ, Girton LE, Morris JC, Buckner RL. Normative estimates of cross-sectional and longitudinal brain volume decline in aging and AD. Neurology. 2005;64:1032&#x2013;1039.</Citation><ArticleIdList><ArticleId IdType="pubmed">15781822</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox NC, Scahill RI, Crum WR, Rossor MN. Correlation between rates of brain atrophy and cognitive decline in AD. Neurology. 1999;52:1687&#x2013;1689.</Citation><ArticleIdList><ArticleId IdType="pubmed">10331700</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisoni GB, Testa C, Zorzan A, Sabattoli F, Beltramello A, Soininen H, Laakso MP. Detection of grey matter loss in mild Alzheimer's disease with voxel based morphometry. J Neurol Neurosurg Psychiatry. 2002;73:657&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1757361</ArticleId><ArticleId IdType="pubmed">12438466</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Isla T, Price JL, McKeel DW, Jr, Morris JC, Growdon JH, Hyman BT. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci. 1996;16:4491&#x2013;4500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578866</ArticleId><ArticleId IdType="pubmed">8699259</ArticleId></ArticleIdList></Reference><Reference><Citation>Good CD, Scahill RI, Fox NC, Ashburner J, Friston KJ, Chan D, Crum WR, Rossor MN, Frackowiak RS. Automatic differentiation of anatomical patterns in the human brain: validation with studies of degenerative dementias. Neuroimage. 2002;17:29&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">12482066</ArticleId></ArticleIdList></Reference><Reference><Citation>Gosche KM, Mortimer JA, Smith CD, Markesbery WR, Snowdon DA. Hippocampal volume as an index of Alzheimer neuropathology: findings from the Nun Study. Neurology. 2002;58:1476&#x2013;1482.</Citation><ArticleIdList><ArticleId IdType="pubmed">12034782</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X, Jovicich J, Salat D, van der Kouwe A, Quinn B, Czanner S, Busa E, Pacheco J, Albert M, Killiany R, et al. Reliability of MRI-derived measurements of human cerebral cortical thickness: the effects of field strength, scanner upgrade and manufacturer. Neuroimage. 2006;32:180&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">16651008</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL. Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science. 1984;225:1168&#x2013;1170.</Citation><ArticleIdList><ArticleId IdType="pubmed">6474172</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Dickson DW, Parisi JE, Xu YC, Cha RH, O'Brien PC, Edland SD, Smith GE, Boeve BF, Tangalos EG, et al. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology. 2002;58:750&#x2013;757.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2745935</ArticleId><ArticleId IdType="pubmed">11889239</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Petersen RC, O'Brien PC, Tangalos EG. MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease. Neurology. 1992;42:183&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">1734300</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Petersen RC, Xu YC, Waring SC, O'Brien PC, Tangalos EG, Smith GE, Ivnik RJ, Kokmen E. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology. 1997;49:786&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730601</ArticleId><ArticleId IdType="pubmed">9305341</ArticleId></ArticleIdList></Reference><Reference><Citation>Juottonen K, Laakso MP, Insausti R, Lehtovirta M, Pitkanen A, Partanen K, Soininen H. Volumes of the entorhinal and perirhinal cortices in Alzheimer's disease. Neurobiol Aging. 1998;19:15&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">9562498</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabani N, Le Goualher G, MacDonald D, Evans AC. Measurement of cortical thickness using an automated 3-D algorithm: a validation study. Neuroimage. 2001;13:375&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pubmed">11162277</ArticleId></ArticleIdList></Reference><Reference><Citation>Karas GB, Burton EJ, Rombouts SA, van Schijndel RA, O'Brien JT, Scheltens P, McKeith IG, Williams D, Ballard C, Barkhof F. A comprehensive study of gray matter loss in patients with Alzheimer's disease using optimized voxel-based morphometry. Neuroimage. 2003;18:895&#x2013;907.</Citation><ArticleIdList><ArticleId IdType="pubmed">12725765</ArticleId></ArticleIdList></Reference><Reference><Citation>Karas GB, Scheltens P, Rombouts SA, Visser PJ, van Schijndel RA, Fox NC, Barkhof F. Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease. Neuroimage. 2004;23:708&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pubmed">15488420</ArticleId></ArticleIdList></Reference><Reference><Citation>Killiany RJ, Gomez-Isla T, Moss M, Kikinis R, Sandor T, Jolesz F, Tanzi R, Jones K, Hyman BT, Albert MS. Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann Neurol. 2000;47:430&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pubmed">10762153</ArticleId></ArticleIdList></Reference><Reference><Citation>Killiany RJ, Moss MB, Albert MS, Sandor T, Tieman J, Jolesz F. Temporal lobe regions on magnetic resonance imaging identify patients with early Alzheimer's disease. Arch Neurol. 1993;50:949&#x2013;954.</Citation><ArticleIdList><ArticleId IdType="pubmed">8363449</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuperberg GR, Broome MR, McGuire PK, David AS, Eddy M, Ozawa F, Goff D, West WC, Williams SC, van der Kouwe AJ, et al. Regionally localized thinning of the cerebral cortex in schizophrenia. Arch Gen Psychiatry. 2003;60:878&#x2013;888.</Citation><ArticleIdList><ArticleId IdType="pubmed">12963669</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerch JP, Pruessner JC, Zijdenbos A, Hampel H, Teipel SJ, Evans AC. Focal decline of cortical thickness in Alzheimer's disease identified by computational neuroanatomy. Cereb Cortex. 2005;15:995&#x2013;1001.</Citation><ArticleIdList><ArticleId IdType="pubmed">15537673</ArticleId></ArticleIdList></Reference><Reference><Citation>MacDonald D, Kabani N, Avis D, Evans AC. Automated 3-D extraction of inner and outer surfaces of cerebral cortex from MRI. Neuroimage. 2000;12:340&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">10944416</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam MM. From sensation to cognition. Brain. 1998;121(Pt 6):1013&#x2013;1052.</Citation><ArticleIdList><ArticleId IdType="pubmed">9648540</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Ernesto C, Schafer K, Coats M, Leon S, Sano M, Thal LJ, Woodbury P. Clinical dementia rating training and reliability in multicenter studies: the Alzheimer's Disease Cooperative Study experience. Neurology. 1997;48:1508&#x2013;1510.</Citation><ArticleIdList><ArticleId IdType="pubmed">9191756</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, McKeel DW, Jr, Fulling K, Torack RM, Berg L. Validation of clinical diagnostic criteria for Alzheimer's disease. Ann Neurol. 1988;24:17&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">3415196</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, Berg L. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol. 2001;58:397&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">11255443</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison JH, Hof PR. Selective vulnerability of corticocortical and hippocampal circuits in aging and Alzheimer's disease. Prog Brain Res. 2002;136:467&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">12143403</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack C, Jagust W, Trojanowski JQ, Toga AW, Beckett L. The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin N Am. 2005;15:869&#x2013;877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2376747</ArticleId><ArticleId IdType="pubmed">16443497</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy SN, Mendis ME, Grethe J, Gollub R, Kennedy D, Rosen BR. A web portal that enables collaborative use of advanced medical image processing and informatics tools through the Biomedical Informatics Research Network (BIRN) AMIA Annu Symp Proc. 2006:579&#x2013;583.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1839506</ArticleId><ArticleId IdType="pubmed">17238407</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Davis PB, Morris JC, White DL. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol Aging. 1991;12:295&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">1961359</ArticleId></ArticleIdList></Reference><Reference><Citation>Regeur L. Increasing loss of brain tissue with increasing dementia: a stereological study of post-mortem brains from elderly females. Eur J Neurol. 2000;7:47&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">10809914</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosas HD, Liu AK, Hersch S, Glessner M, Ferrante RJ, Salat DH, van der Kouwe A, Jenkins BG, Dale AM, Fischl B. Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology. 2002;58:695&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pubmed">11889230</ArticleId></ArticleIdList></Reference><Reference><Citation>Salat DH, Buckner RL, Snyder AZ, Greve DN, Desikan RS, Busa E, Morris JC, Dale AM, Fischl B. Thinning of the cerebral cortex in aging. Cereb Cortex. 2004;14:721&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pubmed">15054051</ArticleId></ArticleIdList></Reference><Reference><Citation>Scahill RI, Schott JM, Stevens JM, Rossor MN, Fox NC. Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI. Proc Natl Acad Sci USA. 2002;99:4703&#x2013;4707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC123711</ArticleId><ArticleId IdType="pubmed">11930016</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff SW, DeKosky ST, Price DA. Quantitative assessment of cortical synaptic density in Alzheimer's disease. Neurobiol Aging. 1990;11:29&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">2325814</ArticleId></ArticleIdList></Reference><Reference><Citation>Schleicher A, Palomero-Gallagher N, Morosan P, Eickhoff SB, Kowalski T, de Vos K, Amunts K, Zilles K. Quantitative architectural analysis: a new approach to cortical mapping. Anat Embryol (Berl). 2005;210:373&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">16249867</ArticleId></ArticleIdList></Reference><Reference><Citation>Silbert LC, Quinn JF, Moore MM, Corbridge E, Ball MJ, Murdoch G, Sexton G, Kaye JA. Changes in premorbid brain volume predict Alzheimer's disease pathology. Neurology. 2003;61:487&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pubmed">12939422</ArticleId></ArticleIdList></Reference><Reference><Citation>Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, Lavretsky H, Burggren AC, Cole GM, Vinters HV, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med. 2006;355:2652&#x2013;2663.</Citation><ArticleIdList><ArticleId IdType="pubmed">17182990</ArticleId></ArticleIdList></Reference><Reference><Citation>Storandt M, Grant EA, Miller JP, Morris JC. Rates of progression in mild cognitive impairment and early Alzheimer's disease. Neurology. 2002;59:1034&#x2013;1041.</Citation><ArticleIdList><ArticleId IdType="pubmed">12370458</ArticleId></ArticleIdList></Reference><Reference><Citation>Storandt M, Grant EA, Miller JP, Morris JC. Progression in mild cognitive impairment (MCI) and PreMCI: a comparison of diagnostic criteria. Neurology. 2006;67:467&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal LJ, Grundman M, Golden R. Alzheimer's disease: a correlational analysis of the Blessed Information-Memory-Concentration Test and the Mini-Mental State Exam. Neurology. 1986;36:262&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">3945395</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson PM, Hayashi KM, de Zubicaray G, Janke AL, Rose SE, Semple J, Herman D, Hong MS, Dittmer SS, Doddrell DM, et al. Dynamics of gray matter loss in Alzheimer's disease. J Neurosci. 2003;23:994&#x2013;1005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741905</ArticleId><ArticleId IdType="pubmed">12574429</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson PM, Mega MS, Woods RP, Zoumalan CI, Lindshield CJ, Blanton RE, Moussai J, Holmes CJ, Cummings JL, Toga AW. Cortical change in Alzheimer's disease detected with a disease-specific population-based brain atlas. Cereb Cortex. 2001;11:1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">11113031</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomlinson BE, Blessed G, Roth M. Observations on the brains of non-demented old people. J Neurol Sci. 1968;7:331&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">5707082</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hoesen GW, Hyman BT, Damasio AR. Cell-specific pathology in neural systems of the temporal lobe in Alzheimer's disease. Prog Brain Res. 1986;70:321&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">3575750</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Shiung MM, Przybelski SA, Weigand SD, Knopman DS, Boeve BF, Petersen RC, Jack CR., Jr MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment. Neurology. 2008;70:512&#x2013;520.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2734138</ArticleId><ArticleId IdType="pubmed">17898323</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright CI, Dickerson BC, Feczko E, Negeira A, Williams D. A functional magnetic resonance imaging study of amygdala responses to human faces in aging and mild Alzheimer's disease. Biol Psychiatry. 2007;62:1388&#x2013;1395.</Citation><ArticleIdList><ArticleId IdType="pubmed">17336945</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright CI, Feczko E, Dickerson B, Williams D. Neuroanatomical correlates of personality in the elderly. Neuroimage. 2007;35:263&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1868480</ArticleId><ArticleId IdType="pubmed">17229578</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18657855</PMID><DateCompleted><Year>2008</Year><Month>08</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-547X</ISSN><JournalIssue CitedMedium="Internet"><Volume>372</Volume><Issue>9637</Issue><PubDate><Year>2008</Year><Month>Aug</Month><Day>09</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Prevalence of dementia in Latin America, India, and China: a population-based cross-sectional survey.</ArticleTitle><Pagination><StartPage>464</StartPage><EndPage>474</EndPage><MedlinePgn>464-74</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(08)61002-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Studies have suggested that the prevalence of dementia is lower in developing than in developed regions. We investigated the prevalence and severity of dementia in sites in low-income and middle-income countries according to two definitions of dementia diagnosis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We undertook one-phase cross-sectional surveys of all residents aged 65 years and older (n=14 960) in 11 sites in seven low-income and middle-income countries (China, India, Cuba, Dominican Republic, Venezuela, Mexico, and Peru). Dementia diagnosis was made according to the culturally and educationally sensitive 10/66 dementia diagnostic algorithm, which had been prevalidated in 25 Latin American, Asian, and African centres; and by computerised application of the dementia criterion from the Diagnostic and Statistical Manual of Mental Disorders (DSM IV). We also compared prevalence of DSM-IV dementia in each of the study sites with that from estimates in European studies.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">The prevalence of DSM-IV dementia varied widely, from 0.3% (95% CI 0.1-0.5) in rural India to 6.3% (5.0-7.7) in Cuba. After standardisation for age and sex, DSM-IV prevalence in urban Latin American sites was four-fifths of that in Europe (standardised morbidity ratio 80 [95% CI 70-91]), but in China the prevalence was only half (56 [32-91] in rural China), and in India and rural Latin America a quarter or less of the European prevalence (18 [5-34] in rural India). 10/66 dementia prevalence was higher than that of DSM-IV dementia, and more consistent across sites, varying between 5.6% (95% CI 4.2-7.0) in rural China and 11.7% (10.3-13.1) in the Dominican Republic. The validity of the 847 of 1345 cases of 10/66 dementia not confirmed by DSM-IV was supported by high levels of associated disability (mean WHO Disability Assessment Schedule II score 33.7 [SD 28.6]).</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">As compared with the 10/66 dementia algorithm, the DSM-IV dementia criterion might underestimate dementia prevalence, especially in regions with low awareness of this emerging public-health problem.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Llibre Rodriguez</LastName><ForeName>Juan J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Facultad de Medicina Finley-Albarran, Medical University of Havana, Havana, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferri</LastName><ForeName>Cleusa P</ForeName><Initials>CP</Initials></Author><Author ValidYN="Y"><LastName>Acosta</LastName><ForeName>Daisy</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Guerra</LastName><ForeName>Mariella</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yueqin</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Jacob</LastName><ForeName>K S</ForeName><Initials>KS</Initials></Author><Author ValidYN="Y"><LastName>Krishnamoorthy</LastName><ForeName>E S</ForeName><Initials>ES</Initials></Author><Author ValidYN="Y"><LastName>Salas</LastName><ForeName>Aquiles</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Sosa</LastName><ForeName>Ana Luisa</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>Acosta</LastName><ForeName>Isaac</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Dewey</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Gaona</LastName><ForeName>Ciro</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Jotheeswaran</LastName><ForeName>A T</ForeName><Initials>AT</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Shuran</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Diana</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Guillermina</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>P Senthil</ForeName><Initials>PS</Initials></Author><Author ValidYN="Y"><LastName>Valhuerdi</LastName><ForeName>Adolfo</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Prince</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><CollectiveName>10/66 Dementia Research Group</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>066133</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>080002</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>GR08002</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>GR066133</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2008 Aug 9;372(9637):430-2. doi: 10.1016/S0140-6736(08)61003-X.</RefSource><PMID Version="1">18667232</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D017677" MajorTopicYN="N">Age Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019049" MajorTopicYN="N">Developed Countries</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003906" MajorTopicYN="N">Developing Countries</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007194" MajorTopicYN="N" Type="Geographic">India</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007843" MajorTopicYN="N" Type="Geographic">Latin America</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011159" MajorTopicYN="N">Population Surveillance</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017678" MajorTopicYN="N">Sex Distribution</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>7</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>7</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>8</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18657855</ArticleId><ArticleId IdType="pmc">PMC2854470</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(08)61002-8</ArticleId><ArticleId IdType="pii">S0140-6736(08)61002-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Prince MJ. The need for research on dementia in developing countries. Trop Med Int Health. 1997;2:993&#x2013;1000.</Citation><ArticleIdList><ArticleId IdType="pubmed">9357490</ArticleId></ArticleIdList></Reference><Reference><Citation>Hendrie HC, Osuntokun BO, Hall KS. Prevalence of Alzheimer's disease and dementia in two communities: Nigerian Africans and African Americans. Am J Psychiatry. 1995;152:1485&#x2013;1492.</Citation><ArticleIdList><ArticleId IdType="pubmed">7573588</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandra V, Ganguli M, Pandav R, Johnston J, Belle S, DeKosky ST. Prevalence of Alzheimer's disease and other dementias in rural India. The Indo-US study. Neurology. 1998;51:1000&#x2013;1008.</Citation><ArticleIdList><ArticleId IdType="pubmed">9781520</ArticleId></ArticleIdList></Reference><Reference><Citation>Hendrie HC, Ogunniyi A, Hall KS. Incidence of dementia and Alzheimer disease in 2 communities: Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana. JAMA. 2001;285:739&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pubmed">11176911</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandra V, Pandav R, Dodge HH. Incidence of Alzheimer's disease in a rural community in India: the Indo-US study. Neurology. 2001;57:985&#x2013;989.</Citation><ArticleIdList><ArticleId IdType="pubmed">11571321</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferri CP, Prince M, Brayne C. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366:2112&#x2013;2117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2850264</ArticleId><ArticleId IdType="pubmed">16360788</ArticleId></ArticleIdList></Reference><Reference><Citation>Molero AE, Pino-Ramirez G, Maestre GE. High prevalence of dementia in a Caribbean population. Neuroepidemiology. 2007;29:107&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17940342</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang ZX, Zahner GE, Roman GC. Socio-demographic variation of dementia subtypes in china: methodology and results of a prevalence study in Beijing, Chengdu, Shanghai, and Xian. Neuroepidemiology. 2006;27:177&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">17035714</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou DF, Wu CS, Qi H. Prevalence of dementia in rural China: impact of age, gender and education. Acta Neurol Scand. 2006;114:273&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pubmed">16942548</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacob KS, Kumar PS, Gayathri K, Abraham S, Prince MJ. The diagnosis of dementia in the community. Int Psychogeriatr. 2007;19:669&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pubmed">17433119</ArticleId></ArticleIdList></Reference><Reference><Citation>Scazufca M, Menezes PR, Vallada HP. High prevalence of dementia among older adults from poor socioeconomic backgrounds in Sao Paulo, Brazil. Int Psychogeriatr. 2008;20:394&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">17559708</ArticleId></ArticleIdList></Reference><Reference><Citation>Prince M, Acosta D, Chiu H, Scazufca M, Varghese M. Dementia diagnosis in developing countries: a cross-cultural validation study. Lancet. 2003;361:909&#x2013;917.</Citation><ArticleIdList><ArticleId IdType="pubmed">12648969</ArticleId></ArticleIdList></Reference><Reference><Citation>Prince M, Ferri CP, Acosta D. The protocols for the 10/66 Dementia Research Group population-based research programme. BMC Public Health. 2007;7:165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1965476</ArticleId><ArticleId IdType="pubmed">17659078</ArticleId></ArticleIdList></Reference><Reference><Citation>Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM. Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000;54:S4&#x2013;S9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10854354</ArticleId></ArticleIdList></Reference><Reference><Citation>Rehm J, Ustun TB, Saxena S. On the development and psychometric testing of the WHO screening instrument to assess disablement in the general population. Int J Methods Psychiatr Res. 2000;8:110&#x2013;122.</Citation></Reference><Reference><Citation>Copeland JRM, Dewey ME, Griffith-Jones HM. A computerised psychiatric diagnostic system and case nomenclature for elderly subjects: GMS and AGECAT. Psychol Med. 1986;16:89&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">3515380</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall KS, Hendrie HH, Brittain HM. The development of a dementia screeing interview in two distinct languages. Int J Methods Psychiatr Res. 1993;3:1&#x2013;28.</Citation></Reference><Reference><Citation>Ganguli M, Chandra V, Gilbey J. Cognitive test performance in a community-based non demented elderly sample in rural India: the Indo-US cross national dementia epidemiology study. Int Psychogeriatr. 1996;8:507&#x2013;524.</Citation><ArticleIdList><ArticleId IdType="pubmed">9147167</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association . Diagnostic and statistical manual of mental disorders. 4th edn. American Medical Association; Washington DC: 1994.</Citation></Reference><Reference><Citation>Prince M, Rodriguez JL, Noriega L. The 10/66 Dementia Research Group's fully operationalised DSM IV dementia computerized diagnostic algorithm, compared with the 10/66 dementia algorithm and a clinician diagnosis: a population validation study. BMC Public Health. 2008;8:219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2474864</ArticleId><ArticleId IdType="pubmed">18577205</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldereschi M, Amato MP, Nencini P. Cross-national interrater agreement on the clinical diagnostic criteria for dementia. WHO-PRA Age-Associated Dementia Working Group, WHO-Program for Research on Aging, Health of Elderly Program. Neurology. 1994;44:239&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">8309565</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Connor DW, Blessed G, Cooper B. Cross-national interrater reliability of dementia diagnosis in the elderly and factors associated with disagreement. Neurology. 1996;47:1194&#x2013;1199.</Citation><ArticleIdList><ArticleId IdType="pubmed">8909429</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539&#x2013;1558.</Citation><ArticleIdList><ArticleId IdType="pubmed">12111919</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie K, Kildea D, Robine JM. The relationship between age and the prevalence of senile dementia: a meta-analysis of recent data. Int J Epidemiol. 1992;21:763&#x2013;769.</Citation><ArticleIdList><ArticleId IdType="pubmed">1387871</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkins AJ, Hui SL, Ogunniyi A. Risk of mortality for dementia in a developing country: the Yoruba in Nigeria. Int J Geriatr Psychiatry. 2002;17:566&#x2013;573.</Citation><ArticleIdList><ArticleId IdType="pubmed">12112181</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitrini R, Caramelli P, Herrera E., Jr Mortality from dementia in a community-dwelling Brazilian population. Int J Geriatr Psychiatry. 2005;20:247&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">15717343</ArticleId></ArticleIdList></Reference><Reference><Citation>Prince M. Commentary: Two-phase surveys. A death is announced; no flowers please. Int J Epidemiol. 2003;32:1078&#x2013;1080.</Citation><ArticleIdList><ArticleId IdType="pubmed">14681278</ArticleId></ArticleIdList></Reference><Reference><Citation>The 10/66 Dementia Research Group Methodological issues in population-based research into dementia in developing countries. A position paper from the 10/66 Dementia Research Group. Int J Geriatr Psychiatry. 2000;15:21&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">10637401</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunn G, Pickles A, Tansella M, Vazquez-Barquero JL. Two-phase epidemiological surveys in psychiatric research. Br J Psychiatry. 1999;174:95&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">10211161</ArticleId></ArticleIdList></Reference><Reference><Citation>Erkinjuntti T, Ostbye T, Steenhuis R, Hachinski V. The effect of different diagnostic criteria on the prevalence of dementia. N Engl J Med. 1997;337:1667&#x2013;1674.</Citation><ArticleIdList><ArticleId IdType="pubmed">9385127</ArticleId></ArticleIdList></Reference><Reference><Citation>Reisberg B, Sartorius N. Diagnostic criteria in dementia. A comparison of current criteria, research challenges, and implications for DSM V and ICD 11. In: Sunderland T, Jeste DV, Baiyewu O, Sirovatka PJ, Regier D, editors. Diagnostic issues in dementia. Advancing the research agenda for DSM V. American Psychiatric Publishing; Arlington, Virginia: 2007. pp. 27&#x2013;50.</Citation></Reference><Reference><Citation>Shaji KS, Smitha K, Praveen Lal K, Prince M. Caregivers of patients with Alzheimer's Disease: a qualitative study from the Indian 10/66 Dementia Research Network. Int J Geriatr Psychiatry. 2002;18:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12497550</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel V, Prince M. Ageing and mental health in a developing country: who cares? Qualitative studies from Goa, India. Psychol Med. 2001;31:29&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">11200957</ArticleId></ArticleIdList></Reference><Reference><Citation>Prince M. Care arrangements for people with dementia in developing countries. Int J Geriatr Psychiatry. 2004;19:170&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">14758582</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferri CP, Ames D, Prince M. Behavioral and psychological symptoms of dementia in developing countries. Int Psychogeriatr. 2004;16:441&#x2013;459.</Citation><ArticleIdList><ArticleId IdType="pubmed">15715360</ArticleId></ArticleIdList></Reference><Reference><Citation>Prince M, Livingston G, Katona C. Mental health care for the elderly in low-income countries: a health systems approach. World Psychiatry. 2007;6:5&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1810377</ArticleId><ArticleId IdType="pubmed">17342213</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18667150</PMID><DateCompleted><Year>2008</Year><Month>08</Month><Day>26</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>59</Volume><Issue>2</Issue><PubDate><Year>2008</Year><Month>Jul</Month><Day>31</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks.</ArticleTitle><Pagination><StartPage>214</StartPage><EndPage>225</EndPage><MedlinePgn>214-25</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2008.06.008</ELocationID><Abstract><AbstractText>Alzheimer's disease is characterized by the deposition of senile plaques and progressive dementia. The molecular mechanisms that couple plaque deposition to neural system failure, however, are unknown. Using transgenic mouse models of AD together with multiphoton imaging, we measured neuronal calcium in individual neurites and spines in vivo using the genetically encoded calcium indicator Yellow Cameleon 3.6. Quantitative imaging revealed elevated [Ca(2+)]i (calcium overload) in approximately 20% of neurites in APP mice with cortical plaques, compared to less than 5% in wild-type mice, PS1 mutant mice, or young APP mice (animals without cortical plaques). Calcium overload depended on the existence and proximity to plaques. The downstream consequences included the loss of spinodendritic calcium compartmentalization (critical for synaptic integration) and a distortion of neuritic morphologies mediated, in part, by the phosphatase calcineurin. Together, these data demonstrate that senile plaques impair neuritic calcium homeostasis in vivo and result in the structural and functional disruption of neuronal networks.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kuchibhotla</LastName><ForeName>Kishore V</ForeName><Initials>KV</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Department of Neurology/Alzheimer's Disease Research Laboratory, 114 16th Street, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldman</LastName><ForeName>Samuel T</ForeName><Initials>ST</Initials></Author><Author ValidYN="Y"><LastName>Lattarulo</LastName><ForeName>Carli R</ForeName><Initials>CR</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Hai-Yan</ForeName><Initials>HY</Initials></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials></Author><Author ValidYN="Y"><LastName>Bacskai</LastName><ForeName>Brian J</ForeName><Initials>BJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR025645</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG008487</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 NS058075</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG08487</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EB000768</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS580752</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>EB000768</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002645" MajorTopicYN="N">Chickens</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003412" MajorTopicYN="N">Cricetulus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2008</Year><Month>4</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>8</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>8</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>7</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18667150</ArticleId><ArticleId IdType="mid">NIHMS63989</ArticleId><ArticleId IdType="pmc">PMC2578820</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2008.06.008</ArticleId><ArticleId IdType="pii">S0896-6273(08)00501-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Akbari Y, Hitt BD, Murphy MP, Dagher NN, Tseng BP, Green KN, Golde TE, LaFerla FM. Presenilin regulates capacitative calcium entry dependently and independently of gamma-secretase activity. Biochem Biophys Res Commun. 2004;322:1145&#x2013;1152.</Citation><ArticleIdList><ArticleId IdType="pubmed">15336962</ArticleId></ArticleIdList></Reference><Reference><Citation>Araya R, Eisenthal KB, Yuste R. Dendritic spines linearize the summation of excitatory potentials. Proceedings of the National Academy of Sciences. 2006;103:18799&#x2013;18804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1693742</ArticleId><ArticleId IdType="pubmed">17132736</ArticleId></ArticleIdList></Reference><Reference><Citation>Arispe N, Pollard HB, Rojas E. Giant multilevel cation channels formed by Alzheimer disease amyloid beta-protein [A beta P-(1&#x2013;40)] in bilayer membranes. Proc Natl Acad Sci U S A. 1993a;90:10573&#x2013;10577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47819</ArticleId><ArticleId IdType="pubmed">7504270</ArticleId></ArticleIdList></Reference><Reference><Citation>Arispe N, Rojas E, Pollard HB. Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc Natl Acad Sci U S A. 1993b;90:567&#x2013;571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC45704</ArticleId><ArticleId IdType="pubmed">8380642</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacskai BJ, Klunk WE, Mathis CA, Hyman BT. Imaging amyloidbeta deposits in vivo. J Cereb Blood Flow Metab. 2002;22:1035&#x2013;1041.</Citation><ArticleIdList><ArticleId IdType="pubmed">12218409</ArticleId></ArticleIdList></Reference><Reference><Citation>Behl C, Davis JB, Lesley R, Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell. 1994;77:817&#x2013;827.</Citation><ArticleIdList><ArticleId IdType="pubmed">8004671</ArticleId></ArticleIdList></Reference><Reference><Citation>Berezovska O, Ramdya P, Skoch J, Wolfe MS, Bacskai BJ, Hyman BT. Amyloid precursor protein associates with a nicastrin-dependent docking site on the presenilin 1-gamma-secretase complex in cells demonstrated by fluorescence lifetime imaging. J Neurosci. 2003;23:4560&#x2013;4566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740808</ArticleId><ArticleId IdType="pubmed">12805296</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, Jenkins NA, Copeland NG, Price DL, Sisodia SS. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron. 1997;19:939&#x2013;945.</Citation><ArticleIdList><ArticleId IdType="pubmed">9354339</ArticleId></ArticleIdList></Reference><Reference><Citation>Brorson JR, Bindokas VP, Iwama T, Marcuccilli CJ, Chisholm JC, Miller RJ. The Ca2+ influx induced by beta-amyloid peptide 25&#x2013;35 in cultured hippocampal neurons results from network excitation. J Neurobiol. 1995;26:325&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">7775966</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter AG, Soler-Llavina GJ, Sabatini BL. Timing and location of synaptic inputs determine modes of subthreshold integration in striatal medium spiny neurons. J Neurosci. 2007;27:8967&#x2013;8977.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672187</ArticleId><ArticleId IdType="pubmed">17699678</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan SL, Mayne M, Holden CP, Geiger JD, Mattson MP. Presenilin-1 mutations increase levels of ryanodine receptors and calcium release in PC12 cells and cortical neurons. J Biol Chem. 2000;275:18195&#x2013;18200.</Citation><ArticleIdList><ArticleId IdType="pubmed">10764737</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox CL, Denk W, Tank DW, Svoboda K. Action potentials reliably invade axonal arbors of rat neocortical neurons. Proc Natl Acad Sci U S A. 2000;97:9724&#x2013;9728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16932</ArticleId><ArticleId IdType="pubmed">10931955</ArticleId></ArticleIdList></Reference><Reference><Citation>Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem. 2005;280:17294&#x2013;17300.</Citation><ArticleIdList><ArticleId IdType="pubmed">15722360</ArticleId></ArticleIdList></Reference><Reference><Citation>Dineley KT, Hogan D, Zhang WR, Taglialatela G. Acute inhibition of calcineurin restores associative learning and memory in Tg2576 APP transgenic mice. Neurobiol Learn Mem. 2007;88:217&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2031869</ArticleId><ArticleId IdType="pubmed">17521929</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekinci FJ, Malik KU, Shea TB. Activation of the L voltage-sensitive calcium channel by mitogen-activated protein (MAP) kinase following exposure of neuronal cells to beta-amyloid. MAP kinase mediates beta-amyloid-induced neurodegeneration. J Biol Chem. 1999;274:30322&#x2013;30327.</Citation><ArticleIdList><ArticleId IdType="pubmed">10514528</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Alloza M, Robbins EM, Zhang-Nunes SX, Purcell SM, Betensky RA, Raju S, Prada C, Greenberg SM, Bacskai BJ, Frosch MP. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis. 2006;24:516&#x2013;524.</Citation><ArticleIdList><ArticleId IdType="pubmed">17029828</ArticleId></ArticleIdList></Reference><Reference><Citation>Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem. 1985;260:3440&#x2013;3450.</Citation><ArticleIdList><ArticleId IdType="pubmed">3838314</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Fu W, Sopher BL, Miller MW, Ware CB, Martin GM, Mattson MP. Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. Nat Med. 1999a;5:101&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">9883847</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Sebastian L, Sopher BL, Miller MW, Ware CB, Martin GM, Mattson MP. Increased vulnerability of hippocampal neurons from presenilin-1 mutant knock-in mice to amyloid beta-peptide toxicity: central roles of superoxide production and caspase activation. J Neurochem. 1999b;72:1019&#x2013;1029.</Citation><ArticleIdList><ArticleId IdType="pubmed">10037473</ArticleId></ArticleIdList></Reference><Reference><Citation>Hara MR, Snyder SH. Cell signaling and neuronal death. Annu Rev Pharmacol Toxicol. 2007;47:117&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pubmed">16879082</ArticleId></ArticleIdList></Reference><Reference><Citation>Helmchen F, Imoto K, Sakmann B. Ca2+ buffering and action potentialevoked Ca2+ signaling in dendrites of pyramidal neurons. Biophys J. 1996;70:1069&#x2013;1081.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1225009</ArticleId><ArticleId IdType="pubmed">8789126</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, Malinow R. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron. 2006;52:831&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850952</ArticleId><ArticleId IdType="pubmed">17145504</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng. 2001;17:157&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">11337275</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy MB, Beale HC, Carlisle HJ, Washburn LR. Integration of biochemical signalling in spines. Nat Rev Neurosci. 2005;6:423.</Citation><ArticleIdList><ArticleId IdType="pubmed">15928715</ArticleId></ArticleIdList></Reference><Reference><Citation>Khachaturian ZS. Calcium hypothesis of Alzheimer's disease and brain aging. Ann N Y Acad Sci. 1994;747:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">7847664</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Bacskai BJ, Mathis CA, Kajdasz ST, McLellan ME, Frosch MP, Debnath ML, Holt DP, Wang Y, Hyman BT. Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol. 2002;61:797&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="pubmed">12230326</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM. Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat Rev Neurosci. 2002;3:862&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">12415294</ArticleId></ArticleIdList></Reference><Reference><Citation>Leissring MA, Akbari Y, Fanger CM, Cahalan MD, Mattson MP, LaFerla FM. Capacitative calcium entry deficits and elevated luminal calcium content in mutant presenilin-1 knockin mice. J Cell Biol. 2000;149:793&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2174559</ArticleId><ArticleId IdType="pubmed">10811821</ArticleId></ArticleIdList></Reference><Reference><Citation>MacManus A, Ramsden M, Murray M, Henderson Z, Pearson HA, Campbell VA. Enhancement of (45)Ca(2+) influx and voltage-dependent Ca(2+) channel activity by beta-amyloid-(1&#x2013;40) in rat cortical synaptosomes and cultured cortical neurons. Modulation by the proinflammatory cytokine interleukin-1beta. J Biol Chem. 2000;275:4713&#x2013;4718.</Citation><ArticleIdList><ArticleId IdType="pubmed">10671502</ArticleId></ArticleIdList></Reference><Reference><Citation>Malenka RC, Bear MF. LTP and LTD: an embarrassment of riches. Neuron. 2004;44:5&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450156</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP. Pathways towards and away from Alzheimer's disease. Nature. 2004;430:631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091392</ArticleId><ArticleId IdType="pubmed">15295589</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP. Calcium and neurodegeneration. Aging Cell. 2007;6:337&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pubmed">17328689</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Barger SW, Cheng B, Lieberburg I, Smith-Swintosky VL, Rydel RE. beta-Amyloid precursor protein metabolites and loss of neuronal Ca2+ homeostasis in Alzheimer's disease. Trends Neurosci. 1993;16:409&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">7504356</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE. beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci. 1992;12:376&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6575616</ArticleId><ArticleId IdType="pubmed">1346802</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature. 2008;451:720&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3264491</ArticleId><ArticleId IdType="pubmed">18256671</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulkey RM, Endo S, Shenolikar S, Malenka RC. Involvement of a calcineurin/inhibitor-1 phosphatase cascade in hippocampal long-term depression. Nature. 1994;369:486&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">7515479</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai T, Yamada S, Tominaga T, Ichikawa M, Miyawaki A. Expanded dynamic range of fluorescent indicators for Ca(2+) by circularly permuted yellow fluorescent proteins. Proc Natl Acad Sci U S A. 2004;101:10554&#x2013;10559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC490022</ArticleId><ArticleId IdType="pubmed">15247428</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollard HB, Rojas E, Arispe N. A new hypothesis for the mechanism of amyloid toxicity, based on the calcium channel activity of amyloid beta protein (A beta P) in phospholipid bilayer membranes. Ann N Y Acad Sci. 1993;695:165&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">8239277</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabatini BL, Oertner TG, Svoboda K. The life cycle of Ca(2+) ions in dendritic spines. Neuron. 2002;33:439&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">11832230</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007;27:2866&#x2013;2875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672572</ArticleId><ArticleId IdType="pubmed">17360908</ArticleId></ArticleIdList></Reference><Reference><Citation>Simakova O, Arispe NJ. Early and late cytotoxic effects of external application of the Alzheimer's Abeta result from the initial formation and function of Abeta ion channels. Biochemistry. 2006;45:5907&#x2013;5915.</Citation><ArticleIdList><ArticleId IdType="pubmed">16669633</ArticleId></ArticleIdList></Reference><Reference><Citation>Skoch J, Hickey GA, Kajdasz ST, Hyman BT, Bacskai BJ. In vivo imaging of amyloid-beta deposits in mouse brain with multiphoton microscopy. Methods Mol Biol. 2005;299:349&#x2013;363.</Citation><ArticleIdList><ArticleId IdType="pubmed">15980616</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith IF, Green KN, LaFerla FM. Calcium dysregulation in Alzheimer's disease: recent advances gained from genetically modified animals. Cell Calcium. 2005a;38:427&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pubmed">16125228</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith IF, Hitt B, Green KN, Oddo S, LaFerla FM. Enhanced caffeine-induced Ca2+ release in the 3xTg-AD mouse model of Alzheimer's disease. J Neurochem. 2005b;94:1711&#x2013;1718.</Citation><ArticleIdList><ArticleId IdType="pubmed">16156741</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, Greengard P. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci. 2005;8:1051&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">16025111</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires TL, Meyer-Luehmann M, Stern EA, McLean PJ, Skoch J, Nguyen PT, Bacskai BJ, Hyman BT. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci. 2005;25:7278&#x2013;7287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1820616</ArticleId><ArticleId IdType="pubmed">16079410</ArticleId></ArticleIdList></Reference><Reference><Citation>Stutzmann GE, Caccamo A, LaFerla FM, Parker I. Dysregulated IP3 signaling in cortical neurons of knock-in mice expressing an Alzheimer's-linked mutation in presenilin1 results in exaggerated Ca2+ signals and altered membrane excitability. J Neurosci. 2004;24:508&#x2013;513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729995</ArticleId><ArticleId IdType="pubmed">14724250</ArticleId></ArticleIdList></Reference><Reference><Citation>Stutzmann GE, Smith I, Caccamo A, Oddo S, LaFerla FM, Parker I. Enhanced Ryanodine Receptor Recruitment Contributes to Ca2+ Disruptions in Young, Adult, and Aged Alzheimer's Disease Mice. J. Neurosci. 2006;26:5180&#x2013;5189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674246</ArticleId><ArticleId IdType="pubmed">16687509</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka K, Khiroug L, Santamaria F, Doi T, Ogasawara H, Ellis-Davies GC, Kawato M, Augustine GJ. Ca2+ requirements for cerebellar long-term synaptic depression: role for a postsynaptic leaky integrator. Neuron. 2007;54:787&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">17553426</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu H, Nelson O, Bezprozvanny A, Wang Z, Lee SF, Hao YH, Serneels L, De Strooper B, Yu G, Bezprozvanny I. Presenilins form ER Ca2+ leak channels, a function disrupted by familial Alzheimer's disease-linked mutations. Cell. 2006;126:981&#x2013;993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3241869</ArticleId><ArticleId IdType="pubmed">16959576</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen Z, Guirland C, Ming GL, Zheng JQ. A CaMKII/calcineurin switch controls the direction of Ca(2+)-dependent growth cone guidance. Neuron. 2004;43:835&#x2013;846.</Citation><ArticleIdList><ArticleId IdType="pubmed">15363394</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature. 1996;382:685&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pubmed">8751438</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo AS, Cheng I, Chung S, Grenfell TZ, Lee H, Pack-Chung E, Handler M, Shen J, Xia W, Tesco G, et al. Presenilin-mediated modulation of capacitative calcium entry. Neuron. 2000;27:561&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">11055438</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan J, Yankner BA. Apoptosis in the nervous system. Nature. 2000;407:802&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pubmed">11048732</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng LH, Xu L, Rensing NR, Sinatra PM, Rothman SM, Wong M. Kainate seizures cause acute dendritic injury and actin depolymerization in vivo. J Neurosci. 2007;27:11604&#x2013;11613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3934634</ArticleId><ArticleId IdType="pubmed">17959803</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18667232</PMID><DateCompleted><Year>2008</Year><Month>08</Month><Day>19</Day></DateCompleted><DateRevised><Year>2015</Year><Month>06</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-547X</ISSN><JournalIssue CitedMedium="Internet"><Volume>372</Volume><Issue>9637</Issue><PubDate><Year>2008</Year><Month>Aug</Month><Day>09</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>The rising tide of dementia worldwide.</ArticleTitle><Pagination><StartPage>430</StartPage><EndPage>432</EndPage><MedlinePgn>430-2</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(08)61003-X</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Larson</LastName><ForeName>Eric B</ForeName><Initials>EB</Initials><AffiliationInfo><Affiliation>Group Health Center for Health Studies, Seattle, WA 98101, USA. larson.e@ghc.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langa</LastName><ForeName>Kenneth M</ForeName><Initials>KM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>07</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Lancet. 2008 Aug 9;372(9637):464-74. doi: 10.1016/S0140-6736(08)61002-8.</RefSource><PMID Version="1">18657855</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="Y">Global Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012959" MajorTopicYN="N">Socioeconomic Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>8</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>8</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18667232</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(08)61003-X</ArticleId><ArticleId IdType="pii">S0140-6736(08)61003-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18669512</PMID><DateCompleted><Year>2008</Year><Month>10</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>131</Volume><Issue>Pt 9</Issue><PubDate><Year>2008</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Ventricular enlargement as a possible measure of Alzheimer's disease progression validated using the Alzheimer's disease neuroimaging initiative database.</ArticleTitle><Pagination><StartPage>2443</StartPage><EndPage>2454</EndPage><MedlinePgn>2443-54</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awn146</ELocationID><Abstract><AbstractText>Ventricular enlargement may be an objective and sensitive measure of neuropathological change associated with mild cognitive impairment (MCI) and Alzheimer's disease (AD), suitable to assess disease progression for multi-centre studies. This study compared (i) ventricular enlargement after six months in subjects with MCI, AD and normal elderly controls (NEC) in a multi-centre study, (ii) volumetric and cognitive changes between Apolipoprotein E genotypes, (iii) ventricular enlargement in subjects who progressed from MCI to AD, and (iv) sample sizes for multi-centre MCI and AD studies based on measures of ventricular enlargement. Three dimensional T(1)-weighted MRI and cognitive measures were acquired from 504 subjects (NEC n = 152, MCI n = 247 and AD n = 105) participating in the multi-centre Alzheimer's Disease Neuroimaging Initiative. Cerebral ventricular volume was quantified at baseline and after six months using semi-automated software. For the primary analysis of ventricle and neurocognitive measures, between group differences were evaluated using an analysis of covariance, and repeated measures t-tests were used for within group comparisons. For secondary analyses, all groups were dichotomized for Apolipoprotein E genotype based on the presence of an epsilon 4 polymorphism. In addition, the MCI group was dichotomized into those individuals who progressed to a clinical diagnosis of AD, and those subjects that remained stable with MCI after six months. Group differences on neurocognitive and ventricle measures were evaluated by independent t-tests. General sample size calculations were computed for all groups derived from ventricle measurements and neurocognitive scores. The AD group had greater ventricular enlargement compared to both subjects with MCI (P = 0.0004) and NEC (P &lt; 0.0001), and subjects with MCI had a greater rate of ventricular enlargement compared to NEC (P = 0.0001). MCI subjects that progressed to clinical AD after six months had greater ventricular enlargement than stable MCI subjects (P = 0.0270). Ventricular enlargement was different between Apolipoprotein E genotypes within the AD group (P = 0.010). The number of subjects required to demonstrate a 20% change in ventricular enlargement was substantially lower than that required to demonstrate a 20% change in cognitive scores. Ventricular enlargement represents a feasible short-term marker of disease progression in subjects with MCI and subjects with AD for multi-centre studies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nestor</LastName><ForeName>Sean M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Medical Biophysics, Centre for Functional and Metabolic Mapping, Robarts Research Institute, University of Western Ontario, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rupsingh</LastName><ForeName>Raul</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Borrie</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Accomazzi</LastName><ForeName>Vittorio</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Wells</LastName><ForeName>Jennie L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Fogarty</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Bartha</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><CollectiveName>Alzheimer's Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>07</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002552" MajorTopicYN="N">Cerebral Ventricles</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004108" MajorTopicYN="N">Dilatation, Pathologic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015588" MajorTopicYN="N">Observer Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011873" MajorTopicYN="N">Radiology Information Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>8</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>10</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>8</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18669512</ArticleId><ArticleId IdType="pmc">PMC2724905</ArticleId><ArticleId IdType="doi">10.1093/brain/awn146</ArticleId><ArticleId IdType="pii">awn146</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Accomazzi V, Lazarowich R, Barlow CJ, Davey B inventors; Cedara Software Corp., assignee. 2005. Feb 10, Image region segmentation system and method. US Patent Application 20050031202.</Citation></Reference><Reference><Citation>Bigler ED, Lowry CM, Anderson CV, Johnson SC, Terry J, Steed M. Dementia, quantitative neuroimaging, and apolipoprotein E genotype. American Journal of Neuroradiology. 2000;21:1857&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7974277</ArticleId><ArticleId IdType="pubmed">11110538</ArticleId></ArticleIdList></Reference><Reference><Citation>Bizzarro A, Marra C, Acciarri A, Valenza A, Tiziano FD, Brahe C, et al. Apolipoprotein E &#x3b5;4 allele differentiates the clinical response to donepezil in Alzheimer's disease. Dementia &amp; Geriatric Cognitive Disorders. 2005;20:254&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">16103669</ArticleId></ArticleIdList></Reference><Reference><Citation>Blesa R, Aguilar M, Casanova JP, Boada M, Martinez S, Alom J, et al. Relationship between the efficacy of rivastigmine and apolipoprotein E (&#x3b5;4) in patients with mild to moderately severe Alzheimer disease. Alzheimer Disease &amp; Associated Disorders. 2006;20:248&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">17132969</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Morphological criteria for the recognition of Alzheimer's disease and the distribution pattern of cortical changes related to this disorder. Neurobiol Aging. 1994;15:355&#x2013;6. 379&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">7936061</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley KM, Bydder GM, Budge MM, Hajnal JV, White SJ, Ripley BD, et al. Serial brain MRI at 3-6 month intervals as a surrogate marker for Alzheimer's disease. Br J Radiol. 2002;75:506&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">12124237</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmichael OT, Kuller LH, Lopez OL, Thompson PM, Dutton RA, Lu A, et al. Ventricular volume and dementia progression in the cardiovascular health study. Neurobiol Aging. 2007;28:389&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2866509</ArticleId><ArticleId IdType="pubmed">16504345</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherbuin N, Leach LS, Christensen H, Anstey KJ. Neuroimaging and APOE genotype: A systematic qualitative review. Dement Geriatr Cogn Disord. 2007;24:348&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">17911980</ArticleId></ArticleIdList></Reference><Reference><Citation>Chetelat G, Baron JC. Early diagnosis of Alzheimer's disease: Contribution of structural neuroimaging. Neuroimage. 2003;18:525&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">12595205</ArticleId></ArticleIdList></Reference><Reference><Citation>ADNI: Alzheimer's Disease Neuroimaging Initiative. Research [Internet] 2008 [cited 2008 June]. Available from:  http://www.loni.ucla.edu/ADNI/Research/</Citation></Reference><Reference><Citation>den Heijer T, Oudkerk M, Launer LJ, van Duijn CM, Hofman A, Breteler MM. Hippocampal, amygdalar, and global brain atrophy in different apolipoprotein E genotypes. Neurology. 2002;59:746&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12221169</ArticleId></ArticleIdList></Reference><Reference><Citation>Devanand DP, Pradhaban G, Liu X, Khandji A, De Santi S, Segal S, et al. Hippocampal and entorhinal atrophy in mild cognitive impairment: Prediction of Alzheimer disease. Neurology. 2007;68:828&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">17353470</ArticleId></ArticleIdList></Reference><Reference><Citation>Duarte A, Hayasaka S, Du A, Schuff N, Jahng GH, Kramer J, et al. Volumetric correlates of memory and executive function in normal elderly, mild cognitive impairment and Alzheimer's disease. Neurosci Lett. 2006;406:60&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1779764</ArticleId><ArticleId IdType="pubmed">16904823</ArticleId></ArticleIdList></Reference><Reference><Citation>Farlow M, Lane R, Kudaravalli S, He Y. Differential qualitative responses to rivastigmine in APOE &#x3b5;4 carriers and noncarriers. Pharmacogenomics Journal. 2004;4:332&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">15289797</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrarini L, Palm WM, Olofsen H, van Buchem MA, Reiber JH, Admiraal-Behloul F. Shape differences of the brain ventricles in Alzheimer's disease. Neuroimage. 2006;32:1060&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16839779</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, Sun S, Taylor C, Ward CP, Gamst AC, Petersen RC, et al. Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment. Neurology. 2008;70:191&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">18195264</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox NC, Freeborough PA. Brain atrophy progression measured from registered serial MRI: Validation and application to Alzheimer's disease. Journal of Magnetic Resonance Imaging. 1997;7:1069&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">9400851</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox NC, Cousens S, Scahill R, Harvey RJ, Rossor MN. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: Power calculations and estimates of sample size to detect treatment effects. Arch Neurol. 2000;57:339&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">10714659</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, et al. AN1792(QS-21)-201 Study. Effects of abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology. 2005;64:1563&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883317</ArticleId></ArticleIdList></Reference><Reference><Citation>Frankfort SV, Appels BA, de Boer A, Tulner LR, van Campen JP, Koks CH, et al. Identification of responders and reactive domains to rivastigmine in Alzheimer's disease. Pharmacoepidemiology &amp; Drug Safety. 2007;16:545&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">17109476</ArticleId></ArticleIdList></Reference><Reference><Citation>Giesel FL, Hahn HK, Thomann PA, Widjaja E, Wignall E, von Tengg-Kobligk H, et al. Temporal horn index and volume of medial temporal lobe atrophy using a new semiautomated method for rapid and precise assessment. Am J Neuroradiol. 2006;27:1454&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7977513</ArticleId><ArticleId IdType="pubmed">16908557</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Petersen RC, Xu YC, Waring SC, O&#x2019;Brien PC, Tangalos EG, et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology. 1997;49:786&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730601</ArticleId><ArticleId IdType="pubmed">9305341</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Petersen RC, Xu YC, O&#x2019;Brien PC, Waring SC, Tangalos EG, et al. Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer's disease. Ann Neurol. 1998;43:303&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2752747</ArticleId><ArticleId IdType="pubmed">9506546</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Shiung MM, Gunter JL, O&#x2019;Brien PC, Weigand SD, Knopman DS, et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology. 2004;62:591&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730165</ArticleId><ArticleId IdType="pubmed">14981176</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Shiung MM, Weigand SD, O&#x2019;Brien PC, Gunter JL, Boeve BF, et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology. 2005;65:1227&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2753547</ArticleId><ArticleId IdType="pubmed">16247049</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, et al. C11 PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain. 2008;131:665&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730157</ArticleId><ArticleId IdType="pubmed">18263627</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, et al. The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008;27:685&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2544629</ArticleId><ArticleId IdType="pubmed">18302232</ArticleId></ArticleIdList></Reference><Reference><Citation>Leinsinger G, Teipel S, Wismuller A, Born C, Meindl T, Flatz W, et al. Volumetric MRI for evaluation of regional pattern and progressin of neocortical degeneration in Alzheimer's disease. Radiologe. 2003;43:537&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">12955216</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352:2379&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">15829527</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridha BH, Anderson VM, Barnes J, Boyes RG, Price SL, Rossor MN, et al. Volumetric MRI and cognitive measures in Alzheimer disease. J Neurol. 2008;255:567&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">18274807</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">6496779</ArticleId></ArticleIdList></Reference><Reference><Citation>Saha PK, Udupa JK, Odhner D. Scale-based fuzzy connected image segmentation: Theory, algorithms, and validation. CVIU. 2000;77:145&#x2013;74.</Citation></Reference><Reference><Citation>Sanchez JL, Rodriguez M, Carro J. Influence of cognitive reserve on neuropsychologic functioning in Alzheimer's disease type sporadic in subjects of spanish nationality. Neuropsychiatry, Neuropsychology, &amp; Behavioral Neurology. 2002;15:113&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">12050474</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci. 1993;90:9649&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47627</ArticleId><ArticleId IdType="pubmed">8415756</ArticleId></ArticleIdList></Reference><Reference><Citation>Schott JM, Price SL, Frost C, Whitwell JL, Rossor MN, Fox NC. Measuring atrophy in Alzheimer disease: A serial MRI study over 6 and 12 months. Neurology. 2005;65:119&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">16009896</ArticleId></ArticleIdList></Reference><Reference><Citation>Silbert LC, Quinn JF, Moore MM, Corbridge E, Ball MJ, Murdoch G, et al. Changes in premorbid brain volume predict Alzheimer's disease pathology. Neurology. 2003;61:487&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">12939422</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SM, Zhang Y, Jenkinson M, Chen J, Matthews PM, Federico A, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage. 2002;17:479&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">12482100</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson PM, Hayashi KM, De Zubicaray GI, Janke AL, Rose SE, Semple J, et al. Mapping hippocampal and ventricular change in Alzheimer disease. Neuroimage. 2004;22:1754&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">15275931</ArticleId></ArticleIdList></Reference><Reference><Citation>van Belle G, Uhlmann RF, Hughes JP, Larson EB. Reliability of estimates of changes in mental status test performance in senile dementia of the Alzheimer type. J Clin Epidemiol. 1990;43:589&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">2348211</ArticleId></ArticleIdList></Reference><Reference><Citation>Vickers AJ. The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: A simulation study. BMC Medical Research Methodology. 2001;1:6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC34605</ArticleId><ArticleId IdType="pubmed">11459516</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser PJ, Scheltens P, Pelgrim E, Verhey FR. Dutch ENA-NL-01 Study G. Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer's disease patients. Dementia &amp; Geriatric Cognitive Disorders. 2005;19:126&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">15627759</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahlund LO, Julin P, Lannfelt L, Lindqvist J, Svensson L. Inheritance of the ApoE &#x3b5;4 allele increases the rate of brain atrophy in dementia patients. Dementia &amp; Geriatric Cognitive Disorders. 1999;10:262&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10364643</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter SD, Eliasziw M, Donner A. Sample size and optimal designs for reliability studies. Stat Med. 1998;17:101&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">9463853</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Chalk JB, Rose SE, de Zubicaray G, Cowin G, Galloway GJ, et al. MR image-based measurement of rates of change in volumes of brain structures. part II: Application to a study of Alzheimer's disease and normal aging. Magn Reson Imaging. 2002;20:41&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11973028</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial. galantamine international-1 study group. BMJ. 2000;321:1445&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27547</ArticleId><ArticleId IdType="pubmed">11110737</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18669654</PMID><DateCompleted><Year>2008</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>105</Volume><Issue>31</Issue><PubDate><Year>2008</Year><Month>Aug</Month><Day>05</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein.</ArticleTitle><Pagination><StartPage>10907</StartPage><EndPage>10912</EndPage><MedlinePgn>10907-12</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0802437105</ELocationID><Abstract><AbstractText>Increased alpha-synuclein gene (SNCA) dosage due to locus multiplication causes autosomal dominant Parkinson's disease (PD). Variation in SNCA expression may be critical in common, genetically complex PD but the underlying regulatory mechanism is unknown. We show that SNCA and the heme metabolism genes ALAS2, FECH, and BLVRB form a block of tightly correlated gene expression in 113 samples of human blood, where SNCA naturally abounds (validated P = 1.6 x 10(-11), 1.8 x 10(-10), and 6.6 x 10(-5)). Genetic complementation analysis revealed that these four genes are co-induced by the transcription factor GATA-1. GATA-1 specifically occupies a conserved region within SNCA intron-1 and directly induces a 6.9-fold increase in alpha-synuclein. Endogenous GATA-2 is highly expressed in substantia nigra vulnerable to PD, occupies intron-1, and modulates SNCA expression in dopaminergic cells. This critical link between GATA factors and SNCA may enable therapies designed to lower alpha-synuclein production.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scherzer</LastName><ForeName>Clemens R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Cambridge, MA 02139, USA. cscherzer@rics.bwh.harvard.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grass</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Zhixiang</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Pepivani</LastName><ForeName>Imelda</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Bin</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Eklund</LastName><ForeName>Aron C</ForeName><Initials>AC</Initials></Author><Author ValidYN="Y"><LastName>Ney</LastName><ForeName>Paul A</ForeName><Initials>PA</Initials></Author><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>Juliana</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>McGoldrick</LastName><ForeName>Meghan</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Mollenhauer</LastName><ForeName>Brit</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Bresnick</LastName><ForeName>Emery H</ForeName><Initials>EH</Initials></Author><Author ValidYN="Y"><LastName>Schlossmacher</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 NS038375</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK050107</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS38375</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 AG024816</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA084214</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DK50107</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK068634</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08AG024816</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 DK050107</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK68634</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>07</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050980">GATA Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.1.37</RegistryNumber><NameOfSubstance UI="D000624">5-Aminolevulinate Synthetase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.1.37</RegistryNumber><NameOfSubstance UI="C480079">ALAS2 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000624" MajorTopicYN="N">5-Aminolevulinate Synthetase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015152" MajorTopicYN="N">Blotting, Northern</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050980" MajorTopicYN="N">GATA Transcription Factors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005816" MajorTopicYN="N">Genetic Complementation Test</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046228" MajorTopicYN="N">Microarray Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Conflict of interest statement: C.R.S., E.H.B., and M.G.S. are listed as coinventors on a United States patent application related to the development of therapeutics for Parkinson's disease.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>8</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>9</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>8</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>2</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18669654</ArticleId><ArticleId IdType="pmc">PMC2504800</ArticleId><ArticleId IdType="doi">10.1073/pnas.0802437105</ArticleId><ArticleId IdType="pii">0802437105</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Singleton AB, et al. &#x3b1;-Synuclein locus triplication causes Parkinson's disease. Science. 2003;302:841.</Citation><ArticleIdList><ArticleId IdType="pubmed">14593171</ArticleId></ArticleIdList></Reference><Reference><Citation>Maraganore DM, et al. Collaborative analysis of &#x3b1;-synuclein gene promoter variability and Parkinson disease. J Am Med Assoc. 2006;296:661&#x2013;670.</Citation><ArticleIdList><ArticleId IdType="pubmed">16896109</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer M, et al. Comparison of kindreds with parkinsonism and &#x3b1;-synuclein genomic multiplications. Ann Neurol. 2004;55:174&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">14755720</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherzer CR, Feany MB. Yeast genetics targets lipids in Parkinson's disease. Trends Genet. 2004;20:273&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">15219388</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein C, Schlossmacher MG. The genetics of Parkinson disease: Implications for neurological care. Nat Clin Pract Neurol. 2006;2:136&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">16932540</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotz ME, Double K, Gerlach M, Youdim MB, Riederer P. The relevance of iron in the pathogenesis of Parkinson's disease. Ann NY Acad Sci. 2004;1012:193&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">15105267</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller DW, et al. &#x3b1;-Synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology. 2004;62:1835&#x2013;1838.</Citation><ArticleIdList><ArticleId IdType="pubmed">15159488</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiba-Falek O, Nussbaum RL. Effect of allelic variation at the NACP-Rep1 repeat upstream of the &#x3b1;-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system. Hum Mol Genet. 2001;10:3101&#x2013;3109.</Citation><ArticleIdList><ArticleId IdType="pubmed">11751692</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, et al. Dopamine-dependent neurotoxicity of &#x3b1;-synuclein: A mechanism for selective neurodegeneration in Parkinson disease. Nat Med. 2002;8:600&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pubmed">12042811</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastinen T, Hudson TJ. Cis-acting regulatory variation in the human genome. Science. 2004;306:647&#x2013;650.</Citation><ArticleIdList><ArticleId IdType="pubmed">15499010</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherzer CR, et al. Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci USA. 2007;104:955&#x2013;960.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1766335</ArticleId><ArticleId IdType="pubmed">17215369</ArticleId></ArticleIdList></Reference><Reference><Citation>Maroteaux L, Campanelli JT, Scheller RH. Synuclein: A neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci. 1988;8:2804&#x2013;2815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6569395</ArticleId><ArticleId IdType="pubmed">3411354</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Agnaf OM, et al. Detection of oligomeric forms of &#x3b1;-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J. 2006;20:419&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pubmed">16507759</ArticleId></ArticleIdList></Reference><Reference><Citation>Michell AW, Luheshi LM, Barker RA. Skin and platelet &#x3b1;-synuclein as peripheral biomarkers of Parkinson's disease. Neurosci Lett. 2005;381:294&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">15896487</ArticleId></ArticleIdList></Reference><Reference><Citation>Shintani N, et al. Expression and extracellular release of transferrin receptors during peripheral erythroid progenitor cell differentiation in liquid culture. Blood. 1994;83:1209&#x2013;1215.</Citation><ArticleIdList><ArticleId IdType="pubmed">8118025</ArticleId></ArticleIdList></Reference><Reference><Citation>Mollenhauer B, et al. Direct quantification of CSF &#x3b1;-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol. 2008 doi: 10.1016/j.expneurol.2008.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2008.06.004</ArticleId><ArticleId IdType="pubmed">18625222</ArticleId></ArticleIdList></Reference><Reference><Citation>Borovecki F, et al. Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. Proc Natl Acad Sci USA. 2005;102:11023&#x2013;11028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1182457</ArticleId><ArticleId IdType="pubmed">16043692</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitney AR, et al. Individuality and variation in gene expression patterns in human blood. Proc Natl Acad Sci USA. 2003;100:1896&#x2013;1901.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC149930</ArticleId><ArticleId IdType="pubmed">12578971</ArticleId></ArticleIdList></Reference><Reference><Citation>Surinya KH, Cox TC, May BK. Transcriptional regulation of the human erythroid 5-aminolevulinate synthase gene. Identification of promoter elements and role of regulatory proteins. J Biol Chem. 1997;272:26585&#x2013;26594.</Citation><ArticleIdList><ArticleId IdType="pubmed">9334239</ArticleId></ArticleIdList></Reference><Reference><Citation>Pal S, et al. Coregulator-dependent facilitation of chromatin occupancy by GATA-1. Proc Natl Acad Sci USA. 2004;101:980&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC327128</ArticleId><ArticleId IdType="pubmed">14715908</ArticleId></ArticleIdList></Reference><Reference><Citation>Taketani S, Mohri T, Hioki K, Tokunaga R, Kohno H. Structure and transcriptional regulation of the mouse ferrochelatase gene. Gene. 1999;227:117&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">10023040</ArticleId></ArticleIdList></Reference><Reference><Citation>Welch JJ, et al. Global regulation of erythroid gene expression by transcription factor GATA-1. Blood. 2004;104:3136&#x2013;3147.</Citation><ArticleIdList><ArticleId IdType="pubmed">15297311</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KD, et al. Friend of GATA-1-independent transcriptional repression: A novel mode of GATA-1 function. Blood. 2007;109:5230&#x2013;5233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1890840</ArticleId><ArticleId IdType="pubmed">17339418</ArticleId></ArticleIdList></Reference><Reference><Citation>Merika M, Orkin SH. DNA-binding specificity of GATA family transcription factors. Mol Cell Biol. 1993;13:3999&#x2013;4010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC359949</ArticleId><ArticleId IdType="pubmed">8321207</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko LJ, Engel JD. DNA-binding specificities of the GATA transcription factor family. Mol Cell Biol. 1993;13:4011&#x2013;4022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC359950</ArticleId><ArticleId IdType="pubmed">8321208</ArticleId></ArticleIdList></Reference><Reference><Citation>Bresnick EH, Johnson KD, Kim SI, Im H. Establishment and regulation of chromatin domains: Mechanistic insights from studies of hemoglobin synthesis. Prog Nucleic Acid Res Mol Biol. 2006;81:435&#x2013;471.</Citation><ArticleIdList><ArticleId IdType="pubmed">16891178</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KD, et al. Cooperative activities of hematopoietic regulators recruit RNA polymerase II to a tissue-specific chromatin domain. Proc Natl Acad Sci USA. 2002;99:11760&#x2013;11765.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC129342</ArticleId><ArticleId IdType="pubmed">12193659</ArticleId></ArticleIdList></Reference><Reference><Citation>Grass JA, et al. Distinct functions of dispersed GATA factor complexes at an endogenous gene locus. Mol Cell Biol. 2006;26:7056&#x2013;7067.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1592882</ArticleId><ArticleId IdType="pubmed">16980610</ArticleId></ArticleIdList></Reference><Reference><Citation>Martowicz ML, Grass JA, Boyer ME, Guend H, Bresnick EH. Dynamic GATA factor interplay at a multicomponent regulatory region of the GATA-2 locus. J Biol Chem. 2005;280:1724&#x2013;1732.</Citation><ArticleIdList><ArticleId IdType="pubmed">15494394</ArticleId></ArticleIdList></Reference><Reference><Citation>Grass JA, et al. GATA-1-dependent transcriptional repression of GATA-2 via disruption of positive autoregulation and domain-wide chromatin remodeling. Proc Natl Acad Sci USA. 2003;100:8811&#x2013;8816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC166395</ArticleId><ArticleId IdType="pubmed">12857954</ArticleId></ArticleIdList></Reference><Reference><Citation>Touchman JW, et al. Human and mouse &#x3b1;-synuclein genes: Comparative genomic sequence analysis and identification of a novel gene regulatory element. Genome Res. 2001;11:78&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC311023</ArticleId><ArticleId IdType="pubmed">11156617</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai FY, et al. An early haematopoietic defect in mice lacking the transcription factor GATA-2. Nature. 1994;371:221&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">8078582</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujiwara Y, Chang AN, Williams AM, Orkin SH. Functional overlap of GATA-1 and GATA-2 in primitive hematopoietic development. Blood. 2004;103:583&#x2013;585.</Citation><ArticleIdList><ArticleId IdType="pubmed">14504093</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss MJ, Keller G, Orkin SH. Novel insights into erythroid development revealed through in vitro differentiation of GATA-1 embryonic stem cells. Genes Dev. 1994;8:1184&#x2013;1197.</Citation><ArticleIdList><ArticleId IdType="pubmed">7926723</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsarovina K, et al. Essential role of Gata transcription factors in sympathetic neuron development. Development. 2004;131:4775&#x2013;4786.</Citation><ArticleIdList><ArticleId IdType="pubmed">15329349</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilodeau ML, Boulineau T, Greulich JD, Hullinger RL, Andrisani OM. Differential expression of sympathoadrenal lineage-determining genes and phenotypic markers in cultured primary neural crest cells. In Vitro Cell Dev Biol Anim. 2001;37:185&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">11370813</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardelli J, Thiesson D, Fujiwara Y, Tsai FY, Orkin SH. Expression and genetic interaction of transcription factors GATA-2 and GATA-3 during development of the mouse central nervous system. Dev Biol. 1999;210:305&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pubmed">10357893</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith JA, McGarr P, Gilleard JS. The Caenorhabditis elegans GATA factor elt-1 is essential for differentiation and maintenance of hypodermal seam cells and for normal locomotion. J Cell Sci. 2005;118:5709&#x2013;5719.</Citation><ArticleIdList><ArticleId IdType="pubmed">16303852</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb J, et al. A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell. 2003;114:323&#x2013;334.</Citation><ArticleIdList><ArticleId IdType="pubmed">12914697</ArticleId></ArticleIdList></Reference><Reference><Citation>Dekker J. Gene regulation in the third dimension. Science. 2008;319:1793&#x2013;1794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2666883</ArticleId><ArticleId IdType="pubmed">18369139</ArticleId></ArticleIdList></Reference><Reference><Citation>Pal S, et al. Neurokinin-B transcription in erythroid cells: Direct activation by the hematopoietic transcription factor GATA-1. J Biol Chem. 2004;279:31348&#x2013;31356.</Citation><ArticleIdList><ArticleId IdType="pubmed">15123623</ArticleId></ArticleIdList></Reference><Reference><Citation>Benchabane H, Wrana JL. GATA- and Smad1-dependent enhancers in the Smad7 gene differentially interpret bone morphogenetic protein concentrations. Mol Cell Biol. 2003;23:6646&#x2013;6661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC193708</ArticleId><ArticleId IdType="pubmed">12944489</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Xing G, Fraizer GC, Saunders GF. Transactivation of an intronic hematopoietic-specific enhancer of the human Wilms' tumor 1 gene by GATA-1 and c-Myb. J Biol Chem. 1997;272:29272&#x2013;29280.</Citation><ArticleIdList><ArticleId IdType="pubmed">9361007</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiba-Falek O, Kowalak JA, Smulson ME, Nussbaum RL. Regulation of &#x3b1;-synuclein expression by poly(ADP ribose) polymerase-1 (PARP-1) binding to the NACP-Rep1 polymorphic site upstream of the SNCA gene. Am J Hum Genet. 2005;76:478&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1196399</ArticleId><ArticleId IdType="pubmed">15672325</ArticleId></ArticleIdList></Reference><Reference><Citation>Goh SH, et al. The human reticulocyte transcriptome. Physiol Genomics. 2007;30:172&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">17405831</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakai M, et al. Expression of &#x3b1;-synuclein, a presynaptic protein implicated in Parkinson's disease, in erythropoietic lineage. Biochem Biophys Res Commun. 2007;358:104&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">17475220</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajioka RS, Phillips JD, Kushner JP. Biosynthesis of heme in mammals. Biochim Biophys Acta. 2006;1763:723&#x2013;736.</Citation><ArticleIdList><ArticleId IdType="pubmed">16839620</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedlich AL, Tanzi RE, Rogers JT. The 5&#x2032;-untranslated region of Parkinson's disease &#x3b1;-synuclein messengerRNA contains a predicted iron responsive element. Mol Psychiatry. 2007;12:222&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">17325711</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayor C, et al. VISTA: Visualizing global DNA sequence alignments of arbitrary length. Bioinformatics. 2000;16:1046&#x2013;1047.</Citation><ArticleIdList><ArticleId IdType="pubmed">11159318</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18669821</PMID><DateCompleted><Year>2008</Year><Month>09</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>321</Volume><Issue>5893</Issue><PubDate><Year>2008</Year><Month>Aug</Month><Day>29</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons.</ArticleTitle><Pagination><StartPage>1218</StartPage><EndPage>1221</EndPage><MedlinePgn>1218-21</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.1158799</ELocationID><Abstract><AbstractText>The generation of pluripotent stem cells from an individual patient would enable the large-scale production of the cell types affected by that patient's disease. These cells could in turn be used for disease modeling, drug discovery, and eventually autologous cell replacement therapies. Although recent studies have demonstrated the reprogramming of human fibroblasts to a pluripotent state, it remains unclear whether these induced pluripotent stem (iPS) cells can be produced directly from elderly patients with chronic disease. We have generated iPS cells from an 82-year-old woman diagnosed with a familial form of amyotrophic lateral sclerosis (ALS). These patient-specific iPS cells possess properties of embryonic stem cells and were successfully directed to differentiate into motor neurons, the cell type destroyed in ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dimos</LastName><ForeName>John T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Harvard Stem Cell Institute, Stowers Medical Institute, Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodolfa</LastName><ForeName>Kit T</ForeName><Initials>KT</Initials></Author><Author ValidYN="Y"><LastName>Niakan</LastName><ForeName>Kathy K</ForeName><Initials>KK</Initials></Author><Author ValidYN="Y"><LastName>Weisenthal</LastName><ForeName>Laurin M</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Mitsumoto</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Wendy</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Croft</LastName><ForeName>Gist F</ForeName><Initials>GF</Initials></Author><Author ValidYN="Y"><LastName>Saphier</LastName><ForeName>Genevieve</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Leibel</LastName><ForeName>Rudy</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Goland</LastName><ForeName>Robin</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Wichterle</LastName><ForeName>Hynek</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Henderson</LastName><ForeName>Christopher E</ForeName><Initials>CE</Initials></Author><Author ValidYN="Y"><LastName>Eggan</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>07</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2008 Aug 29;321(5893):1169-70. doi: 10.1126/science.1163475.</RefSource><PMID Version="1">18755965</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="Y">Cell Differentiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065150" MajorTopicYN="Y">Cellular Reprogramming</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053595" MajorTopicYN="N">Embryonic Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009457" MajorTopicYN="N">Neuroglia</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039904" MajorTopicYN="N">Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012190" MajorTopicYN="N">Retroviridae</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014161" MajorTopicYN="N">Transduction, Genetic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>8</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>9</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>8</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18669821</ArticleId><ArticleId IdType="doi">10.1126/science.1158799</ArticleId><ArticleId IdType="pii">1158799</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18695050</PMID><DateCompleted><Year>2008</Year><Month>11</Month><Day>18</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1538-3687</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>10</Issue><PubDate><Year>2008</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B.</ArticleTitle><Pagination><StartPage>1304</StartPage><EndPage>1309</EndPage><MedlinePgn>1304-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archneur.65.10.noc80013</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To compare carbon 11-labeled Pittsburgh Compound B ([11C]PiB) positron emission tomography (PET) findings in patients with and without Alzheimer disease lesions in frontal cortical biopsy specimens.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Cross-sectional study of [11C]PiB PET findings in patients with or without beta-amyloid (Abeta) aggregates in frontal cortical biopsy specimens.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Two university hospitals in Finland. Patients Ten patients who had undergone intraventricular pressure monitoring with a frontal cortical biopsy (evaluated for Abeta aggregates and hyperphosphorylated tau) for suspected normal-pressure hydrocephalus.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">[11C]PiB PET and evaluation for cognitive impairment using a battery of neuropsychological tests.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Immunohistochemical evaluation for Abeta aggregates and hyperphosphorylated tau in the frontal cortical biopsy specimen and [11C]PiB PET.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In patients with Abeta aggregates in the frontal cortical biopsy specimen, PET imaging revealed higher [11C]PiB uptake (P &lt; .05) in the frontal, parietal, and lateral temporal cortices and in the striatum as compared with the patients without frontal Abeta deposits.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our study supports the use of noninvasive [11C]PiB PET in the assessment of Abeta deposition in the brain. Large prospective studies are required to verify whether [11C]PiB PET will be a diagnostic aid, particularly in early Alzheimer disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Leinonen</LastName><ForeName>Ville</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Kuopio University Hospital, PO Box 1777, 70211 Kuopio, Finland. ville.leinonen@kuh.fi</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alafuzoff</LastName><ForeName>Irina</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Aalto</LastName><ForeName>Sargo</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Suotunen</LastName><ForeName>Timo</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Savolainen</LastName><ForeName>Sakari</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>N&#xe5;gren</LastName><ForeName>Kjell</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Tapiola</LastName><ForeName>Tero</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Pirttil&#xe4;</LastName><ForeName>Tuula</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Rinne</LastName><ForeName>Jaakko</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>J&#xe4;&#xe4;skel&#xe4;inen</LastName><ForeName>Juha E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Soininen</LastName><ForeName>Hilkka</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Rinne</LastName><ForeName>Juha O</ForeName><Initials>JO</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>08</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Arch Neurol. 2008 Oct;65(10):1281-3. doi: 10.1001/archneur.65.10.1281.</RefSource><PMID Version="1">18852340</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="Y">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001706" MajorTopicYN="N">Biopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="N">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006850" MajorTopicYN="N">Hydrocephalus, Normal Pressure</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019586" MajorTopicYN="N">Intracranial Hypertension</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="Y">Thiazoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>8</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>11</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>8</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18695050</ArticleId><ArticleId IdType="doi">10.1001/archneur.65.10.noc80013</ArticleId><ArticleId IdType="pii">65.10.noc80013</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18695053</PMID><DateCompleted><Year>2008</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3687</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>8</Issue><PubDate><Year>2008</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease.</ArticleTitle><Pagination><StartPage>1031</StartPage><EndPage>1038</EndPage><MedlinePgn>1031-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archneur.65.8.1031</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the safety, tolerability, and amyloid beta (Abeta) response to the gamma-secretase inhibitor LY450139 in Alzheimer disease.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Multicenter, randomized, double-blind, dose-escalation, placebo-controlled trial.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Community-based clinical research centers. Patients Fifty-one individuals with mild to moderate Alzheimer disease were randomized to receive placebo (n=15) or LY450139 (100 mg [n=22] or 140 mg [n=14]), with 43 completing the treatment phase. Intervention The LY450139 groups received 60 mg/d for 2 weeks, then 100 mg/d for 6 weeks, and then either 100 or 140 mg/d for 6 additional weeks.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Primary outcome measures were adverse events, plasma and cerebrospinal fluid Abeta levels, vital signs, electrocardiographic data, and laboratory safety test results. Secondary outcome measures included the Alzheimer's Disease Assessment Scale cognitive subscale and the Alzheimer's Disease Cooperative Study Activities of Daily Living Scale.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Group differences were seen in skin and subcutaneous tissue concerns (P=.05), including 3 possible drug rashes and 3 reports of hair color change in the treatment groups. There were 3 adverse event-related discontinuations, including 1 transient bowel obstruction. The plasma Abeta(40) concentration was reduced by 58.2% for the 100-mg group and 64.6% for the 140-mg group (P&lt;.001). No significant reduction was seen in cerebrospinal fluid Abeta levels. No group differences were seen in cognitive or functional measures.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">LY450139 was generally well tolerated at doses of up to 140 mg/d for 14 weeks, with several findings indicating the need for close clinical monitoring in future studies. Decreases in plasma Abeta concentrations were consistent with inhibition of gamma-secretase. Trial Registration clinicaltrials.gov Identifier: NCT00244322.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fleisher</LastName><ForeName>Adam S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>University of California, San Diego, La Jolla, CA 92037, USA. afleisher@ucsd.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raman</LastName><ForeName>Rema</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Siemers</LastName><ForeName>Eric R</ForeName><Initials>ER</Initials></Author><Author ValidYN="Y"><LastName>Becerra</LastName><ForeName>Lida</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Dean</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Galvin</LastName><ForeName>James E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Peskind</LastName><ForeName>Elaine R</ForeName><Initials>ER</Initials></Author><Author ValidYN="Y"><LastName>Quinn</LastName><ForeName>Joseph F</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Sherzai</LastName><ForeName>Abdullah</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Sowell</LastName><ForeName>B Brooke</ForeName><Initials>BB</Initials></Author><Author ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul S</ForeName><Initials>PS</Initials></Author><Author ValidYN="Y"><LastName>Thal</LastName><ForeName>Leon J</ForeName><Initials>LJ</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00244322</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UO1AG10483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001381">Azepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C484278">N2-((2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-L-alaninamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber><NameOfSubstance UI="D000409">Alanine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000647" MajorTopicYN="N">Amnesia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001381" MajorTopicYN="N">Azepines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007415" MajorTopicYN="N">Intestinal Obstruction</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Disclosure:</b> Dr. Siemers and Dr. Dean are employees of Eli Lilly, the manufacturer of the study drug. Eli Lilly and company provided all funding for this study. All study sites were subcontracted through the Alzheimer's Disease Cooperative Study at the University of California, San Diego, which held the primary contract with Eli Lilly. Dr. Farlow has received research grant funding support from Eli Lilly which was independent and unrelated to this trial. For all other authors there are no disclosures to be made of any personal financial support from, or equity positions in, manufacturers of drugs or products mentioned in the manuscript. All authors have agreed to conditions noted on the Author Disclosure Form. All of the authors have been instrumental in the interpretation of the data and its presentation in this paper. This manuscript has not been simultaneously submitted for publication to any other journal. There is no patient identifiable data presented in this manuscript. Written permission for publication has been obtained from all authors.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>8</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>9</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>8</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>5</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18695053</ArticleId><ArticleId IdType="mid">NIHMS106908</ArticleId><ArticleId IdType="pmc">PMC2682361</ArticleId><ArticleId IdType="doi">10.1001/archneur.65.8.1031</ArticleId><ArticleId IdType="pii">65/8/1031</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>May PC, Yang Z, Li WY, Hyslop PA, Siemers E, Boggs LN. Multi-compartmental pharmacodynamic assessment of the functional gamma-secretase inhibitor LY450139 in PDAPP transgenic mice and non-transgenic mice. Neurobiology of Aging. 2004;25(Supplement 2):S65.</Citation></Reference><Reference><Citation>Boggs LN, Fuson KS, Baez M, et al. Clusterin (Apo J) protects against in vitro amyloid-beta (1-40) neurotoxicity. J Neurochem. 1996;67(3):1324&#x2013;1327.</Citation><ArticleIdList><ArticleId IdType="pubmed">8752142</ArticleId></ArticleIdList></Reference><Reference><Citation>Siemers ER, Dean RA, Friedrich S, et al. Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. Clin Neuropharmacol. 2007 Nov-Dec;30(6):317&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">18090456</ArticleId></ArticleIdList></Reference><Reference><Citation>Ness DK, Boggs LN, Hepburn DL, et al. P2-053 Reduced [beta]-amyloid burden, increased C-99 concentrations and evaluation of neuropathology in the brains of PDAPP mice given LY450139 dihydrate daily by gavage for 5 months. Neurobiology of Aging. 2004;25(Supplement 2):S238&#x2013;S239.</Citation></Reference><Reference><Citation>Siemers E, Skinner M, Dean RA, et al. Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin Neuropharmacol. 2005;28(3):126&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">15965311</ArticleId></ArticleIdList></Reference><Reference><Citation>Siemers ER, Quinn JF, Kaye J, et al. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology. 2006;66(4):602&#x2013;604.</Citation><ArticleIdList><ArticleId IdType="pubmed">16505324</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartmann D, Tournoy J, Saftig P, Annaert W, De Strooper B. Implication of APP secretases in notch signaling. J Mol Neurosci. 2001;17(2):171&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">11816790</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohs RC. The Alzheimer's Disease Assessment Scale. Int Psychogeriatr. 1996;8(2):195&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">8994890</ArticleId></ArticleIdList></Reference><Reference><Citation>Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders. 1997;11(Suppl 2):33S&#x2013;39S.</Citation><ArticleIdList><ArticleId IdType="pubmed">9236950</ArticleId></ArticleIdList></Reference><Reference><Citation>R Development Core Team. R Foundation for Statistical Computing; Vienna, Austria: 2006. R: A language and environment for statistical computing.  http://www.R-project.org.</Citation></Reference><Reference><Citation>Wong GT, Manfra D, Poulet FM, et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem. 2004;279(13):12876&#x2013;12882. Epub 12004 Jan 12876.</Citation><ArticleIdList><ArticleId IdType="pubmed">14709552</ArticleId></ArticleIdList></Reference><Reference><Citation>Micchelli CA, Esler WP, Kimberly WT, et al. Gamma-secretase/presenilin inhibitors for Alzheimer's disease phenocopy Notch mutations in Drosophila. Faseb J. 2003;17(1):79&#x2013;81. Epub 2002 Nov 2001.</Citation><ArticleIdList><ArticleId IdType="pubmed">12424225</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanz TA, Karmilowicz MJ, Wood KM, et al. Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139. J Pharmacol Exp Ther Nov. 2006;319(2):924&#x2013;933.</Citation><ArticleIdList><ArticleId IdType="pubmed">16920992</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen LB, Stone JA, Plump A, et al. The gamma secretase inhibitor MK-0752 acutely and significantly reduces CSF Abeta40 concentrations in humans. Alzheimer's and Dementia. 2006;2(3):S79.</Citation></Reference><Reference><Citation>Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med. 2006;12(7):856&#x2013;861. Epub 2006 Jun 2025.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2983090</ArticleId><ArticleId IdType="pubmed">16799555</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18701698</PMID><DateCompleted><Year>2008</Year><Month>09</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>33</Issue><PubDate><Year>2008</Year><Month>Aug</Month><Day>13</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice.</ArticleTitle><Pagination><StartPage>8354</StartPage><EndPage>8360</EndPage><MedlinePgn>8354-60</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0616-08.2008</ELocationID><Abstract><AbstractText>Early microglial accumulation in Alzheimer's disease (AD) delays disease progression by promoting clearance of beta-amyloid (Abeta) before formation of senile plaques. However, persistent Abeta accumulation despite increasing microglial numbers suggests that the ability of microglia to clear Abeta may decrease with age and progression of AD pathology. To determine the effects of aging and Abeta deposition on microglial ability to clear Abeta, we used quantitative PCR to analyze gene expression in freshly isolated adult microglia from 1.5-, 3-, 8-, and 14-month-old transgenic PS1-APP mice, an established mouse model of AD, and from their nontransgenic littermates. We found that microglia from old PS1-APP mice, but not from younger mice, have a twofold to fivefold decrease in expression of the Abeta-binding scavenger receptors scavenger receptor A (SRA), CD36, and RAGE (receptor for advanced-glycosylation endproducts), and the Abeta-degrading enzymes insulysin, neprilysin, and MMP9, compared with their littermate controls. In contrast, PS1-APP microglia had a 2.5-fold increase in the proinflammatory cytokines IL-1beta (interleukin-1beta) and tumor necrosis factor alpha (TNFalpha), suggesting that there is an inverse correlation between cytokine production and Abeta clearance. In support of this possibility, we found that incubation of cultured N9 mouse microglia with TNFalpha decreased the expression of SRA and CD36 and reduced Abeta uptake. Our data indicate that, although early microglial recruitment promotes Abeta clearance and is neuroprotective in AD, as disease progresses, proinflammatory cytokines produced in response to Abeta deposition downregulate genes involved in Abeta clearance and promote Abeta accumulation, therefore contributing to neurodegeneration. Antiinflammatory therapy for AD should take this dichotomous microglial role into consideration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hickman</LastName><ForeName>Suzanne E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy, and Immunology, and Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allison</LastName><ForeName>Elizabeth K</ForeName><Initials>EK</Initials></Author><Author ValidYN="Y"><LastName>El Khoury</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS059005</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>8</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>9</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>8</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>2</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18701698</ArticleId><ArticleId IdType="mid">NIHMS65138</ArticleId><ArticleId IdType="pmc">PMC2597474</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0616-08.2008</ArticleId><ArticleId IdType="pii">28/33/8354</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alarc&#xf3;n R, Fuenzalida C, Santib&#xe1;&#xf1;ez M, von Bernhardi R. Expression of scavenger receptors in glial cells. Comparing the adhesion of astrocytes and microglia from neonatal rats to surface-bound beta-amyloid. J Biol Chem. 2005;280:30406&#x2013;30415.</Citation><ArticleIdList><ArticleId IdType="pubmed">15987691</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, Jenkins NA, Copeland NG, Price DL, Sisodia SS. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron. 1997;19:939&#x2013;945.</Citation><ArticleIdList><ArticleId IdType="pubmed">9354339</ArticleId></ArticleIdList></Reference><Reference><Citation>Coraci IS, Husemann J, Berman JW, Hulette C, Dufour JH, Campanella GK, Luster AD, Silverstein SC, El-Khoury JB. CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen species in response to beta-amyloid fibrils. Am J Pathol. 2002;160:101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1867121</ArticleId><ArticleId IdType="pubmed">11786404</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW. Microglia in Alzheimer's disease and transgenic models. How close the fit? Am J Pathol. 1999;154:1627&#x2013;1631.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866628</ArticleId><ArticleId IdType="pubmed">10362785</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Farlo J, Davies P, Crystal H, Fuld P, Yen SH. Alzheimer's disease. A double-labeling immunohistochemical study of senile plaques. Am J Pathol. 1988;132:86&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1880629</ArticleId><ArticleId IdType="pubmed">2456021</ArticleId></ArticleIdList></Reference><Reference><Citation>El Khoury J, Hickman SE, Thomas CA, Cao L, Silverstein SC, Loike JD. Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils. Nature. 1996;382:716&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pubmed">8751442</ArticleId></ArticleIdList></Reference><Reference><Citation>El Khoury J, Hickman SE, Thomas CA, Loike JD, Silverstein SC. Microglia, scavenger receptors, and the pathogenesis of Alzheimer's disease. Neurobiol Aging. 1998;19:S81&#x2013;S84.</Citation><ArticleIdList><ArticleId IdType="pubmed">9562474</ArticleId></ArticleIdList></Reference><Reference><Citation>El Khoury J, Toft M, Hickman SE, Means TK, Terada K, Geula C, Luster AD. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med. 2007;13:432&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pubmed">17351623</ArticleId></ArticleIdList></Reference><Reference><Citation>El Khoury JB, Moore KJ, Means TK, Leung J, Terada K, Toft M, Freeman MW, Luster AD. CD36 mediates the innate host response to beta-amyloid. J Exp Med. 2003;197:1657&#x2013;1666.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2193948</ArticleId><ArticleId IdType="pubmed">12796468</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiala M, Lin J, Ringman J, Kermani-Arab V, Tsao G, Patel A, Lossinsky AS, Graves MC, Gustavson A, Sayre J, Sofroni E, Suarez T, Chiappelli F, Bernard G. Ineffective phagocytosis of amyloid-beta by macrophages of Alzheimer's disease patients. J Alzheimers Dis. 2005;7:221&#x2013;232. discussion 255&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pubmed">16006665</ArticleId></ArticleIdList></Reference><Reference><Citation>Frautschy SA, Yang F, Irrizarry M, Hyman B, Saido TC, Hsiao K, Cole GM. Microglial response to amyloid plaques in APPsw transgenic mice. Am J Pathol. 1998;152:307&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1858113</ArticleId><ArticleId IdType="pubmed">9422548</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelsins MC, Mastrangelo MA, Oddo S, LaFerla FM, Federoff HJ, Bowers WJ. Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice. J Neuroinflammation. 2005;2:23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1276812</ArticleId><ArticleId IdType="pubmed">16232318</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng. 2001;17:157&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">11337275</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, Younkin SG, Borchelt DR. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet. 2004;13:159&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">14645205</ArticleId></ArticleIdList></Reference><Reference><Citation>Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sun X, Frosch MP, Selkoe DJ. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron. 2003;40:1087&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pubmed">14687544</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao YF, Wang BJ, Cheng HT, Kuo LH, Wolfe MS. Tumor necrosis factor-alpha, interleukin-1beta, and interferon-gamma stimulate gamma-secretase-mediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway. J Biol Chem. 2004;279:49523&#x2013;49532.</Citation><ArticleIdList><ArticleId IdType="pubmed">15347683</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, Itagaki S, Tago H, McGeer EG. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett. 1987;79:195&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">3670729</ArticleId></ArticleIdList></Reference><Reference><Citation>Meda L, Cassatella MA, Szendrei GI, Otvos L, Jr, Baron P, Villalba M, Ferrari D, Rossi F. Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature. 1995;374:647&#x2013;650.</Citation><ArticleIdList><ArticleId IdType="pubmed">7715705</ArticleId></ArticleIdList></Reference><Reference><Citation>Mott RT, Hulette CM. Neuropathology of Alzheimer's disease. Neuroimaging Clin N Am. 2005;15:755&#x2013;765. ix.</Citation><ArticleIdList><ArticleId IdType="pubmed">16443488</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlmutter LS, Barron E, Chui HC. Morphologic association between microglia and senile plaque amyloid in Alzheimer's disease. Neurosci Lett. 1990;119:32&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">2097581</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry VH, Gordon S. Macrophages and microglia in the nervous system. Trends Neurosci. 1988;11:273&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">2465626</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. The origins of Alzheimer disease: a is for amyloid. JAMA. 2000;283:1615&#x2013;1617.</Citation><ArticleIdList><ArticleId IdType="pubmed">10735401</ArticleId></ArticleIdList></Reference><Reference><Citation>Simard AR, Soulet D, Gowing G, Julien JP, Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron. 2006;49:489&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">16476660</ArticleId></ArticleIdList></Reference><Reference><Citation>Stalder M, Phinney A, Probst A, Sommer B, Staufenbiel M, Jucker M. Association of microglia with amyloid plaques in brains of APP23 transgenic mice. Am J Pathol. 1999;154:1673&#x2013;1684.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866618</ArticleId><ArticleId IdType="pubmed">10362792</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas CA, Li Y, Kodama T, Suzuki H, Silverstein SC, El Khoury J. Protection from lethal gram-positive infection by macrophage scavenger receptor-dependent phagocytosis. J Exp Med. 2000;191:147&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2195800</ArticleId><ArticleId IdType="pubmed">10620613</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto M, Kiyota T, Horiba M, Buescher JL, Walsh SM, Gendelman HE, Ikezu T. Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. Am J Pathol. 2007;170:680&#x2013;692.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1851864</ArticleId><ArticleId IdType="pubmed">17255335</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan P, Hu X, Song H, Yin K, Bateman RJ, Cirrito JR, Xiao Q, Hsu FF, Turk JW, Xu J, Hsu CY, Holtzman DM, Lee JM. Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J Biol Chem. 2006;281:24566&#x2013;24574.</Citation><ArticleIdList><ArticleId IdType="pubmed">16787929</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, Schmidt AM. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature. 1996;382:685&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pubmed">8751438</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18704197</PMID><DateCompleted><Year>2008</Year><Month>10</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0021-9738</ISSN><JournalIssue CitedMedium="Print"><Volume>118</Volume><Issue>9</Issue><PubDate><Year>2008</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The Journal of clinical investigation</Title><ISOAbbreviation>J Clin Invest</ISOAbbreviation></Journal><ArticleTitle>Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease.</ArticleTitle><Pagination><StartPage>3087</StartPage><EndPage>3097</EndPage><MedlinePgn>3087-97</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1172/JCI35781</ELocationID><Abstract><AbstractText>Parkinson disease (PD) is characterized by dopaminergic neurodegeneration and intracellular inclusions of alpha-synuclein amyloid fibers, which are stable and difficult to dissolve. Whether inclusions are neuroprotective or pathological remains controversial, because prefibrillar oligomers may be more toxic than amyloid inclusions. Thus, whether therapies should target inclusions, preamyloid oligomers, or both is a critically important issue. In yeast, the protein-remodeling factor Hsp104 cooperates with Hsp70 and Hsp40 to dissolve and reactivate aggregated proteins. Metazoans, however, have no Hsp104 ortholog. Here we introduced Hsp104 into a rat PD model. Remarkably, Hsp104 reduced formation of phosphorylated alpha-synuclein inclusions and prevented nigrostriatal dopaminergic neurodegeneration induced by PD-linked alpha-synuclein (A30P). An in vitro assay employing pure proteins revealed that Hsp104 prevented fibrillization of alpha-synuclein and PD-linked variants (A30P, A53T, E46K). Hsp104 coupled ATP hydrolysis to the disassembly of preamyloid oligomers and amyloid fibers composed of alpha-synuclein. Furthermore, the mammalian Hsp70 and Hsp40 chaperones, Hsc70 and Hdj2, enhanced alpha-synuclein fiber disassembly by Hsp104. Hsp104 likely protects dopaminergic neurons by antagonizing toxic alpha-synuclein assemblies and might have therapeutic potential for PD and other neurodegenerative amyloidoses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lo Bianco</LastName><ForeName>Christophe</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Wallenberg Neuroscience Center, Division of Neurobiology, Department of Experimental Medical Science, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shorter</LastName><ForeName>James</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>R&#xe9;gulier</LastName><ForeName>Etienne</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Lashuel</LastName><ForeName>Hilal</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Iwatsubo</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Lindquist</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Aebischer</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>DP2 OD002177</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP2OD002177</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Invest</MedlineTA><NlmUniqueID>7802877</NlmUniqueID><ISSNLinking>0021-9738</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C107481">DNAJA1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050956">HSP40 Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018840">HSP70 Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006360">Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C532023">Hsp104 protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050956" MajorTopicYN="N">HSP40 Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018840" MajorTopicYN="N">HSP70 Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006360" MajorTopicYN="N">Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>3</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>8</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>10</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>8</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>9</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18704197</ArticleId><ArticleId IdType="pmc">PMC2515383</ArticleId><ArticleId IdType="doi">10.1172/JCI35781</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Skovronsky D.M., Lee V.M., Trojanowski J.Q. Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. Annu. Rev. Pathol. 2006;1:151&#x2013;170. doi: 10.1146/annurev.pathol.1.110304.100113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.pathol.1.110304.100113</ArticleId><ArticleId IdType="pubmed">18039111</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorsey E.R., et al. Projected number of people with Parkinson&#x2019;s disease in the most populous nations, 2005 through 2030. Neurology. 2007;68:384&#x2013;386. doi: 10.1212/01.wnl.0000247740.47667.03.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000247740.47667.03</ArticleId><ArticleId IdType="pubmed">17082464</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H., et al. Staging of brain pathology related to sporadic Parkinson&#x2019;s disease. Neurobiol. Aging. 2003;24:197&#x2013;211. doi: 10.1016/S0197-4580(02)00065-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(02)00065-9</ArticleId><ArticleId IdType="pubmed">12498954</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini M.G., et al. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839&#x2013;840. doi: 10.1038/42166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/42166</ArticleId><ArticleId IdType="pubmed">9278044</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore D.J., West A.B., Dawson V.L., Dawson T.M. Molecular pathophysiology of Parkinson&#x2019;s disease. Annu. Rev. Neurosci. 2005;28:57&#x2013;87. doi: 10.1146/annurev.neuro.28.061604.135718.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.28.061604.135718</ArticleId><ArticleId IdType="pubmed">16022590</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson W.S., Jonas A., Clayton D.F., George J.M. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 1998;273:9443&#x2013;9449. doi: 10.1074/jbc.273.16.9443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.273.16.9443</ArticleId><ArticleId IdType="pubmed">9545270</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway K.A., Harper J.D., Lansbury P.T. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med. 1998;4:1318&#x2013;1320. doi: 10.1038/3311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/3311</ArticleId><ArticleId IdType="pubmed">9809558</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway K.A., et al. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson&#x2019;s disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. U. S. A. 2000;97:571&#x2013;576. doi: 10.1073/pnas.97.2.571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.97.2.571</ArticleId><ArticleId IdType="pmc">PMC15371</ArticleId><ArticleId IdType="pubmed">10639120</ArticleId></ArticleIdList></Reference><Reference><Citation>Serpell L.C., Berriman J., Jakes R., Goedert M., Crowther R.A. Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc. Natl. Acad. Sci. U. S. A. 2000;97:4897&#x2013;4902. doi: 10.1073/pnas.97.9.4897.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.97.9.4897</ArticleId><ArticleId IdType="pmc">PMC18329</ArticleId><ArticleId IdType="pubmed">10781096</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowther R.A., Daniel S.E., Goedert M. Characterisation of isolated alpha-synuclein filaments from substantia nigra of Parkinson&#x2019;s disease brain. Neurosci. Lett. 2000;292:128&#x2013;130. doi: 10.1016/S0304-3940(00)01440-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(00)01440-3</ArticleId><ArticleId IdType="pubmed">10998565</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini M.G., et al. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson&#x2019;s disease and dementia with Lewy bodies. Neurosci. Lett. 1998;251:205&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">9726379</ArticleId></ArticleIdList></Reference><Reference><Citation>Miake H., Mizusawa H., Iwatsubo T., Hasegawa M. Biochemical characterization of the core structure of alpha-synuclein filaments. J. Biol. Chem. 2002;277:19213&#x2013;19219. doi: 10.1074/jbc.M110551200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110551200</ArticleId><ArticleId IdType="pubmed">11893734</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., et al. Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J. Clin. Invest. 2002;110:1429&#x2013;1439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC151810</ArticleId><ArticleId IdType="pubmed">12438441</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R., et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300:486&#x2013;489. doi: 10.1126/science.1079469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1079469</ArticleId><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>Lashuel H.A., et al. Alpha-synuclein, especially the Parkinson&#x2019;s disease-associated mutants, forms pore-like annular and tubular protofibrils. . J. Mol. Biol. 2002;322:1089&#x2013;1102. doi: 10.1016/S0022-2836(02)00735-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-2836(02)00735-0</ArticleId><ArticleId IdType="pubmed">12367530</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharon R., et al. The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson&#x2019;s disease. Neuron. 2003;37:583&#x2013;595. doi: 10.1016/S0896-6273(03)00024-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(03)00024-2</ArticleId><ArticleId IdType="pubmed">12597857</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L., Feany M.B. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat. Neurosci. 2005;8:657&#x2013;663. doi: 10.1038/nn1443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1443</ArticleId><ArticleId IdType="pubmed">15834418</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo Bianco C., et al. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson&#x2019;s disease. Proc. Natl. Acad. Sci. U. S. A. 2004;101:17510&#x2013;17515. doi: 10.1073/pnas.0405313101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0405313101</ArticleId><ArticleId IdType="pmc">PMC536019</ArticleId><ArticleId IdType="pubmed">15576511</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi W., et al. Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein. FEBS Lett. 2004;576:363&#x2013;368. doi: 10.1016/j.febslet.2004.09.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2004.09.038</ArticleId><ArticleId IdType="pubmed">15498564</ArticleId></ArticleIdList></Reference><Reference><Citation>Fredenburg R.A., et al. The impact of the E46K mutation on the properties of alpha-synuclein in its monomeric and oligomeric states. Biochemistry. 2007;46:7107&#x2013;7118. doi: 10.1021/bi7000246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi7000246</ArticleId><ArticleId IdType="pubmed">17530780</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujiwara H., et al. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 2002;4:160&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">11813001</ArticleId></ArticleIdList></Reference><Reference><Citation>Norris E.H., Giasson B.I., Ischiropoulos H., Lee V.M. Effects of oxidative and nitrative challenges on alpha-synuclein fibrillogenesis involve distinct mechanisms of protein modifications. J. Biol. Chem. 2003;278:27230&#x2013;27240. doi: 10.1074/jbc.M212436200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M212436200</ArticleId><ArticleId IdType="pubmed">12857790</ArticleId></ArticleIdList></Reference><Reference><Citation>Balch W.E., Morimoto R.I., Dillin A., Kelly J.W. Adapting proteostasis for disease intervention. Science. 2008;319:916&#x2013;919. doi: 10.1126/science.1141448.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1141448</ArticleId><ArticleId IdType="pubmed">18276881</ArticleId></ArticleIdList></Reference><Reference><Citation>Auluck P.K., Chan H.Y., Trojanowski J.Q., Lee V.M., Bonini N.M. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson&#x2019;s disease. . Science. 2002;295:865&#x2013;868. doi: 10.1126/science.1067389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1067389</ArticleId><ArticleId IdType="pubmed">11823645</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings C.J., et al. Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nat. Genet. 1998;19:148&#x2013;154. doi: 10.1038/502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/502</ArticleId><ArticleId IdType="pubmed">9620770</ArticleId></ArticleIdList></Reference><Reference><Citation>Warrick J.M., et al. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. . Nat. Genet. 1999;23:425&#x2013;428. doi: 10.1038/70532.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/70532</ArticleId><ArticleId IdType="pubmed">10581028</ArticleId></ArticleIdList></Reference><Reference><Citation>Glover J.R., Lindquist S. Hsp104, Hsp70, and Hsp40: a novel chaperone system that rescues previously aggregated proteins. Cell. 1998;94:73&#x2013;82. doi: 10.1016/S0092-8674(00)81223-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(00)81223-4</ArticleId><ArticleId IdType="pubmed">9674429</ArticleId></ArticleIdList></Reference><Reference><Citation>Shorter J. Hsp104: a weapon to combat diverse neurodegenerative disorders. Neurosignals. 2008;16:63&#x2013;74. doi: 10.1159/000109760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000109760</ArticleId><ArticleId IdType="pubmed">18097161</ArticleId></ArticleIdList></Reference><Reference><Citation>Wendler P., et al. Atypical AAA+ subunit packing creates an expanded cavity for disaggregation by the protein-remodeling factor Hsp104. Cell. 2007;131:1366&#x2013;1377. doi: 10.1016/j.cell.2007.10.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2007.10.047</ArticleId><ArticleId IdType="pmc">PMC2211523</ArticleId><ArticleId IdType="pubmed">18160044</ArticleId></ArticleIdList></Reference><Reference><Citation>Parsell D.A., Kowal A.S., Singer M.A., Lindquist S. Protein disaggregation mediated by heat-shock protein Hsp104. Nature. 1994;372:475&#x2013;478. doi: 10.1038/372475a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/372475a0</ArticleId><ArticleId IdType="pubmed">7984243</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez Y., Lindquist S.L. HSP104 required for induced thermotolerance. Science. 1990;248:1112&#x2013;1115. doi: 10.1126/science.2188365.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.2188365</ArticleId><ArticleId IdType="pubmed">2188365</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez Y., Taulien J., Borkovich K.A., Lindquist S. Hsp104 is required for tolerance to many forms of stress. EMBO J. 1992;11:2357&#x2013;2364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC556703</ArticleId><ArticleId IdType="pubmed">1600951</ArticleId></ArticleIdList></Reference><Reference><Citation>Shorter J., Lindquist S. Hsp104 catalyzes formation and elimination of self-replicating Sup35 prion conformers. Science. 2004;304:1793&#x2013;1797. doi: 10.1126/science.1098007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1098007</ArticleId><ArticleId IdType="pubmed">15155912</ArticleId></ArticleIdList></Reference><Reference><Citation>Shorter J., Lindquist S. Destruction or potentiation of different prions catalyzed by similar Hsp104 remodeling activities. Mol. Cell. 2006;23:425&#x2013;438. doi: 10.1016/j.molcel.2006.05.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2006.05.042</ArticleId><ArticleId IdType="pmc">PMC1540446</ArticleId><ArticleId IdType="pubmed">16885031</ArticleId></ArticleIdList></Reference><Reference><Citation>Doyle S.M., et al. Asymmetric deceleration of ClpB or Hsp104 ATPase activity unleashes protein-remodeling activity. Nat. Struct. Mol. Biol. 2007;14:114&#x2013;122. doi: 10.1038/nsmb1198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb1198</ArticleId><ArticleId IdType="pmc">PMC1793998</ArticleId><ArticleId IdType="pubmed">17259993</ArticleId></ArticleIdList></Reference><Reference><Citation>Narayanan S., Walter S., Reif B. Yeast prion-protein, sup35, fibril formation proceeds by addition and substraction of oligomers. Chembiochem. 2006;7:757&#x2013;765. doi: 10.1002/cbic.200500382.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cbic.200500382</ArticleId><ArticleId IdType="pubmed">16570324</ArticleId></ArticleIdList></Reference><Reference><Citation>Savistchenko J., Krzewska J., Fay N., Melki R. Molecular chaperones and the assembly of the prion Ure2p in vitro. J. Biol. Chem. 2008;283:15732&#x2013;15739. doi: 10.1074/jbc.M800728200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M800728200</ArticleId><ArticleId IdType="pmc">PMC3259649</ArticleId><ArticleId IdType="pubmed">18400756</ArticleId></ArticleIdList></Reference><Reference><Citation>Chernoff Y.O., Lindquist S.L., Ono B., Inge-Vechtomov S.G., Liebman S.W. Role of the chaperone protein Hsp104 in propagation of the yeast prion-like factor [PSI+]. . Science. 1995;268:880&#x2013;884. doi: 10.1126/science.7754373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.7754373</ArticleId><ArticleId IdType="pubmed">7754373</ArticleId></ArticleIdList></Reference><Reference><Citation>Dandoy-Dron F., et al. Infection by ME7 prion is not modified in transgenic mice expressing the yeast chaperone Hsp104 in neurons. Neurosci. Lett. 2006;405:181&#x2013;185. doi: 10.1016/j.neulet.2006.05.066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2006.05.066</ArticleId><ArticleId IdType="pubmed">16884849</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosser D.D., Ho S., Glover J.R. Saccharomyces cerevisiae Hsp104 enhances the chaperone capacity of human cells and inhibits heat stress-induced proapoptotic signaling. . Biochemistry. 2004;43:8107&#x2013;8115. doi: 10.1021/bi0493766.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi0493766</ArticleId><ArticleId IdType="pubmed">15209506</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson R., Eisenberg D. Structural models of amyloid-like fibrils. Adv. Protein Chem. 2006;73:235&#x2013;282. doi: 10.1016/S0065-3233(06)73008-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0065-3233(06)73008-X</ArticleId><ArticleId IdType="pubmed">17190616</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo Bianco C., Ridet J.L., Schneider B.L., Deglon N., Aebischer P. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson&#x2019;s disease. Proc. Natl. Acad. Sci. U. S. A. 2002;99:10813&#x2013;10818. doi: 10.1073/pnas.152339799.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.152339799</ArticleId><ArticleId IdType="pmc">PMC125054</ArticleId><ArticleId IdType="pubmed">12122208</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao Y.P., Cook L.J., O&#x2019;Donovan D., Uyama E., Rubinsztein D.C. Mammalian, yeast, bacterial, and chemical chaperones reduce aggregate formation and death in a cell model of oculopharyngeal muscular dystrophy. J. Biol. Chem. 2002;277:12263&#x2013;12269. doi: 10.1074/jbc.M109633200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109633200</ArticleId><ArticleId IdType="pubmed">11796717</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirik D., et al. Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson&#x2019;s disease. Proc. Natl. Acad. Sci. U. S. A. 2003;100:2884&#x2013;2889.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC151435</ArticleId><ArticleId IdType="pubmed">12601150</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirik D., et al. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J. Neurosci. 2002;22:2780&#x2013;2791.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758323</ArticleId><ArticleId IdType="pubmed">11923443</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein R.L., King M.A., Hamby M.E., Meyer E.M. Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra. Hum. Gene Ther. 2002;13:605&#x2013;612. doi: 10.1089/10430340252837206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/10430340252837206</ArticleId><ArticleId IdType="pubmed">11916484</ArticleId></ArticleIdList></Reference><Reference><Citation>Beltramino C.A., de Olmos J.S., Gallyas F., Heimer L., Z&#xe1;borszky L.1993Silver staining as a tool for neurotoxic assessment. NIDA Res. Monogr. 136101&#x2013;126; discussion 126&#x2013;132. .</Citation><ArticleIdList><ArticleId IdType="pubmed">8289909</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandmann-Keil D., Braak H., Okochi M., Haass C., Braak E. Alpha-synuclein immunoreactive Lewy bodies and Lewy neurites in Parkinson&#x2019;s disease are detectable by an advanced silver-staining technique. Acta Neuropathol. 1999;98:461&#x2013;464. doi: 10.1007/s004010051110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004010051110</ArticleId><ArticleId IdType="pubmed">10541868</ArticleId></ArticleIdList></Reference><Reference><Citation>Schirmer E.C., Queitsch C., Kowal A.S., Parsell D.A., Lindquist S. The ATPase activity of Hsp104, effects of environmental conditions and mutations. J. Biol. Chem. 1998;273:15546&#x2013;15552. doi: 10.1074/jbc.273.25.15546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.273.25.15546</ArticleId><ArticleId IdType="pubmed">9624144</ArticleId></ArticleIdList></Reference><Reference><Citation>Lashuel H.A., Hartley D., Petre B.M., Walz T., Lansbury P.T., Jr. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature. 2002;418:291.</Citation><ArticleIdList><ArticleId IdType="pubmed">12124613</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong B., Chae Y., Lee K. Degradation of wild-type alpha-synuclein by a molecular chaperone leads to reduced aggregate formation. Cell Biochem. Funct. 2005;23:125&#x2013;132. doi: 10.1002/cbf.1219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cbf.1219</ArticleId><ArticleId IdType="pubmed">15624119</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong B., Chae Y.K., Lee K. Regulation of in vitro fibril formation of synuclein mutant proteins by Hsp104p. Protein Pept. Lett. 2003;10:491&#x2013;495. doi: 10.2174/0929866033478717.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929866033478717</ArticleId><ArticleId IdType="pubmed">14561138</ArticleId></ArticleIdList></Reference><Reference><Citation>Parsell D.A., Sanchez Y., Stitzel J.D., Lindquist S. Hsp104 is a highly conserved protein with two essential nucleotide-binding sites. Nature. 1991;353:270&#x2013;273. doi: 10.1038/353270a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/353270a0</ArticleId><ArticleId IdType="pubmed">1896074</ArticleId></ArticleIdList></Reference><Reference><Citation>Parsell D.A., Taulien J., Lindquist S. The role of heat-shock proteins in thermotolerance. Philos. Trans. R. Soc. Lond. B Biol. Sci. 1993;339:279&#x2013;286. doi: 10.1098/rstb.1993.0026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rstb.1993.0026</ArticleId><ArticleId IdType="pubmed">8098532</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto A., Lucas J.J., Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington&#x2019;s disease. Cell. 2000;101:57&#x2013;66. doi: 10.1016/S0092-8674(00)80623-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(00)80623-6</ArticleId><ArticleId IdType="pubmed">10778856</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin-Aparicio E., et al. Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington&#x2019;s disease. J. Neurosci. 2001;21:8772&#x2013;8781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762274</ArticleId><ArticleId IdType="pubmed">11698589</ArticleId></ArticleIdList></Reference><Reference><Citation>Shorter J., Lindquist S. Prions as adaptive conduits of memory and inheritance. Nat. Rev. Genet. 2005;6:435&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pubmed">15931169</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Mar C., Greenbaum E.A., Mayne L., Englander S.W., Woods V.L., Jr. Structure and properties of alpha-synuclein and other amyloids determined at the amino acid level. Proc. Natl. Acad. Sci. U. S. A. 2005;102:15477&#x2013;15482. doi: 10.1073/pnas.0507405102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0507405102</ArticleId><ArticleId IdType="pmc">PMC1266128</ArticleId><ArticleId IdType="pubmed">16223878</ArticleId></ArticleIdList></Reference><Reference><Citation>Outeiro T.F., Lindquist S. Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science. 2003;302:1772&#x2013;1775. doi: 10.1126/science.1090439.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1090439</ArticleId><ArticleId IdType="pmc">PMC1780172</ArticleId><ArticleId IdType="pubmed">14657500</ArticleId></ArticleIdList></Reference><Reference><Citation>Cashikar A.G., Duennwald M., Lindquist S.L. A chaperone pathway in protein disaggregation. Hsp26 alters the nature of protein aggregates to facilitate reactivation by Hsp104. J. Biol. Chem. 2005;280:23869&#x2013;23875. doi: 10.1074/jbc.M502854200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M502854200</ArticleId><ArticleId IdType="pmc">PMC1391974</ArticleId><ArticleId IdType="pubmed">15845535</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper A.A., et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson&#x2019;s models. Science. 2006;313:324&#x2013;328. doi: 10.1126/science.1129462.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1129462</ArticleId><ArticleId IdType="pmc">PMC1983366</ArticleId><ArticleId IdType="pubmed">16794039</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitler A.D., et al. The Parkinson&#x2019;s disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc. Natl. Acad. Sci. U. S. A. 2008;105:145&#x2013;150. doi: 10.1073/pnas.0710685105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0710685105</ArticleId><ArticleId IdType="pmc">PMC2224176</ArticleId><ArticleId IdType="pubmed">18162536</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitler A.D., Shorter J. Prime time for alpha-synuclein. J. Neurosci. 2007;27:2433&#x2013;2434. doi: 10.1523/JNEUROSCI.0094-07.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0094-07.2007</ArticleId><ArticleId IdType="pmc">PMC6672516</ArticleId><ArticleId IdType="pubmed">17344380</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmichael J., et al. Bacterial and yeast chaperones reduce both aggregate formation and cell death in mammalian cell models of Huntington&#x2019;s disease. Proc. Natl. Acad. Sci. U. S. A. 2000;97:9701&#x2013;9705. doi: 10.1073/pnas.170280697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.170280697</ArticleId><ArticleId IdType="pmc">PMC16928</ArticleId><ArticleId IdType="pubmed">10920207</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrin V., et al. Neuroprotection by Hsp104 and Hsp27 in lentiviral-based rat models of Huntington&#x2019;s disease. Mol. Ther. 2007;15:903&#x2013;911. doi: 10.1038/mt.sj.6300141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.sj.6300141</ArticleId><ArticleId IdType="pubmed">17375066</ArticleId></ArticleIdList></Reference><Reference><Citation>Vacher C., Garcia-Oroz L., Rubinsztein D.C. Overexpression of yeast hsp104 reduces polyglutamine aggregation and prolongs survival of a transgenic mouse model of Huntington&#x2019;s disease. Hum. Mol. Genet. 2005;14:3425&#x2013;3433. doi: 10.1093/hmg/ddi372.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddi372</ArticleId><ArticleId IdType="pubmed">16204350</ArticleId></ArticleIdList></Reference><Reference><Citation>Deglon N., et al. Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson&#x2019;s disease. Hum. Gene Ther. 2000;11:179&#x2013;190. doi: 10.1089/10430340050016256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/10430340050016256</ArticleId><ArticleId IdType="pubmed">10646649</ArticleId></ArticleIdList></Reference><Reference><Citation>Paxinos, G., and Watson, C. 1998.The rat brain in stereotaxic coordinates. 4th edition. Academic Press. San Diego, California, USA. 256 pp.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18714062</PMID><DateCompleted><Year>2008</Year><Month>08</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>300</Volume><Issue>7</Issue><PubDate><Year>2008</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Within-person across-neuropsychological test variability and incident dementia.</ArticleTitle><Pagination><StartPage>823</StartPage><EndPage>830</EndPage><MedlinePgn>823-30</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.300.7.823</ELocationID><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Neuropsychological tests are used to predict and diagnose dementia. However, to our knowledge, no studies to date have examined whether within-person across-neuropsychological test variability predicts dementia.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine whether within-person across-neuropsychological test variability predicts future dementia.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">The Einstein Aging Study (EAS) is a population-based longitudinal study of aging and dementia located in Bronx County, New York. We used Cox proportional hazards models using age as the time scale to estimate hazard ratios (HRs) for performance on individual neuropsychological tests (Free and Cued Selective Reminding Test, Digit Symbol Substitution subtest of the Wechsler Adult Intelligence Scale Revised, and the Vocabulary subtest of the Wechsler Adult Intelligence Scale Revised) and for within-person across-neuropsychological test variability as predictors of incident dementia. Analyses were stratified by sex, and controlled for education and medical illness.</AbstractText><AbstractText Label="SETTING AND PARTICIPANTS" NlmCategory="METHODS">A total of 1797 participants (age &gt; or = 70 years) enrolled in the EAS between October 1993 and December 2007. Participants seen for the baseline visit only (n = 750), prevalent dementia cases (n = 72), and those with missing follow-up information (n = 78) were excluded. A total of 897 individuals were included in this investigation. Participants had follow-up visits every 12 to 18 months.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURE" NlmCategory="METHODS">Incident dementia.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Sixty-one cases of incident dementia were identified during follow-up (mean [SD], 3.3 [2.4] years), of which 26 were in the highest quartile of within-person across-neuropsychological test variability. Adjusting for sex, education, and medical illness, variability was associated with incident dementia (HR for 1-point difference in variability, 3.93 [95% confidence interval {CI}, 2.04-7.56]). The association persisted even after adjusting for level of performance on individual neuropsychological tests (HR for 1-point difference in variability, 2.10 [95% CI, 1.04-4.23]). Comparing Cox models using neuropsychological tests with and without within-person across-neuropsychological test variability showed that the former improved the prediction of dementia. Sensitivity in a model predicting dementia at 1 year also improved when neuropsychological test variability was included.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this population, within-person across-neuropsychological test variability was associated with development of incident dementia independent of neuropsychological test performance. This finding needs to be confirmed in future studies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Holtzer</LastName><ForeName>Roee</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Albert Einstein College of Medicine, Yeshiva University, Bronx, NY 10461, USA. rholtzer@aecom.yu.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verghese</LastName><ForeName>Joe</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Cuiling</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>Charles B</ForeName><Initials>CB</Initials></Author><Author ValidYN="Y"><LastName>Lipton</LastName><ForeName>Richard B</ForeName><Initials>RB</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG025119</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AGO3949</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG025119</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG030857</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003949</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>JAMA. 2008 Dec 10;300(22):2610</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008959" MajorTopicYN="N">Models, Neurological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="Y">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015588" MajorTopicYN="N">Observer Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>8</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>8</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>9</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18714062</ArticleId><ArticleId IdType="mid">NIHMS130683</ArticleId><ArticleId IdType="pmc">PMC2736784</ArticleId><ArticleId IdType="doi">10.1001/jama.300.7.823</ArticleId><ArticleId IdType="pii">300/7/823</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>DeCarli C. Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment. Lancet Neurol. 2003 Jan;2(1):15&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">12849297</ArticleId></ArticleIdList></Reference><Reference><Citation>Association AP. Diagnostic and Statistical Manual of Mental Disorders. text revision ed. Author; Washington, DC: 2000.</Citation></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984 Jul;34(7):939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001 Dec;58(12):1985&#x2013;1992.</Citation><ArticleIdList><ArticleId IdType="pubmed">11735772</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999 Mar;56(3):303&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">10190820</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter GG, Attix DK. An Integrated Model for Geriatric Neuropsychological Assessment. In: Attix DK, Welsh-Bohmer KA, editors. Geriatric neuropsychology: Assessment and intervention. Guilford Publications; New York, NY: 2006. pp. 5&#x2013;26.</Citation></Reference><Reference><Citation>Grober E, Lipton RB, Hall C, Crystal H. Memory impairment on free and cued selective reminding predicts dementia. Year of Publication 2000. Neurology. 2000 Feb;54(4):827&#x2013;832.</Citation><ArticleIdList><ArticleId IdType="pubmed">10690971</ArticleId></ArticleIdList></Reference><Reference><Citation>Masur DM, Sliwinski M, Lipton RB, Blau AD, Crystal HA. Neuropsychological prediction of dementia and the absence of dementia in healthy elderly persons. Neurology. 1994 Aug;44(8):1427&#x2013;1432.</Citation><ArticleIdList><ArticleId IdType="pubmed">8058143</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, Moss MB, Tanzi R, Jones K. Preclinical prediction of AD using neuropsychological tests. Journal of the International Neuropsychological Society. 2001 Jul;7(5):631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">11459114</ArticleId></ArticleIdList></Reference><Reference><Citation>Backman L, Jones S, Berger AK, Laukka EJ, Small BJ. Cognitive impairment in preclinical Alzheimer&#x2019;s disease: a meta-analysis. Neuropsychology. 2005 Jul;19(4):520&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pubmed">16060827</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall CB, Ying J, Kuo L, et al. Estimation of bivariate measurements having different change points, with application to cognitive ageing. Stat Med. 2001 Dec 30;20(24):3695&#x2013;3714.</Citation><ArticleIdList><ArticleId IdType="pubmed">11782027</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall CB, Ying J, Kuoc L, Lipton RB. Bayesian and profile likelihood change point methods for modeling cognitive function over time. Computational Statistics &amp; Data Analysis. 2003;42:91&#x2013;109.</Citation></Reference><Reference><Citation>Lezak MD, Diane BH, Loring DW. Neuropsychological Assessment. 4 th ed. Oxford University Press; New York: 2004.</Citation></Reference><Reference><Citation>Mitrushina M, Boone KB, Razani J, D&#x2019;Elia L. Handbook of normative data for neuropsychological assessment. 2 nd ed. Oxford University Press; New York: 2005.</Citation></Reference><Reference><Citation>Salthouse TA. Implications of within-person variability in cognitive and neuropsychological functioning for the interpretation of change. Neuropsychology. 2007 Jul;21(4):401&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3838958</ArticleId><ArticleId IdType="pubmed">17605573</ArticleId></ArticleIdList></Reference><Reference><Citation>West R. The transient nature of executive control processes in younger and older adults. European Journal of Cognitive Psychology. 2001 Mar-Jun;13(12):91&#x2013;105.</Citation></Reference><Reference><Citation>Hultsch DF, MacDonald SWS, Hunter MA, Levy-Bencheton J, Strauss E. Intraindividual variability in cognitive performance in older adults: Comparison of adults with mild dementia, adults with arthritis, and healthy adults. Neuropsychology. 2000 Oct;14(4):588&#x2013;598.</Citation><ArticleIdList><ArticleId IdType="pubmed">11055261</ArticleId></ArticleIdList></Reference><Reference><Citation>Knotek PC, Bayles KA, Kaszniak AW. Response consistency on a semantic memory task in persons with dementia of the Alzheimer type. Brain and Language. 1990 May;38(4):465&#x2013;475.</Citation><ArticleIdList><ArticleId IdType="pubmed">2375976</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen H, Dear KB, Anstey KJ, Parslow RA, Sachdev P, Jorm AF. Within-occasion intraindividual variability and preclinical diagnostic status: is intraindividual variability an indicator of mild cognitive impairment? Neuropsychology. 2005 May;19(3):309&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">15910117</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon RA, Garrett DD, Lentz TL, MacDonald SW, Strauss E, Hultsch DF. Neurocognitive markers of cognitive impairment: exploring the roles of speed and inconsistency. Neuropsychology. 2007 May;21(3):381&#x2013;399.</Citation><ArticleIdList><ArticleId IdType="pubmed">17484601</ArticleId></ArticleIdList></Reference><Reference><Citation>Matarazzo JD, Daniel MH, Prifitera A, Herman DO. Inter-subtest scatter in the WAIS--R standardization sample. Journal of Clinical Psychology. 1988 Nov;44(6):940&#x2013;950.</Citation></Reference><Reference><Citation>Matarazzo JD, Prifitera A. Subtest scatter and premorbid intelligence: Lessons from the WAIS--R standardization sample. Psychological Assessment. 1989 Sep;1(3):186&#x2013;191.</Citation></Reference><Reference><Citation>Schretlen DJ, Munro CA, Anthony JC, Pearlson GD. Examining the range of normal intraindividual variability in neuropsychological test performance. Journal of the International Neuropsychological Society. 2003 Sep;9(6):864&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">14632245</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipton RB, Katz MJ, Kuslansky G, et al. Screening for dementia by telephone using the memory impairment screen. J Am Geriatr Soc. 2003 Oct;51(10):1382&#x2013;1390.</Citation><ArticleIdList><ArticleId IdType="pubmed">14511157</ArticleId></ArticleIdList></Reference><Reference><Citation>Verghese J, Katz MJ, Derby CA, Kuslansky G, Hall CB, Lipton RB. Reliability and validity of a telephone-based mobility assessment questionnaire. Age Ageing. 2004 Nov;33(6):628&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pubmed">15501841</ArticleId></ArticleIdList></Reference><Reference><Citation>Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. British Journal of Psychiatry. 1968;114(512):797&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pubmed">5662937</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuld P. Psychological testing in the differential diagnosis of the dementias. In: Katzman RTR, Bick KL, editors. Alzheimer&#x2019;s disease: senile dementia and related disorders. Vol. 7. Raven Press; New York: 1978. pp. 185&#x2013;193.</Citation></Reference><Reference><Citation>Grober E, Dickson D, Sliwinski MJ, et al. Memory and mental status correlates of modified Braak staging. Neurobiol Aging. 1999 Nov-Dec;20(6):573&#x2013;579.</Citation><ArticleIdList><ArticleId IdType="pubmed">10674422</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969 Autumn;9(3):179&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">5349366</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarazin M, Berr C, De Rotrou J, et al. Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study. Neurology. 2007 Nov 6;69(19):1859&#x2013;1867.</Citation><ArticleIdList><ArticleId IdType="pubmed">17984454</ArticleId></ArticleIdList></Reference><Reference><Citation>Verghese J, Lipton RB, Hall CB, Kuslansky G, Katz MJ, Buschke H. Abnormality of gait as a predictor of non-Alzheimer&#x2019;s dementia. N Engl J Med. 2002 Nov 28;347(22):1761&#x2013;1768.</Citation><ArticleIdList><ArticleId IdType="pubmed">12456852</ArticleId></ArticleIdList></Reference><Reference><Citation>Association AP. Diagnostic and Statistical Nanual of Mental Disoders. 4 th ed. ed. Author; Washington: DC: 1994.</Citation></Reference><Reference><Citation>Chui HC, Victoroff JI, Margolin D, Jagust W, Shankle R, Katzman R. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer&#x2019;s Disease Diagnostic and Treatment Centers. Neurology. 1992 Mar;42(3 Pt 1):473&#x2013;480.</Citation><ArticleIdList><ArticleId IdType="pubmed">1549205</ArticleId></ArticleIdList></Reference><Reference><Citation>Crystal HA, Dickson D, Davies P, Masur D, Grober E, Lipton RB. The relative frequency of &#x201c;dementia of unknown etiology&#x201d; increases with age and is nearly 50% in nonagenarians. Arch Neurol. 2000 May;57(5):713&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pubmed">10815138</ArticleId></ArticleIdList></Reference><Reference><Citation>Verghese J, Crystal HA, Dickson DW, Lipton RB. Validity of clinical criteria for the diagnosis of dementia with Lewy bodies. Neurology. 1999 Dec 10;53(9):1974&#x2013;1982.</Citation><ArticleIdList><ArticleId IdType="pubmed">10599768</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzman R, Aronson M, Fuld P, et al. Development of dementing illnesses in an 80-year-old volunteer cohort. Ann Neurol. 1989 Apr;25(4):317&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">2712531</ArticleId></ArticleIdList></Reference><Reference><Citation>Sliwinski M, Buschke H, Stewart WF, Masur D, Lipton RB. The effect of dementia risk factors on comparative and diagnostic selective reminding norms. J Int Neuropsychol Soc. 1997 Jul;3(4):317&#x2013;326.</Citation><ArticleIdList><ArticleId IdType="pubmed">9260441</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzer R, Friedman R, Lipton RB, Katz M, Xue X, Verghese J. The relationship between specific cognitive functions and falls in aging. Neuropsychology. 2007 Sep;21(5):540&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3476056</ArticleId><ArticleId IdType="pubmed">17784802</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzer R, Verghese J, Xue X, Lipton RB. Cognitive Processes Related to Gait Velocity: Results From the Einstein Aging Study. Neuropsychology. 2006 Mar;20(2):215&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">16594782</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. Wechsler Adult Intelligence Scale-revised. The Psychological Corporation; New York: 1981.</Citation></Reference><Reference><Citation>Grober E, Buschke H, Crystal H, Bang S, Dresner R. Screening for dementia by memory testing. Neurology. 1988 Jun;38(6):900&#x2013;903.</Citation><ArticleIdList><ArticleId IdType="pubmed">3368071</ArticleId></ArticleIdList></Reference><Reference><Citation>Kliegel M, Sliwinski M. MMSE cross-domain variability predicts cognitive decline in centenarians. Gerontology. 2004 Jan-Feb;50(1):39&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">14654726</ArticleId></ArticleIdList></Reference><Reference><Citation>Verghese J, Wang C, Lipton RB, Holtzer R, Xue X. Quantitative gait dysfunction and risk of cognitive decline and dementia. J Neurol Neurosurg Psychiatry. 2007 Sep;78(9):929&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1995159</ArticleId><ArticleId IdType="pubmed">17237140</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiebaut AC, Benichou J. Choice of time-scale in Cox&#x2019;s model analysis of epidemiologic cohort data: a simulation study. Stat Med. 2004 Dec 30;23(24):3803&#x2013;3820.</Citation><ArticleIdList><ArticleId IdType="pubmed">15580597</ArticleId></ArticleIdList></Reference><Reference><Citation>Silvey SD. Statistical inference. Chapman &amp; Hall; London: 1975.</Citation></Reference><Reference><Citation>Stuss DT, Murphy KJ, Binns MA, Alexander MP. Staying on the job: the frontal lobes control individual performance variability. Brain. 2003 Nov;126(Pt 11):2363&#x2013;2380.</Citation><ArticleIdList><ArticleId IdType="pubmed">12876148</ArticleId></ArticleIdList></Reference><Reference><Citation>Li SC, Huxhold O, Schmiedek F. Aging and attenuated processing robustness. Evidence from cognitive and sensorimotor functioning. Gerontology. 2004 Jan-Feb;50(1):28&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">14654724</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695&#x2013;699.</Citation><ArticleIdList><ArticleId IdType="pubmed">15817019</ArticleId></ArticleIdList></Reference><Reference><Citation>West R, Murphy KJ, Armilio ML, Craik FI, Stuss DT. Lapses of intention and performance variability reveal age-related increases in fluctuations of executive control. Brain Cogn. 2002 Aug;49(3):402&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pubmed">12139961</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellgrove MA, Hester R, Garavan H. The functional neuroanatomical correlates of response variability: Evidence from a response inhibition task. Neuropsychologia. 2004;42(14):1910&#x2013;1916.</Citation><ArticleIdList><ArticleId IdType="pubmed">15381021</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuss DT, Toth JP, Franchi D, Alexander MP, Tipper S, Craik FI. Dissociation of attentional processes in patients with focal frontal and posterior lesions. Neuropsychologia. 1999 Aug;37(9):1005&#x2013;1027.</Citation><ArticleIdList><ArticleId IdType="pubmed">10468365</ArticleId></ArticleIdList></Reference><Reference><Citation>Jokinen H, Kalska H, Mantyla R, et al. Cognitive profile of subcortical ischaemic vascular disease. J Neurol Neurosurg Psychiatry. 2006 Jan;77(1):28&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2117424</ArticleId><ArticleId IdType="pubmed">16361588</ArticleId></ArticleIdList></Reference><Reference><Citation>McPherson SE, Cummings JL. Neuropsychological aspects of vascular dementia. Brain Cogn. 1996 Jul;31(2):269&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">8812007</ArticleId></ArticleIdList></Reference><Reference><Citation>Bischkopf J, Busse A, Angermeyer MC. Mild cognitive impairment--a review of prevalence, incidence and outcome according to current approaches. Acta Psychiatr Scand. 2002 Dec;106(6):403&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">12392483</ArticleId></ArticleIdList></Reference><Reference><Citation>Collie A, Maruff P, Currie J. Behavioral characterization of mild cognitive impairment. J Clin Exp Neuropsychol. 2002 Sep;24(6):720&#x2013;733.</Citation><ArticleIdList><ArticleId IdType="pubmed">12424647</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18716221</PMID><DateCompleted><Year>2008</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>34</Issue><PubDate><Year>2008</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Reverse of age-dependent memory impairment and mitochondrial DNA damage in microglia by an overexpression of human mitochondrial transcription factor a in mice.</ArticleTitle><Pagination><StartPage>8624</StartPage><EndPage>8634</EndPage><MedlinePgn>8624-34</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.1957-08.2008</ELocationID><Abstract><AbstractText>Mitochondrial DNA (mtDNA) is highly susceptible to injury induced by reactive oxygen species (ROS). During aging, mutations of mtDNA accumulate to induce dysfunction of the respiratory chain, resulting in the enhanced ROS production. Therefore, age-dependent memory impairment may result from oxidative stress derived from the respiratory chain. Mitochondrial transcription factor A (TFAM) is now known to have roles not only in the replication of mtDNA but also its maintenance. We herein report that an overexpression of TFAM in HeLa cells significantly inhibited rotenone-induced mitochondrial ROS generation and the subsequent NF-kappaB (nuclear factor-kappaB) nuclear translocation. Furthermore, TFAM transgenic (TG) mice exhibited a prominent amelioration of an age-dependent accumulation of lipid peroxidation products and a decline in the activities of complexes I and IV in the brain. In the aged TG mice, deficits of the motor learning memory, the working memory, and the hippocampal long-term potentiation (LTP) were also significantly improved. The expression level of interleukin-1beta (IL-1beta) and mtDNA damages, which were predominantly found in microglia, significantly decreased in the aged TG mice. The IL-1beta amount markedly increased in the brain of the TG mice after treatment with lipopolysaccharide (LPS), whereas its mean amount was significantly lower than that of the LPS-treated aged wild-type mice. At the same time, an increased mtDNA damage in microglia and an impaired hippocampal LTP were also observed in the LPS-treated aged TG mice. Together, an overexpression of TFAM is therefore considered to ameliorate age-dependent impairment of the brain functions through the prevention of oxidative stress and mitochondrial dysfunctions in microglia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hayashi</LastName><ForeName>Yoshinori</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Laboratory of Oral Aging Science, Faculty of Dental Sciences, Kyushu University, Fukuoka 812-8582, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshida</LastName><ForeName>Masayoshi</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Yamato</LastName><ForeName>Mayumi</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Ide</LastName><ForeName>Tomomi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Zhou</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Ochi-Shindou</LastName><ForeName>Mayumi</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kanki</LastName><ForeName>Tomotake</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Dongchon</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Sunagawa</LastName><ForeName>Kenji</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Tsutsui</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Nakanishi</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004272">DNA, Mitochondrial</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D024101">Mitochondrial Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C422562">mitochondrial transcription factor A</NameOfSubstance></Chemical><Chemical><RegistryNumber>03L9OT429T</RegistryNumber><NameOfSubstance UI="D012402">Rotenone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001692" MajorTopicYN="N">Biological Transport</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004249" MajorTopicYN="N">DNA Damage</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004272" MajorTopicYN="N">DNA, Mitochondrial</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007425" MajorTopicYN="N">Intracellular Membranes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007858" MajorTopicYN="N">Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D028361" MajorTopicYN="N">Mitochondrial Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024101" MajorTopicYN="N">Mitochondrial Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010084" MajorTopicYN="N">Oxidation-Reduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020127" MajorTopicYN="N">Recovery of Function</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012402" MajorTopicYN="N">Rotenone</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>8</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>9</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>8</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>2</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18716221</ArticleId><ArticleId IdType="pmc">PMC6671051</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.1957-08.2008</ArticleId><ArticleId IdType="pii">28/34/8624</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alam TI, Kanki T, Muta T, Ukaji K, Abe Y, Nakayama H, Takio K, Hamasaki N, Kang D. Human mitochondrial DNA is packaged with TFAM. Nucleic Acids Res. 2003;31:1640&#x2013;1645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC152855</ArticleId><ArticleId IdType="pubmed">12626705</ArticleId></ArticleIdList></Reference><Reference><Citation>Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989;12:366&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">2479133</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckman KB, Ames BN. The free radical theory of aging matures. Physiol Rev. 1998;78:547&#x2013;581.</Citation><ArticleIdList><ArticleId IdType="pubmed">9562038</ArticleId></ArticleIdList></Reference><Reference><Citation>Corral-Debrinski M, Horton T, Lott MT, Shoffner JM, Beal MF, Wallace DC. Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age. Nat Genet. 1992;2:324&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">1303288</ArticleId></ArticleIdList></Reference><Reference><Citation>Emre Y, Hurtaud C, N&#xfc;bel T, Criscuolo F, Ricquier D, Cassard-Doulcier AM. Mitochondria contribute to LPS-induced MAPK activation via uncoupling protein UCP2 in macrophages. Biochem J. 2007;402:271&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1798432</ArticleId><ArticleId IdType="pubmed">17073824</ArticleId></ArticleIdList></Reference><Reference><Citation>Forster MJ, Dubey A, Dawson KM, Stutts WA, Lal H, Sohal RS. Age-related losses of cognitive function and motor skills in mice are associated with oxidative protein damage in the brain. Proc Natl Acad Sci U S A. 1996;93:4765&#x2013;4769.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC39353</ArticleId><ArticleId IdType="pubmed">8643477</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardella S, Andrei C, Lotti LV, Poggi A, Torrisi MR, Zocchi MR, Rubartelli A. CD8+ T lymphocytes induce polarized exocytosis of secretory lysosomes by dendritic cells with release of interleukin-1&#x3b2; and cathepsin D. Blood. 2001;98:2152&#x2013;2159.</Citation><ArticleIdList><ArticleId IdType="pubmed">11568002</ArticleId></ArticleIdList></Reference><Reference><Citation>Gemma C, Fister M, Hudson C, Bickford PC. Improvement of memory for context by inhibition of caspase-1 in aged rats. Eur J Neurosci. 2005;22:1751&#x2013;1756.</Citation><ArticleIdList><ArticleId IdType="pubmed">16197515</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin R, Nally R, Nolan Y, McCartney Y, Linden J, Lynch MA. The age-related attenuation in long-term potentiation is associated with microglial activation. J Neurochem. 2006;99:1263&#x2013;1272.</Citation><ArticleIdList><ArticleId IdType="pubmed">16981890</ArticleId></ArticleIdList></Reference><Reference><Citation>Harman D. Free radical theory of aging: an update: increasing the functional life span. Ann N Y Acad Sci. 2006;1067:10&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">16803965</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi Y, Tomimatsu Y, Suzuki H, Yamada J, Wu Z, Yao H, Kagamiishi Y, Tateishi N, Sawada M, Nakanishi H. The intra-arterial injection of microglia protects hippocampal CA1 neurons against global ischemia-induced functional deficits in rats. Neuroscience. 2006;142:87&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">16844302</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensley K, Kotake Y, Sang H, Pye QN, Wallis GL, Kolker LM, Tabatabaie T, Stewart CA, Konishi Y, Nakae D, Floyd RA. Dietary choline restriction causes complex I dysfunction and increased H2O2 generation in liver mitochondria. Carcinogenesis. 2000;21:983&#x2013;989.</Citation><ArticleIdList><ArticleId IdType="pubmed">10783322</ArticleId></ArticleIdList></Reference><Reference><Citation>Iancu R, Mohapel P, Brundin P, Paul G. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice. Behav Brain Res. 2005;162:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">15922062</ArticleId></ArticleIdList></Reference><Reference><Citation>Ide T, Tsutsui H, Kinugawa S, Utsumi H, Kang D, Hattori N, Uchida K, Arimura K, Egashira K, Takeshita A. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res. 1999;85:357&#x2013;363.</Citation><ArticleIdList><ArticleId IdType="pubmed">10455064</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeuchi M, Matsusaka H, Kang D, Matsushima S, Ide T, Kubota T, Fujiwara T, Hamasaki N, Takeshita A, Sunagawa K, Tsutsui H. Overexpression of mitochondrial transcription factor A ameliorates mitochondrial deficiencies and cardiac failure after myocardial infarction. Circulation. 2005;112:683&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pubmed">16043643</ArticleId></ArticleIdList></Reference><Reference><Citation>Kajitani K, Yamaguchi H, Dan Y, Furuichi M, Kang D, Nakabeppu Y. MTH1, an oxidized purine nucleoside triphosphatase, suppresses the accumulation of oxidative damage of nucleic acids in the hippocampal microglia during kainate-induced excitotoxicity. J Neurosci. 2006;26:1688&#x2013;1698.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793619</ArticleId><ArticleId IdType="pubmed">16467516</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang D, Hamasaki N. Mitochondrial transcription factor A in the maintenance of mitochondrial DNA: overview of its multiple roles. Ann N Y Acad Sci. 2005;1042:101&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">15965051</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanki T, Nakayama H, Sasaki N, Takio K, Alam TI, Hamasaki N, Kang D. Mitochondrial nucleoid and transcription factor A. Ann N Y Acad Sci. 2004a;1011:61&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">15126284</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanki T, Ohgaki K, Gaspari M, Gustafsson CM, Fukuoh A, Sasaki N, Hamasaki N, Kang D. Architectural role of mitochondrial transcription factor A in maintenance of human mitochondrial DNA. Mol Cell Biol. 2004b;24:9823&#x2013;9834.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC525493</ArticleId><ArticleId IdType="pubmed">15509786</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawson LJ, Perry VH, Gordon S. Turnover of resident microglia in the normal adult mouse brain. Neuroscience. 1992;48:405&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pubmed">1603325</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin MT, Simon DK, Ahn CH, Kim LM, Beal MF. High aggregate burden of somatic mtDNA point mutations in aging and Alzheimer's disease brain. Hum Mol Genet. 2002;11:133&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">11809722</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Head E, Gharib AM, Yuan W, Ingersoll RT, Hagen TM, Cotman CW, Ames BN. Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-l-carnitine and/ or R-&#x3b1;-lipoic acid. Proc Natl Acad Sci U S A. 2002;99:2356&#x2013;2361.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122369</ArticleId><ArticleId IdType="pubmed">11854529</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao L, Zabel C, Wacker MA, Nebrich G, Sagi D, Schrade P, Bachmann S, Kowald A, Klose J. Estimation of the mtDNA mutation rate in aging mice by proteome analysis and mathematical modeling. Exp Gerontol. 2006;41:11&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">16307857</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW. A&#x3b2; peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 2000;408:982&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pubmed">11140686</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris RG, Garrud P, Rawlins JN, O'Keefe J. Place navigation impaired in rats with hippocampus lesions. Nature. 1982;297:681&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pubmed">7088155</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarro A, S&#xe1;nchez Del Pino MJ, G&#xf3;mez C, Peralta JL, Boveris A. Behavioral dysfunction, brain oxidative stress, and impaired mitochondrial electron transfer in aging mice. Am J Physiol Regul Integr Comp Physiol. 2002;282:R985&#x2013;R992.</Citation><ArticleIdList><ArticleId IdType="pubmed">11893601</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarro A, Gomez C, L&#xf3;pez-Cepero JM, Boveris A. Beneficial effects of moderate exercise on mice aging: survival, behavior, oxidative stress, and mitochondrial electron transfer. Am J Physiol Regul Integr Comp Physiol. 2004;286:R505&#x2013;R511.</Citation><ArticleIdList><ArticleId IdType="pubmed">14615275</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarro A, G&#xf3;mez C, S&#xe1;nchez-Pino MJ, Gonz&#xe1;lez H, B&#xe1;ndez MJ, Boveris AD, Boveris A. Vitamin E at high doses improves survival, neurological performance, and brain mitochondrial function in aging male mice. Am J Physiol Regul Integr Comp Physiol. 2005;289:R1329&#x2013;R1399.</Citation><ArticleIdList><ArticleId IdType="pubmed">16020519</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohgaki K, Kanki T, Fukuoh A, Kurisaki H, Aoki Y, Ikeuchi M, Kim SH, Hamasaki N, Kang D. The C-terminal tail of mitochondrial transcription factor A markedly strengthens its general binding to DNA. J Biochem. 2007;141:201&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">17167045</ArticleId></ArticleIdList></Reference><Reference><Citation>Okada M, Nakanishi H, Tamura A, Urae A, Mine K, Yamamoto K, Fujiwara M. Long-term spatial cognitive impairment after middle cerebral artery occlusion in rats: no involvement of the hippocampus. J Cereb Blood Flow Metab. 1995;15:1012&#x2013;1021.</Citation><ArticleIdList><ArticleId IdType="pubmed">7593333</ArticleId></ArticleIdList></Reference><Reference><Citation>Parisi MA, Clayton DA. Similarity of human mitochondrial transcription factor 1 to high mobility group proteins. Science. 1991;252:965&#x2013;969.</Citation><ArticleIdList><ArticleId IdType="pubmed">2035027</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawate S, Shen Q, Fan F, Bhat NR. Redox regulation of glial inflammatory response to lipopolysaccharide and interferon &#x3b3;. J Neurosci Res. 2004;77:540&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pubmed">15264224</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin L, Li G, Qian X, Liu Y, Wu X, Liu B, Hong JS, Block ML. Interactive role of the Toll-like receptor 4 and reactive oxygen species in LPS-induced microglia activation. Glia. 2005;52:78&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15920727</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu Y, Franchi L, Nunez G, Dubyak GR. Nonclassical IL-1&#x3b2; secretion stimulated P2X7 receptors is dependent on inflammasome activation and correlated with exosome release in murine macrophages. J Immunol. 2007;179:1913&#x2013;1925.</Citation><ArticleIdList><ArticleId IdType="pubmed">17641058</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;nfeld P, Reiser G. Rotenone-like action of the branched-chain phytanic acid induces oxidative stress in mitochondria. J Biol Chem. 2006;281:7136&#x2013;7142.</Citation><ArticleIdList><ArticleId IdType="pubmed">16410242</ArticleId></ArticleIdList></Reference><Reference><Citation>Sipos I, Tretter L, Adam-Vizi V. Quantitative relationship between inhibition of respiratory complexes and formation of reactive oxygen species in isolated nerve terminals. J Neurochem. 2003;84:112&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">12485407</ArticleId></ArticleIdList></Reference><Reference><Citation>Tillerson JL, Cohen AD, Caudle WM, Zigmond MJ, Schallert T, Miller GW. Forced nonuse in unilateral parkinsonian rats exacerbates injury. J Neurosci. 2002;22:6790&#x2013;6799.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758159</ArticleId><ArticleId IdType="pubmed">12151559</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomimatsu Y, Idemoto S, Moriguchi S, Watanabe S, Nakanishi H. Proteases involved in long-term potentiation. Life Sci. 2002;72:355&#x2013;361.</Citation><ArticleIdList><ArticleId IdType="pubmed">12467876</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson JB, Arnold MM, Ho YS, O'Dell TJ. Age-dependent modulation of hippocampal long-term potentiation by antioxidant enzymes. J Neurosci Res. 2006;84:1564&#x2013;1574.</Citation><ArticleIdList><ArticleId IdType="pubmed">16941635</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo CH, Lim JH, Kim JH. Lipopolysaccharide induces matrix metalloproteinase-9 expression via a mitochondrial reactive oxygen species-p38 kinase-activator protein-1 pathway in raw 264.7 cells. J Immunol. 2004;173:6973&#x2013;6980.</Citation><ArticleIdList><ArticleId IdType="pubmed">15557194</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamasaki R, Zhang J, Koshiishi I, Sastradipura Suniarti DF, Wu Z, Peters C, Schwake M, Uchiyama Y, Kira J, Saftig P, Utsumi H, Nakanishi H. Involvement of lysosomal storage-induced p38 MAP kinase activation in the overproduction of nitric oxide by microglia in cathepsin D-deficient mice. Mol Cell Neurosci. 2007;35:573&#x2013;584.</Citation><ArticleIdList><ArticleId IdType="pubmed">17570679</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18755980</PMID><DateCompleted><Year>2008</Year><Month>09</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>321</Volume><Issue>5893</Issue><PubDate><Year>2008</Year><Month>Aug</Month><Day>29</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Amyloid-beta dynamics correlate with neurological status in the injured human brain.</ArticleTitle><Pagination><StartPage>1221</StartPage><EndPage>1224</EndPage><MedlinePgn>1221-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.1161591</ELocationID><Abstract><AbstractText>The amyloid-beta peptide (Abeta) plays a central pathophysiological role in Alzheimer's disease, but little is known about the concentration and dynamics of this secreted peptide in the extracellular space of the human brain. We used intracerebral microdialysis to obtain serial brain interstitial fluid (ISF) samples in 18 patients who were undergoing invasive intracranial monitoring after acute brain injury. We found a strong positive correlation between changes in brain ISF Abeta concentrations and neurological status, with Abeta concentrations increasing as neurological status improved and falling when neurological status declined. Brain ISF Abeta concentrations were also lower when other cerebral physiological and metabolic abnormalities reflected depressed neuronal function. Such dynamics fit well with the hypothesis that neuronal activity regulates extracellular Abeta concentration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brody</LastName><ForeName>David L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St. Louis, MO 63110, USA. brodyd@neuro.wustl.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magnoni</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Schwetye</LastName><ForeName>Kate E</ForeName><Initials>KE</Initials></Author><Author ValidYN="Y"><LastName>Spinner</LastName><ForeName>Michael L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Esparza</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials></Author><Author ValidYN="Y"><LastName>Stocchetti</LastName><ForeName>Nino</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Zipfel</LastName><ForeName>Gregory J</ForeName><Initials>GJ</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K08 NS049237</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK056341</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>33X04XA5AT</RegistryNumber><NameOfSubstance UI="D019344">Lactic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>8558G7RUTR</RegistryNumber><NameOfSubstance UI="D019289">Pyruvic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>IY9XDZ35W2</RegistryNumber><NameOfSubstance UI="D005947">Glucose</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001930" MajorTopicYN="N">Brain Injuries</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045604" MajorTopicYN="N">Extracellular Fluid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015600" MajorTopicYN="N">Glasgow Coma Scale</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019586" MajorTopicYN="N">Intracranial Hypertension</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019344" MajorTopicYN="N">Lactic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017551" MajorTopicYN="N">Microdialysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019289" MajorTopicYN="N">Pyruvic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>8</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>9</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>8</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>11</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18755980</ArticleId><ArticleId IdType="mid">NIHMS67864</ArticleId><ArticleId IdType="pmc">PMC2577829</ArticleId><ArticleId IdType="doi">10.1126/science.1161591</ArticleId><ArticleId IdType="pii">321/5893/1221</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe DJ. J Clin Invest. 2002;110:1375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC151820</ArticleId><ArticleId IdType="pubmed">12438432</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F, et al. Neuron. 2003;37:925.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, et al. Neuron. 2005;48:913.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, et al. Neuron. 2008;58:42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2390913</ArticleId><ArticleId IdType="pubmed">18400162</ArticleId></ArticleIdList></Reference><Reference><Citation>Hillered L, Vespa PM, Hovda DA. J Neurotrauma. 2005;22:3.</Citation><ArticleIdList><ArticleId IdType="pubmed">15665601</ArticleId></ArticleIdList></Reference><Reference><Citation>Seubert P, et al. Nature. 1992;359:325.</Citation><ArticleIdList><ArticleId IdType="pubmed">1406936</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson-Wood K, et al. Proc Natl Acad Sci USA. 1997;94:1550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19829</ArticleId><ArticleId IdType="pubmed">9037091</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronne-Engstrom E, et al. J Neurosurg. 2001;94:397.</Citation><ArticleIdList><ArticleId IdType="pubmed">11235942</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutchinson PJ, et al. J Neurosurg. 2000;93:37.</Citation><ArticleIdList><ArticleId IdType="pubmed">10883903</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, et al. Nature. 2002;416:535.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesne S, et al. Nature. 2006;440:352.</Citation><ArticleIdList><ArticleId IdType="pubmed">16541076</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, et al. Nat Med. 2008;14:837.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Teasdale G, Jennett B. Lancet. 1974;2:81.</Citation><ArticleIdList><ArticleId IdType="pubmed">4136544</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarov O, Lee M, Peterson DA, Sisodia SS. J Neurosci. 2002;22:9785.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757836</ArticleId><ArticleId IdType="pubmed">12427834</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, et al. J Neurosci. 2005;25:7709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Wen G, Morris JC, Holtzman DM. Neurology. 2007;68:666.</Citation><ArticleIdList><ArticleId IdType="pubmed">17325273</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts GW, et al. J Neurol Neurosurg Psychiatry. 1994;57:419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1072869</ArticleId><ArticleId IdType="pubmed">8163989</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith DH, Chen XH, Iwata A, Graham DI. J Neurosurg. 2003;98:1072.</Citation><ArticleIdList><ArticleId IdType="pubmed">12744368</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic MD, et al. Exp Neurol. 2004;190:192.</Citation><ArticleIdList><ArticleId IdType="pubmed">15473992</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger KA. Curr Opin Neurol. 2004;17:719.</Citation><ArticleIdList><ArticleId IdType="pubmed">15542981</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesco G, et al. Neuron. 2007;54:721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1973166</ArticleId><ArticleId IdType="pubmed">17553422</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith DH, et al. Am J Pathol. 1998;153:1005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1853010</ArticleId><ArticleId IdType="pubmed">9736050</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahamson EE, et al. Exp Neurol. 2006;197:437.</Citation><ArticleIdList><ArticleId IdType="pubmed">16300758</ArticleId></ArticleIdList></Reference><Reference><Citation>Klyubin I, et al. Nat Med. 2005;11:556.</Citation><ArticleIdList><ArticleId IdType="pubmed">15834427</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleary JP, et al. Nat Neurosci. 2005;8:79.</Citation><ArticleIdList><ArticleId IdType="pubmed">15608634</ArticleId></ArticleIdList></Reference><Reference><Citation>Games D, Buttini M, Kobayashi D, Schenk D, Seubert P. J Alzheimers Dis. 2006;9:133.</Citation><ArticleIdList><ArticleId IdType="pubmed">16914852</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbett R, Laptook A, Weatherall P. J Cereb Blood Flow Metab. 1997;17:363.</Citation><ArticleIdList><ArticleId IdType="pubmed">9143218</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinstrup P, et al. Neurosurgery. 2000;47:701.</Citation><ArticleIdList><ArticleId IdType="pubmed">10981758</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18757748</PMID><DateCompleted><Year>2008</Year><Month>10</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>105</Volume><Issue>35</Issue><PubDate><Year>2008</Year><Month>Sep</Month><Day>02</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae.</ArticleTitle><Pagination><StartPage>13145</StartPage><EndPage>13150</EndPage><MedlinePgn>13145-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0806192105</ELocationID><Abstract><AbstractText>The amyloid beta-peptide (Abeta) has been suggested to exert its toxicity intracellularly. Mitochondrial functions can be negatively affected by Abeta and accumulation of Abeta has been detected in mitochondria. Because Abeta is not likely to be produced locally in mitochondria, we decided to investigate the mechanisms for mitochondrial Abeta uptake. Our results from rat mitochondria show that Abeta is transported into mitochondria via the translocase of the outer membrane (TOM) machinery. The import was insensitive to valinomycin, indicating that it is independent of the mitochondrial membrane potential. Subfractionation studies following the import experiments revealed Abeta association with the inner membrane fraction, and immunoelectron microscopy after import showed localization of Abeta to mitochondrial cristae. A similar distribution pattern of Abeta in mitochondria was shown by immunoelectron microscopy in human cortical brain biopsies obtained from living subjects with normal pressure hydrocephalus. Thus, we present a unique import mechanism for Abeta in mitochondria and demonstrate both in vitro and in vivo that Abeta is located to the mitochondrial cristae. Importantly, we also show that extracellulary applied Abeta can be internalized by human neuroblastoma cells and can colocalize with mitochondrial markers. Together, these results provide further insight into the mitochondrial uptake of Abeta, a peptide considered to be of major significance in Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hansson Petersen</LastName><ForeName>Camilla A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Karolinska Institutet Dainippon Sumitomo Pharma Alzheimer Center, NVS, Novum, 141 57 Huddinge, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alikhani</LastName><ForeName>Nyosha</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Behbahani</LastName><ForeName>Homira</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Wiehager</LastName><ForeName>Birgitta</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Pavlov</LastName><ForeName>Pavel F</ForeName><Initials>PF</Initials></Author><Author ValidYN="Y"><LastName>Alafuzoff</LastName><ForeName>Irina</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Leinonen</LastName><ForeName>Ville</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Akira</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Winblad</LastName><ForeName>Bengt</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Glaser</LastName><ForeName>Elzbieta</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Ankarcrona</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>08</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D024101">Mitochondrial Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.64</RegistryNumber><NameOfSubstance UI="D019286">Endopeptidase K</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004705" MajorTopicYN="N">Endocytosis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019286" MajorTopicYN="N">Endopeptidase K</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005110" MajorTopicYN="N">Extracellular Space</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005434" MajorTopicYN="N">Flow Cytometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005455" MajorTopicYN="N">Fluorescent Antibody Technique</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016253" MajorTopicYN="N">Microscopy, Immunoelectron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008930" MajorTopicYN="N">Mitochondria, Liver</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024101" MajorTopicYN="N">Mitochondrial Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009447" MajorTopicYN="N">Neuroblastoma</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>9</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>10</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>9</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>8</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18757748</ArticleId><ArticleId IdType="pmc">PMC2527349</ArticleId><ArticleId IdType="doi">10.1073/pnas.0806192105</ArticleId><ArticleId IdType="pii">0806192105</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vassar R, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimberly WT, et al. Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Proc Natl Acad Sci USA. 2003;100:6382&#x2013;6387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC164455</ArticleId><ArticleId IdType="pubmed">12740439</ArticleId></ArticleIdList></Reference><Reference><Citation>Glenner GG, Wong CW. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun. 1984;122:1131&#x2013;1135.</Citation><ArticleIdList><ArticleId IdType="pubmed">6236805</ArticleId></ArticleIdList></Reference><Reference><Citation>Masters CL, et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA. 1985;82:4245&#x2013;4249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC397973</ArticleId><ArticleId IdType="pubmed">3159021</ArticleId></ArticleIdList></Reference><Reference><Citation>Soderberg L, et al. Analysis of single Alzheimer solid plaque cores by laser capture microscopy and nanoelectrospray/tandem mass spectrometry. Biochemistry. 2006;45:9849&#x2013;9856.</Citation><ArticleIdList><ArticleId IdType="pubmed">16893185</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Tseng BP, Rydel RE, Podlisny MB, Selkoe DJ. The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry. 2000;39:10831&#x2013;10839.</Citation><ArticleIdList><ArticleId IdType="pubmed">10978169</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA. 1998;95:6448&#x2013;6453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi RH, et al. Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain. J Neurosci. 2004;24:3592&#x2013;3599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729733</ArticleId><ArticleId IdType="pubmed">15071107</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouras GK, v Intraneuronal A{beta}42 accumulation in human brain. Am J Pathol. 2000;156:15&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1868613</ArticleId><ArticleId IdType="pubmed">10623648</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirths O, Multhaup G, Bayer TA. A modified &#x3b2;-amyloid hypothesis: intraneuronal accumulation of the &#x3b2;-amyloid peptide&#x2014;the first step of a fatal cascade. J Neurochem. 2004;91:513&#x2013;520.</Citation><ArticleIdList><ArticleId IdType="pubmed">15485483</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Su B, Perry G, Smith MA, Zhu X. Insights into amyloid-beta-induced mitochondrial dysfunction in Alzheimer disease. Free Radic Biol Med. 2007;43:1569&#x2013;1573.</Citation><ArticleIdList><ArticleId IdType="pubmed">18037122</ArticleId></ArticleIdList></Reference><Reference><Citation>Caspersen C, et al. Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J. 2005;19:2040&#x2013;2041.</Citation><ArticleIdList><ArticleId IdType="pubmed">16210396</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirai K, et al. Mitochondrial abnormalities in Alzheimer's disease. J Neurosci. 2001;21:3017&#x2013;3023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762571</ArticleId><ArticleId IdType="pubmed">11312286</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging. 2005;32:486&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">15747152</ArticleId></ArticleIdList></Reference><Reference><Citation>Bubber P, Haroutunian V, Fisch G, Blass JP, Gibson GE. Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann Neurol. 2005;57:695&#x2013;703.</Citation><ArticleIdList><ArticleId IdType="pubmed">15852400</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker WD, Jr, Filley CM, Parks JK. Cytochrome oxidase deficiency in Alzheimer's disease. Neurology. 1990;40:1302&#x2013;1303.</Citation><ArticleIdList><ArticleId IdType="pubmed">2166249</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker WD, Jr, Parks JK. Cytochrome c oxidase in Alzheimer's disease brain: purification and characterization. Neurology. 1995;45:482&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">7898701</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardoso SM, Santana I, Swerdlow RH, Oliveira CR. Mitochondria dysfunction of Alzheimer's disease cybrids enhances Abeta toxicity. J Neurochem. 2004;89:1417&#x2013;1426.</Citation><ArticleIdList><ArticleId IdType="pubmed">15189344</ArticleId></ArticleIdList></Reference><Reference><Citation>Kish SJ, et al. Brain cytochrome oxidase in Alzheimer's disease. J Neurochem. 1992;59:776&#x2013;779.</Citation><ArticleIdList><ArticleId IdType="pubmed">1321237</ArticleId></ArticleIdList></Reference><Reference><Citation>Crouch PJ, et al. Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42. J Neurosci. 2005;25:672&#x2013;679.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725334</ArticleId><ArticleId IdType="pubmed">15659604</ArticleId></ArticleIdList></Reference><Reference><Citation>Lustbader JW, et al. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science. 2004;304:448&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">15087549</ArticleId></ArticleIdList></Reference><Reference><Citation>Falkevall A, et al. Degradation of the amyloid beta-protein by the novel mitochondrial peptidasome, PreP. The J Biol Chem. 2006;281:29096&#x2013;29104.</Citation><ArticleIdList><ArticleId IdType="pubmed">16849325</ArticleId></ArticleIdList></Reference><Reference><Citation>Anandatheerthavarada HK, Biswas G, Robin MA, Avadhani NG. Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells. J Cell Biol. 2003;161:41&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172865</ArticleId><ArticleId IdType="pubmed">12695498</ArticleId></ArticleIdList></Reference><Reference><Citation>Devi L, Prabhu BM, Galati DF, Avadhani NG, Anandatheerthavarada HK. Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction. J Neurosci. 2006;26:9057&#x2013;9068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675337</ArticleId><ArticleId IdType="pubmed">16943564</ArticleId></ArticleIdList></Reference><Reference><Citation>Neupert W, Herrmann J. M. Translocation of proteins into mitochondria. Annu Rev Biochem. 2007;76:723&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pubmed">17263664</ArticleId></ArticleIdList></Reference><Reference><Citation>Rehling P, Pfanner N, Meisinger C. Insertion of hydrophobic membrane proteins into the inner mitochondrial membrane&#x2014;a guided tour. J Mol Biol. 2003;326:639&#x2013;657.</Citation><ArticleIdList><ArticleId IdType="pubmed">12581629</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasola A, Bernardi P. The mitochondrial permeability transition pore and its involvement in cell death and in disease pathogenesis. Apoptosis. 2007;12:815&#x2013;833.</Citation><ArticleIdList><ArticleId IdType="pubmed">17294078</ArticleId></ArticleIdList></Reference><Reference><Citation>Manczak M, et al. Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet. 2006;15:1437&#x2013;1449.</Citation><ArticleIdList><ArticleId IdType="pubmed">16551656</ArticleId></ArticleIdList></Reference><Reference><Citation>Sirk D, et al. Chronic exposure to sub-lethal beta-amyloid (Abeta) inhibits the import of nuclear-encoded proteins to mitochondria in differentiated PC12 cells. J Neurochem. 2007;103:1989&#x2013;2003.</Citation><ArticleIdList><ArticleId IdType="pubmed">17868329</ArticleId></ArticleIdList></Reference><Reference><Citation>Truscott KN, Brandner K, Pfanner N. Mechanisms of protein import into mitochondria. Curr Biol. 2003;13:R326&#x2013;R337.</Citation><ArticleIdList><ArticleId IdType="pubmed">12699647</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundin C, et al. Stable insertion of Alzheimer Abeta peptide into the ER membrane strongly correlates with its length. FEBS Lett. 2007;581:3809&#x2013;3813.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2000821</ArticleId><ArticleId IdType="pubmed">17659280</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouras GK, Almeida CG, Takahashi RH. Intraneuronal Abeta accumulation and origin of plaques in Alzheimer's disease. Neurobiol Aging. 2005;26:1235&#x2013;1244.</Citation><ArticleIdList><ArticleId IdType="pubmed">16023263</ArticleId></ArticleIdList></Reference><Reference><Citation>Saavedra L, Mohamed A, Ma V, Kar S, de Chaves EP. Internalization of beta-amyloid peptide by primary neurons in the absence of apolipoprotein E. J Biol Chem. 2007;282:35722&#x2013;35732.</Citation><ArticleIdList><ArticleId IdType="pubmed">17911110</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattiasson G, Friberg H, Hansson M, Elmer E, Wieloch T. Flow cytometric analysis of mitochondria from CA1 and CA3 regions of rat hippocampus reveals differences in permeability transition pore activation. J Neurochem. 2003;87:532&#x2013;544.</Citation><ArticleIdList><ArticleId IdType="pubmed">14511130</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokuyasu KT. A technique for ultracryotomy of cell suspensions and tissues. J Cell Biol. 1973;57:551&#x2013;565.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2108989</ArticleId><ArticleId IdType="pubmed">4121290</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Noorden S. Tissue preparation and immunostaining techniques for light microscopy. In: Polak JM, Van Noorden S, editors. Immunocytochemistry: Modern Methods and Applications. 2nd Ed. Bristol, England: John Wright &amp; Sons; 1986.</Citation></Reference><Reference><Citation>Sodersten F, et al. Ultrastructural immunolocalization of cartilage oligomeric matrix protein (COMP) in relation to collagen fibrils in the equine tendon. Matrix Biol. 2005;24:376&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pubmed">16005620</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18802446</PMID><DateCompleted><Year>2008</Year><Month>10</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1471-0048</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>10</Issue><PubDate><Year>2008</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Nature reviews. Neuroscience</Title><ISOAbbreviation>Nat Rev Neurosci</ISOAbbreviation></Journal><ArticleTitle>Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses.</ArticleTitle><Pagination><StartPage>768</StartPage><EndPage>778</EndPage><MedlinePgn>768-78</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nrn2494</ELocationID><Abstract><AbstractText>The genetic underpinnings of Alzheimer's disease (AD) remain largely elusive despite early successes in identifying three genes that cause early-onset familial AD (those that encode amyloid precursor protein (APP) and the presenilins (PSEN1 and PSEN2)), and one genetic risk factor for late-onset AD (the gene that encodes apolipoprotein E (APOE)). A large number of studies that aimed to help uncover the remaining disease-related loci have been published in recent decades, collectively proposing or refuting the involvement of over 500 different gene candidates. Systematic meta-analyses of these studies currently highlight more than 20 loci that have modest but significant effects on AD risk. This Review discusses the putative pathogenetic roles and common biochemical pathways of some of the most genetically and biologically compelling of these potential AD risk factors.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bertram</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Diseases, Department of Neurology, Massachusetts General Hospital, 114 16th Street, Charlestown, Massachusetts 02129, USA. bertram@helix.mgh.harvard.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanzi</LastName><ForeName>Rudolph E</ForeName><Initials>RE</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>5R01AG23667</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5R37MH60009</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Rev Neurosci</MedlineTA><NlmUniqueID>100962781</NlmUniqueID><ISSNLinking>1471-003X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053763">Presenilins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015201" MajorTopicYN="Y">Meta-Analysis as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053763" MajorTopicYN="N">Presenilins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>110</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>9</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>10</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>9</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18802446</ArticleId><ArticleId IdType="doi">10.1038/nrn2494</ArticleId><ArticleId IdType="pii">nrn2494</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18926603</PMID><DateCompleted><Year>2010</Year><Month>11</Month><Day>30</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-1497</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>9</Issue><PubDate><Year>2010</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Neurobiology of aging</Title><ISOAbbreviation>Neurobiol Aging</ISOAbbreviation></Journal><ArticleTitle>High-fat diet aggravates amyloid-beta and tau pathologies in the 3xTg-AD mouse model.</ArticleTitle><Pagination><StartPage>1516</StartPage><EndPage>1531</EndPage><MedlinePgn>1516-31</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neurobiolaging.2008.08.022</ELocationID><Abstract><AbstractText>To investigate potential dietary risk factors of Alzheimer's disease (AD), triple transgenic (3xTg-AD) mice were exposed from 4 to 13 months of age to diets with a low n-3:n-6 polyunsaturated fatty acid (PUFA) ratio incorporated in either low-fat (5% w/w) or high-fat (35% w/w) formulas and compared with a control diet. The n-3:n-6 PUFA ratio was decreased independently of the dietary treatments in the frontal cortex of 3xTg-AD mice compared to non-transgenic littermates. Consumption of a high-fat diet with a low n-3:n-6 PUFA ratio increased amyloid-beta (Abeta) 40 and 42 concentrations in detergent-insoluble extracts of parieto-temporal cortex homogenates from 3xTg-AD mice. Low n-3:n-6 PUFA intake ratio increased insoluble tau regardless of total fat consumption, whereas high-fat diet incorporating a low n-3:n-6 PUFA ratio also increased soluble tau compared to controls. Moreover, the high-fat diet decreased cortical levels of the postsynaptic marker drebrin, while leaving presynaptic proteins synaptophysin, SNAP-25 and syntaxin 3 unchanged. Overall, these results suggest that high-fat consumption combined with low n-3 PUFA intake promote AD-like neuropathology.</AbstractText><CopyrightInformation>Copyright 2008 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Julien</LastName><ForeName>Carl</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Faculty of Pharmacy, Laval University, Quebec, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tremblay</LastName><ForeName>Cyntia</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Phivilay</LastName><ForeName>Alix</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Berthiaume</LastName><ForeName>Line</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Emond</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Julien</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Calon</LastName><ForeName>Fr&#xe9;d&#xe9;ric</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CAN-76833</GrantID><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant><Grant><GrantID>MOP74443</GrantID><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>10</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Aging</MedlineTA><NlmUniqueID>8100437</NlmUniqueID><ISSNLinking>0197-4580</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004041">Dietary Fats</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015525">Fatty Acids, Omega-3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004041" MajorTopicYN="N">Dietary Fats</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015525" MajorTopicYN="N">Fatty Acids, Omega-3</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2008</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>10</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>10</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18926603</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2008.08.022</ArticleId><ArticleId IdType="pii">S0197-4580(08)00326-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18942891</PMID><DateCompleted><Year>2009</Year><Month>01</Month><Day>05</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1545-7885</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>10</Issue><PubDate><Year>2008</Year><Month>Oct</Month><Day>21</Day></PubDate></JournalIssue><Title>PLoS biology</Title><ISOAbbreviation>PLoS Biol</ISOAbbreviation></Journal><ArticleTitle>Proteomic profiling of gamma-secretase substrates and mapping of substrate requirements.</ArticleTitle><Pagination><StartPage>e257</StartPage><MedlinePgn>e257</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e257</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pbio.0060257</ELocationID><Abstract><AbstractText>The presenilin/gamma-secretase complex, an unusual intramembrane aspartyl protease, plays an essential role in cellular signaling and membrane protein turnover. Its ability to liberate numerous intracellular signaling proteins from the membrane and also mediate the secretion of amyloid-beta protein (Abeta) has made modulation of gamma-secretase activity a therapeutic goal for cancer and Alzheimer disease. Although the proteolysis of the prototypical substrates Notch and beta-amyloid precursor protein (APP) has been intensely studied, the full spectrum of substrates and the determinants that make a transmembrane protein a substrate remain unclear. Using an unbiased approach to substrate identification, we surveyed the proteome of a human cell line for targets of gamma-secretase and found a relatively small population of new substrates, all of which are type I transmembrane proteins but have diverse biological roles. By comparing these substrates to type I proteins not regulated by gamma-secretase, we determined that besides a short ectodomain, gamma-secretase requires permissive transmembrane and cytoplasmic domains to bind and cleave its substrates. In addition, we provide evidence for at least two mechanisms that can target a substrate for gamma cleavage: one in which a substrate with a short ectodomain is directly cleaved independent of sheddase association, and a second where a substrate requires ectodomain shedding to instruct subsequent gamma-secretase processing. These findings expand our understanding of the mechanisms of substrate selection as well as the diverse cellular processes to which gamma-secretase contributes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hemming</LastName><ForeName>Matthew L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elias</LastName><ForeName>Joshua E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Gygi</LastName><ForeName>Steven P</ForeName><Initials>SP</Initials></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis J</ForeName><Initials>DJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG015379</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HG003456</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG015379</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HG3456</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Biol</MedlineTA><NlmUniqueID>101183755</NlmUniqueID><ISSNLinking>1544-9173</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014280">Triglycerides</NameOfSubstance></Chemical><Chemical><RegistryNumber>56-12-2</RegistryNumber><NameOfSubstance UI="D005680">gamma-Aminobutyric Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>93349-26-9</RegistryNumber><NameOfSubstance UI="C057077">1,2-dilinolenoyl-3-(4-aminobutyryl)propane-1,2,3-triol</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>YOW8V9698H</RegistryNumber><NameOfSubstance UI="D004121">Dimethyl Sulfoxide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002853" MajorTopicYN="N">Chromatography, Liquid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004121" MajorTopicYN="N">Dimethyl Sulfoxide</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004591" MajorTopicYN="N">Electrophoresis, Polyacrylamide Gel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015151" MajorTopicYN="N">Immunoblotting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047468" MajorTopicYN="N">Immunoprecipitation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013379" MajorTopicYN="N">Substrate Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053719" MajorTopicYN="N">Tandem Mass Spectrometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014280" MajorTopicYN="N">Triglycerides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005680" MajorTopicYN="N">gamma-Aminobutyric Acid</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>
<b>Competing interests.</b> The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>10</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>1</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>10</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>10</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18942891</ArticleId><ArticleId IdType="pmc">PMC2570425</ArticleId><ArticleId IdType="doi">10.1371/journal.pbio.0060257</ArticleId><ArticleId IdType="pii">08-PLBI-RA-1539</ArticleId><ArticleId IdType="sici">plbi-06-10-14</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ebinu JO, Yankner BA. A RIP tide in neuronal signal transduction. Neuron. 2002;34:499&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">12062033</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown MS, Ye J, Rawson RB, Goldstein JL. Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans. Cell. 2000;100:391&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">10693756</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer disease: mechanistic understanding predicts novel therapies. Ann Intern Med. 2004;140:627&#x2013;638.</Citation><ArticleIdList><ArticleId IdType="pubmed">15096334</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS. The gamma-secretase complex: membrane-embedded proteolytic ensemble. Biochemistry. 2006;45:7931&#x2013;7939.</Citation><ArticleIdList><ArticleId IdType="pubmed">16800619</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001;81:741&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih Ie M, Wang TL. Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res. 2007;67:1879&#x2013;1882.</Citation><ArticleIdList><ArticleId IdType="pubmed">17332312</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarov VK, Fraering PC, Ye W, Wolfe MS, Selkoe DJ, et al. Electron microscopic structure of purified, active gamma-secretase reveals an aqueous intramembrane chamber and two pores. Proc Natl Acad Sci U S A. 2006;103:6889&#x2013;6894.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1458989</ArticleId><ArticleId IdType="pubmed">16636269</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato C, Morohashi Y, Tomita T, Iwatsubo T. Structure of the catalytic pore of gamma-secretase probed by the accessibility of substituted cysteines. J Neurosci. 2006;26:12081&#x2013;12088.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674866</ArticleId><ArticleId IdType="pubmed">17108181</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopan R, Ilagan MX. Gamma-secretase: proteasome of the membrane. Nat Rev Mol Cell Biol. 2004;5:499&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pubmed">15173829</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakahara S, Saito T, Kondo N, Moriwaki K, Noda K, et al. A secreted type of beta1,6 N-acetylglucosaminyltransferase V (GnT-V), a novel angiogenesis inducer, is regulated by gamma-secretase. Faseb J. 2006;20:2451&#x2013;2459.</Citation><ArticleIdList><ArticleId IdType="pubmed">17142794</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer EL, Strutz N, Gahring LC, Rogers SW. Glutamate receptor subunit 3 is modified by site-specific limited proteolysis including cleavage by gamma-secretase. J Biol Chem. 2003;278:23786&#x2013;23796.</Citation><ArticleIdList><ArticleId IdType="pubmed">12700243</ArticleId></ArticleIdList></Reference><Reference><Citation>Kratchmarova I, Blagoev B, Haack-Sorensen M, Kassem M, Mann M. Mechanism of divergent growth factor effects in mesenchymal stem cell differentiation. Science. 2005;308:1472&#x2013;1477.</Citation><ArticleIdList><ArticleId IdType="pubmed">15933201</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER, 3rd, Hurov KE, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science. 2007;316:1160&#x2013;1166.</Citation><ArticleIdList><ArticleId IdType="pubmed">17525332</ArticleId></ArticleIdList></Reference><Reference><Citation>Everley PA, Bakalarski CE, Elias JE, Waghorne CG, Beausoleil SA, et al. Enhanced analysis of metastatic prostate cancer using stable isotopes and high mass accuracy instrumentation. J Proteome Res. 2006;5:1224&#x2013;1231.</Citation><ArticleIdList><ArticleId IdType="pubmed">16674112</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Fadeeva JV, LaVoie MJ, Paliga K, Eggert S, et al. gamma-Secretase cleavage and binding to FE65 regulate the nuclear translocation of the intracellular C-terminal domain (ICD) of the APP family of proteins. Biochemistry. 2003;42:6664&#x2013;6673.</Citation><ArticleIdList><ArticleId IdType="pubmed">12779321</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamoto I, Kawano Y, Murakami D, Sasayama T, Araki N, et al. Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway. J Cell Biol. 2001;155:755&#x2013;762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2150876</ArticleId><ArticleId IdType="pubmed">11714729</ArticleId></ArticleIdList></Reference><Reference><Citation>Heber S, Herms J, Gajic V, Hainfellner J, Aguzzi A, et al. Mice with combined gene knock-outs reveal essential and partially redundant functions of amyloid precursor protein family members. J Neurosci. 2000;20:7951&#x2013;7963.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772747</ArticleId><ArticleId IdType="pubmed">11050115</ArticleId></ArticleIdList></Reference><Reference><Citation>Carey BW, Kim DY, Kovacs DM. Presenilin/gamma-secretase and alpha-secretase-like peptidases cleave human MHC Class I proteins. Biochem J. 2007;401:121&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1698663</ArticleId><ArticleId IdType="pubmed">17150042</ArticleId></ArticleIdList></Reference><Reference><Citation>May P, Reddy YK, Herz J. Proteolytic processing of low density lipoprotein receptor-related protein mediates regulated release of its intracellular domain. J Biol Chem. 2002;277:18736&#x2013;18743.</Citation><ArticleIdList><ArticleId IdType="pubmed">11907044</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz JG, Annaert W, Vandekerckhove J, Zimmermann P, De Strooper B, et al. Syndecan 3 intramembrane proteolysis is presenilin/gamma-secretase-dependent and modulates cytosolic signaling. J Biol Chem. 2003;278:48651&#x2013;48657.</Citation><ArticleIdList><ArticleId IdType="pubmed">14504279</ArticleId></ArticleIdList></Reference><Reference><Citation>Herreman A, Van Gassen G, Bentahir M, Nyabi O, Craessaerts K, et al. gamma-Secretase activity requires the presenilin-dependent trafficking of nicastrin through the Golgi apparatus but not its complex glycosylation. J Cell Sci. 2003;116:1127&#x2013;1136.</Citation><ArticleIdList><ArticleId IdType="pubmed">12584255</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CX, Ranganathan S, Robinson S, Strickland DK. gamma-Secretase-mediated release of the low density lipoprotein receptor-related protein 1B intracellular domain suppresses anchorage-independent growth of neuroglioma cells. J Biol Chem. 2007;282:7504&#x2013;7511.</Citation><ArticleIdList><ArticleId IdType="pubmed">17227771</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas IG, Frank M, Veron N, Kemler R. Presenilin-dependent processing and nuclear function of gamma-protocadherins. J Biol Chem. 2005;280:9313&#x2013;9319.</Citation><ArticleIdList><ArticleId IdType="pubmed">15611067</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomita T, Tanaka S, Morohashi Y, Iwatsubo T. Presenilin-dependent intramembrane cleavage of ephrin-B1. Mol Neurodegener. 2006;1:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1513130</ArticleId><ArticleId IdType="pubmed">16930449</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda Y, Imai Y, Kumagai H, Nosaka T, Morikawa Y, et al. Vasorin, a transforming growth factor beta-binding protein expressed in vascular smooth muscle cells, modulates the arterial response to injury in vivo. Proc Natl Acad Sci U S A. 2004;101:10732&#x2013;10737.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC490003</ArticleId><ArticleId IdType="pubmed">15247411</ArticleId></ArticleIdList></Reference><Reference><Citation>Barresi R, Campbell KP. Dystroglycan: from biosynthesis to pathogenesis of human disease. J Cell Sci. 2006;119:199&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">16410545</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi YK, Ogawa M, Tagawa K, Noguchi S, Ishihara T, et al. Selective deficiency of alpha-dystroglycan in Fukuyama-type congenital muscular dystrophy. Neurology. 2001;57:115&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pubmed">11445638</ArticleId></ArticleIdList></Reference><Reference><Citation>Holt KH, Crosbie RH, Venzke DP, Campbell KP. Biosynthesis of dystroglycan: processing of a precursor propeptide. FEBS Lett. 2000;468:79&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">10683445</ArticleId></ArticleIdList></Reference><Reference><Citation>Eiraku M, Tohgo A, Ono K, Kaneko M, Fujishima K, et al. DNER acts as a neuron-specific Notch ligand during Bergmann glial development. Nat Neurosci. 2005;8:873&#x2013;880.</Citation><ArticleIdList><ArticleId IdType="pubmed">15965470</ArticleId></ArticleIdList></Reference><Reference><Citation>Tohgo A, Eiraku M, Miyazaki T, Miura E, Kawaguchi SY, et al. Impaired cerebellar functions in mutant mice lacking DNER. Mol Cell Neurosci. 2006;31:326&#x2013;333.</Citation><ArticleIdList><ArticleId IdType="pubmed">16298139</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339:321&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pubmed">9682046</ArticleId></ArticleIdList></Reference><Reference><Citation>Maack T, Suzuki M, Almeida FA, Nussenzveig D, Scarborough RM, et al. Physiological role of silent receptors of atrial natriuretic factor. Science. 1987;238:675&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pubmed">2823385</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaubert J, Jaubert F, Martin N, Washburn LL, Lee BK, et al. Three new allelic mouse mutations that cause skeletal overgrowth involve the natriuretic peptide receptor C gene (Npr3) Proc Natl Acad Sci U S A. 1999;96:10278&#x2013;10283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC17879</ArticleId><ArticleId IdType="pubmed">10468599</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsukawa N, Grzesik WJ, Takahashi N, Pandey KN, Pang S, et al. The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. Proc Natl Acad Sci U S A. 1999;96:7403&#x2013;7408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22098</ArticleId><ArticleId IdType="pubmed">10377427</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose RA, Giles WR. Natriuretic peptide C receptor signalling in the heart and vasculature. J Physiol. 2008;586:353&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2375602</ArticleId><ArticleId IdType="pubmed">18006579</ArticleId></ArticleIdList></Reference><Reference><Citation>Getsios S, Huen AC, Green KJ. Working out the strength and flexibility of desmosomes. Nat Rev Mol Cell Biol. 2004;5:271&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">15071552</ArticleId></ArticleIdList></Reference><Reference><Citation>Brennan D, Hu Y, Joubeh S, Choi YW, Whitaker-Menezes D, et al. Suprabasal Dsg2 expression in transgenic mouse skin confers a hyperproliferative and apoptosis-resistant phenotype to keratinocytes. J Cell Sci. 2007;120:758&#x2013;771.</Citation><ArticleIdList><ArticleId IdType="pubmed">17284515</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller SF, Summerhurst K, Runker AE, Kerjan G, Friedel RH, et al. Expression of Plxdc2/TEM7R in the developing nervous system of the mouse. Gene Expr Patterns. 2007;7:635&#x2013;644.</Citation><ArticleIdList><ArticleId IdType="pubmed">17280871</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson-Walter EB, Watkins DN, Nanda A, Vogelstein B, Kinzler KW, et al. Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res. 2001;61:6649&#x2013;6655.</Citation><ArticleIdList><ArticleId IdType="pubmed">11559528</ArticleId></ArticleIdList></Reference><Reference><Citation>Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110:673&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pubmed">12297042</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlstrom H, Bergman A, Lendahl U, Naslund J, Lundkvist J. A sensitive and quantitative assay for measuring cleavage of presenilin substrates. J Biol Chem. 2002;277:6763&#x2013;6766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11744687</ArticleId></ArticleIdList></Reference><Reference><Citation>Munter LM, Voigt P, Harmeier A, Kaden D, Gottschalk KE, et al. GxxxG motifs within the amyloid precursor protein transmembrane sequence are critical for the etiology of Abeta42. Embo J. 2007;26:1702&#x2013;1712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1829382</ArticleId><ArticleId IdType="pubmed">17332749</ArticleId></ArticleIdList></Reference><Reference><Citation>Sardi SP, Murtie J, Koirala S, Patten BA, Corfas G. Presenilin-dependent ErbB4 nuclear signaling regulates the timing of astrogenesis in the developing brain. Cell. 2006;127:185&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">17018285</ArticleId></ArticleIdList></Reference><Reference><Citation>Struhl G, Adachi A. Requirements for presenilin-dependent cleavage of notch and other transmembrane proteins. Mol Cell. 2000;6:625&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pubmed">11030342</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev. 2006;27:47&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">16291870</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia W, Ray WJ, Ostaszewski BL, Rahmati T, Kimberly WT, et al. Presenilin complexes with the C-terminal fragments of amyloid precursor protein at the sites of amyloid beta-protein generation. Proc Natl Acad Sci U S A. 2000;97:9299&#x2013;9304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16862</ArticleId><ArticleId IdType="pubmed">10922078</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray WJ, Yao M, Nowotny P, Mumm J, Zhang W, et al. Evidence for a physical interaction between presenilin and Notch. Proc Natl Acad Sci U S A. 1999;96:3263&#x2013;3268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15930</ArticleId><ArticleId IdType="pubmed">10077672</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah S, Lee SF, Tabuchi K, Hao YH, Yu C, et al. Nicastrin functions as a gamma-secretase-substrate receptor. Cell. 2005;122:435&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pubmed">16096062</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornilova AY, Bihel F, Das C, Wolfe MS. The initial substrate-binding site of gamma-secretase is located on presenilin near the active site. Proc Natl Acad Sci U S A. 2005;102:3230&#x2013;3235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC552920</ArticleId><ArticleId IdType="pubmed">15722417</ArticleId></ArticleIdList></Reference><Reference><Citation>Urban S. Rhomboid proteins: conserved membrane proteases with divergent biological functions. Genes Dev. 2006;20:3054&#x2013;3068.</Citation><ArticleIdList><ArticleId IdType="pubmed">17114579</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Wolfe MS. Presenilin: running with scissors in the membrane. Cell. 2007;131:215&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">17956719</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin L, Fluhrer R, Reiss K, Kremmer E, Saftig P, et al. Regulated intramembrane proteolysis of Bri2 (Itm2b) by ADAM10 and SPPL2a/SPPL2b. J Biol Chem. 2008;283:1644&#x2013;1652.</Citation><ArticleIdList><ArticleId IdType="pubmed">17965014</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Y, Joachimiak A, Rosner MR, Tang WJ. Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism. Nature. 2006;443:870&#x2013;874.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3366509</ArticleId><ArticleId IdType="pubmed">17051221</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao WA, Aebersold R. Advances in quantitative proteomics via stable isotope tagging and mass spectrometry. Curr Opin Biotechnol. 2003;14:110&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">12566010</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature. 1999;398:518&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206645</ArticleId></ArticleIdList></Reference><Reference><Citation>Marambaud P, Wen PH, Dutt A, Shioi J, Takashima A, et al. A CBP binding transcriptional repressor produced by the PS1/epsilon-cleavage of N-cadherin is inhibited by PS1 FAD mutations. Cell. 2003;114:635&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pubmed">13678586</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma QH, Futagawa T, Yang WL, Jiang XD, Zeng L, et al. A TAG1-APP signalling pathway through Fe65 negatively modulates neurogenesis. Nat Cell Biol. 2008;10:283&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">18278038</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao X, Sudhof TC. A transcriptionally [correction of transcriptively] active complex of APP with Fe65 and histone acetyltransferase Tip60. Science. 2001;293:115&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">11441186</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert SS, Serneels L, Tolia A, Craessaerts K, Derks C, et al. Regulated intramembrane proteolysis of amyloid precursor protein and regulation of expression of putative target genes. EMBO Rep. 2006;7:739&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1500829</ArticleId><ArticleId IdType="pubmed">16729020</ArticleId></ArticleIdList></Reference><Reference><Citation>LaVoie MJ, Selkoe DJ. The Notch ligands, Jagged and Delta, are sequentially processed by alpha-secretase and presenilin/gamma-secretase and release signaling fragments. J Biol Chem. 2003;278:34427&#x2013;34437.</Citation><ArticleIdList><ArticleId IdType="pubmed">12826675</ArticleId></ArticleIdList></Reference><Reference><Citation>Nava P, Laukoetter MG, Hopkins AM, Laur O, Gerner-Smidt K, et al. Desmoglein-2: a novel regulator of apoptosis in the intestinal epithelium. Mol Biol Cell. 2007;18:4565&#x2013;4578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2043542</ArticleId><ArticleId IdType="pubmed">17804817</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Ye W, Wang R, Wolfe MS, Greenberg BD, et al. Proteolysis of chimeric beta-amyloid precursor proteins containing the Notch transmembrane domain yields amyloid beta-like peptides. J Biol Chem. 2002;277:15069&#x2013;15075.</Citation><ArticleIdList><ArticleId IdType="pubmed">11839734</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren Z, Schenk D, Basi GS, Shapiro IP. Amyloid beta-protein precursor juxtamembrane domain regulates specificity of gamma-secretase-dependent cleavages. J Biol Chem. 2007;282:35350&#x2013;35360.</Citation><ArticleIdList><ArticleId IdType="pubmed">17890228</ArticleId></ArticleIdList></Reference><Reference><Citation>Urban S, Freeman M. Substrate specificity of rhomboid intramembrane proteases is governed by helix-breaking residues in the substrate transmembrane domain. Mol Cell. 2003;11:1425&#x2013;1434.</Citation><ArticleIdList><ArticleId IdType="pubmed">12820957</ArticleId></ArticleIdList></Reference><Reference><Citation>Dovey HF, John V, Anderson JP, Chen LZ, de Saint Andrieu P, et al. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem. 2001;76:173&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">11145990</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas W, Faherty BK, Gerber SA, Elias JE, Beausoleil SA, et al. Optimization and use of peptide mass measurement accuracy in shotgun proteomics. Mol Cell Proteomics. 2006;5:1326&#x2013;1337.</Citation><ArticleIdList><ArticleId IdType="pubmed">16635985</ArticleId></ArticleIdList></Reference><Reference><Citation>Elias JE, Gygi SP. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat Methods. 2007;4:207&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">17327847</ArticleId></ArticleIdList></Reference><Reference><Citation>Kersey PJ, Duarte J, Williams A, Karavidopoulou Y, Birney E, et al. The International Protein Index: an integrated database for proteomics experiments. Proteomics. 2004;4:1985&#x2013;1988.</Citation><ArticleIdList><ArticleId IdType="pubmed">15221759</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakalarski CE, Elias JE, Villen J, Haas W, Gerber SA, et al. The impact of peptide abundance and dynamic range on stable-isotope-based quantitative proteomic analyses. J Proteome Res. E-pub ahead of print. PMID: 18798661; 2008.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2746028</ArticleId><ArticleId IdType="pubmed">18798661</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemming ML, Patterson M, Reske-Nielsen C, Lin L, Isacson O, et al.  Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease. PLoS Med. 2007;4(8):e262.  doi: 10.1371/journal.pmed.0040262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.0040262</ArticleId><ArticleId IdType="pmc">PMC1952204</ArticleId><ArticleId IdType="pubmed">17760499</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemming ML, Selkoe DJ. Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem. 2005;280:37644&#x2013;37650.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2409196</ArticleId><ArticleId IdType="pubmed">16154999</ArticleId></ArticleIdList></Reference><Reference><Citation>Osenkowski P, Ye W, Wang R, Wolfe MS, Selkoe DJ. Direct and potent regulation of gamma -secretase by its lipid microenvironment. J Biol Chem. 2008;283:22529&#x2013;22540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2504869</ArticleId><ArticleId IdType="pubmed">18539594</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18945886</PMID><DateCompleted><Year>2008</Year><Month>12</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>43</Issue><PubDate><Year>2008</Year><Month>Oct</Month><Day>22</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Abeta oligomers induce neuronal cell cycle events in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>10786</StartPage><EndPage>10793</EndPage><MedlinePgn>10786-93</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.2441-08.2008</ELocationID><Abstract><AbstractText>Neurons subject to degeneration in Alzheimer's disease (AD) exhibit evidence of re-entry into a mitotic cell cycle even before the development of substantial AD brain pathology. In efforts to identify the initiating factors underlying these cell cycle events (CCEs), we have characterized the appearance of the neuronal CCEs in the genomic-based R1.40 transgenic mouse model of AD. Notably, R1.40 mice exhibit neuronal CCEs in a reproducible temporal and spatial pattern that recapitulates the neuronal vulnerability seen in human AD. Neuronal CCEs first appear at 6 months in the frontal cortex layers II/III. This is 6-8 months before detectable amyloid beta (Abeta) deposition, suggesting that specific amyloid precursor protein (APP) processing products are responsible for the induction of neuronal CCEs. Furthermore, a reduction in the levels of Abeta (achieved by shifting the genetic background from C57BL/6 to the DBA/2 mouse strain) dramatically delays the appearance of neuronal CCEs. More significantly, elimination of beta-secretase activity blocks the appearance of CCEs, providing direct genetic evidence that the amyloidogenic processing of APP is required for the induction of CCEs. Finally, in vitro preparations of oligomeric, but not monomeric, Abeta induce DNA synthesis in dissociated cortical neurons, and this response is blocked by antioligomer specific antibodies. Together, our data suggest that low molecular weight aggregates of Abeta induce neuronal cell cycle re-entry in mouse models of Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Varvel</LastName><ForeName>Nicholas H</ForeName><Initials>NH</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, NC30, Lerner Research Institute, The Cleveland Clinic, Cleveland, Ohio 44195-0001, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhaskar</LastName><ForeName>Kiran</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Patil</LastName><ForeName>Anita R</ForeName><Initials>AR</Initials></Author><Author ValidYN="Y"><LastName>Pimplikar</LastName><ForeName>Sanjay W</ForeName><Initials>SW</Initials></Author><Author ValidYN="Y"><LastName>Herrup</LastName><ForeName>Karl</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Lamb</LastName><ForeName>Bruce T</ForeName><Initials>BT</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG023012</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG024494</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG026146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG026146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG024494</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG023012</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018797">Cell Cycle Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008869">Microtubule-Associated Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C079240">Mtap2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>G34N38R2N1</RegistryNumber><NameOfSubstance UI="D001973">Bromodeoxyuridine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001973" MajorTopicYN="N">Bromodeoxyuridine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002453" MajorTopicYN="N">Cell Cycle</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018797" MajorTopicYN="N">Cell Cycle Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004622" MajorTopicYN="N">Embryo, Mammalian</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008869" MajorTopicYN="N">Microtubule-Associated Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>10</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>12</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>10</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>4</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18945886</ArticleId><ArticleId IdType="mid">NIHMS92048</ArticleId><ArticleId IdType="pmc">PMC2680286</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2441-08.2008</ArticleId><ArticleId IdType="pii">28/43/10786</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>al-Ubaidi MR, Hollyfield JG, Overbeek PA, Baehr W. Photoreceptor degeneration induced by the expression of simian virus 40 large tumor antigen in the retina of transgenic mice. Proc Natl Acad Sci U S A. 1992;89:1194&#x2013;1198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC48415</ArticleId><ArticleId IdType="pubmed">1311085</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendt T, R&#xf6;del L, G&#xe4;rtner U, Holzer M. Expression of the cyclin-dependent kinase inhibitor p16 in Alzheimer's disease. Neuroreport. 1996;7:3047&#x2013;3049.</Citation><ArticleIdList><ArticleId IdType="pubmed">9116237</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18:351&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330961</ArticleId></ArticleIdList></Reference><Reference><Citation>Busser J, Geldmacher DS, Herrup K. Ectopic cell cycle proteins predict the sites of neuronal cell death in Alzheimer's disease brain. J Neurosci. 1998;18:2801&#x2013;2807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792587</ArticleId><ArticleId IdType="pubmed">9525997</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, Wong PC. BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat Neurosci. 2001;4:233&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">11224536</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng IH, Scearce-Levie K, Legleiter J, Palop JJ, Gerstein H, Bien-Ly N, Puoliv&#xe4;li J, Lesn&#xe9; S, Ashe KH, Muchowski PJ, Mucke L. Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem. 2007;282:23818&#x2013;23828.</Citation><ArticleIdList><ArticleId IdType="pubmed">17548355</ArticleId></ArticleIdList></Reference><Reference><Citation>Cicero S, Herrup K. Cyclin-dependent kinase 5 is essential for neuronal cell cycle arrest and differentiation. J Neurosci. 2005;25:9658&#x2013;9668.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725732</ArticleId><ArticleId IdType="pubmed">16237170</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci. 2005;8:79&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15608634</ArticleId></ArticleIdList></Reference><Reference><Citation>De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Ferreira ST, Klein WL. Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem. 2007;282:11590&#x2013;11601.</Citation><ArticleIdList><ArticleId IdType="pubmed">17308309</ArticleId></ArticleIdList></Reference><Reference><Citation>De Felice FG, Wu D, Lambert MP, Fernandez SJ, Velasco PT, Lacor PN, Bigio EH, Jerecic J, Acton PJ, Shughrue PJ, Chen-Dodson E, Kinney GG, Klein WL. Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Abeta oligomers. Neurobiol Aging. 2008;29:1334&#x2013;1347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3142933</ArticleId><ArticleId IdType="pubmed">17403556</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A. 2003;100:10417&#x2013;10422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC193576</ArticleId><ArticleId IdType="pubmed">12925731</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein JA, Longo-Guess CM, Rossmann MP, Seburn KL, Hurd RE, Frankel WN, Bronson RT, Ackerman SL. The harlequin mouse mutation downregulates apoptosis-inducing factor. Nature. 2002;419:367&#x2013;374.</Citation><ArticleIdList><ArticleId IdType="pubmed">12353028</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuan CY, Schloemer AJ, Lu A, Burns KA, Weng WL, Williams MT, Strauss KI, Vorhees CV, Flavell RA, Davis RJ, Sharp FR, Rakic P. Hypoxia-ischemia induces DNA synthesis without cell proliferation in dying neurons in adult rodent brain. J Neurosci. 2004;24:10763&#x2013;10772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2590933</ArticleId><ArticleId IdType="pubmed">15564594</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulnane LS, Lehman EJ, Hock BJ, Tsuchiya KD, Lamb BT. Rapid and efficient detection of transgene homozygosity by FISH of mouse fibroblasts. Mamm Genome. 2002;13:223&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">11956767</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, Viola KL, Klein WL. A&#x3b2; oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci. 2007;27:796&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672917</ArticleId><ArticleId IdType="pubmed">17251419</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb BT. Making models for Alzheimer's disease. Nat Genet. 1995;9:4&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">7704022</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb BT, Sisodia SS, Lawler AM, Slunt HH, Kitt CA, Kearns WG, Pearson PL, Price DL, Gearhart JD. Introduction and expression of the 400 kilobase amyloid precursor protein gene in transgenic mice [corrected] Nat Genet. 1993;5:22&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">8220418</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb BT, Call LM, Slunt HH, Bardel KA, Lawler AM, Eckman CB, Younkin SG, Holtz G, Wagner SL, Price DL, Sisodia SS, Gearhart JD. Altered metabolism of familial Alzheimer's disease-linked amyloid precursor protein variants in yeast artificial chromosome transgenic mice. Hum Mol Genet. 1997;6:1535&#x2013;1541.</Citation><ArticleIdList><ArticleId IdType="pubmed">9285791</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL. Diffusible, nonfibrillar ligands derived from Abeta1&#x2013;42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A. 1998;95:6448&#x2013;6453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Velasco PT, Chang L, Viola KL, Fernandez S, Lacor PN, Khuon D, Gong Y, Bigio EH, Shaw P, De Felice FG, Krafft GA, Klein WL. Monoclonal antibodies that target pathological assemblies of Abeta. J Neurochem. 2007;100:23&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">17116235</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehman EJ, Kulnane LS, Lamb BT. Alterations in &#x3b2;-amyloid production and deposition in brain regions of two transgenic models. Neurobiol Aging. 2003a;24:645&#x2013;653.</Citation><ArticleIdList><ArticleId IdType="pubmed">12885572</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehman EJ, Kulnane LS, Gao Y, Petriello MC, Pimpis KM, Younkin L, Dolios G, Wang R, Younkin SG, Lamb BT. Genetic background regulates &#x3b2;-amyloid precursor protein processing and &#x3b2;-amyloid deposition in the mouse. Hum Mol Genet. 2003b;12:2949&#x2013;2956.</Citation><ArticleIdList><ArticleId IdType="pubmed">14506131</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesn&#xe9; S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH. A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006;440:352&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">16541076</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, Fan W, Kha H, Zhang J, Gong Y, Martin L, Louis JC, Yan Q, Richards WG, Citron M, Vassar R. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci. 2001;4:231&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">11224535</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmrich V, Grimm C, Draguhn A, Barghorn S, Lehmann A, Schoemaker H, Hillen H, Gross G, Ebert U, Bruehl C. Amyloid &#x3b2; oligomers (A&#x3b2;1&#x2013;42 globulomer) suppress spontaneous synaptic activity by inhibition of P/Q-type calcium currents. J Neurosci. 2008;28:788&#x2013;797.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671006</ArticleId><ArticleId IdType="pubmed">18216187</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Tran L, Lambert MP, Glabe CG, Klein WL, LaFerla FM. Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem. 2006;281:1599&#x2013;1604.</Citation><ArticleIdList><ArticleId IdType="pubmed">16282321</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC. Mild cognitive impairment: transition between aging and Alzheimer's disease. Neurologia. 2000;15:93&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">10846869</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberds SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, Chen KS, Freedman SB, Frigon NL, Games D, Hu K, Johnson-Wood K, Kappenman KE, Kawabe TT, Kola I, Kuehn R, Lee M, Liu W, Motter R, Nichols NF, Power M, et al. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum Mol Genet. 2001;10:1317&#x2013;1324.</Citation><ArticleIdList><ArticleId IdType="pubmed">11406613</ArticleId></ArticleIdList></Reference><Reference><Citation>Stine WB, Jr, Dahlgren KN, Krafft GA, LaDu MJ. In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J Biol Chem. 2003;278:11612&#x2013;11622.</Citation><ArticleIdList><ArticleId IdType="pubmed">12499373</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, B&#xfc;rki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A. 1997;94:13287&#x2013;13292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24301</ArticleId><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent I, Rosado M, Davies P. Mitotic mechanisms in Alzheimer's disease? J Cell Biol. 1996;132:413&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2120731</ArticleId><ArticleId IdType="pubmed">8636218</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B, Viola KL, Klein WL, Stine WB, Krafft GA, Trommer BL. Soluble oligomers of beta amyloid (1&#x2013;42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res. 2002;924:133&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">11750898</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Wang R, Herrup K. E2F1 works as a cell cycle suppressor in mature neurons. J Neurosci. 2007;27:12555&#x2013;12564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673327</ArticleId><ArticleId IdType="pubmed">18003834</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Q, Combs C, Cannady SB, Geldmacher DS, Herrup K. Beta-amyloid activated microglia induce cell cycling and cell death in cultured cortical neurons. Neurobiol Aging. 2000;21:797&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pubmed">11124423</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Herrup K. Loss of neuronal cell cycle control in ataxia-telangiectasia: a unified disease mechanism. J Neurosci. 2005;25:2522&#x2013;2529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725172</ArticleId><ArticleId IdType="pubmed">15758161</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Geldmacher DS, Herrup K. DNA replication precedes neuronal cell death in Alzheimer's disease. J Neurosci. 2001;21:2661&#x2013;2668.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762514</ArticleId><ArticleId IdType="pubmed">11306619</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Mufson EJ, Herrup K. Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer's disease. J Neurosci. 2003;23:2557&#x2013;2563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742098</ArticleId><ArticleId IdType="pubmed">12684440</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Varvel NH, Lamb BT, Herrup K. Ectopic cell cycle events link human Alzheimer's disease and amyloid precursor protein transgenic mouse models. J Neurosci. 2006;26:775&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675370</ArticleId><ArticleId IdType="pubmed">16421297</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao WQ, De Felice FG, Fernandez S, Chen H, Lambert MP, Quon MJ, Krafft GA, Klein WL. Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J. 2008;22:246&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">17720802</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18953116</PMID><DateCompleted><Year>2008</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1387-2877</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>2</Issue><PubDate><Year>2008</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of Alzheimer's disease : JAD</Title><ISOAbbreviation>J Alzheimers Dis</ISOAbbreviation></Journal><ArticleTitle>Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?</ArticleTitle><Pagination><StartPage>303</StartPage><EndPage>325</EndPage><MedlinePgn>303-25</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer's disease (AD) drug developments and clinical trials (CT) remain vulnerable to problems that undermine research validity. Investigations of CT methods reveal how numerous factors decrease active drug-placebo group differences and increase variance, thereby reducing power to reach statistical significance for outcome measure differences in AD CTs. Such factors include, amongst many, inaccuracy, imprecision, bias, failures to follow or lack of operational protocols for applying CT methods, inter-site variance, and lack of homogeneous sampling using disorder criteria. After a review of the literature and survey of a sample of AD and Mild Cognitive Impairment (MCI) CTs, the authors question whether problems of human error preclude AD researchers from continuing their dependence on rated outcome measures for CTs. The authors propose that the realities of AD, especially a probable irreversible progression of neuropathology prior to onset of clinical symptoms or signs capable of differentiating persons at risk for AD from normal aged, require AD investigators and clinicians to privilege biomarkers and encourage their development as surrogate targets for preventive AD treatment developments, testing, and use in clinical practice.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>Robert E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Drug Design &amp; Development Section, Laboratory of Neurosciences, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA. rebecker2008@comcast.net</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greig</LastName><ForeName>Nigel H</ForeName><Initials>NH</Initials></Author><Author ValidYN="Y"><LastName>Giacobini</LastName><ForeName>Ezio</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Z01 AG000311</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Alzheimers Dis</MedlineTA><NlmUniqueID>9814863</NlmUniqueID><ISSNLinking>1387-2877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015588" MajorTopicYN="N">Observer Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011643" MajorTopicYN="N">Publishing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>10</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>12</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>10</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>6</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18953116</ArticleId><ArticleId IdType="mid">NIHMS239202</ArticleId><ArticleId IdType="pmc">PMC3372084</ArticleId><ArticleId IdType="doi">10.3233/jad-2008-15213</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Becker R, Greig NH. Alzheimer's disease drug development in 2008 and beyond: problems and opportunities. Curr Alz Res. 2008 April In press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2570097</ArticleId><ArticleId IdType="pubmed">18690832</ArticleId></ArticleIdList></Reference><Reference><Citation>Giacobini E, Becker RE. One hundred years after the discovery of Alzheimer's disease. A turning point for therapy? Journal of Alzheimer's Disease. 2007;12:37&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">17851193</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker RE. Lessons from Darwin: 21st Century designs for clinical trials. Curr Alz Res. 2007;4:458&#x2013;467.</Citation><ArticleIdList><ArticleId IdType="pubmed">17908050</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Feldman HH, Jacova C, DeKosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'Brien J, Pasquier F, Pobert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6:734&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pubmed">17616482</ArticleId></ArticleIdList></Reference><Reference><Citation>Pangalos MN, Schechter LE, Hurko O. Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nature Reviews: Drug Discovery. 2007;6:521&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pubmed">17599084</ArticleId></ArticleIdList></Reference><Reference><Citation>Institute of Medicine, Committee on Treatment of Post Traumatic Stress Disorder. Treatment of Post Traumatic Stress Disorder, An Assessment of the Evidence. Washington (DC): The National Academies Press; 2007.</Citation></Reference><Reference><Citation>American Psychiatric Association (APA), Practice guidelines. Acute stress disorder and posttraumatic stress disorder. Amer J Psychiatry. 2004;161 Supplement</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency. EMEA/CHMP/EWP Workshop. Slowing the progression of neurodegenerative diseases: medicinal products clinical development. London: European Medicines Agency; 2006. Doc Ref. EMEA/512562/2006.</Citation></Reference><Reference><Citation>Mani RB. The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint. Stat Med. 2004;23:305&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pubmed">14716731</ArticleId></ArticleIdList></Reference><Reference><Citation>Pincus T, Stein CM. Why randomized controlled clinical trials do not depict accurately long-term outcomes in rheumatoid arthritis: some explanations and suggestions for future studies. Clin Exp Rheumatol. 1997;15:S27&#x2013;S38.</Citation><ArticleIdList><ArticleId IdType="pubmed">9266130</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal LJ, Kantarci K, Reiman EM, Klunk WE, Weiner MW, Zetterberg H, Galasko D, Pratic&#xf2; D, Griffin S, Schenk D, Siemers E. The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord. 2006;20:6&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1820855</ArticleId><ArticleId IdType="pubmed">16493230</ArticleId></ArticleIdList></Reference><Reference><Citation>Butcher J. The hunt for drugs to modify Alzheimer's disease. Lancet Neurology. 2007;6:1038&#x2013;1039.</Citation><ArticleIdList><ArticleId IdType="pubmed">18031701</ArticleId></ArticleIdList></Reference><Reference><Citation>Dworkin RH, Katz J, Gitlin MJ. Placebo response in clinical trials of depression and its implications for research on chronic neuropathic pain. Neurology. 2005;65:S17&#x2013;S19.</Citation><ArticleIdList><ArticleId IdType="pubmed">16385107</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker RE. Lessons from Darwin: Evolutionary biology implications for Alzheimer's disease research and patient care. Curr Alz Res. 2005;2:319&#x2013;326.</Citation><ArticleIdList><ArticleId IdType="pubmed">15974897</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhardt N, Feiger AD, Cogger KO, Sikich D, DeBrota DJ, Lipsitz JD, Kobak KA, Evans KR, Potter WZ. Rating the Raters: Assessing the Quality of Hamilton Rating Scale for Depression Clinical Interviews in Two Industry-sponsored Clinical Drug Trials. J Clin Psychopharmacol. 2006;26:71&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">16415710</ArticleId></ArticleIdList></Reference><Reference><Citation>Easterbrook PJ, Berlin JA, Gopalan R, Mattews DR. Publication bias in clinical research. Lancet. 1991;337:867&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">1672966</ArticleId></ArticleIdList></Reference><Reference><Citation>Frampton M, Harvey RJ, Kirchner V. Propentofyllin for dementia. Cochrane Data Base of Systematic Reviews. 2003;2:CD002853.</Citation><ArticleIdList><ArticleId IdType="pubmed">12804440</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalmers I. Underreporting research is scientific misconduct. JAMA. 1990;263:1405&#x2013;1408.</Citation><ArticleIdList><ArticleId IdType="pubmed">2304220</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker RE, Colliver JA, Markwell SJ, Moriearty PL, Unni LK, Vicari S, Double-Blind A. Placebo-Controlled Study of Metrifonate, an Acetylcholinesterase Inhibitor, for Alzheimer's Disease. Alzheimer's Disease and Associated Disorders. 1996;10:124&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">8876775</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker RE, Colliver JA, Markwell SJ, Moriearty PL, Unni LK, Varney A, Vicari S. A Six Month Study of the Effects of Metrifonate on Cognitive Decline in Alzheimer's Disease. Alzheimer's Disease and Associated Disorders. 1998;12:54&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">9539412</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker RE, Markwell S. Problems arising from generalizing of treatment efficacy from clinical trials in Alzheimer's disease. Clin Drug Invest. 2000;19:33&#x2013;41.</Citation></Reference><Reference><Citation>Perkins DO, Wyatt RJ, Bartko JJ. Penny-wise and pound-foolish: the impact of measurement error on sample size requirements in clinical trials. Biol Psychiatry. 2000;47:762&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">10773186</ArticleId></ArticleIdList></Reference><Reference><Citation>Lachin JM. The role of measurement reliability in clinical trials. Clin Trials. 2004;1:553&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pubmed">16279296</ArticleId></ArticleIdList></Reference><Reference><Citation>Woods SW, Gueorguieva RV, Baker CB, Makuch RW. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia. Arch Gen Psychiatry. 2005;62:961&#x2013;970.</Citation><ArticleIdList><ArticleId IdType="pubmed">16143728</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobak KA, DeBrota DJ, Engelhardt N, Williams JBW. Site vs. centralized raters in a clinical depression trial, National Institute of Mental Health, New Clinical Drug Evaluation Unit. 46th Annual Meeting; Boca Raton, Fl. 2006, June.</Citation></Reference><Reference><Citation>Varma AR, Snowden JS, Lloyd JJ, Talbot PR, Mann DM, Neary D. Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer's disease and frontotemporal dementia. J Neurol Neurosurg Psychiatry. 1999;66:184&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1736233</ArticleId><ArticleId IdType="pubmed">10071097</ArticleId></ArticleIdList></Reference><Reference><Citation>Cogger KO. Rating rater improvement: a method for estimating increased effect size and reduction of clinical trial costs. J Clin Psychopharmacol. 2007;27:418&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">17632240</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan A, Leventhal RM, Khan SR, Brown WA. Severity of depression and response to antidepressants and placebo: analysis of the Food and Drug Administration database. J Clin Psychopharmacol. 2002;22:40&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">11799341</ArticleId></ArticleIdList></Reference><Reference><Citation>Thase ME. Studying new antidepressants: if there were a light at the end of the tunnel could we see it? J Clin Psychiatry. 2002;63 2:24&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">15453011</ArticleId></ArticleIdList></Reference><Reference><Citation>Leon AC, Marzuk PM, Portera L. More reliable outcome measures can reduce sample size requirements. Arch Gen Psychiatry. 1995;52:867&#x2013;871.</Citation><ArticleIdList><ArticleId IdType="pubmed">7575107</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison J, Minassian SL, Jenkins L, Black RS, Koller M, Grundman M. A neuropsychological test battery for use in Alzheimer disease clinical trials. 2007;64:1323&#x2013;1329.</Citation><ArticleIdList><ArticleId IdType="pubmed">17846273</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller MJ, Szegedi A. Effects of interrater reliability of psychopathologic assessments on power and sample size calculations in clinical trials. J Clin Psychopharmacol. 2002;22:318&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">12006903</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobak KA, Engelhardt N, Lipsitz JD. Enriched rater training using Internet-based technologies: a comparison to traditional rater training. J Psychiatr Res. 2006;3:192&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">16197959</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton M. A rating scale for depression. J Neurology Neurosurg &amp; Psychiatry. 1960;23:56&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC495331</ArticleId><ArticleId IdType="pubmed">14399272</ArticleId></ArticleIdList></Reference><Reference><Citation>Demitrack MA, Faries D, Herrera JM, DeBrota D, Potter WZ. The problem of measurement error in multisite clinical trials. Psychopharmacol Bull. 1998;34:19&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">9564194</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobak KA, Lipsitz JD, Feiger A. Development of a standardized training program for the Hamilton Depression Scale using internet-based technologies: results from a pilot study. J Psychiatr Res. 2003;37:509&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">14563382</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobak KA, Lipsitz JD, Williams JB, Engelhardt N, Bellew KN. A new approach to rater training and certification in a multicenter clinical trial. J Clin Psychopharmacol. 2005;25:407&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pubmed">16160614</ArticleId></ArticleIdList></Reference><Reference><Citation>Targum SD. Evaluating rater competency for CNS clinical trials. J Clin Psychopharmacol. 2006;26:308&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">16702896</ArticleId></ArticleIdList></Reference><Reference><Citation>Rickels K, Robinson DS. Why do clinical trials fail? J Clin Psychopharmacol. 2007;27:420&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">17632242</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobak KA, Kane JM, Thase TE, Nierenberg AA. Reply to comments by Drs Rickels and Robinson. J Clin Psychopharmacol. 2007;27:421.</Citation></Reference><Reference><Citation>Cummings JL. Clinical evaluation as a biomarker for Alzheimer's disease. J Alz Dis. 2005;8:327&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pubmed">16556964</ArticleId></ArticleIdList></Reference><Reference><Citation>Winblad B, Giacobini E, Froelich L, Bruinsma G, Walters E, Friedhoff L. Double-blind placebo-controlled evaluation of the safety and efficacy of phenserine tartrate for the treatment of mild to moderate Alzheimer disease. 9th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy; April (2006); pp. 19&#x2013;22. Abstract 11A.</Citation></Reference><Reference><Citation>Qureshi NN, Hatcher J, Chaturvedi N, Jafar TH, Hypertension Research Group Effect of general practitioner education on adherence to antihypertensive drugs: cluster randomized controlled trail. BMJ. 2007;335:1030&#x2013;1037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2078673</ArticleId><ArticleId IdType="pubmed">17991935</ArticleId></ArticleIdList></Reference><Reference><Citation>Dybicz SB, Keohane DJ, Erwin WG, McRae T, Shah SN. Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis. Am J Geriatr Psychother. 2006;4:154&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">16860262</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt R, Lechner A, Petrovic K. Rivastigmine in outpatient services: experience of 114 neurologists in Austria. Int Clin Psychopharmacol. 2002;17:81&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">11890189</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm. 2006;12:239&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10437940</ArticleId><ArticleId IdType="pubmed">16623608</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellilli G, Lucchi E, Minicuci N, Rozzini L, Bianchetti A, Padovani A, Trabucchi M. Results of a multi-level therapeutic approach for Alzheimer's disease subjects in the &#x201c;real world&#x201d; (CRONOS project): a 36-week follow-up study. Aging Clin Exp Res. 2005;17:54&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">15847123</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallak M, Giacobini E. Physostigmine, tacrine, and metrifonate: the effect of multiple doses on acetylcholine metabolism in rat brain. Neuropharmacology. 1989;28:190&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">2725846</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallak M, Giacobini E. A comparison of the effects of two inhibitors on brain cholinesterase. Neuropharmacology. 1987;26:521&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pubmed">3601008</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori F, Cuadra G, Giacobini E. Metrifonate effects on acetylcholine and biogenic amines in rat cortex. Neurochemical Research. 1995;20:1081&#x2013;1088.</Citation><ArticleIdList><ArticleId IdType="pubmed">8570013</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker RE, Giacobini E. Mechanisms of cholinesterase inhibition in senile dementia of the Alzheimer type: clinical, pharmacological, and therapeutic aspects. Drug Dev Res. 1988;12:163&#x2013;195.</Citation></Reference><Reference><Citation>Becker R, Colliver J, Elble R, Feldman E, Giacobini E, Kumar V, Markwell S, Moriearty P, Parks R, Shillcutt S, Unni L, Vicari S, Womack C, Zec R. Effects of Metifonate, A Long Acting Cholinesterase Inhibitor in Alzheimer Disease: Report of an Open Trial. Drug Dev Res. 1990;9:425&#x2013;434.</Citation></Reference><Reference><Citation>Carroll BJ. Letter to Editor. Lancet. 2006;367:1235&#x2013;1236.</Citation><ArticleIdList><ArticleId IdType="pubmed">16631869</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelloff GJ, Bast RC, Cofffey DS, D'Amico AV, Kerbel RS, Park JW, Ruddon RW, Rustin GJS, Schilsky RL, Sigman CC, Woude GFV. Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update. Clinical Cancer Research. 2004;10:3881&#x2013;3884.</Citation><ArticleIdList><ArticleId IdType="pubmed">15173097</ArticleId></ArticleIdList></Reference><Reference><Citation>Raschetti R, Albanese E, Vanacore N, Maggini M. Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomized trials. Plos Medicine. 2007. pp. 1818&#x2013;1828.  www.plosmedicine.org.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2082649</ArticleId><ArticleId IdType="pubmed">18044984</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams JBW. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry. 1988;45:742&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pubmed">3395203</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC. MCI treatment trials: failure or not? Lancet Neurology. 2007;6:473&#x2013;475.</Citation><ArticleIdList><ArticleId IdType="pubmed">17509475</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers Y. Introduction to the Theory of Error. Palo Alto: Addison-Wesley Publishing Co. Inc.; 1959.</Citation></Reference><Reference><Citation>Ferris SH. Are placebo controls still placebo controls? Neurobiology of Aging. 2006;27 S1:S29.</Citation></Reference><Reference><Citation>Schneider LS. Relevance of clinical trials: can new strategies offer more? Neurobiology of Aging. 2006;27 S1:S76.</Citation></Reference><Reference><Citation>Foster N. Imaging Advances for Early Detection and New Drug Assessment in Alzheimer's Disease. Clinical Neurosciences Center; University of Utah: Nov 28, 2007.</Citation></Reference><Reference><Citation>Weiner M. Appendix. Introductory section background and significance of the overall proposal. Nov 28, 2007.  Hppt: www.loni.ucla.edu/ADNI/pdf/ADNI_Introduction.pdf. Viewed.</Citation></Reference><Reference><Citation>Lopez OL, Swihart AA, Becker JT, Reinmuth OM, Reynolds CF, Rezek DL, Daly FL. Reliability of NINCDS-ADRDA clinical criteria for the diagnosis of Alzheimer's disease. Neurology. 1990;40:1517&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">2215942</ArticleId></ArticleIdList></Reference><Reference><Citation>Temple R. Are Surrogate Markers Adequate to Assess Cardiovascular Disease Drugs? JAMA. 1999;282:790&#x2013;795.</Citation><ArticleIdList><ArticleId IdType="pubmed">10463719</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz R. FDA Evidentiary Standards for Drug Development and Approval. NeuroRx. 2004;1:307&#x2013;316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC534930</ArticleId><ArticleId IdType="pubmed">15717032</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordic Council on Medicines. Good clinical trail practice: Nordic Guidelines, NLN Publication No 28. Uppsala, Sweden: 1989.</Citation></Reference><Reference><Citation>Food and Drug Administration. FDA. US Department of Health and Human Services; Rockville, MD, USA: 1989. Guideline for the format and content of the clinical and statistical sections of new drug applications.</Citation></Reference><Reference><Citation>Kantarci K, Jack CR. Neuroimaging in Alzheimer disease: an evidence-based review. Neuroimaging Clin N Am. 2003;13:197&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pubmed">13677801</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Weigand SD, Shiung MM, Przybelski SA, O'Brien PC, Gunter JL, Knopman DS, Boeve BF, Smith GE, Petersen RC. Atrophy rates accelerate in amnestic mild cognitive impairment. Neurology. 2007 Nov 21; Epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2734477</ArticleId><ArticleId IdType="pubmed">18032747</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Shiung MM, Weigand SD, O'Brien PC, Gunter JL, Boeve BF, Knopman DS, Smith GE, Ivnik RJ, Tangalos EG, Petersen RC. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology. 2005;65:1227&#x2013;1231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2753547</ArticleId><ArticleId IdType="pubmed">16247049</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Dickson DW, Parisi JE, Xu YC, Cha RH, O'Brien PC, Edland SD, Smith GE, Boeve BF, Tangalos EG, Kokmen E, Petersen RC. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology. 2002;58:750&#x2013;757.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2745935</ArticleId><ArticleId IdType="pubmed">11889239</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Petersen RC, Xu Y, O'Brien PC, Smith GE, Ivnik RJ, Boeve BF, Tangalos EG, Kokmen E. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology. 2000;55:484&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2724764</ArticleId><ArticleId IdType="pubmed">10953178</ArticleId></ArticleIdList></Reference><Reference><Citation>den Heijer T, Geerlings MI, Hoebeek FE, Hofman A, Koudstaal PJ, Breteler MM. Use of hippocampal and amygdalar volumes on magnetic resonance imaging to predict dementia in cognitively intact elderly people. Arch Gen Psychiatry. 2006;63:57&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">16389197</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundman M, Jack CR, Petersen RC, Kim HT, Taylor C, Datvian M, Weiner MF, DeCarli C, DeKosky ST, van Dyck C, Darvesh S, Yaffe K, Kaye J, Ferris SH, Thomas RG, Thal LJ. The Alzheimer's Disease Cooperative Study, Hippocampal volume is associated with memory but not nonmemory cognitive performance in patients with mild cognitive impairment. J Mol Neurosci. 2003;20:241&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">14501003</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordberg A. PET imaging of amyloid in Alzheimer's disease. Lancet Neurol. 2004;3:519&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">15324720</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisoni GB, Scheltens P, Galluzzi S, Nobili FM, Fox NC, Robert PH, Soininen H, Wahlund LO, Waldemar G, Salmon E. Neuroimaging tools to rate regional atrophy, subcortical cerebrovascular disease, and regional cerebral blood flow and metabolism: consensus paper of the EADC. J Neurol Neurosurg Psychiatry. 2003;74:1371&#x2013;1381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1757396</ArticleId><ArticleId IdType="pubmed">14570828</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisoni GB, Testa C, Sabattoli F, Beltramello A, Soininen H, Laakso MP. Structural correlates of early and late onset Alzheimer's disease: voxel based morphometric study. J Neurol Neurosurg Psychiatry. 2005;76:112&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1739332</ArticleId><ArticleId IdType="pubmed">15608008</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox NC, Schott JM. Imaging cerebral atrophy: normal ageing to Alzheimer's disease. Lancet. 2004;363:392&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pubmed">15074306</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neuro. 1997;42:85&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">9225689</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan D, Janssen JC, Whitwell JL, Watt HC, Jenkins R, Frost C, Rossor MN, Fox NC. Change in rates of cerebral atrophy over time in early-onset Alzheimer's disease: longitudinal MRI study. Lancet. 2003;362:1121&#x2013;1122.</Citation><ArticleIdList><ArticleId IdType="pubmed">14550701</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheltens P, Fox N, Barkhof F, De Carli C. Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurol. 2002;1:13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">12849541</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox NC, Crum WR, Scahill RI, Stevens JM, Janssen JC, Rossor MN. Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images. Lancet. 2001;358:201&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">11476837</ArticleId></ArticleIdList></Reference><Reference><Citation>Edison P, Archer HA, Hinz R, Hammers A, Pavese N, Tai YF, Hotton G, Cutler D, Fox N, Kennedy A, Rossor M, Brooks DJ. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology. 2007;68:501&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pubmed">17065593</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster NL, Heidebrink JL, Clark CM, Jagust WJ, Arnold SE, Barbas NR, DeCarli CS, Turner RS, Koeppe RA, Higdon R, Minoshima S. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain. 2007;130:2616&#x2013;2635.</Citation><ArticleIdList><ArticleId IdType="pubmed">17704526</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust W, Thisted R, Devous MD, Sr, Van Heertum R, Mayberg H, Jobst K, Smith AD, Borys N. SPECT perfusion imaging in the diagnosis of Alzheimer's disease: a clinical-pathologic study. Neurology. 2001;56:950&#x2013;956.</Citation><ArticleIdList><ArticleId IdType="pubmed">11294935</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstr&#xf6;m M, Savitcheva I, Huang GF, Estrada S, Aus&#xe9;n B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, L&#xe5;ngstr&#xf6;m B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies. Am J Psychiatry. 2002;159:738&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pubmed">11986126</ArticleId></ArticleIdList></Reference><Reference><Citation>Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, Wall A, Ringheim A, Langstrom B, Nordberg A. Two-year followup of amyloid deposition in patients with Alzheimer's disease. Brain. 2006;129:2856&#x2013;2866.</Citation><ArticleIdList><ArticleId IdType="pubmed">16854944</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf H, Jelic V, Gertz HJ, Nordberg A, Julin P, Wahlund LO. A critical discussion of the role of neuroimaging in mild cognitive impairment. Acta Neurologica Scandinavica. 2003;107:52&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">12603252</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong Z, Ewers M, Teipel S, Burger K, Wallin A, Blennow K, He P, McAllister C, Hampel H, Shen Y. Levels of gamma secretase I cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry. 2007;64:718&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">17548753</ArticleId></ArticleIdList></Reference><Reference><Citation>Buerger K, Ewers M, Pirttila T, Zinkowski R, Alafuzoff I, Teipel SJ, DeBernardis J, Kerkman D, McCulloch C, Soininen H, Hampel H. CSF phosphorylated tau protein correlates with neurofibrillary pathology in Alzheimer's diseasem. Brain. 2006;129:3035&#x2013;3041.</Citation><ArticleIdList><ArticleId IdType="pubmed">17012293</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefani A, Martorana A, Bernardini S, Panella M, Mercati F, Orlacchio A, Pierantozzi M. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment. J Neurol Sci. 2006;251:124&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">17097109</ArticleId></ArticleIdList></Reference><Reference><Citation>Huey ED, Mirza N, Putnam KT, Soares H, Csako G, Levy JA, Copenhaver B, Cohen RM, Sunderland T. Stability of CSF beta-amyloid(1-42) and tau levels by APOE genotype in Alzheimer patients. Dement Geriatr Cogn Disord. 2006;22:48&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">16682793</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapiola T, Pirttila T, Mikkonen M, Mehta PD, Alafuzoff I, Koivisto K, Soininen H. Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer's disease. Neurosci Lett. 2000;18:119&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">10686392</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Zeterberg H, Buchhave P, Andreasson U, Londos E, Minthon L, Blennow K. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ration in patients with mild cognitive impairments. Dement Geriatr Cogn Disord. 2007;23:316&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pubmed">17374949</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Y, Wang C. Abeta40 protects non-toxic Abeta42 monomer from aggregation. J Mol Biol. 2007;369:909&#x2013;916.</Citation><ArticleIdList><ArticleId IdType="pubmed">17481654</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Onstead L, Randle S, Price R, Smithson L, Zwizinski C, Dickson DW, Golde T, McGowan E. Abeta40 inhibits amyloid deposition in vivo. J Neurosci. 2007;17:627&#x2013;633.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672801</ArticleId><ArticleId IdType="pubmed">17234594</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesko LJ, Atkinson AJ. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annual Review of Pharmacology and Toxicology. 2001;41:347&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">11264461</ArticleId></ArticleIdList></Reference><Reference><Citation>Granger CB, McMurray JJV. Using measures of disease progression to determine therapeutic effect: a Siren's song. J Am Coll Cardiol. 2006;48:434&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pubmed">16875965</ArticleId></ArticleIdList></Reference><Reference><Citation>Molenberghs G, Burzykowski T, Alonso A, Buyse M. Statistical methods in medical research. Vol. 13. 2004. pp. 177&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">15198486</ArticleId></ArticleIdList></Reference><Reference><Citation>Patsy BM, Weiss NS, Furberg CD, Koepsell TD, Siscovick DS, Rosendaal FR, Smith NL, Heckbert SR, Kaplan RC, Lin D, Fleming TR, Wagner EH. Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors in cardiovascular disease. JAMA. 1999;282:786&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pubmed">10463718</ArticleId></ArticleIdList></Reference><Reference><Citation>Kralawish J. Alzheimer's disease&#x2014;clinical trials and logic of clinical purpose. N Engl J Med. 2006;355:1604&#x2013;1605.</Citation><ArticleIdList><ArticleId IdType="pubmed">17035654</ArticleId></ArticleIdList></Reference><Reference><Citation>Kent DM, Hayward RA. Limitations of applying summary results of clinical trials to individual patients. JAMA. 2006;298:1209&#x2013;1212.</Citation><ArticleIdList><ArticleId IdType="pubmed">17848656</ArticleId></ArticleIdList></Reference><Reference><Citation>Califf RM. Simple principles of clinical trials remain powerful. JAMA. 2005;293:489&#x2013;491.</Citation><ArticleIdList><ArticleId IdType="pubmed">15671435</ArticleId></ArticleIdList></Reference><Reference><Citation>Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA. 2003;290:1624&#x2013;1632.</Citation><ArticleIdList><ArticleId IdType="pubmed">14506122</ArticleId></ArticleIdList></Reference><Reference><Citation>Rich MW. From clinical trials to clinical practice. JAMA. 2002;287:1321&#x2013;1323.</Citation><ArticleIdList><ArticleId IdType="pubmed">11886324</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker RE. Focusing pharmaceutical research on patient care: using clinical trials to develop clinical decision rules. Clin Drug Invest. 2002;22:269&#x2013;278.</Citation></Reference><Reference><Citation>Feldman HH, Ferris S, Winblad B, Sfikas N, Mancione L, He Y, Tekin S, Burns A, Cummings J, del Ser T, Ogogozo-M JM, Sauer H, Scheltens P, Scarpini E, Herrmann N, Farlow M, Potkin S, Charles HC, Fox NC, Lane R. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurology. 2007;6:501&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pubmed">17509485</ArticleId></ArticleIdList></Reference><Reference><Citation>Jelic V. Clinical trials in MCI and what we have learned. Neurobiology of Aging. 2006 27S1:S47.</Citation></Reference><Reference><Citation>Brys M, Pirraglia E, Rich K, Mosconi L, Switalski R, Glodzik-Sobanska L, De Santi S, Zinkowski R, Mehta P, Praticao D, Saint Louis LA, Wallin A, Blennow K, Leon MJ. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging. 2007 e-pub ahead of print.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2774781</ArticleId><ArticleId IdType="pubmed">17889968</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003;2:605&#x2013;613.</Citation><ArticleIdList><ArticleId IdType="pubmed">14505582</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonsen AH, McGuire J, Podust VN, Hagnelius NO, Nilsson TK, Kapaki E, Vassilopoulos D, Waldemar G. A Novel Panel of Cerebrospinal Fluid Biomarkers for the Differential Diagnosis of Alzheimer's Disease versus Normal Aging and Frontotemporal Dementia. Dement Geriatr Cogn Disord. 2007;24:434&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pubmed">17971664</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonsen AH, McGuire J, Podust VN, Davies H, Minthon L, Skoog I, Andreasen N, Wallin A, Waldemar G, Blennow K. Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's Disease. Neurobiol Aging. 2007 Epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="pubmed">17321007</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauthier S, Touchon J. Mild cognitive impairment is not a clinical entity and should not be treated. Arch Neurol. 2005;62:1164&#x2013;1166.</Citation><ArticleIdList><ArticleId IdType="pubmed">16009780</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser PJ, Scheltens P, Verhey FR. Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease? J Neurol Neurosurg Psychiatry. 2005;76:1348&#x2013;1354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1739362</ArticleId><ArticleId IdType="pubmed">16170074</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon MO, Herrling P. List of drugs in development for neurodegenerative diseases. Neurodegenerative Dis. 2005;2:61&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">16909049</ArticleId></ArticleIdList></Reference><Reference><Citation>Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS. A controlled trial of selegilene, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Eng J Med. 1997;336:1216&#x2013;1222.</Citation><ArticleIdList><ArticleId IdType="pubmed">9110909</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcusson J, Rother M, Kittner B, R&#xf6;ssner M, Smith BJ, Babic T, Folnegovic-Smalc V, M&#xf6;ller HJ, Labs KH. A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. The European Propentofylline Study Group. Dement Geriatr Cogn Disord. 1997;8:320&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pubmed">9298634</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazza M, Capuano A, Bria P, Mazza S. Ginkgo bilboa and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study. European Journal of Neurology. 2006;13:981&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pubmed">16930364</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno MDJM. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. Clinical Therapeutics. 2003;25:178&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">12637119</ArticleId></ArticleIdList></Reference><Reference><Citation>Forest Laboratories.  (Viewed Dec. 2007) MEM-MD-01  http://www.forestclinicaltrials.com/CTR/CTRController/CTRViewPdf?_file_id=scsr/SCSR_MEM-MD-01_final.pdf.</Citation></Reference><Reference><Citation>Young JR. &#x2018;Superarchives&#x2019; could hold all scholarly output. The Chronicle of Higher Education. 2002;48:43.</Citation></Reference><Reference><Citation>Aisen PS, Gauthier S, Vellas B, Briand R, Saumier D, Laurin J, Garceau D. Alzhemed: a potential treatment for Alzheimer's disease. Curr Alz Res. 2007;4:473&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pubmed">17908052</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JH, Cook N, Manson J, Buring JE, Grodstein F. Low dose aspirin and cognitive function in the women's health study cognitive cohort. BMJ. 2007;334:987&#x2013;994.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1867896</ArticleId><ArticleId IdType="pubmed">17468120</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker RE. Becker R, Giacobini E. Cholinergic Basis for Alzheimer Therapy. Boston: Birkhauser; 1991. Therapy of the cognitive deficit in Alzheimer's disease: the cholinergic system.</Citation></Reference><Reference><Citation>Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J. A 12-week, double-blind, placebo-controlled, parallel-group study of tacrine in patients with probable Alzheimer's disease. JAMA. 1992;268:2523&#x2013;2529.</Citation><ArticleIdList><ArticleId IdType="pubmed">1404819</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood PC, Castleden CM. A double-blind, placebo-controlled, multicenter study of tacrine for Alzheimer's disease. Int J Geriatric Psychiatry. 1994;9:649&#x2013;654.</Citation></Reference><Reference><Citation>Davis KL, Thal LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, Drachman DA, Schneider LS, Whitehouse PJ, Hoover TM. The Tacrine Collaborative Study Group, Tacrine in patients with Alzheimer's disease: a double-blind placebo-controlled multicenter study. N Engl J Med. 1992;327:1253&#x2013;1259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1406817</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. Donepezil MSAD Study Investigators Group, A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology. 2001;57:613&#x2013;620.</Citation><ArticleIdList><ArticleId IdType="pubmed">11524468</ArticleId></ArticleIdList></Reference><Reference><Citation>Winblad B, Kilander L, Eriksson S, Minthon L, Batsman S, Wetterholm AL, Jansson-Blixt C, Haglund A for the Severe Alzheimer's Disease Study Group. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet. 2006;367:1057&#x2013;1065.</Citation><ArticleIdList><ArticleId IdType="pubmed">16581404</ArticleId></ArticleIdList></Reference><Reference><Citation>Winbald B, Engedal K, Soinenen H, Verhey F, Waldemar G, Wimo A, Wetterholm AL, Zhang R, Haglund A, Subbiah P, Donepezil Nordic Study Group A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001;57:489&#x2013;495.</Citation><ArticleIdList><ArticleId IdType="pubmed">11502918</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard C, Margallo-Lana M, Juszczak E, Douglas S, Swann A, Thomas A, O'Brien J, Everratt A, Sadler S, Maddison C, Lee L, Bannister C, Elvish R, Jacoby R. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomized double blind placebo controlled trial. BMJ. 2005;330:874&#x2013;878.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC556156</ArticleId><ArticleId IdType="pubmed">15722369</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I for the Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291:317&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">14734594</ArticleId></ArticleIdList></Reference><Reference><Citation>Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ for the Memantine Study Group. Mematine in moderate-to-severe Alzheimer's disease. N Eng J Med. 2003;348:1333&#x2013;1341.</Citation><ArticleIdList><ArticleId IdType="pubmed">12672860</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohr E, Nair NP, Sampson M, Murtha S, Belanger G, Pappas B, Mendis T. Treatment of Alzheimer's disease with sabeluzole: functional and structural correlates. Clin Neuropharmacol. 1997;20:338&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pubmed">9260731</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter A, Corwin J, Lang J, Piasecki M, Lenox R, Newhouse PA. Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease. Psychopharmacol. 1999;142:334&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pubmed">10229057</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler NR, Seifert RD, Schleman MM, Sramek JJ, Szylleyko OJ, Howard DR, Barchowsky A, Wardle TS, Brass EP. Acetylcholinesterase inhibition by zilfrosilone: pharmacokinetics and pharmacodynamics. Clin Pharmacol Therapeutics. 1995;58:54&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">7628183</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaultieri F, Manetti D, Romanelli MN, Ghelardini C. Design and study of piracetam-like nootropics: controversial members of the problematic class of cognition-enhancing drugs. Current Pharmaceutical Design. 2002;8:125&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">11812254</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler NR, Shrotriya RC, Sramek JJ, Veroff AE, Seifert RD, Reich LA, Hironaka DY. The use of the Computerized Neuropsychological Test Battery (CNTB) in an efficacy and safety trial of BMY 21,502 in Alzheimer's disease. Ann N Y Acad Sci. 1993;695:332&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">8239308</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway S, Ferris S, Kluger A, Goldman R, Griesing T, Kumar D, Richardson S. for the Donepezil &#x201c;401&#x201d; Study Group, Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology. 2004;63:651&#x2013;657.</Citation><ArticleIdList><ArticleId IdType="pubmed">15326237</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ. Alzheimer's Disease Cooperative Study Group, Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352:2379&#x2013;2388.</Citation><ArticleIdList><ArticleId IdType="pubmed">15829527</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinicalstudyresults.org. Mar 28, 2008.   http://www.clinicalstudyresults.org/documents/company-study_96_1.pdf Viewed.</Citation></Reference><Reference><Citation>Clinicalstudyresults.org. Mar 28, 2008.   http://www.clinicalstudyresults.org/documents/company-study_96_2.pdf Viewed.</Citation></Reference><Reference><Citation>ADAPT Research Group. Lyketsos CG, Breitner JC, Green RC, Martin BK, Meinert C, Piantadosi S, Sabbagh M. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology. 2007;68:1800&#x2013;1808.</Citation><ArticleIdList><ArticleId IdType="pubmed">17460158</ArticleId></ArticleIdList></Reference><Reference><Citation>ClinicalTrials.gov. Mar 28, 2008.   http://clinicaltrials.gov/ct2/show/NCT00567060?term=piracetam&amp;rank=1 Viewed.</Citation></Reference><Reference><Citation>Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ, Alzheimer's Disease Cooperative Study Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003;289:2819&#x2013;2826.</Citation><ArticleIdList><ArticleId IdType="pubmed">12783912</ArticleId></ArticleIdList></Reference><Reference><Citation>Resnick SM, Coker LH, Maki PM, Rapp SR, Espeland MA, Shumaker SA. The Women's Health Initiative Study of Cognitive Aging (WHISCA): a randomized clinical trial of the effects of hormone therapy on age-associated cognitive decline. Clin Trials. 2004;1:440&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pubmed">16279282</ArticleId></ArticleIdList></Reference><Reference><Citation>ClinicalTrials.gov. Mar 28, 2008.   http://clinicaltrials.gov/ct2/show/NCT00083590?term=HUPERZINE&amp;rank=1 Viewed.</Citation></Reference><Reference><Citation>ClinicalTrials.gov. Mar 28, 2008.   http://clinicaltrials.gov/ct2/show/NCT00479557?term=acc-001&amp;rank=1 Viewed.</Citation></Reference><Reference><Citation>ClinicalTrials.gov. Mar 28, 2008.   http://clinicaltrials.gov/ct2/show/NCT00141661?term=TTP+488&amp;rank=2 Viewed.</Citation></Reference><Reference><Citation>Galasko DR, Graff-Radford N, May S, Hendrix S, Cottrell BA, Sagi SA, Mather G, Laughlin M, Zavitz KH, Swabb E, Golde TE, Murphy MP, Koo EH. Alzheimer Dis Assoc Disord. Vol. 21. 2007. pp. 292&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">18090435</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez XA, Cacabelos R, Laredo M, Couceiro V, Sampedro C, Varela M, Corzo L, Fernandez-Novoa L, Vargas M, Aleixandre M, Linares C, Granizo E, Muresanu D, Moessler H. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease. European Journal of Neurology. 2006;13:43&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">16420392</ArticleId></ArticleIdList></Reference><Reference><Citation>ClinicalTrials.gov. Mar 28, 2008.   http://clinicaltrials.gov/ct2/show/NCT00471211?term=PBT2&amp;rank=1 Viewed.</Citation></Reference><Reference><Citation>ClinicalTrials.gov. Mar 28, 2008.   http://clinicaltrials.gov/ct2/show/NCT00117403?term=vitamin+e++CoQ&amp;rank=1 Viewed.</Citation></Reference><Reference><Citation>ClinicalTrials.gov. Mar 28, 2008.   http://clinicaltrials.gov/ct2/show/NCT00440050?term=Docosahexaenoic+Acid&amp;rank=2 Viewed.</Citation></Reference><Reference><Citation>ClinicalTrials.gov. Mar 28, 2008.   http://clinicaltrials.gov/ct2/show/NCT00088673?term=tramiprosate&amp;rank=2 Viewed.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18957434</PMID><DateCompleted><Year>2009</Year><Month>04</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>284</Volume><Issue>8</Issue><PubDate><Year>2009</Year><Month>Feb</Month><Day>20</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Amyloid beta-protein toxicity and the pathogenesis of Alzheimer disease.</ArticleTitle><Pagination><StartPage>4755</StartPage><EndPage>4759</EndPage><MedlinePgn>4755-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1074/jbc.R800018200</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yankner</LastName><ForeName>Bruce A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115, USA. bruce_yankner@hms.harvard.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Tao</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG26651</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS30352</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AG27916</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>10</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508861">PSEN2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053766">Presenilin-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053766" MajorTopicYN="N">Presenilin-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>10</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>4</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>10</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>2</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18957434</ArticleId><ArticleId IdType="pmc">PMC2643502</ArticleId><ArticleId IdType="doi">10.1074/jbc.R800018200</ArticleId><ArticleId IdType="pii">S0021-9258(20)70931-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzheimer, A., Stelzmann, R. A., Schnitzlein, H. N., and Murtagh, F. R. (1995) Clin. Anat. 8 429&#x2013;431</Citation><ArticleIdList><ArticleId IdType="pubmed">8713166</ArticleId></ArticleIdList></Reference><Reference><Citation>Yankner, B. A., Duffy, L. K., and Kirschner, D. A. (1990) Science 250 279&#x2013;282</Citation><ArticleIdList><ArticleId IdType="pubmed">2218531</ArticleId></ArticleIdList></Reference><Reference><Citation>Goate, A., Chartier-Harlin, M. C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., Mant, R., Newton, P., Rooke, K., Roques, P., and Talbot, C. (1991) Nature 349 704&#x2013;706</Citation><ArticleIdList><ArticleId IdType="pubmed">1671712</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., Tsuda, T., Mar, L., Foncin, J.-F., Bruni, A. C., and Montesi, M. P. (1995) Nature 375 754&#x2013;760</Citation><ArticleIdList><ArticleId IdType="pubmed">7651536</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C. E., Jondro, P. D., Schmidt, S. D., Wang, K., Crowley, A. C., Fu, Y.-H., Guenette, S. Y., Galas, D., and Nemens, E. (1995) Science 269 973&#x2013;977</Citation><ArticleIdList><ArticleId IdType="pubmed">7638622</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., Mar, L., Sorbi, S., Nacmias, B., Piacentini, S., and Amaducci, L. (1995) Nature 376 775&#x2013;778</Citation><ArticleIdList><ArticleId IdType="pubmed">7651536</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, J., Ma, J., and Potter, H. (1995) Proc. Natl. Acad. Sci. U. S. A. 92 12180&#x2013;12184</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40320</ArticleId><ArticleId IdType="pubmed">8618867</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki, N., Cheung, T. T., Cai, X. D., Odaka, A., Otvos, L., Jr., Eckman, C., Golde, T. E., and Younkin, S. G. (1994) Science 264 1336&#x2013;1340</Citation><ArticleIdList><ArticleId IdType="pubmed">8191290</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth, M., Tomlinson, B. E., and Blessed, G. (1966) Nature 209 109&#x2013;110</Citation><ArticleIdList><ArticleId IdType="pubmed">5927229</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., and Katzman, R. (1991) Ann. Neurol. 30 572&#x2013;580</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Yankner, B. A., Lu, T., and Loerch, P. (2008) Annu. Rev. Pathol. 3 41&#x2013;66</Citation><ArticleIdList><ArticleId IdType="pubmed">18039130</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrissette, D. A., Parachikova, A., Green, K. N., and LaFerla, F. M. (2009) J. Biol. Chem. 284 in press</Citation><ArticleIdList><ArticleId IdType="pubmed">18948253</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowles, R. B., Wyart, C., Buldyrev, S. V., Cruz, L., Urbanc, B., Hasselmo, M. E., Stanley, H. E., and Hyman, B. T. (1999) Proc. Natl. Acad. Sci. U. S. A. 96 5274&#x2013;5279</Citation><ArticleIdList><ArticleId IdType="pmc">PMC21854</ArticleId><ArticleId IdType="pubmed">10220456</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires, T. L., Meyer-Luehmann, M., Stern, E. A., McLean, P. J., Skoch, J., Nguyen, P. T., Bacskai, B. J., and Hyman, B. T. (2005) J. Neurosci. 25 7278&#x2013;7287</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1820616</ArticleId><ArticleId IdType="pubmed">16079410</ArticleId></ArticleIdList></Reference><Reference><Citation>Urbanc, B., Cruz, L., Le, R., Sanders, J., Ashe, K. H., Duff, K., Stanley, H. E., Irizarry, M. C., and Hyman, B. T. (2002) Proc. Natl. Acad. Sci. U. S. A. 99 13990&#x2013;13995</Citation><ArticleIdList><ArticleId IdType="pmc">PMC137824</ArticleId><ArticleId IdType="pubmed">12374847</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman, D. M., Bales, K. R., Tenkova, T., Fagan, A. M., Parsadanian, M., Sartorius, L. J., Mackey, B., Olney, J., McKeel, D., Wozniak, D., and Paul, S. M. (2000) Proc. Natl. Acad. Sci. U. S. A. 97 2892&#x2013;2897</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16026</ArticleId><ArticleId IdType="pubmed">10694577</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman, D. M., Fagan, A. M., Mackey, B., Tenkova, T., Sartorius, L., Paul, S. M., Bales, K., Ashe, K. H., Irizarry, M. C., and Hyman, B. T. (2000) Ann. Neurol. 47 739&#x2013;747</Citation><ArticleIdList><ArticleId IdType="pubmed">10852539</ArticleId></ArticleIdList></Reference><Reference><Citation>Stokin, G. B., Lillo, C., Falzone, T. L., Brusch, R. G., Rockenstein, E., Mount, S. L., Raman, R., Davies, P., Masliah, E., Williams, D. S., and Goldstein, L. S. (2005) Science 307 1282&#x2013;1288</Citation><ArticleIdList><ArticleId IdType="pubmed">15731448</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann, M., Spires-Jones, T. L., Prada, C., Garcia-Alloza, M., de Calignon, A., Rozkalne, A., Koenigsknecht-Talboo, J., Holtzman, D. M., Bacskai, B. J., and Hyman, B. T. (2008) Nature 451 720&#x2013;724</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3264491</ArticleId><ArticleId IdType="pubmed">18256671</ArticleId></ArticleIdList></Reference><Reference><Citation>Chimon, S., Shaibat, M. A., Jones, C. R., Calero, D. C., Aizezi, B., and Ishii, Y. (2007) Nat. Struct. Mol. Biol. 14 1157&#x2013;1164</Citation><ArticleIdList><ArticleId IdType="pubmed">18059284</ArticleId></ArticleIdList></Reference><Reference><Citation>Games, D., Adams, D., Alessandrini, R., Barbour, R., Berthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) Nature 373 523&#x2013;527</Citation><ArticleIdList><ArticleId IdType="pubmed">7845465</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry, M. C., Soriano, F., McNamara, M., Page, K. J., Schenk, D., Games, D., and Hyman, B. T. (1997) J. Neurosci. 17 7053&#x2013;7059</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573263</ArticleId><ArticleId IdType="pubmed">9278541</ArticleId></ArticleIdList></Reference><Reference><Citation>Geula, C., Wu, C. K., Saroff, D., Lorenzo, A., Yuan, M., and Yankner, B. A. (1998) Nat. Med. 4 827&#x2013;831</Citation><ArticleIdList><ArticleId IdType="pubmed">9662375</ArticleId></ArticleIdList></Reference><Reference><Citation>Pike, C. J., Walencewicz, A. J., Glabe, C. G., and Cotman, C. W. (1991) Eur. J. Pharmacol. 207 367&#x2013;368</Citation><ArticleIdList><ArticleId IdType="pubmed">1783006</ArticleId></ArticleIdList></Reference><Reference><Citation>Busciglio, J., Lorenzo, A., and Yankner, B. A. (1992) Neurobiol. Aging 13 609&#x2013;612</Citation><ArticleIdList><ArticleId IdType="pubmed">1461350</ArticleId></ArticleIdList></Reference><Reference><Citation>Roychaudhuri, R., Yang, M., Hoshi, M. M., and Teplow, D. B. (2009) J. Biol. Chem. 284 4749&#x2013;4753</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3837440</ArticleId><ArticleId IdType="pubmed">18845536</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., Wals, P., Zhang, C., Finch, C. E., Krafft, G. A., and Klein, W. L. (1998) Proc. Natl. Acad. Sci. U. S. A. 95 6448&#x2013;6453</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., and Selkoe, D. J. (2002) Nature 416 535&#x2013;539</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesne, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., and Ashe, K. H. (2006) Nature 440 352&#x2013;357</Citation><ArticleIdList><ArticleId IdType="pubmed">16541076</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng, I. H., Scearce-Levie, K., Legleiter, J., Palop, J. J., Gerstein, H., Bien-Ly, N., Puolivali, J., Lesne, S., Ashe, K. H., Muchowski, P. J., and Mucke, L. (2007) J. Biol. Chem. 282 23818&#x2013;23828</Citation><ArticleIdList><ArticleId IdType="pubmed">17548355</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., Krafft, G. A., and Klein, W. L. (2003) Proc. Natl. Acad. Sci. U. S. A. 100 10417&#x2013;10422</Citation><ArticleIdList><ArticleId IdType="pmc">PMC193576</ArticleId><ArticleId IdType="pubmed">12925731</ArticleId></ArticleIdList></Reference><Reference><Citation>Georganopoulou, D. G., Chang, L., Nam, J. M., Thaxton, C. S., Mufson, E. J., Klein, W. L., and Mirkin, C. A. (2005) Proc. Natl. Acad. Sci. U. S. A. 102 2273&#x2013;2276</Citation><ArticleIdList><ArticleId IdType="pmc">PMC548981</ArticleId><ArticleId IdType="pubmed">15695586</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman, P. F., White, G. L., Jones, M. W., Cooper-Blacketer, D., Marshall, V. J., Irizarry, M., Younkin, L., Good, M. A., Bliss, T. V., Hyman, B. T., Younkin, S. G., and Hsiao, K. K. (1999) Nat. Neurosci. 2 271&#x2013;276</Citation><ArticleIdList><ArticleId IdType="pubmed">10195221</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., and LaFerla, F. M. (2003) Neuron 39 409&#x2013;421</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Billings, L. M., Oddo, S., Green, K. N., McGaugh, J. L., and LaFerla, F. M. (2005) Neuron 45 675&#x2013;688</Citation><ArticleIdList><ArticleId IdType="pubmed">15748844</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsia, A. Y., Masliah, E., McConlogue, L., Yu, G. Q., Tatsuno, G., Hu, K., Kholodenko, D., Malenka, R. C., Nicoll, R. A., and Mucke, L. (1999) Proc. Natl. Acad. Sci. U. S. A. 96 3228&#x2013;3233</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15924</ArticleId><ArticleId IdType="pubmed">10077666</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke, L., Masliah, E., Yu, G. Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., and McConlogue, L. (2000) J. Neurosci. 20 4050&#x2013;4058</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz, F., Tomita, T., Hsieh, H., Seabrook, G., Borchelt, D., Iwatsubo, T., Sisodia, S., and Malinow, R. (2003) Neuron 37 925&#x2013;937</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Priller, C., Bauer, T., Mitteregger, G., Krebs, B., Kretzschmar, H. A., and Herms, J. (2006) J. Neurosci. 26 7212&#x2013;7221</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673945</ArticleId><ArticleId IdType="pubmed">16822978</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito, J. R., Yamada, K. A., Finn, M. B., Sloviter, R. S., Bales, K. R., May, P. C., Schoepp, D. D., Paul, S. M., Mennerick, S., and Holtzman, D. M. (2005) Neuron 48 913&#x2013;922</Citation><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh, H., Boehm, J., Sato, C., Iwatsubo, T., Tomita, T., Sisodia, S., and Malinow, R. (2006) Neuron 52 831&#x2013;843</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850952</ArticleId><ArticleId IdType="pubmed">17145504</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder, E. M., Nong, Y., Almeida, C. G., Paul, S., Moran, T., Choi, E. Y., Nairn, A. C., Salter, M. W., Lombroso, P. J., Gouras, G. K., and Greengard, P. (2005) Nat. Neurosci. 8 1051&#x2013;1058</Citation><ArticleIdList><ArticleId IdType="pubmed">16025111</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., and Sabatini, B. L. (2007) J. Neurosci. 27 2866&#x2013;2875</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672572</ArticleId><ArticleId IdType="pubmed">17360908</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop, J. J., Chin, J., Roberson, E. D., Wang, J., Thwin, M. T., Bien-Ly, N., Yoo, J., Ho, K. O., Yu, G. Q., Kreitzer, A., Finkbeiner, S., Noebels, J. L., and Mucke, L. (2007) Neuron 55 697&#x2013;711</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055171</ArticleId><ArticleId IdType="pubmed">17785178</ArticleId></ArticleIdList></Reference><Reference><Citation>Amatniek, J. C., Hauser, W. A., DelCastillo-Castaneda, C., Jacobs, D. M., Marder, K., Bell, K., Albert, M., Brandt, J., and Stern, Y. (2006) Epilepsia 47 867&#x2013;872</Citation><ArticleIdList><ArticleId IdType="pubmed">16686651</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop, J. J., Jones, B., Kekonius, L., Chin, J., Yu, G. Q., Raber, J., Masliah, E., and Mucke, L. (2003) Proc. Natl. Acad. Sci. U. S. A. 100 9572&#x2013;9577</Citation><ArticleIdList><ArticleId IdType="pmc">PMC170959</ArticleId><ArticleId IdType="pubmed">12881482</ArticleId></ArticleIdList></Reference><Reference><Citation>Guela, C., Bu, J., Nagykery, N., Scinto, L. F., Chan, J., Joseph, J., Parker, R., and Wu, C. K. (2003) J. Comp. Neurol. 455 249&#x2013;259</Citation><ArticleIdList><ArticleId IdType="pubmed">12454989</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu, T., Pan, Y., Kao, S. Y., Li, C., Kohane, I., Chan, J., and Yankner, B. A. (2004) Nature 429 883&#x2013;891</Citation><ArticleIdList><ArticleId IdType="pubmed">15190254</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson, M. P., Rychlik, B., Chu, C., and Christakos, S. (1991) Neuron 6 41&#x2013;51</Citation><ArticleIdList><ArticleId IdType="pubmed">1670921</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrella, J. R., Wang, L., Krishnan, S., Slavin, M. J., Prince, S. E., Tran, T. T., and Doraiswamy, P. M. (2007) Radiology 245 224&#x2013;235</Citation><ArticleIdList><ArticleId IdType="pubmed">17885190</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenzo, A., Yuan, M., Zhang, Z., Paganetti, P. A., Sturchler-Pierrat, C., Staufenbiel, M., Mautino, J., Vigo, F. S., Sommer, B., and Yankner, B. A. (2000) Nat. Neurosci. 3 460&#x2013;464</Citation><ArticleIdList><ArticleId IdType="pubmed">10769385</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu, D. C., Shaked, G. M., Masliah, E., Bredesen, D. E., and Koo, E. H. (2003) Ann. Neurol. 54 781&#x2013;789</Citation><ArticleIdList><ArticleId IdType="pubmed">14681887</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaked, G. M., Kummer, M. P., Lu, D. C., Galvan, V., Bredesen, D. E., and Koo, E. H. (2006) FASEB J. 20 1254&#x2013;1256</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1847355</ArticleId><ArticleId IdType="pubmed">16636103</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu, D. C., Rabizadeh, S., Chandra, S., Shayya, R. F., Ellerby, L. M., Ye, X., Salvesen, G. S., Koo, E. H., and Bredesen, D. E. (2000) Nat. Med. 6 397&#x2013;404</Citation><ArticleIdList><ArticleId IdType="pubmed">10742146</ArticleId></ArticleIdList></Reference><Reference><Citation>Sola Vigo, F., Kedikian, G., Heredia, L., Heredia, F., Anel, A. D., Rosa, A. L., and Lorenzo, A. (2008) Neurobiol. Aging 10.1016/j.neurobiolaging.2007.11.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2007.11.017</ArticleId><ArticleId IdType="pubmed">18187234</ArticleId></ArticleIdList></Reference><Reference><Citation>Galvan, V., Gorostiza, O. F., Banwait, S., Ataie, M., Logvinova, A. V., Sitaraman, S., Carlson, E., Sagi, S. A., Chevallier, N., Jin, K., Greenberg, D. A., and Bredesen, D. E. (2006) Proc. Natl. Acad. Sci. U. S. A. 103 7130&#x2013;7135</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1459029</ArticleId><ArticleId IdType="pubmed">16641106</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk, D., Hagen, M., and Seubert, P. (2004) Curr. Opin. Immunol. 16 599&#x2013;606</Citation><ArticleIdList><ArticleId IdType="pubmed">15342006</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodart, J. C., Bales, K. R., Gannon, K. S., Greene, S. J., DeMattos, R. B., Mathis, C., DeLong, C. A., Wu, S., Wu, X., Holtzman, D. M., and Paul, S. M. (2002) Nat. Neurosci. 5 452&#x2013;457</Citation><ArticleIdList><ArticleId IdType="pubmed">11941374</ArticleId></ArticleIdList></Reference><Reference><Citation>Busciglio, J., Lorenzo, A., Yeh, J., and Yankner, B. A. (1995) Neuron 14 879&#x2013;888</Citation><ArticleIdList><ArticleId IdType="pubmed">7718249</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G. Q., and Mucke, L. (2007) Science 316 750&#x2013;754</Citation><ArticleIdList><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapoport, M., Dawson, H. N., Binder, L. I., Vitek, M. P., and Ferreira, A. (2002) Proc. Natl. Acad. Sci. U. S. A. 99 6364&#x2013;6369</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122954</ArticleId><ArticleId IdType="pubmed">11959919</ArticleId></ArticleIdList></Reference><Reference><Citation>Park, S. Y., and Ferreira, A. (2005) J. Neurosci. 25 5365&#x2013;5375</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1352316</ArticleId><ArticleId IdType="pubmed">15930385</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, T., Perry, G., Chan, H. W., Verdile, G., Martins, R. N., Smith, M. A., and Atwood, C. S. (2004) J. Neurochem. 88 554&#x2013;563</Citation><ArticleIdList><ArticleId IdType="pubmed">14720205</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshpande, A., Mina, E., Glabe, C., and Busciglio, J. (2006) J. Neurosci. 26 6011&#x2013;6018</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675207</ArticleId><ArticleId IdType="pubmed">16738244</ArticleId></ArticleIdList></Reference><Reference><Citation>Behl, C., Davis, J. B., Lesley, R., and Schubert, D. (1994) Cell 77 817&#x2013;827</Citation><ArticleIdList><ArticleId IdType="pubmed">8004671</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., Migheli, A., Nawroth, P., Stern, D., and Schmidt, A. M. (1996) Nature 382 685&#x2013;691</Citation><ArticleIdList><ArticleId IdType="pubmed">8751438</ArticleId></ArticleIdList></Reference><Reference><Citation>Loo, D. T., Copani, A., Pike, C. J., Whittemore, E. R., Walencewicz, A. J., and Cotman, C. W. (1993) Proc. Natl. Acad. Sci. U. S. A. 90 7951&#x2013;7955</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47265</ArticleId><ArticleId IdType="pubmed">8367446</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa, T., Zhu, H., Morishima, N., Li, E., Xu, J., Yankner, B. A., and Yuan, J. (2000) Nature 403 98&#x2013;103</Citation><ArticleIdList><ArticleId IdType="pubmed">10638761</ArticleId></ArticleIdList></Reference><Reference><Citation>Troy, C. M., Rabacchi, S. A., Friedman, W. J., Frappier, T. F., Brown, K., and Shelanski, M. L. (2000) J. Neurosci. 20 1386&#x2013;1392</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772358</ArticleId><ArticleId IdType="pubmed">10662829</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, M. S., Kwon, Y. T., Li, M., Peng, J., Friedlander, R. M., and Tsai, L. H. (2000) Nature 405 360&#x2013;364</Citation><ArticleIdList><ArticleId IdType="pubmed">10830966</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsui, T., Ramasamy, K., Ingelsson, M., Fukumoto, H., Conrad, C., Frosch, M. P., Irizarry, M. C., Yuan, J., and Hyman, B. T. (2006) J. Neuropathol. Exp. Neurol. 65 508&#x2013;515</Citation><ArticleIdList><ArticleId IdType="pubmed">16772874</ArticleId></ArticleIdList></Reference><Reference><Citation>Albrecht, S., Bourdeau, M., Bennett, D., Mufson, E. J., Bhattacharjee, M., and LeBlanc, A. C. (2007) Am. J. Pathol. 170 1200&#x2013;1209</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1829454</ArticleId><ArticleId IdType="pubmed">17392160</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruman, I. I., Wersto, R. P., Cardozo-Pelaez, F., Smilenov, L., Chan, S. L., Chrest, F. J., Emokpae, R., Jr., Gorospe, M., and Mattson, M. P. (2004) Neuron 41 549&#x2013;561</Citation><ArticleIdList><ArticleId IdType="pubmed">14980204</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, Y., Mufson, E. J., and Herrup, K. (2003) J. Neurosci. 23 2557&#x2013;2563</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742098</ArticleId><ArticleId IdType="pubmed">12684440</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen, E., Bieschke, J., Perciavalle, R. M., Kelly, J. W., and Dillin, A. (2006) Science 313 1604&#x2013;1610</Citation><ArticleIdList><ArticleId IdType="pubmed">16902091</ArticleId></ArticleIdList></Reference><Reference><Citation>Isaacs, A. M., Senn, D. B., Yuan, M., Shine, J. P., and Yankner, B. A. (2006) J. Biol. Chem. 281 27916&#x2013;27923</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1595535</ArticleId><ArticleId IdType="pubmed">16870617</ArticleId></ArticleIdList></Reference><Reference><Citation>El Khoury, J., Hickman, S. E., Thomas, C. A., Cao, L., Silverstein, S. C., and Loike, J. D. (1996) Nature 382 716&#x2013;719</Citation><ArticleIdList><ArticleId IdType="pubmed">8751442</ArticleId></ArticleIdList></Reference><Reference><Citation>Coraci, I. S., Husemann, J., Berman, J. W., Hulette, C., Dufour, J. H., Campanella, G. K., Luster, A. D., Silverstein, S. C., and El Khoury, J. B. (2002) Am. J. Pathol. 160 101&#x2013;112</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1867121</ArticleId><ArticleId IdType="pubmed">11786404</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore, K. J., El Khoury, J., Medeiros, L. A., Terada, K., Geula, C., Luster, A. D., and Freeman, M. W. (2002) J. Biol. Chem. 277 47373&#x2013;47379</Citation><ArticleIdList><ArticleId IdType="pubmed">12239221</ArticleId></ArticleIdList></Reference><Reference><Citation>Paresce, D. M., Ghosh, R. N., and Maxfield, F. R. (1996) Neuron 17 553&#x2013;565</Citation><ArticleIdList><ArticleId IdType="pubmed">8816718</ArticleId></ArticleIdList></Reference><Reference><Citation>El Khoury, J., Toft, M., Hickman, S. E., Means, T. K., Terada, K., Geula, C., and Luster, A. D. (2007) Nat. Med. 13 432&#x2013;438</Citation><ArticleIdList><ArticleId IdType="pubmed">17351623</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray, T., and Mucke, L. (2002) Neuron 35 419&#x2013;432</Citation><ArticleIdList><ArticleId IdType="pubmed">12165466</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18973185</PMID><DateCompleted><Year>2009</Year><Month>02</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1096-9896</ISSN><JournalIssue CitedMedium="Internet"><Volume>217</Volume><Issue>1</Issue><PubDate><Year>2009</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The Journal of pathology</Title><ISOAbbreviation>J Pathol</ISOAbbreviation></Journal><ArticleTitle>Herpes simplex virus type 1 DNA is located within Alzheimer's disease amyloid plaques.</ArticleTitle><Pagination><StartPage>131</StartPage><EndPage>138</EndPage><MedlinePgn>131-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/path.2449</ELocationID><Abstract><AbstractText>The brains of Alzheimer's disease sufferers are characterized by amyloid plaques and neurofibrillary tangles. However, the cause(s) of these features and those of the disease are unknown, in sporadic cases. We previously showed that herpes simplex virus type 1 is a strong risk factor for Alzheimer's disease when in the brains of possessors of the type 4 allele of the apolipoprotein E gene (APOE-epsilon4), and that beta-amyloid, the main component of plaques, accumulates in herpes simplex virus type 1-infected cell cultures and mouse brain. The present study aimed to elucidate the relationship of the virus to plaques by determining their proximity in human brain sections. We used in situ polymerase chain reaction to detect herpes simplex virus type 1 DNA, and immunohistochemistry or thioflavin S staining to detect amyloid plaques. We discovered a striking localization of herpes simplex virus type 1 DNA within plaques: in Alzheimer's disease brains, 90% of the plaques contained the viral DNA and 72% of the DNA was associated with plaques; in aged normal brains, which contain amyloid plaques at a lower frequency, 80% of plaques contained herpes simplex virus type 1 DNA but only 24% of the viral DNA was plaque-associated (p &lt; 0.001). We suggest that this is because in aged normal individuals, there is a lesser production and/or greater removal of beta-amyloid (Abeta), so that less of the viral DNA is seen to be associated with Abeta in the brain. Our present data, together with our finding of Abeta accumulation in herpes simplex virus type 1-infected cells and mouse brain, suggest that this virus is a major cause of amyloid plaques and hence probably a significant aetiological factor in Alzheimer's disease. They point to the usage of antiviral agents to treat the disease and possibly of vaccination to prevent it.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wozniak</LastName><ForeName>M A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Faculty of Life Sciences, University of Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mee</LastName><ForeName>A P</ForeName><Initials>AP</Initials></Author><Author ValidYN="Y"><LastName>Itzhaki</LastName><ForeName>R F</ForeName><Initials>RF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Pathol</MedlineTA><NlmUniqueID>0204634</NlmUniqueID><ISSNLinking>0022-3417</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004279">DNA, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004279" MajorTopicYN="N">DNA, Viral</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006561" MajorTopicYN="N">Herpes Simplex</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018259" MajorTopicYN="N">Herpesvirus 1, Human</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016133" MajorTopicYN="N">Polymerase Chain Reaction</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>11</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>11</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>2</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18973185</ArticleId><ArticleId IdType="doi">10.1002/path.2449</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18987181</PMID><DateCompleted><Year>2008</Year><Month>12</Month><Day>31</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>45</Issue><PubDate><Year>2008</Year><Month>Nov</Month><Day>05</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels.</ArticleTitle><Pagination><StartPage>11445</StartPage><EndPage>11453</EndPage><MedlinePgn>11445-53</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.1972-08.2008</ELocationID><Abstract><AbstractText>Inheritance of the apoE4 allele (epsilon4) increases the risk of developing Alzheimer's disease; however, the mechanisms underlying this association remain elusive. Recent data suggest that inheritance of epsilon4 may lead to reduced apoE protein levels in the CNS. We therefore examined apoE protein levels in the brains, CSF and plasma of epsilon2/2, epsilon3/3, and epsilon4/4 targeted replacement mice. These apoE mice showed a genotype-dependent decrease in apoE levels; epsilon2/2 &gt;epsilon3/3 &gt;epsilon4/4. Next, we sought to examine the relative contributions of apoE4 and apoE3 in the epsilon3/4 mouse brains. ApoE4 represented 30-40% of the total apoE. Moreover, the absolute amount of apoE3 per allele was similar between epsilon3/3 and epsilon3/4 mice, implying that the reduced levels of total apoE in epsilon3/4 mice can be explained by the reduction in apoE4 levels. In culture medium from epsilon3/4 human astrocytoma or epsilon3/3, epsilon4/4 and epsilon3/4 primary astrocytes, apoE4 levels were consistently lower than apoE3. Secreted cholesterol levels were also lower from epsilon4/4 astrocytes. Pulse-chase experiments showed an enhanced degradation and reduced half-life of newly synthesized apoE4 compared with apoE3. Together, these data suggest that astrocytes preferentially degrade apoE4, leading to reduced apoE4 secretion and ultimately to reduced brain apoE levels. Moreover, the genotype-dependent decrease in CNS apoE levels, mirror the relative risk of developing AD, and suggest that low levels of total apoE exhibited by epsilon4 carriers may directly contribute to the disease progression, perhaps by reducing the capacity of apoE to promote synaptic repair and/or Abeta clearance.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Riddell</LastName><ForeName>David R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Discovery Neuroscience, Wyeth Research, CN8000, Princeton, New Jersey 08543, USA. riddeld@wyeth.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Hua</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Atchison</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Warwick</LastName><ForeName>Helen K</ForeName><Initials>HK</Initials></Author><Author ValidYN="Y"><LastName>Atkinson</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Jefferson</LastName><ForeName>Julius</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Lin</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Aschmies</LastName><ForeName>Suzan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kirksey</LastName><ForeName>Yolanda</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Yun</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Wagner</LastName><ForeName>Erik</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Parratt</LastName><ForeName>Adrienne</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Jane</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zhuting</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Zaleska</LastName><ForeName>Margaret M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Jacobsen</LastName><ForeName>J Steve</ForeName><Initials>JS</Initials></Author><Author ValidYN="Y"><LastName>Pangalos</LastName><ForeName>Menelas N</ForeName><Initials>MN</Initials></Author><Author ValidYN="Y"><LastName>Reinhart</LastName><ForeName>Peter H</ForeName><Initials>PH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017077">Culture Media, Conditioned</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006845">Hydrocarbons, Fluorinated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C423915">T0901317</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017077" MajorTopicYN="N">Culture Media, Conditioned</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004252" MajorTopicYN="N">DNA Mutational Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006845" MajorTopicYN="N">Hydrocarbons, Fluorinated</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009457" MajorTopicYN="N">Neuroglia</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="Y">Polymorphism, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>11</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>1</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>11</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>5</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18987181</ArticleId><ArticleId IdType="pmc">PMC6671315</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.1972-08.2008</ArticleId><ArticleId IdType="pii">28/45/11445</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Beffert U, Cohn JS, Petit-Turcotte C, Tremblay M, Aumont N, Ramassamy C, Davignon J, Poirier J. Apolipoprotein E and beta-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype dependent. Brain Res. 1999;843:87&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">10528114</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertrand P, Poirier J, Oda T, Finch CE, Pasinetti GM. Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. Brain Res Mol Brain Res. 1995;33:174&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">8774959</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyles JK, Pitas RE, Wilson E, Mahley RW, Taylor JM. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J Clin Invest. 1985;76:1501&#x2013;1513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC424114</ArticleId><ArticleId IdType="pubmed">3932467</ArticleId></ArticleIdList></Reference><Reference><Citation>Brecht WJ, Harris FM, Chang S, Tesseur I, Yu GQ, Xu Q, Dee Fish J, Wyss-Coray T, Buttini M, Mucke L, Mahley RW, Huang Y. Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J Neurosci. 2004;24:2527&#x2013;2534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729489</ArticleId><ArticleId IdType="pubmed">15014128</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns MP, Vardanian L, Pajoohesh-Ganji A, Wang L, Cooper M, Harris DC, Duff K, Rebeck GW. The effects of ABCA1 on cholesterol efflux and Abeta levels in vitro and in vivo. J Neurochem. 2006;98:792&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">16771834</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Lomnitski L, Michaelson DM, Shohami E. Motor and cognitive deficits in apolipoprotein E-deficient mice after closed head injury. Neuroscience. 1997;80:1255&#x2013;1262.</Citation><ArticleIdList><ArticleId IdType="pubmed">9284075</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Ghebremedhin E, Taylor MG, Thal DR, Ohm TG, Braak H. The biphasic relationship between regional brain senile plaque and neurofibrillary tangle distributions: modification by age, sex, and APOE polymorphism. Ann N Y Acad Sci. 2004;1019:24&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">15246987</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB, Bales KR, Parsadanian M, O'Dell MA, Foss EM, Paul SM, Holtzman DM. Plaque-associated disruption of CSF and plasma A&#x3b2; equilibrium in a mouse model of Alzheimer's Disease. J Neurochem. 2002;81:229&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">12064470</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB, Cirrito JR, Parsadanian M, May PC, O'Dell MA, Taylor JW, Harmony JA, Aronow BJ, Bales KR, Paul SM, Holtzman DM. ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron. 2004;41:193&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">14741101</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng J, Rudick V, Dory L. Lysosomal degradation and sorting of apolipoprotein E in macrophages. J Lipid Res. 1995;36:2129&#x2013;2140.</Citation><ArticleIdList><ArticleId IdType="pubmed">8576639</ArticleId></ArticleIdList></Reference><Reference><Citation>Enzinger C, Ropele S, Smith S, Strasser-Fuchs S, Poltrum B, Schmidt H, Matthews PM, Fazekas F. Accelerated evolution of brain atrophy and &#x201c;black holes&#x201d; in MS patients with APOE-epsilon 4. Ann Neurol. 2004;55:563&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pubmed">15048896</ArticleId></ArticleIdList></Reference><Reference><Citation>Eto M, Watanabe K, Ishii K. Reciprocal effects of apolipoprotein E alleles (epsilon 2 and epsilon 4) on plasma lipid levels in normolipidemic subjects. Clin Genet. 1986;29:477&#x2013;484.</Citation><ArticleIdList><ArticleId IdType="pubmed">3461894</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Murphy BA, Patel SN, Kilbridge JF, Mobley WC, Bu G, Holtzman DM. Evidence for normal aging of the septo-hippocampal cholinergic system in apoE (-/-) mice but impaired clearance of axonal degeneration products following injury. Exp Neurol. 1998;151:314&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">9628766</ArticleId></ArticleIdList></Reference><Reference><Citation>Fazekas F, Strasser-Fuchs S, Kollegger H, Berger T, Kristoferitsch W, Schmidt H, Enzinger C, Schiefermeier M, Schwarz C, Kornek B, Reindl M, Huber K, Grass R, Wimmer G, Vass K, Pfeiffer KH, Hartung HP, Schmidt R. Apolipoprotein E epsilon 4 is associated with rapid progression of multiple sclerosis. Neurology. 2001;57:853&#x2013;857.</Citation><ArticleIdList><ArticleId IdType="pubmed">11552016</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Miranda C, Cancelas P, de la Calle A, G&#xf3;mez R, Moreno E, G&#xf3;mez-Gerique J, del Palacio A. Changes in phenotypes of apolipoprotein E and apolipoprotein(a) in liver transplant recipients. Clin Transplant. 1997;11:325&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">9267723</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman G, Froom P, Sazbon L, Grinblatt I, Shochina M, Tsenter J, Babaey S, Yehuda B, Groswasser Z. Apolipoprotein E-epsilon4 genotype predicts a poor outcome in survivors of traumatic brain injury. Neurology. 1999;52:244&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">9932938</ArticleId></ArticleIdList></Reference><Reference><Citation>Fryer JD, Simmons K, Parsadanian M, Bales KR, Paul SM, Sullivan PM, Holtzman DM. Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J Neurosci. 2005;25:2803&#x2013;2810.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725147</ArticleId><ArticleId IdType="pubmed">15772340</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumoto H, Ingelsson M, G&#xe5;revik N, Wahlund LO, Nukina N, Yaguchi Y, Shibata M, Hyman BT, Rebeck GW, Irizarry MC. APOE epsilon 3/ epsilon 4 heterozygotes have an elevated proportion of apolipoprotein E4 in cerebrospinal fluid relative to plasma, independent of Alzheimer's disease diagnosis. Exp Neurol. 2003;183:249&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">12957508</ArticleId></ArticleIdList></Reference><Reference><Citation>Gl&#xf6;ckner F, Meske V, Ohm TG. Genotype-related differences of hippocampal apolipoprotein E levels only in early stages of neuropathological changes in Alzheimer's disease. Neuroscience. 2002;114:1103&#x2013;1114.</Citation><ArticleIdList><ArticleId IdType="pubmed">12379263</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregg RE, Zech LA, Schaefer EJ, Stark D, Wilson D, Brewer HB., Jr Abnormal in vivo metabolism of apolipoprotein E4 in humans. J Clin Invest. 1986;78:815&#x2013;821.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC423680</ArticleId><ArticleId IdType="pubmed">3745440</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerrero AL, Laherr&#xe1;n E, Guti&#xe9;rrez F, Mart&#xed;n-Polo J, Iglesias F, Alc&#xe1;zar C, Peralta J, Rostami P. Apolipoprotein E genotype does not associate with disease severity measured by Multiple Sclerosis Severity Score. Acta Neurol Scand. 2008;117:21&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">17883422</ArticleId></ArticleIdList></Reference><Reference><Citation>Handelmann GE, Boyles JK, Weisgraber KH, Mahley RW, Pitas RE. Effects of apolipoprotein E, beta-very low density lipoproteins, and cholesterol on the extension of neurites by rabbit dorsal root ganglion neurons in vitro. J Lipid Res. 1992;33:1677&#x2013;1688.</Citation><ArticleIdList><ArticleId IdType="pubmed">1464751</ArticleId></ArticleIdList></Reference><Reference><Citation>Hara M, Matsushima T, Satoh H, Iso-o N, Noto H, Togo M, Kimura S, Hashimoto Y, Tsukamoto K. Isoform-dependent cholesterol efflux from macrophages by apolipoprotein E is modulated by cell surface proteoglycans. Arterioscler Thromb Vasc Biol. 2003;23:269&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">12588770</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatters DM, Peters-Libeu CA, Weisgraber KH. Apolipoprotein E structure: insights into function. Trends Biochem Sci. 2006;31:445&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pubmed">16820298</ArticleId></ArticleIdList></Reference><Reference><Citation>Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 1990;31:545&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">2341813</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Liu XQ, Wyss-Coray T, Brecht WJ, Sanan DA, Mahley RW. Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. Proc Natl Acad Sci U S A. 2001;98:8838&#x2013;8843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC37522</ArticleId><ArticleId IdType="pubmed">11447277</ArticleId></ArticleIdList></Reference><Reference><Citation>Jasinska-Myga B, Opala G, Goetz CG, Tustanowski J, Ochudlo S, Gorzkowska A, Tyrpa J. Apolipoprotein E gene polymorphism, total plasma cholesterol level, and Parkinson disease dementia. Arch Neurol. 2007;64:261&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">17296843</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji Y, Gong Y, Gan W, Beach T, Holtzman DM, Wisniewski T. Apolipoprotein E isoform-specific regulation of dendritic spine morphology in apolipoprotein E transgenic mice and Alzheimer's disease patients. Neuroscience. 2003;122:305&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pubmed">14614898</ArticleId></ArticleIdList></Reference><Reference><Citation>Karussis D, Michaelson DM, Grigoriadis N, Korezyn AD, Mizrachi-Koll R, Chapman S, Abramsky O, Chapman J. Lack of apolipoprotein-E exacerbates experimental allergic encephalomyelitis. Mult Scler. 2003;9:476&#x2013;480.</Citation><ArticleIdList><ArticleId IdType="pubmed">14582773</ArticleId></ArticleIdList></Reference><Reference><Citation>Knouff C, Hinsdale ME, Mezdour H, Altenburg MK, Watanabe M, Quarfordt SH, Sullivan PM, Maeda N. Apo E structure determines VLDL clearance and atherosclerosis risk in mice. J Clin Invest. 1999;103:1579&#x2013;1586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC408371</ArticleId><ArticleId IdType="pubmed">10359567</ArticleId></ArticleIdList></Reference><Reference><Citation>Kockx M, Rye KA, Gaus K, Quinn CM, Wright J, Sloane T, Sviridov D, Fu Y, Sullivan D, Burnett JR, Rust S, Assmann G, Anantharamaiah GM, Palgunachari MN, Katz SL, Phillips MC, Dean RT, Jessup W, Kritharides L. Apolipoprotein A-I-stimulated apolipoprotein E secretion from human macrophages is independent of cholesterol efflux. J Biol Chem. 2004;279:25966&#x2013;25977.</Citation><ArticleIdList><ArticleId IdType="pubmed">15066991</ArticleId></ArticleIdList></Reference><Reference><Citation>Koistinaho M, Lin S, Wu X, Esterman M, Koger D, Hanson J, Higgs R, Liu F, Malkani S, Bales KR, Paul SM. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med. 2004;10:719&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">15195085</ArticleId></ArticleIdList></Reference><Reference><Citation>Koldamova RP, Lefterov IM, Staufenbiel M, Wolfe D, Huang S, Glorioso JC, Walter M, Roth MG, Lazo JS. The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. J Biol Chem. 2005;280:4079&#x2013;4088.</Citation><ArticleIdList><ArticleId IdType="pubmed">15557325</ArticleId></ArticleIdList></Reference><Reference><Citation>Krul ES, Cole TG. Quantitation of apolipoprotein E. Methods Enzymol. 1996;263:170&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">8749007</ArticleId></ArticleIdList></Reference><Reference><Citation>LaDu MJ, Gilligan SM, Lukens JR, Cabana VG, Reardon CA, Van Eldik LJ, Holtzman DM. Nascent astrocyte particles differ from lipoproteins in CSF. J Neurochem. 1998;70:2070&#x2013;2081.</Citation><ArticleIdList><ArticleId IdType="pubmed">9572293</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai MK, Tsang SW, Garcia-Alloza M, Minger SL, Nicoll JA, Esiri MM, Wong PT, Chen CP, Ramirez MJ, Francis PT. Selective effects of the APOE epsilon4 allele on presynaptic cholinergic markers in the neocortex of Alzheimer's disease. Neurobiol Dis. 2006;22:555&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pubmed">16473016</ArticleId></ArticleIdList></Reference><Reference><Citation>Laskowitz DT, Sheng H, Bart RD, Joyner KA, Roses AD, Warner DS. Apolipoprotein E-deficient mice have increased susceptibility to focal cerebral ischemia. J Cereb Blood Flow Metab. 1997;17:753&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">9270492</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Y, Lin S, Beyer TP, Zhang Y, Wu X, Bales KR, DeMattos RB, May PC, Li SD, Jiang XC, Eacho PI, Cao G, Paul SM. A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes. J Neurochem. 2004;88:623&#x2013;634.</Citation><ArticleIdList><ArticleId IdType="pubmed">14720212</ArticleId></ArticleIdList></Reference><Reference><Citation>Manelli AM, Stine WB, Van Eldik LJ, LaDu MJ. ApoE and Abeta1&#x2013;42 interactions: effects of isoform and conformation on structure and function. J Mol Neurosci. 2004;23:235&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">15181252</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann KM, Thorngate FE, Katoh-Fukui Y, Hamanaka H, Williams DL, Fujita S, Lamb BT. Independent effects of APOE on cholesterol metabolism and brain Abeta levels in an Alzheimer disease mouse model. Hum Mol Genet. 2004;13:1959&#x2013;1968.</Citation><ArticleIdList><ArticleId IdType="pubmed">15229191</ArticleId></ArticleIdList></Reference><Reference><Citation>Marriott DR, Hirst WD, Ljungberg MC. Astrocytes. In: Cohen J, Wilkin GP, editors. Neural cell culture-a practical approach. Oxford: Oxford UP; 1995. pp. 85&#x2013;96.</Citation></Reference><Reference><Citation>Mauch DH, N&#xe4;gler K, Schumacher S, G&#xf6;ritz C, M&#xfc;ller EC, Otto A, Pfrieger FW. CNS synaptogenesis promoted by glia-derived cholesterol. Science. 2001;294:1354&#x2013;1357.</Citation><ArticleIdList><ArticleId IdType="pubmed">11701931</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrow JA, Hatters DM, Lu B, Hochtl P, Oberg KA, Rupp B, Weisgraber KH. Apolipoprotein E4 forms a molten globule. A potential basis for its association with disease. J Biol Chem. 2002;277:50380&#x2013;50385.</Citation><ArticleIdList><ArticleId IdType="pubmed">12393895</ArticleId></ArticleIdList></Reference><Reference><Citation>Moulard B, Sefiani A, Laamri A, Malafosse A, Camu W. Apolipoprotein E genotyping in sporadic amyotrophic lateral sclerosis: evidence for a major influence on the clinical presentation and prognosis. J Neurol Sci. 1996;139(Suppl):34&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">8899655</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathan BP, Bellosta S, Sanan DA, Weisgraber KH, Mahley RW, Pitas RE. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science. 1994;264:850&#x2013;852.</Citation><ArticleIdList><ArticleId IdType="pubmed">8171342</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Donnell HC, Rosand J, Knudsen KA, Furie KL, Segal AZ, Chiu RI, Ikeda D, Greenberg SM. Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. N Engl J Med. 2000;342:240&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pubmed">10648765</ArticleId></ArticleIdList></Reference><Reference><Citation>Pankratz N, Byder L, Halter C, Rudolph A, Shults CW, Conneally PM, Foroud T, Nichols WC. Presence of an APOE4 allele results in significantly earlier onset of Parkinson's disease and a higher risk with dementia. Mov Disord. 2006;21:45&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">16116614</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfrieger FW. Role of cholesterol in synapse formation and function. Biochim Biophys Acta. 2003;1610:271&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pubmed">12648780</ArticleId></ArticleIdList></Reference><Reference><Citation>Poirier J. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurosci. 1994;17:525&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pubmed">7532337</ArticleId></ArticleIdList></Reference><Reference><Citation>Poirier J. Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease. Neurobiol Aging. 2005;26:355&#x2013;361.</Citation><ArticleIdList><ArticleId IdType="pubmed">15639314</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinet EM, Savio DA, Halpern AR, Chen L, Miller CP, Nambi P. Gene-selective modulation by a synthetic oxysterol ligand of the liver X receptor. J Lipid Res. 2004;45:1929&#x2013;1942.</Citation><ArticleIdList><ArticleId IdType="pubmed">15292374</ArticleId></ArticleIdList></Reference><Reference><Citation>Raber J, Huang Y, Ashford JW. ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol Aging. 2004;25:641&#x2013;650.</Citation><ArticleIdList><ArticleId IdType="pubmed">15172743</ArticleId></ArticleIdList></Reference><Reference><Citation>Raffai RL, Dong LM, Farese RV, Jr, Weisgraber KH. Introduction of human apolipoprotein E4 &#x201c;domain interaction&#x201d; into mouse apolipoprotein E. Proc Natl Acad Sci U S A. 2001;98:11587&#x2013;11591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC58773</ArticleId><ArticleId IdType="pubmed">11553788</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramaswamy G, Xu Q, Huang Y, Weisgraber KH. Effect of domain interaction on apolipoprotein E levels in mouse brain. J Neurosci. 2005;25:10658&#x2013;10663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725862</ArticleId><ArticleId IdType="pubmed">16291938</ArticleId></ArticleIdList></Reference><Reference><Citation>Riddell DR, Zhou H, Comery TA, Kouranova E, Lo CF, Warwick HK, Ring RH, Kirksey Y, Aschmies S, Xu J, Kubek K, Hirst WD, Gonzales C, Chen Y, Murphy E, Leonard S, Vasylyev D, Oganesian A, Martone RL, Pangalos MN, Reinhart PH, Jacobsen JS. The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol Cell Neurosci. 2007;34:621&#x2013;628.</Citation><ArticleIdList><ArticleId IdType="pubmed">17336088</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabo T, Lomnitski L, Nyska A, Beni S, Maronpot RR, Shohami E, Roses AD, Michaelson DM. Susceptibility of transgenic mice expressing human apolipoprotein E to closed head injury: the allele E3 is neuroprotective whereas E4 increases fatalities. Neuroscience. 2000;101:879&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pubmed">11113336</ArticleId></ArticleIdList></Reference><Reference><Citation>Santucci R, Sinibaldi F, Fiorucci L. Protein folding, unfolding and misfolding: role played by intermediate States. Mini Rev Med Chem. 2008;8:57&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">18220985</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Bienias JL, Wilson RS, Berry-Kravis E, Evans DA, Bennett DA. The apolipoprotein E epsilon4 allele increases the odds of chronic cerebral infarction [corrected] detected at autopsy in older persons. Stroke. 2005;36:954&#x2013;959.</Citation><ArticleIdList><ArticleId IdType="pubmed">15774818</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng H, Laskowitz DT, Mackensen GB, Kudo M, Pearlstein RD, Warner DS. Apolipoprotein E deficiency worsens outcome from global cerebral ischemia in the mouse. Stroke. 1999;30:1118&#x2013;1124.</Citation><ArticleIdList><ArticleId IdType="pubmed">10229753</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng H, Laskowitz DT, Bennett E, Schmechel DE, Bart RD, Saunders AM, Pearlstein RD, Roses AD, Warner DS. Apolipoprotein E isoform-specific differences in outcome from focal ischemia in transgenic mice. J Cereb Blood Flow Metab. 1998;18:361&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">9538900</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddique T, Pericak-Vance MA, Caliendo J, Hong ST, Hung WY, Kaplan J, McKenna-Yasek D, Rimmler JB, Sapp P, Saunders AM, Scott WK, Siddique N, Haines JL, Brown RH. Lack of association between apolipoprotein E genotype and sporadic amyotrophic lateral sclerosis. Neurogenetics. 1998;1:213&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">10737125</ArticleId></ArticleIdList></Reference><Reference><Citation>Stratman NC, Castle CK, Taylor BM, Epps DE, Melchior GW, Carter DB. Isoform-specific interactions of human apolipoprotein E to an intermediate conformation of human Alzheimer amyloid-beta peptide. Chem Phys Lipids. 2005;137:52&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">16140289</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan PM, Mace BE, Maeda N, Schmechel DE. Marked regional differences of brain human apolipoprotein E expression in targeted replacement mice. Neuroscience. 2004;124:725&#x2013;733.</Citation><ArticleIdList><ArticleId IdType="pubmed">15026113</ArticleId></ArticleIdList></Reference><Reference><Citation>Trommer BL, Shah C, Yun SH, Gamkrelidze G, Pasternak ES, Stine WB, Manelli A, Sullivan P, Pasternak JF, LaDu MJ. ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1&#x2013;42. Neurobiol Dis. 2005;18:75&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">15649697</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisgraber KH, Mahley RW. Human apolipoprotein E: the Alzheimer's disease connection. Faseb J. 1996;10:1485&#x2013;1494.</Citation><ArticleIdList><ArticleId IdType="pubmed">8940294</ArticleId></ArticleIdList></Reference><Reference><Citation>White F, Nicoll JA, Roses AD, Horsburgh K. Impaired neuronal plasticity in transgenic mice expressing human apolipoprotein E4 compared to E3 in a model of entorhinal cortex lesion. Neurobiol Dis. 2001;8:611&#x2013;625.</Citation><ArticleIdList><ArticleId IdType="pubmed">11493026</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye SQ, Reardon CA, Getz GS. Inhibition of apolipoprotein E degradation in a post-Golgi compartment by a cysteine protease inhibitor. J Biol Chem. 1993;268:8497&#x2013;8502.</Citation><ArticleIdList><ArticleId IdType="pubmed">8473293</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18987185</PMID><DateCompleted><Year>2008</Year><Month>12</Month><Day>31</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>45</Issue><PubDate><Year>2008</Year><Month>Nov</Month><Day>05</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>CLIC1 function is required for beta-amyloid-induced generation of reactive oxygen species by microglia.</ArticleTitle><Pagination><StartPage>11488</StartPage><EndPage>11499</EndPage><MedlinePgn>11488-99</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.2431-08.2008</ELocationID><Abstract><AbstractText>The Alzheimer's disease (AD) brain is characterized by plaques containing beta-amyloid (Abeta) protein surrounded by astrocytes and reactive microglia. Activation of microglia by Abeta initiates production of reactive oxygen species (ROS) by the plasmalemmal NADPH oxidase; the resultant oxidative stress is thought to contribute to neurodegeneration in AD. We have previously shown that Abeta upregulates a chloride current mediated by the chloride intracellular channel 1 (CLIC1) protein in microglia. We now demonstrate that Abeta promotes the acute translocation of CLIC1 from the cytosol to the plasma membrane of microglia, where it mediates a chloride conductance. Both the Abeta induced Cl(-) conductance and ROS generation were prevented by pharmacological inhibition of CLIC1, by replacement of chloride with impermeant anions, by an anti-CLIC1 antibody and by suppression of CLIC1 expression using siRNA. Thus, the CLIC1-mediated Cl(-) conductance is required for Abeta-induced generation of neurotoxic ROS by microglia. Remarkably, CLIC1 activation is itself dependent on oxidation by ROS derived from the activated NADPH oxidase. We therefore propose that CLIC1 translocation from the cytosol to the plasma membrane, in response to redox modulation by NADPH oxidase-derived ROS, provides a feedforward mechanism that facilitates sustained microglial ROS generation by the NAPDH oxidase.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Milton</LastName><ForeName>Rosemary H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Department of Physiology, University College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abeti</LastName><ForeName>Rosella</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Averaimo</LastName><ForeName>Stefania</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>DeBiasi</LastName><ForeName>Silvia</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Vitellaro</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Lele</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Curmi</LastName><ForeName>Paul M G</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><LastName>Breit</LastName><ForeName>Samuel N</ForeName><Initials>SN</Initials></Author><Author ValidYN="Y"><LastName>Duchen</LastName><ForeName>Michael R</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Mazzanti</LastName><ForeName>Michele</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>075045</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0601943</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018118">Chloride Channels</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C501967">Clic1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006016">Glycolates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C074636">amyloid beta-protein (25-35)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>54197-05-6</RegistryNumber><NameOfSubstance UI="C015765">MK 473</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018118" MajorTopicYN="N">Chloride Channels</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006016" MajorTopicYN="N">Glycolates</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008564" MajorTopicYN="N">Membrane Potentials</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018408" MajorTopicYN="N">Patch-Clamp Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>11</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>1</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>11</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>5</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18987185</ArticleId><ArticleId IdType="pmc">PMC6671295</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2431-08.2008</ArticleId><ArticleId IdType="pii">28/45/11488</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abramov AY, Duchen MR. The role of an astrocytic NADPH oxidase in the neurotoxicity of amyloid beta peptides. Philos Trans R Soc Lond B Biol Sci. 2005;360:2309&#x2013;2314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1569597</ArticleId><ArticleId IdType="pubmed">16321801</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramov AY, Canevari L, Duchen MR. Changes in intracellular calcium and glutathione in astrocytes as the primary mechanism of amyloid neurotoxicity. J Neurosci. 2003;23:5088&#x2013;5095.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741151</ArticleId><ArticleId IdType="pubmed">12832532</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramov AY, Jacobson J, Wientjes F, Hothersall J, Canevari L, Duchen MR. Expression and modulation of an NADPH oxidase in mammalian astrocytes. J Neurosci. 2005;25:9176&#x2013;9184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725750</ArticleId><ArticleId IdType="pubmed">16207877</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahluwalia J, Tinker A, Clapp LH, Duchen MR, Abramov AY, Pope S, Nobles M, Segal AW. The large-conductance Ca2+-activated K+ channel is essential for innate immunity. Nature. 2004;427:853&#x2013;858.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2099462</ArticleId><ArticleId IdType="pubmed">14985765</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambroggio EE, Kim DH, Separovic F, Barrow CJ, Barnham KJ, Bagatolli LA, Fidelio GD. Surface behavior and lipid interaction of Alzheimer beta-amyloid peptide 1&#x2013;42: a membrane-disrupting peptide. Biophys J. 2005;88:2706&#x2013;2713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1305366</ArticleId><ArticleId IdType="pubmed">15681641</ArticleId></ArticleIdList></Reference><Reference><Citation>Attwell D, Laughlin SB. An energy budget for signaling in the grey matter of the brain. J Cereb Blood Flow Metab. 2001;21:1133&#x2013;1145.</Citation><ArticleIdList><ArticleId IdType="pubmed">11598490</ArticleId></ArticleIdList></Reference><Reference><Citation>Auricchio A, Hildinger M, O'Connor E, Gao GP, Wilson JM. Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. Hum Gene Ther. 2001;12:71&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">11177544</ArticleId></ArticleIdList></Reference><Reference><Citation>Bankers-Fulbright JL, Gleich GJ, Kephart GM, Kita H, O'Grady SM. Regulation of eosinophil membrane depolarization during NADPH oxidase activation. J Cell Sci. 2003;116:3221&#x2013;3226.</Citation><ArticleIdList><ArticleId IdType="pubmed">12829741</ArticleId></ArticleIdList></Reference><Reference><Citation>Berryman M, Bruno J, Price J, Edwards JC. CLIC-5A functions as a chloride channel in vitro and associates with the cortical actin cytoskeleton in vitro and in vivo. J Biol Chem. 2004;279:34794&#x2013;34801.</Citation><ArticleIdList><ArticleId IdType="pubmed">15184393</ArticleId></ArticleIdList></Reference><Reference><Citation>Bianca VD, Dusi S, Bianchini E, Dal Pr&#xe0; I, Rossi F. beta-amyloid activates the O-2 forming NADPH oxidase in microglia, monocytes, and neutrophils. A possible inflammatory mechanism of neuronal damage in Alzheimer's disease. J Biol Chem. 1999;274:15493&#x2013;15499.</Citation><ArticleIdList><ArticleId IdType="pubmed">10336441</ArticleId></ArticleIdList></Reference><Reference><Citation>Bindokas VP, Jord&#xe1;n J, Lee CC, Miller RJ. Superoxide production in rat hippocampal neurons: selective imaging with hydroethidine. J Neurosci. 1996;16:1324&#x2013;1336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578569</ArticleId><ArticleId IdType="pubmed">8778284</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasi E, Barluzzi R, Bocchini V, Mazzolla R, Bistoni F. Immortalization of murine microglial cells by a v-raf/v-myc carrying retrovirus. J Neuroimmunol. 1990;27:229&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">2110186</ArticleId></ArticleIdList></Reference><Reference><Citation>Block ML, Li G, Qin L, Wu X, Pei Z, Wang T, Wilson B, Yang J, Hong JS. Potent regulation of microglia-derived oxidative stress and dopaminergic neuron survival: substance P vs. dynorphin. FASEB J. 2006;20:251&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pubmed">16449797</ArticleId></ArticleIdList></Reference><Reference><Citation>Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci. 2007;8:57&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">17180163</ArticleId></ArticleIdList></Reference><Reference><Citation>Bocchini V, Mazzolla R, Barluzzi R, Blasi E, Sick P, Kettenmann H. An immortalized cell line expresses properties of activated microglial cells. J Neurosci Res. 1992;31:616&#x2013;621.</Citation><ArticleIdList><ArticleId IdType="pubmed">1578513</ArticleId></ArticleIdList></Reference><Reference><Citation>Butterfield DA, Boyd-Kimball D. Amyloid beta-peptide(1&#x2013;42) contributes to the oxidative stress and neurodegeneration found in Alzheimer disease brain. Brain Pathol. 2004;14:426&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8096022</ArticleId><ArticleId IdType="pubmed">15605990</ArticleId></ArticleIdList></Reference><Reference><Citation>Butterfield DA, Gnjec A, Poon HF, Castegna A, Pierce WM, Klein JB, Martins RN. Redox proteomics identification of oxidatively modified brain proteins in inherited Alzheimer's disease: an initial assessment. J Alzheimers Dis. 2006;10:391&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">17183150</ArticleId></ArticleIdList></Reference><Reference><Citation>DeCoursey TE. Interactions between NADPH oxidase and voltage-gated proton channels: why electron transport depends on proton transport. FEBS Lett. 2003;555:57&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">14630319</ArticleId></ArticleIdList></Reference><Reference><Citation>DeCoursey TE, Morgan D, Cherny VV. The voltage dependence of NADPH oxidase reveals why phagocytes need proton channels. Nature. 2003;422:531&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pubmed">12673252</ArticleId></ArticleIdList></Reference><Reference><Citation>Denti MA, Rosa A, Sthandier O, De Angelis FG, Bozzoni I. A new vector, based on the PolII promoter of the U1 snRNA gene, for the expression of siRNAs in mammalian cells. Mol Ther. 2004;10:191&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">15272480</ArticleId></ArticleIdList></Reference><Reference><Citation>Dringen R, Gutterer JM, Hirrlinger J. Glutathione metabolism in brain metabolic interaction between astrocytes and neurons in the defense against reactive oxygen species. Eur J Biochem. 2000;267:4912&#x2013;4916.</Citation><ArticleIdList><ArticleId IdType="pubmed">10931173</ArticleId></ArticleIdList></Reference><Reference><Citation>Ducharme G, Newell EW, Pinto C, Schlichter LC. Small-conductance Cl- channels contribute to volume regulation and phagocytosis in microglia. Eur J Neurosci. 2007;26:2119&#x2013;2130.</Citation><ArticleIdList><ArticleId IdType="pubmed">17927776</ArticleId></ArticleIdList></Reference><Reference><Citation>Eder C, Klee R, Heinemann U. Involvement of stretch-activated Cl- channels in ramification of murine microglia. J Neurosci. 1998;18:7127&#x2013;7137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793253</ArticleId><ArticleId IdType="pubmed">9736636</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci. 2007;10:1387&#x2013;1394.</Citation><ArticleIdList><ArticleId IdType="pubmed">17965659</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrop SJ, DeMaere MZ, Fairlie WD, Reztsova T, Valenzuela SM, Mazzanti M, Tonini R, Qiu MR, Jankova L, Warton K, Bauskin AR, Wu WM, Pankhurst S, Campbell TJ, Breit SN, Curmi PM. Crystal structure of a soluble form of the intracellular chloride ion channel CLIC1 (NCC27) at 1.4-A resolution. J Biol Chem. 2001;276:44993&#x2013;45000.</Citation><ArticleIdList><ArticleId IdType="pubmed">11551966</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson LM, Chappell JB, Jones OT. The superoxide-generating NADPH oxidase of human neutrophils is electrogenic and associated with an H+ channel. Biochem J. 1987;246:325&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1148280</ArticleId><ArticleId IdType="pubmed">2825632</ArticleId></ArticleIdList></Reference><Reference><Citation>Jekabsone A, Mander PK, Tickler A, Sharpe M, Brown GC. Fibrillar beta-amyloid peptide Abeta1&#x2013;40 activates microglial proliferation via stimulating TNF-alpha release and H2O2 derived from NADPH oxidase: a cell culture study. J Neuroinflammation. 2006;3:24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1574293</ArticleId><ArticleId IdType="pubmed">16959029</ArticleId></ArticleIdList></Reference><Reference><Citation>Littler DR, Harrop SJ, Fairlie WD, Brown LJ, Pankhurst GJ, Pankhurst S, DeMaere MZ, Campbell TJ, Bauskin AR, Tonini R, Mazzanti M, Breit SN, Curmi PM. The intracellular chloride ion channel protein CLIC1 undergoes a redox-controlled structural transition. J Biol Chem. 2004;279:9298&#x2013;9305.</Citation><ArticleIdList><ArticleId IdType="pubmed">14613939</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovell MA, Markesbery WR. Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's disease. Nucleic Acids Res. 2007;35:7497&#x2013;7504.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2190704</ArticleId><ArticleId IdType="pubmed">17947327</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue LF, Walker DG, Brachova L, Beach TG, Rogers J, Schmidt AM, Stern DM, Yan SD. Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp Neurol. 2001;171:29&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520119</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyras L, Cairns NJ, Jenner A, Jenner P, Halliwell B. An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer's disease. J Neurochem. 1997;68:2061&#x2013;2069.</Citation><ArticleIdList><ArticleId IdType="pubmed">9109533</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald DR, Brunden KR, Landreth GE. Amyloid fibrils activate tyrosine kinase-dependent signaling and superoxide production in microglia. J Neurosci. 1997;17:2284&#x2013;2294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573513</ArticleId><ArticleId IdType="pubmed">9065490</ArticleId></ArticleIdList></Reference><Reference><Citation>Meda L, Baron P, Prat E, Scarpini E, Scarlato G, Cassatella MA, Rossi F. Proinflammatory profile of cytokine production by human monocytes and murine microglia stimulated with beta-amyloid[25&#x2013;35] J Neuroimmunol. 1999;93:45&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">10378868</ArticleId></ArticleIdList></Reference><Reference><Citation>Novarino G, Fabrizi C, Tonini R, Denti MA, Malchiodi-Albedi F, Lauro GM, Sacchetti B, Paradisi S, Ferroni A, Curmi PM, Breit SN, Mazzanti M. Involvement of the intracellular ion channel CLIC1 in microglia-mediated beta-amyloid-induced neurotoxicity. J Neurosci. 2004;24:5322&#x2013;5330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729296</ArticleId><ArticleId IdType="pubmed">15190104</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Parachikova A, Agadjanyan MG, Cribbs DH, Blurton-Jones M, Perreau V, Rogers J, Beach TG, Cotman CW. Inflammatory changes parallel the early stages of Alzheimer disease. Neurobiol Aging. 2007;28:1821&#x2013;1833.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2198930</ArticleId><ArticleId IdType="pubmed">17052803</ArticleId></ArticleIdList></Reference><Reference><Citation>Park L, Anrather J, Zhou P, Frys K, Pitstick R, Younkin S, Carlson GA, Iadecola C. NADPH-oxidase-derived reactive oxygen species mediate the cerebrovascular dysfunction induced by the amyloid beta peptide. J Neurosci. 2005;25:1769&#x2013;1777.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725936</ArticleId><ArticleId IdType="pubmed">15716413</ArticleId></ArticleIdList></Reference><Reference><Citation>Park L, Zhou P, Pitstick R, Capone C, Anrather J, Norris EH, Younkin L, Younkin S, Carlson G, McEwen BS, Iadecola C. Nox2-derived radicals contribute to neurovascular and behavioral dysfunction in mice overexpressing the amyloid precursor protein. Proc Natl Acad Sci U S A. 2008;105:1347&#x2013;1352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2234141</ArticleId><ArticleId IdType="pubmed">18202172</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin B, Cartier L, Dubois-Dauphin M, Li B, Serrander L, Krause KH. A key role for the microglial NADPH oxidase in APP-dependent killing of neurons. Neurobiol Aging. 2006;27:1577&#x2013;1587.</Citation><ArticleIdList><ArticleId IdType="pubmed">16260066</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin L, Liu Y, Cooper C, Liu B, Wilson B, Hong JS. Microglia enhance beta-amyloid peptide-induced toxicity in cortical and mesencephalic neurons by producing reactive oxygen species. J Neurochem. 2002;83:973&#x2013;983.</Citation><ArticleIdList><ArticleId IdType="pubmed">12421370</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin L, Liu Y, Wang T, Wei SJ, Block ML, Wilson B, Liu B, Hong JS. NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. J Biol Chem. 2004;279:1415&#x2013;1421.</Citation><ArticleIdList><ArticleId IdType="pubmed">14578353</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin L, Block ML, Liu Y, Bienstock RJ, Pei Z, Zhang W, Wu X, Wilson B, Burka T, Hong JS. Microglial NADPH oxidase is a novel target for femtomolar neuroprotection against oxidative stress. FASEB J. 2005;19:550&#x2013;557.</Citation><ArticleIdList><ArticleId IdType="pubmed">15791005</ArticleId></ArticleIdList></Reference><Reference><Citation>Rada BK, Geiszt M, Hably C, Ligeti E. Consequences of the electrogenic function of the phagocytic NADPH oxidase. Philos Trans R Soc Lond B Biol Sci. 2005;360:2293&#x2013;2300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1569590</ArticleId><ArticleId IdType="pubmed">16321799</ArticleId></ArticleIdList></Reference><Reference><Citation>Sankarapandi S, Zweier JL, Mukherjee G, Quinn MT, Huso DL. Measurement and characterization of superoxide generation in microglial cells: evidence for an NADPH oxidase-dependent pathway. Arch Biochem Biophys. 1998;353:312&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pubmed">9606965</ArticleId></ArticleIdList></Reference><Reference><Citation>Shanks RA, Larocca MC, Berryman M, Edwards JC, Urushidani T, Navarre J, Goldenring JR. AKAP350 at the Golgi apparatus. II. Association of AKAP350 with a novel chloride intracellular channel (CLIC) family member. J Biol Chem. 2002;277:40973&#x2013;40980.</Citation><ArticleIdList><ArticleId IdType="pubmed">12163479</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimohama S, Tanino H, Kawakami N, Okamura N, Kodama H, Yamaguchi T, Hayakawa T, Nunomura A, Chiba S, Perry G, Smith MA, Fujimoto S. Activation of NADPH oxidase in Alzheimer's disease brains. Biochem Biophys Res Commun. 2000;273:5&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10873554</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh H, Ashley RH. Redox regulation of CLIC1 by cysteine residues associated with the putative channel pore. Biophys J. 2006;90:1628&#x2013;1638.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1367314</ArticleId><ArticleId IdType="pubmed">16339885</ArticleId></ArticleIdList></Reference><Reference><Citation>Streit WJ. Microglial cells. In: Kettenmann H, Ransom BR, editors. Neuroglia. Ed 2. New York: Oxford UP; 2005. pp. 60&#x2013;71.</Citation></Reference><Reference><Citation>Thomas MP, Chartrand K, Reynolds A, Vitvitsky V, Banerjee R, Gendelman HE. Ion channel blockade attenuates aggregated alpha synuclein induction of microglial reactive oxygen species: relevance for the pathogenesis of Parkinson's disease. J Neurochem. 2007;100:503&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">17241161</ArticleId></ArticleIdList></Reference><Reference><Citation>Tonini R, Ferroni A, Valenzuela SM, Warton K, Campbell TJ, Breit SN, Mazzanti M. Functional characterization of the NCC27 nuclear protein in stable transfected cho-k1 cells. FASEB J. 2000;14:1171&#x2013;1178.</Citation><ArticleIdList><ArticleId IdType="pubmed">10834939</ArticleId></ArticleIdList></Reference><Reference><Citation>Tulk BM, Kapadia S, Edwards JC. CLIC1 inserts from the aqueous phase into phospholipid membranes, where it functions as an anion channel. Am J Physiol Cell Physiol. 2002;282:C1103&#x2013;C1112.</Citation><ArticleIdList><ArticleId IdType="pubmed">11940526</ArticleId></ArticleIdList></Reference><Reference><Citation>Valenzuela SM, Martin DK, Por SB, Robbins JM, Warton K, Bootcov MR, Schofield PR, Campbell TJ, Breit SN. Molecular cloning and expression of a chloride ion channel of cell nuclei. J Biol Chem. 1997;272:12575&#x2013;12582.</Citation><ArticleIdList><ArticleId IdType="pubmed">9139710</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Walsh DM, Rowan MJ, Selkoe DJ, Anwyl R. Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci. 2004;24:3370&#x2013;3378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730034</ArticleId><ArticleId IdType="pubmed">15056716</ArticleId></ArticleIdList></Reference><Reference><Citation>Warton K, Tonini R, Fairlie WD, Matthews JM, Valenzuela SM, Qiu MR, Wu WM, Pankhurst S, Bauskin AR, Harrop SJ, Campbell TJ, Curmi PM, Breit SN, Mazzanti M. Recombinant CLIC1 (NCC27) assembles in lipid bilayers via a pH-dependent two-state process to form chloride ion channels with identical characteristics to those observed in Chinese hamster ovary cells expressing CLIC1. J Biol Chem. 2002;277:26003&#x2013;26011.</Citation><ArticleIdList><ArticleId IdType="pubmed">11978800</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson BL, Landreth GE. The microglial NADPH oxidase complex as a source of oxidative stress in Alzheimer's disease. J Neuroinflammation. 2006;3:30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1637099</ArticleId><ArticleId IdType="pubmed">17094809</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18987184</PMID><DateCompleted><Year>2008</Year><Month>12</Month><Day>31</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>45</Issue><PubDate><Year>2008</Year><Month>Nov</Month><Day>05</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Folate deficiency induces in vitro and mouse brain region-specific downregulation of leucine carboxyl methyltransferase-1 and protein phosphatase 2A B(alpha) subunit expression that correlate with enhanced tau phosphorylation.</ArticleTitle><Pagination><StartPage>11477</StartPage><EndPage>11487</EndPage><MedlinePgn>11477-87</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.2816-08.2008</ELocationID><Abstract><AbstractText>Altered folate homeostasis is associated with many clinical and pathological manifestations in the CNS. Notably, folate-mediated one-carbon metabolism is essential for methyltransferase-dependent cellular methylation reactions. Biogenesis of protein phosphatase 2A (PP2A) holoenzyme containing the regulatory B(alpha) subunit, a major brain tau phosphatase, is controlled by methylation. Here, we show that folate deprivation in neuroblastoma cells induces downregulation of PP2A leucine carboxyl methyltransferase-1 (LCMT-1) expression, resulting in progressive accumulation of newly synthesized demethylated PP2A pools, concomitant loss of B(alpha), and ultimately cell death. These effects are further accentuated by overexpression of PP2A methylesterase (PME-1) but cannot be rescued by PME-1 knockdown. Overexpression of either LCMT-1 or B(alpha) is sufficient to protect cells against the accumulation of demethylated PP2A, increased tau phosphorylation, and cell death induced by folate starvation. Conversely, knockdown of either protein accelerates folate deficiency-evoked cell toxicity. Significantly, mice maintained for 2 months on low-folate or folate-deficient diets have brain-region-specific alterations in metabolites of the methylation pathway. Those are associated with downregulation of LCMT-1, methylated PP2A, and B(alpha) expression and enhanced tau phosphorylation in susceptible brain regions. Our studies provide novel mechanistic insights into the regulation of PP2A methylation and tau. They establish LCMT-1- and B(alpha)-containing PP2A holoenzymes as key mediators of the role of folate in the brain. Our results suggest that counteracting the neuronal loss of LCMT-1 and B(alpha) could be beneficial for all tauopathies and folate-dependent disorders of the CNS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sontag</LastName><ForeName>Jean-Marie</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9073, USA. estelle.sontag@utsouthwestern.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nunbhakdi-Craig</LastName><ForeName>Viyada</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Montgomery</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Arning</LastName><ForeName>Erland</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Bottiglieri</LastName><ForeName>Teodoro</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Sontag</LastName><ForeName>Estelle</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R56 AG018883</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG18883</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG018883</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AT002311</GrantID><Acronym>AT</Acronym><Agency>NCCIH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AT002311</GrantID><Acronym>AT</Acronym><Agency>NCCIH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>452VLY9402</RegistryNumber><NameOfSubstance UI="D012694">Serine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.1.1.-</RegistryNumber><NameOfSubstance UI="D011497">Protein O-Methyltransferase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.1.-</RegistryNumber><NameOfSubstance UI="D002265">Carboxylic Ester Hydrolases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.1.-</RegistryNumber><NameOfSubstance UI="C119357">protein phosphatase methylesterase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.16</RegistryNumber><NameOfSubstance UI="C117094">Ppp2r3a protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.16</RegistryNumber><NameOfSubstance UI="D054648">Protein Phosphatase 2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002265" MajorTopicYN="N">Carboxylic Ester Hydrolases</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002461" MajorTopicYN="N">Cell Line, Transformed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005494" MajorTopicYN="N">Folic Acid Deficiency</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011497" MajorTopicYN="N">Protein O-Methyltransferase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054648" MajorTopicYN="N">Protein Phosphatase 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012694" MajorTopicYN="N">Serine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>11</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>1</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>11</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>5</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18987184</ArticleId><ArticleId IdType="mid">NIHMS77717</ArticleId><ArticleId IdType="pmc">PMC2688404</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2816-08.2008</ArticleId><ArticleId IdType="pii">28/45/11477</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Boldyrev AA, Johnson P. Homocysteine and its derivatives as possible modulators of neuronal and non-neuronal cell glutamate receptors in Alzheimer's disease. J Alzheimers Dis. 2007;11:219&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pubmed">17522446</ArticleId></ArticleIdList></Reference><Reference><Citation>Bryant JC, Westphal RS, Wadzinski BE. Methylated C-terminal leucine residue of PP2A catalytic subunit is important for binding of regulatory Balpha subunit. Biochem J. 1999;339:241&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1220151</ArticleId><ArticleId IdType="pubmed">10191253</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan A, Shea TB. Dietary and genetically-induced oxidative stress alter tau phosphorylation: influence of folate and apolipoprotein E deficiency. J Alzheimers Dis. 2006;9:399&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">16917148</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan AY, Alsaraby A, Shea TB. Folate deprivation increases tau phosphorylation by homocysteine-induced calcium influx and by inhibition of phosphatase activity: alleviation by S-adenosyl methionine. Brain Res. 2008;1199:133&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">18279842</ArticleId></ArticleIdList></Reference><Reference><Citation>De Baere I, Derua R, Janssens V, Van Hoof C, Waelkens E, Merlevede W, Goris J. Purification of porcine brain protein phosphatase 2A leucine carboxyl methyltransferase and cloning of the human homologue. Biochemistry. 1999;38:16539&#x2013;16547.</Citation><ArticleIdList><ArticleId IdType="pubmed">10600115</ArticleId></ArticleIdList></Reference><Reference><Citation>Djukic A. Folate-responsive neurologic diseases. Pediatr Neurol. 2007;37:387&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">18021918</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan W, Ladenheim B, Cutler RG, Kruman II, Cadet JL, Mattson MP. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem. 2002;80:101&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">11796748</ArticleId></ArticleIdList></Reference><Reference><Citation>Fellner T, Lackner DH, Hombauer H, Piribauer P, Mudrak I, Zaragoza K, Juno C, Ogris E. A novel and essential mechanism determining specificity and activity of protein phosphatase 2A (PP2A) in vivo. Genes Dev. 2003;17:2138&#x2013;2150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC196455</ArticleId><ArticleId IdType="pubmed">12952889</ArticleId></ArticleIdList></Reference><Reference><Citation>Friso S, Choi SW. Gene-nutrient interactions in one-carbon metabolism. Curr Drug Metab. 2005;6:37&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">15720206</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini MG. A century of Alzheimer's disease. Science. 2006;314:777&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pubmed">17082447</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg SG, Davies P, Schein JD, Binder LI. Hydrofluoric acid-treated tau PHF proteins display the same biochemical properties as normal tau. J Biol Chem. 1992;267:564&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pubmed">1370450</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillozet-Bongaarts AL, Glajch KE, Libson EG, Cahill ME, Bigio E, Berry RW, Binder LI. Phosphorylation and cleavage of tau in non-AD tauopathies. Acta Neuropathol. 2007;113:513&#x2013;520.</Citation><ArticleIdList><ArticleId IdType="pubmed">17357802</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho PI, Ashline D, Dhitavat S, Ortiz D, Collins SC, Shea TB, Rogers E. Folate deprivation induces neurodegeneration: roles of oxidative stress and increased homocysteine. Neurobiol Dis. 2003;14:32&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">13678664</ArticleId></ArticleIdList></Reference><Reference><Citation>Hombauer H, Weismann D, Mudrak I, Stanzel C, Fellner T, Lackner DH, Ogris E. Generation of active protein phosphatase 2A is coupled to holoenzyme assembly. PLoS Biol. 2007;5:e155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1885835</ArticleId><ArticleId IdType="pubmed">17550305</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssens V, Longin S, Goris J. PP2A holoenzyme assembly: in cauda venenum (the sting is in the tail) Trends Biochem Sci. 2008;33:113&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pubmed">18291659</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruman II, Kumaravel TS, Lohani A, Pedersen WA, Cutler RG, Kruman Y, Haughey N, Lee J, Evans M, Mattson MP. Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease. J Neurosci. 2002;22:1752&#x2013;1762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758871</ArticleId><ArticleId IdType="pubmed">11880504</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, Chen Y, Tolstykh T, Stock J. A specific protein carboxyl methylesterase that demethylates phosphoprotein phosphatase 2A in bovine brain. Proc Natl Acad Sci U S A. 1996;93:6043&#x2013;6047.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC39185</ArticleId><ArticleId IdType="pubmed">8650216</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JA, Pallas DC. Leucine carboxyl methyltransferase-1 is necessary for normal progression through mitosis in mammalian cells. J Biol Chem. 2007;282:30974&#x2013;30984.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3516869</ArticleId><ArticleId IdType="pubmed">17724024</ArticleId></ArticleIdList></Reference><Reference><Citation>Leulliot N, Quevillon-Cheruel S, Sorel I, de La Sierra-Gallay IL, Collinet B, Graille M, Blondeau K, Bettache N, Poupon A, Janin J, van Tilbeurgh H. Structure of protein phosphatase methyltransferase 1 (PPM1), a leucine carboxyl methyltransferase involved in the regulation of protein phosphatase 2A activity. J Biol Chem. 2004;279:8351&#x2013;8358.</Citation><ArticleIdList><ArticleId IdType="pubmed">14660564</ArticleId></ArticleIdList></Reference><Reference><Citation>Longin S, Jordens J, Martens E, Stevens I, Janssens V, Rondelez E, De Baere I, Derua R, Waelkens E, Goris J, Van Hoof C. An inactive protein phosphatase 2A population is associated with methylesterase and can be re-activated by the phosphotyrosyl phosphatase activator. Biochem J. 2004;380:111&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1224137</ArticleId><ArticleId IdType="pubmed">14748741</ArticleId></ArticleIdList></Reference><Reference><Citation>Longin S, Zwaenepoel K, Louis JV, Dilworth S, Goris J, Janssens V. Selection of protein phosphatase 2A regulatory subunits is mediated by the C terminus of the catalytic subunit. J Biol Chem. 2007;282:26971&#x2013;26980.</Citation><ArticleIdList><ArticleId IdType="pubmed">17635907</ArticleId></ArticleIdList></Reference><Reference><Citation>Longin S, Zwaenepoel K, Martens E, Louis JV, Rondelez E, Goris J, Janssens V. Spatial control of protein phosphatase 2A (de)methylation. Exp Cell Res. 2008;314:68&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">17803990</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y, Zhou X, Yang X, Wang J. Homocysteine induces tau hyperphosphorylation in rats. Neuroreport. 2007;18:2005&#x2013;2008.</Citation><ArticleIdList><ArticleId IdType="pubmed">18007203</ArticleId></ArticleIdList></Reference><Reference><Citation>Meske V, Albert F, Ohm TG. Coupling of mammalian target of rapamycin with phosphoinositide 3-kinase signaling pathway regulates protein phosphatase 2A- and glycogen synthase kinase-3-dependent phosphorylation of Tau. J Biol Chem. 2008;283:100&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pubmed">17971449</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunbhakdi-Craig V, Machleidt T, Ogris E, Bellotto D, White CL, 3rd, Sontag E. Protein phosphatase 2A associates with and regulates atypical PKC and the epithelial tight junction complex. J Cell Biol. 2002;158:967&#x2013;978.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2173154</ArticleId><ArticleId IdType="pubmed">12196510</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunbhakdi-Craig V, Schuechner S, Sontag JM, Montgomery L, Pallas DC, Juno C, Mudrak I, Ogris E, Sontag E. Expression of protein phosphatase 2A mutants and silencing of the regulatory Balpha subunit induce a selective loss of acetylated and detyrosinated microtubules. J Neurochem. 2007;101:959&#x2013;971.</Citation><ArticleIdList><ArticleId IdType="pubmed">17394530</ArticleId></ArticleIdList></Reference><Reference><Citation>Obeid R, Herrmann W. Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia. FEBS Lett. 2006;580:2994&#x2013;3005.</Citation><ArticleIdList><ArticleId IdType="pubmed">16697371</ArticleId></ArticleIdList></Reference><Reference><Citation>Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, Herrmann W. Folate and methylation status in relation to phosphorylated tau protein(181P) and &#x3b2;-amyloid(1&#x2013;42) in cerebrospinal fluid. Clin Chem. 2007a;53:1129&#x2013;1136.</Citation><ArticleIdList><ArticleId IdType="pubmed">17384003</ArticleId></ArticleIdList></Reference><Reference><Citation>Obeid R, McCaddon A, Herrmann W. The role of hyperhomocysteinemia and B-vitamin deficiency in neurological and psychiatric diseases. Clin Chem Lab Med. 2007b;45:1590&#x2013;1606.</Citation><ArticleIdList><ArticleId IdType="pubmed">18067446</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogris E, Gibson DM, Pallas DC. Protein phosphatase 2A subunit assembly: the catalytic subunit carboxy terminus is important for binding cellular B subunit but not polyomavirus middle tumor antigen. Oncogene. 1997;15:911&#x2013;917.</Citation><ArticleIdList><ArticleId IdType="pubmed">9285686</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogris E, Du X, Nelson KC, Mak EK, Yu XX, Lane WS, Pallas DC. A protein phosphatase methylesterase (PME-1) is one of several novel proteins stably associating with two inactive mutants of protein phosphatase 2A. J Biol Chem. 1999;274:14382&#x2013;14391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3503312</ArticleId><ArticleId IdType="pubmed">10318862</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds E. Vitamin B12, folic acid, and the nervous system. Lancet Neurol. 2006;5:949&#x2013;960.</Citation><ArticleIdList><ArticleId IdType="pubmed">17052662</ArticleId></ArticleIdList></Reference><Reference><Citation>Sontag E, Nunbhakdi-Craig V, Lee G, Bloom GS, Mumby MC. Regulation of the phosphorylation state and microtubule-binding activity of Tau by protein phosphatase 2A. Neuron. 1996;17:1201&#x2013;1207.</Citation><ArticleIdList><ArticleId IdType="pubmed">8982166</ArticleId></ArticleIdList></Reference><Reference><Citation>Sontag E, Luangpirom A, Hladik C, Mudrak I, Ogris E, Speciale S, White CL., 3rd Altered expression levels of the protein phosphatase 2A ABalphaC enzyme are associated with Alzheimer disease pathology. J Neuropathol Exp Neurol. 2004a;63:287&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">15099019</ArticleId></ArticleIdList></Reference><Reference><Citation>Sontag E, Hladik C, Montgomery L, Luangpirom A, Mudrak I, Ogris E, White CL., 3rd Downregulation of protein phosphatase 2A carboxyl methylation and methyltransferase may contribute to Alzheimer disease pathogenesis. J Neuropathol Exp Neurol. 2004b;63:1080&#x2013;1091.</Citation><ArticleIdList><ArticleId IdType="pubmed">15535135</ArticleId></ArticleIdList></Reference><Reference><Citation>Sontag E, Nunbhakdi-Craig V, Sontag JM, Diaz-Arrastia R, Ogris E, Dayal S, Lentz SR, Arning E, Bottiglieri T. Protein phosphatase 2A methyltransferase links homocysteine metabolism with tau and amyloid precursor protein regulation. J Neurosci. 2007;27:2751&#x2013;2759.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672573</ArticleId><ArticleId IdType="pubmed">17360897</ArticleId></ArticleIdList></Reference><Reference><Citation>Strack S, Zaucha JA, Ebner FF, Colbran RJ, Wadzinski BE. Brain protein phosphatase 2A: developmental regulation and distinct cellular and subcellular localization by B subunits. J Comp Neurol. 1998;392:515&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">9514514</ArticleId></ArticleIdList></Reference><Reference><Citation>Tjiattas L, Ortiz DO, Dhivant S, Mitton K, Rogers E, Shea TB. Folate deficiency and homocysteine induce toxicity in cultured dorsal root ganglion neurons via cytosolic calcium accumulation. Aging Cell. 2004;3:71&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">15038821</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolstykh T, Lee J, Vafai S, Stock JB. Carboxyl methylation regulates phosphoprotein phosphatase 2A by controlling the association of regulatory B subunits. EMBO J. 2000;19:5682&#x2013;5691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC305779</ArticleId><ArticleId IdType="pubmed">11060019</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Tolstykh T, Lee J, Boyd K, Stock JB, Broach JR. Carboxyl methylation of the phosphoprotein phosphatase 2A catalytic subunit promotes its functional association with regulatory subunits in vivo. EMBO J. 2000;19:5672&#x2013;5681.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC305778</ArticleId><ArticleId IdType="pubmed">11060018</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing Y, Li Z, Chen Y, Stock JB, Jeffrey PD, Shi Y. Structural mechanism of demethylation and inactivation of protein phosphatase 2A. Cell. 2008;133:154&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">18394995</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon SY, Choi HI, Choi JE, Sul CA, Choi JM, Kim DH. Methotrexate decreases PP2A methylation and increases tau phosphorylation in neuron. Biochem Biophys Res Commun. 2007;363:811&#x2013;816.</Citation><ArticleIdList><ArticleId IdType="pubmed">17904102</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu XX, Du X, Moreno CS, Green RE, Ogris E, Feng Q, Chou L, McQuoid MJ, Pallas DC. Methylation of the protein phosphatase 2A catalytic subunit is essential for association of Balpha regulatory subunit but not SG2NA, striatin, or polyomavirus middle tumor antigen. Mol Biol Cell. 2001;12:185&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC30577</ArticleId><ArticleId IdType="pubmed">11160832</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang CE, Tian Q, Wei W, Peng JH, Liu GP, Zhou XW, Wang Q, Wang DW, Wang JZ. Homocysteine induces tau phosphorylation by inactivating protein phosphatase 2A in rat hippocampus. Neurobiol Aging. 2008;29:1654&#x2013;1665.</Citation><ArticleIdList><ArticleId IdType="pubmed">17537547</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu BT. Catechol-O-methyltransferase (COMT)-mediated methylation metabolism of endogenous bioactive catechols and modulation by endobiotics and xenobiotics: importance in pathophysiology and pathogenesis. Curr Drug Metab. 2002;3:321&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">12083324</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18987198</PMID><DateCompleted><Year>2008</Year><Month>12</Month><Day>31</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>45</Issue><PubDate><Year>2008</Year><Month>Nov</Month><Day>05</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Retinoic acid attenuates beta-amyloid deposition and rescues memory deficits in an Alzheimer's disease transgenic mouse model.</ArticleTitle><Pagination><StartPage>11622</StartPage><EndPage>11634</EndPage><MedlinePgn>11622-34</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.3153-08.2008</ELocationID><Abstract><AbstractText>Recent studies have revealed that disruption of vitamin A signaling observed in Alzheimer's disease (AD) leads to beta-amyloid (Abeta) accumulation and memory deficits in rodents. The aim of the present study was to evaluate the therapeutic effect of all-trans retinoic acid (ATRA), an active metabolite of vitamin A, on the neuropathology and deficits of spatial learning and memory in amyloid precursor protein (APP) and presenilin 1 (PS1) double-transgenic mice, a well established AD mouse model. Here we report a robust decrease in brain Abeta deposition and tau phosphorylation in the blinded study of APP/PS1 transgenic mice treated intraperitoneally for 8 weeks with ATRA (20 mg/kg, three times weekly, initiated when the mice were 5 months old). This was accompanied by a significant decrease in the APP phosphorylation and processing. The activity of cyclin-dependent kinase 5, a major kinase involved in both APP and tau phosphorylation, was markedly downregulated by ATRA treatment. The ATRA-treated APP/PS1 mice showed decreased activation of microglia and astrocytes, attenuated neuronal degeneration, and improved spatial learning and memory compared with the vehicle-treated APP/PS1 mice. These results support ATRA as an effective therapeutic agent for the prevention and treatment of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Yun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Veterans Affairs Medical Center, Richmond, Virginia 23249, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiao</LastName><ForeName>Aimin</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ziqing</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Goodwin</LastName><ForeName>J Shawn</ForeName><Initials>JS</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Eun-Sook</ForeName><Initials>ES</Initials></Author><Author ValidYN="Y"><LastName>Block</LastName><ForeName>Michelle L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Allsbrook</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>McDonald</LastName><ForeName>Michael P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Guo-Huang</ForeName><Initials>GH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U54 NS041071</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54NS041071-06</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005904">Glial Fibrillary Acidic Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034722">Heterogeneous-Nuclear Ribonucleoprotein U</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>5688UTC01R</RegistryNumber><NameOfSubstance UI="D014212">Tretinoin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051360">Cyclin-Dependent Kinase 5</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051360" MajorTopicYN="N">Cyclin-Dependent Kinase 5</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005904" MajorTopicYN="N">Glial Fibrillary Acidic Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034722" MajorTopicYN="N">Heterogeneous-Nuclear Ribonucleoprotein U</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011930" MajorTopicYN="N">Reaction Time</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014212" MajorTopicYN="N">Tretinoin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>11</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>1</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>11</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>5</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18987198</ArticleId><ArticleId IdType="pmc">PMC3844785</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.3153-08.2008</ArticleId><ArticleId IdType="pii">28/45/11622</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Anderton BH, Betts J, Blackstock WP, Brion JP, Chapman S, Connell J, Dayanandan R, Gallo JM, Gibb G, Hanger DP, Hutton M, Kardalinou E, Leroy K, Lovestone S, Mack T, Reynolds CH, Van Slegtenhorst M. Sites of phosphorylation in tau and factors affecting their regulation. Biochem Soc Symp. 2001;73</Citation><ArticleIdList><ArticleId IdType="pubmed">11447841</ArticleId></ArticleIdList></Reference><Reference><Citation>Apelt J, Schliebs R. Beta-amyloid-induced glial expression of both pro- and anti-inflammatory cytokines in cerebral cortex of aged transgenic Tg2576 mice with Alzheimer plaque pathology. Brain Res. 2001;894:21&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">11245811</ArticleId></ArticleIdList></Reference><Reference><Citation>Aplin AE, Gibb GM, Jacobsen JS, Gallo JM, Anderton BH. In vitro phosphorylation of the cytoplasmic domain of the amyloid precursor protein by glycogen synthase kinase-3beta. J Neurochem. 1996;67:699&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pubmed">8764598</ArticleId></ArticleIdList></Reference><Reference><Citation>Berse B, Blusztajn JK. Coordinated up-regulation of choline acetyltransferase and vesicular acetylcholine transporter gene expression by the retinoic acid receptor alpha, cAMP, and leukemia inhibitory factor/ciliary neurotrophic factor signaling pathways in a murine septal cell line. J Biol Chem. 1995;270:22101&#x2013;22104.</Citation><ArticleIdList><ArticleId IdType="pubmed">7673184</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanchard V, Moussaoui S, Czech C, Touchet N, Bonici B, Planche M, Canton T, Jedidi I, Gohin M, Wirths O, Bayer TA, Langui D, Duyckaerts C, Tremp G, Pradier L. Time sequence of maturation of dystrophic neurites associated with Abeta deposits in APP/PS1 transgenic mice. Exp Neurol. 2003;184:247&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">14637096</ArticleId></ArticleIdList></Reference><Reference><Citation>Bornemann KD, Wiederhold KH, Pauli C, Ermini F, Stalder M, Schnell L, Sommer B, Jucker M, Staufenbiel M. Abeta-induced inflammatory processes in microglia cells of APP23 transgenic mice. Am J Pathol. 2001;158:63&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850262</ArticleId><ArticleId IdType="pubmed">11141480</ArticleId></ArticleIdList></Reference><Reference><Citation>Calhoun ME, Wiederhold KH, Abramowski D, Phinney AL, Probst A, Sturchler-Pierrat C, Staufenbiel M, Sommer B, Jucker M. Neuron loss in APP transgenic mice. Nature. 1998;395:755&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pubmed">9796810</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang KA, Kim HS, Ha TY, Ha JW, Shin KY, Jeong YH, Lee JP, Park CH, Kim S, Baik TK, Suh YH. Phosphorylation of amyloid precursor protein (APP) at Thr668 regulates the nuclear translocation of the APP intracellular domain and induces neurodegeneration. Mol Cell Biol. 2006;26:4327&#x2013;4338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1489099</ArticleId><ArticleId IdType="pubmed">16705182</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G, Chen KS, Knox J, Inglis J, Bernard A, Martin SJ, Justice A, McConlogue L, Games D, Freedman SB, Morris RG. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature. 2000;408:975&#x2013;979.</Citation><ArticleIdList><ArticleId IdType="pubmed">11140684</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang MY, Misner D, Kempermann G, Schikorski T, Gigu&#xe8;re V, Sucov HM, Gage FH, Stevens CF, Evans RM. An essential role for retinoid receptors RARbeta and RXRgamma in long-term potentiation and depression. Neuron. 1998;21:1353&#x2013;1361.</Citation><ArticleIdList><ArticleId IdType="pubmed">9883728</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi WH, Ji KA, Jeon SB, Yang MS, Kim H, Min KJ, Shong M, Jou I, Joe EH. Anti-inflammatory roles of retinoic acid in rat brain astrocytes: Suppression of interferon-gamma-induced JAK/STAT phosphorylation. Biochem Biophys Res Commun. 2005;329:125&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">15721283</ArticleId></ArticleIdList></Reference><Reference><Citation>Cocco S, Diaz G, Stancampiano R, Diana A, Carta M, Curreli R, Sarais L, Fadda F. Vitamin A deficiency produces spatial learning and memory impairment in rats. Neuroscience. 2002;115:475&#x2013;482.</Citation><ArticleIdList><ArticleId IdType="pubmed">12421614</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen P, Frame S. The renaissance of GSK3. Nat Rev Mol Cell Biol. 2001;2:769&#x2013;776.</Citation><ArticleIdList><ArticleId IdType="pubmed">11584304</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcoran JP, So PL, Maden M. Disruption of the retinoid signalling pathway causes a deposition of amyloid beta in the adult rat brain. Eur J Neurosci. 2004;20:896&#x2013;902.</Citation><ArticleIdList><ArticleId IdType="pubmed">15305858</ArticleId></ArticleIdList></Reference><Reference><Citation>Cremer H, Chazal G, Carleton A, Goridis C, Vincent JD, Lledo PM. Long-term but not short-term plasticity at mossy fiber synapses is impaired in neural cell adhesion molecule-deficient mice. Proc Natl Acad Sci U S A. 1998;95:13242&#x2013;13247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC23769</ArticleId><ArticleId IdType="pubmed">9789073</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz JC, Kim D, Moy LY, Dobbin MM, Sun X, Bronson RT, Tsai LH. p25/cyclin-dependent kinase 5 induces production and intraneuronal accumulation of amyloid &#x3b2; in vivo. J Neurosci. 2006;26:10536&#x2013;10541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674706</ArticleId><ArticleId IdType="pubmed">17035538</ArticleId></ArticleIdList></Reference><Reference><Citation>Culvenor JG, Evin G, Cooney MA, Wardan H, Sharples RA, Maher F, Reed G, Diehlmann A, Weidemann A, Beyreuther K, Masters CL. Presenilin 2 expression in neuronal cells: induction during differentiation of embryonic carcinoma cells. Exp Cell Res. 2000;255:192&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">10694435</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta PK, Reddy RS, Lianos EA. Effects of all-trans-retinoic acid (atRA) on inducible nitric oxide synthase (iNOS) activity and transforming growth factor beta-1 production in experimental anti-GBM antibody-mediated glomerulonephritis. Inflammation. 2001;25:351&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pubmed">11831438</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, Von Figura K, Van Leuven F. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature. 1998;391:387&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pubmed">9450754</ArticleId></ArticleIdList></Reference><Reference><Citation>Dheen ST, Jun Y, Yan Z, Tay SS, Ling EA. Retinoic acid inhibits expression of TNF-alpha and iNOS in activated rat microglia. Glia. 2005;50:21&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">15602748</ArticleId></ArticleIdList></Reference><Reference><Citation>Edbauer D, Winkler E, Regula JT, Pesold B, Steiner H, Haass C. Reconstitution of gamma-secretase activity. Nat Cell Biol. 2003;5:486&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">12679784</ArticleId></ArticleIdList></Reference><Reference><Citation>Etchamendy N, Enderlin V, Marighetto A, Vouimba RM, Pallet V, Jaffard R, Higueret P. Alleviation of a selective age-related relational memory deficit in mice by pharmacologically induced normalization of brain retinoid signaling. J Neurosci. 2001;21:6423&#x2013;6429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763177</ArticleId><ArticleId IdType="pubmed">11487666</ArticleId></ArticleIdList></Reference><Reference><Citation>Etchamendy N, Enderlin V, Marighetto A, Pallet V, Higueret P, Jaffard R. Vitamin A deficiency and relational memory deficit in adult mice: relationships with changes in brain retinoid signalling. Behav Brain Res. 2003;145:37&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">14529804</ArticleId></ArticleIdList></Reference><Reference><Citation>Evin G, Zhu A, Holsinger RM, Masters CL, Li QX. Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets. J Neurosci Res. 2003;74:386&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pubmed">14598315</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca MI, Zhou J, Botto M, Tenner AJ. Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease. J Neurosci. 2004;24:6457&#x2013;6465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729885</ArticleId><ArticleId IdType="pubmed">15269255</ArticleId></ArticleIdList></Reference><Reference><Citation>Frautschy SA, Horn DL, Sigel JJ, Harris-White ME, Mendoza JJ, Yang F, Saido TC, Cole GM. Protease inhibitor coinfusion with amyloid &#x3b2;-protein results in enhanced deposition and toxicity in rat brain. J Neurosci. 1998;18:8311&#x2013;8321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792856</ArticleId><ArticleId IdType="pubmed">9763475</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodman AB. Retinoid receptors, transporters, and metabolizers as therapeutic targets in late onset Alzheimer disease. J Cell Physiol. 2006;209:598&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pubmed">17001693</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodman AB, Pardee AB. Evidence for defective retinoid transport and function in late onset Alzheimer's disease. Proc Natl Acad Sci U S A. 2003;100:2901&#x2013;2905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC151438</ArticleId><ArticleId IdType="pubmed">12604774</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science. 2001;293:1491&#x2013;1495.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520988</ArticleId></ArticleIdList></Reference><Reference><Citation>Gundersen HJ, Jensen EB. The efficiency of systematic sampling in stereology and its prediction. J Microsc. 1987;147:229&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">3430576</ArticleId></ArticleIdList></Reference><Reference><Citation>Han P, Dou F, Li F, Zhang X, Zhang YW, Zheng H, Lipton SA, Xu H, Liao FF. Suppression of cyclin-dependent kinase 5 activation by amyloid precursor protein: a novel excitoprotective mechanism involving modulation of tau phosphorylation. J Neurosci. 2005;25:11542&#x2013;11552.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6726015</ArticleId><ArticleId IdType="pubmed">16354912</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanger DP, Betts JC, Loviny TL, Blackstock WP, Anderton BH. New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J Neurochem. 1998;71:2465&#x2013;2476.</Citation><ArticleIdList><ArticleId IdType="pubmed">9832145</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong CS, Caromile L, Nomata Y, Mori H, Bredesen DE, Koo EH. Contrasting role of presenilin-1 and presenilin-2 in neuronal differentiation in vitro. J Neurosci. 1999;19:637&#x2013;643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782201</ArticleId><ArticleId IdType="pubmed">9880584</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, Kholodenko D, Malenka RC, Nicoll RA, Mucke L. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci U S A. 1999;96:3228&#x2013;3233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15924</ArticleId><ArticleId IdType="pubmed">10077666</ArticleId></ArticleIdList></Reference><Reference><Citation>Husson M, Enderlin V, Delacourte A, Ghenimi N, Alfos S, Pallet V, Higueret P. Retinoic acid normalizes nuclear receptor mediated hypo-expression of proteins involved in beta-amyloid deposits in the cerebral cortex of vitamin A deprived rats. Neurobiol Dis. 2006;23:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">16531051</ArticleId></ArticleIdList></Reference><Reference><Citation>Iijima K, Ando K, Takeda S, Satoh Y, Seki T, Itohara S, Greengard P, Kirino Y, Nairn AC, Suzuki T. Neuron-specific phosphorylation of Alzheimer's beta-amyloid precursor protein by cyclin-dependent kinase 5. J Neurochem. 2000;75:1085&#x2013;1091.</Citation><ArticleIdList><ArticleId IdType="pubmed">10936190</ArticleId></ArticleIdList></Reference><Reference><Citation>Imahori K, Uchida T. Physiology and pathology of tau protein kinases in relation to Alzheimer's disease. J Biochem. 1997;121:179&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">9089387</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal K, Alonso Adel C, Chen S, Chohan MO, El-Akkad E, Gong CX, Khatoon S, Li B, Liu F, Rahman A, Tanimukai H, Grundke-Iqbal I. Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta. 2005;1739:198&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615638</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry MC, McNamara M, Fedorchak K, Hsiao K, Hyman BT. APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol. 1997;56:965&#x2013;973.</Citation><ArticleIdList><ArticleId IdType="pubmed">9291938</ArticleId></ArticleIdList></Reference><Reference><Citation>Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol. 1989;24:173&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">2808689</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyoda M, Hudkins KL, Wietecha TA, Banas MC, Guo S, Liu G, Wang L, Kowalewska J, Alpers CE. All-trans-retinoic acid aggravates cryoglobulin-associated membranoproliferative glomerulonephritis in mice. Nephrol Dial Transplant. 2007;22:3451&#x2013;3461.</Citation><ArticleIdList><ArticleId IdType="pubmed">17686814</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng. 2001;17:157&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">11337275</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, Younkin SG, Borchelt DR. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet. 2004;13:159&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">14645205</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson GV, Hartigan JA. Tau protein in normal and Alzheimer's disease brain: an update. J Alzheimers Dis. 1999;1:329&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">12214129</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalin JR, Starling ME, Hill DL. Disposition of all-trans-retinoic acid in mice following oral doses. Drug Metab Dispos. 1981;9:196&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">6113925</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurlandsky SB, Gamble MV, Ramakrishnan R, Blaner WS. Plasma delivery of retinoic acid to tissues in the rat. J Biol Chem. 1995;270:17850&#x2013;17857.</Citation><ArticleIdList><ArticleId IdType="pubmed">7629087</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurt MA, Davies DC, Kidd M, Duff K, Howlett DR. Hyperphosphorylated tau and paired helical filament-like structures in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes. Neurobiol Dis. 2003;14:89&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">13678670</ArticleId></ArticleIdList></Reference><Reference><Citation>Lahiri S, Buerk DG, Chugh D, Osanai S, Mokashi A. Reciprocal photolabile O2 consumption and chemoreceptor excitation by carbon monoxide in the cat carotid body: evidence for cytochrome a3 as the primary O2 sensor. Brain Res. 1995;684:194&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">7583222</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Doze F, Debruyne D, Albessard F, Barre L, Defer GL. Pharmacokinetics of all-trans retinoic acid, 13-cis retinoic acid, and fenretinide in plasma and brain of rat. Drug Metab Dispos. 2000;28:205&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">10640519</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MS, Kao SC, Lemere CA, Xia W, Tseng HC, Zhou Y, Neve R, Ahlijanian MK, Tsai LH. APP processing is regulated by cytoplasmic phosphorylation. J Cell Biol. 2003;163:83&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2173445</ArticleId><ArticleId IdType="pubmed">14557249</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T, Paudel HK. Glycogen synthase kinase 3beta phosphorylates Alzheimer's disease-specific Ser396 of microtubule-associated protein tau by a sequential mechanism. Biochemistry. 2006;45:3125&#x2013;3133.</Citation><ArticleIdList><ArticleId IdType="pubmed">16519507</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F, Su Y, Li B, Zhou Y, Ryder J, Gonzalez-DeWhitt P, May PC, Ni B. Regulation of amyloid precursor protein (APP) phosphorylation and processing by p35/Cdk5 and p25/Cdk5. FEBS Lett. 2003;547:193&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">12860412</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovestone S, Reynolds CH. The phosphorylation of tau: a critical stage in neurodevelopment and neurodegenerative processes. Neuroscience. 1997;78:309&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">9145789</ArticleId></ArticleIdList></Reference><Reference><Citation>Maden M. Retinoic acid in the development, regeneration and maintenance of the nervous system. Nat Rev Neurosci. 2007;8:755&#x2013;765.</Citation><ArticleIdList><ArticleId IdType="pubmed">17882253</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell. 1995;83:841&#x2013;850.</Citation><ArticleIdList><ArticleId IdType="pubmed">8521508</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Miller A, Terry RD. The synaptic organization of the neocortex in Alzheimer's disease. Med Hypotheses. 1993;41:334&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">8289698</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuoka Y, Picciano M, Malester B, LaFrancois J, Zehr C, Daeschner JM, Olschowka JA, Fonseca MI, O'Banion MK, Tenner AJ, Lemere CA, Duff K. Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. Am J Pathol. 2001;158:1345&#x2013;1354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1891893</ArticleId><ArticleId IdType="pubmed">11290552</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer EG, McGeer PL. Brain inflammation in Alzheimer disease and the therapeutic implications. Curr Pharm Des. 1999;5:821&#x2013;836.</Citation><ArticleIdList><ArticleId IdType="pubmed">10526088</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta K, McQueen T, Tucker S, Pandita R, Aggarwal BB. Inhibition by all-trans-retinoic acid of tumor necrosis factor and nitric oxide production by peritoneal macrophages. J Leukoc Biol. 1994;55:336&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pubmed">8120450</ArticleId></ArticleIdList></Reference><Reference><Citation>Misner DL, Jacobs S, Shimizu Y, de Urquiza AM, Solomin L, Perlmann T, De Luca LM, Stevens CF, Evans RM. Vitamin A deprivation results in reversible loss of hippocampal long-term synaptic plasticity. Proc Natl Acad Sci U S A. 2001;98:11714&#x2013;11719.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC58795</ArticleId><ArticleId IdType="pubmed">11553775</ArticleId></ArticleIdList></Reference><Reference><Citation>Moolman DL, Vitolo OV, Vonsattel JP, Shelanski ML. Dendrite and dendritic spine alterations in Alzheimer models. J Neurocytol. 2004;33:377&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pubmed">15475691</ArticleId></ArticleIdList></Reference><Reference><Citation>Morishima-Kawashima M, Hasegawa M, Takio K, Suzuki M, Yoshida H, Titani K, Ihara Y. Proline-directed and non-proline-directed phosphorylation of PHF-tau. J Biol Chem. 1995;270:823&#x2013;829.</Citation><ArticleIdList><ArticleId IdType="pubmed">7822317</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods. 1984;11:47&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">6471907</ArticleId></ArticleIdList></Reference><Reference><Citation>Neve RL, Rogers J, Higgins GA. The Alzheimer amyloid precursor-related transcript lacking the beta/A4 sequence is specifically increased in Alzheimer's disease brain. Neuron. 1990;5:329&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">2400606</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno M, Chang L, Tseng W, Oakley H, Citron M, Klein WL, Vassar R, Disterhoft JF. Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1. Eur J Neurosci. 2006;23:251&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">16420434</ArticleId></ArticleIdList></Reference><Reference><Citation>Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, Yamada M. Vitamin A exhibits potent antiamyloidogenic and fibril-destabilizing effects in vitro. Exp Neurol. 2004;189:380&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pubmed">15380488</ArticleId></ArticleIdList></Reference><Reference><Citation>Ram&#xed;rez-Amaya V, Balderas I, Sandoval J, Escobar ML, Berm&#xfa;dez-Rattoni F. Spatial long-term memory is related to mossy fiber synaptogenesis. J Neurosci. 2001;21:7340&#x2013;7348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763009</ArticleId><ArticleId IdType="pubmed">11549744</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozemuller AJ, van Gool WA, Eikelenboom P. The neuroinflammatory response in plaques and amyloid angiopathy in Alzheimer's disease: therapeutic implications. Curr Drug Targets CNS Neurol Disord. 2005;4:223&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">15975026</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutten BP, Van der Kolk NM, Schafer S, van Zandvoort MA, Bayer TA, Steinbusch HW, Schmitz C. Age-related loss of synaptophysin immunoreactive presynaptic boutons within the hippocampus of APP751SL, PS1M146L, and APP751SL/PS1M146L transgenic mice. Am J Pathol. 2005;167:161&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1603440</ArticleId><ArticleId IdType="pubmed">15972962</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahin M, Karauzum SB, Perry G, Smith MA, Aliciguzel Y. Retinoic acid isomers protect hippocampal neurons from amyloid-beta induced neurodegeneration. Neurotox Res. 2005;7:243&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">15897158</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh J, Kuroda Y. Amyloid precursor protein beta-secretase (BACE) mRNA expression in human neural cell lines following induction of neuronal differentiation and exposure to cytokines and growth factors. Neuropathology. 2000;20:289&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pubmed">11211053</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindowski K, Bretteville A, Leroy K, B&#xe9;gard S, Brion JP, Hamdane M, Bu&#xe9;e L. Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol. 2006;169:599&#x2013;616.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1698785</ArticleId><ArticleId IdType="pubmed">16877359</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimers Dis. 2001;3:75&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">12214075</ArticleId></ArticleIdList></Reference><Reference><Citation>Sergeant N, David JP, Champain D, Ghestem A, Wattez A, Delacourte A. Progressive decrease of amyloid precursor protein carboxy terminal fragments (APP-CTFs), associated with tau pathology stages, in Alzheimer's disease. J Neurochem. 2002;81:663&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pubmed">12065626</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma P, Sharma M, Amin ND, Albers RW, Pant HC. Regulation of cyclin-dependent kinase 5 catalytic activity by phosphorylation. Proc Natl Acad Sci U S A. 1999;96:11156&#x2013;11160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18003</ArticleId><ArticleId IdType="pubmed">10500146</ArticleId></ArticleIdList></Reference><Reference><Citation>Shelton SB, Johnson GV. Cyclin-dependent kinase-5 in neurodegeneration. J Neurochem. 2004;88:1313&#x2013;1326.</Citation><ArticleIdList><ArticleId IdType="pubmed">15009631</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh TJ, Grundke-Iqbal I, McDonald B, Iqbal K. Comparison of the phosphorylation of microtubule-associated protein tau by non-proline dependent protein kinases. Mol Cell Biochem. 1994;131:181&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">8035784</ArticleId></ArticleIdList></Reference><Reference><Citation>Stalder M, Phinney A, Probst A, Sommer B, Staufenbiel M, Jucker M. Association of microglia with amyloid plaques in brains of APP23 transgenic mice. Am J Pathol. 1999;154:1673&#x2013;1684.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866618</ArticleId><ArticleId IdType="pubmed">10362792</ArticleId></ArticleIdList></Reference><Reference><Citation>Standen CL, Brownlees J, Grierson AJ, Kesavapany S, Lau KF, McLoughlin DM, Miller CC. Phosphorylation of thr(668) in the cytoplasmic domain of the Alzheimer's disease amyloid precursor protein by stress-activated protein kinase 1b (Jun N-terminal kinase-3) J Neurochem. 2001;76:316&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pubmed">11146006</ArticleId></ArticleIdList></Reference><Reference><Citation>Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, Mount SL, Raman R, Davies P, Masliah E, Williams DS, Goldstein LS. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science. 2005;307:1282&#x2013;1288.</Citation><ArticleIdList><ArticleId IdType="pubmed">15731448</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos L, Jr, Eckman C, Golde TE, Younkin SG. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science. 1994;264:1336&#x2013;1340.</Citation><ArticleIdList><ArticleId IdType="pubmed">8191290</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinchese F, Liu S, Battaglia F, Walter S, Mathews PM, Arancio O. Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice. Ann Neurol. 2004;55:801&#x2013;814.</Citation><ArticleIdList><ArticleId IdType="pubmed">15174014</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G, Citron M. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang CC, Campbell S, Furner RL, Hill DL. Disposition of all-trans- and 13-cis-retinoic acids and n-hydroxyethylretinamide in mice after intravenous administration. Drug Metab Dispos. 1980;8:8&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">6102031</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JZ, Wu Q, Smith A, Grundke-Iqbal I, Iqbal K. Tau is phosphorylated by GSK-3 at several sites found in Alzheimer disease and its biological activity markedly inhibited only after it is prephosphorylated by A-kinase. FEBS Lett. 1998;436:28&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">9771888</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JZ, Grundke-Iqbal I, Iqbal K. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci. 2007;25:59&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3191918</ArticleId><ArticleId IdType="pubmed">17241267</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen Y, Planel E, Herman M, Figueroa HY, Wang L, Liu L, Lau LF, Yu WH, Duff KE. Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3 beta mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing. J Neurosci. 2008a;28:2624&#x2013;2632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671193</ArticleId><ArticleId IdType="pubmed">18322105</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen Y, Yu WH, Maloney B, Bailey J, Ma J, Mari&#xe9; I, Maurin T, Wang L, Figueroa H, Herman M, Krishnamurthy P, Liu L, Planel E, Lau LF, Lahiri DK, Duff K. Transcriptional regulation of beta-secretase by p25/cdk5 leads to enhanced amyloidogenic processing. Neuron. 2008b;57:680&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2329816</ArticleId><ArticleId IdType="pubmed">18341989</ArticleId></ArticleIdList></Reference><Reference><Citation>West MJ, Coleman PD, Flood DG, Troncoso JC. Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease. Lancet. 1994;344:769&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pubmed">7916070</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science. 1982;215:1237&#x2013;1239.</Citation><ArticleIdList><ArticleId IdType="pubmed">7058341</ArticleId></ArticleIdList></Reference><Reference><Citation>Wietrzych M, Meziane H, Sutter A, Ghyselinck N, Chapman PF, Chambon P, Krezel W. Working memory deficits in retinoid X receptor gamma-deficient mice. Learn Mem. 2005;12:318&#x2013;326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1142461</ArticleId><ArticleId IdType="pubmed">15897255</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirenfeldt M, Dalmau I, Finsen B. Estimation of absolute microglial cell numbers in mouse fascia dentata using unbiased and efficient stereological cell counting principles. Glia. 2003;44:129&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">14515329</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Quitschke WW, Brewer GJ. Upregulation of amyloid precursor protein gene promoter in rat primary hippocampal neurons by phorbol ester, IL-1 and retinoic acid, but not by reactive oxygen species. Brain Res Mol Brain Res. 1998;60:40&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">9748493</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Gong B, Liu S, Fa' M, Ninan I, Staniszewski A, Arancio O. Synaptic fatigue is more pronounced in the APP/PS1 transgenic mouse model of Alzheimer's disease. Curr Alzheimer Res. 2005;2:137&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">15974910</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou XW, Gustafsson JA, Tanila H, Bjorkdahl C, Liu R, Winblad B, Pei JJ. Tau hyperphosphorylation correlates with reduced methylation of protein phosphatase 2A. Neurobiol Dis. 2008;31:386&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pubmed">18586097</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19001171</PMID><DateCompleted><Year>2008</Year><Month>12</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3687</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>11</Issue><PubDate><Year>2008</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Frequent amyloid deposition without significant cognitive impairment among the elderly.</ArticleTitle><Pagination><StartPage>1509</StartPage><EndPage>1517</EndPage><MedlinePgn>1509-17</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archneur.65.11.1509</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To characterize the prevalence of amyloid deposition in a clinically unimpaired elderly population, as assessed by Pittsburgh Compound B (PiB) positron emission tomography (PET) imaging, and its relationship to cognitive function, measured with a battery of neuropsychological tests.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Subjects underwent cognitive testing and PiB PET imaging (15 mCi for 90 minutes with an ECAT HR+ scanner). Logan graphical analysis was applied to estimate regional PiB retention distribution volume, normalized to a cerebellar reference region volume, to yield distribution volume ratios (DVRs).</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">University medical center.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">From a community-based sample of volunteers, 43 participants aged 65 to 88 years who did not meet diagnostic criteria for Alzheimer disease or mild cognitive impairment were included.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Regional PiB retention and cognitive test performance.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 43 clinically unimpaired elderly persons imaged, 9 (21%) showed evidence of early amyloid deposition in at least 1 brain area using an objectively determined DVR cutoff. Demographic characteristics did not differ significantly between amyloid-positive and amyloid-negative participants, and neurocognitive performance was not significantly worse among amyloid-positive compared with amyloid-negative participants.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Amyloid deposition can be identified among cognitively normal elderly persons during life, and the prevalence of asymptomatic amyloid deposition may be similar to that of symptomatic amyloid deposition. In this group of participants without clinically significant impairment, amyloid deposition was not associated with worse cognitive function, suggesting that an elderly person with a significant amyloid burden can remain cognitively normal. However, this finding is based on relatively small numbers and needs to be replicated in larger cohorts. Longitudinal follow-up of these subjects will be required to support the potential of PiB imaging to identify preclinical Alzheimer disease, or, alternatively, to show that amyloid deposition is not sufficient to cause Alzheimer disease within some specified period.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aizenstein</LastName><ForeName>Howard Jay</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nebes</LastName><ForeName>Robert D</ForeName><Initials>RD</Initials></Author><Author ValidYN="Y"><LastName>Saxton</LastName><ForeName>Judith A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Julie C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Mathis</LastName><ForeName>Chester A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Tsopelas</LastName><ForeName>Nicholas D</ForeName><Initials>ND</Initials></Author><Author ValidYN="Y"><LastName>Ziolko</LastName><ForeName>Scott K</ForeName><Initials>SK</Initials></Author><Author ValidYN="Y"><LastName>James</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Snitz</LastName><ForeName>Beth E</ForeName><Initials>BE</Initials></Author><Author ValidYN="Y"><LastName>Houck</LastName><ForeName>Patricia R</ForeName><Initials>PR</Initials></Author><Author ValidYN="Y"><LastName>Bi</LastName><ForeName>Wenzhu</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Ann D</ForeName><Initials>AD</Initials></Author><Author ValidYN="Y"><LastName>Lopresti</LastName><ForeName>Brian J</ForeName><Initials>BJ</Initials></Author><Author ValidYN="Y"><LastName>DeKosky</LastName><ForeName>Steven T</ForeName><Initials>ST</Initials></Author><Author ValidYN="Y"><LastName>Halligan</LastName><ForeName>Edythe M</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><LastName>Klunk</LastName><ForeName>William E</ForeName><Initials>WE</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 MH001976</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01MH001976</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG018402</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH070729</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG025516</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG025516</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG020226</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K02 AG001039</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG025204</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Clin Pract Neurol. 2009 Mar;5(3):123.</RefSource><PMID Version="1">20408269</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>11</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>12</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>11</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>2</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19001171</ArticleId><ArticleId IdType="mid">NIHMS90168</ArticleId><ArticleId IdType="pmc">PMC2636844</ArticleId><ArticleId IdType="doi">10.1001/archneur.65.11.1509</ArticleId><ArticleId IdType="pii">65/11/1509</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dickson DW, Crystal HA, Mattiace LA, et al. Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol Aging. 1992;13(1):179&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">1311804</ArticleId></ArticleIdList></Reference><Reference><Citation>Haroutunian V, Perl D, Purohit D, et al. Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer&#x2019;s disease. Arch Neurol. 1998;55(9):1185&#x2013;1191.</Citation><ArticleIdList><ArticleId IdType="pubmed">9740112</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Morris JC. Tangles and plaques in nondemented aging and &#x201c;preclinical&#x201d; Alzheimer&#x2019;s disease. Ann Neurol. 1999;45(3):358&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf DS, Gearing M, Snowdon DA, Mori H, Markesbery WR, Mirra SS. Progression of regional neuropathology in Alzheimer disease and normal elderly: findings from the Nun Study. Alzheimer Dis Assoc Disord. 1999;13(4):226&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">10609672</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Jagust WJ, DeKosky ST, et al. Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1. Arch Neurol. 2003;60(10):1385&#x2013;1389.</Citation><ArticleIdList><ArticleId IdType="pubmed">14568808</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003;60(8):1119&#x2013;1122.</Citation><ArticleIdList><ArticleId IdType="pubmed">12925369</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer&#x2019;s disease. Brain. 2008;131(pt 6):1630&#x2013;1645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2408940</ArticleId><ArticleId IdType="pubmed">18339640</ArticleId></ArticleIdList></Reference><Reference><Citation>Lockhart A, Lamb JR, Osredkar T, et al. PIB is a non-specific imaging marker of amyloid-&#x3b2; (A&#x3b2;) peptide-related cerebral amyloidosis. Brain. 2007;130(pt 10):2607&#x2013;2615.</Citation><ArticleIdList><ArticleId IdType="pubmed">17698496</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabbitt P. Does it all go together when it goes? the 19th Bartlett Memorial Lecture. Q J Exp Psychol A. 1993;46(3):385&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">8378549</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy JA, Higgins GA. Alzheimer&#x2019;s disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings BJ, Cotman CW. Image analysis of &#x3b2;-amyloid load in Alzheimer&#x2019;s disease and relation to dementia severity. Lancet. 1995;346(8989):1524&#x2013;1528.</Citation><ArticleIdList><ArticleId IdType="pubmed">7491048</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielson KA, Cummings BJ, Cotman CW. Constructional apraxia in Alzheimer&#x2019;s disease correlates with neuritic neuropathology in occipital cortex. Brain Res. 1996;96(1&#x2013;2):284&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">9001734</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Evolution of neuronal changes in the course of Alzheimer&#x2019;s disease. J Neural Transm Suppl. 1998;53:127&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">9700651</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer&#x2019;s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30(4):572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopresti BJ, Klunk WE, Mathis CA, et al. Simplified quantification of Pittsburgh Compound-B amyloid imaging PET studies: a comparative analysis. J Nucl Med. 2005;46(12):1959&#x2013;1972.</Citation><ArticleIdList><ArticleId IdType="pubmed">16330558</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67(3):446&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Ng S, Ackermann U, et al. Imaging &#x3b2;-amyloid burden in aging and dementia. Neurology. 2007;68(20):1718&#x2013;1725.</Citation><ArticleIdList><ArticleId IdType="pubmed">17502554</ArticleId></ArticleIdList></Reference><Reference><Citation>Nebes RD, Meltzer CC, Whyte EM, et al. The relation of white matter hyperintensities to cognitive performance in the normal old: education matters. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2006;13(3&#x2013;4):326&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">16887777</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Becker JT, Klunk W, et al. Research evaluation and diagnosis of probable Alzheimer&#x2019;s disease over the last two decades: I. Neurology. 2000;55(12):1854&#x2013;1862.</Citation><ArticleIdList><ArticleId IdType="pubmed">11134385</ArticleId></ArticleIdList></Reference><Reference><Citation>The Diagnostic and Statistical Manual of Mental Disorders. 4. Arlington, VA: American Psychiatric Association; 1994.</Citation></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34(7):939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review); Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56(9):1133&#x2013;1142.</Citation><ArticleIdList><ArticleId IdType="pubmed">11342677</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. Mini-mental state&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD), part I: clinical and neuropsychological assessment of Alzheimer&#x2019;s disease. Neurology. 1989;39(9):1159&#x2013;1165.</Citation><ArticleIdList><ArticleId IdType="pubmed">2771064</ArticleId></ArticleIdList></Reference><Reference><Citation>Rey A. L&#x2019;examen psychologique dans les cas d&#x2019;encephalopathie traumatique. Arch Psychol. 1941;28:286&#x2013;340.</Citation></Reference><Reference><Citation>Reitan RM. Validity of the Trail-making Tests as an indication of organic brain damage. Percept Mot Skills. 1958;8:271&#x2013;276.</Citation></Reference><Reference><Citation>Lopez OL, Becker JT, Klunk W, et al. Research evaluation and diagnosis of possible Alzheimer&#x2019;s disease over the last two decades: II. Neurology. 2000;55(12):1863&#x2013;1869.</Citation><ArticleIdList><ArticleId IdType="pubmed">11134386</ArticleId></ArticleIdList></Reference><Reference><Citation>Freedman M. Clock Drawing: A Neuropsychological Analysis. Oxford, England: Oxford University Press; 1994.</Citation></Reference><Reference><Citation>Saxton J, Ratcliff G, Newman A, et al. Cognitive test performance and presence of subclinical cardiovascular disease in the Cardiovascular Health Study. Neuroepidemiology. 2000;19(6):312&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">11060505</ArticleId></ArticleIdList></Reference><Reference><Citation>Benton AL. Differential behavioral effects in frontal lobe disease. Neuropsychologia. 1968;6:53&#x2013;60.</Citation></Reference><Reference><Citation>Borkowski JG, Benton AL, Spreen O. Word fluency and brain damage. Neuropsychologia. 1967;5:135&#x2013;140.</Citation></Reference><Reference><Citation>Wechsler D. Wechsler Test of Adult Reading. New York, NY: Psychological Corporation; 2001.</Citation></Reference><Reference><Citation>Dobbs AR, Rule BG. Adult age differences in working memory. Psychol Aging. 1989;4(4):500&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">2619956</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. Wechsler Adult Intelligence Scale. 3. New York, NY: Psychological Corporation; 1997.</Citation></Reference><Reference><Citation>Spieler DH, Balota DA, Faust ME. Stroop performance in healthy younger and older adults and in individuals with dementia of the Alzheimer&#x2019;s type. J Exp Psychol Hum Percept Perform. 1996;22(2):461&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pubmed">8934854</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess PW, Shallice T. Response suppression, initiation, and strategy use following frontal lobe lesions. Neuropsychologia. 1996;34(4):263&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pubmed">8657357</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinhard K. Applications of 3D PET. In: Bendriem B, Townsend D, editors. The Theory and Practice of 3D PET. Boston, MA: Kluwer Academic Publishers; 1998. pp. 133&#x2013;167.</Citation></Reference><Reference><Citation>Watson CC. New, faster, image-based scatter correction for 3D PET. IEEE Trans Nucl Sci. 2000;47(4):1587&#x2013;1594.</Citation></Reference><Reference><Citation>Price JC, Klunk WE, Lopresti BJ, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005;25(11):1528&#x2013;1547.</Citation><ArticleIdList><ArticleId IdType="pubmed">15944649</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwertman NC, de Silva R. Identifying outliers with sequential fences. Comput Stat Data Anal. 2007;51(8):3800&#x2013;3810.</Citation></Reference><Reference><Citation>Ziolko SK, Weissfeld LA, Klunk WE, et al. Evaluation of voxel-based methods for the statistical analysis of PiB PET amyloid imaging studies in Alzheimer&#x2019;s disease. Neuroimage. 2006;33(1):94&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">16905334</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xe4;slund J, Haroutunian V, Mohs R, et al. Correlation between elevated levels of amyloid &#x3b2; peptide in the brain and cognitive decline. JAMA. 2000;283(12):1571&#x2013;1577.</Citation><ArticleIdList><ArticleId IdType="pubmed">10735393</ArticleId></ArticleIdList></Reference><Reference><Citation>Pike KE, Savage G, Villemagne VL, et al. &#x3b2;-Amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer&#x2019;s disease. Brain. 2007;130(pt 11):2837&#x2013;2844.</Citation><ArticleIdList><ArticleId IdType="pubmed">17928318</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18(4):351&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330961</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis DG, Schmitt FA, Wekstein DR, Markesbery WR. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol. 1999;58(4):376&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">10218633</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Parisi JE, Salviati A, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol. 2003;62(11):1087&#x2013;1095.</Citation><ArticleIdList><ArticleId IdType="pubmed">14656067</ArticleId></ArticleIdList></Reference><Reference><Citation>Driscoll I, Resnick SM, Troncoso JC, An Y, O&#x2019;Brien R, Zonderman AB. Impact of Alzheimer&#x2019;s pathology on cognitive trajectories in nondemented elderly. Ann Neurol. 2006;60(6):688&#x2013;695.</Citation><ArticleIdList><ArticleId IdType="pubmed">17192929</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman WP, Price JL, Storandt M, et al. Absence of cognitive impairment or decline in preclinical Alzheimer&#x2019;s disease. Neurology. 2001;56(3):361&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">11171902</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19013469</PMID><DateCompleted><Year>2009</Year><Month>02</Month><Day>03</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1089-8638</ISSN><JournalIssue CitedMedium="Internet"><Volume>385</Volume><Issue>2</Issue><PubDate><Year>2009</Year><Month>Jan</Month><Day>16</Day></PubDate></JournalIssue><Title>Journal of molecular biology</Title><ISOAbbreviation>J Mol Biol</ISOAbbreviation></Journal><ArticleTitle>Cryoelectron microscopy structure of purified gamma-secretase at 12 A resolution.</ArticleTitle><Pagination><StartPage>642</StartPage><EndPage>652</EndPage><MedlinePgn>642-52</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jmb.2008.10.078</ELocationID><Abstract><AbstractText>Gamma-secretase, an integral membrane protein complex, catalyzes the intramembrane cleavage of the beta-amyloid precursor protein (APP) during the neuronal production of the amyloid beta-peptide. As such, the protease has emerged as a key target for developing agents to treat and prevent Alzheimer's disease. Existing biochemical studies conflict on the oligomeric assembly state of the protease complex, and its detailed structure is not known. Here, we report that purified active human gamma-secretase in digitonin has a total molecular mass of approximately 230 kDa when measured by scanning transmission electron microscopy. This result supports a complex that is monomeric for each of the four component proteins. We further report the three-dimensional structure of the gamma-secretase complex at 12 A resolution as obtained by cryoelectron microscopy and single-particle image reconstruction. The structure reveals several domains on the extracellular side, three solvent-accessible low-density cavities, and a potential substrate-binding surface groove in the transmembrane region of the complex.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Osenkowski</LastName><ForeName>Pamela</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Hua</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Wenjuan</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Dongyang</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Aeschbach</LastName><ForeName>Lorene</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Fraering</LastName><ForeName>Patrick C</ForeName><Initials>PC</Initials></Author><Author ValidYN="Y"><LastName>Wolfe</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Huilin</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG015379</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG000222</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG15379</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>TE AG00222-15</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG029979</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM074985</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM74985</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>11</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Mol Biol</MedlineTA><NlmUniqueID>2985088R</NlmUniqueID><ISSNLinking>0022-2836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D021122">Protein Subunits</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020285" MajorTopicYN="Y">Cryoelectron Microscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008855" MajorTopicYN="N">Microscopy, Electron, Scanning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008970" MajorTopicYN="N">Molecular Weight</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020836" MajorTopicYN="N">Protein Structure, Quaternary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021122" MajorTopicYN="N">Protein Subunits</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2008</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>11</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>2</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>11</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19013469</ArticleId><ArticleId IdType="mid">NIHMS176894</ArticleId><ArticleId IdType="pmc">PMC2830092</ArticleId><ArticleId IdType="doi">10.1016/j.jmb.2008.10.078</ArticleId><ArticleId IdType="pii">S0022-2836(08)01389-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kimberly WT, LaVoie MJ, Ostaszewski BL, Ye W, Wolfe MS, Selkoe DJ. Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Proc Natl Acad Sci U S A. 2003;100:6382&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC164455</ArticleId><ArticleId IdType="pubmed">12740439</ArticleId></ArticleIdList></Reference><Reference><Citation>Takasugi N, Tomita T, Hayashi I, Tsuruoka M, Niimura M, Takahashi Y, Thinakaran G, Iwatsubo T. The role of presenilin cofactors in the gamma-secretase complex. Nature. 2003;422:438&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">12660785</ArticleId></ArticleIdList></Reference><Reference><Citation>Edbauer D, Winkler E, Regula JT, Pesold B, Steiner H, Haass C. Reconstitution of gamma-secretase activity. Nat Cell Biol. 2003;5:486&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12679784</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraering PC, Ye W, Strub JM, Dolios G, LaVoie MJ, Ostaszewski BL, van Dorsselaer A, Wang R, Selkoe DJ, Wolfe MS. Purification and characterization of the human gamma-secretase complex. Biochemistry. 2004;43:9774&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">15274632</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS, Kopan R. Intramembrane proteolysis: theme and variations. Science. 2004;305:1119&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">15326347</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature. 1999;398:513&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206644</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat Cell Biol. 2004;6:1054&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">15516999</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Wolfe MS. Presenilin: running with scissors in the membrane. Cell. 2007;131:215&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">17956719</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Zhang Y, Ha Y. Crystal structure of a rhomboid family intramembrane protease. Nature. 2006;444:179&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">17051161</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z, Yan N, Feng L, Oberstein A, Yan H, Baker RP, Gu L, Jeffrey PD, Urban S, Shi Y. Structural analysis of a rhomboid family intramembrane protease reveals a gating mechanism for substrate entry. Nat Struct Mol Biol. 2006;13:1084&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">17099694</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben-Shem A, Fass D, Bibi E. Structural basis for intramembrane proteolysis by rhomboid serine proteases. Proc Natl Acad Sci U S A. 2007;104:462&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1766407</ArticleId><ArticleId IdType="pubmed">17190827</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemieux MJ, Fischer SJ, Cherney MM, Bateman KS, James MN. The crystal structure of the rhomboid peptidase from Haemophilus influenzae provides insight into intramembrane proteolysis. Proc Natl Acad Sci U S A. 2007;104:750&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1783385</ArticleId><ArticleId IdType="pubmed">17210913</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng L, Yan H, Wu Z, Yan N, Wang Z, Jeffrey PD, Shi Y. Structure of a site-2 protease family intramembrane metalloprotease. Science. 2007;318:1608&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">18063795</ArticleId></ArticleIdList></Reference><Reference><Citation>Urban S, Shi Y. Core principles of intramembrane proteolysis: comparison of rhomboid and site-2 family proteases. Curr Opin Struct Biol. 2008</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2572676</ArticleId><ArticleId IdType="pubmed">18440799</ArticleId></ArticleIdList></Reference><Reference><Citation>Narayanan S, Sato T, Wolfe MS. A C-terminal region of signal peptide peptidase defines a functional domain for intramembrane aspartic protease catalysis. J Biol Chem. 2007;282:20172&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17517891</ArticleId></ArticleIdList></Reference><Reference><Citation>Martoglio B, Golde TE. Intramembrane-cleaving aspartic proteases and disease: presenilins, signal peptide peptidase and their homologs. Hum Mol Genet. 2003;12(Spec No 2):R201&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12966028</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS. The gamma-secretase complex: membrane-embedded proteolytic ensemble. Biochemistry. 2006;45:7931&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16800619</ArticleId></ArticleIdList></Reference><Reference><Citation>Osenkowski P, Ye W, Wang R, Wolfe MS, Selkoe DJ. Direct and potent regulation of gamma -secretase by its lipid microenvironment. J Biol Chem. 2008;283:22529&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2504869</ArticleId><ArticleId IdType="pubmed">18539594</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraering PC, LaVoie MJ, Ye W, Ostaszewski BL, Kimberly WT, Selkoe DJ, Wolfe MS. Detergent-dependent dissociation of active gamma-secretase reveals an interaction between Pen-2 and PS1-NTF and offers a model for subunit organization within the complex. Biochemistry. 2004;43:323&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">14717586</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarov VK, Fraering PC, Ye W, Wolfe MS, Selkoe DJ, Li H. Electron microscopic structure of purified, active {gamma}-secretase reveals an aqueous intramembrane chamber and two pores. Proc Natl Acad Sci U S A. 2006;103:6889&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1458989</ArticleId><ArticleId IdType="pubmed">16636269</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacquevel M, Aeschbach L, Osenkowski P, Li D, Ye W, Wolfe MS, Li H, Selkoe DJ, Fraering PC. Rapid purification of active gamma-secretase, an intramembrane protease implicated in Alzheimer's disease. J Neurochem. 2008;104:210&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">17986218</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeter EH, Ilagan MX, Brunkan AL, Hecimovic S, Li YM, Xu M, Lewis HD, Saxena MT, De Strooper B, Coonrod A, Tomita T, Iwatsubo T, Moore CL, Goate A, Wolfe MS, Shearman M, Kopan R. A presenilin dimer at the core of the gamma-secretase enzyme: insights from parallel analysis of Notch 1 and APP proteolysis. Proc Natl Acad Sci U S A. 2003;100:13075&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC240747</ArticleId><ArticleId IdType="pubmed">14566063</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervantes S, Saura CA, Pomares E, Gonzalez-Duarte R, Marfany G. Functional implications of the presenilin dimerization: reconstitution of gamma-secretase activity by assembly of a catalytic site at the dimer interface of two catalytically inactive presenilins. J Biol Chem. 2004;279:36519&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">15220354</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato T, Diehl TS, Narayanan S, Funamoto S, Ihara Y, De Strooper B, Steiner H, Haass C, Wolfe MS. Active gamma-secretase complexes contain only one of each component. J Biol Chem. 2007;282:33985&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">17911105</ArticleId></ArticleIdList></Reference><Reference><Citation>Edbauer D, Winkler E, Haass C, Steiner H. Presenilin and nicastrin regulate each other and determine amyloid beta-peptide production via complex formation. Proc Natl Acad Sci U S A. 2002;99:8666&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC124353</ArticleId><ArticleId IdType="pubmed">12048259</ArticleId></ArticleIdList></Reference><Reference><Citation>Evin G, Canterford LD, Hoke DE, Sharples RA, Culvenor JG, Masters CL. Transition-state analogue gamma-secretase inhibitors stabilize a 900 kDa presenilin/nicastrin complex. Biochemistry. 2005;44:4332&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">15766262</ArticleId></ArticleIdList></Reference><Reference><Citation>Wall JS, Simon MN, Lin BY, Vinogradov SN. Mass mapping of large globin complexes by scanning transmission electron microscopy. Methods Enzymol. 2008;436:487&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pubmed">18237650</ArticleId></ArticleIdList></Reference><Reference><Citation>Fotiadis D, Jeno P, Mini T, Wirtz S, Muller SA, Fraysse L, Kjellbom P, Engel A. Structural characterization of two aquaporins isolated from native spinach leaf plasma membranes. J Biol Chem. 2001;276:1707&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">11050104</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirotani K, Edbauer D, Kostka M, Steiner H, Haass C. Immature nicastrin stabilizes APH-1 independent of PEN-2 and presenilin: identification of nicastrin mutants that selectively interact with APH-1. J Neurochem. 2004;89:1520&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15189355</ArticleId></ArticleIdList></Reference><Reference><Citation>Capell A, Kaether C, Edbauer D, Shirotani K, Merkl S, Steiner H, Haass C. Nicastrin interacts with gamma-secretase complex components via the N-terminal part of its transmembrane domain. J Biol Chem. 2003;278:52519&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">14602727</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Chavan M, Schindelin H, Lennarz WJ, Li H. Structure of the oligosaccharyl transferase complex at 12 A resolution. Structure. 2008;16:432&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">18334218</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Lee S, Jap BK. Molecular design of aquaporin-1 water channel as revealed by electron crystallography. Nat Struct Biol. 1997;4:263&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">9095192</ArticleId></ArticleIdList></Reference><Reference><Citation>Sui H, Han BG, Lee JK, Walian P, Jap BK. Structural basis of water-specific transport through the AQP1 water channel. Nature. 2001;414:872&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11780053</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JY, Urbatsch IL, Senior AE, Wilkens S. Projection structure of Pglycoprotein by electron microscopy. Evidence for a closed conformation of the nucleotide binding domains. J Biol Chem. 2002;277:40125&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">12163504</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato C, Morohashi Y, Tomita T, Iwatsubo T. Structure of the catalytic pore of gamma-secretase probed by the accessibility of substituted cysteines. J Neurosci. 2006;26:12081&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674866</ArticleId><ArticleId IdType="pubmed">17108181</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolia A, Horre K, De Strooper B. Transmembrane domain 9 of presenilin determines the dynamic conformation of the catalytic site of gamma -secretase. J Biol Chem. 2008</Citation><ArticleIdList><ArticleId IdType="pubmed">18482978</ArticleId></ArticleIdList></Reference><Reference><Citation>Esler WP, Kimberly WT, Ostaszewski BL, Ye W, Diehl TS, Selkoe DJ, Wolfe MS. Activity-dependent isolation of the presenilin- gamma -secretase complex reveals nicastrin and a gamma substrate. Proc Natl Acad Sci U S A. 2002;99:2720&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122414</ArticleId><ArticleId IdType="pubmed">11867728</ArticleId></ArticleIdList></Reference><Reference><Citation>Schagger H, Cramer WA, von Jagow G. Analysis of molecular masses and oligomeric states of protein complexes by blue native electrophoresis and isolation of membrane protein complexes by two-dimensional native electrophoresis. Anal Biochem. 1994;217:220&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">8203750</ArticleId></ArticleIdList></Reference><Reference><Citation>Schagger H, von Jagow G. Blue native electrophoresis for isolation of membrane protein complexes in enzymatically active form. Anal Biochem. 1991;199:223&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">1812789</ArticleId></ArticleIdList></Reference><Reference><Citation>LaVoie MJ, Fraering PC, Ostaszewski BL, Ye W, Kimberly WT, Wolfe MS, Selkoe DJ. Assembly of the gamma-secretase complex involves early formation of an intermediate subcomplex of Aph-1 and nicastrin. J Biol Chem. 2003;278:37213&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">12857757</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludtke SJ, Baldwin PR, Chiu W. EMAN: semiautomated software for high-resolution single-particle reconstructions. J Struct Biol. 1999;128:82&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">10600563</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank J, Radermacher M, Penczek P, Zhu J, Li Y, Ladjadj M, Leith A. SPIDER and WEB: processing and visualization of images in 3D electron microscopy and related fields. J Struct Biol. 1996;116:190&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">8742743</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem. 2004;25:1605&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">15264254</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19015485</PMID><DateCompleted><Year>2008</Year><Month>12</Month><Day>17</Day></DateCompleted><DateRevised><Year>2012</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>21</Issue><PubDate><Year>2008</Year><Month>Nov</Month><Day>18</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial.</ArticleTitle><Pagination><StartPage>1702</StartPage><EndPage>1708</EndPage><MedlinePgn>1702-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/01.wnl.0000335163.88054.e7</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In animals, insulin-like growth factor-1 (IGF-1) increases clearance of beta-amyloid, a pathologic hallmark of Alzheimer disease (AD), from the CNS. Serum IGF-1 level decreases with age, and shows a further decrease in AD. We examined whether the growth hormone secretagogue MK-677 (ibutamoren mesylate), a potent inducer of IGF-1 secretion, slows the rate of progression of symptoms in patients with AD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A double-blind, multicenter study was conducted in which 563 patients with mild to moderate AD were randomized to receive MK-677 25 mg or placebo daily for 12 months. Efficacy measures were mean change from baseline at month 12 on the Clinician's Interview Based Impression of Change with caregiver input (CIBIC-plus), the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog), Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL), and the Clinical Dementia Rating-sum of boxes (CDR-sob).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 416 patients completed treatment and assessments at 12 months. Administration of MK-677 25 mg resulted in a 60.1% increase in serum IGF-1 levels at 6 weeks and a 72.9% increase at 12 months. In mixed-effects models that included treatment, time (month), randomization strata (baseline MMSE score &lt; or =20 vs &gt;20), and interaction of treatment-by-time, there were no significant differences between the treatment groups on the CIBIC-plus or the mean change from baseline scores on the ADAS-Cog, ADCS-ADL, or CDR-sob scores over 12 months.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Despite evidence of target engagement as indicated by an increase in serum insulin-like growth factor-1, the human growth hormone secretagogue MK-677 25 mg was ineffective at slowing the rate of progression of Alzheimer disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sevigny</LastName><ForeName>J J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Merck Research Laboratories, North Wales, PA 19454, USA. jeffrey_sevigny@merck.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>van Dyck</LastName><ForeName>C H</ForeName><Initials>CH</Initials></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Lines</LastName><ForeName>C R</ForeName><Initials>CR</Initials></Author><Author ValidYN="Y"><LastName>Nessly</LastName><ForeName>M L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><CollectiveName>MK-677 Protocol 30 Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007211">Indoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013141">Spiro Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>67763-96-6</RegistryNumber><NameOfSubstance UI="D007334">Insulin-Like Growth Factor I</NameOfSubstance></Chemical><Chemical><RegistryNumber>R90JB6QJ2B</RegistryNumber><NameOfSubstance UI="C094817">ibutamoren mesylate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="Y">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016001" MajorTopicYN="N">Confidence Intervals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007334" MajorTopicYN="N">Insulin-Like Growth Factor I</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013141" MajorTopicYN="N">Spiro Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Antuono</LastName><ForeName>P G</ForeName><Initials>PG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burke</LastName><ForeName>W J</ForeName><Initials>WJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coffey</LastName><ForeName>D J</ForeName><Initials>DJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Derbenwick</LastName><ForeName>M J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doria</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Richenstein</LastName><ForeName>V B</ForeName><Initials>VB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mossberg</LastName><ForeName>J E</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farmer</LastName><ForeName>M V</ForeName><Initials>MV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Forchetti</LastName><ForeName>C M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galvin</LastName><ForeName>J E</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holub</LastName><ForeName>R F</ForeName><Initials>RF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>J K</ForeName><Initials>JK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Littlejohn</LastName><ForeName>T W</ForeName><Initials>TW</Initials><Suffix>3rd</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Bergthold</LastName><ForeName>J H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Machado</LastName><ForeName>J C</ForeName><Initials>JC</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Martinez</LastName><ForeName>W C</ForeName><Initials>WC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moldauer</LastName><ForeName>L P</ForeName><Initials>LP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shanbhag</LastName><ForeName>S R</ForeName><Initials>SR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moreines</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nunez</LastName><ForeName>M C</ForeName><Initials>MC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pomara</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Porsteinsson</LastName><ForeName>A P</ForeName><Initials>AP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rapaport</LastName><ForeName>A M</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Relkin</LastName><ForeName>N R</ForeName><Initials>NR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ross</LastName><ForeName>J S</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Safirstein</LastName><ForeName>B E</ForeName><Initials>BE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schaerf</LastName><ForeName>F W</ForeName><Initials>FW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stedman</LastName><ForeName>M L</ForeName><Initials>ML</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tomlinson</LastName><ForeName>J R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kirby</LastName><ForeName>L C</ForeName><Initials>LC</Initials><Suffix>2nd</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Wilks</LastName><ForeName>K R</ForeName><Initials>KR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lossada-Soto</LastName><ForeName>M J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tuchman</LastName><ForeName>M M</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Newhouse</LastName><ForeName>P A</ForeName><Initials>PA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karp</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Packman</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mangioni</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steinberg</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiss</LastName><ForeName>T R</ForeName><Initials>TR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Strauss</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bailey</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hafez</LastName><ForeName>H M</ForeName><Initials>HM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Joseph</LastName><ForeName>G M</ForeName><Initials>GM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kudrow</LastName><ForeName>D B</ForeName><Initials>DB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levin</LastName><ForeName>K A</ForeName><Initials>KA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Merideth</LastName><ForeName>C H</ForeName><Initials>CH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stoukides</LastName><ForeName>J A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hubbard</LastName><ForeName>R H</ForeName><Initials>RH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kohlenberg</LastName><ForeName>C J</ForeName><Initials>CJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stedman</LastName><ForeName>M L</ForeName><Initials>ML</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>11</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>12</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>11</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19015485</ArticleId><ArticleId IdType="doi">10.1212/01.wnl.0000335163.88054.e7</ArticleId><ArticleId IdType="pii">71/21/1702</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19038214</PMID><DateCompleted><Year>2009</Year><Month>01</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>60</Volume><Issue>4</Issue><PubDate><Year>2008</Year><Month>Nov</Month><Day>26</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Distinct stages of myelination regulated by gamma-secretase and astrocytes in a rapidly myelinating CNS coculture system.</ArticleTitle><Pagination><StartPage>555</StartPage><EndPage>569</EndPage><MedlinePgn>555-69</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2008.09.011</ELocationID><Abstract><AbstractText>Mechanistic studies of CNS myelination have been hindered by the lack of a rapidly myelinating culture system. Here, we describe a versatile CNS coculture method that allows time-lapse microscopy and molecular analysis of distinct stages of myelination. Employing a culture architecture of reaggregated neurons fosters extension of dense beds of axons from purified retinal ganglion cells. Seeding of oligodendrocyte precursor cells on these axons results in differentiation and ensheathment in as few as 3 days, with generation of compact myelin within 6 days. This technique enabled (1) the demonstration that oligodendrocytes initiate new myelin segments only during a brief window early in their differentiation, (2) identification of a contribution of astrocytes to the rate of myelin wrapping, and (3) molecular dissection of the role of oligodendrocyte gamma-secretase activity in controlling the ensheathment of axons. These insights illustrate the value of this defined system for investigating multiple aspects of CNS myelination.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Watkins</LastName><ForeName>Trent A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Stanford University School of Medicine, Department of Neurobiology, Fairchild Science Building D235, Stanford, CA 94305-5125, USA. trentw@gene.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emery</LastName><ForeName>Ben</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Mulinyawe</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Barres</LastName><ForeName>Ben A</ForeName><Initials>BA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 EY010257</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EY10257</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002450" MajorTopicYN="N">Cell Communication</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018929" MajorTopicYN="N">Cell Culture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018920" MajorTopicYN="N">Coculture Techniques</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020439" MajorTopicYN="N">Growth Cones</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009186" MajorTopicYN="N">Myelin Sheath</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009413" MajorTopicYN="N">Nerve Fibers, Myelinated</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055495" MajorTopicYN="N">Neurogenesis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009836" MajorTopicYN="N">Oligodendroglia</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012165" MajorTopicYN="N">Retinal Ganglion Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013234" MajorTopicYN="N">Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2008</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>11</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>1</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>11</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>11</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19038214</ArticleId><ArticleId IdType="mid">NIHMS83346</ArticleId><ArticleId IdType="pmc">PMC2650711</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2008.09.011</ArticleId><ArticleId IdType="pii">S0896-6273(08)00759-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Barres BA, Lazar MA, Raff MC. A novel role for thyroid hormone, glucocorticoids and retinoic acid in timing oligodendrocyte development. Development. 1994;120:1097&#x2013;1108.</Citation><ArticleIdList><ArticleId IdType="pubmed">8026323</ArticleId></ArticleIdList></Reference><Reference><Citation>Bunge RP. Tissue culture observations relevant to the study of axon-Schwann cell interactions during peripheral nerve development and repair. J Exp Biol. 1987;132:21&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">3323401</ArticleId></ArticleIdList></Reference><Reference><Citation>Cahoy JD, Emery B, Kaushal A, Foo LC, Zamanian JL, Christopherson KS, Xing Y, Lubischer JL, Krieg P, Krupenko SA, et al. A Transcriptome Database for Astrocytes, Neurons, and Oligodendrocytes: A New Resource for Understanding Brain Development and Function. J Neurosci. 2007;28:264&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671143</ArticleId><ArticleId IdType="pubmed">18171944</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan JR, Watkins TA, Cosgaya JM, Zhang C, Chen L, Reichardt LF, Shooter EM, Barres BA. NGF controls axonal receptivity to myelination by Schwann cells or oligodendrocytes. Neuron. 2004;43:183&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2758239</ArticleId><ArticleId IdType="pubmed">15260955</ArticleId></ArticleIdList></Reference><Reference><Citation>Crang AJ, Gilson J, Blakemore WF. The demonstration by transplantation of the very restricted remyelinating potential of post-mitotic oligodendrocytes. J Neurocytol. 1998;27:541&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pubmed">11246493</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS, Schroeter EH, Schrijvers V, Wolfe MS, Ray WJ, et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature. 1999;398:518&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206645</ArticleId></ArticleIdList></Reference><Reference><Citation>Dovey HF, John V, Anderson JP, Chen LZ, de Saint Andrieu P, Fang LY, Freedman SB, Folmer B, Goldbach E, Holsztynska EJ, et al. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem. 2001;76:173&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">11145990</ArticleId></ArticleIdList></Reference><Reference><Citation>Dugas JC, Tai YC, Speed TP, Ngai J, Barres BA. Functional genomic analysis of oligodendrocyte differentiation. J Neurosci. 2006;26:10967&#x2013;10983.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674672</ArticleId><ArticleId IdType="pubmed">17065439</ArticleId></ArticleIdList></Reference><Reference><Citation>Genoud S, Lappe-Siefke C, Goebbels S, Radtke F, Aguet M, Scherer SS, Suter U, Nave KA, Mantei N. Notch1 control of oligodendrocyte differentiation in the spinal cord. J Cell Biol. 2002;158:709&#x2013;718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2174019</ArticleId><ArticleId IdType="pubmed">12186854</ArticleId></ArticleIdList></Reference><Reference><Citation>Gow A, Friedrich VL, Jr, Lazzarini RA. Myelin basic protein gene contains separate enhancers for oligodendrocyte and Schwann cell expression. J Cell Biol. 1992;119:605&#x2013;616.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2289674</ArticleId><ArticleId IdType="pubmed">1383235</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishibashi T, Dakin KA, Stevens B, Lee PR, Kozlov SV, Stewart CL, Fields RD. Astrocytes promote myelination in response to electrical impulses. Neuron. 2006;49:823&#x2013;832.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1474838</ArticleId><ArticleId IdType="pubmed">16543131</ArticleId></ArticleIdList></Reference><Reference><Citation>Jurynczyk M, Jurewicz A, Bielecki B, Raine CS, Selmaj K. Inhibition of Notch signaling enhances tissue repair in an animal model of multiple sclerosis. J Neuroimmunol. 2005;170:3&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">16290267</ArticleId></ArticleIdList></Reference><Reference><Citation>Lubetzki C, Demerens C, Anglade P, Villarroya H, Frankfurter A, Lee VM, Zalc B. Even in culture, oligodendrocytes myelinate solely axons. Proc Natl Acad Sci U S A. 1993;90:6820&#x2013;6824.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47024</ArticleId><ArticleId IdType="pubmed">8341704</ArticleId></ArticleIdList></Reference><Reference><Citation>Lubetzki C, Gansmuller A, Lachapelle F, Lombrail P, Gumpel M. Myelination by oligodendrocytes isolated from 4&#x2013;6-week-old rat central nervous system and transplanted into newborn shiverer brain. J Neurol Sci. 1988;88:161&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7118458</ArticleId><ArticleId IdType="pubmed">2465389</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Franke A, Kaplan MR, Pfrieger FW, Barres BA. Characterization of the signaling interactions that promote the survival and growth of developing retinal ganglion cells in culture. Neuron. 1995;15:805&#x2013;819.</Citation><ArticleIdList><ArticleId IdType="pubmed">7576630</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Franke A, Shen S, Barres BA. Astrocytes induce oligodendrocyte processes to align with and adhere to axons. Mol Cell Neurosci. 1999;14:385&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">10588392</ArticleId></ArticleIdList></Reference><Reference><Citation>Mi H, Barres BA. Purification and characterization of astrocyte precursor cells in the developing rat optic nerve. J Neurosci. 1999;19:1049&#x2013;1061.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782146</ArticleId><ArticleId IdType="pubmed">9920668</ArticleId></ArticleIdList></Reference><Reference><Citation>Michailov GV, Sereda MW, Brinkmann BG, Fischer TM, Haug B, Birchmeier C, Role L, Lai C, Schwab MH, Nave KA. Axonal neuregulin-1 regulates myelin sheath thickness. Science. 2004;304:700&#x2013;703.</Citation><ArticleIdList><ArticleId IdType="pubmed">15044753</ArticleId></ArticleIdList></Reference><Reference><Citation>Minter LM, Turley DM, Das P, Shin HM, Joshi I, Lawlor RG, Cho OH, Palaga T, Gottipati S, Telfer JC, et al. Inhibitors of gamma-secretase block in vivo and in vitro T helper type 1 polarization by preventing Notch upregulation of Tbx21. Nat Immunol. 2005;6:680&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">15991363</ArticleId></ArticleIdList></Reference><Reference><Citation>Notterpek LM, Bullock PN, Malek-Hedayat S, Fisher R, Rome LH. Myelination in cerebellar slice cultures: development of a system amenable to biochemical analysis. J Neurosci Res. 1993;36:621&#x2013;634.</Citation><ArticleIdList><ArticleId IdType="pubmed">7511701</ArticleId></ArticleIdList></Reference><Reference><Citation>Radtke F, Wilson A, Stark G, Bauer M, van Meerwijk J, MacDonald HR, Aguet M. Deficient T cell fate specification in mice with an induced inactivation of Notch1. Immunity. 1999;10:547&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pubmed">10367900</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg SS, Powell BL, Chan JR. Receiving mixed signals: uncoupling oligodendrocyte differentiation and myelination. Cell Mol Life Sci 2007</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11136062</ArticleId><ArticleId IdType="pubmed">17876524</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura CA, Choi SY, Beglopoulos V, Malkani S, Zhang D, Shankaranarayana Rao BS, Chattarji S, Kelleher RJ, 3rd, Kandel ER, Duff K, et al. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron. 2004;42:23&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">15066262</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnadelbach O, Ozen I, Blaschuk OW, Meyer RL, Fawcett JW. N-cadherin is involved in axon-oligodendrocyte contact and myelination. Mol Cell Neurosci. 2001;17:1084&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pubmed">11414796</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Wolfe MS. Presenilin: running with scissors in the membrane. Cell. 2007;131:215&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">17956719</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaner NC, Campbell RE, Steinbach PA, Giepmans BN, Palmer AE, Tsien RY. Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein. Nat Biotechnol. 2004;22:1567&#x2013;1572.</Citation><ArticleIdList><ArticleId IdType="pubmed">15558047</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J, Marinovich A, Barres BA. Purification and characterization of adult oligodendrocyte precursor cells from the rat optic nerve. J Neurosci. 1998;18:4627&#x2013;4636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792679</ArticleId><ArticleId IdType="pubmed">9614237</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorensen A, Moffat K, Thomson C, Barnett SC. Astrocytes, but not olfactory ensheathing cells or Schwann cells, promote myelination of CNS axons in vitro. Glia. 2008;56:750&#x2013;763.</Citation><ArticleIdList><ArticleId IdType="pubmed">18293402</ArticleId></ArticleIdList></Reference><Reference><Citation>Sussman CR, Vartanian T, Miller RH. The ErbB4 neuregulin receptor mediates suppression of oligodendrocyte maturation. J Neurosci. 2005;25:5757&#x2013;5762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6724872</ArticleId><ArticleId IdType="pubmed">15958742</ArticleId></ArticleIdList></Reference><Reference><Citation>Svenningsen AF, Shan WS, Colman DR, Pedraza L. Rapid method for culturing embryonic neuron-glial cell cocultures. J Neurosci Res. 2003;72:565&#x2013;573.</Citation><ArticleIdList><ArticleId IdType="pubmed">12749021</ArticleId></ArticleIdList></Reference><Reference><Citation>Taveggia C, Zanazzi G, Petrylak A, Yano H, Rosenbluth J, Einheber S, Xu X, Esper RM, Loeb JA, Shrager P, et al. Neuregulin-1 type III determines the ensheathment fate of axons. Neuron. 2005;47:681&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2387056</ArticleId><ArticleId IdType="pubmed">16129398</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomson CE, Hunter AM, Griffiths IR, Edgar JM, McCulloch MC. Murine spinal cord explants: a model for evaluating axonal growth and myelination in vitro. J Neurosci Res. 2006;84:1703&#x2013;1715.</Citation><ArticleIdList><ArticleId IdType="pubmed">17075918</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Sdrulla AD, diSibio G, Bush G, Nofziger D, Hicks C, Weinmaster G, Barres BA. Notch receptor activation inhibits oligodendrocyte differentiation. Neuron. 1998;21:63&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">9697852</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19042931</PMID><DateCompleted><Year>2009</Year><Month>06</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>132</Volume><Issue>Pt 5</Issue><PubDate><Year>2009</Year><Month>May</Month></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects.</ArticleTitle><Pagination><StartPage>1310</StartPage><EndPage>1323</EndPage><MedlinePgn>1310-23</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awn320</ELocationID><Abstract><AbstractText>Although beta-amyloid (Abeta) plaques are a primary diagnostic criterion for Alzheimer's disease, this pathology is commonly observed in the brains of non-demented older individuals. To explore the importance of this pathology in the absence of dementia, we compared levels of amyloid deposition (via 'Pittsburgh Compound-B' (PIB) positron emission tomography (PET) imaging) to hippocampus volume (HV) and episodic memory (EM) in three groups: (i) normal controls (NC) from the Berkeley Aging Cohort (BAC NC, n = 20); (ii) normal controls (NC) from the Alzheimer's disease neuroimaging initiative (ADNI NC, n = 17); and (iii) PIB+ mild cognitive impairment subjects from the ADNI (ADNI PIB+ MCI, n = 39). Age, gender and education were controlled for in each statistical model, and HV was adjusted for intracranial volume (aHV). In BAC NC, elevated PIB uptake was significantly associated with smaller aHV (P = 0.0016) and worse EM (P = 0.0086). Within ADNI NC, elevated PIB uptake was significantly associated with smaller aHV (P = 0.047) but not EM (P = 0.60); within ADNI PIB+ MCI, elevated PIB uptake was significantly associated with both smaller aHV (P = 0.00070) and worse EM (P = 0.046). To further understand these relationships, a recursive regression procedure was conducted within all ADNI NC and PIB+ MCI subjects (n = 56) to test the hypothesis that HV mediates the relationship between Abeta and EM. Significant correlations were found between PIB index and EM (P = 0.0044), PIB index and aHV (P &lt; 0.0001), as well as between aHV and EM (P &lt; 0.0001). When both aHV and PIB were included in the same model to predict EM, aHV remained significant (P = 0.0015) whereas PIB index was no longer significantly associated with EM (P = 0.50). These results are consistent with a model in which Abeta deposition, hippocampal atrophy, and EM occur sequentially in elderly subjects, with Abeta deposition as the primary event in this cascade. This pattern suggests that declining EM in older individuals may be caused by Abeta-induced hippocampus atrophy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mormino</LastName><ForeName>E C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, CA 94720, USA. jagust@berkeley.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kluth</LastName><ForeName>J T</ForeName><Initials>JT</Initials></Author><Author ValidYN="Y"><LastName>Madison</LastName><ForeName>C M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Rabinovici</LastName><ForeName>G D</ForeName><Initials>GD</Initials></Author><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>S L</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>B L</ForeName><Initials>BL</Initials></Author><Author ValidYN="Y"><LastName>Koeppe</LastName><ForeName>R A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Mathis</LastName><ForeName>C A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>M W</ForeName><Initials>MW</Initials></Author><Author ValidYN="Y"><LastName>Jagust</LastName><ForeName>W J</ForeName><Initials>WJ</Initials></Author><Author ValidYN="Y"><CollectiveName>Alzheimer's Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG027859</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG034570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027342</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG031861</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG027859</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0601846</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P01 AG010491</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>11</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002250">Carbon Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002250" MajorTopicYN="N">Carbon Radioisotopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004522" MajorTopicYN="N">Educational Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016014" MajorTopicYN="N">Linear Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009929" MajorTopicYN="N">Organ Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thal</LastName><ForeName>Leon</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thal</LastName><ForeName>Leon</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Jagust</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trojanowki</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beckett</LastName><ForeName>Laurel</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gamst</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potter</LastName><ForeName>William Z</ForeName><Initials>WZ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montine</LastName><ForeName>Tom</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thal</LastName><ForeName>Leon</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Anders</LastName><ForeName>Dale</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernstein</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Felmlee</LastName><ForeName>Joel</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schuff</LastName><ForeName>Norbert</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alexander</LastName><ForeName>Gene</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jagust</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bandy</LastName><ForeName>Dan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koeppe</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foster</LastName><ForeName>Norm</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Kewei</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trojanowki</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaw</LastName><ForeName>Les</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia M-Y</ForeName><Initials>VM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Korecka</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crawford</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neu</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beckett</LastName><ForeName>Laurel</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harvey</LastName><ForeName>Danielle</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gamst</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kornak</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kachaturian</LastName><ForeName>Zaven</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frank</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Snyder</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Molchan</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaye</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vorobik</LastName><ForeName>Remi</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quinn</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pawluczyk</LastName><ForeName>Sonia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spann</LastName><ForeName>Bryan</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fleisher</LastName><ForeName>Adam S</ForeName><Initials>AS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanderswag</LastName><ForeName>Helen</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heidebrink</LastName><ForeName>Judith L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lord</LastName><ForeName>Joanne L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kris</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doody</LastName><ForeName>Rachelle S</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villanueva-Meyer</LastName><ForeName>Javier</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chowdhury</LastName><ForeName>Munir</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stern</LastName><ForeName>Yaakov</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Honig</LastName><ForeName>Lawrence S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bell</LastName><ForeName>Karen L</ForeName><Initials>KL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Stacy</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marson</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Griffith</LastName><ForeName>Randall</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Badger</LastName><ForeName>Beverly</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grossman</LastName><ForeName>Hillel</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tang</LastName><ForeName>Cheuk</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stern</LastName><ForeName>Jessica</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>deToledo-Morrell</LastName><ForeName>Leyla</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shah</LastName><ForeName>Raj C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bach</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duara</LastName><ForeName>Ranjan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Isaacson</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Strauman</LastName><ForeName>Silvia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albert</LastName><ForeName>Marilyn S</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pedroso</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toroney</LastName><ForeName>Jaimie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rusinek</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Leon</LastName><ForeName>Mony J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Santi</LastName><ForeName>Susan M</ForeName><Initials>SM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doraiswamy</LastName><ForeName>P Murali</ForeName><Initials>PM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petrella</LastName><ForeName>Jeffrey R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aiello</LastName><ForeName>Marilyn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clark</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pham</LastName><ForeName>Cassie</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nunez</LastName><ForeName>Jessica</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Charles D</ForeName><Initials>CD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Given</LastName><ForeName>Curtis A</ForeName><Initials>CA</Initials><Suffix>2nd</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Hardy</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeKosky</LastName><ForeName>Steven T</ForeName><Initials>ST</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oakley</LastName><ForeName>MaryAnn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simpson</LastName><ForeName>Donna M</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ismail</LastName><ForeName>M Saleem</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Porsteinsson</LastName><ForeName>Anton</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCallum</LastName><ForeName>Colleen</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cramer</LastName><ForeName>Steven C</ForeName><Initials>SC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mulnard</LastName><ForeName>Ruth A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>McAdams-Ortiz</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diaz-Arrastia</LastName><ForeName>Ramon</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin-Cook</LastName><ForeName>Kristen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeVous</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan I</ForeName><Initials>AI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lah</LastName><ForeName>James J</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cellar</LastName><ForeName>Janet S</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burns</LastName><ForeName>Jeffrey M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>Heather S</ForeName><Initials>HS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laubinger</LastName><ForeName>Mary M</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartzokis</LastName><ForeName>George</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silverman</LastName><ForeName>Daniel H S</ForeName><Initials>DH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lu</LastName><ForeName>Po H</ForeName><Initials>PH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fletcher</LastName><ForeName>Rita</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parfitt</LastName><ForeName>Francine</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Heather</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herring</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hake</LastName><ForeName>Ann M</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Dyck</LastName><ForeName>Christopher H</ForeName><Initials>CH</Initials></Investigator><Investigator ValidYN="Y"><LastName>MacAvoy</LastName><ForeName>Martha G</ForeName><Initials>MG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bifano</LastName><ForeName>Laurel A</ForeName><Initials>LA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chertkow</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bergman</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hosein</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Black</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graham</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caldwell</LastName><ForeName>Curtis</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feldman</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Assaly</LastName><ForeName>Michele</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hsiung</LastName><ForeName>Ging-Yuek R</ForeName><Initials>GY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kertesz</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rogers</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trost</LastName><ForeName>Dick</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernick</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gitelman</LastName><ForeName>Darren</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesulam</LastName><ForeName>Marsel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sadowsky</LastName><ForeName>Carl</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villena</LastName><ForeName>Teresa</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesner</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul S</ForeName><Initials>PS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kathleen B</ForeName><Initials>KB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Behan</LastName><ForeName>Kelly E</ForeName><Initials>KE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rentz</LastName><ForeName>Dorene M</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosen</LastName><ForeName>Allyson</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tinklenberg</LastName><ForeName>Jared</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ashford</LastName><ForeName>Wes</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabbagh</LastName><ForeName>Marwan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Connor</LastName><ForeName>Donald</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Obradov</LastName><ForeName>Sanja</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Killiany</LastName><ForeName>Ron</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Norbash</LastName><ForeName>Alex</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Obisesan</LastName><ForeName>Thomas O</ForeName><Initials>TO</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jayam-Trouth</LastName><ForeName>Annapurni</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Auchus</LastName><ForeName>Alexander P</ForeName><Initials>AP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huang</LastName><ForeName>Juebin</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Friedland</LastName><ForeName>Robert P</ForeName><Initials>RP</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fletcher</LastName><ForeName>Evan</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carmichael</LastName><ForeName>Owen</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kittur</LastName><ForeName>Smita</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mirje</LastName><ForeName>Seema</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Sterling C</ForeName><Initials>SC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borrie</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>T-Y</ForeName><Initials>TY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Asthana</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carlsson</LastName><ForeName>Cynthia M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potkin</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Highum</LastName><ForeName>Diane</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Preda</LastName><ForeName>Adrian</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Dana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre N</ForeName><Initials>PN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hendin</LastName><ForeName>Barry A</ForeName><Initials>BA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scharre</LastName><ForeName>Douglas W</ForeName><Initials>DW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kataki</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beversdorf</LastName><ForeName>David Q</ForeName><Initials>DQ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zimmerman</LastName><ForeName>Earl A</ForeName><Initials>EA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Celmins</LastName><ForeName>Dzintra</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>Alice D</ForeName><Initials>AD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gandy</LastName><ForeName>Sam</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marenberg</LastName><ForeName>Marjorie E</ForeName><Initials>ME</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rovner</LastName><ForeName>Barry W</ForeName><Initials>BW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pearlson</LastName><ForeName>Godfrey</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blank</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santulli</LastName><ForeName>Robert B</ForeName><Initials>RB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pare</LastName><ForeName>Nadia</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williamson</LastName><ForeName>Jeff D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sink</LastName><ForeName>Kaycee M</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potter</LastName><ForeName>Huntington</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raj</LastName><ForeName>B Ashok</ForeName><Initials>BA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giordano</LastName><ForeName>Amy</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ott</LastName><ForeName>Brian R</ForeName><Initials>BR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>Chuang-Kuo</ForeName><Initials>CK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cohen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilks</LastName><ForeName>Kerri L</ForeName><Initials>KL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Safirstein</LastName><ForeName>Beth E</ForeName><Initials>BE</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>12</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>6</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>12</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19042931</ArticleId><ArticleId IdType="pmc">PMC2677792</ArticleId><ArticleId IdType="doi">10.1093/brain/awn320</ArticleId><ArticleId IdType="pii">awn320</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, et al. Amyloid deposition is frequent and often is not associated with significant cognitive impairment in the elderly. Arch Neurol. 2008;65:1509&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2636844</ArticleId><ArticleId IdType="pubmed">19001171</ArticleId></ArticleIdList></Reference><Reference><Citation>Apostolova LG, Dutton RA, Dinov ID, Hayashi KM, Toga AW, Cummings JL, et al. Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. Arch Neurol. 2006;63:693&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16682538</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb Cortex. 1991;1:103&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">1822725</ArticleId></ArticleIdList></Reference><Reference><Citation>Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol. 1986;51:1173&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">3806354</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66:1837&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">16801647</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol. 2004;61:378&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15023815</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18:351&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330961</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Head D, Parker J, Fotenos AF, Marcus D, Morris JC, et al. A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume. Neuroimage. 2004;23:724&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">15488422</ArticleId></ArticleIdList></Reference><Reference><Citation>Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis. I. Segmentation and surface reconstruction. Neuroimage. 1999;9:179&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">9931268</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis DG, Schmitt FA, Wekstein DR, Markesbery WR. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol. 1999;58:376&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">10218633</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leon MJ, Convit A, George AE, Golomb J, de Santi S, Tarshish C, et al. In vivo structural studies of the hippocampus in normal aging and in incipient Alzheimer's disease. Ann N Y Acad Sci. 1996;777:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">8624070</ArticleId></ArticleIdList></Reference><Reference><Citation>Delis D, Kramer J, Kaplan E, Ober B. California verbal learning test. San Antonio: The Psychological Corporation; 2000.</Citation></Reference><Reference><Citation>Desikan RS, Segonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31:968&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">16530430</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59:512&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, Liu A, Dale AM. Automated manifold surgery: constructing geometrically accurate and topologically correct models of the human cerebral cortex. IEEE Trans Med Imaging. 2001;20:70&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">11293693</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33:341&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">11832223</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008;29:1456&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">17499392</ArticleId></ArticleIdList></Reference><Reference><Citation>Fotenos AF, Mintun MA, Snyder AZ, Morris JC, Buckner RL. Brain volume decline in aging: evidence for a relation between socioeconomic status, preclinical Alzheimer disease, and reserve. Arch Neurol. 2008;65:113&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">18195148</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman WP, Price JL, Storandt M, Grant EA, McKeel DW, Jr, Rubin EH, et al. Absence of cognitive impairment or decline in preclinical Alzheimer's disease. Neurology. 2001;56:361&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">11171902</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci USA. 2004;101:4637&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC384799</ArticleId><ArticleId IdType="pubmed">15070770</ArticleId></ArticleIdList></Reference><Reference><Citation>Grober E, Hall CB, Lipton RB, Zonderman AB, Resnick SM, Kawas C. Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease. J Int Neuropsychol Soc. 2008;14:266&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763488</ArticleId><ArticleId IdType="pubmed">18282324</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulette CM, Welsh-Bohmer KA, Murray MG, Saunders AM, Mash DC, McIntyre LM. Neuropathological and neuropsychological changes in &#x2018;normal&#x2019; aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol. 1998;57:1168&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">9862640</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, et al. The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008a;27:685&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2544629</ArticleId><ArticleId IdType="pubmed">18302232</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Dickson DW, Parisi JE, Xu YC, Cha RH, O&#x2019;Brien PC, et al. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology. 2002;58:750&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2745935</ArticleId><ArticleId IdType="pubmed">11889239</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain. 2008b;131:665&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730157</ArticleId><ArticleId IdType="pubmed">18263627</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Petersen RC, Xu YC, O&#x2019;Brien PC, Smith GE, Ivnik RJ, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology. 1999;52:1397&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730146</ArticleId><ArticleId IdType="pubmed">10227624</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, Parisi JE, Dickson DW, Johnson K, Cha R, Ivnik RJ, et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol. 2006;63:674&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">16682537</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzman R, Terry R, DeTeresa R, Brown T, Davies P, Fuld P, et al. Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol. 1988;23:138&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">2897823</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemppainen NM, Aalto S, Karrasch M, Nagren K, Savisto N, Oikonen V, et al. Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease. Ann Neurol. 2008;63:112&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">18023012</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemppainen NM, Aalto S, Wilson IA, Nagren K, Helin S, Bruck A, et al. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology. 2006;67:1575&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">16971697</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Parisi JE, Salviati A, Floriach-Robert M, Boeve BF, Ivnik RJ, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol. 2003;62:1087&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">14656067</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer JH, Jurik J, Sha SJ, Rankin KP, Rosen HJ, Johnson JK, et al. Distinctive neuropsychological patterns in frontotemporal dementia, semantic dementia, and Alzheimer disease. Cogn Behav Neurol. 2003;16:211&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">14665820</ArticleId></ArticleIdList></Reference><Reference><Citation>Langstrom B, Antoni G, Gullberg P, Halldin C, Malmborg P, Nagren K, et al. Synthesis of L- and D-[methyl-11C]methionine. J Nucl Med. 1987;28:1037&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">3585494</ArticleId></ArticleIdList></Reference><Reference><Citation>Link JM, Krohn KA, Clark JC. Production of [11C]CH3I by single pass reaction of [11C]CH4 with I2. Nucl Med Biol. 1997;24:93&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9080480</ArticleId></ArticleIdList></Reference><Reference><Citation>Lockhart A, Lamb JR, Osredkar T, Sue LI, Joyce JN, Ye L, et al. PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain. 2007;130:2607&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">17698496</ArticleId></ArticleIdList></Reference><Reference><Citation>Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">8784228</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathalon DH, Sullivan EV, Rawles JM, Pfefferbaum A. Correction for head size in brain-imaging measurements. Psychiatry Res. 1993;50:121&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">8378488</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem. 2003;46:2740&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">12801237</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Meltzer CC, Kinahan PE, Greer PJ, Nichols TE, Comtat C, Cantwell MN, et al. Comparative evaluation of MR-based partial-volume correction schemes for PET. J Nucl Med. 1999;40:2053&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">10616886</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, et al. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature. 2008;451:720&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3264491</ArticleId><ArticleId IdType="pubmed">18256671</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology. 1993;43:2412&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain. 2007;130:2837&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">17928318</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005;25:1528&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">15944649</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Morris JC. Tangles and plaques in nondemented aging and &#x2018;preclinical&#x2019; Alzheimer's disease. Ann Neurol. 1999;45:358&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranganath C, Heller A, Cohen MX, Brozinsky CJ, Rissman J. Functional connectivity with the hippocampus during successful memory formation. Hippocampus. 2005;15:997&#x2013;1005.</Citation><ArticleIdList><ArticleId IdType="pubmed">16281291</ArticleId></ArticleIdList></Reference><Reference><Citation>Raz N, Rodrigue KM. Differential aging of the brain: patterns, cognitive correlates and modifiers. Neurosci Biobehav Rev. 2006;30:730&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6601348</ArticleId><ArticleId IdType="pubmed">16919333</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitan RM. Validity of the trailmaking test as an indication of organic brain damage. Percept Mot Skills. 1958;8:271&#x2013;6.</Citation></Reference><Reference><Citation>Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007;68:1718&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">17502554</ArticleId></ArticleIdList></Reference><Reference><Citation>Salthouse TA, Babcock RL, Shaw RJ. Effects of adult age on structural and operational capacities in working memory. Psychol Aging. 1991;6:118&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">2029360</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitt FA, Davis DG, Wekstein DR, Smith CD, Ashford JW, Markesbery WR. &#x2018;Preclinical&#x2019; AD revisited: neuropathology of cognitively normal older adults. Neurology. 2000;55:370&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932270</ArticleId></ArticleIdList></Reference><Reference><Citation>Segonne F, Dale AM, Busa E, Glessner M, Salat D, Hahn HK, et al. A hybrid approach to the skull stripping problem in MRI. Neuroimage. 2004;22:1060&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">15219578</ArticleId></ArticleIdList></Reference><Reference><Citation>Small BJ, Fratiglioni L, Viitanen M, Winblad B, Backman L. The course of cognitive impairment in preclinical Alzheimer disease: three- and 6-year follow-up of a population-based sample. Arch Neurol. 2000;57:839&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">10867781</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Stern Y, Tang M, Mayeux R. Selective decline in memory function among healthy elderly. Neurology. 1999;52:1392&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">10227623</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith CD, Chebrolu H, Wekstein DR, Schmitt FA, Jicha GA, Cooper G, et al. Brain structural alterations before mild cognitive impairment. Neurology. 2007;68:1268&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">17438217</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y. Cognitive reserve and Alzheimer disease. Alzheimer Dis Assoc Disord. 2006;20:S69&#x2013;S74.</Citation><ArticleIdList><ArticleId IdType="pubmed">16917199</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomlinson BE, Blessed G, Roth M. Observations on the brains of non-demented old people. J Neurol Sci. 1968;7:331&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">5707082</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Pike KE, Darby D, Maruff P, Savage G, Ng S, et al. Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia. 2008;46:1688&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">18343463</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Selkoe DJ. A beta oligomers&#x2014;a decade of discovery. J Neurochem. 2007;101:1172&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">17286590</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Zang Y, He Y, Liang M, Zhang X, Tian L, et al. Changes in hippocampal connectivity in the early stages of Alzheimer's disease: evidence from resting state fMRI. Neuroimage. 2006;31:496&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pubmed">16473024</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. Wechsler adult intelligence scale-revised. San Antonio: The Psychological Corporation; 1987a.</Citation></Reference><Reference><Citation>Wechsler D. Wechsler memory scale-revised. San Antonio: The Psychological Corporation; 1987b.</Citation></Reference><Reference><Citation>Wilson AA, Garcia A, Chestakova A, Kung H, Houle S. A rapid one-step radiosynthesis of the beta-amyloid imaging radiotracer N-methyl-[&#x2041;1&#x2041;1C]2-(4&#x2032;-methylaminophenyl)-6-hydroxybenzothiazole ([&#x2041;1&#x2041;1C]-6-OH-BTA-1) J Labelled Compounds and Radiopharmaceuticals. 2004;47:679&#x2013;82.</Citation></Reference><Reference><Citation>Zaidi H, Ruest T, Schoenahl F, Montandon ML. Comparative assessment of statistical brain MR image segmentation algorithms and their impact on partial volume correction in PET. Neuroimage. 2006;32:1591&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pubmed">16828315</ArticleId></ArticleIdList></Reference><Reference><Citation>Zec RF. The stroop color-word test: A paradigm for procedural learning. Arch Clin Neuropsychol. 1986;1:274&#x2013;5.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19046567</PMID><DateCompleted><Year>2009</Year><Month>04</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1932-7420</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>5</Issue><PubDate><Year>2008</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Cell metabolism</Title><ISOAbbreviation>Cell Metab</ISOAbbreviation></Journal><ArticleTitle>Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation.</ArticleTitle><Pagination><StartPage>347</StartPage><EndPage>358</EndPage><MedlinePgn>347-58</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cmet.2008.08.017</ELocationID><Abstract><AbstractText>The NAD(+)-dependent deacetylase SIRT1 controls metabolic processes in response to low nutrient availability. We report the metabolic phenotype of mice treated with SRT1720, a specific and potent synthetic activator of SIRT1 that is devoid of direct action on AMPK. SRT1720 administration robustly enhances endurance running performance and strongly protects from diet-induced obesity and insulin resistance by enhancing oxidative metabolism in skeletal muscle, liver, and brown adipose tissue. These metabolic effects of SRT1720 are mediated by the induction of a genetic network controlling fatty acid oxidation through a multifaceted mechanism that involves the direct deacetylation of PGC-1alpha, FOXO1, and p53 and the indirect stimulation of AMPK signaling through a global metabolic adaptation mimicking low energy levels. Combined with our previous work on resveratrol, the current study further validates SIRT1 as a target for the treatment of metabolic disorders and characterizes the mechanisms underlying the therapeutic potential of SIRT1 activation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Feige</LastName><ForeName>J&#xe9;r&#xf4;me N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Institut de G&#xe9;n&#xe9;tique et de Biologie Mol&#xe9;culaire et Cellulaire, CNRS/INSERM/Universit&#xe9; Louis Pasteur, 67404, Illkirch, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lagouge</LastName><ForeName>Marie</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Canto</LastName><ForeName>Carles</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Strehle</LastName><ForeName>Axelle</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Houten</LastName><ForeName>Sander M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Milne</LastName><ForeName>Jill C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>Philip D</ForeName><Initials>PD</Initials></Author><Author ValidYN="Y"><LastName>Mataki</LastName><ForeName>Chikage</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Elliott</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Auwerx</LastName><ForeName>Johan</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Metab</MedlineTA><NlmUniqueID>101233170</NlmUniqueID><ISSNLinking>1550-4131</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004041">Dietary Fats</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006576">Heterocyclic Compounds, 4 or More Rings</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C525422">SRT1720</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.-</RegistryNumber><NameOfSubstance UI="C470545">Sirt1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.-</RegistryNumber><NameOfSubstance UI="D056564">Sirtuin 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.-</RegistryNumber><NameOfSubstance UI="D037761">Sirtuins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Cell Metab. 2009 Feb;9(2):210</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000107" MajorTopicYN="N">Acetylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004032" MajorTopicYN="N">Diet</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004041" MajorTopicYN="N">Dietary Fats</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004734" MajorTopicYN="N">Energy Metabolism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006576" MajorTopicYN="N">Heterocyclic Compounds, 4 or More Rings</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007333" MajorTopicYN="N">Insulin Resistance</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050356" MajorTopicYN="N">Lipid Metabolism</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008659" MajorTopicYN="N">Metabolic Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009765" MajorTopicYN="N">Obesity</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010084" MajorTopicYN="N">Oxidation-Reduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010805" MajorTopicYN="N">Physical Conditioning, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056564" MajorTopicYN="N">Sirtuin 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D037761" MajorTopicYN="N">Sirtuins</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>2</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2008</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>12</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>4</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>12</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19046567</ArticleId><ArticleId IdType="doi">10.1016/j.cmet.2008.08.017</ArticleId><ArticleId IdType="pii">S1550-4131(08)00284-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19047560</PMID><DateCompleted><Year>2009</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>23</Issue><PubDate><Year>2008</Year><Month>Dec</Month><Day>02</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>How redesigning AD clinical trials might increase study partners' willingness to participate.</ArticleTitle><Pagination><StartPage>1883</StartPage><EndPage>1888</EndPage><MedlinePgn>1883-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/01.wnl.0000336652.05779.ea</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Timely recruiting and retaining participants into Alzheimer disease (AD) clinical trials is a challenge. We used conjoint analysis to identify how alterations in attributes of clinical trial design improve willingness to participate: risk, home visits, car service, or increased chance of receiving intervention.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A total of 108 study partners of patients with very mild to severe stage AD rated willingness to allow their relative to participate in eight clinical trials that varied combinations of the four attributes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The highest utility was for home visits (0.89) which essentially compensated for the disutility of high risk (-0.85). The combination of home visits and car service was redundant, with almost no increase in utility over home visits alone. Seventeen percent were willing to participate in a trial with no amenities; the addition of home visits increased predicted willingness to participate to 27%; low risk, home visits, and higher chance of active treatment increased predicted willingness to 60%. The value of reducing the hassles of travel correlated well with measures of AD severity (activities of daily living r = 0.41, p &lt; 0.001; basic activities of daily living r = 0.38, p &lt; 0.001; Neuropsychiatric Inventory severity p = 0.24, p = 0.01; Neuropsychiatric Inventory distress r = 0.23, p &lt; 0.02). No association was found between degree of study partner burden and willingness to tolerate risk of an intervention.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Clinical trials that reduce travel inconvenience may offset the disincentive of study features such as the risk of intervention and may also increase willingness to participate. Redesigning trials may also help recruit patients with more severe Alzheimer disease. Shorter recruitment periods and increased retention rates may offset costs of these changes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Karlawish</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Jason.karlawish@uphs.upenn.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cary</LastName><ForeName>Mark S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Rubright</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Tenhave</LastName><ForeName>Tom</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30-AG-10124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007722" MajorTopicYN="N">Health Knowledge, Attitudes, Practice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007406" MajorTopicYN="N">Interview, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009042" MajorTopicYN="Y">Motivation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010358" MajorTopicYN="N">Patient Participation</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="Y">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012108" MajorTopicYN="N">Research Personnel</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D035842" MajorTopicYN="N">Research Subjects</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>12</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>4</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>12</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>12</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19047560</ArticleId><ArticleId IdType="mid">NIHMS83360</ArticleId><ArticleId IdType="pmc">PMC2649726</ArticleId><ArticleId IdType="doi">10.1212/01.wnl.0000336652.05779.ea</ArticleId><ArticleId IdType="pii">71/23/1883</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzheimer&#x2019;s Association. What is Alzheimer&#x2019;s? Available at: http://www.alz.org/alzheimers_disease_what_is_alzheimers.asp. Accessed March 7, 2008.</Citation></Reference><Reference><Citation>Sugarman J, Kass NE, Goodman SN, Perentesis P, Fernandes P, Faden RR. What patients say about medical research. IRB: A Review of Human Subjects Research 1998;20:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">11657084</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlawish JHT, Casarett D, Klocinksi J, Sankar P. How do AD patients and their caregivers decide whether to enroll in a clinical trial? Neurology 2001;56:789&#x2013;792.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274319</ArticleId></ArticleIdList></Reference><Reference><Citation>Louviere JJ. Analyzing Decision Making: Metric Conjoint Analysis. Newbury Park, CA: Sage Publications, 1988.</Citation></Reference><Reference><Citation>Green PE, Srinivasan V. Conjoint analysis in marketing: new developments with implications for research and practice. J Marketing 1990;54:3&#x2013;19.</Citation></Reference><Reference><Citation>Orme BK. Getting Started with Conjoint Analysis: Strategies for Product Design and Pricing Research. Madison, WI: Research Publishers, LLC, 2006.</Citation></Reference><Reference><Citation>Moore WL, Louviere JJ, Verma R. Using conjoint analysis to help design product platforms. J Product Innovation Management 1999;16:27&#x2013;39.</Citation></Reference><Reference><Citation>Fraenkel L, Bogardus S, Concato J, Wittink DR. Treatment options in knee osteoarthritis: the patient&#x2019;s perspective. Arch Intern Med 2004;164:1299&#x2013;1304.</Citation><ArticleIdList><ArticleId IdType="pubmed">15226163</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan M, Farrar S. Using conjoint analysis to elicit preferences for health care. BMJ 2000;320:1530&#x2013;1533.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1118112</ArticleId><ArticleId IdType="pubmed">10834905</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E. Clinical diagnosis of Alzheimer&#x2019;s disease. Report of the NINCDS-ADRDA work group under auspices of the Department of Health and Human Services Task Force on Alzheimer&#x2019;s disease. Neurology 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Appelbaum PS, Grisso T. The MacArthur Competence Assessment Tool: Clinical Research. Sarasota, FL: Professional Resources Press, 2000.</Citation></Reference><Reference><Citation>Kuhfeld WF. Marketing Research Methods in SAS: Experimental Design, Choice, Conjoint, and Graphical Techniques. Cary, NC: SAS Institute, Inc., 2004.</Citation></Reference><Reference><Citation>MapQuest. Available at: www.mapquest.com.</Citation></Reference><Reference><Citation>Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged. The Index of ADL: a standardized measure of biological and psychosocial function. JAMA 1963;185:914&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">14044222</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">5349366</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufer DI, Cummings JL, Ketchel P, et al. Validation of the NPI-Q, a Brief Clinical Form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci 2000;12:233&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">11001602</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirschman KB, Shea J, Xie SX, Karlawish JH. The development of a rapid screen for caregiver burden. J Am Geriatr Soc 2004;52:1724&#x2013;1729.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450052</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SY, Kim HM, McCallum C, Tariot PN. What do people at risk for Alzheimer disease think about surrogate consent for research? Neurology 2005;65:1395&#x2013;1401.</Citation><ArticleIdList><ArticleId IdType="pubmed">16275826</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzmaurice GM, Laird NM, Ware JH. Applied Longitudinal Analysis. Hoboken, NJ: Wiley, 2004.</Citation></Reference><Reference><Citation>Littell RC, Stroup WW, Freund RJ. SAS for Linear Models, 4th ed. Cary, NC: SAS Publishing, 2002.</Citation></Reference><Reference><Citation>Marshall P, Bradlow ET. A unified approach to conjoint analysis models. J Am Stat Assoc 2002;97:674&#x2013;682.</Citation></Reference><Reference><Citation>SAS 9.1. Cary, NC: SAS Institute, Inc., 2003.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19074428</PMID><DateCompleted><Year>2009</Year><Month>04</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>284</Volume><Issue>6</Issue><PubDate><Year>2009</Year><Month>Feb</Month><Day>06</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Alzheimer disease Abeta production in the absence of S-palmitoylation-dependent targeting of BACE1 to lipid rafts.</ArticleTitle><Pagination><StartPage>3793</StartPage><EndPage>3803</EndPage><MedlinePgn>3793-803</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1074/jbc.M808920200</ELocationID><Abstract><AbstractText>Alzheimer disease beta-amyloid (Abeta) peptides are generated via sequential proteolysis of amyloid precursor protein (APP) by BACE1 and gamma-secretase. A subset of BACE1 localizes to cholesterol-rich membrane microdomains, termed lipid rafts. BACE1 processing in raft microdomains of cultured cells and neurons was characterized in previous studies by disrupting the integrity of lipid rafts by cholesterol depletion. These studies found either inhibition or elevation of Abeta production depending on the extent of cholesterol depletion, generating controversy. The intricate interplay between cholesterol levels, APP trafficking, and BACE1 processing is not clearly understood because cholesterol depletion has pleiotropic effects on Golgi morphology, vesicular trafficking, and membrane bulk fluidity. In this study, we used an alternate strategy to explore the function of BACE1 in membrane microdomains without altering the cellular cholesterol level. We demonstrate that BACE1 undergoes S-palmitoylation at four Cys residues at the junction of transmembrane and cytosolic domains, and Ala substitution at these four residues is sufficient to displace BACE1 from lipid rafts. Analysis of wild type and mutant BACE1 expressed in BACE1 null fibroblasts and neuroblastoma cells revealed that S-palmitoylation neither contributes to protein stability nor subcellular localization of BACE1. Surprisingly, non-raft localization of palmitoylation-deficient BACE1 did not have discernible influence on BACE1 processing of APP or secretion of Abeta. These results indicate that post-translational S-palmitoylation of BACE1 is not required for APP processing, and that BACE1 can efficiently cleave APP in both raft and non-raft microdomains.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vetrivel</LastName><ForeName>Kulandaivelu S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Neurology, and Pathology, The University of Chicago, Chicago, Illinois 60637, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meckler</LastName><ForeName>Xavier</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Ying</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Phuong D</ForeName><Initials>PD</Initials></Author><Author ValidYN="Y"><LastName>Seidah</LastName><ForeName>Nabil G</ForeName><Initials>NG</Initials></Author><Author ValidYN="Y"><LastName>Vassar</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Philip C</ForeName><Initials>PC</Initials></Author><Author ValidYN="Y"><LastName>Fukata</LastName><ForeName>Masaki</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kounnas</LastName><ForeName>Maria Z</ForeName><Initials>MZ</Initials></Author><Author ValidYN="Y"><LastName>Thinakaran</LastName><ForeName>Gopal</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG019070</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG019070</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG021495</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>12</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010169">Palmitic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004795" MajorTopicYN="N">Enzyme Stability</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006056" MajorTopicYN="N">Golgi Apparatus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021962" MajorTopicYN="N">Membrane Microdomains</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010169" MajorTopicYN="N">Palmitic Acids</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011499" MajorTopicYN="Y">Protein Processing, Post-Translational</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>12</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>12</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>4</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>2</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19074428</ArticleId><ArticleId IdType="pmc">PMC2635050</ArticleId><ArticleId IdType="doi">10.1074/jbc.M808920200</ArticleId><ArticleId IdType="pii">S0021-9258(19)81794-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., Luo, Y., Fisher, S., Fuller, J., Edenson, S., Lile, J., Jarosinski, M. A., Biere, A. L., Curran, E., Burgess, T., Louis, J. C., Collins, F., Treanor, J., Rogers, G., and Citron, M. (1999) Science 286 735-741</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha, S., Anderson, J. P., Barbour, R., Basi, G. S., Caccavello, R., Davis, D., Doan, M., Dovey, H. F., Frigon, N., Hong, J., Jacobson-Croak, K., Jewett, N., Keim, P., Knops, J., Lieberburg, I., Power, M., Tan, H., Tatsuno, G., Tung, J., Schenk, D., Seubert, P., Suomensaari, S. M., Wang, S., Walker, D., Zhao, J., McConlogue, L., and John, V. (1999) Nature 402 537-540</Citation><ArticleIdList><ArticleId IdType="pubmed">10591214</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan, R., Bienkowski, M. J., Shuck, M. E., Miao, H., Tory, M. C., Pauley, A. M., Brashier, J. R., Stratman, N. C., Mathews, W. R., Buhl, A. E., Carter, D. B., Tomasselli, A. G., Parodi, L. A., Heinrikson, R. L., and Gurney, M. E. (1999) Nature 402 533-537</Citation><ArticleIdList><ArticleId IdType="pubmed">10591213</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai, H., Wang, Y., McCarthy, D., Wen, H., Borchelt, D. R., Price, D. L., and Wong, P. C. (2001) Nat. Neurosci. 4 233-234</Citation><ArticleIdList><ArticleId IdType="pubmed">11224536</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole, S. L., and Vassar, R. (2008) J. Biol. Chem. 283 29621-29625</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2662048</ArticleId><ArticleId IdType="pubmed">18650431</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwatsubo, T. (2004) Curr. Opin. Neurobiol. 14 379-383</Citation><ArticleIdList><ArticleId IdType="pubmed">15194119</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo, Y., Bolon, B., Kahn, S., Bennett, B. D., Babu-Khan, S., Denis, P., Fan, W., Kha, H., Zhang, J., Gong, Y., Martin, L., Louis, J. C., Yan, Q., Richards, W. G., Citron, M., and Vassar, R. (2001) Nat. Neurosci. 4 231-232</Citation><ArticleIdList><ArticleId IdType="pubmed">11224535</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao, J., Fu, Y., Yasvoina, M., Shao, P., Hitt, B., O'Connor, T., Logan, S., Maus, E., Citron, M., Berry, R., Binder, L., and Vassar, R. (2007) J. Neurosci. 27 3639-3649</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672403</ArticleId><ArticleId IdType="pubmed">17409228</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, Q., and Sudhof, T. C. (2004) J. Biol. Chem. 279 10542-10550</Citation><ArticleIdList><ArticleId IdType="pubmed">14699153</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichtenthaler, S. F., Dominguez, D. I., Westmeyer, G. G., Reiss, K., Haass, C., Saftig, P., De Strooper, B., and Seed, B. (2003) J. Biol. Chem. 278 48713-48719</Citation><ArticleIdList><ArticleId IdType="pubmed">14507929</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitazume, S., Tachida, Y., Oka, R., Shirotani, K., Saido, T. C., and Hashimoto, Y. (2001) Proc. Natl. Acad. Sci. U. S. A. 98 13554-13559</Citation><ArticleIdList><ArticleId IdType="pmc">PMC61079</ArticleId><ArticleId IdType="pubmed">11698669</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh, Y. H., von Arnim, C. A., Hyman, B. T., Tanzi, R. E., and Tesco, G. (2005) J. Biol. Chem. 280 32499-32504</Citation><ArticleIdList><ArticleId IdType="pubmed">16033761</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong, H. K., Sakurai, T., Oyama, F., Kaneko, K., Wada, K., Miyazaki, H., Kurosawa, M., De Strooper, B., Saftig, P., and Nukina, N. (2005) J. Biol. Chem. 280 23009-23017</Citation><ArticleIdList><ArticleId IdType="pubmed">15824102</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu, X., Hicks, C. W., He, W., Wong, P., Macklin, W. B., Trapp, B. D., and Yan, R. (2006) Nat. Neurosci. 9 1520-1525</Citation><ArticleIdList><ArticleId IdType="pubmed">17099708</ArticleId></ArticleIdList></Reference><Reference><Citation>Willem, M., Garratt, A. N., Novak, B., Citron, M., Kaufmann, S., Rittger, A., DeStrooper, B., Saftig, P., Birchmeier, C., and Haass, C. (2006) Science 314 664-666</Citation><ArticleIdList><ArticleId IdType="pubmed">16990514</ArticleId></ArticleIdList></Reference><Reference><Citation>Capell, A., Steiner, H., Willem, M., Kaiser, H., Meyer, C., Walter, J., Lammich, S., Multhaup, G., and Haass, C. (2000) J. Biol. Chem. 275 30849-30854</Citation><ArticleIdList><ArticleId IdType="pubmed">10801872</ArticleId></ArticleIdList></Reference><Reference><Citation>Creemers, J. W., Ines Dominguez, D., Plets, E., Serneels, L., Taylor, N. A., Multhaup, G., Craessaerts, K., Annaert, W., and De Strooper, B. (2001) J. Biol. Chem. 276 4211-4217</Citation><ArticleIdList><ArticleId IdType="pubmed">11071887</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter, J., Fluhrer, R., Hartung, B., Willem, M., Kaether, C., Capell, A., Lammich, S., Multhaup, G., and Haass, C. (2001) J. Biol. Chem. 276 14634-14641</Citation><ArticleIdList><ArticleId IdType="pubmed">11278841</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjannet, S., Elagoz, A., Wickham, L., Mamarbachi, M., Munzer, J. S., Basak, A., Lazure, C., Cromlish, J. A., Sisodia, S., Checler, F., Chretien, M., and Seidah, N. G. (2001) J. Biol. Chem. 276 10879-10887</Citation><ArticleIdList><ArticleId IdType="pubmed">11152688</ArticleId></ArticleIdList></Reference><Reference><Citation>Costantini, C., Ko, M. H., Jonas, M. C., and Puglielli, L. (2007) Biochem. J. 407 383-395</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2275071</ArticleId><ArticleId IdType="pubmed">17425515</ArticleId></ArticleIdList></Reference><Reference><Citation>Huse, J. T., Pijak, D. S., Leslie, G. J., Lee, V. M., and Doms, R. W. (2000) J. Biol. Chem. 275 33729-33737</Citation><ArticleIdList><ArticleId IdType="pubmed">10924510</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo, E. H., and Squazzo, S. L. (1994) J. Biol. Chem. 269 17386-17389</Citation><ArticleIdList><ArticleId IdType="pubmed">8021238</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass, C., Lemere, C. A., Capell, A., Citron, M., Seubert, P., Schenk, D., Lannfelt, L., and Selkoe, D. J. (1995) Nat. Med. 1 1291-1296</Citation><ArticleIdList><ArticleId IdType="pubmed">7489411</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran, G., Teplow, D. B., Siman, R., Greenberg, B., and Sisodia, S. S. (1996) J. Biol. Chem. 271 9390-9397</Citation><ArticleIdList><ArticleId IdType="pubmed">8621605</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo, E. H., Squazzo, S. L., Selkoe, D. J., and Koo, C. H. (1996) J. Cell Sci. 109 991-998</Citation><ArticleIdList><ArticleId IdType="pubmed">8743946</ArticleId></ArticleIdList></Reference><Reference><Citation>He, X., Zhu, G., Koelsch, G., Rodgers, K. K., Zhang, X. C., and Tang, J. (2003) Biochemistry 42 12174-12180</Citation><ArticleIdList><ArticleId IdType="pubmed">14567678</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiba, T., Kametaka, S., Kawasaki, M., Shibata, M., Waguri, S., Uchiyama, Y., and Wakatsuki, S. (2004) Traffic 5 437-448</Citation><ArticleIdList><ArticleId IdType="pubmed">15117318</ArticleId></ArticleIdList></Reference><Reference><Citation>He, X., Li, F., Chang, W. P., and Tang, J. (2005) J. Biol. Chem. 280 11696-11703</Citation><ArticleIdList><ArticleId IdType="pubmed">15615712</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahle, T., Prager, K., Raffler, N., Haass, C., Famulok, M., and Walter, J. (2005) Mol. Cell. Neurosci. 29 453-461</Citation><ArticleIdList><ArticleId IdType="pubmed">15886016</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahle, T., Thal, D. R., Sastre, M., Rentmeister, A., Bogdanovic, N., Famulok, M., Heneka, M. T., and Walter, J. (2006) J. Neurosci. 26 12838-12846</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674839</ArticleId><ArticleId IdType="pubmed">17151287</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesco, G., Koh, Y. H., Kang, E. L., Cameron, A. N., Das, S., Sena-Esteves, M., Hiltunen, M., Yang, S. H., Zhong, Z., Shen, Y., Simpkins, J. W., and Tanzi, R. E. (2007) Neuron 54 721-737</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1973166</ArticleId><ArticleId IdType="pubmed">17553422</ArticleId></ArticleIdList></Reference><Reference><Citation>Simons, M., Keller, P., De Strooper, B., Beyreuther, K., Dotti, C. G., and Simons, K. (1998) Proc. Natl. Acad. Sci. U. S. A. 95 6460-6464</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27798</ArticleId><ArticleId IdType="pubmed">9600988</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehehalt, R., Keller, P., Haass, C., Thiele, C., and Simons, K. (2003) J. Cell Biol. 160 113-123</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172747</ArticleId><ArticleId IdType="pubmed">12515826</ArticleId></ArticleIdList></Reference><Reference><Citation>Abad-Rodriguez, J., Ledesma, M. D., Craessaerts, K., Perga, S., Medina, M., Delacourte, A., Dingwall, C., De Strooper, B., and Dotti, C. G. (2004) J. Cell Biol. 167 953-960</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172459</ArticleId><ArticleId IdType="pubmed">15583033</ArticleId></ArticleIdList></Reference><Reference><Citation>Simons, K., and Toomre, D. (2000) Nat. Rev. Mol. Cell. Biol. 1 31-39</Citation><ArticleIdList><ArticleId IdType="pubmed">11413487</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown, D. A. (2006) Physiol. (Bethesda) 21 430-439</Citation><ArticleIdList><ArticleId IdType="pubmed">17119156</ArticleId></ArticleIdList></Reference><Reference><Citation>Riddell, D. R., Christie, G., Hussain, I., and Dingwall, C. (2001) Curr. Biol. 11 1288-1293</Citation><ArticleIdList><ArticleId IdType="pubmed">11525745</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordy, J. M., Hussain, I., Dingwall, C., Hooper, N. M., and Turner, A. J. (2003) Proc. Natl. Acad. Sci. U. S. A. 100 11735-11740</Citation><ArticleIdList><ArticleId IdType="pmc">PMC208827</ArticleId><ArticleId IdType="pubmed">14504402</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakurai, T., Kaneko, K., Okuno, M., Wada, K., Kashiyama, T., Shimizu, H., Akagi, T., Hashikawa, T., and Nukina, N. (2008) J. Cell Biol. 183 339-352</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2568028</ArticleId><ArticleId IdType="pubmed">18936252</ArticleId></ArticleIdList></Reference><Reference><Citation>Vetrivel, K. S., Cheng, H., Lin, W., Sakurai, T., Li, T., Nukina, N., Wong, P. C., Xu, H., and Thinakaran, G. (2004) J. Biol. Chem. 279 44945-44954</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1201506</ArticleId><ArticleId IdType="pubmed">15322084</ArticleId></ArticleIdList></Reference><Reference><Citation>Vetrivel, K. S., Cheng, H., Kim, S. H., Chen, Y., Barnes, N. Y., Parent, A. T., Sisodia, S. S., and Thinakaran, G. (2005) J. Biol. Chem. 280 25892-25900</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1201532</ArticleId><ArticleId IdType="pubmed">15886206</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodal, S. K., Skretting, G., Garred, O., Vilhardt, F., van Deurs, B., and Sandvig, K. (1999) Mol. Biol. Cell 10 961-974</Citation><ArticleIdList><ArticleId IdType="pmc">PMC25220</ArticleId><ArticleId IdType="pubmed">10198050</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen, G. H., Niels-Christiansen, L. L., Thorsen, E., Immerdal, L., and Danielsen, E. M. (2000) J. Biol. Chem. 275 5136-5142</Citation><ArticleIdList><ArticleId IdType="pubmed">10671559</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Y., Thiele, C., and Huttner, W. B. (2000) Traffic 1 952-962</Citation><ArticleIdList><ArticleId IdType="pubmed">11208085</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirsch, C., Eckert, G. P., and Mueller, W. E. (2003) Biochem. Pharmacol. 65 843-856</Citation><ArticleIdList><ArticleId IdType="pubmed">12628479</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao, M., Mukherjee, S., Sun, Y., and Maxfield, F. R. (2004) J. Biol. Chem. 279 14171-14178</Citation><ArticleIdList><ArticleId IdType="pubmed">14734557</ArticleId></ArticleIdList></Reference><Reference><Citation>Shvartsman, D. E., Gutman, O., Tietz, A., and Henis, Y. I. (2006) Traffic 7 917-926</Citation><ArticleIdList><ArticleId IdType="pubmed">16787400</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukata, M., Fukata, Y., Adesnik, H., Nicoll, R. A., and Bredt, D. S. (2004) Neuron 44 987-996</Citation><ArticleIdList><ArticleId IdType="pubmed">15603741</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, T., Ma, G., Cai, H., Price, D. L., and Wong, P. C. (2003) J. Neurosci. 23 3272-3277</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742329</ArticleId><ArticleId IdType="pubmed">12716934</ArticleId></ArticleIdList></Reference><Reference><Citation>Onishi, M., Kinoshita, S., Morikawa, Y., Shibuya, A., Phillips, J., Lanier, L. L., Gorman, D. M., Nolan, G. P., Miyajima, A., and Kitamura, T. (1996) Exp. Hematol. 24 324-329</Citation><ArticleIdList><ArticleId IdType="pubmed">8641361</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran, G., Regard, J. B., Bouton, C. M., Harris, C. L., Price, D. L., Borchelt, D. R., and Sisodia, S. S. (1998) Neurobiol. Dis. 4 438-453</Citation><ArticleIdList><ArticleId IdType="pubmed">9666482</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb, B. A., Bardel, K. A., Kulnane, L. S., Anderson, J. J., Holtz, G., Wagner, S. L., Sisodia, S. S., and Hoeger, E. J. (1999) Nat. Neurosci. 2 695-697</Citation><ArticleIdList><ArticleId IdType="pubmed">10412057</ArticleId></ArticleIdList></Reference><Reference><Citation>Vetrivel, K. S., Gong, P., Bowen, J. W., Cheng, H., Chen, Y., Carter, M., Nguyen, P. D., Placanica, L., Wieland, F. T., Li, Y. M., Kounnas, M. Z., and Thinakaran, G. (2007) Mol. Neurodegener. 2 4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1803014</ArticleId><ArticleId IdType="pubmed">17288597</ArticleId></ArticleIdList></Reference><Reference><Citation>Linder, M. E., and Deschenes, R. J. (2007) Nat. Rev. Mol. Cell. Biol. 8 74-84</Citation><ArticleIdList><ArticleId IdType="pubmed">17183362</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng, H., Vetrivel, K. S., Drisdel, R. C., Meckler, X., Gong, P., Leem, J. Y., Li, T., Carter, M., Chen, Y., Nguyen, P., Iwatsubo, T., Tomita, T., Wong, P. C., Green, W. N., Kounnas, M. Z., and Thinakaran, G. (2009) J. Biol. Chem. 284 1373-1384</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2615504</ArticleId><ArticleId IdType="pubmed">19028695</ArticleId></ArticleIdList></Reference><Reference><Citation>McCormick, P. J., Dumaresq-Doiron, K., Pluviose, A. S., Pichette, V., Tosato, G., and Lefrancois, S. (2008) Traffic 9 1984-1997</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3500849</ArticleId><ArticleId IdType="pubmed">18817523</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonas, M. C., Costantini, C., and Puglielli, L. (2008) EMBO Rep. 9 916-922</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2529349</ArticleId><ArticleId IdType="pubmed">18660751</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan, R., Han, P., Miao, H., Greengard, P., and Xu, H. (2001) J. Biol. Chem. 276 36788-36796</Citation><ArticleIdList><ArticleId IdType="pubmed">11466313</ArticleId></ArticleIdList></Reference><Reference><Citation>Smotrys, J. E., and Linder, M. E. (2004) Annu. Rev. Biochem. 73 559-587</Citation><ArticleIdList><ArticleId IdType="pubmed">15189153</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown, D. A., and London, E. (1998) Annu. Rev. Cell Dev. Biol. 14 111-136</Citation><ArticleIdList><ArticleId IdType="pubmed">9891780</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, E. B., Zhang, B., Liu, K., Greenbaum, E. A., Doms, R. W., Trojanowski, J. Q., and Lee, V. M. (2005) J. Cell Biol. 168 291-302</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2171598</ArticleId><ArticleId IdType="pubmed">15642747</ArticleId></ArticleIdList></Reference><Reference><Citation>Vetrivel, K. S., and Thinakaran, G. (2006) Neurology 66 S69-S73</Citation><ArticleIdList><ArticleId IdType="pubmed">16432149</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordy, J. M., Hooper, N. M., and Turner, A. J. (2006) Mol. Membr. Biol. 23 111-122</Citation><ArticleIdList><ArticleId IdType="pubmed">16611586</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng, H., Vetrivel, K. S., Gong, P., Meckler, X., Parent, A., and Thinakaran, G. (2007) Nat. Clin. Pract. Neurol. 3 374-382</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2880530</ArticleId><ArticleId IdType="pubmed">17611486</ArticleId></ArticleIdList></Reference><Reference><Citation>Harder, T., and Simons, K. (1997) Curr. Opin. Cell Biol. 9 534-542</Citation><ArticleIdList><ArticleId IdType="pubmed">9261060</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiu, J., Nordberg, A., Shan, K. R., Yu, W. F., Olsson, J. M., Nordman, T., Mousavi, M., and Guan, Z. Z. (2005) J. Neurosci. Res. 82 531-541</Citation><ArticleIdList><ArticleId IdType="pubmed">16240392</ArticleId></ArticleIdList></Reference><Reference><Citation>Won, J. S., Im, Y. B., Khan, M., Contreras, M., Singh, A. K., and Singh, I. (2008) J. Neurochem. 105 1536-1549</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2707757</ArticleId><ArticleId IdType="pubmed">18266936</ArticleId></ArticleIdList></Reference><Reference><Citation>Melkonian, K. A., Ostermeyer, A. G., Chen, J. Z., Roth, M. G., and Brown, D. A. (1999) J. Biol. Chem. 274 3910-3917</Citation><ArticleIdList><ArticleId IdType="pubmed">9920947</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi, T., Saito, A., Okuno, S., Ferrand-Drake, M., Dodd, R. L., and Chan, P. H. (2005) J. Cereb. Blood Flow Metab. 25 41-53</Citation><ArticleIdList><ArticleId IdType="pubmed">15678111</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, K., and El-Husseini, A. (2005) Curr. Opin. Neurobiol. 15 527-535</Citation><ArticleIdList><ArticleId IdType="pubmed">16125924</ArticleId></ArticleIdList></Reference><Reference><Citation>Munro, S. (2003) Cell 115 377-388</Citation><ArticleIdList><ArticleId IdType="pubmed">14622593</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbal, C., Lambelet, M., Bertaggia, D., Gerbex, C., Martinez, M., Arcaro, A., Schapira, M., and Spertini, O. (2006) Blood 108 3352-3359</Citation><ArticleIdList><ArticleId IdType="pubmed">16849645</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19091971</PMID><DateCompleted><Year>2009</Year><Month>01</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>51</Issue><PubDate><Year>2008</Year><Month>Dec</Month><Day>17</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>13805</StartPage><EndPage>13814</EndPage><MedlinePgn>13805-14</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.4218-08.2008</ELocationID><Abstract><AbstractText>beta-Amyloid (Abeta) pathology is an essential pathogenic component in Alzheimer's disease (AD). However, the significance of Abeta pathology, including Abeta deposits/oligomers and glial reactions, to neurodegeneration is unclear. In particular, despite the Abeta neurotoxicity indicated by in vitro studies, mouse models with significant Abeta deposition lack robust and progressive loss of forebrain neurons. Such results have fueled the view that Abeta pathology is insufficient for neurodegeneration in vivo. In this study, because monoaminergic (MAergic) neurons show degenerative changes at early stages of AD, we examined whether the APPswe/PS1DeltaE9 mouse model recapitulates progressive MAergic neurodegeneration occurring in AD cases. We show that the progression forebrain Abeta deposition in the APPswe/PS1DeltaE9 model is associated with progressive losses of the forebrain MAergic afferents. Significantly, axonal degeneration is associated with significant atrophy of cell bodies and eventually leads to robust loss (approximately 50%) of subcortical MAergic neurons. Degeneration of these neurons occurs without obvious local Abeta or tau pathology at the subcortical sites and precedes the onset of anxiety-associated behavior in the mice. Our results show that a transgenic mouse model of Abeta pathology develops progressive MAergic neurodegeneration occurring in AD cases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pathology, Johns Hopkins University, Baltimore, Maryland 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Mi-Jeong</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Savonenko</LastName><ForeName>Alena</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Stirling</LastName><ForeName>Wanda</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Donald L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Borchelt</LastName><ForeName>David R</ForeName><Initials>DR</Initials></Author><Author ValidYN="Y"><LastName>Mamounas</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Lyons</LastName><ForeName>W Ernest</ForeName><Initials>WE</Initials></Author><Author ValidYN="Y"><LastName>Blue</LastName><ForeName>Mary E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Michael K</ForeName><Initials>MK</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG029401</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015306">Biogenic Monoamines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015306" MajorTopicYN="N">Biogenic Monoamines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001933" MajorTopicYN="N">Brain Stem</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008636" MajorTopicYN="N">Mesencephalon</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009475" MajorTopicYN="N">Neurons, Afferent</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016548" MajorTopicYN="N">Prosencephalon</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>12</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>12</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>1</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>6</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19091971</ArticleId><ArticleId IdType="pmc">PMC6671923</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4218-08.2008</ArticleId><ArticleId IdType="pii">28/51/13805</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Boncristiano S, Calhoun ME, Kelly PH, Pfeifer M, Bondolfi L, Stalder M, Phinney AL, Abramowski D, Sturchler-Pierrat C, Enz A, Sommer B, Staufenbiel M, Jucker M. Cholinergic changes in the APP23 transgenic mouse model of cerebral amyloidosis. J Neurosci. 2002;22:3234&#x2013;3243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757538</ArticleId><ArticleId IdType="pubmed">11943824</ArticleId></ArticleIdList></Reference><Reference><Citation>Calhoun ME, Wiederhold KH, Abramowski D, Phinney AL, Probst A, Sturchler-Pierrat C, Staufenbiel M, Sommer B, Jucker M. Neuron loss in APP transgenic mice. Nature. 1998;395:755&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pubmed">9796810</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleman PD, Yao PJ. Synaptic slaughter in Alzheimer's disease. Neurobiol Aging. 2003;24:1023&#x2013;1027.</Citation><ArticleIdList><ArticleId IdType="pubmed">14643374</ArticleId></ArticleIdList></Reference><Reference><Citation>Crawley JN. Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests. Brain Res. 1999;835:18&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">10448192</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer LR, Culver DG, Tennant P, Davis AA, Wang MS, Castellano-Sanchez A, Khan J, Polak MA, Glass JD. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol. 2004;185:232&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pubmed">14736504</ArticleId></ArticleIdList></Reference><Reference><Citation>German DC, Manaye KF, White CL, III, Woodward DJ, McIntire DD, Smith WK, Kalaria RN, Mann DMA. Disease-specific patterns of locus coeruleus cell loss. Ann Neurol. 1992;32:667&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">1449247</ArticleId></ArticleIdList></Reference><Reference><Citation>Grudzien A, Shaw P, Weintraub S, Bigio E, Mash DC, Mesulam MM. Locus coeruleus neurofibrillary degeneration in aging, mild cognitive impairment and early Alzheimer's disease. Neurobiol Aging. 2007;28:327&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">16574280</ArticleId></ArticleIdList></Reference><Reference><Citation>Gundersen HJG, Bendtsen TF, Korbo L, Marcussen N, Moller A, Nielsen K, Nyengaard JR, Pakkenberg B, Sorensen FB, Vesterby A, West MJ. Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. APMIS. 1988a;96:379&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pubmed">3288247</ArticleId></ArticleIdList></Reference><Reference><Citation>Gundersen HJG, Bagger P, Bendtsen TF, Evans SM, Korbo L, Marcussen N, Moller A, Nielsen K, Nyengaard JR, Pakkenberg B, Sorensen FB, Vesterby A, West MJ. The new stereological tools: disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. APMIS. 1988b;96:857&#x2013;881.</Citation><ArticleIdList><ArticleId IdType="pubmed">3056461</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Ramanathan M, Jacobs AH, Dumitrescu-Ozimek L, Bilkei-Gorzo A, Debeir T, Sastre M, Galldiks N, Zimmer A, Hoehn M, Heiss WD, Klockgether T, Staufenbiel M. Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J Neurosci. 2006;26:1343&#x2013;1354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675491</ArticleId><ArticleId IdType="pubmed">16452658</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry MC, McNamara M, Fedorchak K, Hsiao K, Hyman BT. AppSw transgenic mice develop age-related A&#x3b2; deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol. 1997a;56:965&#x2013;973.</Citation><ArticleIdList><ArticleId IdType="pubmed">9291938</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry MC, Soriano F, McNamara M, Page KJ, Schenk D, Games D, Hyman BT. A&#x3b2; deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci. 1997b;17:7053&#x2013;7059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573263</ArticleId><ArticleId IdType="pubmed">9278541</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, Younkin SG, Borchelt DR. Mutant presenilins specifically elevate the levels of the 42 residue {beta}-amyloid peptide in vivo: evidence for augmentation of a 42-specific {gamma} secretase. Hum Mol Genet. 2004;13:159&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">14645205</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Slunt HH, Gonzales V, Savonenko AV, Wen JC, Jenkins NA, Copeland NG, Younkin LH, Lester HA, Younkin SG, Borchelt DR. Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease. PLoS Med. 2005;2:e355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1283364</ArticleId><ArticleId IdType="pubmed">16279840</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalinin S, Gavrilyuk V, Polak PE, Vasser R, Zhao J, Heneka MT, Feinstein DL. Noradrenaline deficiency in brain increases beta-amyloid plaque burden in an animal model of Alzheimer's disease. Neurobiol Aging. 2007;28:1206&#x2013;1214.</Citation><ArticleIdList><ArticleId IdType="pubmed">16837104</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300:486&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenton L, Boon F, Cain DP. Combined but not individual administration of beta-adrenergic and serotonergic antagonists impairs water maze acquisition in the rat. Neuropsychopharmacology. 2007;33:1298&#x2013;1311.</Citation><ArticleIdList><ArticleId IdType="pubmed">17653108</ArticleId></ArticleIdList></Reference><Reference><Citation>Kostic V, Gurney ME, Deng H-X, Siddique T, Epstein CJ, Przedborski S. Midbrain dopaminergic neuronal degeneration in a transgenic mouse model of familial amyotrophic lateral sclerosis. Ann Neurol. 1997;41:497&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pubmed">9124807</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci. 2007;8:499&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pubmed">17551515</ArticleId></ArticleIdList></Reference><Reference><Citation>Laird FM, Cai HSAV, Farah MH, He K, Melnikova TWH, Chiang H-C, Xu G, Koliatsos VE, Borchelt DR, Price DL, Lee HK, Wong PC. BACE1, a major determinant of selective vulnerability of the brain to A&#x3b2; amyloidogenesis is essential for cognitive, emotional and synaptic functions. J Neurosci. 2005;25:11693&#x2013;11709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2564291</ArticleId><ArticleId IdType="pubmed">16354928</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH. A specific amyloid-[beta] protein assembly in the brain impairs memory. Nature. 2006;440:352&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">16541076</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyness SA, Zarow C, Chui HC. Neuron loss in key cholinergic and aminergic nuclei in Alzheimer disease: a meta-analysis. Neurobiol Aging. 2003;24:1&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">12493547</ArticleId></ArticleIdList></Reference><Reference><Citation>Mamounas LA, Altar CA, Blue ME, Kaplan DR, Tessarollo L, Lyons WE. BDNF promotes the regenerative sprouting, but not survival, of injured serotonergic axons in the adult rat brain. J Neurosci. 2000;20:771&#x2013;782.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772430</ArticleId><ArticleId IdType="pubmed">10632606</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann DMA, Yates PO, Marcyniuk B. Dopaminergic neurotransmitter systems in Alzheimer's disease and in Down's syndrome at middle age. J Neurol Neurosurg Psychiatry. 1987;50:341&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1031800</ArticleId><ArticleId IdType="pubmed">2951499</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcyniuk B, Mann DMA, Yates PO. The topography of cell loss from locus caeruleus in Alzheimer's disease. J Neurol Sci. 1986;76:335&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pubmed">3794754</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP. Free radicals and disruption of neuronal ion homeostasis in AD: a role for amyloid &#x3b2;-peptide? Neurobiol Aging. 1995;16:679&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pubmed">8544920</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayhew TM. A review of recent advances in stereology for quantifying neural structure. J Neurocytol. 1992;21:313&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pubmed">1607876</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer EG, Klegeris A, McGeer PL. Inflammation, the complement system and the diseases of aging. Neurobiol Aging. 2005;26(Suppl 1):94&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">16198446</ArticleId></ArticleIdList></Reference><Reference><Citation>McGowan E, Eriksen J, Hutton M. A decade of modeling Alzheimer's disease in transgenic mice. Trends Genet. 2006;22:281&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">16567017</ArticleId></ArticleIdList></Reference><Reference><Citation>Melnikova T, Savonenko A, Wang Q, Liang X, Hand T, Wu L, Kaufmann WE, Vehmas A, Andreasson KI. Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern. Neuroscience. 2006;141:1149&#x2013;1162.</Citation><ArticleIdList><ArticleId IdType="pubmed">16753269</ArticleId></ArticleIdList></Reference><Reference><Citation>Mouton PR, Gokhale AM, Ward NL, West MJ. Stereological length estimation using spherical probes. J Microsc. 2002;206:54&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">12000563</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson RL, Guo Z, Halagappa VM, Pearson M, Gray AJ, Matsuoka Y, Brown M, Martin B, Iyun T, Maudsley S, Clark RF, Mattson MP. Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice. Exp Neurol. 2007;205:166&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1979096</ArticleId><ArticleId IdType="pubmed">17368447</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26:10129&#x2013;10140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Neil JN, Mouton PR, Tizabi Y, Ottinger MA, Lei DL, Ingram DK, Manaye KF. Catecholaminergic neuronal loss in locus coeruleus of aged female dtg APP/PS1 mice. J Chem Neuroanat. 2007;34:102&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5483173</ArticleId><ArticleId IdType="pubmed">17658239</ArticleId></ArticleIdList></Reference><Reference><Citation>Parvizi J, Van Hoesen GW, Damasio A. The selective vulnerability of brainstem nuclei to Alzheimer's disease. Ann Neurol. 2001;49:53&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">11198297</ArticleId></ArticleIdList></Reference><Reference><Citation>Paxinos G, Franklin KBJ. The mouse brain in sterotaxic coordinates. Ed 2. San Diego: Academic; 2001.</Citation></Reference><Reference><Citation>Perez SE, Lazarov O, Koprich JB, Chen EY, Rodriguez-Menendez V, Lipton JW, Sisodia SS, Mufson EJ. Nigrostriatal dysfunction in familial Alzheimer's disease-linked APPswe/PS1DeltaE9 transgenic mice. J Neurosci. 2005;25:10220&#x2013;10229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725777</ArticleId><ArticleId IdType="pubmed">16267229</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez SE, Dar S, Ikonomovic MD, DeKosky ST, Mufson EJ. Cholinergic forebrain degeneration in the APPswe/PS1DeltaE9 transgenic mouse. Neurobiol Dis. 2007;28:3&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2245889</ArticleId><ArticleId IdType="pubmed">17662610</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science. 2007;316:750&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Rub U, Del Tredici K, Schultz C, Thal DR, Braak E, Braak H. The evolution of Alzheimer's disease-related cytoskeletal pathology in the human raphe nuclei. Neuropathol Appl Neurobiol. 2000;26:553&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pubmed">11123722</ArticleId></ArticleIdList></Reference><Reference><Citation>Savonenko A, Xu GM, Melnikova T, Morton JL, Gonzales V, Wong MP, Price DL, Tang F, Markowska AL, Borchelt DR. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to &#x3b2;-amyloid deposition and neurotransmitter abnormalities. Neurobiol Dis. 2005;18:602&#x2013;617.</Citation><ArticleIdList><ArticleId IdType="pubmed">15755686</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz C, Rutten BP, Pielen A, Schafer S, Wirths O, Tremp G, Czech C, Blanchard V, Multhaup G, Rezaie P, Korr H, Steinbusch HW, Pradier L, Bayer TA. Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease. Am J Pathol. 2004;164:1495&#x2013;1502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1615337</ArticleId><ArticleId IdType="pubmed">15039236</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisodia SS, George-Hyslop PH. gamma-Secretase, Notch, Abeta and Alzheimer's disease: where do the presenilins fit in? Nat Rev Neurosci. 2002;3:281&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">11967558</ArticleId></ArticleIdList></Reference><Reference><Citation>Szapacs ME, Numis AL, Andrews AM. Late onset loss of hippocampal 5-HT and NE is accompanied by increases in BDNF protein expression in mice co-expressing mutant APP and PS1. Neurobiol Dis. 2004;16:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">15262269</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD. The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis. J Neuropathol Exp Neurol. 1996;55:1023&#x2013;1025.</Citation><ArticleIdList><ArticleId IdType="pubmed">8857998</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas B, von Coelln R, Mandir AS, Trinkaus DB, Farah MH, Leong LK, Calingasan NY, Flint BM, Dawson VL, Dawson TM. MPTP and DSP-4 susceptibility of substantia nigra and locus coeruleus catecholaminergic neurons in mice is independent of parkin activity. Neurobiol Dis. 2007;26:312&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1920708</ArticleId><ArticleId IdType="pubmed">17336077</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong TP, Debeir T, Duff K, Cuello C. Reorganization of cholinergic terminals in the cerebral cortex and hippocampus in transgenic mice carrying mutated presenilin-1 and amyloid precursor protein transgenes. J Neurosci. 1999;19:2706&#x2013;2716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6786057</ArticleId><ArticleId IdType="pubmed">10087083</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Varvel NH, Lamb BT, Herrup K. Ectopic cell cycle events link human Alzheimer's disease and amyloid precursor protein transgenic mouse models. J Neurosci. 2006;26:775&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675370</ArticleId><ArticleId IdType="pubmed">16421297</ArticleId></ArticleIdList></Reference><Reference><Citation>Yankner BA. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron. 1996;16:921&#x2013;932.</Citation><ArticleIdList><ArticleId IdType="pubmed">8630250</ArticleId></ArticleIdList></Reference><Reference><Citation>Zweig RM, Ross CA, Hedreen JC, Steele C, Cardillo JE, Whitehouse PJ, Folstein MF, Price DL. The neuropathology of aminergic nuclei in Alzheimer's disease. Ann Neurol. 1988;24:233&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">3178178</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19098903</PMID><DateCompleted><Year>2009</Year><Month>03</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4679</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>2</Issue><PubDate><Year>2009</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Nature cell biology</Title><ISOAbbreviation>Nat Cell Biol</ISOAbbreviation></Journal><ArticleTitle>SRF and myocardin regulate LRP-mediated amyloid-beta clearance in brain vascular cells.</ArticleTitle><Pagination><StartPage>143</StartPage><EndPage>153</EndPage><MedlinePgn>143-53</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/ncb1819</ELocationID><Abstract><AbstractText>Amyloid beta-peptide (Abeta) deposition in cerebral vessels contributes to cerebral amyloid angiopathy (CAA) in Alzheimer's disease (AD). Here, we report that in AD patients and two mouse models of AD, overexpression of serum response factor (SRF) and myocardin (MYOCD) in cerebral vascular smooth muscle cells (VSMCs) generates an Abeta non-clearing VSMC phenotype through transactivation of sterol regulatory element binding protein-2, which downregulates low density lipoprotein receptor-related protein-1, a key Abeta clearance receptor. Hypoxia stimulated SRF/MYOCD expression in human cerebral VSMCs and in animal models of AD. We suggest that SRF and MYOCD function as a transcriptional switch, controlling Abeta cerebrovascular clearance and progression of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bell</LastName><ForeName>Robert D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative and Vascular Brain Disorders, Arthur Kornberg Medical Research Building, University of Rochester School of Medicine &amp; Dentistry, 601 Elmwood Avenue, Rochester, New York 14642, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deane</LastName><ForeName>Rashid</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Chow</LastName><ForeName>Nienwen</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Long</LastName><ForeName>Xiaochun</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Sagare</LastName><ForeName>Abhay</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Itender</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Streb</LastName><ForeName>Jeffrey W</ForeName><Initials>JW</Initials></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Huang</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Rubio</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Van Nostrand</LastName><ForeName>William</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Miano</LastName><ForeName>Joseph M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Zlokovic</LastName><ForeName>Berislav V</ForeName><Initials>BV</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R37 NS034467</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL62572</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG023084</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37NS34467</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS034467</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R42 AG026950</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37AG023084,</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R43 AG02400</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R42AG026950</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL132574</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL091168</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL062572</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>12</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Cell Biol</MedlineTA><NlmUniqueID>100890575</NlmUniqueID><ISSNLinking>1465-7392</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C514519">LDLR-related protein 1A, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026503">Low Density Lipoprotein Receptor-Related Protein-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C476858">SRF protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026362">Serum Response Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051782">Sterol Regulatory Element Binding Protein 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015534">Trans-Activators</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C431508">myocardin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Cell Biol. 2009 Feb;11(2):114-6. doi: 10.1038/ncb0209-114.</RefSource><PMID Version="1">19188916</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002536" MajorTopicYN="N">Cerebral Arteries</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026503" MajorTopicYN="N">Low Density Lipoprotein Receptor-Related Protein-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009131" MajorTopicYN="N">Muscle, Smooth, Vascular</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D026362" MajorTopicYN="N">Serum Response Factor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051782" MajorTopicYN="N">Sterol Regulatory Element Binding Protein 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015534" MajorTopicYN="N">Trans-Activators</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015533" MajorTopicYN="N">Transcriptional Activation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>10</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>12</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>12</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>3</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19098903</ArticleId><ArticleId IdType="mid">NIHMS85537</ArticleId><ArticleId IdType="pmc">PMC2654279</ArticleId><ArticleId IdType="doi">10.1038/ncb1819</ArticleId><ArticleId IdType="pii">ncb1819</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer&#x2019;s disease. Nature Rev. Neurosci. 2004;5:347&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">15100718</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008;57:178&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">18215617</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE, Moir RD, Wagner SL. Clearance of Alzheimer&#x2019;s Abeta peptide: the many roads to perdition. Neuron. 2004;43:605&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">15339642</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer&#x2019;s amyloid beta-peptide. Nature Rev. Mol. Cell Biol. 2007;8:101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg SM, Gurol ME, Rosand J, Smith EE. Amyloid angiopathy-related vascular cognitive impairment. Stroke. 2004;35:2616&#x2013;2619.</Citation><ArticleIdList><ArticleId IdType="pubmed">15459438</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger KA. Alzheimer disease and cerebrovascular pathology: an update. J. Neural Transm. 2002;109:813&#x2013;836.</Citation><ArticleIdList><ArticleId IdType="pubmed">12111471</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen JA, et al. Microbleed topography, leukoaraiosis, and cognition in probable Alzheimer disease from the Sunnybrook Dementia Study. Arch. Neurol. 2008;65:790&#x2013;795.</Citation><ArticleIdList><ArticleId IdType="pubmed">18541799</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV, Yamada S, Holtzman D, Ghiso J, Frangione B. Clearance of amyloid beta-peptide from brain: transport or metabolism? Nature Med. 2000;6:718&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pubmed">10888892</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Clearing the brain&#x2019;s amyloid cobwebs. Neuron. 2001;32:177&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">11683988</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Zlokovic BV. Role of A&#x3b2; transport and clearance in the pathogenesis and treatment of Alzheimer&#x2019;s disease. In: Sisodia SS, Tanzi RE, editors. Alzheimer&#x2019;s Disease: Advances in Genetics, Molecular and Cellular Biology. New York: Springer; 2007. pp. 179&#x2013;198.</Citation></Reference><Reference><Citation>Davis J, et al. Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor. J. Biol. Chem. 2004;279:20296&#x2013;20306.</Citation><ArticleIdList><ArticleId IdType="pubmed">14985348</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron. 2004;43:333&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">15294142</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar-Singh S, et al. Dense-core plaques in Tg2576 and PSAPP mouse models of Alzheimer&#x2019;s disease are centered on vessel walls. Am. J. Pathol. 2005;167:527&#x2013;543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1603563</ArticleId><ArticleId IdType="pubmed">16049337</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata M, et al. Clearance of Alzheimer&#x2019;s amyloid-ss(1&#x2013;40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 2000;106:1489&#x2013;1499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC387254</ArticleId><ArticleId IdType="pubmed">11120756</ArticleId></ArticleIdList></Reference><Reference><Citation>Moir RD, Tanzi RE. LRP-mediated clearance of A&#x3b2; is inhibited by KPI-containing isoforms of APP. Curr. Alzheimer Res. 2005;2:269&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pubmed">15974929</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell RD, et al. Transport pathways for clearance of human Alzheimer&#x2019;s amyloid beta-peptide and apolipoproteins E and J. in the mouse central nervous system. J. Cereb. Blood Flow Metab. 2007;27:909&#x2013;918.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2853021</ArticleId><ArticleId IdType="pubmed">17077814</ArticleId></ArticleIdList></Reference><Reference><Citation>Nazer B, Hong S, Selkoe DJ. LRP promotes endocytosis and degradation, but not transcytosis, of the amyloid-beta peptide in a blood-brain barrier in vitro model. Neurobiol. Dis. 2008;30:94&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2376120</ArticleId><ArticleId IdType="pubmed">18289866</ArticleId></ArticleIdList></Reference><Reference><Citation>Urmoneit B, et al. Cerebrovascular smooth muscle cells internalize Alzheimer amyloid beta protein via a lipoprotein pathway: implications for cerebral amyloid angiopathy. Lab. Invest. 1997;77:157&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pubmed">9274858</ArticleId></ArticleIdList></Reference><Reference><Citation>Miano JM. Serum response factor: toggling between disparate programs of gene expression. J. Mol. Cell. Cardiol. 2003;35:577&#x2013;593.</Citation><ArticleIdList><ArticleId IdType="pubmed">12788374</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, et al. Activation of cardiac gene expression by myocardin, a transcriptional cofactor for serum response factor. Cell. 2001;105:851&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pubmed">11439182</ArticleId></ArticleIdList></Reference><Reference><Citation>Pipes GC, Creemers EE, Olson EN. The myocardin family of transcriptional coactivators: versatile regulators of cell growth, migration, and myogenesis. Genes Dev. 2006;20:1545&#x2013;1556.</Citation><ArticleIdList><ArticleId IdType="pubmed">16778073</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow N, et al. Serum response factor and myocardin mediate arterial hypercontractility and cerebral blood flow dysregulation in Alzheimer&#x2019;s phenotype. Proc. Natl Acad. Sci. USA. 2007;104:823&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1783398</ArticleId><ArticleId IdType="pubmed">17215356</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell. 1997;89:331&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">9150132</ArticleId></ArticleIdList></Reference><Reference><Citation>Llorente-Cort&#xe9;s V, Costales P, Bernu&#xe9;s J, Camino-Lopez S, Badimon L. Sterol regulatory element-binding protein-2 negatively regulates low density lipoprotein receptor-related protein transcription. J. Mol. Biol. 2006;359:950&#x2013;960.</Citation><ArticleIdList><ArticleId IdType="pubmed">16697011</ArticleId></ArticleIdList></Reference><Reference><Citation>Llorente-Cort&#xe9;s V, Royo T, Otero-Vi&#xf1;as M, Berrozpe M, Badimon L. Sterol regulatory element binding proteins downregulate LDL receptor-related protein (LRP1) expression and LRP1-mediated aggregated LDL uptake by human macrophages. Cardiovasc. Res. 2007;74:526&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">17376415</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, et al. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nature Med. 2003;9:453&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">12612547</ArticleId></ArticleIdList></Reference><Reference><Citation>Miano JM, et al. Restricted inactivation of serum response factor to the cardiovascular system. Proc. Natl Acad. Sci. USA. 2004;101:17132&#x2013;17137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC535359</ArticleId><ArticleId IdType="pubmed">15569937</ArticleId></ArticleIdList></Reference><Reference><Citation>Parlakian A, et al. Targeted inactivation of serum response factor in the developing heart results in myocardial defects and embryonic lethality. Mol. Cell. Biol. 2004;24:5281&#x2013;5289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC419888</ArticleId><ArticleId IdType="pubmed">15169892</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu Z, et al. Conditional mutagenesis of the murine serum response factor gene blocks cardiogenesis and the transcription of downstream gene targets. J. Biol. Chem. 2005;280:32531&#x2013;32538.</Citation><ArticleIdList><ArticleId IdType="pubmed">15929941</ArticleId></ArticleIdList></Reference><Reference><Citation>Donahue JE, et al. RAGE, LRP-1, and amyloid-beta protein in Alzheimer&#x2019;s disease. Acta. Neuropathol. 2006;112:405&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pubmed">16865397</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z, et al. Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease. Nature Med. 2005;11:959&#x2013;965.</Citation><ArticleIdList><ArticleId IdType="pubmed">16116430</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Wang DZ, Wang Z, Richardson JA, Olson EN. The serum response factor coactivator myocardin is required for vascular smooth muscle development. Proc. Natl Acad. Sci. USA. 2003;100:9366&#x2013;9370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC170924</ArticleId><ArticleId IdType="pubmed">12867591</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, et al. Cardiomyopathy in transgenic mice with cardiac-specific overexpression of serum response factor. Am. J. Physiol. Heart Circ. Physiol. 2001;280:H1782&#x2013;H1792.</Citation><ArticleIdList><ArticleId IdType="pubmed">11247792</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, et al. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer&#x2019;s disease model. Ann. Neurol. 2000;47:739&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pubmed">10852539</ArticleId></ArticleIdList></Reference><Reference><Citation>Long X, Creemers EE, Wang DZ, Olson EN, Miano JM. Myocardin is a bifunctional switch for smooth versus skeletal muscle differentiation. Proc. Natl Acad. Sci. USA. 2007;104:16570&#x2013;16575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2034223</ArticleId><ArticleId IdType="pubmed">17940050</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberti S, et al. Neuronal migration in the murine rostral migratory stream requires serum response factor. Proc. Natl. Acad. Sci. USA. 2005;102:6148&#x2013;6153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1087932</ArticleId><ArticleId IdType="pubmed">15837932</ArticleId></ArticleIdList></Reference><Reference><Citation>Etkin A, et al. A role in learning for SRF: deletion in the adult forebrain disrupts LTD and the formation of an immediate memory of a novel context. Neuron. 2006;50:127&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">16600861</ArticleId></ArticleIdList></Reference><Reference><Citation>Herz J, Marschang P. Coaxing the LDL receptor family into the fold. Cell. 2003;112:289&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">12581519</ArticleId></ArticleIdList></Reference><Reference><Citation>Herring A, et al. Environmental enrichment counteracts Alzheimer&#x2019;s neurovascular dysfunction in TgCRND8 Mice. Brain Pathol. 2008;18:32&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095618</ArticleId><ArticleId IdType="pubmed">17924982</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagare A, et al. Clearance of amyloid-beta by circulating lipoprotein receptors. Nature Med. 2007;13:1029&#x2013;1031.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2936449</ArticleId><ArticleId IdType="pubmed">17694066</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato R, et al. Assignment of the membrane attachment, DNA binding, and transcriptional activation domains of sterol regulatory element-binding protein-1 (SREBP-1) J. Biol. Chem. 1994;269:17267&#x2013;17273.</Citation><ArticleIdList><ArticleId IdType="pubmed">8006035</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Brown MS, Ho YK, Goldstein JL. Three different rearrangements in a single intron truncate sterol regulatory element binding protein-2 and produce sterol-resistant phenotype in three cell lines. J. Biol. Chem. 1995;270:12152&#x2013;12161.</Citation><ArticleIdList><ArticleId IdType="pubmed">7744865</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 2000;57:1439&#x2013;1443.</Citation><ArticleIdList><ArticleId IdType="pubmed">11030795</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparks DL, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch. Neurol. 2005;62:753&#x2013;757.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883262</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, Wu Z, Zlokovic BV. RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke. 2004;35:2628&#x2013;2631.</Citation><ArticleIdList><ArticleId IdType="pubmed">15459432</ArticleId></ArticleIdList></Reference><Reference><Citation>Puglielli L, et al. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nature Cell Biol. 2001;3:905&#x2013;912.</Citation><ArticleIdList><ArticleId IdType="pubmed">11584272</ArticleId></ArticleIdList></Reference><Reference><Citation>Parsons RB, et al. Statins inhibit the dimerization of beta-secretase via both isoprenoid- and cholesterol-mediated mechanisms. Biochem. J. 2006;399:205&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1609905</ArticleId><ArticleId IdType="pubmed">16803455</ArticleId></ArticleIdList></Reference><Reference><Citation>Vermeer SE, et al. Silent brain infarcts and the risk of dementia and cognitive decline. N. Engl. J. Med. 2003;348:1215&#x2013;1222.</Citation><ArticleIdList><ArticleId IdType="pubmed">12660385</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruitenberg A, et al. Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study. Ann. Neurol. 2005;57:789&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pubmed">15929050</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu P, Huang L, Ge X, Yan F, Wu R, Ao Q. Transdifferentiation of pulmonary arteriolar endothelial cells into smooth muscle-like cells regulated by myocardin involved in hypoxia-induced pulmonary vascular remodeling. Int. J. Exp. Pathol. 2007;87:463&#x2013;474.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2517388</ArticleId><ArticleId IdType="pubmed">17222214</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">1910274</PMID><DateCompleted><Year>1991</Year><Month>10</Month><Day>24</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0364-5134</ISSN><JournalIssue CitedMedium="Print"><Volume>30</Volume><Issue>2</Issue><PubDate><Year>1991</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>Neuritic pathology and dementia in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>156</StartPage><EndPage>165</EndPage><MedlinePgn>156-65</MedlinePgn></Pagination><Abstract><AbstractText>Previous studies of Alzheimer's disease (AD) have correlated the severity of dementia with either the number of senile plaques or neurofibrillary tangles. We used antibodies raised against amyloid beta/A4 protein of senile plaque cores and tau protein as well as thioflavine S and the Campbell-Switzer modification of the Hicks silver method to examine the hippocampal formation and five neocortical regions from 22 nondemented elderly control subjects and 34 demented patients with cerebral senile plaques and neurofibrillary tangles, without complicating disease processes. Ten control subjects (46%) had no beta/A4 protein deposition. Twelve control subjects (54%) had widespread beta/A4 protein deposition but no neocortical neuritic pathology. Of the 34 patients with AD-type changes, 27 (79%) had widespread senile plaques and neurofibrillary tangles, while 7 (21%) had neocortical senile plaques with few neurofibrillary tangles. All demented patients had widespread beta/A4 protein deposition and neocortical tau-immunoreactive, Hicks silver-positive dystrophic neurites. The neurites were found both free in the neuropil as well as surrounding senile plaques. Quantitative analysis showed that dystrophic neurites were significantly increased in patients with AD compared with control subjects and the number of dystrophic neurites and neurofibrillary tangles correlated with the clinical severity of dementia. Widespread cerebral beta/A4 protein deposition may be necessary but by itself is insufficient for the development of dementia in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McKee</LastName><ForeName>A C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Massachusetts General Hospital, Boston 02114.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kosik</LastName><ForeName>K S</ForeName><Initials>KS</Initials></Author><Author ValidYN="Y"><LastName>Kowall</LastName><ForeName>N W</ForeName><Initials>NW</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG05134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG06601</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS 01368-01</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008869">Microtubule-Associated Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008869" MajorTopicYN="N">Microtubule-Associated Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009454" MajorTopicYN="N">Neurofibrils</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1991</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1991</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1991</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1910274</ArticleId><ArticleId IdType="doi">10.1002/ana.410300206</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19104051</PMID><DateCompleted><Year>2009</Year><Month>02</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>106</Volume><Issue>1</Issue><PubDate><Year>2009</Year><Month>Jan</Month><Day>06</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>The Drosophila cell adhesion molecule klingon is required for long-term memory formation and is regulated by Notch.</ArticleTitle><Pagination><StartPage>310</StartPage><EndPage>315</EndPage><MedlinePgn>310-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0807665106</ELocationID><Abstract><AbstractText>The ruslan (rus) mutant was previously identified in a behavioral screen for mutants defective in long-lasting memory, which consists of two consolidated memory types, anesthesia-resistant memory, and protein synthesis-dependent long-term memory (LTM). We demonstrate here that rus is a new allele of klingon (klg), which encodes a homophilic cell adhesion molecule. Klg is acutely required for LTM but not anesthesia-resistant memory formation, and Klg expression increases upon LTM induction. LTM formation also requires activity of the Notch cell-surface receptor. Although defects in Notch have been implicated in memory loss because of Alzheimer's disease, downstream signaling linking Notch to memory have not been determined. Strikingly, we found that Notch activity increases upon LTM induction and regulates Klg expression. Furthermore, Notch-induced enhancement of LTM is disrupted by a klg mutation. We propose that Klg is a downstream effector of Notch signaling that links Notch activity to memory.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Matsuno</LastName><ForeName>Motomi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Tokyo Metropolitan Institute for Neuroscience, 2-6 Musashidai, Fuchu, Tokyo 183-8526, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horiuchi</LastName><ForeName>Junjiro</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Tully</LastName><ForeName>Tim</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Saitoe</LastName><ForeName>Minoru</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH066910</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>12</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015815">Cell Adhesion Molecules</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D029721">Drosophila Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005136">Eye Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051880">Receptors, Notch</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C104843">klg protein, Drosophila</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000758" MajorTopicYN="N">Anesthesia</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015815" MajorTopicYN="N">Cell Adhesion Molecules</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004330" MajorTopicYN="N">Drosophila</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029721" MajorTopicYN="N">Drosophila Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005136" MajorTopicYN="N">Eye Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="Y">Memory</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051880" MajorTopicYN="N">Receptors, Notch</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>12</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>12</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>2</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>12</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19104051</ArticleId><ArticleId IdType="pmc">PMC2606903</ArticleId><ArticleId IdType="doi">10.1073/pnas.0807665106</ArticleId><ArticleId IdType="pii">0807665106</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Greenwald I. LIN-12/Notch signaling: lessons from worms and flies. Genes Dev. 1998;12:1751&#x2013;1762.</Citation><ArticleIdList><ArticleId IdType="pubmed">9637676</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa RM, Honjo T, Silva AJ. Learning and memory deficits in Notch mutant mice. Curr Biol. 2003;13:1348&#x2013;1354.</Citation><ArticleIdList><ArticleId IdType="pubmed">12906797</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge X, et al. Notch signaling in Drosophila long-term memory formation. Proc Natl Acad Sci USA. 2004;101:10172&#x2013;10176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC454384</ArticleId><ArticleId IdType="pubmed">15220476</ArticleId></ArticleIdList></Reference><Reference><Citation>Presente A, Boyles RS, Serway CN, de Belle JS, Andres AJ. Notch is required for long-term memory in Drosophila. Proc Natl Acad Sci USA. 2004;101:1764&#x2013;1768.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC341850</ArticleId><ArticleId IdType="pubmed">14752200</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye Y, Lukinova N, Fortini ME. Neurogenic phenotypes and altered Notch processing in Drosophila presenilin mutants. Nature. 1999;398:525&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206647</ArticleId></ArticleIdList></Reference><Reference><Citation>Struhl G, Greenwald I. Presenilin is required for activity and nuclear access of Notch in Drosophila. Nature. 1999;398:522&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206646</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao X, Sudhof TC. A transcriptionally [correction of transcriptively] active complex of APP with Fe65 and histone acetyltransferase Tip60. Science. 2001;293:115&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">11441186</ArticleId></ArticleIdList></Reference><Reference><Citation>Moehlmann T, et al. Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on Abeta 42 production. Proc Natl Acad Sci USA. 2002;99:8025&#x2013;8030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC123014</ArticleId><ArticleId IdType="pubmed">12048239</ArticleId></ArticleIdList></Reference><Reference><Citation>Roncarati R, et al. The gamma-secretase-generated intracellular domain of beta-amyloid precursor protein binds Numb and inhibits Notch signaling. Proc Natl Acad Sci USA. 2002;99:7102&#x2013;7107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC124535</ArticleId><ArticleId IdType="pubmed">12011466</ArticleId></ArticleIdList></Reference><Reference><Citation>Tully T, Preat T, Boynton SC, Del Vecchio M. Genetic dissection of consolidated memory in Drosophila. Cell. 1994;79:35&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">7923375</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubnau J, et al. The staufen/pumilio pathway is involved in Drosophila long-term memory. Curr Biol. 2003;13:286&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pubmed">12593794</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozdagi O, Shan W, Tanaka H, Benson DL, Huntley GW. Increasing numbers of synaptic puncta during late-phase LTP: N-cadherin is synthesized, recruited to synaptic sites, and required for potentiation. Neuron. 2000;28:245&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">11086998</ArticleId></ArticleIdList></Reference><Reference><Citation>Senkov O, et al. Polysialylated neural cell adhesion molecule is involved in induction of long-term potentiation and memory acquisition and consolidation in a fear-conditioning paradigm. J Neurosci. 2006;26:10888&#x2013;10898.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674738</ArticleId><ArticleId IdType="pubmed">17050727</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler SJ, Ray S, Hiromi Y. Klingon, a novel member of the Drosophila immunoglobulin superfamily, is required for the development of the R7 photoreceptor neuron. Development. 1997;124:781&#x2013;792.</Citation><ArticleIdList><ArticleId IdType="pubmed">9043060</ArticleId></ArticleIdList></Reference><Reference><Citation>Aigaki T, Ohsako T, Toba G, Seong K, Matsuo T. The gene search system: its application to functional genomics in Drosophila melanogaster. J Neurogenet. 2001;15:169&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">12092901</ArticleId></ArticleIdList></Reference><Reference><Citation>Brand AH, Perrimon N. Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development. 1993;118:401&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pubmed">8223268</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper MT, Bray SJ. R7 photoreceptor specification requires Notch activity. Curr Biol. 2000;10:1507&#x2013;1510.</Citation><ArticleIdList><ArticleId IdType="pubmed">11114517</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuster CM, Davis GW, Fetter RD, Goodman CS. Genetic dissection of structural and functional components of synaptic plasticity. II. Fasciclin II controls presynaptic structural plasticity. Neuron. 1996;17:655&#x2013;667.</Citation><ArticleIdList><ArticleId IdType="pubmed">8893023</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y, et al. Drosophila fasciclinII is required for the formation of odor memories and for normal sensitivity to alcohol. Cell. 2001;105:757&#x2013;768.</Citation><ArticleIdList><ArticleId IdType="pubmed">11440718</ArticleId></ArticleIdList></Reference><Reference><Citation>Grotewiel MS, Beck CD, Wu KH, Zhu XR, Davis RL. Integrin-mediated short-term memory in Drosophila. Nature. 1998;391:455&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pubmed">9461212</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrbough J, Grotewiel MS, Davis RL, Broadie K. Integrin-mediated regulation of synaptic morphology, transmission, and plasticity. J Neurosci. 2000;20:6868&#x2013;6878.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772806</ArticleId><ArticleId IdType="pubmed">10995831</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang HP, Lindberg FP, Wang HL, Huang AM, Lee EH. Impaired memory retention and decreased long-term potentiation in integrin-associated protein-deficient mice. Learn Mem. 1999;6:448&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC311315</ArticleId><ArticleId IdType="pubmed">10541465</ArticleId></ArticleIdList></Reference><Reference><Citation>Cremer H, et al. Long-term but not short-term plasticity at mossy fiber synapses is impaired in neural cell adhesion molecule-deficient mice. Proc Natl Acad Sci USA. 1998;95:13242&#x2013;13247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC23769</ArticleId><ArticleId IdType="pubmed">9789073</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascual A, Preat T. Localization of long-term memory within the Drosophila mushroom body. Science. 2001;294:1115&#x2013;1117.</Citation><ArticleIdList><ArticleId IdType="pubmed">11691997</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa RM, Drew C, Silva AJ. Notch to remember. Trends Neurosci. 2005;28:429&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pubmed">15922461</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura CA, et al. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron. 2004;42:23&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">15066262</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashraf SI, McLoon AL, Sclarsic SM, Kunes S. Synaptic protein synthesis associated with memory is regulated by the RISC pathway in Drosophila. Cell. 2006;124:191&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">16413491</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa-Mattioli M, et al. eIF2alpha phosphorylation bidirectionally regulates the switch from short- to long-term synaptic plasticity and memory. Cell. 2007;129:195&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4149214</ArticleId><ArticleId IdType="pubmed">17418795</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu K, Phan T, Mansuy IM, Storm DR. Proteolytic degradation of SCOP in the hippocampus contributes to activation of MAP kinase and memory. Cell. 2007;128:1219&#x2013;1229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1899088</ArticleId><ArticleId IdType="pubmed">17382888</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamura T, et al. Aging specifically impairs amnesiac-dependent memory in Drosophila. Neuron. 2003;40:1003&#x2013;1011.</Citation><ArticleIdList><ArticleId IdType="pubmed">14659098</ArticleId></ArticleIdList></Reference><Reference><Citation>Brand M, Jarman AP, Jan LY, Jan YN. Asense is a Drosophila neural precursor gene and is capable of initiating sense organ formation. Development. 1993;119(1):1&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">8565817</ArticleId></ArticleIdList></Reference><Reference><Citation>Tully T, Quinn WG. Classical conditioning and retention in normal and mutant Drosophila melanogaster. J Comp Physiol [A] 1985;157:263&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">3939242</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamazaki D, et al. The Drosophila DCO mutation suppresses age-related memory impairment without affecting lifespan. Nat Neurosci. 2007;10:478&#x2013;484.</Citation><ArticleIdList><ArticleId IdType="pubmed">17322874</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19109498</PMID><DateCompleted><Year>2009</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>52</Issue><PubDate><Year>2008</Year><Month>Dec</Month><Day>24</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice.</ArticleTitle><Pagination><StartPage>14156</StartPage><EndPage>14164</EndPage><MedlinePgn>14156-64</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.4147-08.2008</ELocationID><Abstract><AbstractText>Aggregation of amyloid-beta (Abeta) peptide in the brain in the form of neuritic plaques and cerebral amyloid angiopathy (CAA) is a key feature of Alzheimer's disease (AD). Microglial cells surround aggregated Abeta and are believed to play a role in AD pathogenesis. A therapy for AD that has entered clinical trials is the administration of anti-Abeta antibodies. One mechanism by which certain anti-Abeta antibodies have been proposed to exert their effects is via antibody-mediated microglial activation. Whether, when, or to what extent microglial activation occurs after systemic administration of anti-Abeta antibodies has not been fully assessed. We administered an anti-Abeta antibody (m3D6) that binds aggregated Abeta to PDAPP mice, an AD mouse model that was bred to contain fluorescent microglia. Three days after systemic administration of m3D6, there was a marked increase in both the number of microglial cells and processes per cell visualized in vivo by multiphoton microscopy. These changes required the Fc domain of m3D6 and were not observed with an antibody specific to soluble Abeta. These findings demonstrate that some effects of antibodies that recognize aggregated Abeta are rapid, involve microglia, and provide insight into the mechanism of action of a specific passive immunotherapy for AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Koenigsknecht-Talboo</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology and Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, Missouri 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyer-Luehmann</LastName><ForeName>Melanie</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Parsadanian</LastName><ForeName>Maia</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Garcia-Alloza</LastName><ForeName>Monica</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Finn</LastName><ForeName>Mary Beth</ForeName><Initials>MB</Initials></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials></Author><Author ValidYN="Y"><LastName>Bacskai</LastName><ForeName>Brian J</ForeName><Initials>BJ</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 NS057105</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS032636</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS32636</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 AG029044</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F33 AG029044</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C465418">1,4-bis(4'-hydroxystyryl)-2-methoxybenzene</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C491049">Aif1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000475">Alkenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001555">Benzene Derivatives</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073883">CX3C Chemokine Receptor 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002135">Calcium-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C471885">Cx3cr1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008840">Microfilament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019707">Receptors, Chemokine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013267">Stilbenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.48</RegistryNumber><NameOfSubstance UI="D017493">Leukocyte Common Antigens</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000475" MajorTopicYN="N">Alkenes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001555" MajorTopicYN="N">Benzene Derivatives</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073883" MajorTopicYN="N">CX3C Chemokine Receptor 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002135" MajorTopicYN="N">Calcium-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002452" MajorTopicYN="N">Cell Count</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016657" MajorTopicYN="N">Cerebral Amyloid Angiopathy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017493" MajorTopicYN="N">Leukocyte Common Antigens</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008840" MajorTopicYN="N">Microfilament Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019707" MajorTopicYN="N">Receptors, Chemokine</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013267" MajorTopicYN="N">Stilbenes</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>12</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>12</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>4</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>6</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19109498</ArticleId><ArticleId IdType="mid">NIHMS85461</ArticleId><ArticleId IdType="pmc">PMC2743894</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4147-08.2008</ArticleId><ArticleId IdType="pii">28/52/14156</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ajami B, Bennett JL, Krieger C, Tetzlaff W, Rossi FM. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat Neurosci. 2007;10:1538&#x2013;1543.</Citation><ArticleIdList><ArticleId IdType="pubmed">18026097</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, et al. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000;21:383&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3887148</ArticleId><ArticleId IdType="pubmed">10858586</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacskai BJ, Kajdasz ST, Christie RH, Carter C, Games D, Seubert P, Schenk D, Hyman BT. Imaging of amyloid-&#x3b2; deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med. 2001;7:369&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">11231639</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacskai BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, Schenk D, Hyman BT. Non-Fc-mediated mechanisms are involved in clearance of amyloid-&#x3b2; in vivo by immunotherapy. J Neurosci. 2002;22:7873&#x2013;7878.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758112</ArticleId><ArticleId IdType="pubmed">12223540</ArticleId></ArticleIdList></Reference><Reference><Citation>Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, et al. Peripherally administered antibodies against amyloid &#x3b2;-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6:916&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932230</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolmont T, Haiss F, Eicke D, Radde R, Mathis CA, Klunk WE, Kohsaka S, Jucker M, Calhoun ME. Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J Neurosci. 2008;28:4283&#x2013;4292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3844768</ArticleId><ArticleId IdType="pubmed">18417708</ArticleId></ArticleIdList></Reference><Reference><Citation>Bornemann KD, Wiederhold KH, Pauli C, Ermini F, Stalder M, Schnell L, Sommer B, Jucker M, Staufenbiel M. A&#x3b2;-induced inflammatory processes in microglia cells of APP23 transgenic mice. Am J Pathol. 2001;158:63&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850262</ArticleId><ArticleId IdType="pubmed">11141480</ArticleId></ArticleIdList></Reference><Reference><Citation>Brendza RP, Bacskai BJ, Cirrito JR, Simmons KA, Skoch JM, Klunk WE, Mathis CA, Bales KR, Paul SM, Hyman BT, Holtzman DM. Anti-A&#x3b2; antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J Clin Invest. 2005;115:428&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC544607</ArticleId><ArticleId IdType="pubmed">15668737</ArticleId></ArticleIdList></Reference><Reference><Citation>Brion JP, Couck AM, Passareiro E, Flament-Durand J. Neurofibrillary tangles of Alzheimer's disease: an immunohistochemical study. J Submicrosc Cytol. 1985;17:89&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">3973960</ArticleId></ArticleIdList></Reference><Reference><Citation>Brody DL, Holtzman DM. Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci. 2008;31:175&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2561172</ArticleId><ArticleId IdType="pubmed">18352830</ArticleId></ArticleIdList></Reference><Reference><Citation>Burbach GJ, Vlachos A, Ghebremedhin E, Del Turco D, Coomaraswamy J, Staufenbiel M, Jucker M, Deller T. Vessel ultrastructure in APP23 transgenic mice after passive anti-A&#x3b2; immunotherapy and subsequent intracerebral hemorrhage. Neurobiol Aging. 2007;28:202&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">16427722</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, May PC, O'Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, DeMattos RB, Holtzman DM. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-&#x3b2; metabolism and half-life. J Neurosci. 2003;23:8844&#x2013;8853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740389</ArticleId><ArticleId IdType="pubmed">14523085</ArticleId></ArticleIdList></Reference><Reference><Citation>Combs CK, Johnson DE, Karlo JC, Cannady SB, Landreth GE. Inflammatory mechanisms in Alzheimer's disease: inhibition of &#x3b2;-amyloid-stimulated proinflammatory responses and neurotoxicity by PPAR&#x3b3; agonists. J Neurosci. 2000;20:558&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772401</ArticleId><ArticleId IdType="pubmed">10632585</ArticleId></ArticleIdList></Reference><Reference><Citation>Combs CK, Karlo JC, Kao SC, Landreth GE. &#x3b2;-Amyloid stimulation of microglia and monocytes results in TNF&#x3b1;-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J Neurosci. 2001;21:1179&#x2013;1188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762255</ArticleId><ArticleId IdType="pubmed">11160388</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Amore JD, Kajdasz ST, McLellan ME, Bacskai BJ, Stern EA, Hyman BT. In vivo multiphoton imaging of a transgenic mouse model of Alzheimer disease reveals marked thioflavine-S-associated alterations in neurite trajectories. J Neuropathol Exp Neurol. 2003;62:137&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">12578223</ArticleId></ArticleIdList></Reference><Reference><Citation>Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F &#x3b2;-amyloid precursor protein. Nature. 1995;373:523&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">7845465</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Alloza M, Ferrara BJ, Dodwell SA, Hickey GA, Hyman BT, Bacskai BJ. A limited role for microglia in antibody mediated plaque clearance in APP mice. Neurobiol Dis. 2007;28:286&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2193669</ArticleId><ArticleId IdType="pubmed">17822910</ArticleId></ArticleIdList></Reference><Reference><Citation>Glenner GG, Henry JH, Fujihara S. Congophilic angiopathy in the pathogenesis of Alzheimer's degeneration. Ann Pathol. 1981;1:120&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">6169353</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung S, Aliberti J, Graemmel P, Sunshine MJ, Kreutzberg GW, Sher A, Littman DR. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol. 2000;20:4106&#x2013;4114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC85780</ArticleId><ArticleId IdType="pubmed">10805752</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenigsknecht J, Landreth G. Microglial phagocytosis of fibrillar &#x3b2;-amyloid through a &#x3b2; 1 integrin-dependent mechanism. J Neurosci. 2004;24:9838&#x2013;9846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730228</ArticleId><ArticleId IdType="pubmed">15525768</ArticleId></ArticleIdList></Reference><Reference><Citation>Lassmann H, Kitz K, Wisniewski HM. Histogenesis of demyelinating lesions in the spinal cord of guinea pigs with chronic relapsing experimental allergic encephalomyelitis. J Neurol Sci. 1981;50:109&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pubmed">7229654</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier M, Peng Y, Jiang L, Seabrook TJ, Carroll MC, Lemere CA. Complement C3 deficiency leads to accelerated amyloid &#x3b2; plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J Neurosci. 2008;28:6333&#x2013;6341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3329761</ArticleId><ArticleId IdType="pubmed">18562603</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandybur TI. The incidence of cerebral amyloid angiopathy in Alzheimer's disease. Neurology. 1975;25:120&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">46597</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT. Rapid appearance and local toxicity of amyloid-&#x3b2; plaques in a mouse model of Alzheimer's disease. Nature. 2008;451:720&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3264491</ArticleId><ArticleId IdType="pubmed">18256671</ArticleId></ArticleIdList></Reference><Reference><Citation>Mildner A, Schmidt H, Nitsche M, Merkler D, Hanisch UK, Mack M, Heikenwalder M, Bruck W, Priller J, Prinz M. Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions. Nat Neurosci. 2007;10:1544&#x2013;1553.</Citation><ArticleIdList><ArticleId IdType="pubmed">18026096</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science. 2005;308:1314&#x2013;1318.</Citation><ArticleIdList><ArticleId IdType="pubmed">15831717</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, Mathews PM, Jucker M. Cerebral hemorrhage after passive anti-A&#x3b2; immunotherapy. Science. 2002;298:1379.</Citation><ArticleIdList><ArticleId IdType="pubmed">12434053</ArticleId></ArticleIdList></Reference><Reference><Citation>Prada CM, Garcia-Alloza M, Betensky RA, Zhang-Nunes SX, Greenberg SM, Bacskai BJ, Frosch MP. Antibody-mediated clearance of amyloid-&#x3b2; peptide from cerebral amyloid angiopathy revealed by quantitative in vivo imaging. J Neurosci. 2007;27:1973&#x2013;1980.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673561</ArticleId><ArticleId IdType="pubmed">17314293</ArticleId></ArticleIdList></Reference><Reference><Citation>Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, Piroozi KS, Jordan WH, Brown DD, Hoffman WP, Holtzman DM, Bales KR, Gitter BD, May PC, Paul SM, DeMattos RB. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid &#x3b2;. J Neurosci. 2005;25:629&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725332</ArticleId><ArticleId IdType="pubmed">15659599</ArticleId></ArticleIdList></Reference><Reference><Citation>Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, Calhoun ME, Jaggi F, Wolburg H, Gengler S, Haass C, Ghetti B, Czech C, Holscher C, Mathews PM, Jucker M. A&#x3b2; 42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 2006;7:940&#x2013;946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1559665</ArticleId><ArticleId IdType="pubmed">16906128</ArticleId></ArticleIdList></Reference><Reference><Citation>Saida T, Saida K, Silberberg DH, Brown MJ. Experimental allergic neuritis induced by galactocerebroside. Ann Neurol. 1981;9(Suppl):87&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">7224618</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeter S, Khan K, Barbour R, Doan M, Chen M, Guido T, Gill D, Basi G, Schenk D, Seubert P, Games D. Immunotherapy reduces vascular amyloid-&#x3b2; in PDAPP mice. J Neurosci. 2008;28:6787&#x2013;6793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670967</ArticleId><ArticleId IdType="pubmed">18596154</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Toward a comprehensive theory for Alzheimer's disease: hypothesis; Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid &#x3b2;-protein. Ann N Y Acad Sci. 2000;924:17&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">11193794</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001;81:741&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Simard AR, Soulet D, Gowing G, Julien JP, Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron. 2006;49:489&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">16476660</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasilevko V, Xu F, Previti ML, Van Nostrand WE, Cribbs DH. Experimental investigation of antibody-mediated clearance mechanisms of amyloid-&#x3b2; in CNS of Tg-SwDI transgenic mice. J Neurosci. 2007;27:13376&#x2013;13383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673094</ArticleId><ArticleId IdType="pubmed">18057195</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinters HV. Cerebral amyloid angiopathy: a critical review. Stroke. 1987;18:311&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">3551211</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, DiCarlo G, Henderson D, Jackson J, Clarke K, Ugen KE, Gordon MN, Morgan D. Intracranially administered anti-A&#x3b2; antibodies reduce &#x3b2;-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci. 2003;23:3745&#x2013;3751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742181</ArticleId><ArticleId IdType="pubmed">12736345</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S, Alamed J, Wilson D, Wilson N, Freeman MJ, Gordon MN, Morgan D. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci. 2004a;24:6144&#x2013;6151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729674</ArticleId><ArticleId IdType="pubmed">15240806</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D. Passive immunotherapy against A&#x3b2; in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation. 2004b;1:24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC539292</ArticleId><ArticleId IdType="pubmed">15588287</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, Alamed J, Gottschall PE, Grimm J, Rosenthal A, Pons J, Ronan V, Symmonds K, Gordon MN, Morgan D. Deglycosylated anti-amyloid-&#x3b2; antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J Neurosci. 2006;26:5340&#x2013;5346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675288</ArticleId><ArticleId IdType="pubmed">16707786</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, Yan F, Lin AH, Lambris JD, Alexander JJ, Quigg RJ, Masliah E. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc Natl Acad Sci U S A. 2002;99:10837&#x2013;10842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125059</ArticleId><ArticleId IdType="pubmed">12119423</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19118172</PMID><DateCompleted><Year>2009</Year><Month>04</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>53</Issue><PubDate><Year>2008</Year><Month>Dec</Month><Day>31</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Deletion of Mint proteins decreases amyloid production in transgenic mouse models of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>14392</StartPage><EndPage>14400</EndPage><MedlinePgn>14392-400</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.2481-08.2008</ELocationID><Abstract><AbstractText>Mints/X11s are neuronal adaptor proteins that bind to amyloid-beta precursor protein (APP). Previous studies suggested that Mint/X11 proteins influence APP cleavage and affect production of pathogenic amyloid-beta (Abeta) peptides in Alzheimer's disease; however, the biological significance of Mint/X11 binding to APP and their possible role in Abeta production remain unclear. Here, we crossed conditional and constitutive Mint1, Mint2, and Mint3 knock-out mice with transgenic mouse models of Alzheimer's disease overproducing human Abeta peptides. We show that deletion of all three individual Mint proteins delays the age-dependent production of amyloid plaque numbers and Abeta40 and Abeta42 levels with loss of Mint2 having the largest effect. Acute conditional deletion of all three Mints in cultured neurons suppresses the accumulation of APP C-terminal fragments and the secretion of ectodomain APP by decreasing beta-cleavage but does not impair subsequent gamma-cleavage. These results suggest that the three Mint/X11 proteins regulate Abeta production by a novel mechanism that may have implications for therapeutic approaches to altering APP cleavage in Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, The University of Texas Southwestern Medical Center, Dallas, Texas 75390-9111, USA. aho1@bu.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xinran</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>S&#xfc;dhof</LastName><ForeName>Thomas C</ForeName><Initials>TC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>K01-AG027311</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-MH069585</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C513072">Apba1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019913">Nuclear Localization Signals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C485184">enhanced green fluorescent protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017353" MajorTopicYN="N">Gene Deletion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019913" MajorTopicYN="N">Nuclear Localization Signals</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">HHMIMS104666</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>1</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>1</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>4</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>6</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19118172</ArticleId><ArticleId IdType="mid">NIHMS104666</ArticleId><ArticleId IdType="pmc">PMC2693334</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2481-08.2008</ArticleId><ArticleId IdType="pii">28/53/14392</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>AtasoyD, Schoch S, Ho A, Nadasy KA, Liu X, Zhang W, Mukherjee K, Nosyreva ED, Fernandez-Chacon R, Missler M, Kavalali ET, S&#xfc;dhof TC (2007) Deletion of CASK in mice is lethal and impairs synaptic function. Proc Natl Acad Sci U S A 104:2525&#x2013;2530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1892970</ArticleId><ArticleId IdType="pubmed">17287346</ArticleId></ArticleIdList></Reference><Reference><Citation>BiedererT, Cao X, S&#xfc;dhof TC, Liu X (2002) Regulation of APP-dependent transcription complexes by Mint/X11s: differential functions of mint isoforms. J Neurosci 22:7340&#x2013;7351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757996</ArticleId><ArticleId IdType="pubmed">12196555</ArticleId></ArticleIdList></Reference><Reference><Citation>BorcheltDR, Ratovitski T, van Lare J, Lee MK, Gonzales V, Jenkins NA, Copeland NG, Price DL, Sisodia SS (1997) Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor protein. Neuron 19:939&#x2013;945.</Citation><ArticleIdList><ArticleId IdType="pubmed">9354339</ArticleId></ArticleIdList></Reference><Reference><Citation>BorgJP, Ooi J, Levy E, Margolis B (1996) The phosphotyrosine interaction domains of X11 and FE65 bind to distinct sites on the YENPTY motif of amyloid precursor protein. Mol Cell Biol 16:6229&#x2013;6241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC231626</ArticleId><ArticleId IdType="pubmed">8887653</ArticleId></ArticleIdList></Reference><Reference><Citation>BorgJP, Yang Y, De Tadd&#xe9;o-Borg M, Margolis B, Turner RS (1998) The X11alpha protein slows cellular amyloid precursor protein processing and reduces Abeta40 and Abeta42 secretion. J Biol Chem 273:14761&#x2013;14766.</Citation><ArticleIdList><ArticleId IdType="pubmed">9614075</ArticleId></ArticleIdList></Reference><Reference><Citation>ButzS, Okamoto M, S&#xfc;dhof TC (1998) A tripartite protein complex with the potential to couple synaptic vesicle exocytosis to cell adhesion in brain. Cell 94:773&#x2013;782.</Citation><ArticleIdList><ArticleId IdType="pubmed">9753324</ArticleId></ArticleIdList></Reference><Reference><Citation>CaoX, S&#xfc;dhof TC (2001) A transcriptionally active complex of APP with Fe65 and histone acetyl-transferase tip60. Science 293:115&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">11441186</ArticleId></ArticleIdList></Reference><Reference><Citation>CupersP, Orlans I, Craessaerts K, Annaert W, De Strooper B (2001) The amyloid precursor protein (APP)-cytoplasmic fragment generated by gamma-secretase is rapidly degraded but distributes partially in a nuclear fraction of neurons in culture. J Neurochem 78:1168&#x2013;1178.</Citation><ArticleIdList><ArticleId IdType="pubmed">11553691</ArticleId></ArticleIdList></Reference><Reference><Citation>De StrooperB, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, Von Figura K, Van Leuven F (1998) Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391:387&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pubmed">9450754</ArticleId></ArticleIdList></Reference><Reference><Citation>GlennerGG, Wong CW (1984) Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120:885&#x2013;890.</Citation><ArticleIdList><ArticleId IdType="pubmed">6375662</ArticleId></ArticleIdList></Reference><Reference><Citation>HaassC, De Strooper B (1999) The presenilins in Alzheimer's disease-proteolysis holds the key. Science 286:917&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">10542139</ArticleId></ArticleIdList></Reference><Reference><Citation>HaassC, Koo EH, Teplow DB, Selkoe DJ (1994) Polarized secretion of &#x3b2;-amyloid precursor protein and amyloid &#x3b2;-peptide in MDCK cells. Proc Natl Acad Sci U S A 91:1564&#x2013;1568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC43200</ArticleId><ArticleId IdType="pubmed">8108445</ArticleId></ArticleIdList></Reference><Reference><Citation>HeX, Cooley K, Chung CH, Dashti N, Tang J (2007) Apolipoprotein receptor 2 and X11&#x3b1;/&#x3b2; mediate apolipoprotein E-induced endocytosis of amyloid-&#x3b2; precursor protein and &#x3b2;-secretase, leading to amyloid-&#x3b2; production. J Neurosci 27:4052&#x2013;4060.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672528</ArticleId><ArticleId IdType="pubmed">17428983</ArticleId></ArticleIdList></Reference><Reference><Citation>HillK, Li Y, Bennett M, McKay M, Zhu X, Shern J, Torre E, Lah JJ, Levey AI, Kahn RA (2003) Munc18 interacting proteins: ADP-ribosylation factor-dependent coat proteins that regulate the traffic of &#x3b2;-Alzheimer's precursor protein. J Biol Chem 278:36032&#x2013;36040.</Citation><ArticleIdList><ArticleId IdType="pubmed">12842896</ArticleId></ArticleIdList></Reference><Reference><Citation>HoA, Morishita W, Hammer RE, Malenka RC, Sudhof TC (2003) A role for Mints in transmitter release: Mint 1 knockout mice exhibit impaired GABAergic synaptic transmission. Proc Natl Acad Sci U S A 100:1409&#x2013;1414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC298786</ArticleId><ArticleId IdType="pubmed">12547917</ArticleId></ArticleIdList></Reference><Reference><Citation>HoA, Morishita W, Atasoy D, Liu X, Tabuchi K, Hammer RE, Malenka RC, S&#xfc;dhof TC (2006) Genetic analysis of Mint/X11 proteins: essential presynaptic functions of a neuronal adaptor protein family. J Neurosci 26:13089&#x2013;13101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674967</ArticleId><ArticleId IdType="pubmed">17167098</ArticleId></ArticleIdList></Reference><Reference><Citation>IkinAF, Annaert WG, Takei K, De Camilli P, Jahn R, Greengard P, Buxbaum JD (1996) Alzheimer amyloid protein precursor is localized in nerve terminal preparations to Rab5-containing vesicular organelles distinct from those implicated in the synaptic vesicle pathway. J Biol Chem 271:31783&#x2013;31786.</Citation><ArticleIdList><ArticleId IdType="pubmed">8943215</ArticleId></ArticleIdList></Reference><Reference><Citation>KamenetzF, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R (2003) APP processing and synaptic function. Neuron 37:925&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>KavalaliET, Klingauf J, Tsien RW (1999) Activity-dependent regulation of synaptic clustering in a hippocampal culture system. Proc Natl Acad Sci U S A 96:12893&#x2013;12900.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC23151</ArticleId><ArticleId IdType="pubmed">10536019</ArticleId></ArticleIdList></Reference><Reference><Citation>KimberlyWT, Zheng JB, Gu&#xe9;nette SY, Selkoe DJ (2001) The intracellular domain of the beta-amyloid precursor protein is stabilized by Fe65 and translocates to the nucleus in a notch-like manner. J Biol Chem 276:40288&#x2013;40292.</Citation><ArticleIdList><ArticleId IdType="pubmed">11544248</ArticleId></ArticleIdList></Reference><Reference><Citation>LauKF, McLoughlin DM, Standen C, Miller CC (2000) X11 alpha and X11 beta interact with presenilin-1 via their PDZ domains. Mol Cell Neurosci 16:557&#x2013;565.</Citation><ArticleIdList><ArticleId IdType="pubmed">11083918</ArticleId></ArticleIdList></Reference><Reference><Citation>LeeJH, Lau KF, Perkinton MS, Standen CL, Shemilt SJ, Mercken L, Cooper JD, McLoughlin DM, Miller CC (2003) The neuronal adaptor protein X11&#x3b1; reduces A&#x3b2; levels in the brains of Alzheimer's APPswe Tg2576 transgenic mice. J Biol Chem 278:47025&#x2013;47029.</Citation><ArticleIdList><ArticleId IdType="pubmed">12970358</ArticleId></ArticleIdList></Reference><Reference><Citation>LeeJH, Lau KF, Perkinton MS, Standen CL, Rogelj B, Falinska A, McLoughlin DM, Miller CCJ (2004) The neuronal adaptor protein X11&#x3b2; reduces amyloid &#x3b2;-protein levels and amyloid plaque formation in the brains of transgenic mice. J Biol Chem 279:49099&#x2013;49104.</Citation><ArticleIdList><ArticleId IdType="pubmed">15347685</ArticleId></ArticleIdList></Reference><Reference><Citation>Marquez-SterlingNR, Lo AC, Sisodia SS, Koo EH (1997) Trafficking of cell-surface beta-amyloid precursor protein: evidence that a sorting intermediate participates in synaptic vesicle recycling. J Neurosci 17:140&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793693</ArticleId><ArticleId IdType="pubmed">8987743</ArticleId></ArticleIdList></Reference><Reference><Citation>McLoughlinDM, Miller CC (1996) The intracellular cytoplasmic domain of the Alzheimer's disease amyloid precursor protein interacts with phosphotyrosine-binding domain proteins in the yeast two-hybrid system. FEBS Lett 397:197&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">8955346</ArticleId></ArticleIdList></Reference><Reference><Citation>MuckeL, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L (2000) High-level neuronal expression of A&#x3b2;1&#x2013;42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>MuellerHT, Borg JP, Margolis B, Turner RS (2000) Modulation of amyloid precursor protein metabolism by X11&#x3b1;/Mint-1. J Biol Chem 275:39302&#x2013;39306.</Citation><ArticleIdList><ArticleId IdType="pubmed">11010978</ArticleId></ArticleIdList></Reference><Reference><Citation>NordstedtC, Caporaso GL, Thyberg J, Gandy SE, Greengard P (1993) Identification of the Alzheimer beta/A4 amyloid precursor protein in clathrin-coated vesicles purified from PC12 cells. J Biol Chem 268:608&#x2013;612.</Citation><ArticleIdList><ArticleId IdType="pubmed">8416966</ArticleId></ArticleIdList></Reference><Reference><Citation>OkamotoM, S&#xfc;dhof TC (1997) Mints, Munc18-interacting proteins in synaptic vesicle exocytosis. J Biol Chem 272:31459&#x2013;31464.</Citation><ArticleIdList><ArticleId IdType="pubmed">9395480</ArticleId></ArticleIdList></Reference><Reference><Citation>OkamotoM, S&#xfc;dhof TC (1998) Mint3: a ubiquitous mint isoform that does not bind to munc18&#x2013;1 or 2. Eur J Cell Biol 77:161&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">9860131</ArticleId></ArticleIdList></Reference><Reference><Citation>SaitoY, Sano Y, Vassar R, Gandy S, Nakaya T, Yamamoto T, Suzuki T (2008) X11 proteins regulate the translocation of APP into detergent resistant membrane and suppress the amyloidogenic cleavage of APP by BACE in brain. J Biol Chem, Advance online publication. Retrieved December 4, 2008.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2602917</ArticleId><ArticleId IdType="pubmed">18845544</ArticleId></ArticleIdList></Reference><Reference><Citation>SanoY, Syuzo-Takabatake A, Nakaya T, Saito Y, Tomita S, Itohara S, Suzuki T (2006) Enhanced amyloidogenic metabolism of the amyloid &#x3b2;-protein precursor in the X11L-deficient mouse brain. J Biol Chem 281:37853&#x2013;37860.</Citation><ArticleIdList><ArticleId IdType="pubmed">17032642</ArticleId></ArticleIdList></Reference><Reference><Citation>SastreM, Turner RS, Levy E (1998) X11 interaction with beta-amyloid precursor protein modulates its cellular stabilization and reduces amyloid beta-protein secretion. J Biol Chem 273:22351&#x2013;22357.</Citation><ArticleIdList><ArticleId IdType="pubmed">9712855</ArticleId></ArticleIdList></Reference><Reference><Citation>SelkoeDJ (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81:741&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>SisodiaSS, St George-Hyslop PH (2002) &#x3b3;-secretase, notch, A&#x3b2; and Alzheimer's disease: where do the presenilins fit in? Nat Rev Neurosci 3:281&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">11967558</ArticleId></ArticleIdList></Reference><Reference><Citation>StruhlG, Adachi A (2000) Requirements for presenilin-dependent cleavage of notch and other transmembrane proteins. Mol Cell 6:625&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pubmed">11030342</ArticleId></ArticleIdList></Reference><Reference><Citation>XieZ, Romano DM, Tanzi RE (2005) RNA interference-mediated silencing of X11alpha and X11beta attenuates amyloid beta-protein levels via differential effects on beta-amyloid precursor protein processing. J Biol Chem 280:15413&#x2013;15421.</Citation><ArticleIdList><ArticleId IdType="pubmed">15699037</ArticleId></ArticleIdList></Reference><Reference><Citation>YuC, Kim SH, Ikeuchi T, Xu H, Gasparini L, Wang R, Sisodia SS (2001) Characterization of a presenilin-mediated amyloid precursor protein carboxyl-terminal fragment gamma. Evidence for distinct mechanisms involved in gamma-secretase processing of the APP and Notch1 transmembrane domains. J Biol Chem 276:43756&#x2013;43760.</Citation><ArticleIdList><ArticleId IdType="pubmed">11583985</ArticleId></ArticleIdList></Reference><Reference><Citation>ZhangZ, Lee CH, Mandiyan V, Borg JP, Margolis B, Schlessinger J, Kuriyan J (1997) Sequence-specific recognition of the internalization motif of the Alzheimer's amyloid precursor protein by the X11 PTB domain. EMBO J 16:6141&#x2013;6150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1326298</ArticleId><ArticleId IdType="pubmed">9321393</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19118188</PMID><DateCompleted><Year>2009</Year><Month>04</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>53</Issue><PubDate><Year>2008</Year><Month>Dec</Month><Day>31</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus.</ArticleTitle><Pagination><StartPage>14537</StartPage><EndPage>14545</EndPage><MedlinePgn>14537-45</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.2692-08.2008</ELocationID><Abstract><AbstractText>Amyloid-beta (Abeta) peptides are produced in high amounts during Alzheimer's disease, causing synaptic and memory dysfunction. However, they are also released in lower amounts in normal brains throughout life during synaptic activity. Here we show that low picomolar concentrations of a preparation containing both Abeta(42) monomers and oligomers cause a marked increase of hippocampal long-term potentiation, whereas high nanomolar concentrations lead to the well established reduction of potentiation. Picomolar levels of Abeta(42) also produce a pronounced enhancement of both reference and contextual fear memory. The mechanism of action of picomolar Abeta(42) on both synaptic plasticity and memory involves alpha7-containing nicotinic acetylcholine receptors. These findings strongly support a model for Abeta effects in which low concentrations play a novel positive, modulatory role on neurotransmission and memory, whereas high concentrations play the well known detrimental effect culminating in dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Puzzo</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pathology, Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Privitera</LastName><ForeName>Lucia</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Leznik</LastName><ForeName>Elena</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>F&#xe0;</LastName><ForeName>Mauro</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Staniszewski</LastName><ForeName>Agnieszka</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Palmeri</LastName><ForeName>Agostino</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Arancio</LastName><ForeName>Ottavio</ForeName><Initials>O</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS040045</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS049442</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002038">Bungarotoxins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C579167">Chrna7 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C579166">Chrna7 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018691">Excitatory Amino Acid Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018733">Nicotinic Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011978">Receptors, Nicotinic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064569">alpha7 Nicotinic Acetylcholine Receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>6EE945D3OK</RegistryNumber><NameOfSubstance UI="D008464">Mecamylamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>76726-92-6</RegistryNumber><NameOfSubstance UI="D015763">2-Amino-5-phosphonovalerate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015763" MajorTopicYN="N">2-Amino-5-phosphonovalerate</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002038" MajorTopicYN="N">Bungarotoxins</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004558" MajorTopicYN="N">Electric Stimulation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018691" MajorTopicYN="N">Excitatory Amino Acid Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019706" MajorTopicYN="N">Excitatory Postsynaptic Potentials</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008464" MajorTopicYN="N">Mecamylamine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018733" MajorTopicYN="N">Nicotinic Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018408" MajorTopicYN="N">Patch-Clamp Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011978" MajorTopicYN="N">Receptors, Nicotinic</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064569" MajorTopicYN="N">alpha7 Nicotinic Acetylcholine Receptor</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>1</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>1</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>4</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>6</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19118188</ArticleId><ArticleId IdType="mid">NIHMS85635</ArticleId><ArticleId IdType="pmc">PMC2673049</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2692-08.2008</ArticleId><ArticleId IdType="pii">28/53/14537</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>ArakiW, Kitaguchi N, Tokushima Y, Ishii K, Aratake H, Shimohama S, Nakamura S, Kimura J (1991) Trophic effect of beta-amyloid precursor protein on cerebral cortical neurons in culture. Biochem Biophys Res Commun 181:265&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pubmed">1958195</ArticleId></ArticleIdList></Reference><Reference><Citation>ArancioO, Chao MV (2007) Neurotrophins, synaptic plasticity and dementia. Curr Opin Neurobiol 17:325&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pubmed">17419049</ArticleId></ArticleIdList></Reference><Reference><Citation>CaoX, S&#xfc;dhof TC (2001) A transcriptionally [correction of transcriptively] active complex of APP with Fe65 and histone acetyltransferase Tip60. Science 293:115&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">11441186</ArticleId></ArticleIdList></Reference><Reference><Citation>CirritoJR, May PC, O'Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, DeMattos RB, Holtzman DM (2003) In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-&#x3b2; metabolism and half-life. J Neurosci 23:8844&#x2013;8853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740389</ArticleId><ArticleId IdType="pubmed">14523085</ArticleId></ArticleIdList></Reference><Reference><Citation>CirritoJR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM (2005) Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 48:913&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>CitronM, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, Johnson-Wood K, Lee M, Seubert P, Davis A, Kholodenko D, Motter R, Sherrington R, Perry B, Yao H, Strome R, Lieberburg I, Rommens J, Kim S, Schenk D, et al (1997) Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med 3:67&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">8986743</ArticleId></ArticleIdList></Reference><Reference><Citation>DawsonGR, Seabrook GR, Zheng H, Smith DW, Graham S, O'Dowd G, Bowery BJ, Boyce S, Trumbauer ME, Chen HY, Van der Ploeg LH, Sirinathsinghji DJ (1999) Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the beta-amyloid precursor protein. Neuroscience 90:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">10188929</ArticleId></ArticleIdList></Reference><Reference><Citation>DewachterI, Ris L, Croes S, Borghgraef P, Voets T, Nilius B, Godaux E, Van Leuven F (2006) Differential affects of presenilin-1 deficiency and mutant presenilin-1 on synaptic activity. In: Alzheimer's Association 10th International Conference on Alzheimer's Disease and Related Disorders p S58, O53-03-08. Madrid. Chicago: Alzheimer's Association.</Citation></Reference><Reference><Citation>DoughertyJJ, Wu J, Nichols RA (2003) &#x3b2;-Amyloid regulation of presynaptic nicotinic receptors in rat hippocampus and neocortex. J Neurosci 23:6740&#x2013;6747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740736</ArticleId><ArticleId IdType="pubmed">12890766</ArticleId></ArticleIdList></Reference><Reference><Citation>FreedmanR, Wetmore C, Str&#xf6;mberg I, Leonard S, Olson L (1993) &#x3b1;-Bungarotoxin binding to hippocampal interneurons: immunocytochemical characterization and effects on growth factor expression. J Neurosci 13:1965&#x2013;1975.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6576554</ArticleId><ArticleId IdType="pubmed">8478687</ArticleId></ArticleIdList></Reference><Reference><Citation>FurukawaK, Sopher BL, Rydel RE, Begley JG, Pham DG, Martin GM, Fox M, Mattson MP (1996) Increased activity-regulating and neuroprotective efficacy of alpha-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain. J Neurochem 67:1882&#x2013;1896.</Citation><ArticleIdList><ArticleId IdType="pubmed">8863493</ArticleId></ArticleIdList></Reference><Reference><Citation>GaoY, Pimplikar SW (2001) The gamma-secretase-cleaved C-terminal fragment of amyloid precursor protein mediates signaling to the nucleus. Proc Natl Acad Sci U S A 98:14979&#x2013;14984.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC64969</ArticleId><ArticleId IdType="pubmed">11742091</ArticleId></ArticleIdList></Reference><Reference><Citation>GenzenJR, McGehee DS (2003) Short- and long-term enhancement of excitatory transmission in the spinal cord dorsal horn by nicotinic acetylcholine receptors. Proc Natl Acad Sci U S A 100:6807&#x2013;6812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC164528</ArticleId><ArticleId IdType="pubmed">12748382</ArticleId></ArticleIdList></Reference><Reference><Citation>GirodR, Barazangi N, McGehee D, Role LW (2000) Facilitation of glutamatergic neurotransmission by presynaptic nicotinic acetylcholine receptors. Neuropharmacology 39:2715&#x2013;2725.</Citation><ArticleIdList><ArticleId IdType="pubmed">11044742</ArticleId></ArticleIdList></Reference><Reference><Citation>GrayR, Rajan AS, Radcliffe KA, Yakehiro M, Dani JA (1996) Hippocampal synaptic transmission enhanced by low concentrations of nicotine. Nature 383:713&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pubmed">8878480</ArticleId></ArticleIdList></Reference><Reference><Citation>HaassC, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8:101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>IshidaA, Furukawa K, Keller JN, Mattson MP (1997) Secreted form of beta-amyloid precursor protein shifts the frequency dependency for induction of LTD, and enhances LTP in hippocampal slices. Neuroreport 8:2133&#x2013;2137.</Citation><ArticleIdList><ArticleId IdType="pubmed">9243598</ArticleId></ArticleIdList></Reference><Reference><Citation>JiD, Lape R, Dani JA (2001) Timing and location of nicotinic activity enhances or depresses hippocampal synaptic plasticity. Neuron 31:131&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pubmed">11498056</ArticleId></ArticleIdList></Reference><Reference><Citation>JonesS, Sudweeks S, Yakel JL (1999) Nicotinic receptors in the brain: correlating physiology with function. Trends Neurosci 22:555&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pubmed">10542436</ArticleId></ArticleIdList></Reference><Reference><Citation>KamenetzF, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R (2003) APP processing and synaptic function. Neuron 37:925&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>KametaniF (2008) Epsilon-secretase: reduction of amyloid precursor protein epsilon-site cleavage in Alzheimer's disease. Curr Alzheimer Res 5:165&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">18393801</ArticleId></ArticleIdList></Reference><Reference><Citation>KimberlyWT, Zheng JB, Gu&#xe9;nette SY, Selkoe DJ (2001) The intracellular domain of the beta-amyloid precursor protein is stabilized by Fe65 and translocates to the nucleus in a notch-like manner. J Biol Chem 276:40288&#x2013;40292.</Citation><ArticleIdList><ArticleId IdType="pubmed">11544248</ArticleId></ArticleIdList></Reference><Reference><Citation>LairdFM, Cai H, Savonenko AV, Farah MH, He K, Melnikova T, Wen H, Chiang HC, Xu G, Koliatsos VE, Borchelt DR, Price DL, Lee HK, Wong PC (2005) BACE1, a major determinant of selective vulnerability of the brain to amyloid-&#x3b2; amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci 25:11693&#x2013;11709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2564291</ArticleId><ArticleId IdType="pubmed">16354928</ArticleId></ArticleIdList></Reference><Reference><Citation>LeissringMA, Murphy MP, Mead TR, Akbari Y, Sugarman MC, Jannatipour M, Anliker B, M&#xfc;ller U, Saftig P, De Strooper B, Wolfe MS, Golde TE, LaFerla FM (2002) A physiologic signaling role for the gamma-secretase-derived intracellular fragment of APP. Proc Natl Acad Sci U S A 99:4697&#x2013;4702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC123710</ArticleId><ArticleId IdType="pubmed">11917117</ArticleId></ArticleIdList></Reference><Reference><Citation>LevinED, Simon BB (1998) Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology (Berl) 138:217&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pubmed">9725745</ArticleId></ArticleIdList></Reference><Reference><Citation>LewczukP, Beck G, Esselmann H, Bruckmoser R, Zimmermann R, Fiszer M, Bibl M, Maler JM, Kornhuber J, Wiltfang J (2006) Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides. Clin Chem 52:332&#x2013;334.</Citation><ArticleIdList><ArticleId IdType="pubmed">16449222</ArticleId></ArticleIdList></Reference><Reference><Citation>LismanJ, Raghavachari S (2006) A unified model of the presynaptic and postsynaptic changes during LTP at CA1 synapses. Sci STKE 2006:re11.</Citation><ArticleIdList><ArticleId IdType="pubmed">17033044</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez-ToledanoMA, Shelanski ML (2004) Neurogenic effect of &#x3b2;-amyloid peptide in the development of neural stem cells. J Neurosci 24:5439&#x2013;5444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729298</ArticleId><ArticleId IdType="pubmed">15190117</ArticleId></ArticleIdList></Reference><Reference><Citation>MaH, Lesn&#xe9; S, Kotilinek L, Steidl-Nichols JV, Sherman M, Younkin L, Younkin S, Forster C, Sergeant N, Delacourte A, Vassar R, Citron M, Kofuji P, Boland LM, Ashe KH (2007) Involvement of beta-site APP cleaving enzyme 1 (BACE1) in amyloid precursor protein-mediated enhancement of memory and activity-dependent synaptic plasticity. Proc Natl Acad Sci U S A 104:8167&#x2013;8172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1859992</ArticleId><ArticleId IdType="pubmed">17470798</ArticleId></ArticleIdList></Reference><Reference><Citation>MastrangeloP, Mathews PM, Chishti MA, Schmidt SD, Gu Y, Yang J, Mazzella MJ, Coomaraswamy J, Horne P, Strome B, Pelly H, Levesque G, Ebeling C, Jiang Y, Nixon RA, Rozmahel R, Fraser PE, St George-Hyslop P, Carlson GA, Westaway D (2005) Dissociated phenotypes in presenilin transgenic mice define functionally distinct gamma-secretases. Proc Natl Acad Sci U S A 102:8972&#x2013;8977.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1149500</ArticleId><ArticleId IdType="pubmed">15951428</ArticleId></ArticleIdList></Reference><Reference><Citation>MattsonMP (1994) Secreted forms of beta-amyloid precursor protein modulate dendrite outgrowth and calcium responses to glutamate in cultured embryonic hippocampal neurons. J Neurobiol 25:439&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pubmed">7915758</ArticleId></ArticleIdList></Reference><Reference><Citation>MezianeH, Dodart JC, Mathis C, Little S, Clemens J, Paul SM, Ungerer A (1998) Memory-enhancing effects of secreted forms of the beta-amyloid precursor protein in normal and amnestic mice. Proc Natl Acad Sci U S A 95:12683&#x2013;12688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22891</ArticleId><ArticleId IdType="pubmed">9770546</ArticleId></ArticleIdList></Reference><Reference><Citation>MuckeL, Masliah E, Johnson WB, Ruppe MD, Alford M, Rockenstein EM, Forss-Petter S, Pietropaolo M, Mallory M, Abraham CR (1994) Synaptotrophic effects of human amyloid beta protein precursors in the cortex of transgenic mice. Brain Res 666:151&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">7882025</ArticleId></ArticleIdList></Reference><Reference><Citation>PawlikM, Sastre M, Calero M, Mathews PM, Schmidt SD, Nixon RA, Levy E (2004) Overexpression of human cystatin C in transgenic mice does not affect levels of endogenous brain amyloid beta peptide. J Mol Neurosci 22:13&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">14742906</ArticleId></ArticleIdList></Reference><Reference><Citation>PaxinosG (1998) Mouse brain in stereotaxic coordinates, Ed 2. New York: Academic.</Citation></Reference><Reference><Citation>PhillipsRG, LeDoux JE (1992) Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. Behav Neurosci 106:274&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">1590953</ArticleId></ArticleIdList></Reference><Reference><Citation>PhinneyAL, Calhoun ME, Wolfer DP, Lipp HP, Zheng H, Jucker M (1999) No hippocampal neuron or synaptic bouton loss in learning-impaired aged beta-amyloid precursor protein-null mice. Neuroscience 90:1207&#x2013;1216.</Citation><ArticleIdList><ArticleId IdType="pubmed">10338291</ArticleId></ArticleIdList></Reference><Reference><Citation>PhinneyAL, Drisaldi B, Schmidt SD, Lugowski S, Coronado V, Liang Y, Horne P, Yang J, Sekoulidis J, Coomaraswamy J, Chishti MA, Cox DW, Mathews PM, Nixon RA, Carlson GA, St George-Hyslop P, Westaway D (2003) In vivo reduction of amyloid-beta by a mutant copper transporter. Proc Natl Acad Sci U S A 100:14193&#x2013;14198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC283568</ArticleId><ArticleId IdType="pubmed">14617772</ArticleId></ArticleIdList></Reference><Reference><Citation>PlantLD, Boyle JP, Smith IF, Peers C, Pearson HA (2003) The production of amyloid &#x3b2; peptide is a critical requirement for the viability of central neurons. J Neurosci 23:5531&#x2013;5535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741264</ArticleId><ArticleId IdType="pubmed">12843253</ArticleId></ArticleIdList></Reference><Reference><Citation>PuzzoD, Vitolo O, Trinchese F, Jacob JP, Palmeri A, Arancio O (2005) Amyloid-&#x3b2; peptide inhibits activation of the nitric oxide/cGMP/cAMP-responsive element-binding protein pathway during hippocampal synaptic plasticity. J Neurosci 25:6887&#x2013;6897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725343</ArticleId><ArticleId IdType="pubmed">16033898</ArticleId></ArticleIdList></Reference><Reference><Citation>RadcliffeKA, Dani JA (1998) Nicotinic stimulation produces multiple forms of increased glutamatergic synaptic transmission. J Neurosci 18:7075&#x2013;7083.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793238</ArticleId><ArticleId IdType="pubmed">9736631</ArticleId></ArticleIdList></Reference><Reference><Citation>RozmahelR, Huang J, Chen F, Liang Y, Nguyen V, Ikeda M, Levesque G, Yu G, Nishimura M, Mathews P, Schmidt SD, Mercken M, Bergeron C, Westaway D, St George-Hyslop P (2002) Normal brain development in PS1 hypomorphic mice with markedly reduced gamma-secretase cleavage of betaAPP. Neurobiol Aging 23:187&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">11804702</ArticleId></ArticleIdList></Reference><Reference><Citation>SauraCA, Choi SY, Beglopoulos V, Malkani S, Zhang D, Shankaranarayana Rao BS, Chattarji S, Kelleher RJ 3rd, Kandel ER, Duff K, Kirkwood A, Shen J (2004) Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron 42:23&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">15066262</ArticleId></ArticleIdList></Reference><Reference><Citation>SchenkF, Morris RG (1985) Dissociation between components of spatial memory in rats after recovery from the effects of retrohippocampal lesions. Exp Brain Res 58:11&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">3987843</ArticleId></ArticleIdList></Reference><Reference><Citation>SchmidtSD, Nixon RA, Mathews PM (2005) ELISA method for measurement of amyloid-beta levels. Methods Mol Biol 299:279&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pubmed">15980612</ArticleId></ArticleIdList></Reference><Reference><Citation>SeabrookGR, Smith DW, Bowery BJ, Easter A, Reynolds T, Fitzjohn SM, Morton RA, Zheng H, Dawson GR, Sirinathsinghji DJ, Davies CH, Collingridge GL, Hill RG (1999) Mechanisms contributing to the deficits in hippocampal synaptic plasticity in mice lacking amyloid precursor protein. Neuropharmacology 38:349&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pubmed">10219973</ArticleId></ArticleIdList></Reference><Reference><Citation>SmallDH, Mok SS, Bornstein JC (2001) Alzheimer's disease and Abeta toxicity: from top to bottom. Nature reviews 2:595&#x2013;598.</Citation><ArticleIdList><ArticleId IdType="pubmed">11484003</ArticleId></ArticleIdList></Reference><Reference><Citation>SmallDH, Maksel D, Kerr ML, Ng J, Hou X, Chu C, Mehrani H, Unabia S, Azari MF, Loiacono R, Aguilar MI, Chebib M (2007) The beta-amyloid protein of Alzheimer's disease binds to membrane lipids but does not bind to the alpha7 nicotinic acetylcholine receptor. J Neurochem 101:1527&#x2013;1538.</Citation><ArticleIdList><ArticleId IdType="pubmed">17286584</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith-SwintoskyVL, Pettigrew LC, Craddock SD, Culwell AR, Rydel RE, Mattson MP (1994) Secreted forms of beta-amyloid precursor protein protect against ischemic brain injury. J Neurochem 63:781&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pubmed">8035204</ArticleId></ArticleIdList></Reference><Reference><Citation>WangHY, Lee DH, D'Andrea MR, Peterson PA, Shank RP, Reitz AB (2000) beta-Amyloid(1&#x2013;42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J Biol Chem 275:5626&#x2013;5632.</Citation><ArticleIdList><ArticleId IdType="pubmed">10681545</ArticleId></ArticleIdList></Reference><Reference><Citation>YanknerBA, Duffy LK, Kirschner DA (1990) Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 250:279&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">2218531</ArticleId></ArticleIdList></Reference><Reference><Citation>YaoJ, Petanceska SS, Montine TJ, Holtzman DM, Schmidt SD, Parker CA, Callahan MJ, Lipinski WJ, Bisgaier CL, Turner BA, Nixon RA, Martins RN, Ouimet C, Smith JD, Davies P, Laska E, Ehrlich ME, Walker LC, Mathews PM, Gandy S (2004) Aging, gender and APOE isotype modulate metabolism of Alzheimer's Abeta peptides and F-isoprostanes in the absence of detectable amyloid deposits. J Neurochem 90:1011&#x2013;1018.</Citation><ArticleIdList><ArticleId IdType="pubmed">15287908</ArticleId></ArticleIdList></Reference><Reference><Citation>ZuckerRS, Regehr WG (2002) Short-term synaptic plasticity. Annu Rev Physiol 64:355&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">11826273</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19118814</PMID><DateCompleted><Year>2009</Year><Month>02</Month><Day>05</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-6605</ISSN><JournalIssue CitedMedium="Internet"><Volume>84</Volume><Issue>1</Issue><PubDate><Year>2009</Year><Month>Jan</Month></PubDate></JournalIssue><Title>American journal of human genetics</Title><ISOAbbreviation>Am J Hum Genet</ISOAbbreviation></Journal><ArticleTitle>Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease.</ArticleTitle><Pagination><StartPage>35</StartPage><EndPage>43</EndPage><MedlinePgn>35-43</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajhg.2008.12.008</ELocationID><Abstract><AbstractText>Only Apolipoprotein E polymorphisms have been consistently associated with the risk of late-onset Alzheimer disease (LOAD), but they represent only a minority of the underlying genetic effect. To identify additional LOAD risk loci, we performed a genome-wide association study (GWAS) on 492 LOAD cases and 498 cognitive controls using Illumina's HumanHap550 beadchip. An additional 238 cases and 220 controls were used as a validation data set for single-nucleotide polymorphisms (SNPs) that met genome-wide significance. To validate additional associated SNPs (p &lt; 0.0001) and nominally associated candidate genes, we imputed SNPs from our GWAS using a previously published LOAD GWAS(1) and the IMPUTE program. Association testing was performed with the Cochran-Armitage trend test and logistic regression, and genome-wide significance was determined with the False Discovery Rate-Beta Uniform Mixture method. Extensive quality-control methods were performed at both the sample and the SNP level. The GWAS confirmed the known APOE association and identified association with a 12q13 locus at genome-wide significance; the 12q13 locus was confirmed in our validation data set. Four additional highly associated signals (1q42, 4q28, 6q14, 19q13) were replicated with the use of the imputed data set, and six candidate genes had SNPs with nominal association in both the GWAS and the joint imputated data set. These results help to further define the genetic architecture of LOAD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Beecham</LastName><ForeName>Gary W</ForeName><Initials>GW</Initials><AffiliationInfo><Affiliation>Miami Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, FL 33101, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Eden R</ForeName><Initials>ER</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yi-Ju</ForeName><Initials>YJ</Initials></Author><Author ValidYN="Y"><LastName>Slifer</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Gilbert</LastName><ForeName>John R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Haines</LastName><ForeName>Jonathan L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Pericak-Vance</LastName><ForeName>Margaret A</ForeName><Initials>MA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG19757</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS031153</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS31153</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027944</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG20135</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG020135</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG019757</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Hum Genet</MedlineTA><NlmUniqueID>0370475</NlmUniqueID><ISSNLinking>0002-9297</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002881" MajorTopicYN="N">Chromosomes, Human, Pair 12</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015894" MajorTopicYN="Y">Genome, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="Y">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2008</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>1</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>1</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>2</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>7</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19118814</ArticleId><ArticleId IdType="pmc">PMC2668056</ArticleId><ArticleId IdType="doi">10.1016/j.ajhg.2008.12.008</ArticleId><ArticleId IdType="pii">S0002-9297(08)00629-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Reiman E.M., Webster J.A., Myers A.J., Hardy J., Dunckley T., Zismann V.L., Joshipura K.D., Pearson J.V., Hu-Lince D., Huentelman M.J. GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron. 2007;5:713&#x2013;720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2587162</ArticleId><ArticleId IdType="pubmed">17553421</ArticleId></ArticleIdList></Reference><Reference><Citation>Pericak-Vance M.A., Bebout J.L., Gaskell P.C., Yamaoka L.H., Hung W.Y., Alberts M.J., Walker A.P., Bartlett R.J., Haynes C.S., Welsh K.A. Linkage studies in familial Alzheimer's disease: Evidence for chromosome 19 linkage. Am. J. Hum. Genet. 1991;48:1034&#x2013;1050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1683100</ArticleId><ArticleId IdType="pubmed">2035524</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders A.M., Strittmatter W.J., Schmechel D., George-Hyslop P.H., Pericak-Vance M.A., Joo S.H., Rosi B.L., Gusella J.F., Crapper-MacLachlan D.R., Alberts M.J. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993;43:1467&#x2013;1472.</Citation><ArticleIdList><ArticleId IdType="pubmed">8350998</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter W.J., Saunders A.M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G.S., Roses A.D. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. USA. 1993;90:1977&#x2013;1981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46003</ArticleId><ArticleId IdType="pubmed">8446617</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;512:921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergen A.L. Heredity in dementia of the Alzheimer type. Clin. Genet. 1994;46:144&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">7988071</ArticleId></ArticleIdList></Reference><Reference><Citation>Lange C., Blacker D., Laird N.M. Family-based association tests for survival and times-to-onset analysis. Stat. Med. 2004;30:179&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">14716720</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L., McQueen M.B., Mullin K., Blacker D., Tanzi R.E. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat. Genet. 2007;1:17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">17192785</ArticleId></ArticleIdList></Reference><Reference><Citation>Maraganore D.M., De Andrade M., Lesnick T.G., Strain K.J., Farrer M.J., Rocca W.A., Pant P.V., Frazer K.A., Cox D.R., Ballinger D.G. High-resolution whole-genome association study of Parkinson disease. Am. J. Hum. Genet. 2005;77:685&#x2013;693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1271381</ArticleId><ArticleId IdType="pubmed">16252231</ArticleId></ArticleIdList></Reference><Reference><Citation>Herbert A., Liu C., Karamohamed S., Liu J., Manning A., Fox C.S., Meigs J.B., Cupples L.A. BMI modifies associations of IL-6 genotypes with insulin resistance: the Framingham Study. Obesity (Silver Spring) 2006;8:1454&#x2013;1461.</Citation><ArticleIdList><ArticleId IdType="pubmed">16988089</ArticleId></ArticleIdList></Reference><Reference><Citation>Duerr R.H., Taylor K.D., Brant S.R., Rioux J.D., Silverberg M.S., Daly M.J., Steinhart A.H., Abraham C., Regueiro M., Griffiths A. A genome-wide association study identifies il23r as an inflammatory bowel disease gene. Science. 2006;314:1461&#x2013;1463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4410764</ArticleId><ArticleId IdType="pubmed">17068223</ArticleId></ArticleIdList></Reference><Reference><Citation>Libioulle C., Louis E., Hansoul S., Sandor C., Farnir F., Franchimont D., Vermeire S., Dewit O., de Vos M., Dixon A. Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4. PLoS Genet. 2007;4:e58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1853118</ArticleId><ArticleId IdType="pubmed">17447842</ArticleId></ArticleIdList></Reference><Reference><Citation>Coon K.D., Myers A.J., Craig D.W., Webster J.A., Pearson J.V., Lince D.H., Zismann V.L., Beach T.G., Leung D., Bryden L. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J. Clin. Psychiatry. 2007;4:613&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pubmed">17474819</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., Wetten S., Li L., St Jean P.L., Upmanyu R., Surh L., Hosford D., Barnes M.R., Briley J.D., Borrie M. Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch. Neurol. 2008;1:45&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">17998437</ArticleId></ArticleIdList></Reference><Reference><Citation>Hafler D.A., Compston A., Sawcer S., Lander E.S., Daly M.J., De&#xa0;Jager P.L., de Bakker P.I., Gabriel S.B., Mirel D.B., International Multiple Sclerosis Genetics Consortium Risk alleles for multiple sclerosis identified by&#xa0;a genomewide study. N. Engl. J. Med. 2007;9:851&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pubmed">17660530</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchini J., Howie B., Myers S., McVean G., Donnelly P. A new multipoint method for genome-wide association studies via imputation of genotypes. Nat. Genet. 2007;39:906&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pubmed">17572673</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G., Drachman D., Folstein M. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng E.L., Chui H.C. The modified Mini-Mental State (3MS) examination. J. Clin. Psychiatry. 1987;48:314&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">3611032</ArticleId></ArticleIdList></Reference><Reference><Citation>Abecasis G.R., Cherny S.S., Cookson W.O., Cardon L.R. GRR: graphical representation of relationship errors. Bioinformatics. 2001;17:742&#x2013;743.</Citation><ArticleIdList><ArticleId IdType="pubmed">11524377</ArticleId></ArticleIdList></Reference><Reference><Citation>Pritchard J.K., Stephens M., Rosenberg N.A., Donnelly P. Association mapping in structured populations. Am. J. Hum. Genet. 2000;67:170&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1287075</ArticleId><ArticleId IdType="pubmed">10827107</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson N., Price A.L., Reich D. Population Structure and Eigenanalysis. PLoS. Genet. 2006;1:e190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1713260</ArticleId><ArticleId IdType="pubmed">17194218</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittke-Thompson J.K., Pluzhnikov A., Cox N.J. Rational inferences about departures from Hardy-Weinberg equilibrium. Am. J. Hum. Genet. 2005;6:967&#x2013;986.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1196455</ArticleId><ArticleId IdType="pubmed">15834813</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryckman K., Williams S.M. Curr Protoc Hum Genet. John Wiley &amp; Sons; New York: 2008. Calculation and use of the Hardy-Weinberg model in association studies.</Citation><ArticleIdList><ArticleId IdType="pubmed">18428419</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell S., Neale B., Todd-Brown K., Thomas L., Ferreira M.A., Bender D., Maller J., Sklar P., de Bakker P.I., Daly M.J. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 2007;3:559&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1950838</ArticleId><ArticleId IdType="pubmed">17701901</ArticleId></ArticleIdList></Reference><Reference><Citation>Armitage P. Tests for linear trends in proportions and frequencies. Biometrics. 1955;11:375&#x2013;386.</Citation></Reference><Reference><Citation>Pounds S., Morris S.W. Estimating the occurrence of false positives and false negatives in microarray studies by approximating and partitioning the empirical distribution of p values. Bioinformatics. 2003;1:1236&#x2013;1242.</Citation><ArticleIdList><ArticleId IdType="pubmed">12835267</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">15297300</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabriel S.B., Schaffner S.F., Nguyen H., Moore J.M., Roy J., Blumenstiel B., Higgins J., DeFelice M., Lochner A., Faggart M. The structure of haplotype blocks in the human genome. Science. 2002;557:2225&#x2013;2229.</Citation><ArticleIdList><ArticleId IdType="pubmed">12029063</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaid D.J., Rowland C.M., Tines D.E., Jacobson R.M., Poland G.A. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am. J. Hum. Genet. 2002;70:425&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC384917</ArticleId><ArticleId IdType="pubmed">11791212</ArticleId></ArticleIdList></Reference><Reference><Citation>Lake S.L., Lyon H., Tantisira K., Silverman E.K., Weiss S.T., Laird N.M., Schaid D.J. Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum. Hered. 2003;55:56&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">12890927</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers A., Wavrant De-Vrieze F., Holmans P., Hamshere M., Crook R., Compton D., Marshall H., Meyer D., Shears S., Booth J. Full genome screen for Alzheimer disease: stage II analysis. Am. J. Med. Genet. 2002;114:235&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">11857588</ArticleId></ArticleIdList></Reference><Reference><Citation>Pericak-Vance M.A., Bass M.P., Yamaoka L.H., Gaskell P.C., Scott W.K., Terwedow H.A., Menold M.M., Conneally P.M., Small G.W., Vance J.M. Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12. JAMA. 1997;278:1237&#x2013;1241.</Citation><ArticleIdList><ArticleId IdType="pubmed">9333264</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayeux R., Lee J.H., Romas S.N., Mayo D., Santana V., Williamson J., Ciappa A., Rondon H.Z., Estevez P., Lantigua R. Chromosome-12 mapping of late-onset Alzheimer disease among Caribbean Hispanics. Am. J. Hum. Genet. 2002;70:237&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC384892</ArticleId><ArticleId IdType="pubmed">11715112</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang X., Schnetz-Boutaud N., Kenealy S.J., Jiang L., Bartlett J., Lynch B., Gaskell P.C., Gwirtsman H., McFarland L., Bembe M.L. Covariate analysis of late-onset Alzheimer disease refines the chromosome 12 locus. Mol Psych. 2006;11:280&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">16222332</ArticleId></ArticleIdList></Reference><Reference><Citation>Gezen-Ak D., Dursun E., Ertan T., Hana&#x11f;asi H., G&#xfc;rvit H., Emre M., Eker E., Ozt&#xfc;rk M., Engin F., Yilmazer S. Association between vitamin D receptor gene polymorphism and Alzheimer's disease. Tohoku J. Exp. Med. 2007;212:275&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">17592215</ArticleId></ArticleIdList></Reference><Reference><Citation>Przybelski R.J., Binkley N.C. Is vitamin D important for preserving cognition? A positive correlation of serum 25-hydroxyvitamin D concentration with cognitive function. Arch. Biochem. Biophys. 2007;460:202&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">17258168</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilpinen H., Ylisaukko-Oja T., Hennah W., Palo O.M., Varilo T., Vanhala R., Nieminen-von Wendt T., von Wendt L., Paunio T., Peltonen L. Association of Dros. Inf. Serv.C1 with autism and Asperger syndrome. Mol. Psychiatry. 2008;13:187&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">17579608</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlis R.H., Purcell S., Fagerness J., Kirby A., Petryshen T.L., Fan J., Sklar P. Family-based association study of lithium-related and other candidate genes in bipolar disorder. Arch. Gen. Psychiatry. 2008;65:53&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">18180429</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodgkinson C.A., Goldman D., Jaeger J., Persaud S., Kane J.M., Lipsky R.H., Malhotra A.K. Disrupted in schizophrenia 1 (Dros. Inf. Serv.C1): association with schizophrenia, schizoaffective disorder, and bipolar disorder. Am. J. Hum. Genet. 2004;75:862&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1182115</ArticleId><ArticleId IdType="pubmed">15386212</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannon T.D., Hennah W., van Erp T.G., Thompson P.M., Lonnqvist J., Huttunen M., Gasperoni T., Tuulio-Henriksson A., Pirkola T., Toga A.W. Association of Dros. Inf. Serv.C1/TRAX haplotypes with schizophrenia, reduced prefrontal gray matter, and impaired short- and long-term memory. Arch. Gen. Psychiatry. 2005;62:1205&#x2013;1213.</Citation><ArticleIdList><ArticleId IdType="pubmed">16275808</ArticleId></ArticleIdList></Reference><Reference><Citation>Hennah W., Tuulio-Henriksson A., Paunio T., Ekelund J., Varilo T., Partonen T., Cannon T.D., L&#xf6;nnqvist J., Peltonen L. A haplotype within the Dros. Inf. Serv.C1 gene is associated with visual memory functions in families with a high density of schizophrenia. Mol. Psychiatry. 2005;10:1097&#x2013;1103.</Citation><ArticleIdList><ArticleId IdType="pubmed">16103888</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Nowotny P., Holmans P., Smemo S., Kauwe J.S., Hinrichs A.L., Tacey K., Doil L., van Luchene R., Garcia V. Association of late-onset Alzheimer's disease with genetic variation in multiple members of the GAPD gene family. Proc. Natl. Acad. Sci. USA. 2004;101:15688&#x2013;15693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC524264</ArticleId><ArticleId IdType="pubmed">15507493</ArticleId></ArticleIdList></Reference><Reference><Citation>Luedecking E.K., DeKosky S.T., Mehdi H., Ganguli M., Kamboh M.I. Analysis of genetic polymorphisms in the transforming growth factor-beta1 gene and the risk of Alzheimer's disease. Hum. Genet. 2000;106:565&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pubmed">10914688</ArticleId></ArticleIdList></Reference><Reference><Citation>R ogaeva E., Meng Y., Lee J.H., Gu Y., Kawarai T., Zou F., Katayama T., Baldwin C.T., Cheng R., Hasegawa H. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat. Genet. 2007;2:168&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2657343</ArticleId><ArticleId IdType="pubmed">17220890</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Rowland C., Catanese J., Morris J., Lovestone S., O'Donovan M.C., Goate A., Owen M., Williams J., Grupe A. SORL1 variants and risk of late-onset Alzheimer's disease. Neurobiol. Dis. 2008;29:293&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2323581</ArticleId><ArticleId IdType="pubmed">17949987</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J.H., Cheng R., Schupf N., Manly J., Lantigua R., Stern Y., Rogaeva E., Wakutani Y., Farrer L., St George-Hyslop P., Mayeux R. The association between genetic variants in SORL1 and Alzheimer disease in an urban, multiethnic, community-based cohort. Arch. Neurol. 2007;64:501&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2639214</ArticleId><ArticleId IdType="pubmed">17420311</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettens K., Brouwers N., Engelborghs S., De Deyn P.P., Van Broeckhoven C., Sleegers K. SORL1 is genetically associated with increased risk for late-onset Alzheimer disease in the Belgian population. Hum. Mutat. 2008;29:769&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pubmed">18407551</ArticleId></ArticleIdList></Reference><Reference><Citation>Minster R.L., DeKosky S.T., Kamboh M.I. No association of SORL1 SNPs with Alzheimer's disease. Neurosci. Lett. 2008;440:190&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2519047</ArticleId><ArticleId IdType="pubmed">18562096</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata N., Ohnuma T., Baba H., Higashi S., Nishioka K., Arai H. Genetic Association between SORL1 Polymorphisms and Alzheimer's Disease in a Japanese Population. Dement. Geriatr. Cogn. Disord. 2008;26:161&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">18685254</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayeux R., Hyslop P.S. Alzheimer's disease: advances in trafficking. Lancet Neurol. 2008;7:2&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2739745</ArticleId><ArticleId IdType="pubmed">18093545</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodson S.E., Gearing M., Lippa C.F., Montine T.J., Levey A.I., Lah J.J. LR11/SorLA expression is reduced in sporadic Alzheimer disease but not in familial Alzheimer disease. J. Neuropathol. Exp. Neurol. 2006;65:866&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2663339</ArticleId><ArticleId IdType="pubmed">16957580</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y., Cui J.G., Lukiw W.J. Reduction of sortilin-1 in Alzheimer hippocampus and in cytokine-stressed human brain cells. Neuroreport. 2007;18:1187&#x2013;1191.</Citation><ArticleIdList><ArticleId IdType="pubmed">17589324</ArticleId></ArticleIdList></Reference><Reference><Citation>Sager K.L., Wuu J., Leurgans S.E., Rees H.D., Gearing M., Mufson E.J., Levey A.I., Lah J.J. Neuronal LR11/sorLA expression is reduced in mild cognitive impairment. Ann. Neurol. 2007;62:640&#x2013;647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2669325</ArticleId><ArticleId IdType="pubmed">17721864</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen L., Madsen P., Moestrup S.K., Lund A.H., Tommerup N., Nykjaer A., Sottrup-Jensen L., Gliemann J., Petersen C.M. Molecular characterization of a novel human hybrid-type receptor that binds the alpha2-macroglobulin receptor-associated protein. J. Biol. Chem. 1996;271:31379&#x2013;31383.</Citation><ArticleIdList><ArticleId IdType="pubmed">8940146</ArticleId></ArticleIdList></Reference><Reference><Citation>Taguchi K., Yamagata H.D., Zhong W., Kamino K., Akatsu H., Hata R., Yamamoto T., Kosaka K., Takeda M., Kondo I., Miki T. Identification of hippocampus-related candidate genes for Alzheimer's disease. Ann. Neurol. 2005;57:585&#x2013;588.</Citation><ArticleIdList><ArticleId IdType="pubmed">15786443</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez-Rodr&#xed;guez E., Infante J., Llorca J., Mateo I., S&#xe1;nchez-Quintana C., Garc&#xed;a-Gorostiaga I., S&#xe1;nchez-Juan P., Berciano J., Combarros O. Age-dependent association of KIBRA genetic variation and Alzheimer's disease risk. Neurobiol. Aging. 2007;30:322&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">17707552</ArticleId></ArticleIdList></Reference><Reference><Citation>Papassotiropoulos A., Stephan D.A., Huentelman M.J., Hoerndli F.J., Craig D.W., Pearson J.V., Huynh K.D., Brunner F., Corneveaux J., Osborne D. Common Kibra alleles are associated with human memory performance. Science. 2006;314:475&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pubmed">17053149</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19122666</PMID><DateCompleted><Year>2009</Year><Month>02</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>2</Issue><PubDate><Year>2009</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Collagen VI protects neurons against Abeta toxicity.</ArticleTitle><Pagination><StartPage>119</StartPage><EndPage>121</EndPage><MedlinePgn>119-21</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.2240</ELocationID><Abstract><AbstractText>Amyloid-beta (Abeta) peptides, widely presumed to cause Alzheimer's disease, increased mouse neuronal expression of collagen VI through a mechanism involving transforming growth factor signaling. Reduction of collagen VI augmented Abeta neurotoxicity, whereas treatment of neurons with soluble collagen VI blocked the association of Abeta oligomers with neurons, enhanced Abeta aggregation and prevented neurotoxicity. These results identify collagen VI as an important component of the neuronal injury response and demonstrate its neuroprotective potential.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Jason S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, 1650 Owens Street, San Francisco, California 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dubal</LastName><ForeName>Dena B</ForeName><Initials>DB</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Daniel H</ForeName><Initials>DH</Initials></Author><Author ValidYN="Y"><LastName>Legleiter</LastName><ForeName>Justin</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Irene H</ForeName><Initials>IH</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Gui-Qiu</ForeName><Initials>GQ</Initials></Author><Author ValidYN="Y"><LastName>Tesseur</LastName><ForeName>Ina</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Wyss-Coray</LastName><ForeName>Tony</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Bonaldo</LastName><ForeName>Paolo</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Mucke</LastName><ForeName>Lennart</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>01</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D024142">Collagen Type VI</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024142" MajorTopicYN="N">Collagen Type VI</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018891" MajorTopicYN="N">Dentate Gyrus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020411" MajorTopicYN="N">Oligonucleotide Array Sequence Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016212" MajorTopicYN="N">Transforming Growth Factor beta</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>11</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>1</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>1</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>2</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>1</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19122666</ArticleId><ArticleId IdType="mid">NIHMS169199</ArticleId><ArticleId IdType="pmc">PMC2812922</ArticleId><ArticleId IdType="doi">10.1038/nn.2240</ArticleId><ArticleId IdType="pii">nn.2240</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cheng IH, et al. J Biol Chem. 2007;282:23818&#x2013;23828.</Citation><ArticleIdList><ArticleId IdType="pubmed">17548355</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, et al. J Neurosci. 2005;25:9686&#x2013;9693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725729</ArticleId><ArticleId IdType="pubmed">16237173</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, et al. Neuron. 2007;55:697&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055171</ArticleId><ArticleId IdType="pubmed">17785178</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, et al. J Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenzo A, et al. Nat Neurosci. 2000;3:460&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">10769385</ArticleId></ArticleIdList></Reference><Reference><Citation>Beher D, Hesse L, Masters CL, Multhaup G. J Biol Chem. 1996;271:1613&#x2013;1620.</Citation><ArticleIdList><ArticleId IdType="pubmed">8576160</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, et al. Nat Med. 2003;9:453&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">12612547</ArticleId></ArticleIdList></Reference><Reference><Citation>Verrecchia F, Chu ML, Mauviel A. J Biol Chem. 2001;276:17058&#x2013;17062.</Citation><ArticleIdList><ArticleId IdType="pubmed">11279127</ArticleId></ArticleIdList></Reference><Reference><Citation>Massagu&#xe9; J, Seoane J, Wotton D. Genes Dev. 2005;19:2783&#x2013;2810.</Citation><ArticleIdList><ArticleId IdType="pubmed">16322555</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesseur I, et al. J Clin Invest. 2006;116:3060&#x2013;3069.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1626127</ArticleId><ArticleId IdType="pubmed">17080199</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin WA, et al. Nat Genet. 2003;35:367&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pubmed">14625552</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonaldo P, et al. Hum Mol Genet. 1998;7:2135&#x2013;2140.</Citation><ArticleIdList><ArticleId IdType="pubmed">9817932</ArticleId></ArticleIdList></Reference><Reference><Citation>Chernoff EAG, Chernoff DA. J Vac Sci Technol. 1992;10:596&#x2013;599.</Citation></Reference><Reference><Citation>Lacor PN, et al. J Neurosci. 2004;24:10191&#x2013;10200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730194</ArticleId><ArticleId IdType="pubmed">15537891</ArticleId></ArticleIdList></Reference><Reference><Citation>Burdick D, Kosmoski J, Knauer MF, Glabe CG. Brain Res. 1997;746:275&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">9037507</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19126811</PMID><DateCompleted><Year>2009</Year><Month>01</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>301</Volume><Issue>1</Issue><PubDate><Year>2009</Year><Month>Jan</Month><Day>07</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial.</ArticleTitle><Pagination><StartPage>63</StartPage><EndPage>73</EndPage><MedlinePgn>63-73</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2008.929</ELocationID><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Deep brain stimulation is an accepted treatment for advanced Parkinson disease (PD), although there are few randomized trials comparing treatments, and most studies exclude older patients.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To compare 6-month outcomes for patients with PD who received deep brain stimulation or best medical therapy.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PATIENTS" NlmCategory="METHODS">Randomized controlled trial of patients who received either deep brain stimulation or best medical therapy, stratified by study site and patient age (&lt; 70 years vs &gt; or = 70 years) at 7 Veterans Affairs and 6 university hospitals between May 2002 and October 2005. A total of 255 patients with PD (Hoehn and Yahr stage &gt; or = 2 while not taking medications) were enrolled; 25% were aged 70 years or older. The final 6-month follow-up visit occurred in May 2006.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">Bilateral deep brain stimulation of the subthalamic nucleus (n = 60) or globus pallidus (n = 61). Patients receiving best medical therapy (n = 134) were actively managed by movement disorder neurologists.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">The primary outcome was time spent in the "on" state (good motor control with unimpeded motor function) without troubling dyskinesia, using motor diaries. Other outcomes included motor function, quality of life, neurocognitive function, and adverse events.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients who received deep brain stimulation gained a mean of 4.6 h/d of on time without troubling dyskinesia compared with 0 h/d for patients who received best medical therapy (between group mean difference, 4.5 h/d [95% CI, 3.7-5.4 h/d]; P &lt; .001). Motor function improved significantly (P &lt; .001) with deep brain stimulation vs best medical therapy, such that 71% of deep brain stimulation patients and 32% of best medical therapy patients experienced clinically meaningful motor function improvements (&gt; or = 5 points). Compared with the best medical therapy group, the deep brain stimulation group experienced significant improvements in the summary measure of quality of life and on 7 of 8 PD quality-of-life scores (P &lt; .001). Neurocognitive testing revealed small decrements in some areas of information processing for patients receiving deep brain stimulation vs best medical therapy. At least 1 serious adverse event occurred in 49 deep brain stimulation patients and 15 best medical therapy patients (P &lt; .001), including 39 adverse events related to the surgical procedure and 1 death secondary to cerebral hemorrhage.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In this randomized controlled trial of patients with advanced PD, deep brain stimulation was more effective than best medical therapy in improving on time without troubling dyskinesias, motor function, and quality of life at 6 months, but was associated with an increased risk of serious adverse events.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">clinicaltrials.gov Identifier: NCT00056563.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weaver</LastName><ForeName>Frances M</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>Hines VA Hospital, Center for Management of Complex Chronic Care, Hines, Illinois 60141, USA. Frances.Weaver@va.gov</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Follett</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Stern</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Hur</LastName><ForeName>Kwan</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>Crystal</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Marks</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>Rothlind</LastName><ForeName>Johannes</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Sagher</LastName><ForeName>Oren</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Reda</LastName><ForeName>Domenic</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Moy</LastName><ForeName>Claudia S</ForeName><Initials>CS</Initials></Author><Author ValidYN="Y"><LastName>Pahwa</LastName><ForeName>Rajesh</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Burchiel</LastName><ForeName>Kim</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Hogarth</LastName><ForeName>Penelope</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Eugene C</ForeName><Initials>EC</Initials></Author><Author ValidYN="Y"><LastName>Duda</LastName><ForeName>John E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Holloway</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Samii</LastName><ForeName>Ali</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Horn</LastName><ForeName>Stacy</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bronstein</LastName><ForeName>Jeff</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Stoner</LastName><ForeName>Gatana</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Heemskerk</LastName><ForeName>Jill</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Grant D</ForeName><Initials>GD</Initials></Author><Author ValidYN="Y"><CollectiveName>CSP 468 Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00056563</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>Y01 NS002006</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2009 Jan 7;301(1):104-5. doi: 10.1001/jama.2008.938.</RefSource><PMID Version="1">19126817</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2009 May 20;301(19):1985; author reply 1985-6. doi: 10.1001/jama.2009.647.</RefSource><PMID Version="1">19454631</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Arch Neurol. 2009 Jun;66(6):778-80. doi: 10.1001/archneurol.2009.82.</RefSource><PMID Version="1">19506140</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Curr Neurol Neurosci Rep. 2009 Jul;9(4):266-7. doi: 10.1007/s11910-009-0039-0.</RefSource><PMID Version="1">19515276</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046690" MajorTopicYN="Y">Deep Brain Stimulation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005917" MajorTopicYN="N">Globus Pallidus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009048" MajorTopicYN="N">Motor Skills</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020531" MajorTopicYN="N">Subthalamic Nucleus</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Follett</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stern</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weaver</LastName><ForeName>Frances</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ippolito</LastName><ForeName>Dolores</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stoner</LastName><ForeName>Gatana</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barnett</LastName><ForeName>Tammy</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bukowski</LastName><ForeName>Ken</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeNicolo</LastName><ForeName>Rosemarie</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hur</LastName><ForeName>Kwan</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jimenez</LastName><ForeName>Joyce</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Luo</LastName><ForeName>Ping</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Motyka</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reda</LastName><ForeName>Domenic</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simon</LastName><ForeName>Theresa</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thakkar</LastName><ForeName>Bharat</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Woolson</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fye</LastName><ForeName>Carol</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gagne</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harris</LastName><ForeName>Crystal</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buckelew</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fye</LastName><ForeName>Carol</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garin</LastName><ForeName>Marilyn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matzek</LastName><ForeName>Sharon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Donna</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heemskerk</LastName><ForeName>Jill</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moy</LastName><ForeName>Claudia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sheehy</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fiore</LastName><ForeName>Louis</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hall</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stroupe</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burchiel</LastName><ForeName>Kim</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Follett</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fye</LastName><ForeName>Carol</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harris</LastName><ForeName>Crystal</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heemskerk</LastName><ForeName>Jill</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hur</LastName><ForeName>Kwan</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koller</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marks</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Moy</LastName><ForeName>Claudia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pahwa</LastName><ForeName>Rajesh</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reda</LastName><ForeName>Domenic</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rothlind</LastName><ForeName>Johannes</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sagher</LastName><ForeName>Oren</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sheehy</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stern</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weaver</LastName><ForeName>Frances</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bakay</LastName><ForeName>Roy</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chappell</LastName><ForeName>Rick</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hart</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holloway</LastName><ForeName>Robert</ForeName><Initials>R</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>McCabe</LastName><ForeName>George</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schenkman</LastName><ForeName>Margaret</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taha</LastName><ForeName>Jamal</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bronstein</LastName><ForeName>Jeff</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duda</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hogarth</LastName><ForeName>Penelope</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holloway</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Horn</LastName><ForeName>Stacy</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lai</LastName><ForeName>Eugene C</ForeName><Initials>EC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marks</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Samii</LastName><ForeName>Ali</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Atassi</LastName><ForeName>Farah</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bello</LastName><ForeName>Cecilia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bunting-Perry</LastName><ForeName>Lisette</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Conn</LastName><ForeName>Tina</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cugley</LastName><ForeName>Alice</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eubank</LastName><ForeName>Nanette</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fincher</LastName><ForeName>Linda</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Franks</LastName><ForeName>Romay</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harris</LastName><ForeName>Tammy</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haselman</LastName><ForeName>Mariann</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heath</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hirsch</LastName><ForeName>Miriam</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Janovsky</LastName><ForeName>Virginia</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lanier</LastName><ForeName>Elaine</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lloyd</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loehner</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Connor</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ordonez</LastName><ForeName>Ligaya</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maccarone</LastName><ForeName>Heather</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Massey-Makhoul</LastName><ForeName>Kelli</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matthews</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meyn</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mimura</LastName><ForeName>Keiko</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morrow</LastName><ForeName>Wes</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Searles</LastName><ForeName>Tammy</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Valotta</LastName><ForeName>Jamye</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vasthare</LastName><ForeName>Usha</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Volz</LastName><ForeName>Monica</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ward</LastName><ForeName>Constance</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Warker</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watson</LastName><ForeName>Heidi</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Willson</LastName><ForeName>Pamela</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baron</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brodsky</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bronstein</LastName><ForeName>Jeff</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Calabrese</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Campbell</LastName><ForeName>Gordon</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Colcher</LastName><ForeName>Amy</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duda</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Faraq</LastName><ForeName>Emad</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Henry</LastName><ForeName>Eva</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hogarth</LastName><ForeName>Penelope</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hou</LastName><ForeName>Jyh-Gong</ForeName><Initials>JG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kang</LastName><ForeName>Gail</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kleiner-Fisman</LastName><ForeName>Galit</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kraakevik</LastName><ForeName>Jeff</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Horn</LastName><ForeName>Stacy</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lai</LastName><ForeName>Eugene C</ForeName><Initials>EC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marks</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Nutt</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ostrem</LastName><ForeName>Jill</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Samii</LastName><ForeName>Ali</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sarwar</LastName><ForeName>Aliya</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Subramanian</LastName><ForeName>Indu</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanek</LastName><ForeName>Zeba</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baltuch</LastName><ForeName>Gordon</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burchiel</LastName><ForeName>Kim</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeSalles</LastName><ForeName>Antonio</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eller</LastName><ForeName>Jorge</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holloway</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Larson</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simpson</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Starr</LastName><ForeName>Philip</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carne</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Erikson</LastName><ForeName>Tom</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jaggi</LastName><ForeName>Jurg</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kreutzer</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mendez</LastName><ForeName>Mario</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moberg</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ragland</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rothlind</LastName><ForeName>Johannes</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seel</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Soety</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Storzbach</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Troster</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>York</LastName><ForeName>Michele</ForeName><Initials>M</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>1</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>1</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>1</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19126811</ArticleId><ArticleId IdType="mid">NIHMS168299</ArticleId><ArticleId IdType="pmc">PMC2814800</ArticleId><ArticleId IdType="doi">10.1001/jama.2008.929</ArticleId><ArticleId IdType="pii">301/1/63</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rodriguez RL, Fernandez HH, Haq I, Okun MS. Pearls in patient selection for deep brain stimulation. Neurologist. 2007;13(5):253&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">17848865</ArticleId></ArticleIdList></Reference><Reference><Citation>Weaver F, Follett K, Hur K, Ippolito D, Stern M. Deep brain stimulation in Parkinson disease: a metaanalysis of patient outcomes. J Neurosurg. 2005;103(6):956&#x2013;967.</Citation><ArticleIdList><ArticleId IdType="pubmed">16381181</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang AE, Houeto JL, Krack P, et al. Deep brain stimulation: preoperative issues. Mov Disord. 2006;21(suppl 14):S171&#x2013;S196.</Citation><ArticleIdList><ArticleId IdType="pubmed">16810718</ArticleId></ArticleIdList></Reference><Reference><Citation>Follett KA. The surgical treatment of Parkinson's disease. Annu Rev Med. 2000;51:135&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">10774457</ArticleId></ArticleIdList></Reference><Reference><Citation>Temel Y, Blokland A, Steinbusch HW, Visser-Vandewalle V. The functional role of the subthalamic nucleus in cognitive and limbic circuits. Prog Neurobiol. 2005;76(6):393&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pubmed">16249050</ArticleId></ArticleIdList></Reference><Reference><Citation>Krack P, Batir A, Van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med. 2003;349(20):1925&#x2013;1934.</Citation><ArticleIdList><ArticleId IdType="pubmed">14614167</ArticleId></ArticleIdList></Reference><Reference><Citation>Deuschl G, Schade-Brittinger C, Krack P, et al. German Parkinson Study Group Neurostimulation Section. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med. 2006;355(9):896&#x2013;908.</Citation><ArticleIdList><ArticleId IdType="pubmed">16943402</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5):427&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pubmed">6067254</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattis S. Dementia Rating Scale: Professional Manual. Psychological Assessment Resources Inc; Odessa, FL: 1973.</Citation></Reference><Reference><Citation>Langston JW, Widner H, Goetz CG, et al. Core assessment program for intracerebral transplantations (CAPIT) Mov Disord. 1992;7(1):2&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">1557062</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201d;Mini-mental state&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Fahn S, Elton RL, Members of the UPDRS Development Committee . Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, editors. Recent Developments in Parkinson's Disease. Vol. 2. Macmillan Health Care Information; Florham Park, NJ: 1987. pp. 153&#x2013;164.</Citation></Reference><Reference><Citation>Schwab RS, England AC. Projection Technique for Evaluating Surgery in Parkinson's Disease: Third Symposium on Parkinson's Disease. Gillingham &amp; Donaldson; Edinburgh, Scotland: 1969.</Citation></Reference><Reference><Citation>Peto V, Jenkinson C, Fitzpatrick R. PDQ-39: a review of the development, validation and application of a Parkinson's disease quality of life questionnaire and its associated measures. J Neurol. 1998;245(suppl 1):S10&#x2013;S14.</Citation><ArticleIdList><ArticleId IdType="pubmed">9617716</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauser RA, Deckers F, Lehert P. Parkinson's disease home diary: further validation and implications for clinical trials. Mov Disord. 2004;19(12):1409&#x2013;1413.</Citation><ArticleIdList><ArticleId IdType="pubmed">15390057</ArticleId></ArticleIdList></Reference><Reference><Citation>Goetz CG, Stebbins GT, Blasucci LM, Grobman MS. Efficacy of a patient-training videotape on motor fluctuations for on-off diaries in Parkinson's disease. Mov Disord. 1997;12(6):1039&#x2013;1041.</Citation><ArticleIdList><ArticleId IdType="pubmed">9399233</ArticleId></ArticleIdList></Reference><Reference><Citation>Pahwa R, Wilkinson SB, Overman J, Lyons KE. Bilateral subthalamic stimulation in patients with Parkinson disease: long-term follow up. J Neurosurg. 2003;99(1):71&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">12854747</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Erlbaum; Hillsdale, NJ: 1988.</Citation></Reference><Reference><Citation>Schrag A, Sampaio C, Counsell N, Poewe W. Minimal clinically important change on the United Parkinson's Disease Rating Scale. Mov Disord. 2006;21(8):1200&#x2013;1207.</Citation><ArticleIdList><ArticleId IdType="pubmed">16673410</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkinson Study Group DATATOP: a multi-center controlled clinical trial in early Parkinson's disease. Arch Neurol. 1989;46(10):1052&#x2013;1060.</Citation><ArticleIdList><ArticleId IdType="pubmed">2508608</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkinson's Study Group Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol. 1997;42(5):747&#x2013;755.</Citation><ArticleIdList><ArticleId IdType="pubmed">9392574</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkinson's Study Group A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol. 2005;62(2):241&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">15710852</ArticleId></ArticleIdList></Reference><Reference><Citation>Straits-Tr&#xf6;ster K, Fields JA, Wilkinson SB, et al. Health-related quality of life in Parkinson's disease after pallidotomy and deep brain stimulation. Brain Cogn. 2000;42(3):399&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pubmed">10753487</ArticleId></ArticleIdList></Reference><Reference><Citation>Just H, Ostergaard K. Health-related quality of life in patients with advanced Parkinson's disease treated with deep brain stimulation of the subthalamic nuclei. Mov Disord. 2002;17(3):539&#x2013;545.</Citation><ArticleIdList><ArticleId IdType="pubmed">12112204</ArticleId></ArticleIdList></Reference><Reference><Citation>Limousin P, Martinez-Torres I. Deep brain stimulation for Parkinson's disease. Neurotherapeutics. 2008;5(2):309&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5084172</ArticleId><ArticleId IdType="pubmed">18394572</ArticleId></ArticleIdList></Reference><Reference><Citation>Witt K, Daniels C, Reiff J, et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre trial. Lancet Neurol. 2008;7(7):605&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pubmed">18538636</ArticleId></ArticleIdList></Reference><Reference><Citation>Alegret M, Junque C, Valldeoriola F, et al. Effects of bilateral subthalamic stimulation on cognitive function in Parkinson disease. Arch Neurol. 2001;58(8):1223&#x2013;1227.</Citation><ArticleIdList><ArticleId IdType="pubmed">11493162</ArticleId></ArticleIdList></Reference><Reference><Citation>Appleby BS, Duggan PS, Regenberg A, Rabins PV. Psychiatric and neuropsychiatric adverse events associated with deep brain stimulation: a meta-analysis of ten years' experience. Mov Disord. 2007;22(12):1722&#x2013;1728.</Citation><ArticleIdList><ArticleId IdType="pubmed">17721929</ArticleId></ArticleIdList></Reference><Reference><Citation>Temel Y, Kessels A, Tan S, Topdag A, Boon P, Visser-Vandewalle V. Behavioural changes after bilateral subthalamic stimulation in advanced Parkinson disease: a systematic review. Parkinsonism Relat Disord. 2006;12(5):265&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pubmed">16621661</ArticleId></ArticleIdList></Reference><Reference><Citation>Burchiel KJ, Anderson VC, Favre J, Hammerstad JP. Comparison of pallidal and subthalamic nucleus deep brain stimulation for advanced Parkinson's disease: results of a randomized, blinded pilot study. Neurosurgery. 1999;45(6):1375&#x2013;1382.</Citation><ArticleIdList><ArticleId IdType="pubmed">10598706</ArticleId></ArticleIdList></Reference><Reference><Citation>Hariz MI, Rehncrona S, Quinn NP, Speelman JD, Wensing C, Multicentre Advanced Parkinson's Disease Deep Brain Stimulation Group Multicenter study on deep brain stimulation in Parkinson's disease: an independent assessment of reported adverse events at 4 years. Mov Disord. 2008;23(3):416&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">18067188</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19129379</PMID><DateCompleted><Year>2009</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>1</Issue><PubDate><Year>2009</Year><Month>Jan</Month><Day>07</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Microglial VEGF receptor response is an integral chemotactic component in Alzheimer's disease pathology.</ArticleTitle><Pagination><StartPage>3</StartPage><EndPage>13</EndPage><MedlinePgn>3-13</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.2888-08.2009</ELocationID><Abstract><AbstractText>We hypothesize that microglial chemotactic responses to amyloid-beta peptide (Abeta(1-42)) serve as an early and integral component of inflammatory response in Alzheimer's disease (AD) brain. This study reports a receptor for vascular endothelial growth factor (VEGF), termed VEGF-1 (Flt-1), subserves microglial chemotactic responses induced by Abeta(1-42) stimulation, in vivo and in vitro. Expression of Flt-1 was significantly increased in tissue obtained from AD patients [compared with tissue from nondemented (ND) individuals], in Abeta(1-42)-injected rat hippocampus, and in peptide-stimulated human microglia. Single and double immunohistochemical staining demonstrated marked immunoreactivity, for both Flt-1 and its ligand VEGF, in association with microglia and Abeta deposits in AD, but not ND, brain tissue. Functionally, treatment with anti-Flt-1 antibody was highly effective in inhibiting microglial mobility and chemotactic responses measured in vitro using a transwell migration assay. In vivo, transplanted enhanced green fluorescent protein (EGFP)-labeled microglia exhibited Flt-1-dependent chemotaxis induced by peptide injection with anti-Flt-1 effective in blocking migration of cells. Importantly, anti-Flt-1 reduction of microglial mobility was neuroprotective in peptide-injected hippocampus and associated with a significant increase in numbers of viable hippocampal neurons. The results of this study suggest critical functional roles for Flt-1 in mediating microglial chemotactic inflammatory responses which contribute to pathological conditions in AD brain.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ryu</LastName><ForeName>Jae K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Pharmacology, and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada V6T 1Z3.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Taesup</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Hyun B</ForeName><Initials>HB</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yu Tian</ForeName><Initials>YT</Initials></Author><Author ValidYN="Y"><LastName>McLarnon</LastName><ForeName>James G</ForeName><Initials>JG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D039481">CD11b Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005904">Glial Fibrillary Acidic Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006684">HLA-DR Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C485184">enhanced green fluorescent protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="C501162">FLT1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D040262">Receptors, Vascular Endothelial Growth Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D040281">Vascular Endothelial Growth Factor Receptor-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 4.2.1.11</RegistryNumber><NameOfSubstance UI="D010751">Phosphopyruvate Hydratase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039481" MajorTopicYN="N">CD11b Antigen</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018728" MajorTopicYN="N">Entorhinal Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005904" MajorTopicYN="N">Glial Fibrillary Acidic Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006684" MajorTopicYN="N">HLA-DR Antigens</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010751" MajorTopicYN="N">Phosphopyruvate Hydratase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011180" MajorTopicYN="N">Postmortem Changes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040262" MajorTopicYN="N">Receptors, Vascular Endothelial Growth Factor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040281" MajorTopicYN="N">Vascular Endothelial Growth Factor Receptor-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>1</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>1</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>4</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>7</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19129379</ArticleId><ArticleId IdType="pmc">PMC6664925</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2888-08.2009</ArticleId><ArticleId IdType="pii">29/1/3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aarum J, Sandberg K, Haeberlein SL, Persson MA. Migration and differentiation of neural precursor cells can be directed by microglia. Proc Natl Acad Sci U S A. 2003;100:15983&#x2013;15988.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC307679</ArticleId><ArticleId IdType="pubmed">14668448</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambati BK, Nozaki M, Singh N, Takeda A, Jani PD, Suthar T, Albuquerque RJ, Richter E, Sakurai E, Newcomb MT, Kleinman ME, Caldwell RB, Lin Q, Ogura Y, Orecchia A, Samuelson DA, Agnew DW, St Leger J, Green WR, Mahasreshti PJ, et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature. 2006;443:993&#x2013;997.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656128</ArticleId><ArticleId IdType="pubmed">17051153</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Miklossy J, Klegeris A, Guo JP, McGeer PL. Thrombin and prothrombin are expressed by neurons and glial cells and accumulate in neurofibrillary tangles in Alzheimer disease brain. J Neuropathol Exp Neurol. 2006;65:19&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">16410745</ArticleId></ArticleIdList></Reference><Reference><Citation>Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marm&#xe9; D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood. 1996;87:3336&#x2013;3343.</Citation><ArticleIdList><ArticleId IdType="pubmed">8605350</ArticleId></ArticleIdList></Reference><Reference><Citation>Casolini P, Domenici MR, Cinque C, Alem&#xe0; GS, Chiodi V, Galluzzo M, Musumeci M, Mairesse J, Zuena AR, Matteucci P, Marano G, Maccari S, Nicoletti F, Catalani A. Maternal exposure to low levels of corticosterone during lactation protects the adult offspring against ischemic brain damage. J Neurosci. 2007;27:7041&#x2013;7046.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672222</ArticleId><ArticleId IdType="pubmed">17596453</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi HB, Ryu JK, Kim SU, McLarnon JG. Modulation of the purinergic P2X7 receptor attenuates lipopolysaccharide-mediated microglial activation and neuronal damage in inflamed brain. J Neurosci. 2007;27:4957&#x2013;4968.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672082</ArticleId><ArticleId IdType="pubmed">17475804</ArticleId></ArticleIdList></Reference><Reference><Citation>Combs CK, Karlo JC, Kao SC, Landreth GE. &#x3b2;-Amyloid stimulation of microglia and monocytes results in TNF&#x3b1;-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J Neurosci. 2001;21:1179&#x2013;1188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762255</ArticleId><ArticleId IdType="pubmed">11160388</ArticleId></ArticleIdList></Reference><Reference><Citation>De Bandt M, Ben Mahdi MH, Ollivier V, Grossin M, Dupuis M, Gaudry M, Bohlen P, Lipson KE, Rice A, Wu Y, Gougerot-Pocidalo MA, Pasquier C. Blockade of vascular endothelial growth factor receptor I (VEGF-RI), but not VEGF-RII, suppresses joint destruction in the K/BxN model of rheumatoid arthritis. J Immunol. 2003;171:4853&#x2013;4859.</Citation><ArticleIdList><ArticleId IdType="pubmed">14568965</ArticleId></ArticleIdList></Reference><Reference><Citation>Feistritzer C, Kaneider NC, Sturn DH, Mosheimer BA, K&#xe4;hler CM, Wiedermann CJ. Expression and function of the vascular endothelial growth factor receptor Flt-1 in human eosinophils. Am J Respir Cell Mol Biol. 2004;30:729&#x2013;735.</Citation><ArticleIdList><ArticleId IdType="pubmed">14607815</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiala M, Liu QN, Sayre J, Pop V, Brahmandam V, Graves MC, Vinters HV. Cyclooxygenase-2-positive macrophages infiltrate the Alzheimer's disease brain and damage the blood-brain barrier. Eur J Clin Invest. 2002;32:360&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pubmed">12027877</ArticleId></ArticleIdList></Reference><Reference><Citation>Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature. 1995;376:66&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">7596436</ArticleId></ArticleIdList></Reference><Reference><Citation>Forstreuter F, Lucius R, Mentlein R. Vascular endothelial growth factor induces chemotaxis and proliferation of microglial cells. J Neuroimmunol. 2002;132:93&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">12417438</ArticleId></ArticleIdList></Reference><Reference><Citation>Franciosi S, Ryu JK, Choi HB, Radov L, Kim SU, McLarnon JG. Broad-spectrum effects of 4-aminopyridine to modulate amyloid &#x3b2;1&#x2013;42-induced cell signaling and functional responses in human microglia. J Neurosci. 2006;26:11652&#x2013;11664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674791</ArticleId><ArticleId IdType="pubmed">17093087</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JP, Arai T, Miklossy J, McGeer PL. Abeta and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer's disease. Proc Natl Acad Sci U S A. 2006;103:1953&#x2013;1958.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1413647</ArticleId><ArticleId IdType="pubmed">16446437</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashemzadeh-Bonehi L, Phillips RG, Cairns NJ, Mosaheb S, Thorpe JR. Pin1 protein associates with neuronal lipofuscin: potential consequences in age-related neurodegeneration. Exp Neurol. 2006;199:328&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">16480979</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoshino M, Takahashi M, Aoike N. Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis. J Allergy Clin Immunol. 2001;107:295&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">11174196</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue LF, Brachova L, Walker DG, Rogers J. Characterization of glial cultures from rapid autopsies of Alzheimer's and control patients. Neurobiol Aging. 1996;17:421&#x2013;429.</Citation><ArticleIdList><ArticleId IdType="pubmed">8725904</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue LF, Rydel R, Brigham EF, Yang LB, Hampel H, Murphy GM, Jr, Brachova L, Yan SD, Walker DG, Shen Y, Rogers J. Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro. Glia. 2001;35:72&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">11424194</ArticleId></ArticleIdList></Reference><Reference><Citation>McLarnon JG, Choi HB, Lue LF, Walker DG, Kim SU. Perturbations in calcium-mediated signal transduction in microglia from Alzheimer's disease patients. J Neurosci Res. 2005;81:426&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pubmed">15948178</ArticleId></ArticleIdList></Reference><Reference><Citation>McLarnon JG, Ryu JK, Walker DG, Choi HB. Upregulated expression of purinergic P2X(7) receptor in Alzheimer disease and amyloid-beta peptide-treated microglia and in peptide-injected rat hippocampus. J Neuropathol Exp Neurol. 2006;65:1090&#x2013;1097.</Citation><ArticleIdList><ArticleId IdType="pubmed">17086106</ArticleId></ArticleIdList></Reference><Reference><Citation>Miklossy J, Qing H, Guo JP, Yu S, Wszolek ZK, Calne D, McGeer EG, McGeer PL. Lrrk2 and chronic inflammation are linked to pallido-ponto-nigral degeneration caused by the N279K tau mutation. Acta Neuropathol. 2007;114:243&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">17639429</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrak RE, Griffin WS. Common inflammatory mechanisms in Lewy body disease and Alzheimer disease. J Neuropathol Exp Neurol. 2007;66:683&#x2013;686.</Citation><ArticleIdList><ArticleId IdType="pubmed">17882012</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami M, Iwai S, Hiratsuka S, Yamauchi M, Nakamura K, Iwakura Y, Shibuya M. Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocytes/macrophages. Blood. 2006;108:1849&#x2013;1856.</Citation><ArticleIdList><ArticleId IdType="pubmed">16709927</ArticleId></ArticleIdList></Reference><Reference><Citation>Park L, Anrather J, Zhou P, Frys K, Pitstick R, Younkin S, Carlson GA, Iadecola C. NADPH-oxidase-derived reactive oxygen species mediate the cerebrovascular dysfunction induced by the amyloid &#x3b2; peptide. J Neurosci. 2005;25:1769&#x2013;1777.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725936</ArticleId><ArticleId IdType="pubmed">15716413</ArticleId></ArticleIdList></Reference><Reference><Citation>Pogue AI, Lukiw WJ. Angiogenic signaling in Alzheimer's disease. Neuroreport. 2004;15:1507&#x2013;1510.</Citation><ArticleIdList><ArticleId IdType="pubmed">15194884</ArticleId></ArticleIdList></Reference><Reference><Citation>Prat A, Biernacki K, Wosik K, Antel JP. Glial cell influence on the human blood-brain barrier. Glia. 2001;36:145&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pubmed">11596123</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu JK, McLarnon JG. Minocycline or iNOS inhibition block 3-nitrotyrosine increases and blood-brain barrier leakiness in amyloid beta-peptide-injected rat hippocampus. Exp Neurol. 2006;198:552&#x2013;557.</Citation><ArticleIdList><ArticleId IdType="pubmed">16480717</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu JK, McLarnon JG. Thalidomide inhibition of perturbed vasculature and glial-derived tumor necrosis factor-&#x3b1; in an animal model of inflamed Alzheimer's disease brain. Neurobiol Dis. 2008;29:254&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">17964176</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu JK, Kim J, Cho SJ, Hatori K, Nagai A, Choi HB, Lee MC, McLarnon JG, Kim SU. Proactive transplantation of human neural stem cells prevents degeneration of striatal neurons in a rat model of Huntington disease. Neurobiol Dis. 2004;16:68&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">15207263</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu JK, Choi HB, McLarnon JG. Combined minocycline plus pyruvate treatment enhances effects of each agent to inhibit inflammation, oxidative damage, and neuronal loss in an excitotoxic animal model of Huntington's disease. Neuroscience. 2006;141:1835&#x2013;1848.</Citation><ArticleIdList><ArticleId IdType="pubmed">16809003</ArticleId></ArticleIdList></Reference><Reference><Citation>Skarsgard ED, Huang L, Reebye SC, Yeung AY, Jia WW. Lentiviral vector-mediated, in vivo gene transfer to the tracheobronchial tree in fetal rabbits. J Pediatr Surg. 2005;40:1817&#x2013;1821.</Citation><ArticleIdList><ArticleId IdType="pubmed">16338297</ArticleId></ArticleIdList></Reference><Reference><Citation>Sk&#xf6;ld MK, von Gertten C, Sandberg-Nordqvist AC, Mathiesen T, Holmin S. VEGF and VEGF receptor expression after experimental brain contusion in rat. J Neurotrauma. 2005;22:353&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">15785231</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires TL, Meyer-Luehmann M, Stern EA, McLean PJ, Skoch J, Nguyen PT, Bacskai BJ, Hyman BT. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci. 2005;25:7278&#x2013;7287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1820616</ArticleId><ArticleId IdType="pubmed">16079410</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, B&#xfc;rki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A. 1997;94:13287&#x2013;13292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24301</ArticleId><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarkowski E, Issa R, Sj&#xf6;gren M, Wallin A, Blennow K, Tarkowski A, Kumar P. Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia. Neurobiol Aging. 2002;23:237&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">11804709</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran KC, Ryu JK, McLarnon JG. Induction of angiogenesis by platelet-activating factor in the rat striatum. Neuroreport. 2005;16:1579&#x2013;1583.</Citation><ArticleIdList><ArticleId IdType="pubmed">16148749</ArticleId></ArticleIdList></Reference><Reference><Citation>Vagnucci AH, Jr, Li WW. Alzheimer's disease and angiogenesis. Lancet. 2003;361:605&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">12598159</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker DG, Kim SU, McGeer PL. Complement and cytokine gene expression in cultured microglia derived from post-mortem brains. J Neurosci Res. 1995;40:478&#x2013;493.</Citation><ArticleIdList><ArticleId IdType="pubmed">7616608</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker DG, Link J, Lue LF, Dalsing-Hernandez JE, Boyes BE. Gene expression changes by amyloid beta peptide-stimulated human postmortem brain microglia identify activation of multiple inflammatory processes. J Leukoc Biol. 2006;79:596&#x2013;610.</Citation><ArticleIdList><ArticleId IdType="pubmed">16365156</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang MS, Ji KA, Jeon SB, Jin BK, Kim SU, Jou I, Joe E. Interleukin-13 enhances cyclooxygenase-2 expression in activated rat brain microglia: implications for death of activated microglia. J Immunol. 2006;177:1323&#x2013;1329.</Citation><ArticleIdList><ArticleId IdType="pubmed">16818793</ArticleId></ArticleIdList></Reference><Reference><Citation>Zipser BD, Johanson CE, Gonzalez L, Berzin TM, Tavares R, Hulette CM, Vitek MP, Hovanesian V, Stopa EG. Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol Aging. 2007;28:977&#x2013;986.</Citation><ArticleIdList><ArticleId IdType="pubmed">16782234</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci. 2005;28:202&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">15808355</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19136949</PMID><DateCompleted><Year>2009</Year><Month>02</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1718</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>2</Issue><PubDate><Year>2009</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Nature genetics</Title><ISOAbbreviation>Nat Genet</ISOAbbreviation></Journal><ArticleTitle>Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease.</ArticleTitle><Pagination><StartPage>192</StartPage><EndPage>198</EndPage><MedlinePgn>192-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/ng.305</ELocationID><Abstract><AbstractText>By analyzing late-onset Alzheimer's disease (LOAD) in a genome-wide association study (313,504 SNPs, three series, 844 cases and 1,255 controls) and evaluating the 25 SNPs with the most significant allelic association in four additional series (1,547 cases and 1,209 controls), we identified a SNP (rs5984894) on Xq21.3 in PCDH11X that is strongly associated with LOAD in individuals of European descent from the United States. Analysis of rs5984894 by multivariable logistic regression adjusted for sex gave global P values of 5.7 x 10(-5) in stage 1, 4.8 x 10(-6) in stage 2 and 3.9 x 10(-12) in the combined data. Odds ratios were 1.75 (95% CI = 1.42-2.16) for female homozygotes (P = 2.0 x 10(-7)) and 1.26 (95% CI = 1.05-1.51) for female heterozygotes (P = 0.01) compared to female noncarriers. For male hemizygotes (P = 0.07) compared to male noncarriers, the odds ratio was 1.18 (95% CI = 0.99-1.41).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carrasquillo</LastName><ForeName>Minerva M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, Florida 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zou</LastName><ForeName>Fanggeng</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Pankratz</LastName><ForeName>V Shane</ForeName><Initials>VS</Initials></Author><Author ValidYN="Y"><LastName>Wilcox</LastName><ForeName>Samantha L</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Li</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Louise P</ForeName><Initials>LP</Initials></Author><Author ValidYN="Y"><LastName>Younkin</LastName><ForeName>Samuel G</ForeName><Initials>SG</Initials></Author><Author ValidYN="Y"><LastName>Younkin</LastName><ForeName>Curtis S</ForeName><Initials>CS</Initials></Author><Author ValidYN="Y"><LastName>Younkin</LastName><ForeName>Linda H</ForeName><Initials>LH</Initials></Author><Author ValidYN="Y"><LastName>Bisceglio</LastName><ForeName>Gina D</ForeName><Initials>GD</Initials></Author><Author ValidYN="Y"><LastName>Ertekin-Taner</LastName><ForeName>Nilufer</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Crook</LastName><ForeName>Julia E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials></Author><Author ValidYN="Y"><LastName>Younkin</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG16574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003949</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG017216</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG018023</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG03949</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 AG020903</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG06576</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG12716</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG25711</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG18023</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG21886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025711</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>01</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Genet</MedlineTA><NlmUniqueID>9216904</NlmUniqueID><ISSNLinking>1061-4036</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015820">Cadherins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C404498">PCDH11X protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000091363">Protocadherins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015820" MajorTopicYN="N">Cadherins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="Y">Genetic Variation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015810" MajorTopicYN="N">Linkage Disequilibrium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000091363" MajorTopicYN="N">Protocadherins</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>11</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>1</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>1</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>2</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>5</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19136949</ArticleId><ArticleId IdType="mid">NIHMS173120</ArticleId><ArticleId IdType="pmc">PMC2873177</ArticleId><ArticleId IdType="doi">10.1038/ng.305</ArticleId><ArticleId IdType="pii">ng.305</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Evans DA, et al. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. Jama. 1989;262:2551&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">2810583</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994;7:180&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">7920638</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. Jama. 1997;278:1349&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatz M, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry. 2006;63:168&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">16461860</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell S, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1950838</ArticleId><ArticleId IdType="pubmed">17701901</ArticleId></ArticleIdList></Reference><Reference><Citation>Price AL, et al. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006;38:904&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862161</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams NA, Close JP, Giouzeli M, Crow TJ. Accelerated evolution of Protocadherin11X/Y: a candidate gene-pair for cerebral asymmetry and language. Am J Med Genet B Neuropsychiatr Genet. 2006;141:623&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">16874762</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes AM, et al. Inactivation status of PCDH11X: sexual dimorphisms in gene expression levels in brain. Hum Genet. 2006;119:267&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">16425037</ArticleId></ArticleIdList></Reference><Reference><Citation>Durand CM, et al. Expression and genetic variability of PCDH11Y, a gene specific to Homo sapiens and candidate for susceptibility to psychiatric disorders. Am J Med Genet B Neuropsychiatr Genet. 2006;141:67&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4867006</ArticleId><ArticleId IdType="pubmed">16331680</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco P, Sargent CA, Boucher CA, Mitchell M, Affara NA. Conservation of PCDHX in mammals; expression of human X/Y genes predominantly in brain. Mamm Genome. 2000;11:906&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">11003707</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco-Arias P, Sargent CA, Affara NA. Protocadherin X (PCDHX) and Y (PCDHY) genes; multiple mRNA isoforms encoding variant signal peptides and cytoplasmic domains. Mamm Genome. 2004;15:41&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">14727141</ArticleId></ArticleIdList></Reference><Reference><Citation>Senzaki K, Ogawa M, Yagi T. Proteins of the CNR family are multiple receptors for Reelin. Cell. 1999;99:635&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">10612399</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas IG, Frank M, Veron N, Kemler R. Presenilin-dependent processing and nuclear function of gamma-protocadherins. J Biol Chem. 2005;280:9313&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15611067</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">15297300</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19138567</PMID><DateCompleted><Year>2009</Year><Month>03</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1474-4422</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>2</Issue><PubDate><Year>2009</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial.</ArticleTitle><Pagination><StartPage>151</StartPage><EndPage>157</EndPage><MedlinePgn>151-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(08)70295-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Data from 12-week placebo-controlled trials have led to mounting concerns about increased mortality in patients with Alzheimer's disease (AD) who are prescribed antipsychotics; however, there are no mortality data from long-term placebo-controlled trials. We aimed to assess whether continued treatment with antipsychotics in people with AD is associated with an increased risk of mortality.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Between October, 2001, and December, 2004, patients with AD who resided in care facilities in the UK were enrolled into a randomised, placebo-controlled, parallel, two-group treatment discontinuation trial. Participants were randomly assigned to continue with their antipsychotic treatment (thioridazine, chlorpromazine, haloperidol, trifluoperazine, or risperidone) for 12 months or to switch their medication to an oral placebo. The primary outcome was mortality at 12 months. An additional follow-up telephone assessment was done to establish whether each participant was still alive 24 months after the enrollment of the last participant (range 24-54 months). Causes of death were obtained from death certificates. Analysis was by intention to treat (ITT) and modified intention to treat (mITT). This trial is registered with the Cochrane Central Registry of Controlled Trials/National Research Register, number ISRCTN33368770.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">165 patients were randomised (83 to continue antipsychotic treatment and 82 to placebo), of whom 128 (78%) started treatment (64 continued with their treatment and 64 received placebo). There was a reduction in survival in the patients who continued to receive antipsychotics compared with those who received placebo. Cumulative probability of survival during the 12 months was 70% (95% CI 58-80%) in the continue treatment group versus 77% (64-85%) in the placebo group for the mITT population. Kaplan-Meier estimates of mortality for the whole study period showed a significantly increased risk of mortality for patients who were allocated to continue antipsychotic treatment compared with those allocated to placebo (mITT log rank p=0.03; ITT p=0.02). The hazard ratio for the mITT group was 0.58 (95% CI 0.35 to 0.95) and 0.58 (0.36 to 0.92) for the ITT population. The more pronounced differences between groups during periods of follow up longer than 12 months were evident at specific timepoints (24-month survival 46%vs 71%; 36-month survival 30%vs 59%).</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">There is an increased long-term risk of mortality in patients with AD who are prescribed antipsychotic medication; these results further highlight the need to seek less harmful alternatives for the long-term treatment of neuropsychiatric symptoms in these patients.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">UK Alzheimer's Research Trust.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ballard</LastName><ForeName>Clive</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Wolfson Centre for Age-Related Diseases, King's College London, London, UK. clive.ballard@kcl.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanney</LastName><ForeName>Maria Luisa</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Theodoulou</LastName><ForeName>Megan</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Douglas</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>McShane</LastName><ForeName>Rupert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Kossakowski</LastName><ForeName>Katja</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Gill</LastName><ForeName>Randeep</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Juszczak</LastName><ForeName>Edmund</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Ly-Mee</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Jacoby</LastName><ForeName>Robin</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><CollectiveName>DART-AD investigators</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ISRCTN</DataBankName><AccessionNumberList><AccessionNumber>ISRCTN33368770</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>01</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2009 Feb;8(2):125. doi: 10.1016/S1474-4422(09)70001-8.</RefSource><PMID Version="1">19161899</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Ann Intern Med. 2009 Jun 16;150(12):JC6-8. doi: 10.7326/0003-4819-150-12-200906160-02008.</RefSource><PMID Version="1">19528553</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Evid Based Med. 2009 Aug;14(4):115. doi: 10.1136/ebm.14.4.115.</RefSource><PMID Version="1">19648431</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>1</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>1</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>3</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19138567</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(08)70295-3</ArticleId><ArticleId IdType="pii">S1474-4422(08)70295-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19139910</PMID><DateCompleted><Year>2009</Year><Month>02</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-0533</ISSN><JournalIssue CitedMedium="Internet"><Volume>117</Volume><Issue>2</Issue><PubDate><Year>2009</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Acta neuropathologica</Title><ISOAbbreviation>Acta Neuropathol</ISOAbbreviation></Journal><ArticleTitle>Alzheimer disease macrophages shuttle amyloid-beta from neurons to vessels, contributing to amyloid angiopathy.</ArticleTitle><Pagination><StartPage>111</StartPage><EndPage>124</EndPage><MedlinePgn>111-24</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00401-008-0481-0</ELocationID><Abstract><AbstractText>Neuronal accumulation of oligomeric amyloid-beta (Alphabeta) is considered the proximal cause of neuronal demise in Alzheimer disease (AD) patients. Blood-borne macrophages might reduce Abeta stress to neurons by immigration into the brain and phagocytosis of Alphabeta. We tested migration and export across a blood-brain barrier model, and phagocytosis and clearance of Alphabeta by AD and normal subjects' macrophages. Both AD and normal macrophages were inhibited in Alphabeta export across the blood-brain barrier due to adherence of Abeta-engorged macrophages to the endothelial layer. In comparison to normal subjects' macrophages, AD macrophages ingested and cleared less Alphabeta, and underwent apoptosis upon exposure to soluble, protofibrillar, or fibrillar Alphabeta. Confocal microscopy of stained AD brain sections revealed oligomeric Abeta in neurons and apoptotic macrophages, which surrounded and infiltrated congophilic microvessels, and fibrillar Abeta in plaques and microvessel walls. After incubation with AD brain sections, normal subjects' monocytes intruded into neurons and uploaded oligomeric Abeta. In conclusion, in patients with AD, macrophages appear to shuttle Abeta from neurons to vessels where their apoptosis may release fibrillar Abeta, contributing to cerebral amyloid angiopathy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zaghi</LastName><ForeName>Justin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, UCLA-Orthopaedic Hospital Research Center, Los Angeles, CA 90095-7358, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldenson</LastName><ForeName>Ben</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Inayathullah</LastName><ForeName>Mohammed</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lossinsky</LastName><ForeName>Albert S</ForeName><Initials>AS</Initials></Author><Author ValidYN="Y"><LastName>Masoumi</LastName><ForeName>Ava</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Avagyan</LastName><ForeName>Hripsime</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Mahanian</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bernas</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Weinand</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Rosenthal</LastName><ForeName>Mark J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Espinosa-Jeffrey</LastName><ForeName>Araceli</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>de Vellis</LastName><ForeName>Jean</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Teplow</LastName><ForeName>David B</ForeName><Initials>DB</Initials></Author><Author ValidYN="Y"><LastName>Fiala</LastName><ForeName>Milan</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG027818</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG027818</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Acta Neuropathol</MedlineTA><NlmUniqueID>0412041</NlmUniqueID><ISSNLinking>0001-6322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016657" MajorTopicYN="N">Cerebral Amyloid Angiopathy</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055806" MajorTopicYN="N">Microvessels</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of interest statement</b> This work was supported by the Alzheimer&#x2019;s Association, MPBio Ltd (MF) and NIH grant AG027818 (DBT).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>12</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2008</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>1</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>1</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>2</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>10</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19139910</ArticleId><ArticleId IdType="mid">NIHMS901996</ArticleId><ArticleId IdType="pmc">PMC5650912</ArticleId><ArticleId IdType="doi">10.1007/s00401-008-0481-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O&#x2019;Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T. Inflammation and Alzheimer&#x2019;s disease. Neurobiol Aging. 2000;21:383&#x2013;421. doi: 10.1016/S0197-4580(00)00124-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(00)00124-X</ArticleId><ArticleId IdType="pmc">PMC3887148</ArticleId><ArticleId IdType="pubmed">10858586</ArticleId></ArticleIdList></Reference><Reference><Citation>Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6:916&#x2013;919. doi: 10.1038/78682.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/78682</ArticleId><ArticleId IdType="pubmed">10932230</ArticleId></ArticleIdList></Reference><Reference><Citation>Carare RO, Bernardes-Silva M, Newman TA, Page AM, Nicoll JA, Perry VH, Weller RO. Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries: significance for cerebral amyloid angiopathy and neuroimmunology. Neuropathol Appl Neurobiol. 2008;34:131&#x2013;144. doi: 10.1111/j.1365-2990.2007.00926.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2990.2007.00926.x</ArticleId><ArticleId IdType="pubmed">18208483</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen K, Iribarren P, Hu J, Chen J, Gong W, Cho EH, Lockett S, Dunlop NM, Wang JM. Activation of Toll-like receptor 2 on microglia promotes cell uptake of Alzheimer disease-associated amyloid beta peptide. J Biol Chem. 2006;281:3651&#x2013;3659. doi: 10.1074/jbc.M508125200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M508125200</ArticleId><ArticleId IdType="pubmed">16339765</ArticleId></ArticleIdList></Reference><Reference><Citation>Colton CA, Brown CM, Cook D, Needham LK, Xu Q, Czapiga M, Saunders AM, Schmechel DE, Rasheed K, Vitek MP. APOE and the regulation of microglial nitric oxide production: a link between genetic risk and oxidative stress. Neurobiol Aging. 2002;23:777&#x2013;785. doi: 10.1016/S0197-4580(02)00016-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(02)00016-7</ArticleId><ArticleId IdType="pubmed">12392781</ArticleId></ArticleIdList></Reference><Reference><Citation>El Khoury JB, Moore KJ, Means TK, Leung J, Terada K, Toft M, Freeman MW, Luster AD. CD36 mediates the innate host response to beta-amyloid. J Exp Med. 2003;197:1657&#x2013;1666. doi: 10.1084/jem.20021546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20021546</ArticleId><ArticleId IdType="pmc">PMC2193948</ArticleId><ArticleId IdType="pubmed">12796468</ArticleId></ArticleIdList></Reference><Reference><Citation>El Khoury J, Toft M, Hickman SE, Means TK, Terada K, Geula C, Luster AD. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med. 2007;13:432&#x2013;438. doi: 10.1038/nm1555.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1555</ArticleId><ArticleId IdType="pubmed">17351623</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiala M, Looney DJ, Stins M, Way DD, Zhang L, Gan X, Chiappelli F, Schweitzer ES, Shapshak P, Weinand M, Graves MC, Witte M, Kim KS. TNF-alpha opens a paracellular route for HIV-1 invasion across the blood-brain barrier. Mol Med. 1997;3:553&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2230176</ArticleId><ArticleId IdType="pubmed">9307983</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiala M, Zhang L, Gan X, Sherry B, Taub D, Graves MC, Hama S, Way D, Weinand M, Witte M, Lorton D, Kuo YM, Roher AE. Amyloid-beta induces chemokine secretion and monocyte migration across a human blood&#x2013;brain barrier model. Mol Med. 1998;4:480&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2230332</ArticleId><ArticleId IdType="pubmed">9713826</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiala M, Liu NQ, Reddy S, Graves M. Macrophages infiltrate the brain and express COX-2 and iNOS in Alzheimer&#x2019;s disease and AIDS. Alzheimers Rep. 2001;4:1&#x2013;7.</Citation></Reference><Reference><Citation>Fiala M, Liu QN, Sayre J, Pop V, Brahmandam V, Graves MC, Vinters HV. Cyclooxygenase-2-positive macrophages infiltrate the Alzheimer&#x2019;s disease brain and damage the blood-brain barrier. Eur J Clin Invest. 2002;32:360&#x2013;371. doi: 10.1046/j.1365-2362.2002.00994.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2362.2002.00994.x</ArticleId><ArticleId IdType="pubmed">12027877</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiala M, Eshleman AJ, Cashman J, Lin J, Losssinsky AS, Suarez V, Yang W, Zhang J, Popik W, Singer EJ, Chiappelli F, Carro E, Weinand M, Witte M, Arthos J. Cocaine increases human immunodeficiency virus type 1 neuroinvasion through remodeling brain microvascular endothelial cells. J Neurovirol. 2005;11:1&#x2013;11. doi: 10.1080/13550280590952835.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13550280590952835</ArticleId><ArticleId IdType="pubmed">16036808</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiala M, Lin J, Ringman J, Kermani-Arab V, Tsao G, Patel A, Lossinsky AS, Graves MC, Gustavson A, Sayre J, Sofroni E, Suarez T, Chiappelli F, Bernard G. Ineffective phagocytosis of amyloid-beta by macrophages of Alzheimer&#x2019;s disease patients. J Alzheimers Dis. 2005;7:221&#x2013;232. discussion 255&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pubmed">16006665</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiala M, Cribbs DH, Rosenthal M, Bernard G. Phagocytosis of amyloid-beta and inflammation: two faces of innate immunity in Alzheimer&#x2019;s disease. J Alzheimers Dis. 2007;11:457&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pubmed">17656824</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiala M, Liu PT, Espinosa-Jeffrey A, Rosenthal MJ, Bernard G, Ringman JM, Sayre J, Zhang L, Zaghi J, Dejbakhsh S, Chiang B, Hui J, Mahanian M, Baghaee A, Hong P, Cashman J. Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer&#x2019;s disease patients are improved by bisdemethoxycurcumin. Proc Natl Acad Sci USA. 2007;104:12849&#x2013;12854. doi: 10.1073/pnas.0701267104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0701267104</ArticleId><ArticleId IdType="pmc">PMC1937555</ArticleId><ArticleId IdType="pubmed">17652175</ArticleId></ArticleIdList></Reference><Reference><Citation>Frautschy SA, Yang F, Irrizarry M, Hyman B, Saido TC, Hsiao K, Cole GM. Microglial response to amyloid plaques in APPsw transgenic mice. Am J Pathol. 1998;152:307&#x2013;317. see comments.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1858113</ArticleId><ArticleId IdType="pubmed">9422548</ArticleId></ArticleIdList></Reference><Reference><Citation>Giri R, Shen Y, Stins M, Du Yan S, Schmidt AM, Stern D, Kim KS, Zlokovic B, Kalra VK. Beta-amyloid-induced migration of monocytes across human brain endothelial cells involves RAGE and PECAM-1. Am J Physiol Cell Physiol. 2000;279:C1772&#x2013;C1781.</Citation><ArticleIdList><ArticleId IdType="pubmed">11078691</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouras GK, Almeida CG, Takahashi RH. Intraneuronal Abeta accumulation and origin of plaques in Alzheimer&#x2019;s disease. Neurobiol Aging. 2005;26:1235&#x2013;1244. doi: 10.1016/j.neurobiolaging.2005.05.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2005.05.022</ArticleId><ArticleId IdType="pubmed">16023263</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton JA, Whitty G, White AR, Jobling MF, Thompson A, Barrow CJ, Cappai R, Beyreuther K, Masters CL. Alzheimer&#x2019;s disease amyloid beta and prion protein amyloidogenic peptides promote macrophage survival, DNA synthesis and enhanced proliferative response to CSF-1 (M-CSF) Brain Res. 2002;940:49&#x2013;54. doi: 10.1016/S0006-8993(02)02589-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-8993(02)02589-1</ArticleId><ArticleId IdType="pubmed">12020874</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356. doi: 10.1126/science.1072994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1072994</ArticleId><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Husemann J, Loike JD, Anankov R, Febbraio M, Silverstein SC. Scavenger receptors in neurobiology and neuropathology: their role on microglia and other cells of the nervous system. Glia. 2002;40:195&#x2013;205. doi: 10.1002/glia.10148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.10148</ArticleId><ArticleId IdType="pubmed">12379907</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300:486&#x2013;489. doi: 10.1126/science.1079469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1079469</ArticleId><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, Head E, Sarsoza F, Saing T, Cotman CW, Necula M, Margol L, Wu J, Breydo L, Thompson JL, Rasool S, Gurlo T, Butler P, Glabe CG. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener. 2007;2:18. doi: 10.1186/1750-1326-2-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-2-18</ArticleId><ArticleId IdType="pmc">PMC2100048</ArticleId><ArticleId IdType="pubmed">17897471</ArticleId></ArticleIdList></Reference><Reference><Citation>Krajewska M, Rosenthal RE, Mikolajczyk J, Stennicke HR, Wiesenthal T, Mai J, Naito M, Salvesen GS, Reed JC, Fiskum G, Krajewski S. Early processing of Bid and caspase-6, -8, -10, -14 in the canine brain during cardiac arrest and resuscitation. Exp Neurol. 2004;189:261&#x2013;279. doi: 10.1016/j.expneurol.2004.05.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2004.05.020</ArticleId><ArticleId IdType="pubmed">15380478</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer&#x2019;s disease. Nat Rev Neurosci. 2007;8:499&#x2013;509. doi: 10.1038/nrn2168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2168</ArticleId><ArticleId IdType="pubmed">17551515</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu NQ, Lossinsky AS, Popik W, Li X, Gujuluva C, Kriederman B, Roberts J, Pushkarsky T, Bukrinsky M, Witte M, Weinand M, Fiala M. Human immunodeficiency virus type 1 enters brain microvascular endothelia by macropinocytosis dependent on lipid rafts and the mitogen-activated protein kinase signaling pathway. J Virol. 2002;76:6689&#x2013;6700. doi: 10.1128/JVI.76.13.6689-6700.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.76.13.6689-6700.2002</ArticleId><ArticleId IdType="pmc">PMC136265</ArticleId><ArticleId IdType="pubmed">12050382</ArticleId></ArticleIdList></Reference><Reference><Citation>Lossinsky AS, Shivers RR. Studies of cerebral endothelium by scanning and high-voltage electron microscopy. In: Nag S, editor. The blood-brain barrier: biology and research protocols. Vol. 89. Humana Press; Totawa: 2003. pp. 67&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">12958413</ArticleId></ArticleIdList></Reference><Reference><Citation>Majumdar A, Chung H, Dolios G, Wang R, Asamoah N, Lobel P, Maxfield FR. Degradation of fibrillar forms of Alzheimer&#x2019;s amyloid beta-peptide by macrophages. Neurobiol Aging. 2008;29:707&#x2013;715. doi: 10.1016/j.neurobiolaging.2006.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2006.12.001</ArticleId><ArticleId IdType="pmc">PMC2424018</ArticleId><ArticleId IdType="pubmed">17222479</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Mildner A, Schmidt H, Nitsche M, Merkler D, Hanisch UK, Mack M, Heikenwalder M, Bruck W, Priller J, Prinz M. Microglia in the adult brain arise from Ly-6C(hi)CCR2(+) monocytes only under defined host conditions. Nat Neurosci. 2007;10:1544&#x2013;1553. doi: 10.1038/nn2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn2015</ArticleId><ArticleId IdType="pubmed">18026096</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrak RE, Griffin WS. Potential inflammatory biomarkers in Alzheimer&#x2019;s disease. J Alzheimers Dis. 2005;8:369&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">16556968</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA. Autophagy, amyloidogenesis and Alzheimer disease. J Cell Sci. 2007;120:4081&#x2013;4091. doi: 10.1242/jcs.019265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.019265</ArticleId><ArticleId IdType="pubmed">18032783</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Tran L, Lambert MP, Glabe CG, Klein WL, LaFerla FM. Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem. 2006;281:1599&#x2013;1604. doi: 10.1074/jbc.M507892200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M507892200</ArticleId><ArticleId IdType="pubmed">16282321</ArticleId></ArticleIdList></Reference><Reference><Citation>Paresce DM, Ghosh RN, Maxfield FR. Microglial cells internalize aggregates of the Alzheimer&#x2019;s disease amyloid beta-protein via a scavenger receptor. Neuron. 1996;17:553&#x2013;565. doi: 10.1016/S0896-6273(00)80187-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)80187-7</ArticleId><ArticleId IdType="pubmed">8816718</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagare A, Deane R, Bell RD, Johnson B, Hamm K, Pendu R, Marky A, Lenting PJ, Wu Z, Zarcone T, Goate A, Mayo K, Perlmutter D, Coma M, Zhong Z, Zlokovic BV. Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med. 2007;13:1029&#x2013;1031. doi: 10.1038/nm1635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1635</ArticleId><ArticleId IdType="pmc">PMC2936449</ArticleId><ArticleId IdType="pubmed">17694066</ArticleId></ArticleIdList></Reference><Reference><Citation>Simard AR, Rivest S. Neuroprotective properties of the innate immune system and bone marrow stem cells in Alzheimer&#x2019;s disease. Mol Psychiatry. 2006;11:327&#x2013;335. doi: 10.1038/sj.mp.4001809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.mp.4001809</ArticleId><ArticleId IdType="pubmed">16491130</ArticleId></ArticleIdList></Reference><Reference><Citation>Simard AR, Soulet D, Gowing G, Julien JP, Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer&#x2019;s disease. Neuron. 2006;49:489&#x2013;502. doi: 10.1016/j.neuron.2006.01.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2006.01.022</ArticleId><ArticleId IdType="pubmed">16476660</ArticleId></ArticleIdList></Reference><Reference><Citation>Smits HA, Rijsmus A, van Loon JH, Wat JW, Verhoef J, Boven LA, Nottet HS. Amyloid-beta-induced chemokine production in primary human macrophages and astrocytes. J Neuroimmunol. 2002;127:160&#x2013;168. doi: 10.1016/S0165-5728(02)00112-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-5728(02)00112-1</ArticleId><ArticleId IdType="pubmed">12044988</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon B. Intravenous immunoglobulin and Alzheimer&#x2019;s disease immunotherapy. Curr Opin Mol Ther. 2007;9:79&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">17330405</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoll G, Jander S. The role of microglia and macrophages in the pathophysiology of the CNS. Prog Neurobiol. 1999;58:233&#x2013;247. doi: 10.1016/S0301-0082(98)00083-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0301-0082(98)00083-5</ArticleId><ArticleId IdType="pubmed">10341362</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart LM, Bell SA, Stewart CR, Silver JM, Richard J, Goss JL, Tseng AA, Zhang A, El Khoury JB, Moore KJ. CD36 signals to the actin cytoskeleton and regulates microglial migration via a p130Cas complex. J Biol Chem. 2007;282:27392&#x2013;27401. doi: 10.1074/jbc.M702887200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M702887200</ArticleId><ArticleId IdType="pubmed">17623670</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE, Moir RD, Wagner SL. Clearance of Alzheimer&#x2019;s Abeta peptide: the many roads to perdition. Neuron. 2004;43:605&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">15339642</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng BP, Green KN, Chan JL, Blurton-Jones M, LaFerla FM. Abeta inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol Aging. 2008;29:1607&#x2013;1618. doi: 10.1016/j.neurobiolaging.2007.04.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2007.04.014</ArticleId><ArticleId IdType="pmc">PMC2664168</ArticleId><ArticleId IdType="pubmed">17544172</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Dorpe J, Smeijers L, Dewachter I, Nuyens D, Spittaels K, Van Den Haute C, Mercken M, Moechars D, Laenen I, Kuiperi C, Bruynseels K, Tesseur I, Loos R, Vanderstichele H, Checler F, Sciot R, Van Leuven F. Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the London mutant of human APP in neurons. Am J Pathol. 2000;157:1283&#x2013;1298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850171</ArticleId><ArticleId IdType="pubmed">11021833</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster SD, Yang AJ, Margol L, Garzon-Rodriguez W, Glabe CG, Tenner AJ. Complement component C1q modulates the phagocytosis of Abeta by microglia. Exp Neurol. 2000;161:127&#x2013;138. doi: 10.1006/exnr.1999.7260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/exnr.1999.7260</ArticleId><ArticleId IdType="pubmed">10683279</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster SD, Galvan MD, Ferran E, Garzon-Rodriguez W, Glabe CG, Tenner AJ. Antibody-mediated phagocytosis of the amyloid beta-peptide in microglia is differentially modulated by C1q. J Immunol. 2001;166:7496&#x2013;7503.</Citation><ArticleIdList><ArticleId IdType="pubmed">11390503</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegiel J, Kuchna I, Nowicki K, Frackowiak J, Mazur-Kolecka B, Imaki H, Mehta PD, Silverman WP, Reisberg B, Deleon M, Wisniewski T, Pirttilla T, Frey H, Lehtimaki T, Kivimaki T, Visser FE, Kamphorst W, Potempska A, Bolton D, Currie JR, Miller DL. Intraneuronal Abeta immunoreactivity is not a predictor of brain amyloidosis-beta or neurofibrillary degeneration. Acta Neuropathol. 2007;113:389&#x2013;402. doi: 10.1007/s00401-006-0191-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-006-0191-4</ArticleId><ArticleId IdType="pmc">PMC1824787</ArticleId><ArticleId IdType="pubmed">17237937</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner HL, Frenkel D. Immunology and immunotherapy of Alzheimer&#x2019;s disease. Nat Rev Immunol. 2006;6:404&#x2013;416. doi: 10.1038/nri1843.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri1843</ArticleId><ArticleId IdType="pubmed">16639431</ArticleId></ArticleIdList></Reference><Reference><Citation>Weller RO, Nicoll JA. Cerebral amyloid angiopathy: pathogenesis and effects on the ageing and Alzheimer brain. Neurol Res. 2003;25:611&#x2013;616. doi: 10.1179/016164103101202057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/016164103101202057</ArticleId><ArticleId IdType="pubmed">14503015</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, DiCarlo G, Henderson D, Jackson J, Clarke K, Ugen KE, Gordon MN, Morgan D. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci. 2003;23:3745&#x2013;3751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742181</ArticleId><ArticleId IdType="pubmed">12736345</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski HM, Wegiel J. Beta-amyloid formation by myocytes of leptomeningeal vessels. Acta Neuropathol. 1994;87:233&#x2013;241. doi: 10.1007/BF00296738.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00296738</ArticleId><ArticleId IdType="pubmed">8009955</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski HM, Wegiel J, Wang KC, Lach B. Ultrastructural studies of the cells forming amyloid in the cortical vessel wall in Alzheimer&#x2019;s disease. Acta Neuropathol. 1992;84:117&#x2013;127. doi: 10.1007/BF00311383.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00311383</ArticleId><ArticleId IdType="pubmed">1381856</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada M, Itoh Y, Shintaku M, Kawamura J, Jensson O, Thorsteinsson L, Suematsu N, Matsushita M, Otomo E. Immune reactions associated with cerebral amyloid angiopathy. Stroke. 1996;27:1155&#x2013;1162.</Citation><ArticleIdList><ArticleId IdType="pubmed">8685920</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Fiala M, Cashman J, Sayre J, Espinosa-Jeffrey A, Mahanian M, Zaghi J, Badmaev V, Graves M, Bernard G, Rosenthal M. Curcuminoids enhance amyloid-beta uptake by macrophages of Alzheimer&#x2019;s disease patients. J Alzheimers Dis. 2006;10:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16988474</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19164538</PMID><DateCompleted><Year>2009</Year><Month>02</Month><Day>27</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>106</Volume><Issue>5</Issue><PubDate><Year>2009</Year><Month>Feb</Month><Day>03</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>A helix-to-coil transition at the epsilon-cut site in the transmembrane dimer of the amyloid precursor protein is required for proteolysis.</ArticleTitle><Pagination><StartPage>1421</StartPage><EndPage>1426</EndPage><MedlinePgn>1421-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0812261106</ELocationID><Abstract><AbstractText>Processing of amyloid precursor protein (APP) by gamma-secretase is the last step in the formation of the Abeta peptides associated Alzheimer's disease. Solid-state NMR spectroscopy is used to establish the structural features of the transmembrane (TM) and juxtamembrane (JM) domains of APP that facilitate proteolysis. Using peptides corresponding to the APP TM and JM regions (residues 618-660), we show that the TM domain forms an alpha-helical homodimer mediated by consecutive GxxxG motifs. We find that the APP TM helix is disrupted at the intracellular membrane boundary near the epsilon-cleavage site. This helix-to-coil transition is required for gamma-secretase processing; mutations that extend the TM alpha-helix inhibit epsilon cleavage, leading to a low production of Abeta peptides and an accumulation of the alpha- and beta-C-terminal fragments. Our data support a progressive cleavage mechanism for APP proteolysis that depends on the helix-to-coil transition at the TM-JM boundary and unraveling of the TM alpha-helix.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Cell Biology, Center for Structural Biology, Stony Brook University, Stony Brook, NY 11794-5115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Tzu-Chun</ForeName><Initials>TC</Initials></Author><Author ValidYN="Y"><LastName>Reubins</LastName><ForeName>Gabriella</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Fei</LastName><ForeName>Jeffrey Z</ForeName><Initials>JZ</Initials></Author><Author ValidYN="Y"><LastName>Fujimoto</LastName><ForeName>Taiki</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Kienlen-Campard</LastName><ForeName>Pascal</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Constantinescu</LastName><ForeName>Stefan N</ForeName><Initials>SN</Initials></Author><Author ValidYN="Y"><LastName>Octave</LastName><ForeName>Jean-Noel</ForeName><Initials>JN</Initials></Author><Author ValidYN="Y"><LastName>Aimoto</LastName><ForeName>Saburo</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Steven O</ForeName><Initials>SO</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG027317</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM046732</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG-27317</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>GM-46732</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>01</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003412" MajorTopicYN="N">Cricetulus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003593" MajorTopicYN="N">Cytoplasm</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019281" MajorTopicYN="N">Dimerization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006868" MajorTopicYN="N">Hydrolysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019906" MajorTopicYN="N">Nuclear Magnetic Resonance, Biomolecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017550" MajorTopicYN="N">Spectroscopy, Fourier Transform Infrared</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>1</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>1</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>2</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>8</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19164538</ArticleId><ArticleId IdType="pmc">PMC2635791</ArticleId><ArticleId IdType="doi">10.1073/pnas.0812261106</ArticleId><ArticleId IdType="pii">0812261106</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe DJ. Alzheimer disease: Mechanistic understanding predicts novel therapies. Ann Intern Med. 2004;140:627&#x2013;638.</Citation><ArticleIdList><ArticleId IdType="pubmed">15096334</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao XW, S&#xfc;dhof TC. A transcriptively active complex of APP with Fe65 and histone acetyltransferase Tip60. Science. 2001;293:115&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">11441186</ArticleId></ArticleIdList></Reference><Reference><Citation>Burdick D, et al. Assembly and aggregation properties of synthetic Alzheimer's A4/&#x3b2; amyloid peptide analogs. J Biol Chem. 1992;267:546&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pubmed">1730616</ArticleId></ArticleIdList></Reference><Reference><Citation>Weidemann A, et al. A novel epsilon-cleavage within the transmembrane domain of the Alzheimer amyloid precursor protein demonstrates homology with notch processing. Biochemistry. 2002;41:2825&#x2013;2835.</Citation><ArticleIdList><ArticleId IdType="pubmed">11851430</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye J, Dave UP, Grishin NV, Goldstein JL, Brown MS. Asparagine-proline sequence within membrane-spanning segment of SREBP triggers intramembrane cleavage by Site-2 protease. Proc Natl Acad Sci USA. 2000;97:5123&#x2013;5128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC25792</ArticleId><ArticleId IdType="pubmed">10805775</ArticleId></ArticleIdList></Reference><Reference><Citation>Li SC, Deber CM. Glycine and &#x3b2;-branched residues support and modulate peptide helicity in membrane environments. FEBS Lett. 1992;311:217&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">1397317</ArticleId></ArticleIdList></Reference><Reference><Citation>Deber CM, et al. Val&#x2013;&gt;Ala mutations selectively alter helix-helix packing in the transmembrane segment of phage M13 coat protein. Proc Natl Acad Sci USA. 1993;90:11648&#x2013;11652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC48041</ArticleId><ArticleId IdType="pubmed">8265602</ArticleId></ArticleIdList></Reference><Reference><Citation>Russ WP, Engelman DM. The GxxxG motif: A framework for transmembrane helix-helix association. J Mol Biol. 2000;296:911&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">10677291</ArticleId></ArticleIdList></Reference><Reference><Citation>Munter LM, et al. GxxxG motifs within the amyloid precursor protein transmembrane sequence are critical for the etiology of A&#x3b2;42. EMBO J. 2007;26:1702&#x2013;1712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1829382</ArticleId><ArticleId IdType="pubmed">17332749</ArticleId></ArticleIdList></Reference><Reference><Citation>Kienlen-Campard P, et al. Amyloidogenic processing but not amyloid precursor protein (APP) intracellular C-terminal domain production requires a precisely oriented APP dimer assembled by transmembrane GXXXG motifs. J Biol Chem. 2008;283:7733&#x2013;7744.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702479</ArticleId><ArticleId IdType="pubmed">18201969</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorman PM, et al. Dimerization of the transmembrane domain of amyloid precursor proteins and familial Alzheimer's disease mutants. BMC Neuroscience. 2008;9:17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2266763</ArticleId><ArticleId IdType="pubmed">18234110</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SO, et al. Implications of threonine hydrogen bonding in the glycophorin A transmembrane helix dimer. Biophys J. 2002;82:2476&#x2013;2486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1302037</ArticleId><ArticleId IdType="pubmed">11964235</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito H, Tuzi S, Naito A. Empirical versus nonempirical evaluation of secondary structure of fibrous and membrane proteins by solid-state NMR: A practical approach. Annu Rep NMR Spectrosc. 1998;36:79&#x2013;121.</Citation></Reference><Reference><Citation>Scheuermann S, et al. Homodimerization of amyloid precursor protein and its implication in the amyloidogenic pathway of Alzheimer's disease. J Biol Chem. 2001;276:33923&#x2013;33929.</Citation><ArticleIdList><ArticleId IdType="pubmed">11438549</ArticleId></ArticleIdList></Reference><Reference><Citation>Vooijs M, Schroeter EH, Pan YH, Blandford M, Kopan R. Ectodomain shedding and intramembrane cleavage of mammalian notch proteins is not regulated through oligomerization. J Biol Chem. 2004;279:50864&#x2013;50873.</Citation><ArticleIdList><ArticleId IdType="pubmed">15448134</ArticleId></ArticleIdList></Reference><Reference><Citation>Senes A, Ubarretxena-Belandia I, Engelman DM. The C&#x3b1;-H&#x2026;.O hydrogen bond: A determinant of stability and specificity in transmembrane helix interactions. Proc Natl Acad Sci USA. 2001;98:9056&#x2013;9061.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC55372</ArticleId><ArticleId IdType="pubmed">11481472</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramelot TA, Gentile LN, Nicholson LK. Transient structure of the amyloid precursor protein cytoplasmic tail indicates preordering of structure for binding to cytosolic factors. Biochemistry. 2000;39:2714&#x2013;2725.</Citation><ArticleIdList><ArticleId IdType="pubmed">10704223</ArticleId></ArticleIdList></Reference><Reference><Citation>Theresa A, Ramelot TA, Nicholson LK. Phosphorylation-induced structural changes in the amyloid precursor protein cytoplasmic tail detected by NMR. J Mol Biol. 2001;307:871&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pubmed">11273707</ArticleId></ArticleIdList></Reference><Reference><Citation>Dovey HF, et al. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem. 2001;76:173&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">11145990</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B. Loss-of-function presenilin mutations in Alzheimer disease - Talking point on the role of presenilin mutations in Alzheimer disease. EMBO Rep. 2007;8:141&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1796779</ArticleId><ArticleId IdType="pubmed">17268505</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu CJ, et al. Characterization of a presenilin-mediated amyloid precursor protein carboxyl-terminal fragment gamma - Evidence for distinct mechanisms involved in gamma-secretase processing or the APP and Notch1 transmembrane domains. J Biol Chem. 2001;276:43756&#x2013;43760.</Citation><ArticleIdList><ArticleId IdType="pubmed">11583985</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi-Takahara Y, et al. Longer forms of amyloid &#x3b2; protein: Implications for the mechanism of intramembrane cleavage by gamma-secretase. J Neurosci. 2005;25:436&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725472</ArticleId><ArticleId IdType="pubmed">15647487</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakuda N, et al. Equimolar production of amyloid &#x3b2;-protein and amyloid precursor protein intracellular domain from &#x3b2;-carboxyl-terminal fragment by &#x3b3;-secretase. J Biol Chem. 2006;281:14776&#x2013;14786.</Citation><ArticleIdList><ArticleId IdType="pubmed">16595682</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandu D, Huppert SS, Kopan R. Analysis of transmembrane domain mutants is consistent with sequential cleavage of Notch by &#x3b3;-secretase. J Neurochem. 2006;96:228&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">16300632</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiley JC, Hudson M, Kanning KC, Schecterson LC, Bothwell M. Familial Alzheimer's disease mutations inhibit &#x3b3;-secretase-mediated liberation of &#x3b2;-amyloid precursor protein carboxy-terminal fragment. J Neurochem. 2005;94:1189&#x2013;1201.</Citation><ArticleIdList><ArticleId IdType="pubmed">15992373</ArticleId></ArticleIdList></Reference><Reference><Citation>Hecimovic S, et al. Mutations in APP have independent effects on A&#x3b2; and CTF&#x3b3; generation. Neurobiol Dis. 2004;17:205&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pubmed">15474359</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YC, Zhang YJ, Ha Y. Crystal structure of a rhomboid family intramembrane protease. Nature. 2006;444:179&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">17051161</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng L, et al. Structure of a site-2 protease family intramembrane metalloprotease. Science. 2007;318:1608&#x2013;1612.</Citation><ArticleIdList><ArticleId IdType="pubmed">18063795</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncan EA, Dave UP, Sakai J, Goldstein JL, Brown MS. Second-site cleavage in sterol regulatory element-binding protein occurs at transmembrane junction as determined by cysteine panning. J Biol Chem. 1998;273:17801&#x2013;17809.</Citation><ArticleIdList><ArticleId IdType="pubmed">9651382</ArticleId></ArticleIdList></Reference><Reference><Citation>Takegoshi K, Nakamura S, Terao T. 13C-1H dipolar-assisted rotational resonance in magic-angle spinning NMR. Chem Phys Lett. 2001;344:631&#x2013;637.</Citation></Reference><Reference><Citation>Huysseune S, Kienlen-Campard P, Octave JN. Fe65 does not stabilize AICD during activation of transcription in a luciferase assay. Biochem Biophys Res Commun. 2007;361:317&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pubmed">17651693</ArticleId></ArticleIdList></Reference><Reference><Citation>Sergeant N, et al. Progressive decrease of amyloid precursor protein carboxy terminal fragments (APP-CTFs), associated with tau pathology stages, in Alzheimer's disease. J Neurochem. 2002;81:663&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pubmed">12065626</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19164579</PMID><DateCompleted><Year>2009</Year><Month>02</Month><Day>27</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>106</Volume><Issue>5</Issue><PubDate><Year>2009</Year><Month>Feb</Month><Day>03</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Altered temporal correlations in parietal alpha and prefrontal theta oscillations in early-stage Alzheimer disease.</ArticleTitle><Pagination><StartPage>1614</StartPage><EndPage>1619</EndPage><MedlinePgn>1614-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0811699106</ELocationID><Abstract><AbstractText>Encoding and retention of information in memory are associated with a sustained increase in the amplitude of neuronal oscillations for up to several seconds. We reasoned that coordination of oscillatory activity over time might be important for memory and, therefore, that the amplitude modulation of oscillations may be abnormal in Alzheimer disease (AD). To test this hypothesis, we measured magnetoencephalography (MEG) during eyes-closed rest in 19 patients diagnosed with early-stage AD and 16 age-matched control subjects and characterized the autocorrelation structure of ongoing oscillations using detrended fluctuation analysis and an analysis of the life- and waiting-time statistics of oscillation bursts. We found that Alzheimer's patients had a strongly reduced incidence of alpha-band oscillation bursts with long life- or waiting-times (&lt; 1 s) over temporo-parietal regions and markedly weaker autocorrelations on long time scales (1-25 seconds). Interestingly, the life- and waiting-times of theta oscillations over medial prefrontal regions were greatly increased. Whereas both temporo-parietal alpha and medial prefrontal theta oscillations are associated with retrieval and retention of information, metabolic and structural deficits in early-stage AD are observed primarily in temporo-parietal areas, suggesting that the enhanced oscillations in medial prefrontal cortex reflect a compensatory mechanism. Together, our results suggest that amplitude modulation of neuronal oscillations is important for cognition and that indices of amplitude dynamics of oscillations may prove useful as neuroimaging biomarkers of early-stage AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Montez</LastName><ForeName>Teresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute of Biophysics and Biomedical Engineering, Faculty of Sciences of the University of Lisbon, Campo Grande, 1749-016 Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poil</LastName><ForeName>Simon-Shlomo</ForeName><Initials>SS</Initials></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Bethany F</ForeName><Initials>BF</Initials></Author><Author ValidYN="Y"><LastName>Manshanden</LastName><ForeName>Ilonka</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Verbunt</LastName><ForeName>Jeroen P A</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>van Dijk</LastName><ForeName>Bob W</ForeName><Initials>BW</Initials></Author><Author ValidYN="Y"><LastName>Brussaard</LastName><ForeName>Arjen B</ForeName><Initials>AB</Initials></Author><Author ValidYN="Y"><LastName>van Ooyen</LastName><ForeName>Arjen</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Stam</LastName><ForeName>Cornelis J</ForeName><Initials>CJ</Initials></Author><Author ValidYN="Y"><LastName>Scheltens</LastName><ForeName>Philip</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Linkenkaer-Hansen</LastName><ForeName>Klaus</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>01</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010296" MajorTopicYN="N">Parietal Lobe</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>1</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>1</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>2</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>8</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19164579</ArticleId><ArticleId IdType="pmc">PMC2635782</ArticleId><ArticleId IdType="doi">10.1073/pnas.0811699106</ArticleId><ArticleId IdType="pii">0811699106</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Binder R, et al. Conceptual processing during the conscious resting state: a functional MRI study. J Cognit Neurosci. 1999;11:80&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">9950716</ArticleId></ArticleIdList></Reference><Reference><Citation>Mason MF, et al. Wandering minds: the default network and stimulus-independent thought. Science. 2007;315:393&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1821121</ArticleId><ArticleId IdType="pubmed">17234951</ArticleId></ArticleIdList></Reference><Reference><Citation>Smallwood J, Schooler JW. The restless mind. Psycholl Bull. 2006;132:946&#x2013;958.</Citation><ArticleIdList><ArticleId IdType="pubmed">17073528</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox MD, Raichle ME. Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging. Nat Rev Neurosci. 2007;8:700&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pubmed">17704812</ArticleId></ArticleIdList></Reference><Reference><Citation>Damoiseaux JS, et al. Consistent resting-state networks across healthy subjects. Proc Natl Acad Sci USA. 2006;103:13848&#x2013;13853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1564249</ArticleId><ArticleId IdType="pubmed">16945915</ArticleId></ArticleIdList></Reference><Reference><Citation>Gusnard DA, Raichle ME. Searching for a baseline: functional imaging and the resting human brain. Nat Rev Neurosci. 2001;2:685&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pubmed">11584306</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci USA. 2004;101:4637&#x2013;4642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC384799</ArticleId><ArticleId IdType="pubmed">15070770</ArticleId></ArticleIdList></Reference><Reference><Citation>Babiloni C, et al. Abnormal fronto-parietal coupling of brain rhythms in mild Alzheimer's disease: a multicentric EEG study. Eur J Neurosci. 2004;19:2583&#x2013;2590.</Citation><ArticleIdList><ArticleId IdType="pubmed">15128412</ArticleId></ArticleIdList></Reference><Reference><Citation>Stam CJ, et al. Magnetoencephalographic evaluation of resting-state functional connectivity in Alzheimer's disease. NeuroImage. 2006;32:1335&#x2013;1344.</Citation><ArticleIdList><ArticleId IdType="pubmed">16815039</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, et al. Resting-state functional connectivity in major depression: abnormally increased contributions from subgenual cingulate cortex and thalamus. Biol Psych. 2007;62:429&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2001244</ArticleId><ArticleId IdType="pubmed">17210143</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Andrews-Hanna JR, Schacter DL. Anatomy, function, and relevance to disease. Ann NY Acad Sci. 2008;1124:1&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">18400922</ArticleId></ArticleIdList></Reference><Reference><Citation>Linkenkaer-Hansen K, et al. Breakdown of long-range temporal correlations in theta oscillations in patients with major depressive disorder. J Neurosci. 2005;25:10131&#x2013;10137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725784</ArticleId><ArticleId IdType="pubmed">16267220</ArticleId></ArticleIdList></Reference><Reference><Citation>Cowan N. Visual and auditory working memory capacity. Trends Cogn Sci. 1998;2:77&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">21227076</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghavachari S, et al. Gating of human theta oscillations by a working memory task. J Neurosci. 2001;21:3175&#x2013;3183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762557</ArticleId><ArticleId IdType="pubmed">11312302</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen O, Gelfand J, Kounios J, Lisman JE. Oscillations in the alpha band (9&#x2013;12 Hz) increase with memory load during retention in a short-term memory task. Cereb Cortex. 2002;12:877&#x2013;882.</Citation><ArticleIdList><ArticleId IdType="pubmed">12122036</ArticleId></ArticleIdList></Reference><Reference><Citation>Jokisch D, Jensen O. Modulation of gamma and alpha activity during a working memory task engaging the dorsal or ventral stream. J Neurosci. 2007;27:3244&#x2013;3251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672464</ArticleId><ArticleId IdType="pubmed">17376984</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong J. EEG dynamics in patients with Alzheimer's disease. Clin Neurophysiol. 2004;115:1490&#x2013;1505.</Citation><ArticleIdList><ArticleId IdType="pubmed">15203050</ArticleId></ArticleIdList></Reference><Reference><Citation>Osipova D, et al. Altered generation of spontaneous oscillations in Alzheimer's disease. NeuroImage. 2005;27:835&#x2013;841.</Citation><ArticleIdList><ArticleId IdType="pubmed">15961323</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez A, et al. Focal temporoparietal slow activity in Alzheimer's disease revealed by magnetoencephalography. Biol Psych. 2002;52:764&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pubmed">12372668</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris TE. The Theory of Branching Processes. New York: Courier Dover Publications; 2002.</Citation></Reference><Reference><Citation>Plenz D, Thiagarajan TC. The organizing principles of neuronal avalanches: cell assemblies in the cortex? Trends Neurosci. 2007;30:101&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">17275102</ArticleId></ArticleIdList></Reference><Reference><Citation>Linkenkaer-Hansen K, et al. Genetic contributions to long-range temporal correlations in ongoing oscillations. J Neurosci. 2007;27:13882&#x2013;13889.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673639</ArticleId><ArticleId IdType="pubmed">18077700</ArticleId></ArticleIdList></Reference><Reference><Citation>Linkenkaer-Hansen K, Nikouline VV, Palva JM, Ilmoniemi RJ. Long-range temporal correlations and scaling behavior in human brain oscillations. J Neurosci. 2001;21:1370&#x2013;1377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762238</ArticleId><ArticleId IdType="pubmed">11160408</ArticleId></ArticleIdList></Reference><Reference><Citation>Beran J. Statistics for Long-Memory Processes. Palm Beach: Chapman &amp; Hall/CRC; 1994.</Citation></Reference><Reference><Citation>Poil S-S, van Ooyen A, Linkenkaer-Hansen K. Avalanche dynamics of human brain oscillations: relation to critical branching processes and temporal correlations. Hum Brain Mapp. 2008;29:770&#x2013;777.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871218</ArticleId><ArticleId IdType="pubmed">18454457</ArticleId></ArticleIdList></Reference><Reference><Citation>Monto S, Vanhatalo S, Holmes MD, Palva JM. Epileptogenic neocortical networks are revealed by abnormal temporal dynamics in seizure-rree subdural EEG. Cereb Cortex. 2007;17:1386&#x2013;1393.</Citation><ArticleIdList><ArticleId IdType="pubmed">16908492</ArticleId></ArticleIdList></Reference><Reference><Citation>Parish LM, et al. Long-range temporal correlations in epileptogenic and non-epileptogenic human hippocampus. Neuroscience. 2004;125:1069&#x2013;1076.</Citation><ArticleIdList><ArticleId IdType="pubmed">15120866</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL. Memory and executive function in aging and AD: multiple factors that cause decline and reserve factors that compensate. Neuron. 2004;44:195&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450170</ArticleId></ArticleIdList></Reference><Reference><Citation>Johannsen P, Jakobsen J, Gjedde A. Statistical maps of cerebral blood flow deficits in Alzheimer's disease. Eur J Neurol. 2000;7:385&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pubmed">10971597</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson PM, et al. Dynamics of gray matter loss in Alzheimer's disease. J Neurosci. 2003;23:994&#x2013;1005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741905</ArticleId><ArticleId IdType="pubmed">12574429</ArticleId></ArticleIdList></Reference><Reference><Citation>Gevins A. High-resolution EEG mapping of cortical activation related to working memory: effects of task difficulty, type of processing, and practice. Cereb Cortex. 1997;7:374&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pubmed">9177767</ArticleId></ArticleIdList></Reference><Reference><Citation>Bressler SL, Tognoli E. Operational principles of neurocognitive networks. Int J Psychophysiol. 2006;60:139&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">16490271</ArticleId></ArticleIdList></Reference><Reference><Citation>Honey CJ, Kotter R, Breakspear M, Sporns O. Network structure of cerebral cortex shapes functional connectivity on multiple time scales. Proc Natl Acad Sci USA. 2007;104:10245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1891224</ArticleId><ArticleId IdType="pubmed">17548818</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikouline VV, Linkenkaer-Hansen K, Huttunen J, Ilmoniemi RJ. Interhemispheric phase synchrony and amplitude correlation of spontaneous beta oscillations in human subjects: a magnetoencephalographic study. NeuroReport. 2001;12:2487&#x2013;2491.</Citation><ArticleIdList><ArticleId IdType="pubmed">11496135</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhl BA, Dudukovic NM, Kahn I, Wagner AD. Decreased demands on cognitive control reveal the neural processing benefits of forgetting. Nat Neurosci. 2007;10:908&#x2013;914.</Citation><ArticleIdList><ArticleId IdType="pubmed">17558403</ArticleId></ArticleIdList></Reference><Reference><Citation>Delbeuck X, Van der Linden M, Collette F. Alzheimer' disease as a disconnection syndrome? Neuropsych Rev. 2003;13:79&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">12887040</ArticleId></ArticleIdList></Reference><Reference><Citation>Rombouts SA, et al. Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: an fMRI study. Hum Brain Mapp. 2005;26:231&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871685</ArticleId><ArticleId IdType="pubmed">15954139</ArticleId></ArticleIdList></Reference><Reference><Citation>Lustig C, et al. Functional deactivations: change with age and dementia of the Alzheimer type. Proc Natl Acad Sci USA. 2003;100:14504&#x2013;14509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC283621</ArticleId><ArticleId IdType="pubmed">14608034</ArticleId></ArticleIdList></Reference><Reference><Citation>Stam CJ, et al. Disturbed fluctuations of resting state EEG synchronization in Alzheimer's disease. Clin Neurophysiol. 2005;116:708&#x2013;715.</Citation><ArticleIdList><ArticleId IdType="pubmed">15721085</ArticleId></ArticleIdList></Reference><Reference><Citation>Osipova D, et al. Effects of scopolamine on MEG spectral power and coherence in elderly subjects. Clin Neurophysiol. 2003;114:1902&#x2013;1907.</Citation><ArticleIdList><ArticleId IdType="pubmed">14499752</ArticleId></ArticleIdList></Reference><Reference><Citation>Maxim V, et al. Fractional Gaussian noise, functional MRI and Alzheimer's disease. NeuroImage. 2005;25:141&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">15734351</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal LJ, et al. The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord. 2006;20:6&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1820855</ArticleId><ArticleId IdType="pubmed">16493230</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psych Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Delorme A, Makeig S. EEGLAB: an open source toolbox for analysis of single-trial EEG dynamics including independent component analysis. J Neurosci Meth. 2004;134:9&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">15102499</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastiaansen MCM, Knosche TR. Tangential derivative mapping of axial MEG applied to event-related desynchronization research. Clin Neurophysiol. 2000;111:1300&#x2013;1305.</Citation><ArticleIdList><ArticleId IdType="pubmed">10880806</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng CK, et al. Mosaic organization of DNA nucleotides. Physical Review E Stat Phys Plasmas Fluids Relat Interdiscip Topics. 1994;49:1685&#x2013;1689.</Citation><ArticleIdList><ArticleId IdType="pubmed">9961383</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao J, et al. Assessment of long-range correlation in time series: how to avoid pitfalls. Physical Review E Stat Nonlin Soft Matter Phys. 2006;73 016117.</Citation><ArticleIdList><ArticleId IdType="pubmed">16486226</ArticleId></ArticleIdList></Reference><Reference><Citation>Linkenkaer-Hansen K, et al. Stimulus-induced change in long-range temporal correlations and scaling behaviour of sensorimotor oscillations. Eur J Neurosci. 2004;19:203&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pubmed">14750978</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikulin VV, Brismar T. Long-range temporal correlations in electroencephalographic oscillations: relation to topography, frequency band, age and gender. Neuroscience. 2005;130:549&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pubmed">15664711</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19164591</PMID><DateCompleted><Year>2009</Year><Month>02</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>106</Volume><Issue>4</Issue><PubDate><Year>2009</Year><Month>Jan</Month><Day>27</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Selective targeting of perivascular macrophages for clearance of beta-amyloid in cerebral amyloid angiopathy.</ArticleTitle><Pagination><StartPage>1261</StartPage><EndPage>1266</EndPage><MedlinePgn>1261-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0805453106</ELocationID><Abstract><AbstractText>Cerebral amyloid angiopathy (CAA), the deposition of beta-amyloid (Abeta) peptides in leptomeningeal and cortical blood vessels, affects the majority of patients with Alzheimer's disease (AD). Evidence suggests that vascular amyloid deposits may result from impaired clearance of neuronal Abeta along perivascular spaces. We investigated the role of perivascular macrophages in regulating CAA severity in the TgCRND8 mouse model of AD. Depletion of perivascular macrophages significantly increased the number of thioflavin S-positive cortical blood vessels. ELISA confirmed that this increase was underscored by elevations in total vascular Abeta(42) levels. Conversely, stimulation of perivascular macrophage turnover reduced cerebral CAA load, an effect that was not mediated through clearance by microglia or astrocytes. These results highlight a function for the physiological role of perivascular macrophages in the regulation of CAA and suggest that selective targeting of perivascular macrophage activation might constitute a therapeutic strategy to clear vascular amyloid.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hawkes</LastName><ForeName>Cheryl A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Centre for Research in Neurodegenerative , University of Toronto, Toronto, Ontario, Canada M5S 3H2.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McLaurin</LastName><ForeName>Joanne</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>01</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008081">Liposomes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0813BZ6866</RegistryNumber><NameOfSubstance UI="D004002">Clodronic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>1398-61-4</RegistryNumber><NameOfSubstance UI="D002686">Chitin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016657" MajorTopicYN="N">Cerebral Amyloid Angiopathy</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002686" MajorTopicYN="N">Chitin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004002" MajorTopicYN="N">Clodronic Acid</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008081" MajorTopicYN="N">Liposomes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008262" MajorTopicYN="N">Macrophage Activation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>1</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>1</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>2</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>7</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19164591</ArticleId><ArticleId IdType="pmc">PMC2633563</ArticleId><ArticleId IdType="doi">10.1073/pnas.0805453106</ArticleId><ArticleId IdType="pii">0805453106</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Attems J, Lauda F, Jellinger KA. Unexpectedly low prevalence of intracerebral hemorrhages in sporadic cerebral amyloid angiopathy: an autopsy study. J Neurol. 2008;255:70&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">18202817</ArticleId></ArticleIdList></Reference><Reference><Citation>Miao J, et al. Cerebral microvascular amyloid beta protein deposition induces vascular degeneration and neuroinflammation in transgenic mice expressing human vasculotropic mutant amyloid beta precursor protein. Am J Pathol. 2005;167:505&#x2013;515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1603574</ArticleId><ArticleId IdType="pubmed">16049335</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin HK, et al. Age-dependent cerebrovascular dysfunction in a transgenic mouse model of cerebral amyloid angiopathy. Brain. 2007;130:2310&#x2013;2319.</Citation><ArticleIdList><ArticleId IdType="pubmed">17638859</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlmutter LS. Microvascular pathology and vascular basement membrane components in Alzheimer's disease. Mol Neurobiol. 1994;9:33&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">7888105</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian J, et al. Relationships in Alzheimer's disease between the extent of Abeta deposition in cerebral blood vessel walls, as cerebral amyloid angiopathy, and the amount of cerebrovascular smooth muscle cells and collagen. Neuropathol Appl Neurobiol. 2006;32:332&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">16640651</ArticleId></ArticleIdList></Reference><Reference><Citation>Attems J, Quass M, Jellinger KA, Lintner F. Topographical distribution of cerebral amyloid angiopathy and its effect on cognitive decline are influenced by Alzheimer disease pathology. J Neurol Sci. 2007;257:49&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">17306303</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll JA, et al. Cerebral amyloid angiopathy plays a direct role in the pathogenesis of Alzheimer's disease. Pro-CAA position statement. Neurobiol Aging. 2004;25:589&#x2013;597.</Citation><ArticleIdList><ArticleId IdType="pubmed">15172734</ArticleId></ArticleIdList></Reference><Reference><Citation>Carare RO, et al. Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries: Significance for cerebral amyloid angiopathy and neuroimmunology. Neuropathol Appl Neurobiol. 2008;34:131&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">18208483</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeifer M, et al. Cerebral hemorrhage after passive anti-A&#x3b2; immunotherapy. Science. 2002;298:1379.</Citation><ArticleIdList><ArticleId IdType="pubmed">12434053</ArticleId></ArticleIdList></Reference><Reference><Citation>Bechmann I, Galea I, Perry VH. What is the blood-brain barrier (not)? Trends Immunol. 2007;28:5&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">17140851</ArticleId></ArticleIdList></Reference><Reference><Citation>Galea I, et al. Mannose receptor expression specifically reveals perivascular macrophages in normal, injured, and diseased mouse brain. Glia. 2005;49:375&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">15538754</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim WK, et al. CD163 identifies perivascular macrophages in normal and viral encephalitic brains and potential precursors to perivascular macrophages in blood. Am J Pathol. 2006;168:822&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1606539</ArticleId><ArticleId IdType="pubmed">16507898</ArticleId></ArticleIdList></Reference><Reference><Citation>Bechmann I, et al. Turnover of rat brain perivascular cells. Exp Neurol. 2001;168:242&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">11259112</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams K, Alvarez X, Lackner AA. Central nervous system perivascular cells are immunoregulatory cells that connect the CNS with the peripheral immune system. Glia. 2001;36:156&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">11596124</ArticleId></ArticleIdList></Reference><Reference><Citation>Bechmann I, et al. Immune surveillance of mouse brain perivascular spaces by blood-borne macrophages. Eur J Neurosci. 2001;14:1651&#x2013;1658.</Citation><ArticleIdList><ArticleId IdType="pubmed">11860459</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiala M, et al. Ineffective phagocytosis of amyloid-beta by macrophages of Alzheimer's disease patients. J Alzheimers Dis. 2005;7:221&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">16006665</ArticleId></ArticleIdList></Reference><Reference><Citation>Chishti MA, et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem. 2001;276:21562&#x2013;21570.</Citation><ArticleIdList><ArticleId IdType="pubmed">11279122</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Rooijen N, Sanders A. Liposome mediated depletion of macrophages: Mechanism of action, preparation of liposomes and applications. J Immunol Methods. 1994;174:83&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">8083541</ArticleId></ArticleIdList></Reference><Reference><Citation>Polfliet MM, et al. A method for the selective depletion of perivascular and meningeal macrophages in the central nervous system. J Neuroimmunol. 2001;116:188&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">11438173</ArticleId></ArticleIdList></Reference><Reference><Citation>Burudi EM, Regnier-Vigouroux A. Regional and cellular expression of the mannose receptor in the post-natal developing mouse brain. Cell Tissue Res. 2001;303:307&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">11320646</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, et al. Chronic overproduction of transforming growth factor-beta1 by astrocytes promotes Alzheimer's disease-like microvascular degeneration in transgenic mice. Am J Pathol. 2000;156:139&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1868631</ArticleId><ArticleId IdType="pubmed">10623661</ArticleId></ArticleIdList></Reference><Reference><Citation>Patton RL, et al. Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: A biochemical analysis. Am J Pathol. 2006;169:1048&#x2013;1063.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1698828</ArticleId><ArticleId IdType="pubmed">16936277</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19167330</PMID><DateCompleted><Year>2009</Year><Month>02</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>136</Volume><Issue>2</Issue><PubDate><Year>2009</Year><Month>Jan</Month><Day>23</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Age-dependent deterioration of nuclear pore complexes causes a loss of nuclear integrity in postmitotic cells.</ArticleTitle><Pagination><StartPage>284</StartPage><EndPage>295</EndPage><MedlinePgn>284-95</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2008.11.037</ELocationID><Abstract><AbstractText>In dividing cells, nuclear pore complexes (NPCs) disassemble during mitosis and reassemble into the newly forming nuclei. However, the fate of nuclear pores in postmitotic cells is unknown. Here, we show that NPCs, unlike other nuclear structures, do not turn over in differentiated cells. While a subset of NPC components, like Nup153 and Nup50, are continuously exchanged, scaffold nucleoporins, like the Nup107/160 complex, are extremely long-lived and remain incorporated in the nuclear membrane during the entire cellular life span. Besides the lack of nucleoporin expression and NPC turnover, we discovered an age-related deterioration of NPCs, leading to an increase in nuclear permeability and the leaking of cytoplasmic proteins into the nucleus. Our finding that nuclear "leakiness" is dramatically accelerated during aging and that a subset of nucleoporins is oxidatively damaged in old cells suggests that the accumulation of damage at the NPC might be a crucial aging event.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>D'Angelo</LastName><ForeName>Maximiliano A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Salk Institute for Biological Studies, Molecular and Cell Biology Laboratory, 10010 North Torrey Pines Road, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raices</LastName><ForeName>Marcela</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Panowski</LastName><ForeName>Siler H</ForeName><Initials>SH</Initials></Author><Author ValidYN="Y"><LastName>Hetzer</LastName><ForeName>Martin W</ForeName><Initials>MW</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 GM057438</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D028861">Nuclear Pore Complex Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Cell. 2009 Jan 23;136(2):211-2. doi: 10.1016/j.cell.2009.01.004.</RefSource><PMID Version="1">19167324</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017173" MajorTopicYN="N">Caenorhabditis elegans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008938" MajorTopicYN="Y">Mitosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D022022" MajorTopicYN="N">Nuclear Pore</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D028861" MajorTopicYN="N">Nuclear Pore Complex Proteins</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2008</Year><Month>10</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>1</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>1</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>2</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>1</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19167330</ArticleId><ArticleId IdType="mid">NIHMS159799</ArticleId><ArticleId IdType="pmc">PMC2805151</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2008.11.037</ArticleId><ArticleId IdType="pii">S0092-8674(08)01512-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aguilaniu H, Gustafsson L, Rigoulet M, Nystrom T. Asymmetric inheritance of oxidatively damaged proteins during cytokinesis. Science. 2003;299:1751&#x2013;1753.</Citation><ArticleIdList><ArticleId IdType="pubmed">12610228</ArticleId></ArticleIdList></Reference><Reference><Citation>Alber F, Dokudovskaya S, Veenhoff LM, Zhang W, Kipper J, Devos D, Suprapto A, Karni-Schmidt O, Williams R, Chait BT, et al. The molecular architecture of the nuclear pore complex. Nature. 2007;450:695&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pubmed">18046406</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonin W, Franz C, Haselmann U, Antony C, Mattaj IW. The Integral Membrane Nucleoporin pom121 Functionally Links Nuclear Pore Complex Assembly and Nuclear Envelope Formation. Mol Cell. 2005;17:83&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">15629719</ArticleId></ArticleIdList></Reference><Reference><Citation>Apfeld J, Kenyon C. Cell nonautonomy of C. elegans daf-2 function in the regulation of diapause and life span. Cell. 1998;95:199&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">9790527</ArticleId></ArticleIdList></Reference><Reference><Citation>Beanan MJ, Strome S. Characterization of a germ-line proliferation mutation in C. elegans. Development. 1992;116:755&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">1289064</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck M, Forster F, Ecke M, Plitzko JM, Melchior F, Gerisch G, Baumeister W, Medalia O. Nuclear pore complex structure and dynamics revealed by cryoelectron tomography. Science. 2004;306:1387&#x2013;1390.</Citation><ArticleIdList><ArticleId IdType="pubmed">15514115</ArticleId></ArticleIdList></Reference><Reference><Citation>Belgareh N, Rabut G, Bai SW, van Overbeek M, Beaudouin J, Daigle N, Zatsepina OV, Pasteau F, Labas V, Fromont-Racine M, et al. An evolutionarily conserved NPC subcomplex, which redistributes in part to kinetochores in mammalian cells. J Cell Biol. 2001;154:1147&#x2013;1160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2150808</ArticleId><ArticleId IdType="pubmed">11564755</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodoor K, Shaikh S, Salina D, Raharjo WH, Bastos R, Lohka M, Burke B. Sequential recruitment of NPC proteins to the nuclear periphery at the end of mitosis. J Cell Sci. 1999;112 ( Pt 13):2253&#x2013;2264.</Citation><ArticleIdList><ArticleId IdType="pubmed">10362555</ArticleId></ArticleIdList></Reference><Reference><Citation>Bookout AL, Jeong Y, Downes M, Yu RT, Evans RM, Mangelsdorf DJ. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell. 2006;126:789&#x2013;799.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6211849</ArticleId><ArticleId IdType="pubmed">16923397</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner S. The genetics of Caenorhabditis elegans. Genetics. 1974;77:71&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1213120</ArticleId><ArticleId IdType="pubmed">4366476</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke B, Ellenberg J. Remodelling the walls of the nucleus. Nat Rev Mol Cell Biol. 2002;3:487&#x2013;497.</Citation><ArticleIdList><ArticleId IdType="pubmed">12094215</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakravarti B, Chakravarti DN. Oxidative modification of proteins: age-related changes. Gerontology. 2007;53:128&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">17164550</ArticleId></ArticleIdList></Reference><Reference><Citation>Commerford SL, Carsten AL, Cronkite EP. Histone turnover within nonproliferating cells. Proc Natl Acad Sci U S A. 1982;79:1163&#x2013;1165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC345921</ArticleId><ArticleId IdType="pubmed">6951165</ArticleId></ArticleIdList></Reference><Reference><Citation>Crittenden SL, Leonhard KA, Byrd DT, Kimble J. Cellular analyses of the mitotic region in the Caenorhabditis elegans adult germ line. Mol Biol Cell. 2006;17:3051&#x2013;3061.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1552046</ArticleId><ArticleId IdType="pubmed">16672375</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Angelo MA, Anderson DJ, Richard E, Hetzer MW. Nuclear pores form de novo from both sides of the nuclear envelope. Science. 2006;312:440&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pubmed">16627745</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Angelo MA, Hetzer MW. The role of the nuclear envelope in cellular organization. Cell Mol Life Sci. 2006;63:316&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11136033</ArticleId><ArticleId IdType="pubmed">16389459</ArticleId></ArticleIdList></Reference><Reference><Citation>Daigle N, Beaudouin J, Hartnell L, Imreh G, Hallberg E, Lippincott-Schwartz J, Ellenberg J. Nuclear pore complexes form immobile networks and have a very low turnover in live mammalian cells. J Cell Biol. 2001;154:71&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2196857</ArticleId><ArticleId IdType="pubmed">11448991</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalle-Donne I, Aldini G, Carini M, Colombo R, Rossi R, Milzani A. Protein carbonylation, cellular dysfunction, and disease progression. J Cell Mol Med. 2006;10:389&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3933129</ArticleId><ArticleId IdType="pubmed">16796807</ArticleId></ArticleIdList></Reference><Reference><Citation>Danielson SR, Andersen JK. Oxidative and nitrative protein modifications in Parkinson&#x2019;s disease. Free Radic Biol Med. 2008;44:1787&#x2013;1794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2422863</ArticleId><ArticleId IdType="pubmed">18395015</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis LI, Blobel G. Nuclear pore complex contains a family of glycoproteins that includes p62: glycosylation through a previously unidentified cellular pathway. Proc Natl Acad Sci U S A. 1987;84:7552&#x2013;7556.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC299337</ArticleId><ArticleId IdType="pubmed">3313397</ArticleId></ArticleIdList></Reference><Reference><Citation>Dillin A, Crawford DK, Kenyon C. Timing requirements for insulin/IGF-1 signaling in C. elegans. Science. 2002;298:830&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399591</ArticleId></ArticleIdList></Reference><Reference><Citation>Felsani A, Mileo AM, Paggi MG. Retinoblastoma family proteins as key targets of the small DNA virus oncoproteins. Oncogene. 2006;25:5277&#x2013;5285.</Citation><ArticleIdList><ArticleId IdType="pubmed">16936748</ArticleId></ArticleIdList></Reference><Reference><Citation>Frosst P, Guan T, Subauste C, Hahn K, Gerace L. Tpr is localized within the nuclear basket of the pore complex and has a role in nuclear protein export. J Cell Biol. 2002;156:617&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2174070</ArticleId><ArticleId IdType="pubmed">11839768</ArticleId></ArticleIdList></Reference><Reference><Citation>Galy V, Mattaj IW, Askjaer P. Caenorhabditis elegans nucleoporins Nup93 and Nup205 determine the limit of nuclear pore complex size exclusion in vivo. Mol Biol Cell. 2003;14:5104&#x2013;5115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC284812</ArticleId><ArticleId IdType="pubmed">12937276</ArticleId></ArticleIdList></Reference><Reference><Citation>Grandi P, Dang T, Pane N, Shevchenko A, Mann M, Forbes D, Hurt E. Nup93, a vertebrate homologue of yeast Nic96p, forms a complex with a novel 205-kDa protein and is required for correct nuclear pore assembly. Mol Biol Cell. 1997;8:2017&#x2013;2038.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC25664</ArticleId><ArticleId IdType="pubmed">9348540</ArticleId></ArticleIdList></Reference><Reference><Citation>Haithcock E, Dayani Y, Neufeld E, Zahand AJ, Feinstein N, Mattout A, Gruenbaum Y, Liu J. Age-related changes of nuclear architecture in Caenorhabditis elegans. Proc Natl Acad Sci U S A. 2005;102:16690&#x2013;16695.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1283819</ArticleId><ArticleId IdType="pubmed">16269543</ArticleId></ArticleIdList></Reference><Reference><Citation>Harel A, Orjalo AV, Vincent T, Lachish-Zalait A, Vasu S, Shah S, Zimmerman E, Elbaum M, Forbes DJ. Removal of a single pore subcomplex results in vertebrate nuclei devoid of nuclear pores. Mol Cell. 2003;11:853&#x2013;864.</Citation><ArticleIdList><ArticleId IdType="pubmed">12718872</ArticleId></ArticleIdList></Reference><Reference><Citation>Honda Y, Honda S. The daf-2 gene network for longevity regulates oxidative stress resistance and Mn-superoxide dismutase gene expression in Caenorhabditis elegans. FASEB J. 1999;13:1385&#x2013;1393.</Citation><ArticleIdList><ArticleId IdType="pubmed">10428762</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenyon C, Chang J, Gensch E, Rudner A, Tabtiang R. A C. elegans mutant that lives twice as long as wild type. Nature. 1993;366:461&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">8247153</ArticleId></ArticleIdList></Reference><Reference><Citation>Ketting RF, Fischer SE, Bernstein E, Sijen T, Hannon GJ, Plasterk RH. Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans. Genes Dev. 2001;15:2654&#x2013;2659.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC312808</ArticleId><ArticleId IdType="pubmed">11641272</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y, Sun H. Functional genomic approach to identify novel genes involved in the regulation of oxidative stress resistance and animal lifespan. Aging Cell. 2007;6:489&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">17608836</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura KD, Tissenbaum HA, Liu Y, Ruvkun G. daf-2, an insulin receptor-like gene that regulates longevity and diapause in Caenorhabditis elegans. Science. 1997;277:942&#x2013;946.</Citation><ArticleIdList><ArticleId IdType="pubmed">9252323</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiseleva E, Allen TD, Rutherford S, Bucci M, Wente SR, Goldberg MW. Yeast nuclear pore complexes have a cytoplasmic ring and internal filaments. J Struct Biol. 2004;145:272&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">14960378</ArticleId></ArticleIdList></Reference><Reference><Citation>Krull S, Thyberg J, Bjorkroth B, Rackwitz HR, Cordes VC. Nucleoporins as components of the nuclear pore complex core structure and tpr as the architectural element of the nuclear basket. Mol Biol Cell. 2004;15:4261&#x2013;4277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC515357</ArticleId><ArticleId IdType="pubmed">15229283</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenart P, Ellenberg J. Monitoring the permeability of the nuclear envelope during the cell cycle. Methods. 2006;38:17&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">16343937</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenart P, Rabut G, Daigle N, Hand AR, Terasaki M, Ellenberg J. Nuclear envelope breakdown in starfish oocytes proceeds by partial NPC disassembly followed by a rapidly spreading fenestration of nuclear membranes. J Cell Biol. 2003;160:1055&#x2013;1068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172766</ArticleId><ArticleId IdType="pubmed">12654902</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovtrup-Rein H, McEwen BS. Isolation and fractionation of rat brain nuclei. J Cell Biol. 1966;30:405&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2107004</ArticleId><ArticleId IdType="pubmed">5968977</ArticleId></ArticleIdList></Reference><Reference><Citation>Mansfeld J, Guttinger S, Hawryluk-Gara LA, Pante N, Mall M, Galy V, Haselmann U, Muhlhausser P, Wozniak RW, Mattaj IW, et al. The conserved transmembrane nucleoporin NDC1 is required for nuclear pore complex assembly in vertebrate cells. Mol Cell. 2006;22:93&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">16600873</ArticleId></ArticleIdList></Reference><Reference><Citation>Maul GG, Maul HM, Scogna JE, Lieberman MW, Stein GS, Hsu BY, Borun TW. Time sequence of nuclear pore formation in phytohemagglutinin-stimulated lymphocytes and in HeLa cells during the cell cycle. J Cell Biol. 1972;55:433&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2108790</ArticleId><ArticleId IdType="pubmed">5076782</ArticleId></ArticleIdList></Reference><Reference><Citation>McClellan KA, Slack RS. Specific in vivo roles for E2Fs in differentiation and development. Cell Cycle. 2007;6:2917&#x2013;2927.</Citation><ArticleIdList><ArticleId IdType="pubmed">17993781</ArticleId></ArticleIdList></Reference><Reference><Citation>Oeda T, Shimohama S, Kitagawa N, Kohno R, Imura T, Shibasaki H, Ishii N. Oxidative stress causes abnormal accumulation of familial amyotrophic lateral sclerosis-related mutant SOD1 in transgenic Caenorhabditis elegans. Hum Mol Genet. 2001;10:2013&#x2013;2023.</Citation><ArticleIdList><ArticleId IdType="pubmed">11590119</ArticleId></ArticleIdList></Reference><Reference><Citation>Panowski SH, Wolff S, Aguilaniu H, Durieux J, Dillin A. PHA-4/Foxa mediates diet-restriction-induced longevity of C. elegans. Nature. 2007;447:550&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">17476212</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabut G, Doye V, Ellenberg J. Mapping the dynamic organization of the nuclear pore complex inside single living cells. Nat Cell Biol. 2004a;6:1114&#x2013;1121.</Citation><ArticleIdList><ArticleId IdType="pubmed">15502822</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabut G, Lenart P, Ellenberg J. Dynamics of nuclear pore complex organization through the cell cycle. Curr Opin Cell Biol. 2004b;16:314&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pubmed">15145357</ArticleId></ArticleIdList></Reference><Reference><Citation>Raices M, Maruyama H, Dillin A, Karlseder J. Uncoupling of longevity and telomere length in C. elegans. PLoS Genet. 2005;1:e30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1200426</ArticleId><ArticleId IdType="pubmed">16151516</ArticleId></ArticleIdList></Reference><Reference><Citation>Reichelt R, Holzenburg A, Buhle EL, Jr, Jarnik M, Engel A, Aebi U. Correlation between structure and mass distribution of the nuclear pore complex and of distinct pore complex components. J Cell Biol. 1990;110:883&#x2013;894.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2116066</ArticleId><ArticleId IdType="pubmed">2324201</ArticleId></ArticleIdList></Reference><Reference><Citation>Salama NR, Yeung T, Schekman RW. The Sec13p complex and reconstitution of vesicle budding from the ER with purified cytosolic proteins. Embo J. 1993;12:4073&#x2013;4082.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC413700</ArticleId><ArticleId IdType="pubmed">8223424</ArticleId></ArticleIdList></Reference><Reference><Citation>Scaffidi P, Misteli T. Lamin A-dependent nuclear defects in human aging. Science. 2006;312:1059&#x2013;1063.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1855250</ArticleId><ArticleId IdType="pubmed">16645051</ArticleId></ArticleIdList></Reference><Reference><Citation>Shcheprova Z, Baldi S, Frei SB, Gonnet G, Barral Y. A mechanism for asymmetric segregation of age during yeast budding. Nature. 2008;454:728&#x2013;734.</Citation><ArticleIdList><ArticleId IdType="pubmed">18660802</ArticleId></ArticleIdList></Reference><Reference><Citation>Walther TC, Alves A, Pickersgill H, Loiodice I, Hetzer M, Galy V, Hulsmann BB, Kocher T, Wilm M, Allen T, et al. The conserved Nup107&#x2013;160 complex is critical for nuclear pore complex assembly. Cell. 2003;113:195&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">12705868</ArticleId></ArticleIdList></Reference><Reference><Citation>Weis K. Regulating access to the genome: nucleocytoplasmic transport throughout the cell cycle. Cell. 2003;112:441&#x2013;451.</Citation><ArticleIdList><ArticleId IdType="pubmed">12600309</ArticleId></ArticleIdList></Reference><Reference><Citation>Woulfe JM. Abnormalities of the nucleus and nuclear inclusions in neurodegenerative disease: a work in progress. Neuropathol Appl Neurobiol. 2007;33:2&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">17239006</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X, Su B, Wang X, Smith MA, Perry G. Causes of oxidative stress in Alzheimer disease. Cell Mol Life Sci. 2007;64:2202&#x2013;2210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11136009</ArticleId><ArticleId IdType="pubmed">17605000</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19176801</PMID><DateCompleted><Year>2009</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>4</Issue><PubDate><Year>2009</Year><Month>Jan</Month><Day>28</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>A novel nicotinic acetylcholine receptor subtype in basal forebrain cholinergic neurons with high sensitivity to amyloid peptides.</ArticleTitle><Pagination><StartPage>918</StartPage><EndPage>929</EndPage><MedlinePgn>918-29</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.3952-08.2009</ELocationID><Abstract><AbstractText>Nicotinic acetylcholine receptors (nAChRs) containing alpha7 subunits are thought to assemble as homomers. alpha7-nAChR function has been implicated in learning and memory, and alterations of alpha7-nAChR have been found in patients with Alzheimer's disease (AD). Here we report findings consistent with a novel, naturally occurring nAChR subtype in rodent, basal forebrain cholinergic neurons. In these cells, alpha7 subunits are coexpressed, colocalize, and coassemble with beta2 subunit(s). Compared with homomeric alpha7-nAChRs from ventral tegmental area neurons, functional, presumably heteromeric alpha7beta2-nAChRs on cholinergic neurons freshly dissociated from medial septum/diagonal band (MS/DB) exhibit relatively slow kinetics of whole-cell current responses to nicotinic agonists and are more sensitive to the beta2 subunit-containing nAChR-selective antagonist, dihydro-beta-erythroidine (DHbetaE). Interestingly, presumed, heteromeric alpha7beta2-nAChRs are highly sensitive to functional inhibition by pathologically relevant concentrations of oligomeric, but not monomeric or fibrillar, forms of amyloid beta(1-42) (Abeta(1-42)). Slow whole-cell current kinetics, sensitivity to DHbetaE, and specific antagonism by oligomeric Abeta(1-42) also are characteristics of heteromeric alpha7beta2-nAChRs, but not of homomeric alpha7-nAChRs, heterologously expressed in Xenopus oocytes. Moreover, choline-induced currents have faster kinetics and less sensitivity to Abeta when elicited from MS/DB neurons derived from nAChR beta2 subunit knock-out mice rather than from wild-type mice. The presence of novel, functional, heteromeric alpha7beta2-nAChRs on basal forebrain cholinergic neurons and their high sensitivity to blockade by low concentrations of oligomeric Abeta(1-42) suggests possible mechanisms for deficits in cholinergic signaling that could occur early in the etiopathogenesis of AD and might be targeted by disease therapies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Qiang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Divisions of Neurology, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona 85013-4496, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yao</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Xue</LastName><ForeName>Fenqin</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Simard</LastName><ForeName>Alain</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>DeChon</LastName><ForeName>Jamie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Guohui</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jianliang</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Lucero</LastName><ForeName>Linda</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Min</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Sierks</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Gang</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Yongchang</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Lukas</LastName><ForeName>Ronald J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jie</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 DA015389</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018678">Cholinergic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C579166">Chrna7 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C579165">Chrna7 protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D021122">Protein Subunits</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011978">Receptors, Nicotinic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064569">alpha7 Nicotinic Acetylcholine Receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C419363">nicotinic receptor beta2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.1.6</RegistryNumber><NameOfSubstance UI="D002795">Choline O-Acetyltransferase</NameOfSubstance></Chemical><Chemical><RegistryNumber>N9YNS0M02X</RegistryNumber><NameOfSubstance UI="D000109">Acetylcholine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000109" MajorTopicYN="N">Acetylcholine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002795" MajorTopicYN="N">Choline O-Acetyltransferase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018678" MajorTopicYN="N">Cholinergic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047468" MajorTopicYN="N">Immunoprecipitation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008564" MajorTopicYN="N">Membrane Potentials</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009865" MajorTopicYN="N">Oocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018408" MajorTopicYN="N">Patch-Clamp Techniques</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016548" MajorTopicYN="N">Prosencephalon</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021122" MajorTopicYN="N">Protein Subunits</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011978" MajorTopicYN="N">Receptors, Nicotinic</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014982" MajorTopicYN="N">Xenopus laevis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064569" MajorTopicYN="N">alpha7 Nicotinic Acetylcholine Receptor</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>1</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>1</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>4</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>7</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19176801</ArticleId><ArticleId IdType="mid">NIHMS93323</ArticleId><ArticleId IdType="pmc">PMC2857410</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.3952-08.2009</ArticleId><ArticleId IdType="pii">29/4/918</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Azam L, Winzer-Serhan U, Leslie FM. Co-expression of alpha7 and beta2 nicotinic acetylcholine receptor subunit mRNAs within rat brain cholinergic neurons. Neuroscience. 2003;119:965&#x2013;977.</Citation><ArticleIdList><ArticleId IdType="pubmed">12831856</ArticleId></ArticleIdList></Reference><Reference><Citation>Burghaus L, Sch&#xfc;tz U, Krempel U, de Vos RA, Jansen Steur EN, Wevers A, Lindstrom J, Schr&#xf6;der H. Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients. Brain Res Mol Brain Res. 2000;76:385&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">10762715</ArticleId></ArticleIdList></Reference><Reference><Citation>Counts SE, He B, Che S, Ikonomovic MD, DeKosky ST, Ginsberg SD, Mufson EJ. Alpha7 nicotinic receptor up-regulation in cholinergic basal forebrain neurons in Alzheimer disease. Arch Neurol. 2007;64:1771&#x2013;1776.</Citation><ArticleIdList><ArticleId IdType="pubmed">18071042</ArticleId></ArticleIdList></Reference><Reference><Citation>Dineley KT, Xia X, Bui D, Sweatt JD, Zheng H. Accelerated plaque accumulation, associative learning deficits, and up-regulation of alpha 7 nicotinic receptor protein in transgenic mice co-expressing mutant human presenilin 1 and amyloid precursor proteins. J Biol Chem. 2002a;277:22768&#x2013;22780.</Citation><ArticleIdList><ArticleId IdType="pubmed">11912199</ArticleId></ArticleIdList></Reference><Reference><Citation>Dineley KT, Bell KA, Bui D, Sweatt JD. beta-Amyloid peptide activates alpha 7 nicotinic acetylcholine receptors expressed in Xenopus oocytes. J Biol Chem. 2002b;277:25056&#x2013;25061.</Citation><ArticleIdList><ArticleId IdType="pubmed">11983690</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolezal V, Kasparov&#xe1; J. &#x3b2;-Amyloid and cholinergic neurons. Neurochem Res. 2003;28:499&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pubmed">12675138</ArticleId></ArticleIdList></Reference><Reference><Citation>Dougherty JJ, Wu J, Nichols RA. &#x3b2;-Amyloid regulation of presynaptic nicotinic receptors in rat hippocampus and neocortex. J Neurosci. 2003;23:6740&#x2013;6747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740736</ArticleId><ArticleId IdType="pubmed">12890766</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Hajj RA, McKay SB, McKay DB. Pharmacological and immunological identification of native alpha7 nicotinic receptors: evidence for homomeric and heteromeric alpha7 receptors. Life Sci. 2007;81:1317&#x2013;1322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2083560</ArticleId><ArticleId IdType="pubmed">17928008</ArticleId></ArticleIdList></Reference><Reference><Citation>Flores CM, Rogers SW, Pabreza LA, Wolfe BB, Kellar KJ. A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment. Mol Pharmacol. 1992;41:31&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">1732720</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu W, Jhamandas JH. &#x3b2;-Amyloid peptide activates non-alpha7 nicotinic acetylcholine receptors in rat basal forebrain neurons. J Neurophysiol. 2003;90:3130&#x2013;3136.</Citation><ArticleIdList><ArticleId IdType="pubmed">12890800</ArticleId></ArticleIdList></Reference><Reference><Citation>Geerts H. Indicators of neuroprotection with galantamine. Brain Res Bull. 2005;64:519&#x2013;524.</Citation><ArticleIdList><ArticleId IdType="pubmed">15639548</ArticleId></ArticleIdList></Reference><Reference><Citation>Gopalakrishnan M, Monteggia LM, Anderson DJ, Molinari EJ, Piattoni-Kaplan M, Donnelly-Roberts D, Arneric SP, Sullivan JP. Stable expression, pharmacologic properties and regulation of the human neuronal nicotinic acetylcholine alpha 4 beta 2 receptor. J Pharmacol Exp Ther. 1996;276:289&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pubmed">8558445</ArticleId></ArticleIdList></Reference><Reference><Citation>Grassi F, Palma E, Tonini R, Amici M, Ballivet M, Eusebi F. Amyloid beta(1&#x2013;42) peptide alters the gating of human and mouse alpha-bungarotoxin-sensitive nicotinic receptors. J Physiol. 2003;547:147&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2342606</ArticleId><ArticleId IdType="pubmed">12562926</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8:101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson Z, Boros A, Janzso G, Westwood AJ, Monyer H, Halasy K. Somato-dendritic nicotinic receptor responses recorded in vitro from the medial septal diagonal band complex of the rodent. J Physiol. 2005;562:165&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1665480</ArticleId><ArticleId IdType="pubmed">15528250</ArticleId></ArticleIdList></Reference><Reference><Citation>Horn R, Marty A. Muscarinic activation of ionic currents measured by a new whole-cell recording method. J Gen Physiol. 1988;92:145&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2228899</ArticleId><ArticleId IdType="pubmed">2459299</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen AA, Fr&#xf8;lund B, Liljefors T, Krogsgaard-Larsen P. Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations. J Med Chem. 2005;48:4705&#x2013;4745.</Citation><ArticleIdList><ArticleId IdType="pubmed">16033252</ArticleId></ArticleIdList></Reference><Reference><Citation>Khiroug SS, Harkness PC, Lamb PW, Sudweeks SN, Khiroug L, Millar NS, Yakel JL. Rat nicotinic ACh receptor alpha7 and beta2 subunits co-assemble to form functional heteromeric nicotinic receptor channels. J Physiol. 2002;540:425&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2290261</ArticleId><ArticleId IdType="pubmed">11956333</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo YM, Kokjohn TA, Watson MD, Woods AS, Cotter RJ, Sue LI, Kalback WM, Emmerling MR, Beach TG, Roher AE. Elevated abeta42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of AbetaPP metabolism. Am J Pathol. 2000;156:797&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1876838</ArticleId><ArticleId IdType="pubmed">10702395</ArticleId></ArticleIdList></Reference><Reference><Citation>Lahiri DK, Utsuki T, Chen D, Farlow MR, Shoaib M, Ingram DK, Greig NH. Nicotine reduces the secretion of Alzheimer's beta-amyloid precursor protein containing beta-amyloid peptide in the rat without altering synaptic proteins. Ann N Y Acad Sci. 2002;965:364&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">12105112</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb PW, Melton MA, Yakel JL. Inhibition of neuronal nicotinic acetylcholine receptor channels expressed in Xenopus oocytes by beta-amyloid1&#x2013;42 peptide. J Mol Neurosci. 2005;27:13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">16055943</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin ED, Rezvani AH. Nicotinic treatment for cognitive dysfunction. Curr Drug Targets CNS Neurol Disord. 2002;1:423&#x2013;431.</Citation><ArticleIdList><ArticleId IdType="pubmed">12769614</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindstrom J. Neuronal nicotinic acetylcholine receptors. Ion Channels. 1996;4:377&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pubmed">8744214</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindstrom J, Anand R, Gerzanich V, Peng X, Wang F, Wells G. Structure and function of neuronal nicotinic acetylcholine receptors. Prog Brain Res. 1996;109:125&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">9009699</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Kawai H, Berg DK. beta-Amyloid peptide blocks the response of alpha 7-containing nicotinic receptors on hippocampal neurons. Proc Natl Acad Sci U S A. 2001;98:4734&#x2013;4739.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC31903</ArticleId><ArticleId IdType="pubmed">11274373</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Zhang J, Zhu H, Qin C, Chen Q, Zhao B. Dissecting the signaling pathway of nicotine-mediated neuroprotection in a mouse Alzheimer disease model. FASEB J. 2007;21:61&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">17135361</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Zhang J, Berg DK. Role of endogenous nicotinic signaling in guiding neuronal development. Biochem Pharmacol. 2007;74:1112&#x2013;1119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2116993</ArticleId><ArticleId IdType="pubmed">17603025</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukas RJ, Changeux JP, Le Nov&#xe8;re N, Albuquerque EX, Balfour DJ, Berg DK, Bertrand D, Chiappinelli VA, Clarke PB, Collins AC, Dani JA, Grady SR, Kellar KJ, Lindstrom JM, Marks MJ, Quik M, Taylor PW, Wonnacott S. International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol Rev. 1999;51:397&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">10353988</ArticleId></ArticleIdList></Reference><Reference><Citation>Mansvelder HD, van Aerde KI, Couey JJ, Brussaard AB. Nicotinic modulation of neuronal networks: from receptors to cognition. Psychopharmacology. 2006;184:292&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">16001117</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta PD, Pirttil&#xe4; T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1&#x2013;40 and 1&#x2013;42 in Alzheimer disease. Arch Neurol. 2000;57:100&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">10634455</ArticleId></ArticleIdList></Reference><Reference><Citation>Moser N, Mechawar N, Jones I, Gochberg-Sarver A, Orr-Urtreger A, Plomann M, Salas R, Molles B, Marubio L, Roth U, Maskos U, Winzer-Serhan U, Bourgeois JP, Le Sourd AM, De Biasi M, Schr&#xf6;der H, Lindstrom J, Maelicke A, Changeux JP, Wevers A. Evaluating the suitability of nicotinic acetylcholine receptor antibodies for standard immunodetection procedures. J Neurochem. 2007;102:479&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pubmed">17419810</ArticleId></ArticleIdList></Reference><Reference><Citation>Mudo G, Belluardo N, Fuxe K. Nicotinic receptor agonists as neuroprotective/neurotrophic drugs. Progress in molecular mechanisms. J Neural Transm. 2007;114:135&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">16906354</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagele RG, D'Andrea MR, Anderson WJ, Wang HY. Intracellular accumulation of beta-amyloid(1&#x2013;42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer's disease. Neuroscience. 2002;110:199&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">11958863</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordberg A. Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications. Biol Psychiatry. 2001;49:200&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">11230871</ArticleId></ArticleIdList></Reference><Reference><Citation>Paxinos G, Watson C. The rat brain in stereotaxic coordinates. Orlando, FL: Academic; 1986.</Citation><ArticleIdList><ArticleId IdType="pubmed">6110810</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettit DL, Shao Z, Yakel JL. &#x3b2;-Amyloid1&#x2013;42 peptide directly modulates nicotinic receptors in the rat hippocampal slice. J Neurosci. 2001;21(RC120):1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762461</ArticleId><ArticleId IdType="pubmed">11150356</ArticleId></ArticleIdList></Reference><Reference><Citation>Pym L, Kemp M, Raymond-Delpech V, Buckingham S, Boyd CA, Sattelle D. Subtype-specific actions of beta-amyloid peptides on recombinant human neuronal nicotinic acetylcholine receptors (alpha7, alpha4beta2, alpha3beta4) expressed in Xenopus laevis oocytes. Br J Pharmacol. 2005;146:964&#x2013;971.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1751230</ArticleId><ArticleId IdType="pubmed">16184187</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadot E, Gurwitz D, Barg J, Behar L, Ginzburg I, Fisher A. Activation of m1 muscarinic acetylcholine receptor regulates tau phosphorylation in transfected PC12 cells. J Neurochem. 1996;66:877&#x2013;880.</Citation><ArticleIdList><ArticleId IdType="pubmed">8592166</ArticleId></ArticleIdList></Reference><Reference><Citation>Saragoza PA, Modir JG, Goel N, French KL, Li L, Nowak MW, Stitzel JA. Identification of an alternatively processed nicotinic receptor alpha7 subunit RNA in mouse brain. Brain Res Mol Brain Res. 2003;117:15&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">14499477</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature. 1999;399:A23&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">10392577</ArticleId></ArticleIdList></Reference><Reference><Citation>Severance EG, Cuevas J. Distribution and synaptic localization of nicotinic acetylcholine receptors containing a novel alpha7 subunit isoform in embryonic rat cortical neurons. Neurosci Lett. 2004;372:104&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pubmed">15531097</ArticleId></ArticleIdList></Reference><Reference><Citation>Severance EG, Zhang H, Cruz Y, Pakhlevaniants S, Hadley SH, Amin J, Wecker L, Reed C, Cuevas J. The alpha7 nicotinic acetylcholine receptor subunit exists in two isoforms that contribute to functional ligand-gated ion channels. Mol Pharmacol. 2004;66:420&#x2013;429.</Citation><ArticleIdList><ArticleId IdType="pubmed">15322233</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivaprakasam K. Towards a unifying hypothesis of Alzheimer's disease: cholinergic system linked to plaques, tangles and neuroinflammation. Curr Med Chem. 2006;13:2179&#x2013;2188.</Citation><ArticleIdList><ArticleId IdType="pubmed">16918347</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinschmidt JS, Frazier CJ, King MA, Meyer EM, Papke RL. Medial septal/diagonal band cells express multiple functional nicotinic receptor subtypes that are correlated with firing frequency. Neurosci Lett. 2005;389:163&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">16112453</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HY, Lee DH, D'Andrea MR, Peterson PA, Shank RP, Reitz AB. beta-Amyloid(1&#x2013;42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J Biol Chem. 2000;275:5626&#x2013;5632.</Citation><ArticleIdList><ArticleId IdType="pubmed">10681545</ArticleId></ArticleIdList></Reference><Reference><Citation>Whiting PJ, Schoepfer R, Swanson LW, Simmons DM, Lindstrom JM. Functional acetylcholine receptor in PC12 cells reacts with a monoclonal antibody to brain nicotinic receptors. Nature. 1987;327:515&#x2013;518.</Citation><ArticleIdList><ArticleId IdType="pubmed">2438558</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Chan P, Schroeder KM, Ellsworth K, Partridge LD. 1-Methyl-4-phenylpridinium (MPP+)-induced functional run-down of GABA(A) receptor-mediated currents in acutely dissociated dopaminergic neurons. J Neurochem. 2002;83:87&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">12358732</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Kuo YP, George AA, Xu L, Hu J, Lukas RJ. beta-Amyloid directly inhibits human alpha4beta2-nicotinic acetylcholine receptors heterologously expressed in human SH-EP1 cells. J Biol Chem. 2004a;279:37842&#x2013;37851.</Citation><ArticleIdList><ArticleId IdType="pubmed">15234980</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, George AA, Schroeder KM, Xu L, Marxer-Miller S, Lucero L, Lukas RJ. Electrophysiological, pharmacological, and molecular evidence for alpha7-nicotinic acetylcholine receptors in rat midbrain dopamine neurons. J Pharmacol Exp Ther. 2004b;311:80&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">15178698</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Z, Feng J. Alzheimer's disease: interactions between cholinergic functions and beta-amyloid. Curr Alzheimer Res. 2004;1:241&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">15975053</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu CR, Role LW. Functional contribution of the alpha5 subunit to neuronal nicotinic channels expressed by chick sympathetic ganglion neurones. J Physiol. 1998;509:667&#x2013;681.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2231009</ArticleId><ArticleId IdType="pubmed">9596790</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19176820</PMID><DateCompleted><Year>2009</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>4</Issue><PubDate><Year>2009</Year><Month>Jan</Month><Day>28</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Neuropeptide Y fragments derived from neprilysin processing are neuroprotective in a transgenic model of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1115</StartPage><EndPage>1125</EndPage><MedlinePgn>1115-25</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.4220-08.2009</ELocationID><Abstract><AbstractText>The endopeptidase neprilysin (NEP) is a major amyloid-beta (Abeta) degrading enzyme and has been implicated in the pathogenesis of Alzheimer's disease. Because NEP cleaves substrates other than Abeta, we investigated the potential role of NEP-mediated processing of neuropeptides in the mechanisms of neuroprotection in vivo. Overexpression of NEP at low levels in transgenic (tg) mice affected primarily the levels of neuropeptide Y (NPY) compared with other neuropeptides. Ex vivo and in vivo studies in tg mice and in mice that received lentiviral vector injections showed that NEP cleaved NPY into C-terminal fragments (CTFs), whereas silencing NEP reduced NPY processing. Immunoblot and mass spectrometry analysis showed that NPY 21-36 and 31-36 were the most abundant fragments generated by NEP activity in vivo. Infusion of these NPY CTFs into the brains of APP (amyloid precursor protein) tg mice ameliorated the neurodegenerative pathology in this model. Moreover, the amidated NPY CTFs protected human neuronal cultures from the neurotoxic effects of Abeta. This study supports the possibility that the NPY CTFs generated during NEP-mediated proteolysis might exert neuroprotective effects in vivo. This function of NEP represents a unique example of a proteolytic enzyme with dual action, namely, degradation of Abeta as well as processing of NPY.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rose</LastName><ForeName>John B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, California 92093-0624, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crews</LastName><ForeName>Leslie</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Rockenstein</LastName><ForeName>Edward</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Adame</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Mante</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Hersh</LastName><ForeName>Louis B</ForeName><Initials>LB</Initials></Author><Author ValidYN="Y"><LastName>Gage</LastName><ForeName>Fred H</ForeName><Initials>FH</Initials></Author><Author ValidYN="Y"><LastName>Spencer</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Potkar</LastName><ForeName>Rewati</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Marr</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Masliah</LastName><ForeName>Eliezer</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG10435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG018440</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG031097</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG022074</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG5131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG018440</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG010435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG18440</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG022074</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C092926">BIBP 3226</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001552">Benzazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009414">Nerve Growth Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009478">Neuropeptide Y</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017476">Receptors, Neuropeptide Y</NameOfSubstance></Chemical><Chemical><RegistryNumber>94ZLA3W45F</RegistryNumber><NameOfSubstance UI="D001120">Arginine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.11</RegistryNumber><NameOfSubstance UI="D015260">Neprilysin</NameOfSubstance></Chemical><Chemical><RegistryNumber>N3Z657H81X</RegistryNumber><NameOfSubstance UI="C403256">BIIE 0246</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001120" MajorTopicYN="N">Arginine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001552" MajorTopicYN="N">Benzazepines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015260" MajorTopicYN="N">Neprilysin</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009414" MajorTopicYN="N">Nerve Growth Factors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009478" MajorTopicYN="N">Neuropeptide Y</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017476" MajorTopicYN="N">Receptors, Neuropeptide Y</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>1</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>1</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>4</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>7</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19176820</ArticleId><ArticleId IdType="mid">NIHMS93327</ArticleId><ArticleId IdType="pmc">PMC2768399</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4220-08.2009</ArticleId><ArticleId IdType="pii">29/4/1115</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Akiyama H, Kondo H, Ikeda K, Kato M, McGeer PL. Immunohistochemical localization of neprilysin in the human cerebral cortex: inverse association with vulnerability to amyloid &#x3b2;-protein (A&#x3b2;) deposition. Brain Res. 2001;902:277&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">11384622</ArticleId></ArticleIdList></Reference><Reference><Citation>Albers HE, Ferris CF. Neuropeptide Y: role in light-dark cycle entrainment of hamster circadian rhythms. Neurosci Lett. 1984;50:163&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">6548555</ArticleId></ArticleIdList></Reference><Reference><Citation>Amatniek JC, Hauser WA, DelCastillo-Castaneda C, Jacobs DM, Marder K, Bell K, Albert M, Brandt J, Stern Y. Incidence and predictors of seizures in patients with Alzheimer's disease. Epilepsia. 2006;47:867&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">16686651</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashford JW. APOE genotype effects on Alzheimer's disease onset and epidemiology. J Mol Neurosci. 2004;23:157&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">15181244</ArticleId></ArticleIdList></Reference><Reference><Citation>Caccamo A, Oddo S, Sugarman MC, Akbari Y, LaFerla FM. Age- and region-dependent alterations in A&#x3b2;-degrading enzymes: implications for A&#x3b2;-induced disorders. Neurobiol Aging. 2005;26:645&#x2013;654.</Citation><ArticleIdList><ArticleId IdType="pubmed">15708439</ArticleId></ArticleIdList></Reference><Reference><Citation>Cadacio CL, Milner TA, Gallagher M, Pierce JP. Hilar neuropeptide Y interneuron loss in the aged rat hippocampal formation. Exp Neurol. 2003;183:147&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">12957498</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter TL, Pedrini S, Ghiso J, Ehrlich ME, Gandy S. Brain neprilysin activity and susceptibility to transgene-induced Alzheimer amyloidosis. Neurosci Lett. 2006;392:235&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">16233955</ArticleId></ArticleIdList></Reference><Reference><Citation>Cha CI, Lee YI, Lee EY, Park KH, Baik SH. Age-related changes of VIP, NPY and somatostatin-immunoreactive neurons in the cerebral cortex of aged rats. Brain Res. 1997;753:235&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">9125408</ArticleId></ArticleIdList></Reference><Reference><Citation>Chana G, Landau S, Beasley C, Everall IP, Cotter D. Two-dimensional assessment of cytoarchitecture in the anterior cingulate cortex in major depressive disorder, bipolar disorder, and schizophrenia: evidence for decreased neuronal somal size and increased neuronal density. Biol Psychiatry. 2003;53:1086&#x2013;1098.</Citation><ArticleIdList><ArticleId IdType="pubmed">12814860</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan-Palay V, Lang W, Allen YS, Haesler U, Polak JM. Cortical neurons immunoreactive with antisera against neuropeptide Y are altered in Alzheimer's-type dementia. J Comp Neurol. 1985;238:390&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pubmed">2413088</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarim&#xf3;n J, Mu&#xf1;oz FJ, Boada M, T&#xe0;rraga L, Sunyer J, Bertranpetit J, Comas D. Possible increased risk for Alzheimer's disease associated with neprilysin gene. J Neural Transm. 2003;110:651&#x2013;657.</Citation><ArticleIdList><ArticleId IdType="pubmed">12768360</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies CA, Morroll DR, Prinja D, Mann DM, Gibbs A. A quantitative assessment of somatostatin-like and neuropeptide Y-like immunostained cells in the frontal and temporal cortex of patients with Alzheimer's disease. J Neurol Sci. 1990;96:59&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">1972185</ArticleId></ArticleIdList></Reference><Reference><Citation>Diez M, Koistinaho J, Kahn K, Games D, H&#xf6;kfelt T. Neuropeptides in hippocampus and cortex in transgenic mice overexpressing V717F &#x3b2;-amyloid precursor protein&#x2014;initial observations. Neuroscience. 2000;100:259&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">11008166</ArticleId></ArticleIdList></Reference><Reference><Citation>Diez M, Danner S, Frey P, Sommer B, Staufenbiel M, Wiederhold KH, H&#xf6;kfelt T. Neuropeptide alterations in the hippocampal formation and cortex of transgenic mice overexpressing &#x3b2;-amyloid precursor protein (APP) with the Swedish double mutation (APP23) Neurobiol Dis. 2003;14:579&#x2013;594.</Citation><ArticleIdList><ArticleId IdType="pubmed">14678773</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Amouri SS, Zhu H, Yu J, Marr R, Verma IM, Kindy MS. Neprilysin: an enzyme candidate to slow the progression of Alzheimer's disease. Am J Pathol. 2008;172:1342&#x2013;1354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2329843</ArticleId><ArticleId IdType="pubmed">18403590</ArticleId></ArticleIdList></Reference><Reference><Citation>Farris W, Sch&#xfc;tz SG, Cirrito JR, Shankar GM, Sun X, George A, Leissring MA, Walsh DM, Qiu WQ, Holtzman DM, Selkoe DJ. Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. Am J Pathol. 2007;171:241&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1941603</ArticleId><ArticleId IdType="pubmed">17591969</ArticleId></ArticleIdList></Reference><Reference><Citation>Foti S, Haberman RP, Samulski RJ, McCown TJ. Adeno-associated virus-mediated expression and constitutive secretion of NPY or NPY13&#x2013;36 suppresses seizure activity in vivo. Gene Ther. 2007;14:1534&#x2013;1536.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3557464</ArticleId><ArticleId IdType="pubmed">17713567</ArticleId></ArticleIdList></Reference><Reference><Citation>Glabe CC. Amyloid accumulation and pathogensis of Alzheimer's disease: significance of monomeric, oligomeric and fibrillar A&#x3b2;. Subcell Biochem. 2005;38:167&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">15709478</ArticleId></ArticleIdList></Reference><Reference><Citation>Glabe CG, Kayed R. Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology. 2006;66:S74&#x2013;S78.</Citation><ArticleIdList><ArticleId IdType="pubmed">16432151</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemming ML, Patterson M, Reske-Nielsen C, Lin L, Isacson O, Selkoe DJ. Reducing amyloid plaque burden via ex vivo gene delivery of an A&#x3b2;-degrading protease: a novel therapeutic approach to Alzheimer disease. PLoS Med. 2007;4:e262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1952204</ArticleId><ArticleId IdType="pubmed">17760499</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong CS, Goins WF, Goss JR, Burton EA, Glorioso JC. Herpes simplex virus RNAi and neprilysin gene transfer vectors reduce accumulation of Alzheimer's disease-related amyloid-&#x3b2; peptide in vivo. Gene Ther. 2006;13:1068&#x2013;1079.</Citation><ArticleIdList><ArticleId IdType="pubmed">16541122</ArticleId></ArticleIdList></Reference><Reference><Citation>Howell OW, Doyle K, Goodman JH, Scharfman HE, Herzog H, Pringle A, Beck-Sickinger AG, Gray WP. Neuropeptide Y stimulates neuronal precursor proliferation in the post-natal and adult dentate gyrus. J Neurochem. 2005;93:560&#x2013;570.</Citation><ArticleIdList><ArticleId IdType="pubmed">15836615</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang SM, Mouri A, Kokubo H, Nakajima R, Suemoto T, Higuchi M, Staufenbiel M, Noda Y, Yamaguchi H, Nabeshima T, Saido TC, Iwata N. Neprilysin-sensitive synapse-associated amyloid-&#x3b2; peptide oligomers impair neuronal plasticity and cognitive function. J Biol Chem. 2006;281:17941&#x2013;17951.</Citation><ArticleIdList><ArticleId IdType="pubmed">16636059</ArticleId></ArticleIdList></Reference><Reference><Citation>Iijima-Ando K, Hearn SA, Granger L, Shenton C, Gatt A, Chiang HC, Hakker I, Zhong Y, Iijima K. Overexpression of neprilysin reduces alzheimer amyloid-&#x3b2;42 (A&#x3b2;42)-induced neuron loss and intraneuronal A&#x3b2;42 deposits but causes a reduction in cAMP-responsive element-binding protein-mediated transcription, age-dependent axon pathology, and premature death in Drosophila. J Biol Chem. 2008;283:19066&#x2013;19076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2441542</ArticleId><ArticleId IdType="pubmed">18463098</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, Kawashima-Morishima M, Lee HJ, Hama E, Sekine-Aizawa Y, Saido TC. Identification of the major A&#x3b2;1&#x2013;42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med. 2000;6:143&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">10655101</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, Gerard C, Hama E, Lee HJ, Saido TC. Metabolic regulation of brain A&#x3b2; by neprilysin. Science. 2001;292:1550&#x2013;1552.</Citation><ArticleIdList><ArticleId IdType="pubmed">11375493</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata N, Mizukami H, Shirotani K, Takaki Y, Muramatsu S, Lu B, Gerard NP, Gerard C, Ozawa K, Saido TC. Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-&#x3b2; peptide in mouse brain. J Neurosci. 2004;24:991&#x2013;998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729819</ArticleId><ArticleId IdType="pubmed">14749444</ArticleId></ArticleIdList></Reference><Reference><Citation>Jinno S, Kosaka T. Patterns of expression of neuropeptides in GABAergic nonprincipal neurons in the mouse hippocampus: quantitative analysis with optical disector. J Comp Neurol. 2003;461:333&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">12746872</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaga T, Fujimiya M, Inui A. Emerging functions of neuropeptide Y Y(2) receptors in the brain. Peptides. 2001;22:501&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pubmed">11287107</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawahara K, Hashimoto M, Bar-On P, Ho GJ, Crews L, Mizuno H, Rockenstein E, Imam SZ, Masliah E. &#x3b1;-Synuclein aggregates interfere with Parkin solubility and distribution: role in the pathogenesis of Parkinson disease. J Biol Chem. 2008;283:6979&#x2013;6987.</Citation><ArticleIdList><ArticleId IdType="pubmed">18195004</ArticleId></ArticleIdList></Reference><Reference><Citation>Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sun X, Frosch MP, Selkoe DJ. Enhanced proteolysis of &#x3b2;-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron. 2003;40:1087&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pubmed">14687544</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu B, Gerard NP, Kolakowski LF, Jr, Bozza M, Zurakowski D, Finco O, Carroll MC, Gerard C. Neutral endopeptidase modulation of septic shock. J Exp Med. 1995;181:2271&#x2013;2275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2192063</ArticleId><ArticleId IdType="pubmed">7760013</ArticleId></ArticleIdList></Reference><Reference><Citation>Marr RA, Rockenstein E, Mukherjee A, Kindy MS, Hersh LB, Gage FH, Verma IM, Masliah E. Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J Neurosci. 2003;23:1992&#x2013;1996.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742010</ArticleId><ArticleId IdType="pubmed">12657655</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science. 2000;287:1265&#x2013;1269.</Citation><ArticleIdList><ArticleId IdType="pubmed">10678833</ArticleId></ArticleIdList></Reference><Reference><Citation>Medeiros MS, Turner AJ. Post-secretory processing of regulatory peptides: the pancreatic polypeptide family as a model example. Biochimie. 1994;76:283&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pubmed">7819336</ArticleId></ArticleIdList></Reference><Reference><Citation>Medeiros Mdos S, Turner AJ. Metabolism and functions of neuropeptide Y. Neurochem Res. 1996;21:1125&#x2013;1132.</Citation><ArticleIdList><ArticleId IdType="pubmed">8897476</ArticleId></ArticleIdList></Reference><Reference><Citation>Minthon L, Edvinsson L, Ekman R, Gustafson L. Neuropeptide levels in Alzheimer's disease and dementia with frontotemporal degeneration. J Neural Transm Suppl. 1990;30:57&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">1975266</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohajeri MH, Kuehnle K, Li H, Poirier R, Tracy J, Nitsch RM. Anti-amyloid activity of neprilysin in plaque-bearing mouse models of Alzheimer's disease. FEBS Lett. 2004;562:16&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">15043995</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Abraham CR, Ruppe MD, Rockenstein EM, Toggas SM, Mallory M, Alford M, Masliah E. Protection against HIV-1 gp120-induced brain damage by neuronal overexpression of human amyloid precursor protein (hAPP) J Exp Med. 1995;181:1551&#x2013;1556.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2191956</ArticleId><ArticleId IdType="pubmed">7699335</ArticleId></ArticleIdList></Reference><Reference><Citation>Naveilhan P, Hassani H, Canals JM, Ekstrand AJ, Larefalk A, Chhajlani V, Arenas E, Gedda K, Svensson L, Thoren P, Ernfors P. Normal feeding behavior, body weight and leptin response require the neuropeptide Y Y2 receptor. Nat Med. 1999;5:1188&#x2013;1193.</Citation><ArticleIdList><ArticleId IdType="pubmed">10502824</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson CL, Brinkmalm A, Minthon L, Blennow K, Ekman R. Processing of neuropeptide Y, galanin, and somatostatin in the cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. Peptides. 2001;22:2105&#x2013;2112.</Citation><ArticleIdList><ArticleId IdType="pubmed">11786197</ArticleId></ArticleIdList></Reference><Reference><Citation>Oda M, Morino H, Maruyama H, Terasawa H, Izumi Y, Torii T, Sasaki K, Nakamura S, Kawakami H. Dinucleotide repeat polymorphisms in the neprilysin gene are not associated with sporadic Alzheimer's disease. Neurosci Lett. 2002;320:105&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">11849775</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, Yu GQ, Kreitzer A, Finkbeiner S, Noebels JL, Mucke L. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron. 2007;55:697&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055171</ArticleId><ArticleId IdType="pubmed">17785178</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos B, Baglietto-Vargas D, del Rio JC, Moreno-Gonzalez I, Santa-Maria C, Jimenez S, Caballero C, Lopez-Tellez JF, Khan ZU, Ruano D, Gutierrez A, Vitorica J. Early neuropathology of somatostatin/NPY GABAergic cells in the hippocampus of a PS1&#xd7;APP transgenic model of Alzheimer's disease. Neurobiol Aging. 2006;27:1658&#x2013;1672.</Citation><ArticleIdList><ArticleId IdType="pubmed">16271420</ArticleId></ArticleIdList></Reference><Reference><Citation>Redrobe JP, Dumont Y, St-Pierre JA, Quirion R. Multiple receptors for neuropeptide Y in the hippocampus: putative roles in seizures and cognition. Brain Res. 1999;848:153&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pubmed">10612707</ArticleId></ArticleIdList></Reference><Reference><Citation>Redrobe JP, Dumont Y, Herzog H, Quirion R. Characterization of neuropeptide Y, Y(2) receptor knockout mice in two animal models of learning and memory processing. J Mol Neurosci. 2004;22:159&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pubmed">14997009</ArticleId></ArticleIdList></Reference><Reference><Citation>Reilly CE. Neprilysin content is reduced in Alzheimer brain areas. J Neurol. 2001;248:159&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">11284139</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockenstein E, Mallory M, Mante M, Sisk A, Masliaha E. Early formation of mature amyloid-b proteins deposits in a mutant APP transgenic model depends on levels of A&#x3b2;1&#x2013;42. J Neurosci Res. 2001;66:573&#x2013;582.</Citation><ArticleIdList><ArticleId IdType="pubmed">11746377</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockenstein E, Mallory M, Mante M, Alford M, Windisch M, Moessler H, Masliah E. Effects of Cerebrolysin on amyloid-&#x3b2; deposition in a transgenic model of Alzheimer's disease. J Neural Transm Suppl. 2002a;2002:327&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">12456076</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockenstein E, Mallory M, Hashimoto M, Song D, Shults CW, Lang I, Masliah E. Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res. 2002b;68:568&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pubmed">12111846</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockenstein E, Schwach G, Ingolic E, Adame A, Crews L, Mante M, Pfragner R, Schreiner E, Windisch M, Masliah E. Lysosomal pathology associated with alpha-synuclein accumulation in transgenic models using an eGFP fusion protein. J Neurosci Res. 2005a;80:247&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">15765523</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockenstein E, Mante M, Alford M, Adame A, Crews L, Hashimoto M, Esposito L, Mucke L, Masliah E. High &#x3b2;-secretase activity elicits neurodegeneration in transgenic mice despite reductions in amyloid-&#x3b2; levels: implications for the treatment of Alzheimer disease. J Biol Chem. 2005b;280:32957&#x2013;32967.</Citation><ArticleIdList><ArticleId IdType="pubmed">16027115</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Cell biology of the amyloid &#x3b2;-protein precursor and the mechanisms of Alzheimer's disease. Annu Rev Cell Biol. 1994a;10:373&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">7888181</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease: a central role for amyloid. J Neuropathol Exp Neurol. 1994b;53:438&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pubmed">8083687</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva AP, Pinheiro PS, Carvalho AP, Carvalho CM, Jakobsen B, Zimmer J, Malva JO. Activation of neuropeptide Y receptors is neuroprotective against excitotoxicity in organotypic hippocampal slice cultures. FASEB J. 2003;17:1118&#x2013;1120.</Citation><ArticleIdList><ArticleId IdType="pubmed">12692082</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva AP, Xapelli S, Grouzmann E, Cavadas C. The putative neuroprotective role of neuropeptide Y in the central nervous system. Curr Drug Targets CNS Neurol Disord. 2005;4:331&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">16101553</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer O, Marr RA, Rockenstein E, Crews L, Coufal NG, Gage FH, Verma IM, Masliah E. Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci. 2005;8:1343&#x2013;1349.</Citation><ArticleIdList><ArticleId IdType="pubmed">16136043</ArticleId></ArticleIdList></Reference><Reference><Citation>Skidgel RA, Erd&#xf6;s EG. Angiotensin converting enzyme (ACE) and neprilysin hydrolyze neuropeptides: a brief history, the beginning and follow-ups to early studies. Peptides. 2004;25:521&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">15134871</ArticleId></ArticleIdList></Reference><Reference><Citation>Sodeyama N, Mizusawa H, Yamada M, Itoh Y, Otomo E, Matsushita M. Lack of association of neprilysin polymorphism with Alzheimer's disease and Alzheimer's disease-type neuropathological changes. J Neurol Neurosurg Psychiatry. 2001;71:817&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1737626</ArticleId><ArticleId IdType="pubmed">11762318</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokolowski MB. NPY and the regulation of behavioral development. Neuron. 2003;39:6&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12848927</ArticleId></ArticleIdList></Reference><Reference><Citation>Toggas SM, Masliah E, Rockenstein EM, Rall GF, Abraham CR, Mucke L. Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature. 1994;367:188&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">8114918</ArticleId></ArticleIdList></Reference><Reference><Citation>Veinbergs I, Van Uden E, Mallory M, Alford M, McGiffert C, DeTeresa R, Orlando R, Masliah E. Role of apolipoprotein E receptors in regulating the differential in vivo neurotrophic effects of apolipoprotein E. Exp Neurol. 2001;170:15&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">11421580</ArticleId></ArticleIdList></Reference><Reference><Citation>Vezzani A, Sperk G, Colmers WF. Neuropeptide Y: emerging evidence for a functional role in seizure modulation. Trends Neurosci. 1999;22:25&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">10088996</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Selkoe DJ. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett. 2004;11:213&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pubmed">15182223</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood LS, Pickering EH, McHale D, Dechairo BM. Association between neprilysin polymorphisms and sporadic Alzheimer's disease. Neurosci Lett. 2007;427:103&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">17928142</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasojima K, Akiyama H, McGeer EG, McGeer PL. Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of &#x3b2;-amyloid peptide. Neurosci Lett. 2001a;297:97&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">11121879</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasojima K, McGeer EG, McGeer PL. Relationship between &#x3b2; amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain. Brain Res. 2001b;919:115&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pubmed">11689168</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19182805</PMID><DateCompleted><Year>2009</Year><Month>04</Month><Day>02</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1718</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>3</Issue><PubDate><Year>2009</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Nature genetics</Title><ISOAbbreviation>Nat Genet</ISOAbbreviation></Journal><ArticleTitle>Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity.</ArticleTitle><Pagination><StartPage>308</StartPage><EndPage>315</EndPage><MedlinePgn>308-15</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/ng.300</ELocationID><Abstract><AbstractText>Parkinson's disease (PD), dementia with Lewy bodies and multiple system atrophy, collectively referred to as synucleinopathies, are associated with a diverse group of genetic and environmental susceptibilities. The best studied of these is PD. alpha-Synuclein (alpha-syn) has a key role in the pathogenesis of both familial and sporadic PD, but evidence linking it to other predisposition factors is limited. Here we report a strong genetic interaction between alpha-syn and the yeast ortholog of the PD-linked gene ATP13A2 (also known as PARK9). Dopaminergic neuron loss caused by alpha-syn overexpression in animal and neuronal PD models is rescued by coexpression of PARK9. Further, knockdown of the ATP13A2 ortholog in Caenorhabditis elegans enhances alpha-syn misfolding. These data provide a direct functional connection between alpha-syn and another PD susceptibility locus. Manganese exposure is an environmental risk factor linked to PD and PD-like syndromes. We discovered that yeast PARK9 helps to protect cells from manganese toxicity, revealing a connection between PD genetics (alpha-syn and PARK9) and an environmental risk factor (PARK9 and manganese). Finally, we show that additional genes from our yeast screen, with diverse functions, are potent modifiers of alpha-syn-induced neuron loss in animals, establishing a diverse, highly conserved interaction network for alpha-syn.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gitler</LastName><ForeName>Aaron D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Whitehead Institute for Biomedical Research and Howard Hughes Medical Institute, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chesi</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Geddie</LastName><ForeName>Melissa L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Strathearn</LastName><ForeName>Katherine E</ForeName><Initials>KE</Initials></Author><Author ValidYN="Y"><LastName>Hamamichi</LastName><ForeName>Shusei</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>Kathryn J</ForeName><Initials>KJ</Initials></Author><Author ValidYN="Y"><LastName>Caldwell</LastName><ForeName>Kim A</ForeName><Initials>KA</Initials></Author><Author ValidYN="Y"><LastName>Caldwell</LastName><ForeName>Guy A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>Antony A</ForeName><Initials>AA</Initials></Author><Author ValidYN="Y"><LastName>Rochet</LastName><ForeName>Jean-Christophe</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Lindquist</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1-DP2-OD004417-01</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP2 OD004417</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS049221</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS038372</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS038372</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS049221</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>02</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Genet</MedlineTA><NlmUniqueID>9216904</NlmUniqueID><ISSNLinking>1061-4036</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D029701">Saccharomyces cerevisiae Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>42Z2K6ZL8P</RegistryNumber><NameOfSubstance UI="D008345">Manganese</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.3.-</RegistryNumber><NameOfSubstance UI="C539310">YPK9 protein, S cerevisiae</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.3.14</RegistryNumber><NameOfSubstance UI="D006180">Proton-Translocating ATPases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017173" MajorTopicYN="N">Caenorhabditis elegans</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017124" MajorTopicYN="N">Conserved Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004351" MajorTopicYN="N">Drug Resistance</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004843" MajorTopicYN="N">Epistasis, Genetic</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053263" MajorTopicYN="N">Gene Regulatory Networks</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008345" MajorTopicYN="N">Manganese</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006180" MajorTopicYN="N">Proton-Translocating ATPases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012441" MajorTopicYN="N">Saccharomyces cerevisiae</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029701" MajorTopicYN="N">Saccharomyces cerevisiae Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014018" MajorTopicYN="N">Tissue Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>2</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>2</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>4</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19182805</ArticleId><ArticleId IdType="mid">NIHMS109987</ArticleId><ArticleId IdType="pmc">PMC2683786</ArticleId><ArticleId IdType="doi">10.1038/ng.300</ArticleId><ArticleId IdType="pii">ng.300</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lee VM, Trojanowski JQ. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery. Neuron. 2006;52:33&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17015225</ArticleId></ArticleIdList></Reference><Reference><Citation>Chartier-Harlin MC, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet. 2004;364:1167&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15451224</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibanez P, et al. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet. 2004;364:1169&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">15451225</ArticleId></ArticleIdList></Reference><Reference><Citation>Singleton AB, et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science. 2003;302:841.</Citation><ArticleIdList><ArticleId IdType="pubmed">14593171</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, et al. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">9278044</ArticleId></ArticleIdList></Reference><Reference><Citation>Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science. 2002;295:865&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11823645</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao S, Gelwix CC, Caldwell KA, Caldwell GA. Torsin-mediated protection from cellular stress in the dopaminergic neurons of Caenorhabditis elegans. J Neurosci. 2005;25:3801&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6724936</ArticleId><ArticleId IdType="pubmed">15829632</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science. 2000;287:1265&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10678833</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo Bianco C, Ridet JL, Schneider BL, Deglon N, Aebischer P. alpha - Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc Natl Acad Sci U S A. 2002;99:10813&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125054</ArticleId><ArticleId IdType="pubmed">12122208</ArticleId></ArticleIdList></Reference><Reference><Citation>Outeiro TF, Lindquist S. Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science. 2003;302:1772&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1780172</ArticleId><ArticleId IdType="pubmed">14657500</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitler AD. Beer and Bread to Brains and Beyond: Can Yeast Cells Teach Us about Neurodegenerative Disease? Neurosignals. 2008;16:52&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">18097160</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper AA, et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science. 2006;313:324&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1983366</ArticleId><ArticleId IdType="pubmed">16794039</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeger-Lotem E, et al. 2008. Manuscript submitted.</Citation></Reference><Reference><Citation>Clark IE, et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature. 2006;441:1162&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">16672981</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J, et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature. 2006;441:1157&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">16672980</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, et al. Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc Natl Acad Sci U S A. 2006;103:10793&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1502310</ArticleId><ArticleId IdType="pubmed">16818890</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F, Nguyen JL, Hulleman JD, Li L, Rochet JC. Mechanisms of DJ-1 neuroprotection in a cellular model of Parkinson's disease. J Neurochem. 2008</Citation><ArticleIdList><ArticleId IdType="pubmed">18331584</ArticleId></ArticleIdList></Reference><Reference><Citation>Meulener MC, et al. DJ-1 is present in a large molecular complex in human brain tissue and interacts with alpha-synuclein. J Neurochem. 2005;93:1524&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">15935068</ArticleId></ArticleIdList></Reference><Reference><Citation>Batelli S, et al. DJ-1 modulates alpha-synuclein aggregation state in a cellular model of oxidative stress: relevance for Parkinson's disease and involvement of HSP70. PLoS ONE. 2008;3:e1884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2270347</ArticleId><ArticleId IdType="pubmed">18382667</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou W, Freed CR. DJ-1 up-regulates glutathione synthesis during oxidative stress and inhibits A53T alpha-synuclein toxicity. J Biol Chem. 2005;280:43150&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">16227205</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Fonzo A, et al. ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology. 2007;68:1557&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">17485642</ArticleId></ArticleIdList></Reference><Reference><Citation>Lees AJ, Singleton AB. Clinical heterogeneity of ATP13A2 linked disease (Kufor-Rakeb) justifies a PARK designation. Neurology. 2007;68:1553&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">17485640</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez A, et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet. 2006;38:1184&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">16964263</ArticleId></ArticleIdList></Reference><Reference><Citation>Su LJ, et al. Chemical Suppressors of alpha-Synuclein Toxicity Link Defects in ER-Golgi Trafficking and Mitochondria. Submitted. 2008</Citation></Reference><Reference><Citation>Gitler AD, et al. The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc Natl Acad Sci U S A. 2008;105:145&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2224176</ArticleId><ArticleId IdType="pubmed">18162536</ArticleId></ArticleIdList></Reference><Reference><Citation>Soper JH, et al. {alpha}-Synuclein Induced Aggregation of Cytoplasmic Vesicles in Saccharomyces cerevisiae. Mol Biol Cell. 2008</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2262993</ArticleId><ArticleId IdType="pubmed">18172022</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy S, Wang D, Ruvkun G. A conserved siRNA-degrading RNase negatively regulates RNA interference in C. elegans. Nature. 2004;427:645&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">14961122</ArticleId></ArticleIdList></Reference><Reference><Citation>Caldwell GA, et al. Suppression of polyglutamine-induced protein aggregation in Caenorhabditis elegans by torsin proteins. Hum Mol Genet. 2003;12:307&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">12554684</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen E, Bieschke J, Perciavalle RM, Kelly JW, Dillin A. Opposing activities protect against age-onset proteotoxicity. Science. 2006;313:1604&#x2013;1610.</Citation><ArticleIdList><ArticleId IdType="pubmed">16902091</ArticleId></ArticleIdList></Reference><Reference><Citation>Link CD. Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Proc Natl Acad Sci U S A. 1995;92:9368&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40986</ArticleId><ArticleId IdType="pubmed">7568134</ArticleId></ArticleIdList></Reference><Reference><Citation>Satyal SH, et al. Polyglutamine aggregates alter protein folding homeostasis in Caenorhabditis elegans. Proc Natl Acad Sci U S A. 2000;97:5750&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18505</ArticleId><ArticleId IdType="pubmed">10811890</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean PJ, et al. TorsinA and heat shock proteins act as molecular chaperones: suppression of alpha-synuclein aggregation. J Neurochem. 2002;83:846&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">12421356</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma N, et al. A close association of torsinA and alpha-synuclein in Lewy bodies: a fluorescence resonance energy transfer study. Am J Pathol. 2001;159:339&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850427</ArticleId><ArticleId IdType="pubmed">11438481</ArticleId></ArticleIdList></Reference><Reference><Citation>Outeiro TF, et al. Sirtuin 2 Inhibitors Rescue {alpha}-Synuclein-Mediated Toxicity in Models of Parkinson's Disease. Science. 2007</Citation><ArticleIdList><ArticleId IdType="pubmed">17588900</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhlbrandt W. Biology, structure and mechanism of P-type ATPases. Nat Rev Mol Cell Biol. 2004;5:282&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">15071553</ArticleId></ArticleIdList></Reference><Reference><Citation>Axelsen KB, Palmgren MG. Evolution of substrate specificities in the P-type ATPase superfamily. J Mol Evol. 1998;46:84&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">9419228</ArticleId></ArticleIdList></Reference><Reference><Citation>Gosavi N, Lee HJ, Lee JS, Patel S, Lee SJ. Golgi fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion. J Biol Chem. 2002;277:48984&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">12351643</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsen KE, et al. Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J Neurosci. 2006;26:11915&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674868</ArticleId><ArticleId IdType="pubmed">17108165</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubo S, et al. A combinatorial code for the interaction of alpha-synuclein with membranes. J Biol Chem. 2005;280:31664&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">16020543</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury PT., Jr. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry. 1996;35:13709&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">8901511</ArticleId></ArticleIdList></Reference><Reference><Citation>Eliezer D, Kutluay E, Bussell R, Jr., Browne G. Conformational properties of alpha-synuclein in its free and lipid-associated states. J Mol Biol. 2001;307:1061&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">11286556</ArticleId></ArticleIdList></Reference><Reference><Citation>Volles MJ, Lansbury PT., Jr. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry. 2003;42:7871&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12834338</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman MS, Trojanowski JQ, Lee VM. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med. 2004;10:1055&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">15459709</ArticleId></ArticleIdList></Reference><Reference><Citation>Norris EH, et al. Pesticide exposure exacerbates alpha-synucleinopathy in an A53T transgenic mouse model. Am J Pathol. 2007;170:658&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1851868</ArticleId><ArticleId IdType="pubmed">17255333</ArticleId></ArticleIdList></Reference><Reference><Citation>Dauer W, et al. Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci U S A. 2002;99:14524&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC137916</ArticleId><ArticleId IdType="pubmed">12376616</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberti S, Gitler AD, Lindquist S. A suite of Gateway((R)) cloning vectors for high-throughput genetic analysis in Saccharomyces cerevisiae. Yeast. 2007;24:913&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2190539</ArticleId><ArticleId IdType="pubmed">17583893</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner S. The genetics of Caenorhabditis elegans. Genetics. 1974;77:71&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1213120</ArticleId><ArticleId IdType="pubmed">4366476</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamath RS, Ahringer J. Genome-wide RNAi screening in Caenorhabditis elegans. Methods. 2003;30:313&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">12828945</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19196968</PMID><DateCompleted><Year>2009</Year><Month>03</Month><Day>27</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>106</Volume><Issue>7</Issue><PubDate><Year>2009</Year><Month>Feb</Month><Day>17</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>A mouse forward genetics screen identifies LISTERIN as an E3 ubiquitin ligase involved in neurodegeneration.</ArticleTitle><Pagination><StartPage>2097</StartPage><EndPage>2103</EndPage><MedlinePgn>2097-103</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0812819106</ELocationID><Abstract><AbstractText>A mouse neurological mutant, lister, was identified through a genome-wide N-ethyl-N-nitrosourea (ENU) mutagenesis screen. Homozygous lister mice exhibit profound early-onset and progressive neurological and motor dysfunction. lister encodes a RING finger protein, LISTERIN, which functions as an E3 ubiquitin ligase in vitro. Although lister is widely expressed in all tissues, motor and sensory neurons and neuronal processes in the brainstem and spinal cord are primarily affected in the mutant. Pathological signs include gliosis, dystrophic neurites, vacuolated mitochondria, and accumulation of soluble hyperphosphorylated tau. Analysis with a different lister allele generated through targeted gene trap insertion reveals LISTERIN is required for embryonic development and confirms that direct perturbation of a LISTERIN-regulated process causes neurodegeneration. The lister mouse uncovers a pathway involved in neurodegeneration and may serves as a model for understanding the molecular mechanisms underlying human neurodegenerative disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>Jessie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Institute for Childhood and Neglected Diseases, The Scripps Research Institute, ICND216, 10550 North Torrey Pines Road, La Jolla, CA 90237, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Nancy A</ForeName><Initials>NA</Initials></Author><Author ValidYN="Y"><LastName>Masuda</LastName><ForeName>Claudio A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Jenkins</LastName><ForeName>Brian V</ForeName><Initials>BV</Initials></Author><Author ValidYN="Y"><LastName>Nelms</LastName><ForeName>Keats A</ForeName><Initials>KA</Initials></Author><Author ValidYN="Y"><LastName>Goodnow</LastName><ForeName>Christopher C</ForeName><Initials>CC</Initials></Author><Author ValidYN="Y"><LastName>Glynne</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Hua</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Masliah</LastName><ForeName>Eliezer</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Joazeiro</LastName><ForeName>Claudio A P</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Kay</LastName><ForeName>Steve A</ForeName><Initials>SA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>02</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.3.2.27</RegistryNumber><NameOfSubstance UI="C539338">Ltn1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.2.27</RegistryNumber><NameOfSubstance UI="D044767">Ubiquitin-Protein Ligases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006720" MajorTopicYN="N">Homozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016296" MajorTopicYN="N">Mutagenesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014018" MajorTopicYN="N">Tissue Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044767" MajorTopicYN="N">Ubiquitin-Protein Ligases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>2</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>2</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>3</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>8</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19196968</ArticleId><ArticleId IdType="pmc">PMC2650114</ArticleId><ArticleId IdType="doi">10.1073/pnas.0812819106</ArticleId><ArticleId IdType="pii">0812819106</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Singleton AB, et al. Alpha-Synuclein locus triplication causes Parkinson's disease. Science. 2003;302:841.</Citation><ArticleIdList><ArticleId IdType="pubmed">14593171</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, et al. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">9278044</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruger R, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet. 1998;18:106&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">9462735</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarranz JJ, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol. 2004;55:164&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pubmed">14755719</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer MJ. Genetics of Parkinson disease: Paradigm shifts and future prospects. Nat Rev Genet. 2006;7:306&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">16543934</ArticleId></ArticleIdList></Reference><Reference><Citation>Figlewicz DA, Orrell RW. The genetics of motor neuron diseases. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4:225&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">14753656</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Orr H. The genetics of neurodegenerative diseases. J Neurochem. 2006;97:1690&#x2013;1699.</Citation><ArticleIdList><ArticleId IdType="pubmed">16805777</ArticleId></ArticleIdList></Reference><Reference><Citation>Nolan PM, Hugill A, Cox RD. ENU mutagenesis in the mouse: Application to human genetic disease. Brief Funct Genomic Proteomic. 2002;1:278&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">15239894</ArticleId></ArticleIdList></Reference><Reference><Citation>Smits BM, et al. Identification of a rat model for usher syndrome type 1B by N-ethyl-N-nitrosourea mutagenesis-driven forward genetics. Genetics. 2005;170:1887&#x2013;1896.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1449770</ArticleId><ArticleId IdType="pubmed">15965244</ArticleId></ArticleIdList></Reference><Reference><Citation>Hafezparast M, et al. Mutations in dynein link motor neuron degeneration to defects in retrograde transport. Science. 2003;300:808&#x2013;812.</Citation><ArticleIdList><ArticleId IdType="pubmed">12730604</ArticleId></ArticleIdList></Reference><Reference><Citation>Puls I, et al. Mutant dynactin in motor neuron disease. Nat Genet. 2003;33:455&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pubmed">12627231</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, Lee VM, Trojanowski JQ. The cytoskeleton in neurodegenerative diseases. J Pathol. 2004;204:438&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3011821</ArticleId><ArticleId IdType="pubmed">15495240</ArticleId></ArticleIdList></Reference><Reference><Citation>Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev. 2000;33:95&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">10967355</ArticleId></ArticleIdList></Reference><Reference><Citation>Farah CA, Nguyen MD, Julien JP, Leclerc N. Altered levels and distribution of microtubule-associated proteins before disease onset in a mouse model of amyotrophic lateral sclerosis. J Neurochem. 2003;84:77&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">12485403</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittmann CW, et al. Tauopathy in Drosophila: Neurodegeneration without neurofibrillary tangles. Science. 2001;293:711&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">11408621</ArticleId></ArticleIdList></Reference><Reference><Citation>Duff K, Planel E. Untangling memory deficits. Nat Med. 2005;11:826&#x2013;827.</Citation><ArticleIdList><ArticleId IdType="pubmed">16079873</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki S, Warita H, Murakami T, Abe K, Iwata M. Ultrastructural study of mitochondria in the spinal cord of transgenic mice with a G93A mutant SOD1 gene. Acta Neuropathol. 2004;107:461&#x2013;474.</Citation><ArticleIdList><ArticleId IdType="pubmed">15029445</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolnay M, Clavaquera F. Argyrophilic grain disease: A late-onset dementia with distinctive features among tauopathies. Neuropathology. 2004;24:269&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pubmed">15641585</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobue G, Hashizume Y, Mitsuma T, Takahashi A. Size-dependent myelinated fiber loss in the corticospinal tract in Shy-Drager syndrome and amyotrophic lateral sclerosis. Neurology 3. 1987;7:529&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pubmed">3822153</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Tu P, Abtahian F, Trojanowski JQ, Lee VM. Neurofilaments and orthograde transport are reduced in ventral root axons of transgenic mice that express human SOD1 with a G93A mutation. J Cell Biol. 1997;139:1307&#x2013;1315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2140205</ArticleId><ArticleId IdType="pubmed">9382875</ArticleId></ArticleIdList></Reference><Reference><Citation>Su AI, et al. Large-scale analysis of the human and mouse transcriptomes. Proc Natl Acad Sci USA. 2002;99:4465&#x2013;4470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC123671</ArticleId><ArticleId IdType="pubmed">11904358</ArticleId></ArticleIdList></Reference><Reference><Citation>Joazeiro CA, Weissman AM. RING finger proteins: Mediators of ubiquitin ligase activity. Cell. 2000;102:549&#x2013;552.</Citation><ArticleIdList><ArticleId IdType="pubmed">11007473</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshaies R, Joazeiro CA. RING domain E3 ubiquitin ligases. Annu Rev Biochem. 2009;78 in press.</Citation><ArticleIdList><ArticleId IdType="pubmed">19489725</ArticleId></ArticleIdList></Reference><Reference><Citation>Hershko A, Ciechanover A, Varshavsky A. Basic Medical Research Award. The ubiquitin system. Nat Med. 2000;6:1073&#x2013;1081.</Citation><ArticleIdList><ArticleId IdType="pubmed">11017125</ArticleId></ArticleIdList></Reference><Reference><Citation>Green SL, Tolwani RJ. Animal models for motor neuron disease. Lab Anim Sci. 1999;49:480&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pubmed">10551448</ArticleId></ArticleIdList></Reference><Reference><Citation>Pramatarova A, Laganiere J, Roussel J, Brisebois K, Rouleau GA. Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. J Neurosci. 2001;21:3369&#x2013;3374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762496</ArticleId><ArticleId IdType="pubmed">11331366</ArticleId></ArticleIdList></Reference><Reference><Citation>Lino MM, Schneider C, Caroni P. Accumulation of SOD1 mutants in postnatal motoneurons does not cause motoneuron pathology or motoneuron disease. J Neurosci. 2002;22:4825&#x2013;4832.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757755</ArticleId><ArticleId IdType="pubmed">12077179</ArticleId></ArticleIdList></Reference><Reference><Citation>Clement AM, et al. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science. 2003;302:113&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">14526083</ArticleId></ArticleIdList></Reference><Reference><Citation>Hand CK, Rouleau GA. Familial amyotrophic lateral sclerosis. Muscle Nerve. 2002;25:135&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">11870681</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, et al. Primary sensory neurons in X-linked recessive bulbospinal neuropathy: Histopathology and androgen receptor gene expression. Muscle Nerve. 1995;18:301&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">7870107</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabin BA, et al. Autosomal dominant juvenile amyotrophic lateral sclerosis. Brain. 1999;122:1539&#x2013;1550.</Citation><ArticleIdList><ArticleId IdType="pubmed">10430837</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy J, Henry R, Lomen-Hoerth C. Establishing subtypes of the continuum of frontal lobe impairment in amyotrophic lateral sclerosis. Arch Neurol. 2007;64:330&#x2013;334.</Citation><ArticleIdList><ArticleId IdType="pubmed">17353375</ArticleId></ArticleIdList></Reference><Reference><Citation>Berke SJ, Paulson HL. Protein aggregation and the ubiquitin proteasome pathway: Gaining the UPPer hand on neurodegeneration. Curr Opin Genet Dev. 2003;13:253&#x2013;261.</Citation><ArticleIdList><ArticleId IdType="pubmed">12787787</ArticleId></ArticleIdList></Reference><Reference><Citation>Kishino T, Lalande M, Wagstaff J. UBE3A/E6-AP mutations cause Angelman syndrome. Nat Genet. 1997;15:70&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">8988171</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuura T, et al. De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome. Nat Genet. 1997;15:74&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">8988172</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson's disease. Science. 2003;302:819&#x2013;822.</Citation><ArticleIdList><ArticleId IdType="pubmed">14593166</ArticleId></ArticleIdList></Reference><Reference><Citation>Leroy E, et al. The ubiquitin pathway in Parkinson's disease. Nature. 1998;395:451&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">9774100</ArticleId></ArticleIdList></Reference><Reference><Citation>He L, et al. Spongiform degeneration in mahoganoid mutant mice. Science. 2003;299:710&#x2013;712.</Citation><ArticleIdList><ArticleId IdType="pubmed">12560552</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SM, et al. Synaptic defects in ataxia mice result from a mutation in Usp14, encoding a ubiquitin-specific protease. Nat Genet. 2002;32:420&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pubmed">12368914</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun JE, et al. Identifying the MAGUK protein Carma-1 as a central regulator of humoral immune responses and atopy by genome-wide mouse mutagenesis. Immunity. 2003;18:751&#x2013;762.</Citation><ArticleIdList><ArticleId IdType="pubmed">12818157</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia ML, et al. NF-M is an essential target for the myelin-directed &#x201c;outside-in&#x201d; signaling cascade that mediates radial axonal growth. J Cell Biol. 2003;163:1011&#x2013;1020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2173620</ArticleId><ArticleId IdType="pubmed">14662745</ArticleId></ArticleIdList></Reference><Reference><Citation>Joazeiro CA, et al. The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science. 1999;286:309&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">10514377</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19198615</PMID><DateCompleted><Year>2009</Year><Month>03</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>3</Issue><PubDate><Year>2009</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>331</StartPage><EndPage>337</EndPage><MedlinePgn>331-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nm.1912</ELocationID><Abstract><AbstractText>Profound neuronal dysfunction in the entorhinal cortex contributes to early loss of short-term memory in Alzheimer's disease. Here we show broad neuroprotective effects of entorhinal brain-derived neurotrophic factor (BDNF) administration in several animal models of Alzheimer's disease, with extension of therapeutic benefits into the degenerating hippocampus. In amyloid-transgenic mice, BDNF gene delivery, when administered after disease onset, reverses synapse loss, partially normalizes aberrant gene expression, improves cell signaling and restores learning and memory. These outcomes occur independently of effects on amyloid plaque load. In aged rats, BDNF infusion reverses cognitive decline, improves age-related perturbations in gene expression and restores cell signaling. In adult rats and primates, BDNF prevents lesion-induced death of entorhinal cortical neurons. In aged primates, BDNF reverses neuronal atrophy and ameliorates age-related cognitive impairment. Collectively, these findings indicate that BDNF exerts substantial protective effects on crucial neuronal circuitry involved in Alzheimer's disease, acting through amyloid-independent mechanisms. BDNF therapeutic delivery merits exploration as a potential therapy for Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nagahara</LastName><ForeName>Alan H</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Department of Neurosciences-0626, 9500 Gilman Drive, University of California-San Diego, La Jolla, California 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merrill</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Coppola</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Tsukada</LastName><ForeName>Shingo</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Schroeder</LastName><ForeName>Brock E</ForeName><Initials>BE</Initials></Author><Author ValidYN="Y"><LastName>Shaked</LastName><ForeName>Gideon M</ForeName><Initials>GM</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ling</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Blesch</LastName><ForeName>Armin</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Albert</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Conner</LastName><ForeName>James M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Rockenstein</LastName><ForeName>Edward</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Chao</LastName><ForeName>Moses V</ForeName><Initials>MV</Initials></Author><Author ValidYN="Y"><LastName>Koo</LastName><ForeName>Edward H</ForeName><Initials>EH</Initials></Author><Author ValidYN="Y"><LastName>Geschwind</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Masliah</LastName><ForeName>Eliezer</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Chiba</LastName><ForeName>Andrea A</ForeName><Initials>AA</Initials></Author><Author ValidYN="Y"><LastName>Tuszynski</LastName><ForeName>Mark H</ForeName><Initials>MH</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>GEO</DataBankName><AccessionNumberList><AccessionNumber>GSE14522</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG010435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG022074</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG018440</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG10435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>02</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019208">Brain-Derived Neurotrophic Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Drug Discov. 2009 Apr;8(4):275. doi: 10.1038/nrd2855.</RefSource><PMID Version="1">19348027</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019208" MajorTopicYN="N">Brain-Derived Neurotrophic Factor</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011323" MajorTopicYN="N">Primates</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>2</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>2</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>3</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>3</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19198615</ArticleId><ArticleId IdType="mid">NIHMS181778</ArticleId><ArticleId IdType="pmc">PMC2838375</ArticleId><ArticleId IdType="doi">10.1038/nm.1912</ArticleId><ArticleId IdType="pii">nm.1912</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gomez-Isla T, et al. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer&#x2019;s disease. J. Neurosci. 1996;16:4491&#x2013;4500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578866</ArticleId><ArticleId IdType="pubmed">8699259</ArticleId></ArticleIdList></Reference><Reference><Citation>Kordower JH, et al. Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. Ann. Neurol. 2001;49:202&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">11220740</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch. Neurol. 2001;58:1395&#x2013;1402.</Citation><ArticleIdList><ArticleId IdType="pubmed">11559310</ArticleId></ArticleIdList></Reference><Reference><Citation>Squire LR, Kandel ER. Memory. New York: Scientific American Library; 2000. Chapter 5.</Citation></Reference><Reference><Citation>Yan Q, et al. Immunocytochemical localization of TrkB in the central nervous system of the adult rat. J. Comp. Neurol. 1997;378:135&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">9120052</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan DR, Miller FD. Neurotrophin signal transduction in the nervous system. Curr. Opin. Neurobiol. 2000;10:381&#x2013;391.</Citation><ArticleIdList><ArticleId IdType="pubmed">10851172</ArticleId></ArticleIdList></Reference><Reference><Citation>Narisawa-Saito M, Wakabayashi K, Tsuji S, Takahashi H, Nawa H. Regional specificity of alterations in NGF, BDNF and NT-3 levels in Alzheimer&#x2019;s disease. Neuroreport. 1996;7:2925&#x2013;2928.</Citation><ArticleIdList><ArticleId IdType="pubmed">9116211</ArticleId></ArticleIdList></Reference><Reference><Citation>Connor B, et al. Brain-derived neurotrophic factor is reduced in Alzheimer&#x2019;s disease. Brain Res. Mol. Brain Res. 1997;49:71&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">9387865</ArticleId></ArticleIdList></Reference><Reference><Citation>Hock C, Heese K, Hulette C, Rosenberg C, Otten U. Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch. Neurol. 2000;57:846&#x2013;851.</Citation><ArticleIdList><ArticleId IdType="pubmed">10867782</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, et al. High-level neuronal expression of a&#x3b2; 1&#x2013;42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, et al. Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer&#x2019;s disease-related cognitive deficits. Proc. Natl. Acad. Sci. USA. 2003;100:9572&#x2013;9577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC170959</ArticleId><ArticleId IdType="pubmed">12881482</ArticleId></ArticleIdList></Reference><Reference><Citation>Boddaert J, et al. Evidence of a role for lactadherin in Alzheimer&#x2019;s disease. Am. J. Pathol. 2007;170:921&#x2013;929.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1864868</ArticleId><ArticleId IdType="pubmed">17322377</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy PH, et al. Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer&#x2019;s disease. Hum. Mol. Genet. 2004;13:1225&#x2013;1240.</Citation><ArticleIdList><ArticleId IdType="pubmed">15115763</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherzer CR, et al. Molecular markers of early Parkinson&#x2019;s disease based on gene expression in blood. Proc. Natl. Acad. Sci. USA. 2007;104:955&#x2013;960.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1766335</ArticleId><ArticleId IdType="pubmed">17215369</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison JH, Hof PR. Life and death of neurons in the aging brain. Science. 1997;278:412&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pubmed">9334292</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill DA, Chiba AA, Tuszynski MH. Conservation of neuronal number and size in the entorhinal cortex of behaviorally characterized aged rats. J. Comp. Neurol. 2001;438:445&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pubmed">11559900</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill DA, Roberts JA, Tuszynski MH. Conservation of neuron number and size in entorhinal cortex layers II, III and V/VI of aged primates. J. Comp. Neurol. 2000;422:396&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">10861515</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe WB, et al. Hippocampal expression analyses reveal selective association of immediate-early, neuroenergetic and myelinogenic pathways with cognitive impairment in aged rats. J. Neurosci. 2007;27:3098&#x2013;3110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672456</ArticleId><ArticleId IdType="pubmed">17376971</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, et al. TrkA expression in the CNS: evidence for the existence of several novel NGF-responsive CNS neurons. J. Neurosci. 1995;15:1567&#x2013;1576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2710116</ArticleId><ArticleId IdType="pubmed">7869118</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterson DA, Lucidi-Phillipi CA, Eagle KL, Gage FH. Perforant path damage results in progressive neuronal death and somal atrophy in layer II of entorhinal cortex and functional impairment with increasing postdamage age. J. Neurosci. 1994;14:6872&#x2013;6885.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577234</ArticleId><ArticleId IdType="pubmed">7965084</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohn TT, Rissman RA, Head E, Cotman CW. Caspase activation in the Alzheimer&#x2019;s disease brain: tortuous and torturous. Drug News Perspect. 2002;15:549&#x2013;557.</Citation><ArticleIdList><ArticleId IdType="pubmed">12677194</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomac A, et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature. 1995;373:335&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pubmed">7830766</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler C, Sauer H, Lee CS, Bjorklund A. Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson&#x2019;s disease. J. Neurosci. 1996;16:7206&#x2013;7215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578933</ArticleId><ArticleId IdType="pubmed">8929429</ArticleId></ArticleIdList></Reference><Reference><Citation>Gash DM, et al. Functional recovery in parkinsonian monkeys treated with GDNF. Nature. 1996;380:252&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">8637574</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaspar BK, Llado J, Sherkat N, Rothstein JD, Gage FH. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science. 2003;301:839&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pubmed">12907804</ArticleId></ArticleIdList></Reference><Reference><Citation>Gazzaley AH, Thakker MM, Hof PR, Morrison JH. Preserved number of entorhinal cortex layer II neurons in aged macaque monkeys. Neurobiol. Aging. 1997;18:549&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pubmed">9390783</ArticleId></ArticleIdList></Reference><Reference><Citation>Taffe MA, Weed MR, Gutierrez T, Davis SA, Gold LH. Modeling a task that is sensitive to dementia of the Alzheimer&#x2019;s type: individual differences in acquisition of a visuo-spatial paired-associate learning task in rhesus monkeys. Behav. Brain Res. 2004;149:123&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">15129776</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould RL, Brown RG, Owen AM, Fytche DH, Howard RJ. fMRI BOLD response to increasing task difficulty during successful paired associates learning. Neuroimage. 2003;20:1006&#x2013;1019.</Citation><ArticleIdList><ArticleId IdType="pubmed">14568470</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoop R, Poo MM. Synaptic modulation by neurotrophic factors. Prog. Brain Res. 1996;109:359&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pubmed">9009723</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine ES, Crozier RA, Black IB, Plummer MR. Brain-derived neurotrophic factor modulates hippocampal synaptic transmission by increasing N-methyl-d-aspartic acid receptor activity. Proc. Natl. Acad. Sci. USA. 1998;95:10235&#x2013;10239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC21491</ArticleId><ArticleId IdType="pubmed">9707630</ArticleId></ArticleIdList></Reference><Reference><Citation>Figurov A, Pozzo-Miller LD, Olafsson P, Wang T, Lu B. Regulation of synaptic responses to high-frequency stimulation and LTP by neurotrophins in the hippocampus. Nature. 1996;381:706&#x2013;709.</Citation><ArticleIdList><ArticleId IdType="pubmed">8649517</ArticleId></ArticleIdList></Reference><Reference><Citation>Thoenen H, Sendtmer M. Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches. Nat. Neurosci. 2002;5:1046&#x2013;1050.</Citation><ArticleIdList><ArticleId IdType="pubmed">12403983</ArticleId></ArticleIdList></Reference><Reference><Citation>Kordower JH, et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson&#x2019;s disease. Ann. Neurol. 1999;46:419&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pubmed">10482276</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill SS, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 2003;9:589&#x2013;595.</Citation><ArticleIdList><ArticleId IdType="pubmed">12669033</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuszynski MH, et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat. Med. 2005;11:551&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">15852017</ArticleId></ArticleIdList></Reference><Reference><Citation>Marks WJ, Jr, et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson&#x2019;s disease: an open-label, phase I trial. Lancet Neurol. 2008;7:400&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">18387850</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplitt MG, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson&#x2019;s disease: an open label, phase I trial. Lancet. 2007;369:2097&#x2013;2105.</Citation><ArticleIdList><ArticleId IdType="pubmed">17586305</ArticleId></ArticleIdList></Reference><Reference><Citation>Smyth GK, Michaud J, Scott HS. Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics. 2005;21:2067&#x2013;2075.</Citation><ArticleIdList><ArticleId IdType="pubmed">15657102</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen AM, Roberts AC, Polkey CE, Sahakian BJ, Robbins TW. Extra-dimensional versus intra-dimensional set shifting performance following frontal lobe excisions, temporal lobe excisions or amygdalo-hippocampectomy in man. Neuropsychologia. 1991;29:993&#x2013;1006.</Citation><ArticleIdList><ArticleId IdType="pubmed">1762678</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19211887</PMID><DateCompleted><Year>2009</Year><Month>03</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>6</Issue><PubDate><Year>2009</Year><Month>Feb</Month><Day>11</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Hippocampal and cognitive aging across the lifespan: a bioenergetic shift precedes and increased cholesterol trafficking parallels memory impairment.</ArticleTitle><Pagination><StartPage>1805</StartPage><EndPage>1816</EndPage><MedlinePgn>1805-16</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.4599-08.2009</ELocationID><Abstract><AbstractText>Multiple hippocampal processes and cognitive functions change with aging or Alzheimer's disease, but the potential triggers of these aging cascades are not well understood. Here, we quantified hippocampal expression profiles and behavior across the adult lifespan to identify early aging changes and changes that coincide with subsequent onset of cognitive impairment. Well powered microarray analyses (N = 49 arrays), immunohistochemistry, and Morris spatial maze learning were used to study male F344 rats at five age points. Genes that changed with aging (by ANOVA) were assigned to one of four onset age ranges based on template pattern matching; functional pathways represented by these genes were identified statistically (Gene Ontology). In the earliest onset age range (3-6 months old), upregulation began for genes in lipid/protein catabolic and lysosomal pathways, indicating a shift in metabolic substrates, whereas downregulation began for lipid synthesis, GTP/ATP-dependent signaling, and neural development genes. By 6-9 months of age, upregulation of immune/inflammatory cytokines was pronounced. Cognitive impairment first appeared in the midlife range (9-12 months) and coincided and correlated primarily with midlife upregulation of genes associated with cholesterol trafficking (apolipoprotein E), myelinogenic, and proteolytic/major histocompatibility complex antigen-presenting pathways. Immunolabeling revealed that cholesterol trafficking proteins were substantially increased in astrocytes and that myelination increased with aging. Together, our data suggest a novel sequential model in which an early-adult metabolic shift, favoring lipid/ketone body oxidation, triggers inflammatory degradation of myelin and resultant excess cholesterol that, by midlife, activates cholesterol transport from astrocytes to remyelinating oligodendrocytes. These processes may damage structure and compete with neuronal pathways for bioenergetic resources, thereby impairing cognitive function.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kadish</LastName><ForeName>Inga</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, University of Alabama, Birmingham, Alabama 35294, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thibault</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Blalock</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Kuey-C</ForeName><Initials>KC</Initials></Author><Author ValidYN="Y"><LastName>Gant</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Porter</LastName><ForeName>Nada M</ForeName><Initials>NM</Initials></Author><Author ValidYN="Y"><LastName>Landfield</LastName><ForeName>Philip W</ForeName><Initials>PW</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG010836</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG004542</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG04542</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG10836</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004734" MajorTopicYN="N">Energy Metabolism</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011916" MajorTopicYN="N">Rats, Inbred F344</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>2</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>2</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>3</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>8</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19211887</ArticleId><ArticleId IdType="mid">NIHMS93858</ArticleId><ArticleId IdType="pmc">PMC2661568</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4599-08.2009</ArticleId><ArticleId IdType="pii">29/6/1805</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abildayeva K, Jansen PJ, Hirsch-Reinshagen V, Bloks VW, Bakker AH, Ramaekers FC, de Vente J, Groen AK, Wellington CL, Kuipers F, Mulder M. 24(S)-hydroxycholesterol participates in a liver X receptor-controlled pathway in astrocytes that regulates apolipoprotein E-mediated cholesterol efflux. J Biol Chem. 2006;281:12799&#x2013;12808.</Citation><ArticleIdList><ArticleId IdType="pubmed">16524875</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25:25&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3037419</ArticleId><ArticleId IdType="pubmed">10802651</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartzokis G, Lu PH, Mintz J. Human brain myelination and amyloid beta deposition in Alzheimer's disease. Alzheimers Dement. 2007;3:122&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2442864</ArticleId><ArticleId IdType="pubmed">18596894</ArticleId></ArticleIdList></Reference><Reference><Citation>Bi X, Yong AP, Zhou J, Gall CM, Lynch G. Regionally selective changes in brain lysosomes occur in the transition from young adulthood to middle age in rats. Neuroscience. 2000;97:395&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">10799771</ArticleId></ArticleIdList></Reference><Reference><Citation>Bj&#xf6;rkhem I. Crossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain. J Intern Med. 2006;260:493&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pubmed">17116000</ArticleId></ArticleIdList></Reference><Reference><Citation>Blalock EM, Chen KC, Sharrow K, Herman JP, Porter NM, Foster TC, Landfield PW. Gene microarrays in hippocampal aging: statistical profiling identifies novel processes correlated with cognitive impairment. J Neurosci. 2003;23:3807&#x2013;3819.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742177</ArticleId><ArticleId IdType="pubmed">12736351</ArticleId></ArticleIdList></Reference><Reference><Citation>Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, Landfield PW. Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci U S A. 2004;101:2173&#x2013;2178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC357071</ArticleId><ArticleId IdType="pubmed">14769913</ArticleId></ArticleIdList></Reference><Reference><Citation>Blalock EM, Chen KC, Stromberg AJ, Norris CM, Kadish I, Kraner SD, Porter NM, Landfield PW. Harnessing the power of gene microarrays for the study of brain aging and Alzheimer's disease: statistical reliability and functional correlation. Ageing Res Rev. 2005;4:481&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pubmed">16257272</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinton RD. Estrogen regulation of glucose metabolism and mitochondrial function: therapeutic implications for prevention of Alzheimer's disease. Adv Drug Deliv Rev. 2008;60:1504&#x2013;1511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2993571</ArticleId><ArticleId IdType="pubmed">18647624</ArticleId></ArticleIdList></Reference><Reference><Citation>Burger C, L&#xf3;pez MC, Feller JA, Baker HV, Muzyczka N, Mandel RJ. Changes in transcription within the CA1 field of the hippocampus are associated with age-related spatial learning impairments. Neurobiol Learn Mem. 2007;87:21&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">16829144</ArticleId></ArticleIdList></Reference><Reference><Citation>Butterfield DA, Poon HF, St Clair D, Keller JN, Pierce WM, Klein JB, Markesbery WR. Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease. Neurobiol Dis. 2006;22:223&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">16466929</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao G, Bales KR, DeMattos RB, Paul SM. Liver X receptor-mediated gene regulation and cholesterol homeostasis in brain: relevance to Alzheimer's disease therapeutics. Curr Alzheimer Res. 2007;4:179&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">17430244</ArticleId></ArticleIdList></Reference><Reference><Citation>Connor JR, Menzies SL. Relationship of iron to oligodendrocytes and myelination. Glia. 1996;17:83&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">8776576</ArticleId></ArticleIdList></Reference><Reference><Citation>Craft S. Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications. Alzheimer Dis Assoc Disord. 2006;20:298&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">17132977</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis G, Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003;4:P3.</Citation><ArticleIdList><ArticleId IdType="pubmed">12734009</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickey CA, Loring JF, Montgomery J, Gordon MN, Eastman PS, Morgan D. Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein + presenilin-1 transgenic mice. J Neurosci. 2003;23:5219&#x2013;5226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741153</ArticleId><ArticleId IdType="pubmed">12832546</ArticleId></ArticleIdList></Reference><Reference><Citation>Dietschy JM, Turley SD. Cholesterol metabolism in the brain. Curr Opin Lipidol. 2001;12:105&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">11264981</ArticleId></ArticleIdList></Reference><Reference><Citation>Disterhoft JF, Oh MM. Learning, aging and intrinsic neuronal plasticity. Trends Neurosci. 2006;29:587&#x2013;599.</Citation><ArticleIdList><ArticleId IdType="pubmed">16942805</ArticleId></ArticleIdList></Reference><Reference><Citation>Finch CE, Morgan TE. Systemic inflammation, infection, ApoE alleles, and Alzheimer disease: a position paper. Curr Alzheimer Res. 2007;4:185&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">17430245</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank MG, Barrientos RM, Biedenkapp JC, Rudy JW, Watkins LR, Maier SF. mRNA up-regulation of MHC II and pivotal pro-inflammatory genes in normal brain aging. Neurobiol Aging. 2006;27:717&#x2013;722.</Citation><ArticleIdList><ArticleId IdType="pubmed">15890435</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallagher M, Bizon JL, Hoyt EC, Helm KA, Lund PK. Effects of aging on the hippocampal formation in a naturally occurring animal model of mild cognitive impairment. Exp Gerontol. 2003;38:71&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">12543263</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallardo G, Schl&#xfc;ter OM, S&#xfc;dhof TC. A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides. Nat Neurosci. 2008;11:301&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">18297066</ArticleId></ArticleIdList></Reference><Reference><Citation>Gant JC, Sama MM, Landfield PW, Thibault O. Early and simultaneous emergence of multiple hippocampal biomarkers of aging is mediated by Ca2+-induced Ca2+ release. J Neurosci. 2006;26:3482&#x2013;3490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673869</ArticleId><ArticleId IdType="pubmed">16571755</ArticleId></ArticleIdList></Reference><Reference><Citation>Gemma C, Bickford PC. Interleukin-1beta and caspase-1: players in the regulation of age-related cognitive dysfunction. Rev Neurosci. 2007;18:137&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">17593876</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson GE, Karuppagounder SS, Shi Q. Oxidant-induced changes in mitochondria and calcium dynamics in the pathophysiology of Alzheimer's disease. Ann N Y Acad Sci. 2008;1147:221&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2744687</ArticleId><ArticleId IdType="pubmed">19076444</ArticleId></ArticleIdList></Reference><Reference><Citation>Green PS, Simpkins JW. Neuroprotective effects of estrogens: potential mechanisms of action. Int J Dev Neurosci. 2000;18:347&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">10817919</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing. Stat Med. 1990;9:811&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pubmed">2218183</ArticleId></ArticleIdList></Reference><Reference><Citation>Holness MJ, Sugden MC. Regulation of pyruvate dehydrogenase complex activity by reversible phosphorylation. Biochem Soc Trans. 2003;31:1143&#x2013;1151.</Citation><ArticleIdList><ArticleId IdType="pubmed">14641014</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D, Paul SM. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2000;97:2892&#x2013;2897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16026</ArticleId><ArticleId IdType="pubmed">10694577</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishibashi T, Dakin KA, Stevens B, Lee PR, Kozlov SV, Stewart CL, Fields RD. Astrocytes promote myelination in response to electrical impulses. Neuron. 2006;49:823&#x2013;832.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1474838</ArticleId><ArticleId IdType="pubmed">16543131</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadish I, Van Groen T. Low levels of estrogen significantly diminish axonal sprouting after entorhinal cortex lesions in the mouse. J Neurosci. 2002;22:4095&#x2013;4102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757658</ArticleId><ArticleId IdType="pubmed">12019328</ArticleId></ArticleIdList></Reference><Reference><Citation>Koldamova R, Lefterov I. Role of LXR and ABCA1 in the pathogenesis of Alzheimer's disease: implications for a new therapeutic approach. Curr Alzheimer Res. 2007;4:171&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">17430243</ArticleId></ArticleIdList></Reference><Reference><Citation>Landfield PW, Baskin RK, Pitler TA. Brain aging correlates: retardation by hormonal-pharmacological treatments. Science. 1981;214:581&#x2013;584.</Citation><ArticleIdList><ArticleId IdType="pubmed">6270791</ArticleId></ArticleIdList></Reference><Reference><Citation>Landreth G, Jiang Q, Mandrekar S, Heneka M. PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics. 2008;5:481&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2593876</ArticleId><ArticleId IdType="pubmed">18625459</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CK, Weindruch R, Prolla TA. Gene-expression profile of the ageing brain in mice. Nat Genet. 2000;25:294&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pubmed">10888876</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Y, Lin S, Beyer TP, Zhang Y, Wu X, Bales KR, DeMattos RB, May PC, Li SD, Jiang XC, Eacho PI, Cao G, Paul SM. A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes. J Neurochem. 2004;88:623&#x2013;634.</Citation><ArticleIdList><ArticleId IdType="pubmed">14720212</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu T, Pan Y, Kao SY, Li C, Kohane I, Chan J, Yankner BA. Gene regulation and DNA damage in the ageing human brain. Nature. 2004;429:883&#x2013;891.</Citation><ArticleIdList><ArticleId IdType="pubmed">15190254</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch G, Rex CS, Gall CM. Synaptic plasticity in early aging. Ageing Res Rev. 2006;5:255&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pubmed">16935034</ArticleId></ArticleIdList></Reference><Reference><Citation>Markowska AL, Savonenko AV. Protective effect of practice on cognition during aging: implications for predictive characteristics of performance and efficacy of practice. Neurobiol Learn Mem. 2002;78:294&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pubmed">12431419</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, McGeer EG. Inflammation and the degenerative diseases of aging. Ann N Y Acad Sci. 2004;1035:104&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">15681803</ArticleId></ArticleIdList></Reference><Reference><Citation>Mi H, Haeberle H, Barres BA. Induction of astrocyte differentiation by endothelial cells. J Neurosci. 2001;21:1538&#x2013;1547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762957</ArticleId><ArticleId IdType="pubmed">11222644</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirnics K, Pevsner J. Progress in the use of microarray technology to study the neurobiology of disease. Nat Neurosci. 2004;7:434&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pubmed">15114354</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods. 1984;11:47&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">6471907</ArticleId></ArticleIdList></Reference><Reference><Citation>Moser EI, Krobert KA, Moser MB, Morris RG. Impaired spatial learning after saturation of long-term potentiation. Science. 1998;281:2038&#x2013;2042.</Citation><ArticleIdList><ArticleId IdType="pubmed">9748165</ArticleId></ArticleIdList></Reference><Reference><Citation>Moser MB, Moser EI. Functional differentiation in the hippocampus. Hippocampus. 1998;8:608&#x2013;619.</Citation><ArticleIdList><ArticleId IdType="pubmed">9882018</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrak RE, Griffin WS. Potential inflammatory biomarkers in Alzheimer's disease. J Alzheimers Dis. 2005;8:369&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">16556968</ArticleId></ArticleIdList></Reference><Reference><Citation>Mufson EJ, Counts SE, Che S, Ginsberg SD. Neuronal gene expression profiling: uncovering the molecular biology of neurodegenerative disease. Prog Brain Res. 2006;158:197&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pubmed">17027698</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA, Cataldo AM. Lysosomal system pathways: genes to neurodegeneration in Alzheimer's disease. J Alzheimers Dis. 2006;9:277&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">16914867</ArticleId></ArticleIdList></Reference><Reference><Citation>Norris CM, Kadish I, Blalock EM, Chen KC, Thibault V, Porter NM, Landfield PW, Kraner SD. Calcineurin triggers reactive/inflammatory processes in astrocytes and is upregulated in aging and Alzheimer's models. J Neurosci. 2005;25:4649&#x2013;4658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1201418</ArticleId><ArticleId IdType="pubmed">15872113</ArticleId></ArticleIdList></Reference><Reference><Citation>Petanceska SS, DeRosa S, Olm V, Diaz N, Sharma A, Thomas-Bryant T, Duff K, Pappolla M, Refolo LM. Statin therapy for Alzheimer's disease: will it work? J Mol Neurosci. 2002;19:155&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pubmed">12212773</ArticleId></ArticleIdList></Reference><Reference><Citation>Petanceska SS, DeRosa S, Sharma A, Diaz N, Duff K, Tint SG, Refolo LM, Pappolla M. Changes in apolipoprotein E expression in response to dietary and pharmacological modulation of cholesterol. J Mol Neurosci. 2003;20:395&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">14501024</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters A, Moss MB, Sethares C. Effects of aging on myelinated nerve fibers in monkey primary visual cortex. J Comp Neurol. 2000;419:364&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">10723011</ArticleId></ArticleIdList></Reference><Reference><Citation>Puglielli L, Tanzi RE, Kovacs DM. Alzheimer's disease: the cholesterol connection. Nat Neurosci. 2003;6:345&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">12658281</ArticleId></ArticleIdList></Reference><Reference><Citation>Randle PJ. Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diabetes Metab Rev. 1998;14:263&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pubmed">10095997</ArticleId></ArticleIdList></Reference><Reference><Citation>Rebeck GW, Kindy M, LaDu MJ. Apolipoprotein E and Alzheimer's disease: the protective effects of ApoE2 and E3. J Alzheimers Dis. 2002;4:145&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pubmed">12226533</ArticleId></ArticleIdList></Reference><Reference><Citation>Roses AD. On the discovery of the genetic association of Apolipoprotein E genotypes and common late-onset Alzheimer disease. J Alzheimers Dis. 2006;9:361&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">16914873</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe WB, Blalock EM, Chen KC, Kadish I, Wang D, Barrett JE, Thibault O, Porter NM, Rose GM, Landfield PW. Hippocampal expression analyses reveal selective association of immediate-early, neuroenergetic, and myelinogenic pathways with cognitive impairment in aged rats. J Neurosci. 2007;27:3098&#x2013;3110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672456</ArticleId><ArticleId IdType="pubmed">17376971</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparks DL, Petanceska S, Sabbagh M, Connor D, Soares H, Adler C, Lopez J, Ziolkowski C, Lochhead J, Browne P. Cholesterol, copper and Abeta in controls, MCI, AD and the AD cholesterol-lowering treatment trial (ADCLT) Curr Alzheimer Res. 2005;2:527&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">16375656</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolozin B. Cholesterol, statins and dementia. Curr Opin Lipidol. 2004;15:667&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pubmed">15529026</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, Mucke L. Inflammation in neurodegenerative disease: a double-edged sword. Neuron. 2002;35:419&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">12165466</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Kanaya A, Lindquist K, Simonsick EM, Harris T, Shorr RI, Tylavsky FA, Newman AB. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA. 2004;292:2237&#x2013;2242.</Citation><ArticleIdList><ArticleId IdType="pubmed">15536110</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19213921</PMID><DateCompleted><Year>2009</Year><Month>02</Month><Day>26</Day></DateCompleted><DateRevised><Year>2010</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>323</Volume><Issue>5916</Issue><PubDate><Year>2009</Year><Month>Feb</Month><Day>13</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>The orphan G protein-coupled receptor 3 modulates amyloid-beta peptide generation in neurons.</ArticleTitle><Pagination><StartPage>946</StartPage><EndPage>951</EndPage><MedlinePgn>946-51</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.1160649</ELocationID><Abstract><AbstractText>Deposition of the amyloid-beta peptide is a pathological hallmark of Alzheimer's disease. A high-throughput functional genomics screen identified G protein-coupled receptor 3 (GPR3), a constitutively active orphan G protein-coupled receptor, as a modulator of amyloid-beta production. Overexpression of GPR3 stimulated amyloid-beta production, whereas genetic ablation of GPR3 prevented accumulation of the amyloid-beta peptide in vitro and in an Alzheimer's disease mouse model. GPR3 expression led to increased formation and cell-surface localization of the mature gamma-secretase complex in the absence of an effect on Notch processing. GPR3 is highly expressed in areas of the normal human brain implicated in Alzheimer's disease and is elevated in the sporadic Alzheimer's disease brain. Thus, GPR3 represents a potential therapeutic target for the treatment of Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thathiah</LastName><ForeName>Amantha</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Molecular and Developmental Genetics, Vlaams Institute for Biotechnology, Center for Human Genetics, Catholic University of Leuven, Herestraat 49, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spittaels</LastName><ForeName>Kurt</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Hoffmann</LastName><ForeName>Marcel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Staes</LastName><ForeName>Mik</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Adrian</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Horr&#xe9;</LastName><ForeName>Katri&#xe9;n</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Vanbrabant</LastName><ForeName>Mieke</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Coun</LastName><ForeName>Frea</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Baekelandt</LastName><ForeName>Veerle</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Delacourte</LastName><ForeName>Andr&#xe9;</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Fischer</LastName><ForeName>David F</ForeName><Initials>DF</Initials></Author><Author ValidYN="Y"><LastName>Pollet</LastName><ForeName>Dirk</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>De Strooper</LastName><ForeName>Bart</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Merchiers</LastName><ForeName>Pascal</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C092794">GPR3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043562">Receptors, G-Protein-Coupled</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051880">Receptors, Notch</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Drug Discov. 2009 Apr;8(4):276. doi: 10.1038/nrd2858.</RefSource><PMID Version="1">19348030</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043562" MajorTopicYN="N">Receptors, G-Protein-Coupled</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051880" MajorTopicYN="N">Receptors, Notch</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>2</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>2</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>2</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19213921</ArticleId><ArticleId IdType="doi">10.1126/science.1160649</ArticleId><ArticleId IdType="pii">323/5916/946</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19223593</PMID><DateCompleted><Year>2009</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>106</Volume><Issue>9</Issue><PubDate><Year>2009</Year><Month>Mar</Month><Day>03</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Protein stability and resistance to oxidative stress are determinants of longevity in the longest-living rodent, the naked mole-rat.</ArticleTitle><Pagination><StartPage>3059</StartPage><EndPage>3064</EndPage><MedlinePgn>3059-64</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0809620106</ELocationID><Abstract><AbstractText>The widely accepted oxidative stress theory of aging postulates that aging results from accumulation of oxidative damage. Surprisingly, data from the longest-living rodent known, naked mole-rats [MRs; mass 35 g; maximum lifespan (MLSP) &gt; 28.3 years], when compared with mice (MLSP 3.5 years) exhibit higher levels of lipid peroxidation, protein carbonylation, and DNA oxidative damage even at a young age. We hypothesize that age-related changes in protein structural stability, oxidation, and degradation are abrogated over the lifespan of the MR. We performed a comprehensive study of oxidation states of protein cysteines [both reversible (sulfenic, disulfide) and indirectly irreversible (sulfinic/sulfonic acids)] in liver from young and old C57BL/6 mice (6 and 28 months) and MRs (2 and &gt;24 years). Furthermore, we compared interspecific differences in urea-induced protein unfolding and ubiquitination and proteasomal activity. Compared with data from young mice, young MRs have 1.6 times as much free protein thiol groups and similar amounts of reversible oxidative damage to cysteine. In addition, they show less urea-induced protein unfolding, less protein ubiquitination, and higher proteasome activity. Mice show a significant age-related increase in cysteine oxidation and higher levels of ubiquitination. In contrast, none of these parameters were significantly altered over 2 decades in MRs. Clearly MRs have markedly attenuated age-related accrual of oxidation damage to thiol groups and age-associated up-regulation of homeostatic proteolytic activity. These pivotal mechanistic interspecies differences may contribute to the divergent aging profiles and strongly implicate maintenance of protein stability and integrity in successful aging.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>P&#xe9;rez</LastName><ForeName>Viviana I</ForeName><Initials>VI</Initials><AffiliationInfo><Affiliation>Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, TX 78229, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buffenstein</LastName><ForeName>Rochelle</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Masamsetti</LastName><ForeName>Venkata</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Leonard</LastName><ForeName>Shanique</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Salmon</LastName><ForeName>Adam B</ForeName><Initials>AB</Initials></Author><Author ValidYN="Y"><LastName>Mele</LastName><ForeName>James</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Andziak</LastName><ForeName>Blazej</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Ting</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Edrey</LastName><ForeName>Yael</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Friguet</LastName><ForeName>Bertrand</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Ward</LastName><ForeName>Walter</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Richardson</LastName><ForeName>Arlan</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Chaudhuri</LastName><ForeName>Asish</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R37 AG26557</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG025362</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG022891</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG025362</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG026557</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG023843</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K07 AG025063</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K07 AG025063 04</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG-022891</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>02</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>K848JZ4886</RegistryNumber><NameOfSubstance UI="D003545">Cysteine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003545" MajorTopicYN="N">Cysteine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008136" MajorTopicYN="N">Longevity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019577" MajorTopicYN="N">Mole Rats</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010084" MajorTopicYN="N">Oxidation-Reduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="Y">Oxidative Stress</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="N">Protein Folding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055550" MajorTopicYN="N">Protein Stability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054875" MajorTopicYN="N">Ubiquitination</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>2</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>2</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>4</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>9</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19223593</ArticleId><ArticleId IdType="pmc">PMC2651236</ArticleId><ArticleId IdType="doi">10.1073/pnas.0809620106</ArticleId><ArticleId IdType="pii">0809620106</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Buffenstein R, Jarvis J U. The naked mole rat: A new record for the oldest living rodent. Sci Aging Knowledge Environ. 2002;2002:pe7.</Citation><ArticleIdList><ArticleId IdType="pubmed">14602989</ArticleId></ArticleIdList></Reference><Reference><Citation>de Magalhaes JP, Costa J, Church GM. An analysis of the relationship between metabolism, developmental schedules, and longevity using phylogenetic independent contrasts. J Gerontol A Biol Sci Med Sci. 2007;62:149&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2288695</ArticleId><ArticleId IdType="pubmed">17339640</ArticleId></ArticleIdList></Reference><Reference><Citation>Buffenstein R. Negligible senescence in the longest living rodent, the naked mole-rat: Insights from a successfully aging species. J Comp Physiol B. 2008;178:439&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pubmed">18180931</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Connor TP, Lee A, Jarvis JU, Buffenstein R. Prolonged longevity in naked mole-rats: Age-related changes in metabolism, body composition, and gastrointestinal function. Comp Biochem Physiol A Mol Integr Physiol. 2002;133:835&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pubmed">12443939</ArticleId></ArticleIdList></Reference><Reference><Citation>Csiszar A, et al. Vascular aging in the longest-living rodent, the naked mole-rat. Am J Physiol. 2007;293:H919&#x2013;H927.</Citation><ArticleIdList><ArticleId IdType="pubmed">17468332</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulbert AJ, Faulks SC, Buffenstein R. Oxidation-resistant membrane phospholipids can explain longevity differences among the longest-living rodents and similarly-sized mice. J Gerontol A Biol Sci Med Sci. 2006;61:1009&#x2013;1018.</Citation><ArticleIdList><ArticleId IdType="pubmed">17077193</ArticleId></ArticleIdList></Reference><Reference><Citation>Buffenstein R. The naked mole-rat: A new long-living model for human aging research. J Gerontol A Biol Sci Med Sci. 2005;60:1369&#x2013;1377.</Citation><ArticleIdList><ArticleId IdType="pubmed">16339321</ArticleId></ArticleIdList></Reference><Reference><Citation>Harman D. Aging: A theory based on free radical and radiation chemistry. J Gerontol. 1956;11:298&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">13332224</ArticleId></ArticleIdList></Reference><Reference><Citation>Barja G, et al. Low mitochondrial free radical production per unit O2 consumption can explain the simultaneous presence of high longevity and high aerobic metabolic rate in birds. Free Radical Res. 1994;21:317&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">7842141</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckman KB, Ames BN. The free radical theory of aging matures. Physiol Rev. 1998;78:547&#x2013;581.</Citation><ArticleIdList><ArticleId IdType="pubmed">9562038</ArticleId></ArticleIdList></Reference><Reference><Citation>Droge W, Schipper HM. Oxidative stress and aberrant signaling in aging and cognitive decline. Aging Cell. 2007;6:361&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1974775</ArticleId><ArticleId IdType="pubmed">17517043</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohal RS. Role of oxidative stress and protein oxidation in the aging process. Free Radical Biol Med. 2002;33:37&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">12086680</ArticleId></ArticleIdList></Reference><Reference><Citation>Miwa S, Riyahi K, Partridge L, Brand MD. Lack of correlation between mitochondrial reactive oxygen species production and life span in Drosophila. Ann N Y Acad Sci. 2004;1019:388&#x2013;391.</Citation><ArticleIdList><ArticleId IdType="pubmed">15247051</ArticleId></ArticleIdList></Reference><Reference><Citation>Andziak B, et al. High oxidative damage levels in the longest-living rodent, the naked mole-rat. Aging Cell. 2006;5:463&#x2013;471.</Citation><ArticleIdList><ArticleId IdType="pubmed">17054663</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilhelm Filho D, Althoff SL, Dafre AL, Boveris A. Antioxidant defenses, longevity, and ecophysiology of South American bats. Comp Biochem Physiol C Toxicol Pharmacol. 2007;146:214&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">17257902</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Remmen H, et al. Life-long reduction in MnSOD activity results in increased DNA damage and higher incidence of cancer but does not accelerate aging. Physiol Genomics. 2003;16:29&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">14679299</ArticleId></ArticleIdList></Reference><Reference><Citation>Labinskyy N, et al. Comparison of endothelial function, O2-* and H2O2 production, and vascular oxidative stress resistance between the longest-living rodent, the naked mole-rat, and mice. Am J Physiol. 2006;291:H2698&#x2013;H2704.</Citation><ArticleIdList><ArticleId IdType="pubmed">17090784</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert AJ, et al. Low rates of hydrogen peroxide production by isolated heart mitochondria associate with long maximum lifespan in vertebrate homeotherms. Aging Cell. 2007;6:607&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pubmed">17596208</ArticleId></ArticleIdList></Reference><Reference><Citation>Andziak B, O'Connor TP, Buffenstein R. Antioxidants do not explain the disparate longevity between mice and the longest-living rodent, the naked mole-rat. Mech Ageing Dev. 2005;126:1206&#x2013;1212.</Citation><ArticleIdList><ArticleId IdType="pubmed">16087218</ArticleId></ArticleIdList></Reference><Reference><Citation>Andziak B, Buffenstein R. Disparate patterns of age-related changes in lipid peroxidation in long-lived naked mole-rats and shorter-lived mice. Aging Cell. 2006;5:525&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pubmed">17129214</ArticleId></ArticleIdList></Reference><Reference><Citation>Salmon AB, Akha AA, Buffenstein R, Miller RA. Fibroblasts from naked mole-rats are resistant to multiple forms of cell injury, but sensitive to peroxide, ultraviolet light, and endoplasmic reticulum stress. J Gerontol A Biol Sci Med Sci. 2008;63:232&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2710579</ArticleId><ArticleId IdType="pubmed">18375872</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung T, Bader N, Grune T. Oxidized proteins: Intracellular distribution and recognition by the proteasome. Arch Biochem Biophys. 2007;462:231&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">17362872</ArticleId></ArticleIdList></Reference><Reference><Citation>Eaton P. Protein thiol oxidation in health and disease: Techniques for measuring disulfides and related modifications in complex protein mixtures. Free Radical Biol Med. 2006;40:1889&#x2013;1899.</Citation><ArticleIdList><ArticleId IdType="pubmed">16716890</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas JA, Mallis RJ. Aging and oxidation of reactive protein sulfhydryls. Exp Gerontol. 2001;36:1519&#x2013;1526.</Citation><ArticleIdList><ArticleId IdType="pubmed">11525874</ArticleId></ArticleIdList></Reference><Reference><Citation>Arner ES, Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem. 2000;267:6102&#x2013;6109.</Citation><ArticleIdList><ArticleId IdType="pubmed">11012661</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannervik B, Axelsson K, Sundewall AC, Holmgren A. Relative contributions of thioltransferase-and thioredoxin-dependent systems in reduction of low-molecular-mass and protein disulphides. Biochem J. 1983;213:519&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1152157</ArticleId><ArticleId IdType="pubmed">6351844</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez A, et al. Extracellular cysteine/cystine redox potential controls lung fibroblast proliferation and matrix expression through up-regulation of transforming growth factor-beta. Am J Physiol. 2007;293:L972&#x2013;L981.</Citation><ArticleIdList><ArticleId IdType="pubmed">17644756</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemp M, Go YM, Jones DP. Nonequilibrium thermodynamics of thiol/disulfide redox systems: A perspective on redox systems biology. Free Radical Biol Med. 2008;44:921&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2587159</ArticleId><ArticleId IdType="pubmed">18155672</ArticleId></ArticleIdList></Reference><Reference><Citation>Saibil HR. Chaperone machines in action. Curr Opin Struct Biol. 2008;18:35&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">18242075</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang C, Chang JY. Isomers of human &#x3b1;-synuclein stabilized by disulfide bonds exhibit distinct structural and aggregative properties. Biochemistry. 2007;46:602&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">17209570</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez VI, et al. Thioredoxin 2 haploinsufficiency in mice results in impaired mitochondrial function and increased oxidative stress. Free Radical Biol Med. 2008;44:882&#x2013;892.</Citation><ArticleIdList><ArticleId IdType="pubmed">18164269</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierce AP, et al. Oxidation and structural perturbation of redox-sensitive enzymes in injured skeletal muscle. Free Radical Biol Med. 2007;43:1584&#x2013;1593.</Citation><ArticleIdList><ArticleId IdType="pubmed">18037124</ArticleId></ArticleIdList></Reference><Reference><Citation>Walss-Bass C, et al. Clozapine causes oxidation of proteins involved in energy metabolism: A possible mechanism for antipsychotic-induced metabolic alterations. Int J Neuropsychopharmacol. 2008;11:1097&#x2013;1104.</Citation><ArticleIdList><ArticleId IdType="pubmed">18466668</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierce A, et al. A novel approach for screening the proteome for changes in protein conformation. Biochemistry. 2006;45:3077&#x2013;3085.</Citation><ArticleIdList><ArticleId IdType="pubmed">16503663</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JR, et al. Identification of proteins containing cysteine residues that are sensitive to oxidation by hydrogen peroxide at neutral pH. Anal Biochem. 2000;283:214&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">10906242</ArticleId></ArticleIdList></Reference><Reference><Citation>Breusing N, Grune T. Regulation of proteasome-mediated protein degradation during oxidative stress and aging. Biol Chem. 2008;389:203&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pubmed">18208355</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulteau AL, Szweda LI, Friguet B. Age-dependent declines in proteasome activity in the heart. Arch Biochem Biophys. 2002;397:298&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">11795886</ArticleId></ArticleIdList></Reference><Reference><Citation>Conconi M, et al. Age-related decline of rat liver multicatalytic proteinase activity and protection from oxidative inactivation by heat-shock protein 90. Arch Biochem Biophys. 1996;331:232&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pubmed">8660703</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson KD. Roles of ubiquitinylation in proteolysis and cellular regulation. Annu Rev Nutr. 1995;15:161&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">8527216</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang F, Nowell TR, Jr, Taylor A. Removal of oxidatively damaged proteins from lens cells by the ubiquitin-proteasome pathway. Exp Eye Res. 2001;73:229&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">11446773</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhuri AR, Khan IA, Luduena RF. Detection of disulfide bonds in bovine brain tubulin and their role in protein folding and microtubule assembly in vitro: A novel disulfide detection approach. Biochemistry. 2001;40:8834&#x2013;8841.</Citation><ArticleIdList><ArticleId IdType="pubmed">11467944</ArticleId></ArticleIdList></Reference><Reference><Citation>Rafter GW, Chaykin S, Krebs EG. The action of glyceraldehyde-3-phosphate dehydrogenase on reduced diphosphopyridine nucleotide. J Biol Chem. 1954;208:799&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pubmed">13174589</ArticleId></ArticleIdList></Reference><Reference><Citation>Harting J, Velick SF. Transfer reactions of acetyl phosphate catalyzed by glyceraldehyde-3-phosphate dehydrogenase. J Biol Chem. 1954;207:867&#x2013;878.</Citation><ArticleIdList><ArticleId IdType="pubmed">13163072</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19228947</PMID><DateCompleted><Year>2009</Year><Month>03</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>106</Volume><Issue>10</Issue><PubDate><Year>2009</Year><Month>Mar</Month><Day>10</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques.</ArticleTitle><Pagination><StartPage>4012</StartPage><EndPage>4017</EndPage><MedlinePgn>4012-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0811698106</ELocationID><Abstract><AbstractText>Synapse loss correlates with a cognitive decline in Alzheimer's disease (AD), but whether this is caused by fibrillar deposits known as senile plaques or soluble oligomeric forms of amyloid beta (Abeta) is controversial. By using array tomography, a technique that combines ultrathin sectioning of tissue with immunofluorescence, allowing precise quantification of small structures, such as synapses, we have tested the hypothesis that oligomeric Abeta surrounding plaques contributes to synapse loss in a mouse model of AD. We find that senile plaques are surrounded by a halo of oligomeric Abeta. Analysis of &gt;14,000 synapses (represented by PSD95-stained excitatory synapses) shows that there is a 60% loss of excitatory synapses in the halo of oligomeric Abeta surrounding plaques and that the density increases to reach almost control levels in volumes further than 50 microm from a plaque in an approximately linear fashion (linear regression, r(2) = 0.9; P &lt; 0.0001). Further, in transgenic cortex, microdeposits of oligomeric Abeta associate with a subset of excitatory synapses, which are significantly smaller than those not in contact with oligomeric Abeta. The proportion of excitatory synapses associated with Abeta correlates with decreasing density (correlation, -0.588; P &lt; 0.0001). These data show that senile plaques are a potential reservoir of oligomeric Abeta, which colocalizes with the postsynaptic density and is associated with spine collapse, reconciling the apparently competing schools of thought of "plaque" vs. "oligomeric Abeta" as the synaptotoxic species in the brain of AD patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Koffie</LastName><ForeName>Robert M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Neurology Department, Massachusetts General Hospital, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyer-Luehmann</LastName><ForeName>Melanie</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Hashimoto</LastName><ForeName>Tadafumi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Adams</LastName><ForeName>Kenneth W</ForeName><Initials>KW</Initials></Author><Author ValidYN="Y"><LastName>Mielke</LastName><ForeName>Matthew L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Garcia-Alloza</LastName><ForeName>Monica</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Micheva</LastName><ForeName>Kristina D</ForeName><Initials>KD</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>M Leo</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia M</ForeName><Initials>VM</Initials></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials></Author><Author ValidYN="Y"><LastName>Spires-Jones</LastName><ForeName>Tara L</ForeName><Initials>TL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG008487</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007753</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>2 P50 AG05134-24</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG08487</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>02</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019706" MajorTopicYN="Y">Excitatory Postsynaptic Potentials</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020836" MajorTopicYN="N">Protein Structure, Quaternary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014054" MajorTopicYN="N">Tomography</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>2</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>2</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>3</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>9</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19228947</ArticleId><ArticleId IdType="pmc">PMC2656196</ArticleId><ArticleId IdType="doi">10.1073/pnas.0811698106</ArticleId><ArticleId IdType="pii">0811698106</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Terry RD, et al. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky ST, Scheff SW, Styren SD. Structural correlates of cognition in dementia: Quantification and assessment of synapse change. Neurodegeneration. 1996;5:417&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">9117556</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleman PD, Yao PJ. Synaptic slaughter in Alzheimer's disease. Neurobiol Aging. 2003;24:1023&#x2013;1027.</Citation><ArticleIdList><ArticleId IdType="pubmed">14643374</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, et al. Amyloid-&#x3b2; protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008;14:837&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder EM, et al. Regulation of NMDA receptor trafficking by amyloid-&#x3b2;. Nat Neurosci. 2005;8:1051&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">16025111</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh H, et al. AMPAR removal underlies A&#x3b2;-induced synaptic depression and dendritic spine loss. Neuron. 2006;52:831&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850952</ArticleId><ArticleId IdType="pubmed">17145504</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai J, Grutzendler J, Duff K, Gan WB. Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat Neurosci. 2004;7:1181&#x2013;1183.</Citation><ArticleIdList><ArticleId IdType="pubmed">15475950</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires TL, et al. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci. 2005;25:7278&#x2013;7287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1820616</ArticleId><ArticleId IdType="pubmed">16079410</ArticleId></ArticleIdList></Reference><Reference><Citation>Knafo S, et al. Widespread changes in dendritic spines in a model of Alzheimer's disease. Cereb Cortex. 2008 in press.</Citation><ArticleIdList><ArticleId IdType="pubmed">18632740</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong H, Martin MV, Chambers S, Csernansky JG. Spatial relationship between synapse loss and &#x3b2;-amyloid deposition in Tg2576 mice. J Comp Neurol. 2007;500:311&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1661843</ArticleId><ArticleId IdType="pubmed">17111375</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires-Jones TL, et al. Impaired spine stability underlies plaque-related spine loss in an Alzheimer's disease mouse model. Am J Pathol. 2007;171:1304&#x2013;1311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1988879</ArticleId><ArticleId IdType="pubmed">17717139</ArticleId></ArticleIdList></Reference><Reference><Citation>Micheva KD, Smith SJ. Array tomography: A new tool for imaging the molecular architecture and ultrastructure of neural circuits. Neuron. 2007;55:25&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2080672</ArticleId><ArticleId IdType="pubmed">17610815</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, et al. Co-expression of multiple transgenes in mouse CNS: A comparison of strategies. Biomol Eng. 2001;17:157&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">11337275</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, et al. Targeting amyloid-&#x3b2; peptide (A&#x3b2;) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in A&#x3b2; precursor protein (APP) transgenic mice. J Biol Chem. 2006;281:4292&#x2013;4299.</Citation><ArticleIdList><ArticleId IdType="pubmed">16361260</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q, Homma KJ, Poo MM. Shrinkage of dendritic spines associated with long-term depression of hippocampal synapses. Neuron. 2004;44:749&#x2013;757.</Citation><ArticleIdList><ArticleId IdType="pubmed">15572107</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires-Jones TL, et al. Passive immunotherapy rapidly increases structural plasticity in a mouse model of Alzheimer disease. Neurobiol Dis. 2009;33:213&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2672591</ArticleId><ArticleId IdType="pubmed">19028582</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, et al. Natural oligomers of the Alzheimer amyloid-&#x3b2; protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007;27:2866&#x2013;2875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672572</ArticleId><ArticleId IdType="pubmed">17360908</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor PN, et al. A&#x3b2; oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci. 2007;27:796&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672917</ArticleId><ArticleId IdType="pubmed">17251419</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, et al. Diffusible, nonfibrillar ligands derived from A&#x3b2;1&#x2013;42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA. 1998;95:6448&#x2013;6453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor PN, et al. Synaptic targeting by Alzheimer's-related amyloid &#x3b2; oligomers. J Neurosci. 2004;24:10191&#x2013;10200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730194</ArticleId><ArticleId IdType="pubmed">15537891</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesn&#xe9; S, et al. A specific amyloid-&#x3b2; protein assembly in the brain impairs memory. Nature. 2006;440:352&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">16541076</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesne S, Kotilinek L, Ashe KH. Plaque-bearing mice with reduced levels of oligomeric amyloid-&#x3b2; assemblies have intact memory function. Neuroscience. 2008;151:745&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677385</ArticleId><ArticleId IdType="pubmed">18155846</ArticleId></ArticleIdList></Reference><Reference><Citation>Lassmann H, Fischer P, Jellinger K. Synaptic pathology of Alzheimer's disease. Ann NY Acad Sci. 1993;695:59&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">8239314</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi RH, et al. Oligomerization of Alzheimer's &#x3b2;-amyloid within processes and synapses of cultured neurons and brain. J Neurosci. 2004;24:3592&#x2013;3599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729733</ArticleId><ArticleId IdType="pubmed">15071107</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, et al. Naturally secreted oligomers of amyloid &#x3b2; protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleary JP, et al. Natural oligomers of the amyloid-&#x3b2; protein specifically disrupt cognitive function. Nat Neurosci. 2005;8:79&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15608634</ArticleId></ArticleIdList></Reference><Reference><Citation>Nusser Z, et al. Cell type and pathway dependence of synaptic AMPA receptor number and variability in the hippocampus. Neuron. 1998;21:545&#x2013;559.</Citation><ArticleIdList><ArticleId IdType="pubmed">9768841</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris KM, Stevens JK. Dendritic spines of CA 1 pyramidal cells in the rat hippocampus: Serial electron microscopy with reference to their biophysical characteristics. J Neurosci. 1989;9:2982&#x2013;2997.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6569708</ArticleId><ArticleId IdType="pubmed">2769375</ArticleId></ArticleIdList></Reference><Reference><Citation>Skoch J, Hickey GA, Kajdasz ST, Hyman BT, Bacskai BJ. In: Amyloid Proteins: Methods and Protocols. Sigurdsson EM, editor. Totowa, NJ: Humana; 2004. pp. 349&#x2013;364.</Citation></Reference><Reference><Citation>Thevenaz P, Ruttimann UE, Unser M. A pyramid approach to subpixel registration based on intensity. IEEE Trans Image Process. 1998;7:27&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">18267377</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19228967</PMID><DateCompleted><Year>2009</Year><Month>04</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>7</Issue><PubDate><Year>2009</Year><Month>Feb</Month><Day>18</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>The cochaperone BAG2 sweeps paired helical filament- insoluble tau from the microtubule.</ArticleTitle><Pagination><StartPage>2151</StartPage><EndPage>2161</EndPage><MedlinePgn>2151-61</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.4660-08.2009</ELocationID><Abstract><AbstractText>Tau inclusions are a prominent feature of many neurodegenerative diseases including Alzheimer's disease. Their accumulation in neurons as ubiquitinated filaments suggests a failure in the degradation limb of the Tau pathway. The components of a Tau protein triage system consisting of CHIP/Hsp70 and other chaperones have begun to emerge. However, the site of triage and the master regulatory elements are unknown. Here, we report an elegant mechanism of Tau degradation involving the cochaperone BAG2. The BAG2/Hsp70 complex is tethered to the microtubule and this complex can capture and deliver Tau to the proteasome for ubiquitin-independent degradation. This complex preferentially degrades Sarkosyl insoluble Tau and phosphorylated Tau. BAG2 levels in cells are under the physiological control of the microRNA miR-128a, which can tune paired helical filament Tau levels in neurons. Thus, we propose that ubiquitinated Tau inclusions arise due to shunting of Tau degradation toward a less efficient ubiquitin-dependent pathway.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carrettiero</LastName><ForeName>Daniel C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Neuroscience Research Institute, University of California Santa Barbara, Santa Barbara, California 93106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Israel</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Neveu</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Papagiannakopoulos</LastName><ForeName>Thales</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Kosik</LastName><ForeName>Kenneth S</ForeName><Initials>KS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG023100</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C492980">BAG2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018840">HSP70 Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D046911">Macromolecular Substances</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018832">Molecular Chaperones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.25.1</RegistryNumber><NameOfSubstance UI="D046988">Proteasome Endopeptidase Complex</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019556" MajorTopicYN="N">COS Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018840" MajorTopicYN="N">HSP70 Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002479" MajorTopicYN="N">Inclusion Bodies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046911" MajorTopicYN="N">Macromolecular Substances</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008870" MajorTopicYN="N">Microtubules</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018832" MajorTopicYN="N">Molecular Chaperones</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046988" MajorTopicYN="N">Proteasome Endopeptidase Complex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054875" MajorTopicYN="N">Ubiquitination</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>2</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>2</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>4</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>8</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19228967</ArticleId><ArticleId IdType="mid">NIHMS96959</ArticleId><ArticleId IdType="pmc">PMC2768429</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4660-08.2009</ArticleId><ArticleId IdType="pii">29/7/2151</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ackmann M, Wiech H, Mandelkow E. Nonsaturable binding indicates clustering of tau on the microtubule surface in a paired helical filament-like conformation. J Biol Chem. 2000;275:30335&#x2013;30343.</Citation><ArticleIdList><ArticleId IdType="pubmed">10869348</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberti S, Demand J, Esser C, Emmerich N, Schild H, Hohfeld J. Ubiquitylation of BAG-1 suggests a novel regulatory mechanism during the sorting of chaperone substrates to the proteasome. J Biol Chem. 2002;277:45920&#x2013;45927.</Citation><ArticleIdList><ArticleId IdType="pubmed">12297498</ArticleId></ArticleIdList></Reference><Reference><Citation>Arndt V, Daniel C, Nastainczyk W, Alberti S, H&#xf6;hfeld J. BAG-2 acts as an inhibitor of the chaperone-associated ubiquitin ligase CHIP. Mol Biol Cell. 2005;16:5891&#x2013;5900.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1289430</ArticleId><ArticleId IdType="pubmed">16207813</ArticleId></ArticleIdList></Reference><Reference><Citation>Asher G, Lotem J, Kama R, Sachs L, Shaul Y. NQO1 stabilizes p53 through a distinct pathway. Proc Natl Acad Sci U S A. 2002;99:3099&#x2013;3104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122479</ArticleId><ArticleId IdType="pubmed">11867746</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci. 2007;8:663&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pubmed">17684513</ArticleId></ArticleIdList></Reference><Reference><Citation>Baugh JM, Pilipenko EV. 20S proteasome differentially alters translation of different mRNAs via the cleavage of eIF4F and eIF3. Mol Cell. 2004;16:575&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pubmed">15546617</ArticleId></ArticleIdList></Reference><Reference><Citation>Bence NF, Sampat RM, Kopito RR. Impairment of the ubiquitin-proteasome system by protein aggregation. Science. 2001;292:1552&#x2013;1555.</Citation><ArticleIdList><ArticleId IdType="pubmed">11375494</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger Z, Ravikumar B, Menzies FM, Oroz LG, Underwood BR, Pangalos MN, Schmitt I, Wullner U, Evert BO, O'Kane CJ, Rubinsztein DC. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet. 2006;15:433&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pubmed">16368705</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergink S, Salomons FA, Hoogstraten D, Groothuis TA, de Waard H, Wu J, Yuan L, Citterio E, Houtsmuller AB, Neefjes J, Hoeijmakers JH, Vermeulen W, Dantuma NP. DNA damage triggers nucleotide excision repair-dependent monoubiquitylation of histone H2A. Genes Dev. 2006;20:1343&#x2013;1352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1472908</ArticleId><ArticleId IdType="pubmed">16702407</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry RW, Abraha A, Lagalwar S, LaPointe N, Gamblin TC, Cryns VL, Binder LI. Inhibition of tau polymerization by its carboxy-terminal caspase cleavage fragment. Biochemistry. 2003;42:8325&#x2013;8331.</Citation><ArticleIdList><ArticleId IdType="pubmed">12846581</ArticleId></ArticleIdList></Reference><Reference><Citation>Bimston D, Song J, Winchester D, Takayama S, Reed JC, Morimoto RI. BAG-1, a negative regulator of Hsp70 chaperone activity, uncouples nucleotide hydrolysis from substrate release. EMBO J. 1998;17:6871&#x2013;6878.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1171035</ArticleId><ArticleId IdType="pubmed">9843493</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardozo C, Michaud C. Proteasome-mediated degradation of tau proteins occurs independently of the chymotrypsin-like activity by a nonprocessive pathway. Arch Biochem Biophys. 2002;408:103&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">12485608</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Chi Y, Bloecher A, Aebersold R, Clurman BE, Roberts JM. N-acetylation and ubiquitin-independent proteasomal degradation of p21(Cip1) Mol Cell. 2004;16:839&#x2013;847.</Citation><ArticleIdList><ArticleId IdType="pubmed">15574338</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho JH, Johnson GV. Glycogen synthase kinase 3 beta induces caspase-cleaved tau aggregation in situ. J Biol Chem. 2004;279:54716&#x2013;54723.</Citation><ArticleIdList><ArticleId IdType="pubmed">15494420</ArticleId></ArticleIdList></Reference><Reference><Citation>Cripps D, Thomas SN, Jeng Y, Yang F, Davies P, Yang AJ. Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-Tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation. J Biol Chem. 2006;281:10825&#x2013;10838.</Citation><ArticleIdList><ArticleId IdType="pubmed">16443603</ArticleId></ArticleIdList></Reference><Reference><Citation>Dantuma NP, Groothuis TA, Salomons FA, Neefjes J. A dynamic ubiquitin equilibrium couples proteasomal activity to chromatin remodeling. J Cell Biol. 2006;173:19&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2063781</ArticleId><ArticleId IdType="pubmed">16606690</ArticleId></ArticleIdList></Reference><Reference><Citation>David DC, Layfield R, Serpell L, Narain Y, Goedert M, Spillantini MG. Proteasomal degradation of tau protein. J Neurochem. 2002;83:176&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">12358741</ArticleId></ArticleIdList></Reference><Reference><Citation>Demand J, Alberti S, Patterson C, H&#xf6;hfeld J. Cooperation of a ubiquitin domain protein and an E3 ubiquitin ligase during chaperone/proteasome coupling. Curr Biol. 2001;11:1569&#x2013;1577.</Citation><ArticleIdList><ArticleId IdType="pubmed">11676916</ArticleId></ArticleIdList></Reference><Reference><Citation>DeTure M, Ko LW, Easson C, Yen SH. Tau assembly in inducible transfectants expressing wild-type or FTDP-17 tau. Am J Pathol. 2002;161:1711&#x2013;1722.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850799</ArticleId><ArticleId IdType="pubmed">12414518</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickey CA, Yue M, Lin WL, Dickson DW, Dunmore JH, Lee WC, Zehr C, West G, Cao S, Clark AM, Caldwell GA, Caldwell KA, Eckman C, Patterson C, Hutton M, Petrucelli L. Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phospho- and caspase-3-cleaved tau species. J Neurosci. 2006;26:6985&#x2013;6996.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673930</ArticleId><ArticleId IdType="pubmed">16807328</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickey CA, Kamal A, Lundgren K, Klosak N, Bailey RM, Dunmore J, Ash P, Shoraka S, Zlatkovic J, Eckman CB, Patterson C, Dickson DW, Nahman NS, Jr, Hutton M, Burrows F, Petrucelli L. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest. 2007;117:648&#x2013;658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1794119</ArticleId><ArticleId IdType="pubmed">17304350</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding H, Matthews TA, Johnson GV. Site-specific phosphorylation and caspase cleavage differentially impact tau-microtubule interactions and tau aggregation. J Biol Chem. 2006;281:19107&#x2013;19114.</Citation><ArticleIdList><ArticleId IdType="pubmed">16687396</ArticleId></ArticleIdList></Reference><Reference><Citation>Elliott E, Tsvetkov P, Ginzburg I. BAG-1 associates with Hsc70.Tau complex and regulates the proteasomal degradation of Tau protein. J Biol Chem. 2007;282:37276&#x2013;37284.</Citation><ArticleIdList><ArticleId IdType="pubmed">17954934</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenteany G, Schreiber SL. Lactacystin, proteasome function, and cell fate. J Biol Chem. 1998;273:8545&#x2013;8548.</Citation><ArticleIdList><ArticleId IdType="pubmed">9535824</ArticleId></ArticleIdList></Reference><Reference><Citation>Gache V, Louwagie M, Garin J, Caudron N, Lafanechere L, Valiron O. Identification of proteins binding the native tubulin dimer. Biochem Biophys Res Commun. 2005;327:35&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">15629426</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell. 2007;27:91&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3800283</ArticleId><ArticleId IdType="pubmed">17612493</ArticleId></ArticleIdList></Reference><Reference><Citation>Heale BS, Soifer HS, Bowers C, Rossi JJ. siRNA target site secondary structure predictions using local stable substructures. Nucleic Acids Res. 2005;33:e30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC549425</ArticleId><ArticleId IdType="pubmed">15722476</ArticleId></ArticleIdList></Reference><Reference><Citation>Ii K, Ito H, Tanaka K, Hirano A. Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly. J Neuropathol Exp Neurol. 1997;56:125&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">9034365</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal K, Grundke-Iqbal I. Ubiquitination and abnormal phosphorylation of paired helical filaments in Alzheimer's disease. Mol Neurobiol. 1991;5:399&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pubmed">1726645</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkins SM, Zinnerman M, Garner C, Johnson GV. Modulation of tau phosphorylation and intracellular localization by cellular stress. Biochem J. 2000;345:263&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1220755</ArticleId><ArticleId IdType="pubmed">10620503</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, O'Donnell A, Weaver C, Angeletti R, Davies P. Hierarchical phosphorylation of recombinant tau by the paired-helical filament-associated protein kinase is dependent on cyclic AMP-dependent protein kinase. J Neurochem. 1999;72:214&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">9886072</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson GV. Tau phosphorylation and proteolysis: insights and perspectives. J Alzheimers Dis. 2006;9:243&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">16914862</ArticleId></ArticleIdList></Reference><Reference><Citation>Konzack S, Thies E, Marx A, Mandelkow EM, Mandelkow E. Swimming against the tide: mobility of the microtubule-associated protein tau in neurons. J Neurosci. 2007;27:9916&#x2013;9927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672630</ArticleId><ArticleId IdType="pubmed">17855606</ArticleId></ArticleIdList></Reference><Reference><Citation>Krek A, Gr&#xfc;n D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M, Rajewsky N. Combinatorial microRNA target predictions. Nat Genet. 2005;37:495&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">15806104</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang-Rollin I, Vekrellis K, Wang Q, Rideout HJ, Stefanis L. Application of proteasomal inhibitors to mouse sympathetic neurons activates the intrinsic apoptotic pathway. J Neurochem. 2004;90:1511&#x2013;1520.</Citation><ArticleIdList><ArticleId IdType="pubmed">15341534</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Amazit L, Long W, Lonard DM, Monaco JJ, O'Malley BW. Ubiquitin- and ATP-independent proteolytic turnover of p21 by the REGgamma-proteasome pathway. Mol Cell. 2007;26:831&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pubmed">17588518</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CW, Corboy MJ, DeMartino GN, Thomas PJ. Endoproteolytic activity of the proteasome. Science. 2003;299:408&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3516294</ArticleId><ArticleId IdType="pubmed">12481023</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu M, Kosik KS. Competition for microtubule-binding with dual expression of tau missense and splice isoforms. Mol Biol Cell. 2001;12:171&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC30576</ArticleId><ArticleId IdType="pubmed">11160831</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xfc;ders J, Demand J, H&#xf6;hfeld J. The ubiquitin-related BAG-1 provides a link between the molecular chaperones Hsc70/Hsp70 and the proteasome. J Biol Chem. 2000;275:4613&#x2013;4617.</Citation><ArticleIdList><ArticleId IdType="pubmed">10671488</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukiw WJ. Micro-RNA speciation in fetal, adult and Alzheimer's disease hippocampus. Neuroreport. 2007;18:297&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">17314675</ArticleId></ArticleIdList></Reference><Reference><Citation>Makrides V, Massie MR, Feinstein SC, Lew J. Evidence for two distinct binding sites for tau on microtubules. Proc Natl Acad Sci U S A. 2004;101:6746&#x2013;6751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC404116</ArticleId><ArticleId IdType="pubmed">15096589</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercken M, Fischer I, Kosik KS, Nixon RA. Three distinct axonal transport rates for tau, tubulin, and other microtubule-associated proteins: evidence for dynamic interactions of tau with microtubules in vivo. J Neurosci. 1995;15:8259&#x2013;8267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577949</ArticleId><ArticleId IdType="pubmed">8613759</ArticleId></ArticleIdList></Reference><Reference><Citation>Morishima-Kawashima M, Hasegawa M, Takio K, Suzuki M, Titani K, Ihara Y. Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments. Neuron. 1993;10:1151&#x2013;1160.</Citation><ArticleIdList><ArticleId IdType="pubmed">8391280</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SY, Tournell C, Sinjoanu RC, Ferreira A. Caspase-3- and calpain-mediated tau cleavage are differentially prevented by estrogen and testosterone in beta-amyloid-treated hippocampal neurons. Neuroscience. 2007;144:119&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1955430</ArticleId><ArticleId IdType="pubmed">17055174</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrucelli L, Dickson D, Kehoe K, Taylor J, Snyder H, Grover A, De Lucia M, McGowan E, Lewis J, Prihar G, Kim J, Dillmann WH, Browne SE, Hall A, Voellmy R, Tsuboi Y, Dawson TM, Wolozin B, Hardy J, Hutton M. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet. 2004;13:703&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">14962978</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian SB, McDonough H, Boellmann F, Cyr DM, Patterson C. CHIP-mediated stress recovery by sequential ubiquitination of substrates and Hsp70. Nature. 2006;440:551&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4112096</ArticleId><ArticleId IdType="pubmed">16554822</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruben GC, Iqbal K, Grundke-Iqbal I, Wisniewski HM, Ciardelli TL, Johnson JE., Jr The microtubule-associated protein tau forms a triple-stranded left-hand helical polymer. J Biol Chem. 1991;266:22019&#x2013;22027.</Citation><ArticleIdList><ArticleId IdType="pubmed">1939223</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahara N, Murayama M, Mizoroki T, Urushitani M, Imai Y, Takahashi R, Murata S, Tanaka K, Takashima A. In vivo evidence of CHIP up-regulation attenuating tau aggregation. J Neurochem. 2005;94:1254&#x2013;1263.</Citation><ArticleIdList><ArticleId IdType="pubmed">16111477</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheaff RJ, Singer JD, Swanger J, Smitherman M, Roberts JM, Clurman BE. Proteasomal turnover of p21Cip1 does not require p21Cip1 ubiquitination. Mol Cell. 2000;5:403&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pubmed">10882081</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimura H, Miura-Shimura Y, Kosik KS. Binding of tau to heat shock protein 27 leads to decreased concentration of hyperphosphorylated tau and enhanced cell survival. J Biol Chem. 2004;279:17957&#x2013;17962.</Citation><ArticleIdList><ArticleId IdType="pubmed">14963027</ArticleId></ArticleIdList></Reference><Reference><Citation>Takayama S, Bimston DN, Matsuzawa S, Freeman BC, Aime-Sempe C, Xie Z, Morimoto RI, Reed JC. BAG-1 modulates the chaperone activity of Hsp70/Hsc70. EMBO J. 1997;16:4887&#x2013;4896.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1170124</ArticleId><ArticleId IdType="pubmed">9305631</ArticleId></ArticleIdList></Reference><Reference><Citation>Takayama S, Xie Z, Reed JC. An evolutionarily conserved family of Hsp70/Hsc70 molecular chaperone regulators. J Biol Chem. 1999;274:781&#x2013;786.</Citation><ArticleIdList><ArticleId IdType="pubmed">9873016</ArticleId></ArticleIdList></Reference><Reference><Citation>Tofaris GK, Layfield R, Spillantini MG. alpha-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome. FEBS Lett. 2001;509:22&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">11734199</ArticleId></ArticleIdList></Reference><Reference><Citation>Touitou R, Richardson J, Bose S, Nakanishi M, Rivett J, Allday MJ. A degradation signal located in the C-terminus of p21WAF1/CIP1 is a binding site for the C8 alpha-subunit of the 20S proteasome. EMBO J. 2001;20:2367&#x2013;2375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125454</ArticleId><ArticleId IdType="pubmed">11350925</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sj&#xf6;gren M, Andreasen N, Blennow K. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett. 2000;285:49&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">10788705</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury PT., Jr NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry. 1996;35:13709&#x2013;13715.</Citation><ArticleIdList><ArticleId IdType="pubmed">8901511</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokota S, Kitahara M, Nagata K. Benzylidene lactam compound, KNK437, a novel inhibitor of acquisition of thermotolerance and heat shock protein induction in human colon carcinoma cells. Cancer Res. 2000;60:2942&#x2013;2948.</Citation><ArticleIdList><ArticleId IdType="pubmed">10850441</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeiner M, Gebauer M, Gehring U. Mammalian protein RAP46: an interaction partner and modulator of 70 kDa heat shock proteins. EMBO J. 1997;16:5483&#x2013;5490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1170180</ArticleId><ArticleId IdType="pubmed">9312007</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19246392</PMID><DateCompleted><Year>2009</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>106</Volume><Issue>11</Issue><PubDate><Year>2009</Year><Month>Mar</Month><Day>17</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Intracerebroventricular amyloid-beta antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice.</ArticleTitle><Pagination><StartPage>4501</StartPage><EndPage>4506</EndPage><MedlinePgn>4501-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0813404106</ELocationID><Abstract><AbstractText>Although immunization against amyloid-beta (Abeta) holds promise as a disease-modifying therapy for Alzheimer disease (AD), it is associated with an undesirable accumulation of amyloid in the cerebrovasculature [i.e., cerebral amyloid angiopathy (CAA)] and a heightened risk of micro-hemorrhages. The central and peripheral mechanisms postulated to modulate amyloid with anti-Abeta immunotherapy remain largely elusive. Here, we compared the effects of prolonged intracerebroventricular (i.c.v.) versus systemic delivery of anti-Abeta antibodies on the behavioral and pathological changes in an aged Tg2576 mouse model of AD. Prolonged i.c.v. infusions of anti-Abeta antibodies dose-dependently reduced the parenchymal plaque burden, astrogliosis, and dystrophic neurites at doses 10- to 50-fold lower than used with systemic delivery of the same antibody. Both i.c.v. and systemic anti-Abeta antibodies reversed the behavioral impairment in contextual fear conditioning. More importantly, unlike systemically delivered anti-Abeta antibodies that aggravated vascular pathology, i.c.v.-infused antibodies globally reduced CAA and associated micro-hemorrhages. We present data suggesting that the divergent effects of i.c.v.-delivered anti-Abeta antibodies result from gradually engaging the local (i.e., central) mechanisms for amyloid clearance, distinct from the mechanisms engaged by high doses of anti-Abeta antibodies that circulate in the vasculature following systemic delivery. With robust efficacy in reversing AD-related pathology and an unexpected benefit in reducing CAA and associated micro-hemorrhages, i.c.v.-targeted passive immunotherapy offers a promising therapeutic approach for the long-term management of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thakker</LastName><ForeName>Deepak R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Medtronic, Inc., Minneapolis, MN 55432, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weatherspoon</LastName><ForeName>Marcy R</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Harrison</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Keene</LastName><ForeName>Thomas E</ForeName><Initials>TE</Initials></Author><Author ValidYN="Y"><LastName>Lane</LastName><ForeName>Deanna S</ForeName><Initials>DS</Initials></Author><Author ValidYN="Y"><LastName>Kaemmerer</LastName><ForeName>William F</ForeName><Initials>WF</Initials></Author><Author ValidYN="Y"><LastName>Stewart</LastName><ForeName>Gregory R</ForeName><Initials>GR</Initials></Author><Author ValidYN="Y"><LastName>Shafer</LastName><ForeName>Lisa L</ForeName><Initials>LL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>02</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016657" MajorTopicYN="N">Cerebral Amyloid Angiopathy</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002543" MajorTopicYN="N">Cerebral Hemorrhage</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005239" MajorTopicYN="N">Fear</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Conflict of interest statement: All authors are either current or past employees of Medtronic, Inc.; this work was funded by Medtronic, Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>2</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>2</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>4</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>2</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19246392</ArticleId><ArticleId IdType="pmc">PMC2647980</ArticleId><ArticleId IdType="doi">10.1073/pnas.0813404106</ArticleId><ArticleId IdType="pii">0813404106</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde TE, Eckman CB, Younkin SG. Biochemical detection of A&#x3b2; isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. Biochim Biophys Acta. 2000;1502:172&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">10899442</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HG, et al. Amyloid-&#x3b2; in Alzheimer disease: the null versus the alternate hypotheses. J Pharmacol Exp Ther. 2007;321:823&#x2013;829.</Citation><ArticleIdList><ArticleId IdType="pubmed">17229880</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk D. Amyloid-&#x3b2; immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci. 2002;3:824&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pubmed">12360327</ArticleId></ArticleIdList></Reference><Reference><Citation>Brody DL, Holtzman DM. Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci. 2008;31:175&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2561172</ArticleId><ArticleId IdType="pubmed">18352830</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasilevko V, Cribbs DH. Novel approaches for immunotherapeutic intervention in Alzheimer's disease. Neurochem Int. 2006;49:113&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">16765487</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk D, et al. Immunization with amyloid-&#x3b2; attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">10408445</ArticleId></ArticleIdList></Reference><Reference><Citation>Janus C, et al. A&#x3b2; peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 2000;408:979&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pubmed">11140685</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan D, et al. A&#x3b2; peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 2000;408:982&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pubmed">11140686</ArticleId></ArticleIdList></Reference><Reference><Citation>Bard F, et al. Peripherally administered antibodies against amyloid &#x3b2;-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6:916&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932230</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB, et al. Peripheral anti-A&#x3b2; antibody alters CNS and plasma A&#x3b2; clearance and decreases brain A&#x3b2; burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA. 2001;98:8850&#x2013;8855.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC37524</ArticleId><ArticleId IdType="pubmed">11438712</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodart JC, et al. Immunization reverses memory deficits without reducing brain A&#x3b2; burden in Alzheimer's disease model. Nat Neurosci. 2002;5:452&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">11941374</ArticleId></ArticleIdList></Reference><Reference><Citation>Frazer ME, et al. Reduced pathology and improved behavioral performance in Alzheimer's disease mice vaccinated with HSV amplicons expressing amyloid-beta and interleukin-4. Mol Ther. 2008;16:845&#x2013;853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2441486</ArticleId><ArticleId IdType="pubmed">18388924</ArticleId></ArticleIdList></Reference><Reference><Citation>Hock C, et al. Antibodies against &#x3b2;-amyloid slow cognitive decline in Alzheimer's disease. Neuron. 2003;38:547&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pubmed">12765607</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilman S, et al. Clinical effects of A&#x3b2; immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64:1553&#x2013;1562.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883316</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll JA, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-&#x3b2; peptide: a case report. Nat Med. 2003;9:448&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">12640446</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-&#x3b2; immunization in Alzheimer's disease. Brain Pathol. 2004;14:11&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095815</ArticleId><ArticleId IdType="pubmed">14997933</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, et al. A&#x3b2; vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology. 2005;64:129&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">15642916</ArticleId></ArticleIdList></Reference><Reference><Citation>Patton RL, et al. Amyloid-&#x3b2; peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol. 2006;169:1048&#x2013;1063.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1698828</ArticleId><ArticleId IdType="pubmed">16936277</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll JA, et al. A&#x3b2; species removal after A&#x3b2;42 immunization. J Neuropathol Exp Neurol. 2006;65:1040&#x2013;1048.</Citation><ArticleIdList><ArticleId IdType="pubmed">17086100</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, et al. Passive immunotherapy against A&#x3b2; in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation. 2004;1:24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC539292</ArticleId><ArticleId IdType="pubmed">15588287</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, et al. Deglycosylated anti-amyloid-&#x3b2; antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J Neurosci. 2006;26:5340&#x2013;5346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675288</ArticleId><ArticleId IdType="pubmed">16707786</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeifer M, et al. Cerebral hemorrhage after passive anti-A&#x3b2; immunotherapy. Science. 2002;298:1379.</Citation><ArticleIdList><ArticleId IdType="pubmed">12434053</ArticleId></ArticleIdList></Reference><Reference><Citation>Racke MM, et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid &#x3b2;. J Neurosci. 2005;25:629&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725332</ArticleId><ArticleId IdType="pubmed">15659599</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg SM, Gurol ME, Rosand J, Smith EE. Amyloid angiopathy-related vascular cognitive impairment. Stroke. 2004;35:2616&#x2013;2619.</Citation><ArticleIdList><ArticleId IdType="pubmed">15459438</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger KA. Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm. 2002;109:813&#x2013;836.</Citation><ArticleIdList><ArticleId IdType="pubmed">12111471</ArticleId></ArticleIdList></Reference><Reference><Citation>Levites Y, et al. Insights into the mechanisms of action of anti-A&#x3b2; antibodies in Alzheimer's disease mouse models. FASEB J. 2006;20:2576&#x2013;2578.</Citation><ArticleIdList><ArticleId IdType="pubmed">17068112</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemere CA, et al. Evidence for peripheral clearance of cerebral A&#x3b2; protein following chronic, active A&#x3b2; immunization in PSAPP mice. Neurobiol Dis. 2003;14:10&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">13678662</ArticleId></ArticleIdList></Reference><Reference><Citation>Banks WA, et al. Passage of amyloid &#x3b2; protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease. Peptides. 2002;23:2223&#x2013;2226.</Citation><ArticleIdList><ArticleId IdType="pubmed">12535702</ArticleId></ArticleIdList></Reference><Reference><Citation>Klyubin I, et al. Amyloid &#x3b2; protein immunotherapy neutralizes A&#x3b2; oligomers that disrupt synaptic plasticity in vivo. Nat Med. 2005;11:556&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pubmed">15834427</ArticleId></ArticleIdList></Reference><Reference><Citation>Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM. Intraneuronal A&#x3b2; causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron. 2005;45:675&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">15748844</ArticleId></ArticleIdList></Reference><Reference><Citation>Dineley KT, Xia X, Bui D, Sweatt JD, Zheng H. Accelerated plaque accumulation, associative learning deficits, and up-regulation of &#x3b1;7 nicotinic receptor protein in transgenic mice co-expressing mutant human presenilin 1 and amyloid precursor proteins. J Biol Chem. 2002;277:22768&#x2013;22780.</Citation><ArticleIdList><ArticleId IdType="pubmed">11912199</ArticleId></ArticleIdList></Reference><Reference><Citation>He P, et al. Deletion of tumor necrosis factor death receptor inhibits amyloid &#x3b2; generation and prevents learning and memory deficits in Alzheimer's mice. J Cell Biol. 2007;178:829&#x2013;841.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2064547</ArticleId><ArticleId IdType="pubmed">17724122</ArticleId></ArticleIdList></Reference><Reference><Citation>Hock C, et al. Generation of antibodies specific for &#x3b2;-amyloid by vaccination of patients with Alzheimer disease. Nat Med. 2002;8:1270&#x2013;1275.</Citation><ArticleIdList><ArticleId IdType="pubmed">12379846</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M, et al. A&#x3b2;42 immunization in Alzheimer's disease generates A&#x3b2; N-terminal antibodies. Ann Neurol. 2005;58:430&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pubmed">16130106</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesne S, et al. A specific amyloid-&#x3b2; protein assembly in the brain impairs memory. Nature. 2006;440:352&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">16541076</ArticleId></ArticleIdList></Reference><Reference><Citation>Tampellini D, et al. Internalized antibodies to the A&#x3b2; domain of APP reduce neuronal A&#x3b2; and protect against synaptic alterations. J Biol Chem. 2007;282:18895&#x2013;18906.</Citation><ArticleIdList><ArticleId IdType="pubmed">17468102</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci. 2004;24:6144&#x2013;6151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729674</ArticleId><ArticleId IdType="pubmed">15240806</ArticleId></ArticleIdList></Reference><Reference><Citation>Callahan MJ, et al. Augmented senile plaque load in aged female &#x3b2;-amyloid precursor protein-transgenic mice. Am J Pathol. 2001;158:1173&#x2013;1177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850367</ArticleId><ArticleId IdType="pubmed">11238065</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Vickle GD, et al. TgCRND8 amyloid precursor protein transgenic mice exhibit an altered &#x3b3;-secretase processing and an aggressive, additive amyloid pathology subject to immunotherapeutic modulation. Biochemistry. 2007;46:10317&#x2013;10327.</Citation><ArticleIdList><ArticleId IdType="pubmed">17705508</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, et al. Correlative memory deficits, A&#x3b2; elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawarabayashi T, et al. Age-dependent changes in brain, CSF, and plasma amyloid (&#x3b2;) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci. 2001;21:372&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763819</ArticleId><ArticleId IdType="pubmed">11160418</ArticleId></ArticleIdList></Reference><Reference><Citation>Robbins EM, et al. Kinetics of cerebral amyloid angiopathy progression in a transgenic mouse model of Alzheimer disease. J Neurosci. 2006;26:365&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674403</ArticleId><ArticleId IdType="pubmed">16407531</ArticleId></ArticleIdList></Reference><Reference><Citation>Domnitz SB, et al. Progression of cerebral amyloid angiopathy in transgenic mouse models of Alzheimer disease. J Neuropathol Exp Neurol. 2005;64:588&#x2013;594.</Citation><ArticleIdList><ArticleId IdType="pubmed">16042310</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, Gordon MN, Morgan D. Quantification of cerebral amyloid angiopathy and parenchymal amyloid plaques with Congo red histochemical stain. Nat Protoc. 2006;1:1591&#x2013;1595.</Citation><ArticleIdList><ArticleId IdType="pubmed">17406451</ArticleId></ArticleIdList></Reference><Reference><Citation>Bard F, et al. Epitope and isotype specificities of antibodies to &#x3b2;-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci USA. 2003;100:2023&#x2013;2028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC149952</ArticleId><ArticleId IdType="pubmed">12566568</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan D. Mechanisms of A&#x3b2; plaque clearance following passive A&#x3b2; immunization. Neurodegener Dis. 2005;2:261&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">16909007</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauhan NB, Siegel GJ, Lichtor T. Distribution of intraventricularly administered anti-amyloid &#x3b2; peptide (A&#x3b2;) antibody in the mouse brain. J Neurosci Res. 2001;66:231&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">11592118</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauhan NB, Siegel GJ. Reversal of amyloid &#x3b2; toxicity in Alzheimer's disease model Tg2576 by intraventricular anti-amyloid &#x3b2; antibody. J Neurosci Res. 2002;69:10&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">12111811</ArticleId></ArticleIdList></Reference><Reference><Citation>Rensink AA, de Waal RM, Kremer B, Verbeek MM. Pathogenesis of cerebral amyloid angiopathy. Brain Res Brain Res Rev. 2003;43:207&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">14572915</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM. Alzheimer's disease: moving towards a vaccine. Nature. 2008;454:418&#x2013;420.</Citation><ArticleIdList><ArticleId IdType="pubmed">18650906</ArticleId></ArticleIdList></Reference><Reference><Citation>Levites Y, et al. Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid &#x3b2;, amyloid &#x3b2;40, and amyloid &#x3b2;42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice. J Neurosci. 2006;26:11923&#x2013;11928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674861</ArticleId><ArticleId IdType="pubmed">17108166</ArticleId></ArticleIdList></Reference><Reference><Citation>Prada CM, et al. Antibody-mediated clearance of amyloid-&#x3b2; peptide from cerebral amyloid angiopathy revealed by quantitative in vivo imaging. J Neurosci. 2007;27:1973&#x2013;1980.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673561</ArticleId><ArticleId IdType="pubmed">17314293</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, et al. Microglial activation facilitates A&#x3b2; plaque removal following intracranial anti-A&#x3b2; antibody administration. Neurobiol Dis. 2004;15:11&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">14751766</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakker DR, et al. Time- and dose-dependent clearance of cerebral amyloid &#x3b2; load via intracerebroventricular passive immunotherapy in the Tg2576 mouse model of Alzheimer's disease. Soc Neurosci Abstr. 2007:485.10.</Citation></Reference><Reference><Citation>Bacskai BJ, et al. Non-Fc-mediated mechanisms are involved in clearance of amyloid-&#x3b2; in vivo by immunotherapy. J Neurosci. 2002;22:7873&#x2013;7878.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758112</ArticleId><ArticleId IdType="pubmed">12223540</ArticleId></ArticleIdList></Reference><Reference><Citation>Das P, et al. Amyloid-&#x3b2; immunization effectively reduces amyloid deposition in FcR&#x3b3;-/- knock-out mice. J Neurosci. 2003;23:8532&#x2013;8538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740360</ArticleId><ArticleId IdType="pubmed">13679422</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, et al. Intracranially administered anti-A&#x3b2; antibodies reduce &#x3b2;-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci. 2003;23:3745&#x2013;3751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742181</ArticleId><ArticleId IdType="pubmed">12736345</ArticleId></ArticleIdList></Reference><Reference><Citation>Klyubin I, et al. Amyloid &#x3b2; protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci. 2008;28:4231&#x2013;4237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2685151</ArticleId><ArticleId IdType="pubmed">18417702</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, et al. IgG-assisted age-dependent clearance of Alzheimer's amyloid &#x3b2; peptide by the blood-brain barrier neonatal Fc receptor. J Neurosci. 2005;25:11495&#x2013;11503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6726020</ArticleId><ArticleId IdType="pubmed">16354907</ArticleId></ArticleIdList></Reference><Reference><Citation>Mamikonyan G, et al. Anti-A&#x3b2;1&#x2013;11 antibody binds to different &#x3b2;-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers. J Biol Chem. 2007;282:22376&#x2013;22386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2435219</ArticleId><ArticleId IdType="pubmed">17545160</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma QL, et al. Antibodies against &#x3b2;-amyloid reduce A&#x3b2; oligomers, glycogen synthase kinase-3&#x3b2; activation and tau phosphorylation in vivo and in vitro. J Neurosci Res. 2006;83:374&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">16385556</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakker DR, et al. Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference. Proc Natl Acad Sci USA. 2004;101:17270&#x2013;17275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC535368</ArticleId><ArticleId IdType="pubmed">15569935</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA. 2000;97:2892&#x2013;2897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16026</ArticleId><ArticleId IdType="pubmed">10694577</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19251629</PMID><DateCompleted><Year>2009</Year><Month>03</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>323</Volume><Issue>5918</Issue><PubDate><Year>2009</Year><Month>Feb</Month><Day>27</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Synchronous hyperactivity and intercellular calcium waves in astrocytes in Alzheimer mice.</ArticleTitle><Pagination><StartPage>1211</StartPage><EndPage>1215</EndPage><MedlinePgn>1211-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.1169096</ELocationID><Abstract><AbstractText>Although senile plaques focally disrupt neuronal health, the functional response of astrocytes to Alzheimer's disease pathology is unknown. Using multiphoton fluorescence lifetime imaging microscopy in vivo, we quantitatively imaged astrocytic calcium homeostasis in a mouse model of Alzheimer's disease. Resting calcium was globally elevated in the astrocytic network, but was independent of proximity to individual plaques. Time-lapse imaging revealed that calcium transients in astrocytes were more frequent, synchronously coordinated across long distances, and uncoupled from neuronal activity. Furthermore, rare intercellular calcium waves were observed, but only in mice with amyloid-beta plaques, originating near plaques and spreading radially at least 200 micrometers. Thus, although neurotoxicity is observed near amyloid-beta deposits, there exists a more general astrocyte-based network response to focal pathology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kuchibhotla</LastName><ForeName>Kishore V</ForeName><Initials>KV</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Department of Neurology/Alzheimer's Disease Research Laboratory, 114 16th Street, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lattarulo</LastName><ForeName>Carli R</ForeName><Initials>CR</Initials></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials></Author><Author ValidYN="Y"><LastName>Bacskai</LastName><ForeName>Brian J</ForeName><Initials>BJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR025645</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG008487</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 NS058075</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EB000768</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS580752</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>EB000768</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020013" MajorTopicYN="Y">Calcium Signaling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036641" MajorTopicYN="N">Microscopy, Fluorescence, Multiphoton</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>3</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>3</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>3</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>6</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19251629</ArticleId><ArticleId IdType="mid">NIHMS206076</ArticleId><ArticleId IdType="pmc">PMC2884172</ArticleId><ArticleId IdType="doi">10.1126/science.1169096</ArticleId><ArticleId IdType="pii">323/5918/1211</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Meyer-Luehmann M, et al. Nature. 2008 Feb 7;451:720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3264491</ArticleId><ArticleId IdType="pubmed">18256671</ArticleId></ArticleIdList></Reference><Reference><Citation>Busche MA, et al. Science. 2008 Sep 19;321:1686.</Citation><ArticleIdList><ArticleId IdType="pubmed">18802001</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires TL, et al. J Neurosci. 2005 Aug 3;25:7278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1820616</ArticleId><ArticleId IdType="pubmed">16079410</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuchibhotla KV, et al. Neuron. 2008 Jul 31;59:214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2578820</ArticleId><ArticleId IdType="pubmed">18667150</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, et al. Nat Neurosci. 2006 Jun;9:816.</Citation><ArticleIdList><ArticleId IdType="pubmed">16699507</ArticleId></ArticleIdList></Reference><Reference><Citation>Schummers J, Yu H, Sur M. Science. 2008 Jun 20;320:1638.</Citation><ArticleIdList><ArticleId IdType="pubmed">18566287</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirase H, Qian L, Bartho P, Buzsaki G. PLoS Biol. 2004 Apr;2:E96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC387267</ArticleId><ArticleId IdType="pubmed">15094801</ArticleId></ArticleIdList></Reference><Reference><Citation>Maragakis NJ, Rothstein JD. Nat Clin Pract Neurol. 2006 Dec;2:679.</Citation><ArticleIdList><ArticleId IdType="pubmed">17117171</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegiel J, et al. Neurobiol Aging. 2001 Jan&#x2013;Feb;22:49.</Citation><ArticleIdList><ArticleId IdType="pubmed">11164276</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, et al. Nat Med. 2003 Apr;9:453.</Citation><ArticleIdList><ArticleId IdType="pubmed">12612547</ArticleId></ArticleIdList></Reference><Reference><Citation>Takano T, Han X, Deane R, Zlokovic B, Nedergaard M. Ann N Y Acad Sci. 2007 Feb;1097:40.</Citation><ArticleIdList><ArticleId IdType="pubmed">17413008</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilms CD, Schmidt H, Eilers J. Cell Calcium. 2006 Jul;40:73.</Citation><ArticleIdList><ArticleId IdType="pubmed">16690123</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Alloza M, et al. Neurobiol Dis. 2006 Dec;24:516.</Citation><ArticleIdList><ArticleId IdType="pubmed">17029828</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, et al. Neuron. 1997 Oct;19:939.</Citation><ArticleIdList><ArticleId IdType="pubmed">9354339</ArticleId></ArticleIdList></Reference><Reference><Citation>Agulhon C, et al. Neuron. 2008 Sep 25;59:932.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3623689</ArticleId><ArticleId IdType="pubmed">18817732</ArticleId></ArticleIdList></Reference><Reference><Citation>Scemes E, Giaume C. Glia. 2006 Nov 15;54:716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2605018</ArticleId><ArticleId IdType="pubmed">17006900</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornell-Bell AH, Finkbeiner SM, Cooper MS, Smith SJ. Science. 1990 Jan 26;247:470.</Citation><ArticleIdList><ArticleId IdType="pubmed">1967852</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiacco TA, McCarthy KD. Glia. 2006 Nov 15;54:676.</Citation><ArticleIdList><ArticleId IdType="pubmed">17006896</ArticleId></ArticleIdList></Reference><Reference><Citation>Boitano S, Dirksen ER, Sanderson MJ. Science. 1992 Oct 9;258:292.</Citation><ArticleIdList><ArticleId IdType="pubmed">1411526</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotrina ML, Lin JH, Lopez-Garcia JC, Naus CC, Nedergaard M. J Neurosci. 2000 Apr 15;20:2835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772203</ArticleId><ArticleId IdType="pubmed">10751435</ArticleId></ArticleIdList></Reference><Reference><Citation>Guthrie PB, et al. J Neurosci. 1999 Jan 15;19:520.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782195</ArticleId><ArticleId IdType="pubmed">9880572</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Alloza M, Dodwell SA, Meyer-Luehmann M, Hyman BT, Bacskai BJ. J Neuropathol Exp Neurol. 2006 Nov;65:1082.</Citation><ArticleIdList><ArticleId IdType="pubmed">17086105</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramov AY, Canevari L, Duchen MR. J Neurosci. 2003 Jun 15;23:5088.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741151</ArticleId><ArticleId IdType="pubmed">12832532</ArticleId></ArticleIdList></Reference><Reference><Citation>Petravicz J, Fiacco TA, McCarthy KD. J Neurosci. 2008 May 7;28:4967.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2709811</ArticleId><ArticleId IdType="pubmed">18463250</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19276086</PMID><DateCompleted><Year>2009</Year><Month>06</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>284</Volume><Issue>18</Issue><PubDate><Year>2009</Year><Month>May</Month><Day>01</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Intracellular trafficking of presenilin 1 is regulated by beta-amyloid precursor protein and phospholipase D1.</ArticleTitle><Pagination><StartPage>12145</StartPage><EndPage>12152</EndPage><MedlinePgn>12145-52</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1074/jbc.M808497200</ELocationID><Abstract><AbstractText>Excessive accumulation of beta-amyloid peptides in the brain is a major cause for the pathogenesis of Alzheimer disease. beta-Amyloid is derived from beta-amyloid precursor protein (APP) through sequential cleavages by beta- and gamma-secretases, whose enzymatic activities are tightly controlled by subcellular localization. Delineation of how intracellular trafficking of these secretases and APP is regulated is important for understanding Alzheimer disease pathogenesis. Although APP trafficking is regulated by multiple factors including presenilin 1 (PS1), a major component of the gamma-secretase complex, and phospholipase D1 (PLD1), a phospholipid-modifying enzyme, regulation of intracellular trafficking of PS1/gamma-secretase and beta-secretase is less clear. Here we demonstrate that APP can reciprocally regulate PS1 trafficking; APP deficiency results in faster transport of PS1 from the trans-Golgi network to the cell surface and increased steady state levels of PS1 at the cell surface, which can be reversed by restoring APP levels. Restoration of APP in APP-deficient cells also reduces steady state levels of other gamma-secretase components (nicastrin, APH-1, and PEN-2) and the cleavage of Notch by PS1/gamma-secretase that is more highly correlated with cell surface levels of PS1 than with APP overexpression levels, supporting the notion that Notch is mainly cleaved at the cell surface. In contrast, intracellular trafficking of beta-secretase (BACE1) is not regulated by APP. Moreover, we find that PLD1 also regulates PS1 trafficking and that PLD1 overexpression promotes cell surface accumulation of PS1 in an APP-independent manner. Our results clearly elucidate a physiological function of APP in regulating protein trafficking and suggest that intracellular trafficking of PS1/gamma-secretase is regulated by multiple factors, including APP and PLD1.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Burnham Institute for Medical Research, La Jolla, California 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yun-Wu</ForeName><Initials>YW</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xin</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Han</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Xiaoqing</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Francesca-Fang</ForeName><Initials>FF</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Huaxi</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG030197</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS046673</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS054880</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>03</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C413604">nicastrin protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.4</RegistryNumber><NameOfSubstance UI="D010739">Phospholipase D</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.4.4</RegistryNumber><NameOfSubstance UI="C106801">phospholipase D1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010739" MajorTopicYN="N">Phospholipase D</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021601" MajorTopicYN="N">trans-Golgi Network</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>3</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>3</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>6</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19276086</ArticleId><ArticleId IdType="pmc">PMC2673283</ArticleId><ArticleId IdType="doi">10.1074/jbc.M808497200</ArticleId><ArticleId IdType="pii">S0021-9258(20)58374-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe, D. J. (1998) Trends Cell Biol. 8 447-453</Citation><ArticleIdList><ArticleId IdType="pubmed">9854312</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Y. W., and Xu, H. (2007) Curr. Mol. Med. 7 687-696</Citation><ArticleIdList><ArticleId IdType="pubmed">18045146</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., Luo, Y., Fisher, S., Fuller, J., Edenson, S., Lile, J., Jarosinski, M. A., Biere, A. L., Curran, E., Burgess, T., Louis, J. C., Collins, F., Treanor, J., Rogers, G., and Citron, M. (1999) Science 286 735-741</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha, S., Anderson, J. P., Barbour, R., Basi, G. S., Caccavello, R., Davis, D., Doan, M., Dovey, H. F., Frigon, N., Hong, J., Jacobson-Croak, K., Jewett, N., Keim, P., Knops, J., Lieberburg, I., Power, M., Tan, H., Tatsuno, G., Tung, J., Schenk, D., Seubert, P., Suomensaari, S. M., Wang, S., Walker, D., Zhao, J., McConlogue, L., and John, V. (1999) Nature 402 537-540</Citation><ArticleIdList><ArticleId IdType="pubmed">10591214</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimberly, W. T., LaVoie, M. J., Ostaszewski, B. L., Ye, W., Wolfe, M. S., and Selkoe, D. J. (2003) Proc. Natl. Acad. Sci. U. S. A. 100 6382-6387</Citation><ArticleIdList><ArticleId IdType="pmc">PMC164455</ArticleId><ArticleId IdType="pubmed">12740439</ArticleId></ArticleIdList></Reference><Reference><Citation>Takasugi, N., Tomita, T., Hayashi, I., Tsuruoka, M., Niimura, M., Takahashi, Y., Thinakaran, G., and Iwatsubo, T. (2003) Nature 422 438-441</Citation><ArticleIdList><ArticleId IdType="pubmed">12660785</ArticleId></ArticleIdList></Reference><Reference><Citation>Wasco, W., Bupp, K., Magendantz, M., Gusella, J. F., Tanzi, R. E., and Solomon, F. (1992) Proc. Natl. Acad. Sci. U. S. A. 89 10758-10762</Citation><ArticleIdList><ArticleId IdType="pmc">PMC50421</ArticleId><ArticleId IdType="pubmed">1279693</ArticleId></ArticleIdList></Reference><Reference><Citation>Wasco, W., Gurubhagavatula, S., Paradis, M. D., Romano, D. M., Sisodia, S. S., Hyman, B. T., Neve, R. L., and Tanzi, R. E. (1993) Nat. Genet. 5 95-100</Citation><ArticleIdList><ArticleId IdType="pubmed">8220435</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu, H., Sweeney, D., Wang, R., Thinakaran, G., Lo, A. C., Sisodia, S. S., Greengard, P., and Gandy, S. (1997) Proc. Natl. Acad. Sci. U. S. A. 94 3748-3752</Citation><ArticleIdList><ArticleId IdType="pmc">PMC20512</ArticleId><ArticleId IdType="pubmed">9108049</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartmann, T., Bieger, S. C., Bruhl, B., Tienari, P. J., Ida, N., Allsop, D., Roberts, G. W., Masters, C. L., Dotti, C. G., Unsicker, K., and Beyreuther, K. (1997) Nat. Med. 3 1016-1020</Citation><ArticleIdList><ArticleId IdType="pubmed">9288729</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenfield, J. P., Tsai, J., Gouras, G. K., Hai, B., Thinakaran, G., Checler, F., Sisodia, S. S., Greengard, P., and Xu, H. (1999) Proc. Natl. Acad. Sci. U. S. A. 96 742-747</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15207</ArticleId><ArticleId IdType="pubmed">9892704</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisodia, S. S. (1992) Proc. Natl. Acad. Sci. U. S. A. 89 6075-6079</Citation><ArticleIdList><ArticleId IdType="pmc">PMC49440</ArticleId><ArticleId IdType="pubmed">1631093</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordstedt, C., Caporaso, G. L., Thyberg, J., Gandy, S. E., and Greengard, P. (1993) J. Biol. Chem. 268 608-612</Citation><ArticleIdList><ArticleId IdType="pubmed">8416966</ArticleId></ArticleIdList></Reference><Reference><Citation>Caporaso, G. L., Takei, K., Gandy, S. E., Matteoli, M., Mundigl, O., Greengard, P., and De Camilli, P. (1994) J. Neurosci. 14 3122-3138</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577440</ArticleId><ArticleId IdType="pubmed">8182461</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass, C., Hung, A. Y., Schlossmacher, M. G., Teplow, D. B., and Selkoe, D. J. (1993) J. Biol. Chem. 268 3021-3024</Citation><ArticleIdList><ArticleId IdType="pubmed">8428976</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass, C., Hung, A. Y., Schlossmacher, M. G., Oltersdorf, T., Teplow, D. B., and Selkoe, D. J. (1993) Ann. N. Y. Acad. Sci. 695 109-116</Citation><ArticleIdList><ArticleId IdType="pubmed">8239267</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa, K., Sopher, B. L., Rydel, R. E., Begley, J. G., Pham, D. G., Martin, G. M., Fox, M., and Mattson, M. P. (1996) J. Neurochem. 67 1882-1896</Citation><ArticleIdList><ArticleId IdType="pubmed">8863493</ArticleId></ArticleIdList></Reference><Reference><Citation>Han, P., Dou, F., Li, F., Zhang, X., Zhang, Y. W., Zheng, H., Lipton, S. A., Xu, H., and Liao, F. F. (2005) J. Neurosci. 25 11542-11552</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6726015</ArticleId><ArticleId IdType="pubmed">16354912</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., Tsuda, T., Mar, L., Foncin, J. F., Bruni, A. C., Montesi, M. P., Sorbi, S., Rainero, I., Pinessi, L., Nee, L., Chumakov, I., Pollen, D., Brookes, A., Sansosu, P., Polinsky, R. J., Wasco, W., Da Silva, H. A. R., Haines, J. L., Pericak-Vance, M. A., Tanzi, R. E., Roses, A. D., Fraser, P. E., Rommens, J. M., and St George-Hyslop, P. (1995) Nature 375 754-760</Citation><ArticleIdList><ArticleId IdType="pubmed">7596406</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C. E., Jondro, P. D., Schmidt, S. D., Wang, K., Crowley, A. C., Fu, Y.-H., Guenette, S. Y., Galas, D., Nemens, E., Wijsman, E. M., Bird, T. D., Schellenberg, G. D., and Tanzi, R. E. (1995) Science 269 973-977</Citation><ArticleIdList><ArticleId IdType="pubmed">7638622</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt, D. R., Thinakaran, G., Eckman, C. B., Lee, M. K., Davenport, F., Ratovitsky, T., Prada, C. M., Kim, G., Seekins, S., Yager, D., Slunt, H. H., Wang, R., Seeger, M., Levey, A. I., Gandy, S. E., Copeland, N. G., Jenkins, N. A., Price, D. L., Younkin, S. G., and Sisodia, S. S. (1996) Neuron 17 1005-1013</Citation><ArticleIdList><ArticleId IdType="pubmed">8938131</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, Y. M., Lai, M. T., Xu, M., Huang, Q., DiMuzio-Mower, J., Sardana, M. K., Shi, X. P., Yin, K. C., Shafer, J. A., and Gardell, S. J. (2000) Proc. Natl. Acad. Sci. U. S. A. 97 6138-6143</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18571</ArticleId><ArticleId IdType="pubmed">10801983</ArticleId></ArticleIdList></Reference><Reference><Citation>Cupers, P., Bentahir, M., Craessaerts, K., Orlans, I., Vanderstichele, H., Saftig, P., De Strooper, B., and Annaert, W. (2001) J. Cell Biol. 154 731-740</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2196466</ArticleId><ArticleId IdType="pubmed">11502763</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs, D. M., Fausett, H. J., Page, K. J., Kim, T. W., Moir, R. D., Merriam, D. E., Hollister, R. D., Hallmark, O. G., Mancini, R., Felsenstein, K. M., Hyman, B. T., Tanzi, R. E., and Wasco, W. (1996) Nat. Med. 2 224-229</Citation><ArticleIdList><ArticleId IdType="pubmed">8574969</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass, C., and De Strooper, B. (1999) Science 286 916-919</Citation><ArticleIdList><ArticleId IdType="pubmed">10542139</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, F., Hasegawa, H., Schmitt-Ulms, G., Kawarai, T., Bohm, C., Katayama, T., Gu, Y., Sanjo, N., Glista, M., Rogaeva, E., Wakutani, Y., Pardossi-Piquard, R., Ruan, X., Tandon, A., Checler, F., Marambaud, P., Hansen, K., Westaway, D., St George-Hyslop, P., and Fraser, P. (2006) Nature 440 1208-1212</Citation><ArticleIdList><ArticleId IdType="pubmed">16641999</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo, Y., Bolon, B., Kahn, S., Bennett, B. D., Babu-Khan, S., Denis, P., Fan, W., Kha, H., Zhang, J., Gong, Y., Martin, L., Louis, J. C., Yan, Q., Richards, W. G., Citron, M., and Vassar, R. (2001) Nat. Neurosci. 4 231-232</Citation><ArticleIdList><ArticleId IdType="pubmed">11224535</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter, J., Fluhrer, R., Hartung, B., Willem, M., Kaether, C., Capell, A., Lammich, S., Multhaup, G., and Haass, C. (2001) J. Biol. Chem. 276 14634-14641</Citation><ArticleIdList><ArticleId IdType="pubmed">11278841</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarassishin, L., Yin, Y. I., Bassit, B., and Li, Y. M. (2004) Proc. Natl. Acad. Sci. U. S. A. 101 17050-17055</Citation><ArticleIdList><ArticleId IdType="pmc">PMC535399</ArticleId><ArticleId IdType="pubmed">15563588</ArticleId></ArticleIdList></Reference><Reference><Citation>Vetrivel, K. S., Zhang, Y. W., Xu, H., and Thinakaran, G. (2006) Mol. Neurodegener. 1 4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1513131</ArticleId><ArticleId IdType="pubmed">16930451</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai, D., Netzer, W. J., Zhong, M., Lin, Y., Du, G., Frohman, M., Foster, D. A., Sisodia, S. S., Xu, H., Gorelick, F. S., and Greengard, P. (2006) Proc. Natl. Acad. Sci. U. S. A. 103 1941-1946</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1413665</ArticleId><ArticleId IdType="pubmed">16449386</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai, D., Zhong, M., Wang, R., Netzer, W. J., Shields, D., Zheng, H., Sisodia, S. S., Foster, D. A., Gorelick, F. S., Xu, H., and Greengard, P. (2006) Proc. Natl. Acad. Sci. U. S. A. 103 1936-1940</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1413666</ArticleId><ArticleId IdType="pubmed">16449385</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamal, A., Almenar-Queralt, A., LeBlanc, J. F., Roberts, E. A., and Goldstein, L. S. (2001) Nature 414 643-648</Citation><ArticleIdList><ArticleId IdType="pubmed">11740561</ArticleId></ArticleIdList></Reference><Reference><Citation>Salehi, A., Delcroix, J. D., Belichenko, P. V., Zhan, K., Wu, C., Valletta, J. S., Takimoto-Kimura, R., Kleschevnikov, A. M., Sambamurti, K., Chung, P. P., Xia, W., Villar, A., Campbell, W. A., Kulnane, L. S., Nixon, R. A., Lamb, B. T., Epstein, C. J., Stokin, G. B., Goldstein, L. S., and Mobley, W. C. (2006) Neuron 51 29-42</Citation><ArticleIdList><ArticleId IdType="pubmed">16815330</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Y. W., Wang, R., Liu, Q., Zhang, H., Liao, F. F., and Xu, H. (2007) Proc. Natl. Acad. Sci. U. S. A. 104 10613-10618</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1888796</ArticleId><ArticleId IdType="pubmed">17556541</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin, P., Li, F., Zhang, Y. W., Huang, H., Tong, G., Farquhar, M. G., and Xu, H. (2007) J. Neurochem. 100 1505-1514</Citation><ArticleIdList><ArticleId IdType="pubmed">17348862</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, R., Zhang, Y. W., Zhang, X., Liu, R., Zhang, X., Hong, S., Xia, K., Xia, J., Zhang, Z., and Xu, H. (2006) FASEB J. 20 1275-1277</Citation><ArticleIdList><ArticleId IdType="pubmed">16645044</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo, W. J., Wang, H., Li, H., Kim, B. S., Shah, S., Lee, H. J., Thinakaran, G., Kim, T. W., Yu, G., and Xu, H. (2003) J. Biol. Chem. 278 7850-7854</Citation><ArticleIdList><ArticleId IdType="pubmed">12522139</ArticleId></ArticleIdList></Reference><Reference><Citation>Buxbaum, J. D., Gandy, S. E., Cicchetti, P., Ehrlich, M. E., Czernik, A. J., Fracasso, R. P., Ramabhadran, T. V., Unterbeck, A. J., and Greengard, P. (1990) Proc. Natl. Acad. Sci. U. S. A. 87 6003-6006</Citation><ArticleIdList><ArticleId IdType="pmc">PMC54458</ArticleId><ArticleId IdType="pubmed">2116015</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu, H., Gouras, G. K., Greenfield, J. P., Vincent, B., Naslund, J., Mazzarelli, L., Fried, G., Jovanovic, J. N., Seeger, M., Relkin, N. R., Liao, F., Checler, F., Buxbaum, J. D., Chait, B. T., Thinakaran, G., Sisodia, S. S., Wang, R., Greengard, P., and Gandy, S. (1998) Nat. Med. 4 447-451</Citation><ArticleIdList><ArticleId IdType="pubmed">9546791</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan, R., Han, P., Miao, H., Greengard, P., and Xu, H. (2001) J. Biol. Chem. 276 36788-36796</Citation><ArticleIdList><ArticleId IdType="pubmed">11466313</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Y. W., Luo, W. J., Wang, H., Lin, P., Vetrivel, K. S., Liao, F., Li, F., Wong, P. C., Farquhar, M. G., Thinakaran, G., and Xu, H. (2005) J. Biol. Chem. 280 17020-17026</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1201533</ArticleId><ArticleId IdType="pubmed">15711015</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, S. F., Shah, S., Li, H., Yu, C., Han, W., and Yu, G. (2002) J. Biol. Chem. 277 45013-45019</Citation><ArticleIdList><ArticleId IdType="pubmed">12297508</ArticleId></ArticleIdList></Reference><Reference><Citation>Leem, J. Y., Vijayan, S., Han, P., Cai, D., Machura, M., Lopes, K. O., Veselits, M. L., Xu, H., and Thinakaran, G. (2002) J. Biol. Chem. 277 19236-19240</Citation><ArticleIdList><ArticleId IdType="pubmed">11943765</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, H., Luo, W. J., Zhang, Y. W., Li, Y. M., Thinakaran, G., Greengard, P., and Xu, H. (2004) J. Biol. Chem. 279 40560-40566</Citation><ArticleIdList><ArticleId IdType="pubmed">15247291</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasparini, L., Gouras, G. K., Wang, R., Gross, R. S., Beal, M. F., Greengard, P., and Xu, H. (2001) J. Neurosci. 21 2561-2570</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762523</ArticleId><ArticleId IdType="pubmed">11306609</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia, W., Zhang, J., Perez, R., Koo, E. H., and Selkoe, D. J. (1997) Proc. Natl. Acad. Sci. U. S. A. 94 8208-8213</Citation><ArticleIdList><ArticleId IdType="pmc">PMC21582</ArticleId><ArticleId IdType="pubmed">9223340</ArticleId></ArticleIdList></Reference><Reference><Citation>Waragai, M., Imafuku, I., Takeuchi, S., Kanazawa, I., Oyama, F., Udagawa, Y., Kawabata, M., and Okazawa, H. (1997) Biochem. Biophys. Res. Commun. 239 480-482</Citation><ArticleIdList><ArticleId IdType="pubmed">9344855</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai, D., Leem, J. Y., Greenfield, J. P., Wang, P., Kim, B. S., Wang, R., Lopes, K. O., Kim, S. H., Zheng, H., Greengard, P., Sisodia, S. S., Thinakaran, G., and Xu, H. (2003) J. Biol. Chem. 278 3446-3454</Citation><ArticleIdList><ArticleId IdType="pubmed">12435726</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopan, R., Schroeter, E. H., Weintraub, H., and Nye, J. S. (1996) Proc. Natl. Acad. Sci. U. S. A. 93 1683-1688</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40002</ArticleId><ArticleId IdType="pubmed">8643690</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopan, R., and Goate, A. (2000) Genes Dev. 14 2799-2806</Citation><ArticleIdList><ArticleId IdType="pubmed">11090127</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeter, E. H., Kisslinger, J. A., and Kopan, R. (1998) Nature 393 382-386</Citation><ArticleIdList><ArticleId IdType="pubmed">9620803</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng, H., and Koo, E. H. (2006) Mol. Neurodegener. 1 5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1538601</ArticleId><ArticleId IdType="pubmed">16930452</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson, M. P. (1997) Physiol. Rev. 77 1081-1132</Citation><ArticleIdList><ArticleId IdType="pubmed">9354812</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, Q., Zerbinatti, C. V., Zhang, J., Hoe, H. S., Wang, B., Cole, S. L., Herz, J., Muglia, L., and Bu, G. (2007) Neuron 56 66-78</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2045076</ArticleId><ArticleId IdType="pubmed">17920016</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunawardena, S., and Goldstein, L. S. (2001) Neuron 32 389-401</Citation><ArticleIdList><ArticleId IdType="pubmed">11709151</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisodia, S. S. (2002) Science 295 805-807</Citation><ArticleIdList><ArticleId IdType="pubmed">11823626</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamal, A., Stokin, G. B., Yang, Z., Xia, C. H., and Goldstein, L. S. (2000) Neuron 28 449-459</Citation><ArticleIdList><ArticleId IdType="pubmed">11144355</ArticleId></ArticleIdList></Reference><Reference><Citation>Satpute-Krishnan, P., DeGiorgis, J. A., and Bearer, E. L. (2003) Aging Cell 2 305-318</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622731</ArticleId><ArticleId IdType="pubmed">14677633</ArticleId></ArticleIdList></Reference><Reference><Citation>Satpute-Krishnan, P., DeGiorgis, J. A., Conley, M. P., Jang, M., and Bearer, E. L. (2006) Proc. Natl. Acad. Sci. U. S. A. 103 16532-16537</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1621108</ArticleId><ArticleId IdType="pubmed">17062754</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett, B. D., Denis, P., Haniu, M., Teplow, D. B., Kahn, S., Louis, J. C., Citron, M., and Vassar, R. (2000) J. Biol. Chem. 275 37712-37717</Citation><ArticleIdList><ArticleId IdType="pubmed">10956649</ArticleId></ArticleIdList></Reference><Reference><Citation>Creemers, J. W., Ines Dominguez, D., Plets, E., Serneels, L., Taylor, N. A., Multhaup, G., Craessaerts, K., Annaert, W., and De Strooper, B. (2001) J. Biol. Chem. 276 4211-4217</Citation><ArticleIdList><ArticleId IdType="pubmed">11071887</ArticleId></ArticleIdList></Reference><Reference><Citation>Huse, J. T., Pijak, D. S., Leslie, G. J., Lee, V. M., and Doms, R. W. (2000) J. Biol. Chem. 275 33729-33737</Citation><ArticleIdList><ArticleId IdType="pubmed">10924510</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau, K. F., McLoughlin, D. M., Standen, C., and Miller, C. C. (2000) Mol. Cell Neurosci. 16 557-565</Citation><ArticleIdList><ArticleId IdType="pubmed">11083918</ArticleId></ArticleIdList></Reference><Reference><Citation>He, X., Li, F., Chang, W. P., and Tang, J. (2005) J. Biol. Chem. 280 11696-11703</Citation><ArticleIdList><ArticleId IdType="pubmed">15615712</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahle, T., Prager, K., Raffler, N., Haass, C., Famulok, M., and Walter, J. (2005) Mol. Cell Neurosci. 29 453-461</Citation><ArticleIdList><ArticleId IdType="pubmed">15886016</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesco, G., Koh, Y. H., Kang, E. L., Cameron, A. N., Das, S., Sena-Esteves, M., Hiltunen, M., Yang, S. H., Zhong, Z., Shen, Y., Simpkins, J. W., and Tanzi, R. E. (2007) Neuron 54 721-737</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1973166</ArticleId><ArticleId IdType="pubmed">17553422</ArticleId></ArticleIdList></Reference><Reference><Citation>Multhaup, G. (2006) Neurodegener. Dis. 3 270-274</Citation><ArticleIdList><ArticleId IdType="pubmed">17047367</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmechel, A., Strauss, M., Schlicksupp, A., Pipkorn, R., Haass, C., Bayer, T. A., and Multhaup, G. (2004) J. Biol. Chem. 279 39710-39717</Citation><ArticleIdList><ArticleId IdType="pubmed">15247262</ArticleId></ArticleIdList></Reference><Reference><Citation>Spoelgen, R., von Arnim, C. A., Thomas, A. V., Peltan, I. D., Koker, M., Deng, A., Irizarry, M. C., Andersen, O. M., Willnow, T. E., and Hyman, B. T. (2006) J. Neurosci. 26 418-428</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674411</ArticleId><ArticleId IdType="pubmed">16407538</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen, O. M., Reiche, J., Schmidt, V., Gotthardt, M., Spoelgen, R., Behlke, J., von Arnim, C. A., Breiderhoff, T., Jansen, P., Wu, X., Bales, K. R., Cappai, R., Masters, C. L., Gliemann, J., Mufson, E. J., Hyman, B. T., Paul, S. M., Nykjaer, A., and Willnow, T. E. (2005) Proc. Natl. Acad. Sci. U. S. A. 102 13461-13466</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1224625</ArticleId><ArticleId IdType="pubmed">16174740</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuzuya, A., Uemura, K., Kitagawa, N., Aoyagi, N., Kihara, T., Ninomiya, H., Ishiura, S., Takahashi, R., and Shimohama, S. (2007) J. Neurosci. Res. 85 153-165</Citation><ArticleIdList><ArticleId IdType="pubmed">17075903</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumanchin, C., Czech, C., Campion, D., Cuif, M. H., Poyot, T., Martin, C., Charbonnier, F., Goud, B., Pradier, L., and Frebourg, T. (1999) Hum. Mol. Genet. 8 1263-1269</Citation><ArticleIdList><ArticleId IdType="pubmed">10369872</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheper, W., Zwart, R., Sluijs, P., Annaert, W., Gool, W. A., and Baas, F. (2000) Hum. Mol. Genet. 9 303-310</Citation><ArticleIdList><ArticleId IdType="pubmed">10607841</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheper, W., Zwart, R., and Baas, F. (2004) Brain Res. Mol. Brain Res. 122 17-23</Citation><ArticleIdList><ArticleId IdType="pubmed">14992812</ArticleId></ArticleIdList></Reference><Reference><Citation>King, G. D., and Scott Turner, R. (2004) Exp. Neurol. 185 208-219</Citation><ArticleIdList><ArticleId IdType="pubmed">14736502</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogelj, B., Mitchell, J. C., Miller, C. C., and McLoughlin, D. M. (2006) Brain Res. Rev. 52 305-315</Citation><ArticleIdList><ArticleId IdType="pubmed">16764936</ArticleId></ArticleIdList></Reference><Reference><Citation>Borg, J. P., Ooi, J., Levy, E., and Margolis, B. (1996) Mol. Cell. Biol. 16 6229-6241</Citation><ArticleIdList><ArticleId IdType="pmc">PMC231626</ArticleId><ArticleId IdType="pubmed">8887653</ArticleId></ArticleIdList></Reference><Reference><Citation>Borg, J. P., Yang, Y., De Taddeo-Borg, M., Margolis, B., and Turner, R. S. (1998) J. Biol. Chem. 273 14761-14766</Citation><ArticleIdList><ArticleId IdType="pubmed">9614075</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19282473</PMID><DateCompleted><Year>2009</Year><Month>05</Month><Day>07</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>106</Volume><Issue>13</Issue><PubDate><Year>2009</Year><Month>Mar</Month><Day>31</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Fe65 is required for Tip60-directed histone H4 acetylation at DNA strand breaks.</ArticleTitle><Pagination><StartPage>5093</StartPage><EndPage>5098</EndPage><MedlinePgn>5093-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0810869106</ELocationID><Abstract><AbstractText>Fe65 is a binding partner of the Alzheimer's beta-amyloid precursor protein APP. The possible involvement of this protein in the cellular response to DNA damage was suggested by the observation that Fe65 null mice are more sensitive to genotoxic stress than WT counterpart. Fe65 associated with chromatin under basal conditions and its involvement in DNA damage repair requires this association. A known partner of Fe65 is the histone acetyltransferase Tip60. Considering the crucial role of Tip60 in DNA repair, we explored the hypothesis that the phenotype of Fe65 null cells depended on its interaction with Tip60. We demonstrated that Fe65 knockdown impaired recruitment of Tip60-TRRAP complex to DNA double strand breaks and decreased histone H4 acetylation. Accordingly, the efficiency of DNA repair was decreased upon Fe65 suppression. To explore whether APP has a role in this mechanism, we analyzed a Fe65 mutant unable to bind to APP. This mutant failed to rescue the phenotypes of Fe65 null cells; furthermore, APP/APLP2 suppression results in the impairment of recruitment of Tip60-TRRAP complex to DNA double strand breaks, decreased histone H4 acetylation and repair efficiency. On these bases, we propose that Fe65 and its interaction with APP play an important role in the response to DNA damage by assisting the recruitment of Tip60-TRRAP to DNA damage sites.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stante</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>CEINGE Centro d'Ingegneria Genetica Biotecnologie Avanzate, European School of Molecular Medicine, and Dipartimento di Biochimica e Biotecnologie Mediche, Universit&#xe0; di Napoli Federico II, I-80145 Napoli, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minopoli</LastName><ForeName>Giuseppina</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Passaro</LastName><ForeName>Fabiana</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Raia</LastName><ForeName>Maddalena</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Vecchio</LastName><ForeName>Luigi Del</ForeName><Initials>LD</Initials></Author><Author ValidYN="Y"><LastName>Russo</LastName><ForeName>Tommaso</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>03</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C486243">Apbb1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006657">Histones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058255">Protease Nexins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015534">Trans-Activators</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C113829">transformation-transcription domain-associated protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.1.48</RegistryNumber><NameOfSubstance UI="D051548">Histone Acetyltransferases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.1.48</RegistryNumber><NameOfSubstance UI="C523065">Kat5 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.1.48</RegistryNumber><NameOfSubstance UI="D000074443">Lysine Acetyltransferase 5</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000107" MajorTopicYN="N">Acetylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053960" MajorTopicYN="Y">DNA Breaks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004260" MajorTopicYN="N">DNA Repair</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051548" MajorTopicYN="N">Histone Acetyltransferases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006657" MajorTopicYN="N">Histones</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000074443" MajorTopicYN="N">Lysine Acetyltransferase 5</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058255" MajorTopicYN="N">Protease Nexins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011956" MajorTopicYN="N">Receptors, Cell Surface</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015534" MajorTopicYN="N">Trans-Activators</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>3</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>3</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>5</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19282473</ArticleId><ArticleId IdType="pmc">PMC2664056</ArticleId><ArticleId IdType="doi">10.1073/pnas.0810869106</ArticleId><ArticleId IdType="pii">0810869106</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Reinhard C, H&#xe9;bert SS, De Strooper B. The amyloid-beta precursor protein: Integrating structure with biological function. EMBO J. 2005;24:3996&#x2013;4006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1356301</ArticleId><ArticleId IdType="pubmed">16252002</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiore F, et al. The regions of the Fe65 protein homologous to the phosphotyrosine interaction/phosphotyrosine binding domain of Shc bind the intracellular domain of the Alzheimer's amyloid precursor protein. J Biol Chem. 1995;270:30853&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">8537337</ArticleId></ArticleIdList></Reference><Reference><Citation>Borg JP, Ooi J, Levy E, Margolis B. The phosphotyrosine interaction domains of X11 and FE65 bind to distinct sites on the YENPTY motif of amyloid precursor protein. Mol Cell Biol. 1996;16:6229&#x2013;6241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC231626</ArticleId><ArticleId IdType="pubmed">8887653</ArticleId></ArticleIdList></Reference><Reference><Citation>Zambrano N, et al. Interaction of the phosphotyrosine interaction/phosphotyrosine binding-related domains of Fe65 with wild-type and mutant Alzheimer's beta-amyloid precursor proteins. J Biol Chem. 1997;272:6399&#x2013;6405.</Citation><ArticleIdList><ArticleId IdType="pubmed">9045663</ArticleId></ArticleIdList></Reference><Reference><Citation>Cupers P, Orlans I, Craessaerts K, Annaert W, De Strooper B. The amyloid precursor protein (APP)-cytoplasmic fragment generated by gamma-secretase is rapidly degraded but distributes partially in a nuclear fraction of neurones in culture. J Neurochem. 2001;78:1168&#x2013;1178.</Citation><ArticleIdList><ArticleId IdType="pubmed">11553691</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabo SL, Ikin AF, Buxbaum JD, Greengard P. The amyloid precursor protein and its regulatory protein, FE65, in growth cones and synapses in vitro and in vivo. J Neurosci. 2003;23:5407&#x2013;5415.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741254</ArticleId><ArticleId IdType="pubmed">12843239</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabo SL, Ikin AF, Buxbaum JD, Greengard P. The Alzheimer amyloid precursor protein (APP) and FE65, an APP-binding protein, regulate cell movement. J Cell Biol. 2001;153:1403&#x2013;1414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2150733</ArticleId><ArticleId IdType="pubmed">11425871</ArticleId></ArticleIdList></Reference><Reference><Citation>Ermekova KS, et al. The WW domain of neural protein FE65 interacts with proline-rich motifs in Mena, the mammalian homolog of Drosophila enabled. J Biol Chem. 1997;272:32869&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">9407065</ArticleId></ArticleIdList></Reference><Reference><Citation>Trommsdorff M, Borg JP, Margolis B, Herz J. Interaction of cytosolic adaptor proteins with neuronal apolipoprotein E receptors and the amyloid precursor protein. J Biol Chem. 1998;273:33556&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">9837937</ArticleId></ArticleIdList></Reference><Reference><Citation>Herms J, et al. Cortical dysplasia resembling human type 2 lissencephaly in mice lacking all three APP family members. EMBO J. 2004;23:4106&#x2013;4115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC524337</ArticleId><ArticleId IdType="pubmed">15385965</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu&#xe9;nette S, et al. Essential roles for the FE65 amyloid precursor protein-interacting proteins in brain development. EMBO J. 2006;25:420&#x2013;431.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1383510</ArticleId><ArticleId IdType="pubmed">16407979</ArticleId></ArticleIdList></Reference><Reference><Citation>Minopoli G, et al. The beta-amyloid precursor protein functions as a cytosolic anchoring site that prevents Fe65 nuclear translocation. J Biol Chem. 2001;276:6545&#x2013;6550.</Citation><ArticleIdList><ArticleId IdType="pubmed">11085987</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao X, S&#xfc;dhof TC. A transcriptionally active complex of APP with Fe65 and histone acetyltransferase Tip60. Science. 2001;293:115&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">11441186</ArticleId></ArticleIdList></Reference><Reference><Citation>Telese F, et al. Transcription regulation by the adaptor protein Fe65 and the nucleosome assembly factor SET. EMBO Rep. 2005;6:77&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1299219</ArticleId><ArticleId IdType="pubmed">15592452</ArticleId></ArticleIdList></Reference><Reference><Citation>Zambrano N, Minopoli G, de Candia P, Russo T. The Fe65 adaptor protein interacts through its PID1 domain with the transcription factor CP2/LSF/LBP1. J Biol Chem. 1998;273:20128&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">9685356</ArticleId></ArticleIdList></Reference><Reference><Citation>Baek SH, et al. Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-kappaB and beta-amyloid precursor protein. Cell. 2002;110:55&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">12150997</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao J, et al. Suppression of beta-amyloid precursor protein signaling into the nucleus by estrogens mediated through complex formation between the estrogen receptor and Fe65. Mol Cell Biol. 2007;27:1321&#x2013;1333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1800721</ArticleId><ArticleId IdType="pubmed">17130235</ArticleId></ArticleIdList></Reference><Reference><Citation>von Rotz RC, et al. The APP intracellular domain forms nuclear multiprotein complexes and regulates the transcription of its own precursor. J Cell Sci. 2004;117:4435&#x2013;4448.</Citation><ArticleIdList><ArticleId IdType="pubmed">15331662</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardossi-Piquard R, et al. Presenilin-dependent transcriptional control of the A&#x3b2;-degrading enzyme neprilysin by intracellular domains of betaAPP and APLP. Neuron. 2005;46:541&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pubmed">15944124</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, et al. Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neuron. 2007;56:66&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2045076</ArticleId><ArticleId IdType="pubmed">17920016</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe9;bert SS, et al. Regulated intramembrane proteolysis of amyloid precursor protein and regulation of expression of putative target genes. EMBO Rep. 2006;7:739&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1500829</ArticleId><ArticleId IdType="pubmed">16729020</ArticleId></ArticleIdList></Reference><Reference><Citation>Minopoli G, et al. Essential roles for Fe65, Alzheimer amyloid precursor-binding protein, in the cellular response to DNA damage. J Biol Chem. 2007;282:831&#x2013;835. T.</Citation><ArticleIdList><ArticleId IdType="pubmed">17121854</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrivastav M, De Haro LP, Nickoloff JA. Regulation of DNA double-strand break repair pathway choice. Cell Res. 2008;18:134&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">18157161</ArticleId></ArticleIdList></Reference><Reference><Citation>Escargueil AE, Soares DG, Salvador M, Larsen AK, Henriques JA. What histone code for DNA repair? Mutat Res. 2008;658:259&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pubmed">18296106</ArticleId></ArticleIdList></Reference><Reference><Citation>Downs JA, Allard S, Jobin-Robitaille O, Javaheri A, Auger A, Bouchard N, Kron SJ, Jackson SP, C&#xf4;t&#xe9; J. Binding of chromatin-modifying activities to phosphorylated histone H2A at DNA damage sites. Mol Cell. 2004;16:979&#x2013;990.</Citation><ArticleIdList><ArticleId IdType="pubmed">15610740</ArticleId></ArticleIdList></Reference><Reference><Citation>Squatrito M, Gorrini C, Amati B. Tip60 in DNA damage response and growth control: Many tricks in one HAT. Trends Cell Biol. 2006;16:433&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pubmed">16904321</ArticleId></ArticleIdList></Reference><Reference><Citation>Murr R, et al. Histone acetylation by Trrap-Tip60 modulates loading of repair proteins and repair of DNA double-strand breaks. Nat Cell Biol. 2006;8:91&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">16341205</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao X, S&#xfc;dhof TC. Dissection of amyloid-&#x3b2; precursor protein-dependent transcriptional activation. J Biol Chem. 2004;279:24601&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">15044485</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson C, Elliott B, Jasin M. Chromosomal double-strand breaks introduced in mammalian cells by expression of I-Sce I endonuclease. Methods Mol Biol. 1999;113:453&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pubmed">10443442</ArticleId></ArticleIdList></Reference><Reference><Citation>Ando K, Iijima KI, Elliott JI, Kirino Y, Suzuki T. Phosphorylation-dependent regulation of the interaction of amyloid precursor protein with Fe65 affects the production of beta-amyloid. J Biol Chem. 2001;276:40353&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">11517218</ArticleId></ArticleIdList></Reference><Reference><Citation>Shogren-Knaak M, et al. Histone H4&#x2013;K16 acetylation controls chromatin structure and protein interactions. Science. 2006;31:844&#x2013;847.</Citation><ArticleIdList><ArticleId IdType="pubmed">16469925</ArticleId></ArticleIdList></Reference><Reference><Citation>Zambrano N, et al. The beta-amyloid precursor protein APP is tyrosine-phosphorylated in cells expressing a constitutively active form of the Abl protoncogene. J Biol Chem. 2001;276:19787&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">11279131</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo SB, et al. Regulation of histone acetylation and transcription by INHAT, a human cellular complex containing the set oncoprotein. Cell. 2001;104:119&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">11163245</ArticleId></ArticleIdList></Reference><Reference><Citation>Kharbanda S, et al. Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents. Nature. 1995;376:785&#x2013;788.</Citation><ArticleIdList><ArticleId IdType="pubmed">7651539</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovell MA, Markesbery WR. Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer'sdisease. Nucleic Acids Res. 2007;35:7497&#x2013;7504.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2190704</ArticleId><ArticleId IdType="pubmed">17947327</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19287391</PMID><DateCompleted><Year>2009</Year><Month>05</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>4</Issue><PubDate><Year>2009</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Amyloid precursor protein secretases as therapeutic targets for traumatic brain injury.</ArticleTitle><Pagination><StartPage>377</StartPage><EndPage>379</EndPage><MedlinePgn>377-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nm.1940</ELocationID><Abstract><AbstractText>Amyloid-beta (Abeta) peptides, found in Alzheimer's disease brain, accumulate rapidly after traumatic brain injury (TBI) in both humans and animals. Here we show that blocking either beta- or gamma-secretase, enzymes required for production of Abeta from amyloid precursor protein (APP), can ameliorate motor and cognitive deficits and reduce cell loss after experimental TBI in mice. Thus, APP secretases are promising targets for treatment of TBI.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Loane</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Georgetown University Medical Center, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pocivavsek</LastName><ForeName>Ana</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Moussa</LastName><ForeName>Charbel E-H</ForeName><Initials>CE</Initials></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Rachel</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Matsuoka</LastName><ForeName>Yasuji</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Faden</LastName><ForeName>Alan I</ForeName><Initials>AI</Initials></Author><Author ValidYN="Y"><LastName>Rebeck</LastName><ForeName>G William</ForeName><Initials>GW</Initials></Author><Author ValidYN="Y"><LastName>Burns</LastName><ForeName>Mark P</ForeName><Initials>MP</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R24 HD050845</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03NS57635</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03 NS057635</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R24HD050845</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG030378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>03</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001930" MajorTopicYN="N">Brain Injuries</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>2</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>3</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>3</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>5</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>3</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19287391</ArticleId><ArticleId IdType="mid">NIHMS182677</ArticleId><ArticleId IdType="pmc">PMC2844765</ArticleId><ArticleId IdType="doi">10.1038/nm.1940</ArticleId><ArticleId IdType="pii">nm.1940</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Maas AI, Stocchetti N, Bullock R. Lancet Neurol. 2008;7:728&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">18635021</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenzlinger PM, Morganti-Kossmann MC, Laurer HL, McIntosh TK. Mol Neurobiol. 2001;24:169&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">11831551</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Chen Y, Jenkins LW, Kochanek PM, Clark RS. Crit Care. 2005;9:66&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1065095</ArticleId><ArticleId IdType="pubmed">15693986</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayeux R, et al. Ann Neurol. 1993;33:494&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pubmed">8498827</ArticleId></ArticleIdList></Reference><Reference><Citation>van Duijn CM, et al. Am J Epidemiol. 1992;135:775&#x2013;782.</Citation><ArticleIdList><ArticleId IdType="pubmed">1595677</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts GW, Gentleman SM, Lynch A, Graham DI. Lancet. 1991;338:1422&#x2013;1423.</Citation><ArticleIdList><ArticleId IdType="pubmed">1683421</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts GW, et al. J Neurol Neurosurg Psychiatry. 1994;57:419&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1072869</ArticleId><ArticleId IdType="pubmed">8163989</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic MD, et al. Exp Neurol. 2004;190:192&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">15473992</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen XH, et al. Am J Pathol. 2004;165:357&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618579</ArticleId><ArticleId IdType="pubmed">15277212</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata A, Chen XH, McIntosh TK, Browne KD, Smith DH. J Neuropathol Exp Neurol. 2002;61:1056&#x2013;1068.</Citation><ArticleIdList><ArticleId IdType="pubmed">12484568</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasko I, et al. J Neural Transm. 2004;111:523&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">15057522</ArticleId></ArticleIdList></Reference><Reference><Citation>Cribbs DH, Chen LS, Cotman CW, LaFerla FM. Neuroreport. 1996;7:1773&#x2013;1776.</Citation><ArticleIdList><ArticleId IdType="pubmed">8905662</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadler Y, et al. Glia. 2008;56:552&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pubmed">18240300</ArticleId></ArticleIdList></Reference><Reference><Citation>Uryu K, et al. Exp Neurol. 2007;208:185&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3979356</ArticleId><ArticleId IdType="pubmed">17826768</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuoka Y, et al. Am J Pathol. 2001;158:1345&#x2013;1354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1891893</ArticleId><ArticleId IdType="pubmed">11290552</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, et al. J Neurosci. 1992;12:376&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6575616</ArticleId><ArticleId IdType="pubmed">1346802</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, Mucke L. Neuron. 2002;35:419&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">12165466</ArticleId></ArticleIdList></Reference><Reference><Citation>Yankner BA, et al. Science. 1989;245:417&#x2013;420.</Citation><ArticleIdList><ArticleId IdType="pubmed">2474201</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito L, Gan L, Yu GQ, Essrich C, Mucke L. J Neurochem. 2004;91:1260&#x2013;1274.</Citation><ArticleIdList><ArticleId IdType="pubmed">15584903</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockenstein E, et al. J Biol Chem. 2005;280:32957&#x2013;32967.</Citation><ArticleIdList><ArticleId IdType="pubmed">16027115</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox GB, Fan L, Levasseur RA, Faden AI. J Neurotrauma. 1998;15:599&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pubmed">9726259</ArticleId></ArticleIdList></Reference><Reference><Citation>Brody DL, et al. Science. 2008;321:1221&#x2013;1224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2577829</ArticleId><ArticleId IdType="pubmed">18755980</ArticleId></ArticleIdList></Reference><Reference><Citation>Thornton E, Vink R, Blumbergs PC, Van Den HC. Brain Res. 2006;1094:38&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">16697978</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai H, et al. Nat Neurosci. 2001;4:233&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">11224536</ArticleId></ArticleIdList></Reference><Reference><Citation>Duff K, et al. Nature. 1996;383:710&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pubmed">8878479</ArticleId></ArticleIdList></Reference><Reference><Citation>Dovey HF, et al. J Neurochem. 2001;76:173&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">11145990</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramowski D, et al. J Pharmacol Exp Ther. 2008;327:411&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pubmed">18687920</ArticleId></ArticleIdList></Reference><Reference><Citation>El Mouedden M, Vandermeeren M, Meert T, Mercken M. Curr Pharm Des. 2006;12:671&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">16472156</ArticleId></ArticleIdList></Reference><Reference><Citation>Arumugam TV, et al. Nat Med. 2006;12:621&#x2013;623.</Citation><ArticleIdList><ArticleId IdType="pubmed">16680150</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19295161</PMID><DateCompleted><Year>2009</Year><Month>04</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>11</Issue><PubDate><Year>2009</Year><Month>Mar</Month><Day>18</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>The cleavage products of amyloid-beta precursor protein are sorted to distinct carrier vesicles that are independently transported within neurites.</ArticleTitle><Pagination><StartPage>3565</StartPage><EndPage>3578</EndPage><MedlinePgn>3565-78</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.2558-08.2009</ELocationID><Abstract><AbstractText>The amyloid-beta (Abeta) precursor protein (APP), a transmembrane protein that undergoes proteolytic cleavage into defined fragments, has been implicated in axonal transport. The proposed role of APP as a vesicle receptor for the microtubule motor kinesin-1 has relevance for the pathogenesis of Alzheimer's disease. Nevertheless, this function, which relies on the transport to the cell periphery of full-length APP rather than its cleavage fragments, remains controversial. Other proposed functions of APP, such as regulating transcription, neurogenesis, cell movement, or neurite growth also rely on APP's presence as a full-length protein at the cell surface, implying that APP cleavage occurs after its transport to the cell periphery. To test this hypothesis, we mapped the localization of various APP epitopes in neurons in culture and in the mouse brain. Surprisingly, epitopes from the N-terminal, C-terminal, and central (Abeta) domains of APP each showed a distinct distribution throughout the cell and rarely colocalized. Within neurites, these epitopes were localized to distinct transport vesicles that associated with different sets of microtubules and, occasionally, actin filaments. C-terminal APP fragments were preferentially transported into neurites as phosphorylated forms, entered the lamellipodium and filopodia of growth cones, and concentrated in regions of growth cone turning and advancement (unlike the N-terminal and Abeta fragments). We conclude that, under normal conditions, the proteolytic cleavage of APP primarily occurs before its sorting into axonal transport vesicles and the cleaved fragments segregate into separate vesicle populations that reach different destinations, and thus have different functions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Muresan</LastName><ForeName>Virgil</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Physiology, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, New Jersey 07103, USA. muresavi@umdnj.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Varvel</LastName><ForeName>Nicholas H</ForeName><Initials>NH</Initials></Author><Author ValidYN="Y"><LastName>Lamb</LastName><ForeName>Bruce T</ForeName><Initials>BT</Initials></Author><Author ValidYN="Y"><LastName>Muresan</LastName><ForeName>Zoia</ForeName><Initials>Z</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG023012</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM068596</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG023012</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>GM068596</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001370" MajorTopicYN="N">Axonal Transport</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006868" MajorTopicYN="N">Hydrolysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007424" MajorTopicYN="N">Intracellular Fluid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016501" MajorTopicYN="N">Neurites</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013572" MajorTopicYN="N">Synaptic Vesicles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>3</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>3</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>4</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>9</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19295161</ArticleId><ArticleId IdType="mid">NIHMS103407</ArticleId><ArticleId IdType="pmc">PMC2669751</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2558-08.2009</ArticleId><ArticleId IdType="pii">29/11/3565</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Molecular biology of the cell. Ed 4. New York: Garland Science; 2002.</Citation></Reference><Reference><Citation>Amaratunga A, Fine RE. Generation of amyloidogenic C-terminal fragments during rapid axonal transport in vivo of beta-amyloid precursor protein in the optic nerve. J Biol Chem. 1995;270:17268&#x2013;17272.</Citation><ArticleIdList><ArticleId IdType="pubmed">7542234</ArticleId></ArticleIdList></Reference><Reference><Citation>Ando K, Iijima KI, Elliott JI, Kirino Y, Suzuki T. Phosphorylation-dependent regulation of the interaction of amyloid precursor protein with Fe65 affects the production of beta-amyloid. J Biol Chem. 2001;276:40353&#x2013;40361.</Citation><ArticleIdList><ArticleId IdType="pubmed">11517218</ArticleId></ArticleIdList></Reference><Reference><Citation>Annaert WG, Levesque L, Craessaerts K, Dierinck I, Snellings G, Westaway D, George-Hyslop PS, Cordell B, Fraser P, De Strooper B. Presenilin 1 controls gamma-secretase processing of amyloid precursor protein in pre-golgi compartments of hippocampal neurons. J Cell Biol. 1999;147:277&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2174229</ArticleId><ArticleId IdType="pubmed">10525535</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai Y, Markham K, Chen F, Weerasekera R, Watts J, Horne P, Wakutani Y, Mathews PM, Fraser PE, Westaway D, St George-Hyslop P, Schmitt-Ulms G. The in vivo brain interactome of the amyloid precursor protein. Mol Cell Proteomics. 2007;7:15&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">17934213</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg JS, Cheney RE. Myosin-X is an unconventional myosin that undergoes intrafilopodial motility. Nat Cell Biol. 2002;4:246&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">11854753</ArticleId></ArticleIdList></Reference><Reference><Citation>Borg JP, Ooi J, Levy E, Margolis B. The phosphotyrosine interaction domains of X11 and FE65 bind to distinct sites on the YENPTY motif of amyloid precursor protein. Mol Cell Biol. 1996;16:6229&#x2013;6241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC231626</ArticleId><ArticleId IdType="pubmed">8887653</ArticleId></ArticleIdList></Reference><Reference><Citation>Buxbaum JD, Thinakaran G, Koliatsos V, O'Callahan J, Slunt HH, Price DL, Sisodia SS. Alzheimer amyloid protein precursor in the rat hippocampus: transport and processing through the perforant path. J Neurosci. 1998;18:9629&#x2013;9637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793291</ArticleId><ArticleId IdType="pubmed">9822724</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao X, Sudhof TC. A transcriptionally [correction of transcriptively] active complex of APP with Fe65 and histone acetyltransferase Tip60. Science. 2001;293:115&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">11441186</ArticleId></ArticleIdList></Reference><Reference><Citation>Capell A, Grunberg J, Pesold B, Diehlmann A, Citron M, Nixon R, Beyreuther K, Selkoe DJ, Haass C. The proteolytic fragments of the Alzheimer's disease-associated presenilin-1 form heterodimers and occur as a 100&#x2013;150-kDa molecular mass complex. J Biol Chem. 1998;273:3205&#x2013;3211.</Citation><ArticleIdList><ArticleId IdType="pubmed">9452432</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook DG, Forman MS, Sung JC, Leight S, Kolson DL, Iwatsubo T, Lee VM, Doms RW. Alzheimer's A beta(1&#x2013;42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells. Nat Med. 1997;3:1021&#x2013;1023.</Citation><ArticleIdList><ArticleId IdType="pubmed">9288730</ArticleId></ArticleIdList></Reference><Reference><Citation>Dajas-Bailador F, Jones EV, Whitmarsh AJ. The JIP1 scaffold protein regulates axonal development in cortical neurons. Curr Biol. 2008;18:221&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2258314</ArticleId><ArticleId IdType="pubmed">18261906</ArticleId></ArticleIdList></Reference><Reference><Citation>Deboer SR, You Y, Szodorai A, Kaminska A, Pigino G, Nwabuisi E, Wang B, Estrada-Hernandez T, Kins S, Brady ST, Morfini G. Conventional Kinesin holoenzymes are composed of heavy and light chain homodimers. Biochemistry. 2008;47:4535&#x2013;4543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2644488</ArticleId><ArticleId IdType="pubmed">18361505</ArticleId></ArticleIdList></Reference><Reference><Citation>DeGiorgio LA, Shimizu Y, Chun HS, Kim YS, Sugama S, Son JH, Joh TH, Volpe BT. Amyloid precursor protein gene disruption attenuates degeneration of substantia nigra compacta neurons following axotomy. Brain Res. 2002;938:38&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">12031533</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Annaert W. Proteolytic processing and cell biological functions of the amyloid precursor protein. J Cell Sci. 2000;113:1857&#x2013;1870.</Citation><ArticleIdList><ArticleId IdType="pubmed">10806097</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunn S, Morrison EE, Liverpool TB, Molina-Paris C, Cross RA, Alonso MC, Peckham M. Differential trafficking of Kif5c on tyrosinated and detyrosinated microtubules in live cells. J Cell Sci. 2008;121:1085&#x2013;1095.</Citation><ArticleIdList><ArticleId IdType="pubmed">18334549</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldsbury C, Mocanu MM, Thies E, Kaether C, Haass C, Keller P, Biernat J, Mandelkow E, Mandelkow EM. Inhibition of APP Trafficking by Tau Protein does not Increase the generation of amyloid-beta peptides. Traffic. 2006;7:873&#x2013;888.</Citation><ArticleIdList><ArticleId IdType="pubmed">16734669</ArticleId></ArticleIdList></Reference><Reference><Citation>Goslin K, Banker G. Characterizing and studying neuronal cultures. In: Banker G, Goslin K, editors. Culturing nerve cells. Cambridge, MA: MIT; 1991. pp. 75&#x2013;109.</Citation></Reference><Reference><Citation>Grundke-Iqbal I, Iqbal K, George L, Tung YC, Kim KS, Wisniewski HM. Amyloid protein and neurofibrillary tangles coexist in the same neuron in Alzheimer disease. Proc Natl Acad Sci USA. 1989;86:2853&#x2013;2857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC287017</ArticleId><ArticleId IdType="pubmed">2649895</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8:101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartmann T, Bieger SC, Bruhl B, Tienari PJ, Ida N, Allsop D, Roberts GW, Masters CL, Dotti CG, Unsicker K, Beyreuther K. Distinct sites of intracellular production for Alzheimer's disease A beta40/42 amyloid peptides. Nat Med. 1997;3:1016&#x2013;1020.</Citation><ArticleIdList><ArticleId IdType="pubmed">9288729</ArticleId></ArticleIdList></Reference><Reference><Citation>He X, Cooley K, Chung CH, Dashti N, Tang J. Apolipoprotein receptor 2 and X11 alpha/beta mediate apolipoprotein E-induced endocytosis of amyloid-beta precursor protein and beta-secretase, leading to amyloid-beta production. J Neurosci. 2007;27:4052&#x2013;4060.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672528</ArticleId><ArticleId IdType="pubmed">17428983</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilbich C, Monning U, Grund C, Masters CL, Beyreuther K. Amyloid-like properties of peptides flanking the epitope of amyloid precursor protein-specific monoclonal antibody 22C11. J Biol Chem. 1993;268:26571&#x2013;26577.</Citation><ArticleIdList><ArticleId IdType="pubmed">7504673</ArticleId></ArticleIdList></Reference><Reference><Citation>Iijima K, Ando K, Takeda S, Satoh Y, Seki T, Itohara S, Greengard P, Kirino Y, Nairn AC, Suzuki T. Neuron-specific phosphorylation of Alzheimer's beta-amyloid precursor protein by cyclin-dependent kinase 5. J Neurochem. 2000;75:1085&#x2013;1091.</Citation><ArticleIdList><ArticleId IdType="pubmed">10936190</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaether C, Skehel P, Dotti CG. Axonal membrane proteins are transported in distinct carriers: a two-color video microscopy study in cultured hippocampal neurons. Mol Biol Cell. 2000;11:1213&#x2013;1224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC14842</ArticleId><ArticleId IdType="pubmed">10749925</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamal A, Stokin GB, Yang Z, Xia C, Goldstein LS. Axonal transport of amyloid precursor protein is mediated by direct binding to the kinesin light chain subunit of kinesin-I [In Process Citation] Neuron. 2000;28:449&#x2013;459.</Citation><ArticleIdList><ArticleId IdType="pubmed">11144355</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamal A, Almenar-Queralt A, LeBlanc JF, Roberts EA, Goldstein LSB. Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP. Nature. 2001;414:643&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pubmed">11740561</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Kleizen B, Choy R, Thinakaran G, Sisodia SS, Schekman RW. Biogenesis of gamma-secretase early in the secretory pathway. J Cell Biol. 2007;179:951&#x2013;963.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2099203</ArticleId><ArticleId IdType="pubmed">18056412</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimberly WT, Zheng JB, Town T, Flavell RA, Selkoe DJ. Physiological regulation of the beta-amyloid precursor protein signaling domain by c-Jun N-terminal kinase JNK3 during neuronal differentiation. J Neurosci. 2005;25:5533&#x2013;5543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6724978</ArticleId><ArticleId IdType="pubmed">15944381</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinoshita A, Whelan CM, Smith CJ, Berezovska O, Hyman BT. Direct visualization of the gamma secretase-generated carboxyl-terminal domain of the amyloid precursor protein: association with Fe65 and translocation to the nucleus. J Neurochem. 2002;82:839&#x2013;847.</Citation><ArticleIdList><ArticleId IdType="pubmed">12358789</ArticleId></ArticleIdList></Reference><Reference><Citation>Konecna A, Frischknecht R, Kinter J, Ludwig A, Steuble M, Meskenaite V, Indermuhle M, Engel M, Cen C, Mateos JM, Streit P, Sonderegger P. Calsyntenin-1 docks vesicular cargo to kinesin-1. Mol Biol Cell. 2006;17:3651&#x2013;3663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1525238</ArticleId><ArticleId IdType="pubmed">16760430</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo EH, Squazzo SL. Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J Biol Chem. 1994;269:17386&#x2013;17389.</Citation><ArticleIdList><ArticleId IdType="pubmed">8021238</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb BT, Call LM, Slunt HH, Bardel KA, Lawler AM, Eckman CB, Younkin SG, Holtz G, Wagner SL, Price DL, Sisodia SS, Gearhart JD. Altered metabolism of familial Alzheimer's disease-linked amyloid precursor protein variants in yeast artificial chromosome transgenic mice. Hum Mol Genet. 1997;6:1535&#x2013;1541.</Citation><ArticleIdList><ArticleId IdType="pubmed">9285791</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarov O, Lee M, Peterson DA, Sisodia SS. Evidence that synaptically released beta-amyloid accumulates as extracellular deposits in the hippocampus of transgenic mice. J Neurosci. 2002;22:9785&#x2013;9793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757836</ArticleId><ArticleId IdType="pubmed">12427834</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarov O, Morfini GA, Lee EB, Farah MH, Szodorai A, DeBoer SR, Koliatsos VE, Kins S, Lee VM, Wong PC, Price DL, Brady ST, Sisodia SS. Axonal transport, amyloid precursor protein, kinesin-1, and the processing apparatus: revisited. J Neurosci. 2005;25:2386&#x2013;2395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6726084</ArticleId><ArticleId IdType="pubmed">15745965</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MS, Kao SC, Lemere CA, Xia W, Tseng HC, Zhou Y, Neve R, Ahlijanian MK, Tsai LH. APP processing is regulated by cytoplasmic phosphorylation. J Cell Biol. 2003;163:83&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2173445</ArticleId><ArticleId IdType="pubmed">14557249</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehman EJ, Kulnane LS, Lamb BT. Alterations in beta-amyloid production and deposition in brain regions of two transgenic models. Neurobiol Aging. 2003;24:645&#x2013;653.</Citation><ArticleIdList><ArticleId IdType="pubmed">12885572</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Low SH, Miura M, Weimbs T. SNARE expression and localization in renal epithelial cells suggest mechanism for variability of trafficking phenotypes. Am J Physiol Renal Physiol. 2002;283:F1111&#x2013;F1122.</Citation><ArticleIdList><ArticleId IdType="pubmed">12372788</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Hou LX, Aktiv A, Dahlstrom A. Immunohistochemical characterisation of differentiated CAD cells: expression of peptides and chromogranins. Histochem Cell Biol. 2005;124:25&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">16007468</ArticleId></ArticleIdList></Reference><Reference><Citation>Luduena RF, Banerjee A, Khan IA. Tubulin structure and biochemistry. Curr Opin Cell Biol. 1992;4:53&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">1558754</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma QH, Futagawa T, Yang WL, Jiang XD, Zeng L, Takeda Y, Xu RX, Bagnard D, Schachner M, Furley AJ, Karagogeos D, Watanabe K, Dawe GS, Xiao ZC. A TAG1-APP signalling pathway through Fe65 negatively modulates neurogenesis. Nat Cell Biol. 2008;10:283&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">18278038</ArticleId></ArticleIdList></Reference><Reference><Citation>Muresan V. One axon, many kinesins: What's the logic? J Neurocytol. 2000;29:799&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pubmed">11466472</ArticleId></ArticleIdList></Reference><Reference><Citation>Muresan Z, Muresan V. A phosphorylated, carboxy-terminal fragment of {beta}-amyloid precursor protein localizes to the splicing factor compartment. Hum Mol Genet. 2004;13:475&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">14722157</ArticleId></ArticleIdList></Reference><Reference><Citation>Muresan Z, Muresan V. c-Jun NH2-terminal kinase-interacting protein-3 facilitates phosphorylation and controls localization of amyloid-beta precursor protein. J Neurosci. 2005a;25:3741&#x2013;3751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6724916</ArticleId><ArticleId IdType="pubmed">15829626</ArticleId></ArticleIdList></Reference><Reference><Citation>Muresan Z, Muresan V. Coordinated transport of phosphorylated amyloid-beta precursor protein and c-Jun NH2-terminal kinase-interacting protein-1. J Cell Biol. 2005b;171:615&#x2013;625.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2171566</ArticleId><ArticleId IdType="pubmed">16301330</ArticleId></ArticleIdList></Reference><Reference><Citation>Muresan Z, Muresan V. Neuritic deposits of amyloid-{beta} peptide in a subpopulation of central nervous system-derived neuronal cells. Mol Cell Biol. 2006;26:4982&#x2013;4997.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1489158</ArticleId><ArticleId IdType="pubmed">16782885</ArticleId></ArticleIdList></Reference><Reference><Citation>Muresan Z, Muresan V. The amyloid-beta precursor protein is phosphorylated via distinct pathways during differentiation, mitosis, stress, and degeneration. Mol Biol Cell. 2007;18:3835&#x2013;3844.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1995701</ArticleId><ArticleId IdType="pubmed">17634293</ArticleId></ArticleIdList></Reference><Reference><Citation>Muresan Z, Muresan V. Seeding neuritic plaques from the distance: a possible role for brainstem neurons in the development of Alzheimer's disease pathology. Neurodegener Dis. 2008;5:250&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2562573</ArticleId><ArticleId IdType="pubmed">18322404</ArticleId></ArticleIdList></Reference><Reference><Citation>Peretti D, Peris L, Rosso S, Quiroga S, Caceres A. Evidence for the involvement of KIF4 in the anterograde transport of L1-containing vesicles. J Cell Biol. 2000;149:141&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2175094</ArticleId><ArticleId IdType="pubmed">10747093</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi Y, Wang JK, McMillian M, Chikaraishi DM. Characterization of a CNS cell line, CAD, in which morphological differentiation is initiated by serum deprivation. J Neurosci. 1997;17:1217&#x2013;1225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793738</ArticleId><ArticleId IdType="pubmed">9006967</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed NA, Cai D, Blasius TL, Jih GT, Meyhofer E, Gaertig J, Verhey KJ. Microtubule acetylation promotes kinesin-1 binding and transport. Curr Biol. 2006;16:2166&#x2013;2172.</Citation><ArticleIdList><ArticleId IdType="pubmed">17084703</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy S, Zhang B, Lee VM, Trojanowski JQ. Axonal transport defects: a common theme in neurodegenerative diseases. Acta Neuropathol (Berl) 2005;109:5&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">15645263</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabo SL, Ikin AF, Buxbaum JD, Greengard P. The Alzheimer amyloid precursor protein (APP) and FE65, an APP-binding protein, regulate cell movement. J Cell Biol. 2001;153:1403&#x2013;1414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2150733</ArticleId><ArticleId IdType="pubmed">11425871</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabo SL, Ikin AF, Buxbaum JD, Greengard P. The amyloid precursor protein and its regulatory protein, FE65, in growth cones and synapses in vitro and in vivo. J Neurosci. 2003;23:5407&#x2013;5415.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741254</ArticleId><ArticleId IdType="pubmed">12843239</ArticleId></ArticleIdList></Reference><Reference><Citation>Sambamurti K, Refolo LM, Shioi J, Pappolla MA, Robakis NK. The Alzheimer's amyloid precursor is cleaved intracellularly in the trans-Golgi network or in a post-Golgi compartment. Ann N Y Acad Sci. 1992;674:118&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">1283818</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaefer AW, Kabir N, Forscher P. Filopodia and actin arcs guide the assembly and transport of two populations of microtubules with unique dynamic parameters in neuronal growth cones. J Cell Biol. 2002;158:139&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2173029</ArticleId><ArticleId IdType="pubmed">12105186</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature. 1999;399:A23&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">10392577</ArticleId></ArticleIdList></Reference><Reference><Citation>Setou M, Nakagawa T, Seog DH, Hirokawa N. Kinesin superfamily motor protein KIF17 and mLin-10 in NMDA receptor- containing vesicle transport. Science. 2000;288:1796&#x2013;1802.</Citation><ArticleIdList><ArticleId IdType="pubmed">10846156</ArticleId></ArticleIdList></Reference><Reference><Citation>Sousa AD, Cheney RE. Myosin-X: a molecular motor at the cell's fingertips. Trends Cell Biol. 2005;15:533&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">16140532</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamer K, Vogel R, Thies E, Mandelkow E, Mandelkow EM. Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J Cell Biol. 2002;156:1051&#x2013;1063.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2173473</ArticleId><ArticleId IdType="pubmed">11901170</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter J, Fluhrer R, Hartung B, Willem M, Kaether C, Capell A, Lammich S, Multhaup G, Haass C. Phosphorylation regulates intracellular trafficking of beta-secretase. J Biol Chem. 2001;276:14634&#x2013;14641.</Citation><ArticleIdList><ArticleId IdType="pubmed">11278841</ArticleId></ArticleIdList></Reference><Reference><Citation>Weidemann A, Konig G, Bunke D, Fischer P, Salbaum JM, Masters CL, Beyreuther K. Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein. Cell. 1989;57:115&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">2649245</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson CA, Doms RW, Zheng H, Lee VM. Presenilins are not required for Abeta42 production in the early secretory pathway. Nat Neurosci. 2002;5:849&#x2013;855.</Citation><ArticleIdList><ArticleId IdType="pubmed">12145638</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamazaki T, Selkoe DJ, Koo EH. Trafficking of cell surface beta-amyloid precursor protein: retrograde and transcytotic transport in cultured neurons. J Cell Biol. 1995;129:431&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2199904</ArticleId><ArticleId IdType="pubmed">7721945</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Varvel NH, Lamb BT, Herrup K. Ectopic cell cycle events link human Alzheimer's disease and amyloid precursor protein transgenic mouse models. J Neurosci. 2006;26:775&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675370</ArticleId><ArticleId IdType="pubmed">16421297</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu WH, Cuervo AM, Kumar A, Peterhoff CM, Schmidt SD, Lee JH, Mohan PS, Mercken M, Farmery MR, Tjernberg LO, Jiang Y, Duff K, Uchiyama Y, Naslund J, Mathews PM, Cataldo AM, Nixon RA. Macroautophagy&#x2014;a novel Beta-amyloid peptide-generating pathway activated in Alzheimer's disease. J Cell Biol. 2005;171:87&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2171227</ArticleId><ArticleId IdType="pubmed">16203860</ArticleId></ArticleIdList></Reference><Reference><Citation>Zar JH. Biostatistical analysis. Upper Saddler River, NJ: Prentice Hall; 1999.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19295162</PMID><DateCompleted><Year>2009</Year><Month>04</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>11</Issue><PubDate><Year>2009</Year><Month>Mar</Month><Day>18</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Specific loss of brain ABCA1 increases brain cholesterol uptake and influences neuronal structure and function.</ArticleTitle><Pagination><StartPage>3579</StartPage><EndPage>3589</EndPage><MedlinePgn>3579-89</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.4741-08.2009</ELocationID><Abstract><AbstractText>The expression of the cholesterol transporter ATP-binding cassette transporter A1 (ABCA1) in the brain and its role in the lipidation of apolipoproteins indicate that ABCA1 may play a critical role in brain cholesterol metabolism. To investigate the role of ABCA1 in brain cholesterol homeostasis and trafficking, we characterized mice that specifically lacked ABCA1 in the CNS, generated using the Cre/loxP recombination system. These mice showed reduced plasma high-density lipoprotein (HDL) cholesterol levels associated with decreased brain cholesterol content and enhanced brain uptake of esterified cholesterol from plasma HDL. Increased levels of HDL receptor SR-BI in brain capillaries and apolipoprotein A-I in brain and CSF of mutant mice were evident. Cholesterol homeostasis changes were mirrored by disturbances in motor activity and sensorimotor function. Changes in synaptic ultrastructure including reduced synapse and synaptic vesicle numbers were observed. These data show that ABCA1 is a key regulator of brain cholesterol metabolism and that disturbances in cholesterol transport in the CNS are associated with structural and functional deficits in neurons. Moreover, our findings also demonstrate that specific changes in brain cholesterol metabolism can lead to alterations in cholesterol uptake from plasma to brain.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Karasinska</LastName><ForeName>Joanna M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Centre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, British Columbia, V5Z 4H4 Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rinninger</LastName><ForeName>Franz</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>L&#xfc;tjohann</LastName><ForeName>Dieter</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Ruddle</LastName><ForeName>Piers</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Franciosi</LastName><ForeName>Sonia</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kruit</LastName><ForeName>Janine K</ForeName><Initials>JK</Initials></Author><Author ValidYN="Y"><LastName>Singaraja</LastName><ForeName>Roshni R</ForeName><Initials>RR</Initials></Author><Author ValidYN="Y"><LastName>Hirsch-Reinshagen</LastName><ForeName>Veronica</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Jianjia</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Brunham</LastName><ForeName>Liam R</ForeName><Initials>LR</Initials></Author><Author ValidYN="Y"><LastName>Bissada</LastName><ForeName>Nagat</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Ramakrishnan</LastName><ForeName>Rajasekhar</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Wellington</LastName><ForeName>Cheryl L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Parks</LastName><ForeName>John S</ForeName><Initials>JS</Initials></Author><Author ValidYN="Y"><LastName>Hayden</LastName><ForeName>Michael R</ForeName><Initials>MR</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 HL049373</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL 49373</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064286">ATP Binding Cassette Transporter 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018528">ATP-Binding Cassette Transporters</NameOfSubstance></Chemical><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D064286" MajorTopicYN="N">ATP Binding Cassette Transporter 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018528" MajorTopicYN="N">ATP-Binding Cassette Transporters</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001519" MajorTopicYN="N">Behavior</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>3</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>3</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>4</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>9</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19295162</ArticleId><ArticleId IdType="mid">NIHMS103424</ArticleId><ArticleId IdType="pmc">PMC2678874</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4741-08.2009</ArticleId><ArticleId IdType="pii">29/11/3579</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science. 1996;271:518&#x2013;520.</Citation><ArticleIdList><ArticleId IdType="pubmed">8560269</ArticleId></ArticleIdList></Reference><Reference><Citation>Barres BA, Smith SJ. Neurobiology. Cholesterol&#x2014;making or breaking the synapse. Science. 2001;294:1296&#x2013;1297.</Citation><ArticleIdList><ArticleId IdType="pubmed">11701918</ArticleId></ArticleIdList></Reference><Reference><Citation>Berge KE. Sitosterolemia: a gateway to new knowledge about cholesterol metabolism. Ann Med. 2003;35:502&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pubmed">14649332</ArticleId></ArticleIdList></Reference><Reference><Citation>Bj&#xf6;rkhem I, Meaney S. Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol. 2004;24:806&#x2013;815.</Citation><ArticleIdList><ArticleId IdType="pubmed">14764421</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowman GL, Kaye JA, Moore M, Waichunas D, Carlson NE, Quinn JF. Blood-brain barrier impairment in Alzheimer disease: stability and functional significance. Neurology. 2007;68:1809&#x2013;1814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668699</ArticleId><ArticleId IdType="pubmed">17515542</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, van Dam M, Yu L, Brewer C, Collins JA, Molhuizen HO, Loubser O, Ouelette BF, Fichter K, Ashbourne-Excoffon KJ, Sensen CW, Scherer S, Mott S, Denis M, Martindale D, Frohlich J, et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet. 1999;22:336&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pubmed">10431236</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown J, 3rd, Theisler C, Silberman S, Magnuson D, Gottardi-Littell N, Lee JM, Yager D, Crowley J, Sambamurti K, Rahman MM, Reiss AB, Eckman CB, Wolozin B. Differential expression of cholesterol hydroxylases in Alzheimer's disease. J Biol Chem. 2004;279:34674&#x2013;34681.</Citation><ArticleIdList><ArticleId IdType="pubmed">15148325</ArticleId></ArticleIdList></Reference><Reference><Citation>Brundert M, Ewert A, Heeren J, Behrendt B, Ramakrishnan R, Greten H, Merkel M, Rinninger F. Scavenger receptor class B type I mediates the selective uptake of high-density lipoprotein-associated cholesteryl ester by the liver in mice. Arterioscler Thromb Vasc Biol. 2005;25:143&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">15528479</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunham LR, Kruit JK, Iqbal J, Fievet C, Timmins JM, Pape TD, Coburn BA, Bissada N, Staels B, Groen AK, Hussain MM, Parks JS, Kuipers F, Hayden MR. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J Clin Invest. 2006;116:1052&#x2013;1062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1401485</ArticleId><ArticleId IdType="pubmed">16543947</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunham LR, Kruit JK, Pape TD, Timmins JM, Reuwer AQ, Vasanji Z, Marsh BJ, Rodrigues B, Johnson JD, Parks JS, Verchere CB, Hayden MR. Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med. 2007;13:340&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">17322896</ArticleId></ArticleIdList></Reference><Reference><Citation>Butchbach ME, Tian G, Guo H, Lin CL. Association of excitatory amino acid transporters, especially EAAT2, with cholesterol-rich lipid raft microdomains: importance for excitatory amino acid transporter localization and function. J Biol Chem. 2004;279:34388&#x2013;34396.</Citation><ArticleIdList><ArticleId IdType="pubmed">15187084</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlin RK, Siekevitz P. Plasticity in the central nervous system: do synapses divide? Proc Natl Acad Sci U S A. 1983;80:3517&#x2013;3521.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC394076</ArticleId><ArticleId IdType="pubmed">6574496</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellanos FX, Fine EJ, Kaysen D, Marsh WL, Rapoport JL, Hallett M. Sensorimotor gating in boys with Tourette's syndrome and ADHD: preliminary results. Biol Psychiatry. 1996;39:33&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">8719124</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu LW, Li Y, Li Z, Tang AY, Cheung BM, Leung RY, Yik PY, Jin DY, Song YQ. A novel intronic polymorphism of ABCA1 gene reveals risk for sporadic Alzheimer's disease in Chinese. Am J Med Genet B Neuropsychiatr Genet. 2007;144B:1007&#x2013;1013.</Citation><ArticleIdList><ArticleId IdType="pubmed">17510949</ArticleId></ArticleIdList></Reference><Reference><Citation>Dehouck B, Fenart L, Dehouck MP, Pierce A, Torpier G, Cecchelli R. A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier. J Cell Biol. 1997;138:877&#x2013;889.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2138047</ArticleId><ArticleId IdType="pubmed">9265653</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB, Bales KR, Parsadanian M, O'Dell MA, Foss EM, Paul SM, Holtzman DM. Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease. J Neurochem. 2002;81:229&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">12064470</ArticleId></ArticleIdList></Reference><Reference><Citation>Dietschy JM, Turley SD. Thematic review series: brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res. 2004;45:1375&#x2013;1397.</Citation><ArticleIdList><ArticleId IdType="pubmed">15254070</ArticleId></ArticleIdList></Reference><Reference><Citation>Elshourbagy NA, Boguski MS, Liao WS, Jefferson LS, Gordon JI, Taylor JM. Expression of rat apolipoprotein A-IV and A-I genes: mRNA induction during development and in response to glucocorticoids and insulin. Proc Natl Acad Sci U S A. 1985;82:8242&#x2013;8246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC391479</ArticleId><ArticleId IdType="pubmed">3934672</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujiyoshi M, Ohtsuki S, Hori S, Tachikawa M, Terasaki T. 24S-hydroxycholesterol induces cholesterol release from choroid plexus epithelial cells in an apical- and apoE isoform-dependent manner concomitantly with the induction of ABCA1 and ABCG1 expression. J Neurochem. 2007;100:968&#x2013;978.</Citation><ArticleIdList><ArticleId IdType="pubmed">17101031</ArticleId></ArticleIdList></Reference><Reference><Citation>Geyer MA, McIlwain KL, Paylor R. Mouse genetic models for prepulse inhibition: an early review. Mol Psychiatry. 2002;7:1039&#x2013;1053.</Citation><ArticleIdList><ArticleId IdType="pubmed">12476318</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass C, Pittman RC, Weinstein DB, Steinberg D. Dissociation of tissue uptake of cholesterol ester from that of apoprotein A-I of rat plasma high density lipoprotein: selective delivery of cholesterol ester to liver, adrenal, and gonad. Proc Natl Acad Sci U S A. 1983a;80:5435&#x2013;5439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC384271</ArticleId><ArticleId IdType="pubmed">6412229</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass CK, Pittman RC, Keller GA, Steinberg D. Tissue sites of degradation of apoprotein A-I in the rat. J Biol Chem. 1983b;258:7161&#x2013;7167.</Citation><ArticleIdList><ArticleId IdType="pubmed">6406495</ArticleId></ArticleIdList></Reference><Reference><Citation>Gleiberman AS, Encinas JM, Mignone JL, Michurina T, Rosenfeld MG, Enikolopov G. Expression of nestin-green fluorescent protein transgene marks oval cells in the adult liver. Dev Dyn. 2005;234:413&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2751636</ArticleId><ArticleId IdType="pubmed">16127706</ArticleId></ArticleIdList></Reference><Reference><Citation>Goritz C, Mauch DH, Pfrieger FW. Multiple mechanisms mediate cholesterol-induced synaptogenesis in a CNS neuron. Mol Cell Neurosci. 2005;29:190&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">15911344</ArticleId></ArticleIdList></Reference><Reference><Citation>Goti D, Hrzenjak A, Levak-Frank S, Frank S, van der Westhuyzen DR, Malle E, Sattler W. Scavenger receptor class B, type I is expressed in porcine brain capillary endothelial cells and contributes to selective uptake of HDL-associated vitamin E. J Neurochem. 2001;76:498&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pubmed">11208913</ArticleId></ArticleIdList></Reference><Reference><Citation>Herz J, Chen Y. Reelin, lipoprotein receptors and synaptic plasticity. Nat Rev Neurosci. 2006;7:850&#x2013;859.</Citation><ArticleIdList><ArticleId IdType="pubmed">17053810</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsch-Reinshagen V, Zhou S, Burgess BL, Bernier L, McIsaac SA, Chan JY, Tansley GH, Cohn JS, Hayden MR, Wellington CL. Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. J Biol Chem. 2004;279:41197&#x2013;41207.</Citation><ArticleIdList><ArticleId IdType="pubmed">15269218</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen PJ, L&#xfc;tjohann D, Abildayeva K, Vanmierlo T, Pl&#xf6;sch T, Plat J, von Bergmann K, Groen AK, Ramaekers FC, Kuipers F, Mulder M. Dietary plant sterols accumulate in the brain. Biochim Biophys Acta. 2006;1761:445&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">16677856</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tontonoz P, Landreth GE. ApoE promotes the proteolytic degradation of Abeta. Neuron. 2008;58:681&#x2013;693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2493297</ArticleId><ArticleId IdType="pubmed">18549781</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotti TJ, Ramirez DM, Pfeiffer BE, Huber KM, Russell DW. Brain cholesterol turnover required for geranylgeraniol production and learning in mice. Proc Natl Acad Sci U S A. 2006;103:3869&#x2013;3874.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1450160</ArticleId><ArticleId IdType="pubmed">16505352</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindenthal B, Sudhop T, Schiedermaier P, Agnan M, Sauerbruch T, von Bergmann K. Serum plant sterols and biliary cholesterol secretion in humans: studies with ursodeoxycholic acid. J Lipid Res. 2002;43:1072&#x2013;1077.</Citation><ArticleIdList><ArticleId IdType="pubmed">12091491</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund EG, Guileyardo JM, Russell DW. cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc Natl Acad Sci U S A. 1999;96:7238&#x2013;7243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22064</ArticleId><ArticleId IdType="pubmed">10377398</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund EG, Xie C, Kotti T, Turley SD, Dietschy JM, Russell DW. Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover. J Biol Chem. 2003;278:22980&#x2013;22988.</Citation><ArticleIdList><ArticleId IdType="pubmed">12686551</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xfc;tjohann D, Papassotiropoulos A, Bj&#xf6;rkhem I, Locatelli S, Bagli M, Oehring RD, Schlegel U, Jessen F, Rao ML, von Bergmann K, Heun R. Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J Lipid Res. 2000;41:195&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">10681402</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xfc;tjohann D, Brzezinka A, Barth E, Abramowski D, Staufenbiel M, von Bergmann K, Beyreuther K, Multhaup G, Bayer TA. Profile of cholesterol-related sterols in aged amyloid precursor protein transgenic mouse brain. J Lipid Res. 2002;43:1078&#x2013;1085.</Citation><ArticleIdList><ArticleId IdType="pubmed">12091492</ArticleId></ArticleIdList></Reference><Reference><Citation>Maehara S, Hikichi H, Satow A, Okuda S, Ohta H. Antipsychotic property of a muscarinic receptor agonist in animal models for schizophrenia. Pharmacol Biochem Behav. 2008;91:140&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">18651995</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnani F, Tate CG, Wynne S, Williams C, Haase J. Partitioning of the serotonin transporter into lipid microdomains modulates transport of serotonin. J Biol Chem. 2004;279:38770&#x2013;38778.</Citation><ArticleIdList><ArticleId IdType="pubmed">15226315</ArticleId></ArticleIdList></Reference><Reference><Citation>Mauch DH, N&#xe4;gler K, Schumacher S, G&#xf6;ritz C, M&#xfc;ller EC, Otto A, Pfrieger FW. CNS synaptogenesis promoted by glia-derived cholesterol. Science. 2001;294:1354&#x2013;1357.</Citation><ArticleIdList><ArticleId IdType="pubmed">11701931</ArticleId></ArticleIdList></Reference><Reference><Citation>Merched A, Xia Y, Visvikis S, Serot JM, Siest G. Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease. Neurobiol Aging. 2000;21:27&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">10794845</ArticleId></ArticleIdList></Reference><Reference><Citation>Oram JF, Heinecke JW. ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. Physiol Rev. 2005;85:1343&#x2013;1372.</Citation><ArticleIdList><ArticleId IdType="pubmed">16183915</ArticleId></ArticleIdList></Reference><Reference><Citation>Panzenboeck U, Balazs Z, Sovic A, Hrzenjak A, Levak-Frank S, Wintersperger A, Malle E, Sattler W. ABCA1 and scavenger receptor class B, type I, are modulators of reverse sterol transport at an in vitro blood-brain barrier constituted of porcine brain capillary endothelial cells. J Biol Chem. 2002;277:42781&#x2013;42789.</Citation><ArticleIdList><ArticleId IdType="pubmed">12202492</ArticleId></ArticleIdList></Reference><Reference><Citation>Panzenboeck U, Kratzer I, Sovic A, Wintersperger A, Bernhart E, Hammer A, Malle E, Sattler W. Regulatory effects of synthetic liver X receptor- and peroxisome-proliferator activated receptor agonists on sterol transport pathways in polarized cerebrovascular endothelial cells. Int J Biochem Cell Biol. 2006;38:1314&#x2013;1329.</Citation><ArticleIdList><ArticleId IdType="pubmed">16530456</ArticleId></ArticleIdList></Reference><Reference><Citation>Papassotiropoulos A, L&#xfc;tjohann D, Bagli M, Locatelli S, Jessen F, Buschfort R, Ptok U, Bj&#xf6;rkhem I, von Bergmann K, Heun R. 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J Psychiatr Res. 2002;36:27&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">11755458</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitas RE, Boyles JK, Lee SH, Hui D, Weisgraber KH. Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. J Biol Chem. 1987;262:14352&#x2013;14360.</Citation><ArticleIdList><ArticleId IdType="pubmed">3115992</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittman RC, Taylor CA., Jr Methods for assessment of tissue sites of lipoprotein degradation. Methods Enzymol. 1986;129:612&#x2013;628.</Citation><ArticleIdList><ArticleId IdType="pubmed">3088396</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittman RC, Carew TE, Glass CK, Green SR, Taylor CA, Jr, Attie AD. A radioiodinated, intracellularly trapped ligand for determining the sites of plasma protein degradation in vivo. Biochem J. 1983;212:791&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1153156</ArticleId><ArticleId IdType="pubmed">6882394</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittman RC, Knecht TP, Rosenbaum MS, Taylor CA., Jr A nonendocytotic mechanism for the selective uptake of high density lipoprotein-associated cholesterol esters. J Biol Chem. 1987;262:2443&#x2013;2450.</Citation><ArticleIdList><ArticleId IdType="pubmed">2434485</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponce J, de la Ossa NP, Hurtado O, Millan M, Arenillas JF, D&#xe1;valos A, Gasull T. Simvastatin reduces the association of NMDA receptors to lipid rafts: a cholesterol-mediated effect in neuroprotection. Stroke. 2008;39:1269&#x2013;1275.</Citation><ArticleIdList><ArticleId IdType="pubmed">18323503</ArticleId></ArticleIdList></Reference><Reference><Citation>Quan G, Xie C, Dietschy JM, Turley SD. Ontogenesis and regulation of cholesterol metabolism in the central nervous system of the mouse. Brain Res Dev Brain Res. 2003;146:87&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">14643015</ArticleId></ArticleIdList></Reference><Reference><Citation>Ralph RJ, Paulus MP, Fumagalli F, Caron MG, Geyer MA. Prepulse inhibition deficits and perseverative motor patterns in dopamine transporter knock-out mice: differential effects of D1 and D2 receptor antagonists. J Neurosci. 2001;21:305&#x2013;313.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762423</ArticleId><ArticleId IdType="pubmed">11150348</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez-Rodr&#xed;guez E, Mateo I, Llorca J, S&#xe1;nchez-Quintana C, Infante J, Garca-Gorostiaga I, S&#xe1;nchez-Juan P, Berciano J, Combarros O. Association of genetic variants of ABCA1 with Alzheimer's disease risk. Am J Med Genet B Neuropsychiatr Genet. 2007;144B:964&#x2013;968.</Citation><ArticleIdList><ArticleId IdType="pubmed">17510946</ArticleId></ArticleIdList></Reference><Reference><Citation>Saher G, Br&#xfc;gger B, Lappe-Siefke C, M&#xf6;bius W, Tozawa R, Wehr MC, Wieland F, Ishibashi S, Nave KA. High cholesterol level is essential for myelin membrane growth. Nat Neurosci. 2005;8:468&#x2013;475.</Citation><ArticleIdList><ArticleId IdType="pubmed">15793579</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;nknecht P, L&#xfc;tjohann D, Pantel J, Bardenheuer H, Hartmann T, von Bergmann K, Beyreuther K, Schr&#xf6;der J. Cerebrospinal fluid 24S-hydroxycholesterol is increased in patients with Alzheimer's disease compared to healthy controls. Neurosci Lett. 2002;324:83&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">11983301</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh-Manoux A, Gimeno D, Kivimaki M, Brunner E, Marmot MG. Low HDL cholesterol is a risk factor for deficit and decline in memory in midlife: the Whitehall II study. Arterioscler Thromb Vasc Biol. 2008;28:1556&#x2013;1562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2581752</ArticleId><ArticleId IdType="pubmed">18591462</ArticleId></ArticleIdList></Reference><Reference><Citation>Tachikawa M, Watanabe M, Hori S, Fukaya M, Ohtsuki S, Asashima T, Terasaki T. Distinct spatio-temporal expression of ABCA and ABCG transporters in the developing and adult mouse brain. J Neurochem. 2005;95:294&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">16181433</ArticleId></ArticleIdList></Reference><Reference><Citation>Temel RE, Gebre AK, Parks JS, Rudel LL. Compared with Acyl-CoA:cholesterol O-acyltransferase (ACAT) 1 and lecithin:cholesterol acyltransferase, ACAT2 displays the greatest capacity to differentiate cholesterol from sitosterol. J Biol Chem. 2003;278:47594&#x2013;47601.</Citation><ArticleIdList><ArticleId IdType="pubmed">12975367</ArticleId></ArticleIdList></Reference><Reference><Citation>Timmins JM, Lee JY, Boudyguina E, Kluckman KD, Brunham LR, Mulya A, Gebre AK, Coutinho JM, Colvin PL, Smith TL, Hayden MR, Maeda N, Parks JS. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest. 2005;115:1333&#x2013;1342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1074680</ArticleId><ArticleId IdType="pubmed">15841208</ArticleId></ArticleIdList></Reference><Reference><Citation>Triguero D, Buciak J, Pardridge WM. Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins. J Neurochem. 1990;54:1882&#x2013;1888.</Citation><ArticleIdList><ArticleId IdType="pubmed">2338547</ArticleId></ArticleIdList></Reference><Reference><Citation>Tronche F, Kellendonk C, Kretz O, Gass P, Anlag K, Orban PC, Bock R, Klein R, Sch&#xfc;tz G. Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety. Nat Genet. 1999;23:99&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">10471508</ArticleId></ArticleIdList></Reference><Reference><Citation>Valenza M, Rigamonti D, Goffredo D, Zuccato C, Fenu S, Jamot L, Strand A, Tarditi A, Woodman B, Racchi M, Mariotti C, Di Donato S, Corsini A, Bates G, Pruss R, Olson JM, Sipione S, Tartari M, Cattaneo E. Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. J Neurosci. 2005;25:9932&#x2013;9939.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725556</ArticleId><ArticleId IdType="pubmed">16251441</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance JE, Hayashi H, Karten B. Cholesterol homeostasis in neurons and glial cells. Semin Cell Dev Biol. 2005;16:193&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">15797830</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle SE, Jiang H, Parsadanian M, Legleiter J, Han X, Fryer JD, Kowalewski T, Holtzman DM. ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J Biol Chem. 2004;279:40987&#x2013;40993.</Citation><ArticleIdList><ArticleId IdType="pubmed">15269217</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A, Jain S, Hirsch-Reinshagen V, Wellington CL, Bales KR, Paul SM, Holtzman DM. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest. 2008;118:671&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2200302</ArticleId><ArticleId IdType="pubmed">18202749</ArticleId></ArticleIdList></Reference><Reference><Citation>Waterham HR, Koster J, Romeijn GJ, Hennekam RC, Vreken P, Andersson HC, FitzPatrick DR, Kelley RI, Wanders RJ. Mutations in the 3beta-hydroxysterol Delta24-reductase gene cause desmosterolosis, an autosomal recessive disorder of cholesterol biosynthesis. Am J Hum Genet. 2001;69:685&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1226055</ArticleId><ArticleId IdType="pubmed">11519011</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiler-G&#xfc;ttler H, Sommerfeldt M, Papandrikopoulou A, Mischek U, Bonitz D, Frey A, Grupe M, Scheerer J, Gassen HG. Synthesis of apolipoprotein A-1 in pig brain microvascular endothelial cells. J Neurochem. 1990;54:444&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pubmed">2105375</ArticleId></ArticleIdList></Reference><Reference><Citation>Wellington CL, Walker EK, Suarez A, Kwok A, Bissada N, Singaraja R, Yang YZ, Zhang LH, James E, Wilson JE, Francone O, McManus BM, Hayden MR. ABCA1 mRNA and protein distribution patterns predict multiple different roles and levels of regulation. Lab Invest. 2002;82:273&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pubmed">11896206</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19304802</PMID><DateCompleted><Year>2009</Year><Month>05</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>106</Volume><Issue>14</Issue><PubDate><Year>2009</Year><Month>Apr</Month><Day>07</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Synaptic transmission block by presynaptic injection of oligomeric amyloid beta.</ArticleTitle><Pagination><StartPage>5901</StartPage><EndPage>5906</EndPage><MedlinePgn>5901-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0900944106</ELocationID><Abstract><AbstractText>Early Alzheimer's disease (AD) pathophysiology is characterized by synaptic changes induced by degradation products of amyloid precursor protein (APP). The exact mechanisms of such modulation are unknown. Here, we report that nanomolar concentrations of intraaxonal oligomeric (o)Abeta42, but not oAbeta40 or extracellular oAbeta42, acutely inhibited synaptic transmission at the squid giant synapse. Further characterization of this phenotype demonstrated that presynaptic calcium currents were unaffected. However, electron microscopy experiments revealed diminished docked synaptic vesicles in oAbeta42-microinjected terminals, without affecting clathrin-coated vesicles. The molecular events of this modulation involved casein kinase 2 and the synaptic vesicle rapid endocytosis pathway. These findings open the possibility of a new therapeutic target aimed at ameliorating synaptic dysfunction in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moreno</LastName><ForeName>Herman</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology and Physiology/Pharmacology, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Eunah</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Pigino</LastName><ForeName>Gustavo</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Alejandro I</ForeName><Initials>AI</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Natalia</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Moreira</LastName><ForeName>Jorge E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Sugimori</LastName><ForeName>Mutsuyuki</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Llin&#xe1;s</LastName><ForeName>Rodolfo R</ForeName><Initials>RR</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K08 AG027476</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS013742</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG027476</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS13742-30</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>03</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D047390">Casein Kinase II</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047390" MajorTopicYN="N">Casein Kinase II</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049832" MajorTopicYN="N">Decapodiformes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004594" MajorTopicYN="N">Electrophysiology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004705" MajorTopicYN="N">Endocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008854" MajorTopicYN="N">Microscopy, Electron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017729" MajorTopicYN="Y">Presynaptic Terminals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>3</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>3</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>5</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>3</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19304802</ArticleId><ArticleId IdType="pmc">PMC2659170</ArticleId><ArticleId IdType="doi">10.1073/pnas.0900944106</ArticleId><ArticleId IdType="pii">0900944106</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hutton M, P&#xe9;rez-Tur J, Hardy J. Genetics of Alzheimer's disease. Essays Biochem. 1998;33:117&#x2013;131. Review.</Citation><ArticleIdList><ArticleId IdType="pubmed">10488446</ArticleId></ArticleIdList></Reference><Reference><Citation>Younkin SG. The role of A beta 42 in Alzheimer's disease. J Physiol Paris. 1998;92:289&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">9789825</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisodia SS, Kim SH, Thinakaran G. Function and dysfunction of the presenilins. Am J Hum Genet. 1999;65:7&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1378068</ArticleId><ArticleId IdType="pubmed">10364510</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease: Genes, proteins, and therapy. Physiol Rev. 2001;81:741&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci. 2007;8:499&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pubmed">17551515</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannakopoulos P, et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology. 2003;60:1495&#x2013;1500.</Citation><ArticleIdList><ArticleId IdType="pubmed">12743238</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinerman JR, et al. Distinct pools of beta-amyloid in Alzheimer disease-affected brain: A clinicopathologic study. Arch Neurol. 2008;65:906&#x2013;912.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2586606</ArticleId><ArticleId IdType="pubmed">18625856</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, et al. BACE overexpression alters the subcellular processing of APP and inhibits Abeta deposition in vivo. J Cell Biol. 2005;168:291&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2171598</ArticleId><ArticleId IdType="pubmed">15642747</ArticleId></ArticleIdList></Reference><Reference><Citation>Llin&#xe1;s R, Steinberg IZ, Walton K. Relationship between presynaptic calcium current and postsynaptic potential in squid giant synapse. Biophys J. 1981;33:323&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1327434</ArticleId><ArticleId IdType="pubmed">6261850</ArticleId></ArticleIdList></Reference><Reference><Citation>Kusano K, Landau EM. Depression and recovery of transmission at the squid giant synapse. J Physiol. 1975;245:13&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1330842</ArticleId><ArticleId IdType="pubmed">165284</ArticleId></ArticleIdList></Reference><Reference><Citation>Daly C, Sugimori M, Moreira JE, Ziff EB, Llin&#xe1;s R. Synaptophysin regulates clathrin-independent endocytosis of synaptic vesicles. Proc Natl Acad Sci USA. 2000;97:6120&#x2013;6125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18568</ArticleId><ArticleId IdType="pubmed">10823955</ArticleId></ArticleIdList></Reference><Reference><Citation>Puzzo D, et al. Amyloid-beta peptide inhibits activation of the nitric oxide/cGMP/cAMP-responsive element-binding protein pathway during hippocampal synaptic plasticity. J Neurosci. 2005;25:6887&#x2013;6897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725343</ArticleId><ArticleId IdType="pubmed">16033898</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang KA, Suh YH. Pathophysiological roles of amyloidogenic carboxy-terminal fragments of the beta-amyloid precursor protein in Alzheimer's disease. J Pharmacol Sci. 2005;97:461&#x2013;471.</Citation><ArticleIdList><ArticleId IdType="pubmed">15821343</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RB, et al. Signal transduction cascades associated with oxidative stress in Alzheimer's disease. J Alzheimers Dis. 2007;11:143&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pubmed">17522439</ArticleId></ArticleIdList></Reference><Reference><Citation>Milton NG. Phosphorylated amyloid-beta: The toxic intermediate in alzheimer's disease neurodegeneration. Subcell Biochem. 2005;38:381&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">15709490</ArticleId></ArticleIdList></Reference><Reference><Citation>Raftery M, et al. Phosphorylation of apolipoprotein-E at an atypical protein kinase CK2 PSD/E site in vitro. Biochemistry. 2005;44:7346&#x2013;7353.</Citation><ArticleIdList><ArticleId IdType="pubmed">15882073</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilfiker S, Pieribone VA, Nordstedt C, Greengard P, Czernik AJ. Regulation of synaptotagmin I phosphorylation by multiple protein kinases. J Neurochem. 1999;73:921&#x2013;932.</Citation><ArticleIdList><ArticleId IdType="pubmed">10461881</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberman DN, Mody I. Casein kinase-II regulates NMDA channel function in hippocampal neurons. Nat Neurosci. 1999;2:125&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195195</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi M, Amin N, Grant P, Pant HC. P13suc1 associates with a cdc2-like kinase in a multimeric cytoskeletal complex in squid axoplasm. J Neurosci. 1995;15:6222&#x2013;6229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577658</ArticleId><ArticleId IdType="pubmed">7666204</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleman PD, Yao PJ. Synaptic slaughter in Alzheimer's disease. Neurobiol Aging. 2003;24:1023&#x2013;1027.</Citation><ArticleIdList><ArticleId IdType="pubmed">14643374</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy JA, Higgins GA. Alzheimer's disease: The amyloid cascade hypothesis. Science. 1992;256:184&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouras GK, Almeida CG, Takahashi RH. Intraneuronal Abeta accumulation and origin of plaques in Alzheimer's disease. Neurobiol Aging. 2005;26:1235&#x2013;1244.</Citation><ArticleIdList><ArticleId IdType="pubmed">16023263</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM, Tinkle BT, Bieberich CJ, Haudenschild CC, Jay G. The Alzheimer's A beta peptide induces neurodegeneration and apoptotic cell death in transgenic mice. Nat Genet. 1995;9:21&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">7704018</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Andrea MR, Nagele RG, Wang HY, Peterson PA, Lee DH. Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease. Histopathology. 2001;38:120&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">11207825</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahr BA, et al. Amyloid beta protein is internalized selectively by hippocampal field CA1 and causes neurons to accumulate amyloidogenic carboxyterminal fragments of the amyloid precursor protein. J Comp Neurol. 1998;397:139&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">9671284</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi RH, et al. Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain. J Neurosci. 2004;24:3592&#x2013;3599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729733</ArticleId><ArticleId IdType="pubmed">15071107</ArticleId></ArticleIdList></Reference><Reference><Citation>LeBlanc AC, Xue R, Gambetti P. Amyloid precursor protein metabolism in primary cell cultures of neurons, astrocytes, and microglia. J Neurochem. 1996;6:2300&#x2013;2310.</Citation><ArticleIdList><ArticleId IdType="pubmed">8632152</ArticleId></ArticleIdList></Reference><Reference><Citation>Llinas R. The Squid Giant Synapse: A Model for Chemical Transmission. New York: Oxford Univ Press; 1999.</Citation></Reference><Reference><Citation>Li QX, et al. Intracellular accumulation of detergent-soluble amyloidogenic A beta fragment of Alzheimer's disease precursor protein in the hippocampus of aged transgenic mice. J Neurochem. 1999;72:2479&#x2013;2487.</Citation><ArticleIdList><ArticleId IdType="pubmed">10349858</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida CG, Takahashi RH, Gouras GK. Beta-amyloid accumulation impairs multivesicular body sorting by inhibiting the ubiquitin-proteasome system. J Neurosci. 2006;26:4277&#x2013;4288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673997</ArticleId><ArticleId IdType="pubmed">16624948</ArticleId></ArticleIdList></Reference><Reference><Citation>Adalbert R, Gilley J, Coleman MP. Abeta, tau and ApoE4 in Alzheimer's disease: The axonal connection. Trends Mol Med. 2007;13:135&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">17344096</ArticleId></ArticleIdList></Reference><Reference><Citation>Muresan Z, Muresan V. Neuritic deposits of amyloid-beta peptide in a subpopulation of central nervous system-derived neuronal cells. Mol Cell Biol. 2006;26:4982&#x2013;4997.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1489158</ArticleId><ArticleId IdType="pubmed">16782885</ArticleId></ArticleIdList></Reference><Reference><Citation>Stokin GB, et al. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science. 2005;307:1282&#x2013;1288.</Citation><ArticleIdList><ArticleId IdType="pubmed">15731448</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarov O, et al. Axonal transport, amyloid precursor protein, kinesin-1, and the processing apparatus: Revisited. J Neurosci. 2005;25:2386&#x2013;2395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6726084</ArticleId><ArticleId IdType="pubmed">15745965</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Liu J, Suo WZ. GRK5 deficiency exaggerates inflammatory changes in TgAPPsw mice. J Neuroinflammation. 2008;5:24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2442054</ArticleId><ArticleId IdType="pubmed">18522748</ArticleId></ArticleIdList></Reference><Reference><Citation>Song MS, Saavedra L, de Chaves EI. Apoptosis is secondary to non-apoptotic axonal degeneration in neurons exposed to Abeta in distal axons. Neurobiol Aging. 2006;27:1224&#x2013;1238.</Citation><ArticleIdList><ArticleId IdType="pubmed">16122841</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanquet PR. Casein kinase 2 as a potentially important enzyme in the nervous system. Prog Neurobiol. 2000;60:211&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">10658642</ArticleId></ArticleIdList></Reference><Reference><Citation>Stine WB, Jr, Dahlgren KN, Krafft GA, LaDu MJ. In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J Biol Chem. 2003;278:11612&#x2013;11622.</Citation><ArticleIdList><ArticleId IdType="pubmed">12499373</ArticleId></ArticleIdList></Reference><Reference><Citation>Pigino G, et al. Disruption of fast axonal transport is a pathogenic mechanism for intraneuronal amyloid beta. Proc Natl Acad Sci USA. 2009 in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2667037</ArticleId><ArticleId IdType="pubmed">19321417</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19318468</PMID><DateCompleted><Year>2009</Year><Month>05</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">1549-5485</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>4</Issue><PubDate><Year>2009</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Learning &amp; memory (Cold Spring Harbor, N.Y.)</Title><ISOAbbreviation>Learn Mem</ISOAbbreviation></Journal><ArticleTitle>Amyloid beta mediates memory formation.</ArticleTitle><Pagination><StartPage>267</StartPage><EndPage>272</EndPage><MedlinePgn>267-72</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1101/lm.1310209</ELocationID><Abstract><AbstractText>The amyloid precursor protein (APP) undergoes sequential cleavages to generate various polypeptides, including the amyloid beta (1-42) peptide (Abeta[1-42]), which is believed to play a major role in amyloid plaque formation in Alzheimer's disease (AD). Here we provide evidence that, in contrast with its pathological role when accumulated, endogenous Abeta in normal hippocampi mediates learning and memory formation. Furthermore, hippocampal injection of picomolar concentrations of exogenous Abeta(1-42) enhances memory consolidation. Correlative data suggest that Abeta peptides may exert their function via nicotinic acethylcoline receptors. Hence, Abeta peptides, including Abeta(1-42), play an important physiological role in hippocampal memory formation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garcia-Osta</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mount Sinai School of Medicine, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alberini</LastName><ForeName>Cristina M</ForeName><Initials>CM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH065635</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>03</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Learn Mem</MedlineTA><NlmUniqueID>9435678</NlmUniqueID><ISSNLinking>1072-0502</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020318" MajorTopicYN="N">Rats, Long-Evans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>3</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>3</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>5</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19318468</ArticleId><ArticleId IdType="pmc">PMC2661754</ArticleId><ArticleId IdType="doi">10.1101/lm.1310209</ArticleId><ArticleId IdType="pii">16/4/267</ArticleId><ArticleId IdType="medline">9435678</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Allinson T.M., Parkin E.T., Turner A.J., Hooper N.M. ADAMs family members as amyloid precursor protein &#x3b1;-secretases. J. Neurosci. Res. 2003;74:342&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">14598310</ArticleId></ArticleIdList></Reference><Reference><Citation>Canal C.E., Gold P.E. Different temporal profiles of amnesia after intra-hippocampus and intra-amygdala infusions of anisomycin. Behav. Neurosci. 2007;121:732&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">17663598</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter R.B. Differentiating analgesic and non-analgesic drug activities on rat hot plate: Effect of behavioral endpoint. Pain. 1991;47:211&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">1762817</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G., Chen P., Tan H., Ma D., Dou F., Feng J., Yan Z. Regulation of the NMDA receptor-mediated synaptic response by acetylcholinesterase inhibitors and its impairment in an animal model of Alzheimer's disease. Neurobiol. Aging. 2008;29:1795&#x2013;1804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2613405</ArticleId><ArticleId IdType="pubmed">17555845</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin J.H., Ma L., MacTavish D., Jhamandas J.H. Amyloid &#x3b2; protein modulates glutamate-mediated neurotransmission in the rat basal forebrain: Involvement of presynaptic neuronal nicotinic acetylcholine and metabotropic glutamate receptors. J. Neurosci. 2007;27:9262&#x2013;9269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673123</ArticleId><ArticleId IdType="pubmed">17728440</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito J.R., May P.C., O'Dell M.A., Taylor J.W., Parsadanian M., Cramer J.W., Audia J.E., Nissen J.S., Bales K.R., Paul S.M., et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-&#x3b2; metabolism and half-life. J. Neurosci. 2003;23:8844&#x2013;8853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740389</ArticleId><ArticleId IdType="pubmed">14523085</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleary J., Hittner J.M., Semotuk M., Mantyh P., O'Hare E. Beta-amyloid (1&#x2013;40) effects on behavior and memory. Brain Res. 1995;682:69&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">7552329</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleary J.P., Walsh D.M., Hofmeister J.J., Shankar G.M., Kuskowski M.A., Selkoe D.J., Ashe K.H. Natural oligomers of the amyloid-&#x3b2; protein specifically disrupt cognitive function. Nat. Neurosci. 2005;8:79&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15608634</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahlgren K.N., Manelli A.M., Stine W.B., Jr, Baker L.K., Krafft G.A., LaDu M.J. Oligomeric and fibrillar species of amyloid-&#x3b2; peptides differentially affect neuronal viability. J. Biol. Chem. 2002;277:32046&#x2013;32053.</Citation><ArticleIdList><ArticleId IdType="pubmed">12058030</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson G.R., Seabrook G.R., Zheng H., Smith D.W., Graham S., O'Dowd G., Bowery B.J., Boyce S., Trumbauer M.E., Chen H.Y., et al. Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the &#x3b2;-amyloid precursor protein. Neuroscience. 1999;90:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">10188929</ArticleId></ArticleIdList></Reference><Reference><Citation>Dineley K.T., Bell K.A., Bui D., Sweatt J.D. &#x3b2;-Amyloid peptide activates &#x3b1;7 nicotinic acetylcholine receptors expressed in Xenopus oocytes. J. Biol. Chem. 2002;277:25056&#x2013;25061.</Citation><ArticleIdList><ArticleId IdType="pubmed">11983690</ArticleId></ArticleIdList></Reference><Reference><Citation>Dougherty J.J., Wu J., Nichols R.A. &#x3b2;-Amyloid regulation of presynaptic nicotinic receptors in rat hippocampus and neocortex. J. Neurosci. 2003;23:6740&#x2013;6747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740736</ArticleId><ArticleId IdType="pubmed">12890766</ArticleId></ArticleIdList></Reference><Reference><Citation>Doyle E., Bruce M.T., Breen K.C., Smith D.C., Anderton B., Regan C.M. Intraventricular infusions of antibodies to amyloid-&#x3b2;&#x2013;protein precursor impair the acquisition of a passive avoidance response in the rat. Neurosci. Lett. 1990;115:97&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">2120637</ArticleId></ArticleIdList></Reference><Reference><Citation>Flood J.F., Morley J.E., Roberts E. Amnestic effects in mice of four synthetic peptides homologous to amyloid-&#x3b2; protein from patients with Alzheimer disease. Proc. Natl. Acad. Sci. 1991;88:3363&#x2013;3366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC51447</ArticleId><ArticleId IdType="pubmed">2014256</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu W., Jhamandas J.H. &#x3b2;-Amyloid peptide activates non-&#x3b1;7 nicotinic acetylcholine receptors in rat basal forebrain neurons. J. Neurophysiol. 2003;90:3130&#x2013;3136.</Citation><ArticleIdList><ArticleId IdType="pubmed">12890800</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Osta A., Tsokas P., Pollonini G., Landau E., Blitzer R., Alberini C.M. MuSK expressed in the brain mediates cholinergic responses, synaptic plasticity and memory formation. J. Neurosci. 2006;26:7919&#x2013;7932.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674217</ArticleId><ArticleId IdType="pubmed">16870737</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge S., Dani J.A. Nicotinic acetylcholine receptors at glutamate synapses facilitate long-term depression or potentiation. J. Neurosci. 2005;25:6084&#x2013;6091.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725070</ArticleId><ArticleId IdType="pubmed">15987938</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C. Take five&#x2014;BACE and the &#x3b3;-secretase quartet conduct Alzheimer's amyloid &#x3b2;-peptide generation. EMBO J. 2004;23:483&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1271800</ArticleId><ArticleId IdType="pubmed">14749724</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid &#x3b2;-peptide. Nat. Rev. Mol. Cell Biol. 2007;8:101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber G., Martin J.R., L&#xf6;ffler J., Moreau J.L. Involvement of amyloid precursor protein in memory formation in the rat: An indirect antibody approach. Brain Res. 1993;603:348&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">8461988</ArticleId></ArticleIdList></Reference><Reference><Citation>Irvine G.B., El-Agnaf O.M., Shankar G.M., Walsh D.M. Protein aggregation in the brain: The molecular basis for Alzheimer's and Parkinson's diseases. Mol. Med. 2008;14:451&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2274891</ArticleId><ArticleId IdType="pubmed">18368143</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson L.V., Leitner W.P., Rivest A.J., Staples M.K., Radeke M.J., Anderson D.H. The Alzheimer's A &#x3b2;-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc. Natl. Acad. Sci. 2002;99:11830&#x2013;11835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC129354</ArticleId><ArticleId IdType="pubmed">12189211</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F., Tomita T., Hsieh H., Seabrook G., Borchelt D., Iwatsubo T., Sisodia S., Malinow R. APP processing and synaptic function. Neuron. 2003;37:925&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K.S., Wen G.Y., Bancher C., Chen C.-M.J., Sapienza V.J., Hong H., Wisniewski H.M. Detection and quantitation of amyloid &#x3b2;-peptide with 2 monoclonal antibodies. Neurosci. Res. Commun. 1990;7:113&#x2013;122.</Citation></Reference><Reference><Citation>Laird F.M., Cai H., Savonenko A.V., Farah M.H., He K., Melnikova T., Wen H., Chiang H.C., Xu G., Koliatsos V.E., et al. BACE1, a major determinant of selective vulnerability of the brain to amyloid-&#x3b2; amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J. Neurosci. 2005;25:11693&#x2013;11709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2564291</ArticleId><ArticleId IdType="pubmed">16354928</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb P.W., Melton M.A., Yakel J.L. Inhibition of neuronal nicotinic acetylcholine receptor channels expressed in Xenopus oocytes by &#x3b2;-amyloid1-42 peptide. J. Mol. Neurosci. 2005;27:13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">16055943</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechner H.A., Squire L.R., Byrne J.H. 100 years of consolidation&#x2014;remembering M&#xfc;ller and Pilzecker. Learn. Mem. 1999;6:77&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">10327233</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo L., Tully T., White K. Human amyloid precursor protein ameliorates behavioral deficit of flies deleted for Appl gene. Neuron. 1992;9:595&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pubmed">1389179</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma H., Lesne S., Kotilinek L., Steidl-Nichols J.V., Sherman M., Younkin L., Younkin S., Forster C., Sergeant N., Delacourte A., et al. Involvement of &#x3b2;-site APP cleaving enzyme 1 (BACE1) in amyloid precursor protein-mediated enhancement of memory and activity-dependent synaptic plasticity. Proc. Natl. Acad. Sci. 2007;104:8167&#x2013;8172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1859992</ArticleId><ArticleId IdType="pubmed">17470798</ArticleId></ArticleIdList></Reference><Reference><Citation>Marksteiner J., Humpel C. &#x3b2;-Amyloid expression, release and extracellular deposition in aged rat brain slices. Mol. Psychiatry. 2008;13:939&#x2013;952.</Citation><ArticleIdList><ArticleId IdType="pubmed">17712316</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurice T., Lockhart B.P., Privat A. Amnesia induced in mice by centrally administered &#x3b2;-amyloid peptides involves cholinergic dysfunction. Brain Res. 1996;706:181&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">8822355</ArticleId></ArticleIdList></Reference><Reference><Citation>Meziane H., Dodart J.C., Mathis C., Little S., Clemens J., Paul S.M., Ungerer A. Memory-enhancing effects of secreted forms of the &#x3b2;-amyloid precursor protein in normal and amnestic mice. Proc. Natl. Acad. Sci. 1998;95:12683&#x2013;12688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22891</ArticleId><ArticleId IdType="pubmed">9770546</ArticleId></ArticleIdList></Reference><Reference><Citation>Mileusnic R., Lancashire C.L., Johnston A.N., Rose S.P. APP is required during an early phase of memory formation. Eur. J. Neurosci. 2000;12:4487&#x2013;4495.</Citation><ArticleIdList><ArticleId IdType="pubmed">11122359</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller U., Cristina N., Li Z.W., Wolfer D.P., Lipp H.P., Rulicke T., Brandner S., Aguzzi A., Weissmann C. Behavioral and anatomical deficits in mice homozygous for a modified &#x3b2;-amyloid precursor protein gene. Cell. 1994;79:755&#x2013;765.</Citation><ArticleIdList><ArticleId IdType="pubmed">8001115</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitsch R.M., Slack B.E., Wurtman R.J., Growdon J.H. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science. 1992;258:304&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pubmed">1411529</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno M., Yamamoto T., Watanabe S. Blockade of hippocampal nicotinic receptors impairs working memory but not reference memory in rats. Pharmacol. Biochem. Behav. 1993;45:89&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">8516378</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno M., Sametsky E.A., Younkin L.H., Oakley H., Younkin S.G., Citron M., Vassar R., Disterhoft J.F. BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron. 2004;41:27&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">14715132</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettit D.L., Shao Z., Yakel J.L. &#x3b2;-Amyloid1&#x2013;42 peptide directly modulates nicotinic receptors in the rat hippocampal slice. J. Neurosci. 2001;21:1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762461</ArticleId><ArticleId IdType="pubmed">11150356</ArticleId></ArticleIdList></Reference><Reference><Citation>Price D.L., Sisodia S.S. Mutant genes in familial Alzheimer's disease and transgenic models. Annu. Rev. Neurosci. 1998;21:479&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pubmed">9530504</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsden M., Nyborg A.C., Murphy M.P., Chang L., Stanczyk F.Z., Golde T.E., Pike C.J. Androgens modulate &#x3b2;-amyloid levels in male rat brain. J. Neurochem. 2003;87:1052&#x2013;1055.</Citation><ArticleIdList><ArticleId IdType="pubmed">14622134</ArticleId></ArticleIdList></Reference><Reference><Citation>Roesler R., Vianna M.R., de-Paris F., Rodrigues C., Sant'Anna M.K., Quevedo J., Ferreira M.B. NMDA receptor antagonism in the basolateral amygdala blocks enhancement of inhibitory avoidance learning in previously trained rats. Behav. Brain Res. 2000;112:99&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">10862940</ArticleId></ArticleIdList></Reference><Reference><Citation>Seabrook G.R., Smith D.W., Bowery B.J., Easter A., Reynolds T., Fitzjohn S.M., Morton R.A., Zheng H., Dawson G.R., Sirinathsinghji D.J., et al. Mechanisms contributing to the deficits in hippocampal synaptic plasticity in mice lacking amyloid precursor protein. Neuropharmacology. 1999;38:349&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pubmed">10219973</ArticleId></ArticleIdList></Reference><Reference><Citation>Senechal Y., Larmet Y., Dev K.K. Unraveling in vivo functions of amyloid precursor protein: Insights from knockout and knockdown studies. Neurodegener. Dis. 2006;3:134&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">16954700</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar G.M., Bloodgood B.L., Townsend M., Walsh D.M., Selkoe D.J., Sabatini B.L. Natural oligomers of the Alzheimer amyloid-&#x3b2; protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 2007;27:2866&#x2013;2875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672572</ArticleId><ArticleId IdType="pubmed">17360908</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar G.M., Li S., Mehta T.H., Garcia-Munoz A., Shepardson N.E., Smith I., Brett F.M., Farrell M.A., Rowan M.J., Lemere C.A., et al. Amyloid-&#x3b2; protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 2008;14:837&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Sipos E., Kurunczi A., Kasza A., Horvath J., Felszeghy K., Laroche S., Toldi J., Parducz A., Penke B., Penke Z. &#x3b2;-Amyloid pathology in the entorhinal cortex of rats induces memory deficits: Implications for Alzheimer's disease. Neuroscience. 2007;147:28&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">17499931</ArticleId></ArticleIdList></Reference><Reference><Citation>Squire L.R. Memory and the hippocampus: A synthesis from findings with rats, monkeys, and humans. Psychol. Rev. 1992;99:195&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">1594723</ArticleId></ArticleIdList></Reference><Reference><Citation>Taubenfeld S.M., Milekic M., Monti B., Alberini C.M. The consolidation of new but not reactivated memory requires hippocampal C/EBP&#x3b2;. Nat. Neurosci. 2001;4:813&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pubmed">11477427</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomiyama T., Nagata T., Shimada H., Teraoka R., Fukushima A., Kanemitsu H., Takuma H., Kuwano R., Imagawa M., Ataka S., et al. A new amyloid &#x3b2; variant favoring oligomerization in Alzheimer's-type dementia. Ann. Neurol. 2008;63:377&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pubmed">18300294</ArticleId></ArticleIdList></Reference><Reference><Citation>Tronel S., Milekic M., Alberini C.M. Linking new information to a reactivate memory requires consolidation but not reconsolidation mechanisms. PLoS Biol. 2005;3:e293. doi: 10.1371/journal.pbio.0030293.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.0030293</ArticleId><ArticleId IdType="pmc">PMC1188238</ArticleId><ArticleId IdType="pubmed">16104829</ArticleId></ArticleIdList></Reference><Reference><Citation>Vago D.R., Kesner R.P. Cholinergic modulation of Pavlovian fear conditioning in rats: Differential effects of intrahippocampal infusion of mecamylamine and methyllycaconitine. Neurobiol. Learn. Mem. 2007;87:441&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1951534</ArticleId><ArticleId IdType="pubmed">17178240</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh D.M., Selkoe D.J. A&#x3b2; oligomers&#x2014;a decade of discovery. J. Neurochem. 2007;101:1172&#x2013;1184.</Citation><ArticleIdList><ArticleId IdType="pubmed">17286590</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H.Y., Lee D.H., D'Andrea M.R., Peterson P.A., Shank R.P., Reitz A.B. &#x3b2;-Amyloid1&#x2013;42 binds to &#x3b1;7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J. Biol. Chem. 2000a;275:5626&#x2013;5632.</Citation><ArticleIdList><ArticleId IdType="pubmed">10681545</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H.Y., Lee D.H., Davis C.B., Shank R.P. Amyloid peptide A&#x3b2;(1&#x2013;42) binds selectively and with picomolar affinity to &#x3b1;7 nicotinic acetylcholine receptors. J. Neurochem. 2000b;75:1155&#x2013;1161.</Citation><ArticleIdList><ArticleId IdType="pubmed">10936198</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J., Kuo Y.P., George A.A., Xu L., Hu J., Lukas R.J. &#x3b2;-Amyloid directly inhibits human &#x3b1;4&#x3b2;2-nicotinic acetylcholine receptors heterologously expressed in human SH-EP1 cells. J. Biol. Chem. 2004;279:37842&#x2013;37851.</Citation><ArticleIdList><ArticleId IdType="pubmed">15234980</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu H., Saura C.A., Choi S.Y., Sun L.D., Yang X., Handler M., Kawarabayashi T., Younkin L., Fedeles B., Wilson M.A., et al. APP processing and synaptic plasticity in presenilin-1 conditional knockout mice. Neuron. 2001;31:713&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">11567612</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19321417</PMID><DateCompleted><Year>2009</Year><Month>05</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>106</Volume><Issue>14</Issue><PubDate><Year>2009</Year><Month>Apr</Month><Day>07</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Disruption of fast axonal transport is a pathogenic mechanism for intraneuronal amyloid beta.</ArticleTitle><Pagination><StartPage>5907</StartPage><EndPage>5912</EndPage><MedlinePgn>5907-12</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0901229106</ELocationID><Abstract><AbstractText>The pathological mechanism by which Abeta causes neuronal dysfunction and death remains largely unknown. Deficiencies in fast axonal transport (FAT) were suggested to play a crucial role in neuronal dysfunction and loss for a diverse set of dying back neuropathologies including Alzheimer's disease (AD), but the molecular basis for pathological changes in FAT were undetermined. Recent findings indicate that soluble intracellular oligomeric Abeta (oAbeta) species may play a critical role in AD pathology. Real-time analysis of vesicle mobility in isolated axoplasms perfused with oAbeta showed bidirectional axonal transport inhibition as a consequence of endogenous casein kinase 2 (CK2) activation. Conversely, neither unaggregated amyloid beta nor fibrillar amyloid beta affected FAT. Inhibition of FAT by oAbeta was prevented by two specific pharmacological inhibitors of CK2, as well as by competition with a CK2 substrate peptide. Furthermore, perfusion of axoplasms with active CK2 mimics the inhibitory effects of oAbeta on FAT. Both oAbeta and CK2 treatment of axoplasm led to increased phosphorylation of kinesin-1 light chains and subsequent release of kinesin from its cargoes. Therefore pharmacological modulation of CK2 activity may represent a promising target for therapeutic intervention in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pigino</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Cell Biology, University of Illinois, Chicago, IL 60612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morfini</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Atagi</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Deshpande</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Jungbauer</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>LaDu</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Busciglio</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Brady</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS043408</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS41170</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS023320</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS43408</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG030128</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS041170</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS023868</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS23320</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>03</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D047390">Casein Kinase II</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.4</RegistryNumber><NameOfSubstance UI="D016547">Kinesins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001370" MajorTopicYN="N">Axonal Transport</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047390" MajorTopicYN="N">Casein Kinase II</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016547" MajorTopicYN="N">Kinesins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055503" MajorTopicYN="N">Protein Multimerization</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>3</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>3</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>5</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>10</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19321417</ArticleId><ArticleId IdType="pmc">PMC2667037</ArticleId><ArticleId IdType="doi">10.1073/pnas.0901229106</ArticleId><ArticleId IdType="pii">0901229106</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Maeda S, et al. Increased levels of granular tau oligomers: An early sign of brain aging and Alzheimer's disease. Neurosci Res. 2006;54:197&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">16406150</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Davies P. Dementia of the Alzheimer type. Annu Rev Neurosci. 1980;3:77&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">6251745</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Terry RD, DeTeresa RM, Hansen LA. Immunohistochemical quantification of the synapse-related protein synaptophysin in Alzheimer disease. Neurosci Lett. 1989;103:234&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">2505201</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy JA, Higgins GA. Alzheimer's disease: The amyloid cascade hypothesis. Science. 1992;256:184&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, et al. Diffusible, nonfibrillar ligands derived from Abeta1&#x2013;42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA. 1998;95:6448&#x2013;6453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahlgren KN, et al. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem. 2002;277:32046&#x2013;32053.</Citation><ArticleIdList><ArticleId IdType="pubmed">12058030</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshpande A, Mina E, Glabe C, Busciglio J. Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J Neurosci. 2006;26:6011&#x2013;6018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675207</ArticleId><ArticleId IdType="pubmed">16738244</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor PN, et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci. 2007;27:796&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672917</ArticleId><ArticleId IdType="pubmed">17251419</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesne S, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006;440:352&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">16541076</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleary JP, et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci. 2005;8:79&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15608634</ArticleId></ArticleIdList></Reference><Reference><Citation>Wertkin AM, et al. Human neurons derived from a teratocarcinoma cell line express solely the 695-amino acid amyloid precursor protein and produce intracellular beta-amyloid or A4 peptides. Proc Natl Acad Sci USA. 1993;90:9513&#x2013;9517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47599</ArticleId><ArticleId IdType="pubmed">8415732</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouras GK, et al. Intraneuronal Abeta42 accumulation in human brain. Am J Pathol. 2000;156:15&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1868613</ArticleId><ArticleId IdType="pubmed">10623648</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi RH, et al. Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain. J Neurosci. 2004;24:3592&#x2013;3599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729733</ArticleId><ArticleId IdType="pubmed">15071107</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi RH, et al. Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol. 2002;161:1869&#x2013;1879.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850783</ArticleId><ArticleId IdType="pubmed">12414533</ArticleId></ArticleIdList></Reference><Reference><Citation>Gyure KA, Durham R, Stewart WF, Smialek JE, Troncoso JC. Intraneuronal abeta-amyloid precedes development of amyloid plaques in Down syndrome. Arch Pathol Lab Med. 2001;125:489&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pubmed">11260621</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM, Tinkle BT, Bieberich CJ, Haudenschild CC, Jay G. The Alzheimer's A beta peptide induces neurodegeneration and apoptotic cell death in transgenic mice. Nat Genet. 1995;9:21&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">7704018</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowther DC, et al. Intraneuronal Abeta, non-amyloid aggregates and neurodegeneration in a Drosophila model of Alzheimer's disease. Neuroscience. 2005;132:123&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">15780472</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, McLaughlin R, Goodyer C, LeBlanc A. Selective cytotoxicity of intracellular amyloid beta peptide1&#x2013;42 through p53 and Bax in cultured primary human neurons. J Cell Biol. 2002;156:519&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2173346</ArticleId><ArticleId IdType="pubmed">11815632</ArticleId></ArticleIdList></Reference><Reference><Citation>Joachim CL, Mori H, Selkoe DJ. Amyloid beta-protein deposition in tissues other than brain in Alzheimer's disease. Nature. 1989;341:226&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pubmed">2528696</ArticleId></ArticleIdList></Reference><Reference><Citation>Hafezparast M, et al. Mutations in dynein link motor neuron degeneration to defects in retrograde transport. Science. 2003;300:808&#x2013;812.</Citation><ArticleIdList><ArticleId IdType="pubmed">12730604</ArticleId></ArticleIdList></Reference><Reference><Citation>Reid E, et al. A Kinesin Heavy Chain (KIF5A) Mutation in Hereditary Spastic Paraplegia (SPG10) Am J Hum Genet. 2002;71:1189&#x2013;1194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC385095</ArticleId><ArticleId IdType="pubmed">12355402</ArticleId></ArticleIdList></Reference><Reference><Citation>Morfini G, Szebenyi G, Elluru R, Ratner N, Brady ST. Glycogen synthase kinase 3 phosphorylates kinesin light chains and negatively regulates kinesin-based motility. EMBO J. 2002;23:281&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125832</ArticleId><ArticleId IdType="pubmed">11823421</ArticleId></ArticleIdList></Reference><Reference><Citation>Pigino G, Morfini G, Mattson MP, Brady ST, Busciglio J. Alzheimer's presenilin 1 mutations impair kinesin-based axonal transport. J Neurosci. 2003;23:4499&#x2013;4508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740780</ArticleId><ArticleId IdType="pubmed">12805290</ArticleId></ArticleIdList></Reference><Reference><Citation>Morfini G, et al. JNK mediates pathogenic effects of polyglutamine-expanded androgen receptor on fast axonal transport. Nat Neurosci. 2006;9:907&#x2013;916.</Citation><ArticleIdList><ArticleId IdType="pubmed">16751763</ArticleId></ArticleIdList></Reference><Reference><Citation>Szebenyi G, et al. Neuropathogenic forms of Huntingtin and androgen receptor inhibit fast axonal transport. Neuron. 2003;40:41&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">14527432</ArticleId></ArticleIdList></Reference><Reference><Citation>Morfini G, et al. 1-Methyl-4-phenylpyridinium affects fast axonal transport by activation of caspase and protein kinase C. Proc Natl Acad Sci USA. 2007;104:2442&#x2013;2447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1892945</ArticleId><ArticleId IdType="pubmed">17287338</ArticleId></ArticleIdList></Reference><Reference><Citation>Stine WB, Jr, Dahlgren KN, Krafft GA, LaDu MJ. In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J Biol Chem. 2003;278:11612&#x2013;11622.</Citation><ArticleIdList><ArticleId IdType="pubmed">12499373</ArticleId></ArticleIdList></Reference><Reference><Citation>Morfini G, Szebenyi G, Richards B, Brady ST. Regulation of kinesin: Implications for neuronal development. Dev Neurosci. 2001;23:364&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">11756752</ArticleId></ArticleIdList></Reference><Reference><Citation>Morfini G, Pigino G, Beffert U, Busciglio J, Brady ST. Fast axonal transport misregulation and Alzheimer's disease. Neuromol Med. 2002;2:89&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">12428805</ArticleId></ArticleIdList></Reference><Reference><Citation>Pei JJ, et al. Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J Neuropathol Exp Neurol. 1997;56:70&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">8990130</ArticleId></ArticleIdList></Reference><Reference><Citation>Pei JJ, et al. Localization of active forms of C-jun kinase (JNK) and p38 kinase in Alzheimer's disease brains at different stages of neurofibrillary degeneration. J Alzheimers Dis. 2001;3:41&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">12214071</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MS, Tsai LH. Cdk5: One of the links between senile plaques and neurofibrillary tangles? J Alzheimers Dis. 2003;5:127&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">12719630</ArticleId></ArticleIdList></Reference><Reference><Citation>Morfini G, et al. A novel CDK5-dependent pathway for regulating GSK3 activity and kinesin-driven motility in neurons. EMBO J. 2004;23:2235&#x2013;2245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC419914</ArticleId><ArticleId IdType="pubmed">15152189</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, et al. Casein kinase II alteration precedes tau accumulation in tangle formation. Am J Pathol. 1992;140:263&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1886426</ArticleId><ArticleId IdType="pubmed">1739121</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauhan A, Chauhan VP, Murakami N, Brockerhoff H, Wisniewski HM. Amyloid beta-protein stimulates casein kinase I and casein kinase II activities. Brain Res. 1993;629:47&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">8287280</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagano MA, et al. 2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: A novel powerful and selective inhibitor of protein kinase CK2. Biochem Biophys Res Commun. 2004;321:1040&#x2013;1044.</Citation><ArticleIdList><ArticleId IdType="pubmed">15358133</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagano MA, et al. Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors. Chembiochem. 2007;8:129&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">17133643</ArticleId></ArticleIdList></Reference><Reference><Citation>Stenoien DS, Brady ST. Immunochemical analysis of kinesin light chain function. Molec Biol Cell. 1997;8:675&#x2013;689.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC276118</ArticleId><ArticleId IdType="pubmed">9247647</ArticleId></ArticleIdList></Reference><Reference><Citation>Donelan MJ, et al. Ca2+-dependent dephosphorylation of kinesin heavy chain on beta-granules in pancreatic beta-cells. Implications for regulated beta-granule transport and insulin exocytosis. J Biol Chem. 2002;277:24232&#x2013;24242.</Citation><ArticleIdList><ArticleId IdType="pubmed">11978799</ArticleId></ArticleIdList></Reference><Reference><Citation>Lapointe NE, et al. The amino terminus of tau inhibits kinesin-dependent axonal transport: Implications for filament toxicity. J Neurosci Res. 2009;87:440&#x2013;451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2739042</ArticleId><ArticleId IdType="pubmed">18798283</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno H, et al. Nerve growth factor acutely reduces chemical transmission by means of postsynaptic TrkA-like receptors in squid giant synapse. Proc Natl Acad Sci USA. 1998;95:14997&#x2013;15002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24564</ArticleId><ArticleId IdType="pubmed">9844004</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein WL. Abeta toxicity in Alzheimer's disease: Globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int. 2002;41:345&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">12176077</ArticleId></ArticleIdList></Reference><Reference><Citation>Busciglio J, et al. Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome. Neuron. 2002;33:677&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">11879646</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci. 2007;8:499&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pubmed">17551515</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002;298:789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Wishart TM, Parson SH, Gillingwater TH. Synaptic vulnerability in neurodegenerative disease. J Neuropathol Exp Neurol. 2006;65:733&#x2013;739.</Citation><ArticleIdList><ArticleId IdType="pubmed">16896307</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleman M. Axon degeneration mechanisms: Commonality amid diversity. Nat Rev Neurosci. 2005;6:889&#x2013;898.</Citation><ArticleIdList><ArticleId IdType="pubmed">16224497</ArticleId></ArticleIdList></Reference><Reference><Citation>Meggio F, Pinna LA. One-thousand-and-one substrates of protein kinase CK2? FASEB J. 2003;17:349&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">12631575</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno HH, et al. Synaptic transmission block by pre-synaptic injection of oligomeric amyloid beta. Proc Natl Acad Sci USA. 2009 10.1073.0900944106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2659170</ArticleId><ArticleId IdType="pubmed">19304802</ArticleId></ArticleIdList></Reference><Reference><Citation>Shata A, Saisu H, Odani S, Abe T. Phosphorylated synaphin/complexin found in the brain exhibits enhanced SNARE complex binding. Biochem Biophys Res Commun. 2007;354:808&#x2013;813.</Citation><ArticleIdList><ArticleId IdType="pubmed">17266930</ArticleId></ArticleIdList></Reference><Reference><Citation>Deboer SR, et al. Conventional kinesin holoenzymes are composed of heavy and light chain homodimers. Biochemistry. 2008;47:4535&#x2013;4543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2644488</ArticleId><ArticleId IdType="pubmed">18361505</ArticleId></ArticleIdList></Reference><Reference><Citation>Pigino G, Pelsman A, Mori H, Busciglio J. Presenilin-1 mutations reduce cytoskeletal association, deregulate neurite growth, and potentiate neuronal dystrophy and tau phosphorylation. J Neurosci. 2001;21:834&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762317</ArticleId><ArticleId IdType="pubmed">11157069</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady ST, Lasek RJ, Allen RD. Video microscopy of fast axonal transport in isolated axoplasm: A new model for study of molecular mechanisms. Cell Motility. 1985;5:81&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">2580632</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady ST, Richards BW, Leopold PL. Assay of vesicle motility in squid axoplasm. Meth Cell Biol. 1993;39:191&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">7504159</ArticleId></ArticleIdList></Reference><Reference><Citation>Morfini G, Pigino G, Brady ST. Approaches to kinesin-1 phosphorylation. In: Sperry A, editor. Molecular Motors: Methods and Protocols, Methods in Molecular Biology. Vol 392. Clifton, NJ: Humana Press; 2006. pp. 51&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">17951710</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19321751</PMID><DateCompleted><Year>2009</Year><Month>05</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>106</Volume><Issue>14</Issue><PubDate><Year>2009</Year><Month>Apr</Month><Day>07</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Recruitment of adult-generated neurons into functional hippocampal networks contributes to updating and strengthening of spatial memory.</ArticleTitle><Pagination><StartPage>5919</StartPage><EndPage>5924</EndPage><MedlinePgn>5919-24</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0811054106</ELocationID><Abstract><AbstractText>The dentate gyrus (DG), a hippocampal subregion, continuously produces new neurons in the adult mammalian brain that become functionally integrated into existing neural circuits. To what extent this form of plasticity contributes to memory functions remains to be elucidated. Using mapping of activity-dependent gene expression, we visualized in mice injected with the birthdating marker 5-bromo-2'-deoxyuridine the recruitment of new neurons in a set of controlled water maze procedures that engage specific spatial memory processes and require hippocampal-cortical networks. Here, we provide new evidence that adult-generated hippocampal neurons make a specific but differential contribution to the processing of remote spatial memories. First, we show that new neurons in the DG are recruited into neuronal networks that support retrieval of remote spatial memory and that their activation is situation-specific. We further reveal that once selected, new hippocampal neurons are durably incorporated into memory circuits, and also that their recruitment into hippocampal networks contributes predominantly to the updating and strengthening of a previously encoded memory. We find that initial spatial training during a critical period, when new neurons are more receptive to surrounding neuronal activity, favors their subsequent recruitment upon remote memory retrieval. We therefore hypothesize that new neurons activated during this critical period become tagged so that once mature, they are preferentially recruited into hippocampal networks underlying remote spatial memory representation when encountering a similar experience.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Trouche</LastName><ForeName>St&#xe9;phanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Toulouse, Universit&#xe9; Paul Sabatier, Centre de Recherches sur la Cognition Animale, 118 Route de Narbonne, F-31062 Toulouse Cedex 9, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bontempi</LastName><ForeName>Bruno</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Roullet</LastName><ForeName>Pascal</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Rampon</LastName><ForeName>Claire</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>03</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>G34N38R2N1</RegistryNumber><NameOfSubstance UI="D001973">Bromodeoxyuridine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001973" MajorTopicYN="N">Bromodeoxyuridine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018891" MajorTopicYN="N">Dentate Gyrus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="Y">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="Y">Neuronal Plasticity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013028" MajorTopicYN="N">Space Perception</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>3</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>3</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>5</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>10</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19321751</ArticleId><ArticleId IdType="pmc">PMC2667087</ArticleId><ArticleId IdType="doi">10.1073/pnas.0811054106</ArticleId><ArticleId IdType="pii">0811054106</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shors TJ, et al. Neurogenesis in the adult is involved in the formation of trace memories. Nature. 2001;410:372&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">11268214</ArticleId></ArticleIdList></Reference><Reference><Citation>Winocur G, Wojtowicz JM, Sekeres M, Snyder JS, Wang S. Inhibition of neurogenesis interferes with hippocampus-dependent memory function. Hippocampus. 2006;16:296&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">16411241</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder JS, Hong NS, McDonald RJ, Wojtowicz JM. A role for adult neurogenesis in spatial long-term memory. Neuroscience. 2005;130:843&#x2013;852.</Citation><ArticleIdList><ArticleId IdType="pubmed">15652983</ArticleId></ArticleIdList></Reference><Reference><Citation>Kee N, Teixeira CM, Wang AH, Frankland PW. Preferential incorporation of adult-generated granule cells into spatial memory networks in the dentate gyrus. Nat Neurosci. 2007;10:355&#x2013;362.</Citation><ArticleIdList><ArticleId IdType="pubmed">17277773</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuner B, et al. Learning enhances the survival of new neurons beyond the time when the hippocampus is required for memory. J Neurosci. 2004;24:7477&#x2013;7481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3279157</ArticleId><ArticleId IdType="pubmed">15329394</ArticleId></ArticleIdList></Reference><Reference><Citation>Tashiro A, Makino H, Gage FH. Experience-specific functional modification of the dentate gyrus through adult neurogenesis: A critical period during an immature stage. J Neurosci. 2007;27:3252&#x2013;3259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672473</ArticleId><ArticleId IdType="pubmed">17376985</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez-Amaya V, Marrone DF, Gage FH, Worley PF, Barnes CA. Integration of new neurons into functional neural networks. J Neurosci. 2006;26:12237&#x2013;12241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675440</ArticleId><ArticleId IdType="pubmed">17122048</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge S, Yang CH, Hsu KS, Ming GL, Song H. A critical period for enhanced synaptic plasticity in newly generated neurons of the adult brain. Neuron. 2007;54:559&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2040308</ArticleId><ArticleId IdType="pubmed">17521569</ArticleId></ArticleIdList></Reference><Reference><Citation>Dayer AG, Ford AA, Cleaver KM, Yassaee M, Cameron HA. Short-term and long-term survival of new neurons in the rat dentate gyrus. J Comp Neurology. 2003;460:563&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">12717714</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruel-Jungerman E, Davis S, Rampon C, Laroche S. Long-term potentiation enhances neurogenesis in the adult dentate gyrus. J Neurosci. 2006;26:5888&#x2013;5893.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675234</ArticleId><ArticleId IdType="pubmed">16738230</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao C, Teng EM, Summers RG, Jr, Ming GL, Gage FH. Distinct morphological stages of dentate granule neuron maturation in the adult mouse hippocampus. J Neurosci. 2006;26:3&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674324</ArticleId><ArticleId IdType="pubmed">16399667</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould E, Beylin A, Tanapat P, Reeves A, Shors TJ. Learning enhances adult neurogenesis in the hippocampal formation. Nat Neurosci. 1999;2:260&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195219</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupret D, et al. Spatial learning depends on both the addition and removal of new hippocampal neurons. PLoS Biol. 2007;5:e214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1939885</ArticleId><ArticleId IdType="pubmed">17683201</ArticleId></ArticleIdList></Reference><Reference><Citation>Epp JR, Spritzer MD, Galea LA. Hippocampus-dependent learning promotes survival of new neurons in the dentate gyrus at a specific time during cell maturation. Neuroscience. 2007;149:273&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">17900815</ArticleId></ArticleIdList></Reference><Reference><Citation>Vann SD, Brown MW, Erichsen JT, Aggleton JP. Fos imaging reveals differential patterns of hippocampal and parahippocampal subfield activation in rats in response to different spatial memory tests. J Neurosci. 2000;20:2711&#x2013;2718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772240</ArticleId><ArticleId IdType="pubmed">10729352</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall J, Thomas KL, Everitt BJ. Cellular imaging of zif268 expression in the hippocampus and amygdala during contextual and cued fear memory retrieval: Selective activation of hippocampal CA1 neurons during the recall of contextual memories. J Neurosci. 2001;21:2186&#x2013;2193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762622</ArticleId><ArticleId IdType="pubmed">11245703</ArticleId></ArticleIdList></Reference><Reference><Citation>Teixeira CM, Pomedli SR, Maei HR, Kee N, Frankland PW. Involvement of the anterior cingulate cortex in the expression of remote spatial memory. J Neurosci. 2006;26:7555&#x2013;7564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674278</ArticleId><ArticleId IdType="pubmed">16855083</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris RG, et al. Memory reconsolidation: Sensitivity of spatial memory to inhibition of protein synthesis in dorsal hippocampus during encoding and retrieval. Neuron. 2006;50:479&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">16675401</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki A, et al. Memory reconsolidation and extinction have distinct temporal and biochemical signatures. J Neurosci. 2004;24:4787&#x2013;4795.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729467</ArticleId><ArticleId IdType="pubmed">15152039</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez J, Vasconcelos AP, Cassel JC. Differential sensitivity of recent vs. remote memory traces to extinction in a water-maze task in rats. Neurobiol Learn Mem. 2008;90:460&#x2013;466.</Citation><ArticleIdList><ArticleId IdType="pubmed">18573346</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark RE, Broadbent NJ, Squire LR. The hippocampus and spatial memory: Findings with a novel modification of the water maze. J Neurosci. 2007;27:6647&#x2013;6654.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2553679</ArticleId><ArticleId IdType="pubmed">17581951</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutherland RJ, et al. Retrograde amnesia after hippocampal damage: recent vs. remote memories in two tasks. Hippocampus. 2001;11:27&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">11261770</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark RE, Broadbent NJ, Squire LR. Hippocampus and remote spatial memory in rats. Hippocampus. 2005;15:260&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2754168</ArticleId><ArticleId IdType="pubmed">15523608</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisti HM, Glass AL, Shors TJ. Neurogenesis and the spacing effect: learning over time enhances memory and the survival of new neurons. Learn Mem. 2007;14:368&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1876761</ArticleId><ArticleId IdType="pubmed">17522028</ArticleId></ArticleIdList></Reference><Reference><Citation>Lisman JE, Otmakhova NA. Storage, recall, and novelty detection of sequences by the hippocampus: Elaborating on the SOCRATIC model to account for normal and aberrant effects of dopamine. Hippocampus. 2001;11:551&#x2013;568.</Citation><ArticleIdList><ArticleId IdType="pubmed">11732708</ArticleId></ArticleIdList></Reference><Reference><Citation>McHugh TJ, et al. Dentate gyrus NMDA receptors mediate rapid pattern separation in the hippocampal network. Science. 2007;317:94&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">17556551</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Keefe J, Dostrovsky J. The hippocampus as a spatial map. Preliminary evidence from unit activity in the freely-moving rat. Brain Res. 1971;34:171&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">5124915</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung MW, Wiener SI, McNaughton BL. Comparison of spatial firing characteristics of units in dorsal and ventral hippocampus of the rat. J Neurosci. 1994;14:7347&#x2013;7356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6576902</ArticleId><ArticleId IdType="pubmed">7996180</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt-Hieber C, Jonas P, Bischofberger J. Enhanced synaptic plasticity in newly generated granule cells of the adult hippocampus. Nature. 2004;429:184&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">15107864</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito MS, et al. Neuronal differentiation in the adult hippocampus recapitulates embryonic development. J Neurosci. 2005;25:10074&#x2013;10086.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725804</ArticleId><ArticleId IdType="pubmed">16267214</ArticleId></ArticleIdList></Reference><Reference><Citation>Hastings NB, Gould E. Rapid extension of axons into the CA3 region by adult-generated granule cells. J Comp Neurol. 1999;413:146&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pubmed">10464376</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanfield BB, Trice JE. Evidence that granule cells generated in the dentate gyrus of adult rats extend axonal projections. Exp Brain Res. 1988;72:399&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">2465172</ArticleId></ArticleIdList></Reference><Reference><Citation>Markakis EA, Gage FH. Adult-generated neurons in the dentate gyrus send axonal projections to field CA3 and are surrounded by synaptic vesicles. J Comp Neurol. 1999;406:449&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pubmed">10205022</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Scott BW, Wojtowicz JM. Heterogenous properties of dentate granule neurons in the adult rat. J Neurobiol. 2000;42:248&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pubmed">10640331</ArticleId></ArticleIdList></Reference><Reference><Citation>van Praag H, et al. Functional neurogenesis in the adult hippocampus. Nature. 2002;415:1030&#x2013;1034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9284568</ArticleId><ArticleId IdType="pubmed">11875571</ArticleId></ArticleIdList></Reference><Reference><Citation>Jessberger S, Kempermann G. Adult-born hippocampal neurons mature into activity-dependent responsiveness. Eur J Neurosci. 2003;18:2707&#x2013;2712.</Citation><ArticleIdList><ArticleId IdType="pubmed">14656319</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin KC, Kosik KS. Synaptic tagging&#x2013;who's it? Nat Rev. 2002;3:813&#x2013;820.</Citation><ArticleIdList><ArticleId IdType="pubmed">12360325</ArticleId></ArticleIdList></Reference><Reference><Citation>Frankland PW, Bontempi B. The organization of recent and remote memories. Nat Rev. 2005;6:119&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">15685217</ArticleId></ArticleIdList></Reference><Reference><Citation>Tse D, et al. Schemas and memory consolidation. Science. 2007;316:76&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">17412951</ArticleId></ArticleIdList></Reference><Reference><Citation>Aimone JB, Wiles J, Gage FH. Potential role for adult neurogenesis in the encoding of time in new memories. Nat Neurosci. 2006;9:723&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pubmed">16732202</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19328456</PMID><DateCompleted><Year>2009</Year><Month>06</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1552-5279</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>2</Issue><PubDate><Year>2009</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</Title><ISOAbbreviation>Alzheimers Dement</ISOAbbreviation></Journal><ArticleTitle>Early risk assessment for Alzheimer's disease.</ArticleTitle><Pagination><StartPage>182</StartPage><EndPage>196</EndPage><MedlinePgn>182-96</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jalz.2009.01.019</ELocationID><Abstract><AbstractText>The purpose of the Alzheimer's Association Research Roundtable meeting was to discuss the potential of finding diagnostic tools to determine the earliest risk factors for Alzheimer's disease (AD). Currently, drugs approved for AD address symptoms which are generally manifest after the disease is already well-established, but there is a growing pipeline of drugs that may alter the underlying pathology and therefore slow or halt progression of the disease. As these drugs become available, it will become increasingly imperative that those at risk for AD be detected and possibly treated early, especially given recent indications that the disease process may start decades before the first clinical symptoms are recognized. Early detection must go hand-in-hand with qualified tools to determine the efficacy of drugs in people who may be asymptomatic or who have only very mild symptoms of the disease. Devising strategies and screening tools to identify and monitor those at risk in order to perform "prevention" trials is seen by many as a top public-health priority, made all the more urgent by an impending growth in the elderly population worldwide.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carrillo</LastName><ForeName>Maria C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Alzheimer's Association, Chicago, IL, USA. Maria.Carrillo@alz.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blackwell</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Hampel</LastName><ForeName>Harald</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Lindborg</LastName><ForeName>Johan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Schenk</LastName><ForeName>Dale</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Sevigny</LastName><ForeName>Jeffrey J</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Ferris</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Craft</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Timothy</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Klunk</LastName><ForeName>William</ForeName><Initials>W</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG008051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement</MedlineTA><NlmUniqueID>101231978</NlmUniqueID><ISSNLinking>1552-5260</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="N">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008403" MajorTopicYN="N">Mass Screening</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040242" MajorTopicYN="Y">Risk Reduction Behavior</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>126</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>1</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>1</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>3</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>3</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>7</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19328456</ArticleId><ArticleId IdType="doi">10.1016/j.jalz.2009.01.019</ArticleId><ArticleId IdType="pii">S1552-5260(09)00016-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19329226</PMID><DateCompleted><Year>2011</Year><Month>03</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-1497</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>2</Issue><PubDate><Year>2011</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Neurobiology of aging</Title><ISOAbbreviation>Neurobiol Aging</ISOAbbreviation></Journal><ArticleTitle>PIB binding in aged primate brain: enrichment of high-affinity sites in humans with Alzheimer's disease.</ArticleTitle><Pagination><StartPage>223</StartPage><EndPage>234</EndPage><MedlinePgn>223-34</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neurobiolaging.2009.02.011</ELocationID><Abstract><AbstractText>Aged nonhuman primates accumulate large amounts of human-sequence amyloid &#x3b2; (A&#x3b2;) in the brain, yet they do not manifest the full phenotype of Alzheimer's disease (AD). To assess the biophysical properties of A&#x3b2; that might govern its pathogenic potential in humans and nonhuman primates, we incubated the benzothiazole imaging agent Pittsburgh Compound B (PIB) with cortical tissue homogenates from normal aged humans, humans with AD, and from aged squirrel monkeys, rhesus monkeys, and chimpanzees with cerebral A&#x3b2;-amyloidosis. Relative to humans with AD, high-affinity PIB binding is markedly reduced in cortical extracts from aged nonhuman primates containing levels of insoluble A&#x3b2; similar to those in AD. The high-affinity binding of PIB may be selective for a pathologic, human-specific conformation of multimeric A&#x3b2;, and thus could be a useful experimental tool for clarifying the unique predisposition of humans to Alzheimer's disease.</AbstractText><CopyrightInformation>Copyright &#xa9; 2009 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>Rebecca F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>Division of Neuroscience, Yerkes National Primate Research Center, Emory University, Atlanta, GA 30322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Lary C</ForeName><Initials>LC</Initials></Author><Author ValidYN="Y"><LastName>Levine</LastName><ForeName>Harry</ForeName><Initials>H</Initials><Suffix>3rd</Suffix></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01AG026423</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P51 RR000165</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026423</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RR-00165</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>03</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Aging</MedlineTA><NlmUniqueID>8100437</NlmUniqueID><ISSNLinking>0197-4580</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>10028-17-8</RegistryNumber><NameOfSubstance UI="D014316">Tritium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001345" MajorTopicYN="N">Autoradiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002533" MajorTopicYN="N">Cerebral Angiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016014" MajorTopicYN="N">Linear Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011323" MajorTopicYN="N">Primates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014316" MajorTopicYN="N">Tritium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>2</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>2</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>3</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>3</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19329226</ArticleId><ArticleId IdType="mid">NIHMS97467</ArticleId><ArticleId IdType="pmc">PMC2891164</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2009.02.011</ArticleId><ArticleId IdType="pii">S0197-4580(09)00046-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arriagada PV, Marzloff K, Hyman BT. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer&#x2019;s disease. Neurology. 1992;42:1681&#x2013;1688.</Citation><ArticleIdList><ArticleId IdType="pubmed">1307688</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacskai BJ, Frosch MP, Freeman SH, Raymond SB, Augustinack JC, Johnson KA, Irizarry MC, Klunk WE, Mathis CA, Dekosky ST, Greenberg SM, Hyman BT, Growdon JH. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol. 2007;64:431&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">17353389</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, Wilson RS. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66:1837&#x2013;1844.</Citation><ArticleIdList><ArticleId IdType="pubmed">16801647</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien P, Weissman JS, DePace AH. Emerging principles of conformation-based prion inheritance. Annu Rev Biochem. 2004;73:617&#x2013;656.</Citation><ArticleIdList><ArticleId IdType="pubmed">15189155</ArticleId></ArticleIdList></Reference><Reference><Citation>Collinge J, Clarke AR. A general model of prion strains and their pathogenicity. Science. 2007;318:930&#x2013;936.</Citation><ArticleIdList><ArticleId IdType="pubmed">17991853</ArticleId></ArticleIdList></Reference><Reference><Citation>Crystal H, Dickson D, Fuld P, Masur D, Scott R, Mehler M, Masdeu J, Kawas C, Aronson M, Wolfson L. Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer&#x2019;s disease. Neurology. 1988;38:1682&#x2013;1687.</Citation><ArticleIdList><ArticleId IdType="pubmed">3185902</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL. Alzheimer&#x2019;s disease. N Engl J Med. 2004;351:56&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">15229308</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodart JC, May P. Overview on rodent models of Alzheimer&#x2019;s disease. Curr Protoc Neurosci. 2005 Chapter 9, Unit 9.22.</Citation><ArticleIdList><ArticleId IdType="pubmed">18428631</ArticleId></ArticleIdList></Reference><Reference><Citation>Elfenbein HA, Rosen RF, Stephens SL, Switzer RC, Smith Y, Pare J, Mehta PD, Warzok R, Walker LC. Cerebral beta-amyloid angiopathy in aged squirrel monkeys. Histol Histopathol. 2007;22:155&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">17149688</ArticleId></ArticleIdList></Reference><Reference><Citation>Fodero-Tavoletti MT, Smith DP, McLean CA, Adlard PA, Barnham KJ, Foster LE, Leone L, Perez K, Cortes M, Culvenor JG, Li Q-X, Laughton KM, Rowe CC, Masters CL, Cappai R, Villemagne VL. In vitro characterization of Pittsburgh Compound-B binding to Lewy bodies. J Neurosci. 2007;27:10365&#x2013;10371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673163</ArticleId><ArticleId IdType="pubmed">17898208</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannakopoulos P, Gold G, Kovari E, von Gunten A, Imhof A, Bouras C, Hof PR. Assessing the cognitive impact of Alzheimer disease pathology and vascular burden in the aging brain: the Geneva experience. Acta Neuropathol (Berl) 2007;113:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">17036244</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa K, Yamaguchi I, Omata S, Gejyo F, Naiki H. Interaction between A beta(1&#x2013;42) and A beta(1&#x2013;40) in Alzheimer&#x2019;s beta-amyloid fibril formation in vitro. Biochemistry. 1999;38:15514&#x2013;15521.</Citation><ArticleIdList><ArticleId IdType="pubmed">10569934</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, Lopresti BJ, Ziolko S, Bi W, Paljug WR, Debnath ML, Hope CE, Isanski BA, Hamilton RL, DeKosky ST. Post-mortem correlates of in vivo PIB-PET amyloid imaging in a typical case of Alzheimer&#x2019;s disease. Brain. 2008;131:1630&#x2013;1645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2408940</ArticleId><ArticleId IdType="pubmed">18339640</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, Moran EK, Smith EE, Rosand J, Rentz DM, Klunk WE, Mathis CA, Price JC, Dekosky ST, Fischman AJ, Greenberg SM. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol. 2007;62:229&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">17683091</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Wang Y, Huang GF, Debnath ML, Holt DP, Shao L, Hamilton RL, Ikonomovic MD, DeKosky ST, Mathis CA. The binding of 2-(4&#x2032;-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci. 2003a;23:2086&#x2013;2092.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741999</ArticleId><ArticleId IdType="pubmed">12657667</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, Bacskai BJ, Wang Y, Price JC, Bergstrom M, Hyman BT, Langstrom B, Mathis CA. Imaging the pathology of Alzheimer&#x2019;s disease: amyloid-imaging with positron emission tomography. Neuroimaging Clin N Am. 2003b;13:781&#x2013;789. ix.</Citation><ArticleIdList><ArticleId IdType="pubmed">15024961</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, Abrahamson EE, Debnath ML, Holt DP, Huang GF, Shao L, DeKosky ST, Price JC, Mathis CA. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer&#x2019;s disease brain but not in transgenic mouse brain. J Neurosci. 2005;25:10598&#x2013;10606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725842</ArticleId><ArticleId IdType="pubmed">16291932</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, et al. Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo Y-M, Kokjohn TA, Beach TG, Sue LI, Brune D, Lopez JC, Kalback WM, Abramowski D, Sturchler-Pierrat C, Staufenbiel M, Roher AE. Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer&#x2019;s disease brains. J Biol Chem. 2001;276:12991&#x2013;12998.</Citation><ArticleIdList><ArticleId IdType="pubmed">11152675</ArticleId></ArticleIdList></Reference><Reference><Citation>Leinonen V, Alafuzoff I, Aalto S, Suotunen T, Savolainen S, Nagren K, Tapiola T, Pirttila T, Rinne J, Jaaskelainen JE, Soininen H, Rinne JO. Assessment of {beta}-Amyloid in a Frontal Cortical Brain Biopsy Specimen and by Positron Emission Tomography With Carbon 11-Labeled Pittsburgh Compound B. Arch Neurol 2008</Citation><ArticleIdList><ArticleId IdType="pubmed">18695050</ArticleId></ArticleIdList></Reference><Reference><Citation>LeVine H, III, Walker LC. Models of Alzheimer&#x2019;s disease. In: Conn PM, editor. Handbook of Models for Human Aging. Academic Press; Burlington: 2006. pp. 121&#x2013;134.</Citation></Reference><Reference><Citation>LeVine H, III, Walker LC. Molecular polymorphism of Abeta in Alzheimer&#x2019;s disease. Neurobiol Aging 2008</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2842206</ArticleId><ArticleId IdType="pubmed">18619711</ArticleId></ArticleIdList></Reference><Reference><Citation>Lockhart A, Ye L, Judd DB, Merritt AT, Lowe PN, Morgenstern JL, Hong G, Gee AD, Brown J. Evidence for the presence of three distinct binding sites for the thioflavin T class of Alzheimer&#x2019;s disease PET imaging agents on beta-amyloid peptide fibrils. J Biol Chem. 2005;280:7677&#x2013;7684.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615711</ArticleId></ArticleIdList></Reference><Reference><Citation>Lockhart A, Lamb JR, Osredkar T, Sue LI, Joyce JN, Ye L, Libri V, Leppert D, Beach TG. PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain. 2007;130:2607&#x2013;2615.</Citation><ArticleIdList><ArticleId IdType="pubmed">17698496</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeda J, Ji B, Irie T, Tomiyama T, Maruyama M, Okauchi T, Staufenbiel M, Iwata N, Ono M, Saido TC, Suzuki K, Mori H, Higuchi M, Suhara T. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer&#x2019;s disease enabled by positron emission tomography. J Neurosci. 2007;27:10957&#x2013;10968.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672864</ArticleId><ArticleId IdType="pubmed">17928437</ArticleId></ArticleIdList></Reference><Reference><Citation>Makarava N, Baskakov IV. The same primary structure of the prion protein yields two distinct self-propagating states. J Biol Chem. 2008;283:15988&#x2013;15996.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2414308</ArticleId><ArticleId IdType="pubmed">18400757</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis CA, Wang Y, Klunk WE. Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain. Curr Pharm Des. 2004;10:1469&#x2013;1492.</Citation><ArticleIdList><ArticleId IdType="pubmed">15134570</ArticleId></ArticleIdList></Reference><Reference><Citation>McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L, Murphy MP, Beard J, Das P, Jansen K, Delucia M, Lin WL, Dolios G, Wang R, Eckman CB, Dickson DW, Hutton M, Hardy J, Golde T. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron. 2005;47:191&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1373682</ArticleId><ArticleId IdType="pubmed">16039562</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Kilger E, Neuenschwander A, Abramowski D, Frey P, Jaton AL, Vigouret JM, Paganetti P, Walsh DM, Mathews PM, Ghiso J, Staufenbiel M, Walker LC, Jucker M. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science. 2006;313:1781&#x2013;1784.</Citation><ArticleIdList><ArticleId IdType="pubmed">16990547</ArticleId></ArticleIdList></Reference><Reference><Citation>Noda A, Murakami Y, Nishiyama S, Fukumoto D, Miyoshi S, Tsukada H, Nishimura S. Amyloid imaging in aged and young macaques with [11C]PIB and [18F]FDDNP. Synapse. 2008;62:472&#x2013;475.</Citation><ArticleIdList><ArticleId IdType="pubmed">18361444</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordberg A. Amyloid plaque imaging in vivo: current achievement and future prospects. Eur J Nucl Med Mol Imaging. 2008;35(Suppl 1):S46&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">18188557</ArticleId></ArticleIdList></Reference><Reference><Citation>Otvos L, Jr, Szendrei GI, Lee VMY, Mantsch HH. Human and rodent Alzheimer beta-amyloid peptides acquire distinct conformations in membrane-mimicking solvents. European Journal of Biochemistry. 1993;211:249&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pubmed">8425535</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkova AT, Leapman RD, Guo Z, Yau WM, Mattson MP, Tycko R. Self-propagating, molecular-level polymorphism in Alzheimer&#x2019;s beta-amyloid fibrils. Science. 2005;307:262&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">15653506</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen RF, III, LeVine H, Pohl J, Preuss TM, Reed M, Tomidokoro Y, Farberg A, Rosene DL, Voytko ML, Lah JJ, Murphy MP, Gearing M, Ghiso JA, Walker LC. 2006 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience; 2006. Mass spectrometric detection of modified cerebral Abeta peptides in Alzheimer&#x2019;s disease, aged humans, and aged nonhuman primates. Program # 170.22. Program No. 170.22.</Citation></Reference><Reference><Citation>Rosen RF, Farberg AS, Gearing M, Dooyema J, Long PM, Anderson DC, Davis-Turak J, Coppola G, Geschwind DH, Pare JF, Duong TQ, Hopkins WD, Preuss TM, Walker LC. Tauopathy with paired helical filaments in an aged chimpanzee. J Comp Neurol. 2008;509:259&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2573460</ArticleId><ArticleId IdType="pubmed">18481275</ArticleId></ArticleIdList></Reference><Reference><Citation>Serdons K, Verduyckt T, Vanderghinste D, Cleynhens J, Borghgraef P, Vermaelen P, Terwinghe C, Leuven FV, Laere KV, Kung H, Bormans G, Verbruggen A. Synthesis of 18F-labelled 2-(4&#x2032;-fluorophenyl)-1,3-benzothiazole and evaluation as amyloid imaging agent in comparison with [11C]PIB. Bioorganic &amp; Medicinal Chemistry Letters. 2009;19:602&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pubmed">19147351</ArticleId></ArticleIdList></Reference><Reference><Citation>Svedberg MM, Hall H, Hellstrom-Lindahl E, Estrada S, Guan Z, Nordberg A, Langstrom B. [(11)C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients. Neurochem Int 2008</Citation><ArticleIdList><ArticleId IdType="pubmed">19162107</ArticleId></ArticleIdList></Reference><Reference><Citation>Toyama H, Ye D, Ichise M, Liow JS, Cai L, Jacobowitz D, Musachio JL, Hong J, Crescenzo M, Tipre D, Lu JQ, Zoghbi S, Vines DC, Seidel J, Katada K, Green MV, Pike VW, Cohen RM, Innis RB. PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer&#x2019;s disease. Eur J Nucl Med Mol Imaging. 2005;32:593&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pubmed">15791432</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinters HV, Wang ZZ, Secor DL. Brain Parenchymal and Microvascular Amyloid in Alzheimer&#x2019;s Disease. Brain Pathology. 1996;6:179&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">8737932</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker LC, Cork LC. The Neurobiology of Aging in Nonhuman Primates. In: Terry RD, Katzman R, Bick KL, Sisodia SS, editors. Alzheimer Disease. 2. Lippincott Williams &amp; Wilkins; Philadelphia: 1999. pp. 233&#x2013;243.</Citation></Reference><Reference><Citation>Walker LC, Pahnke J, Madauss M, Vogelgesang S, Pahnke A, Herbst EW, Stausske D, Walther R, Kessler C, Warzok RW. Apolipoprotein E4 promotes the early deposition of Abeta42 and then Abeta40 in the elderly. Acta Neuropathol. 2000;100:36&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">10912918</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock GK, Esiri MM. Plaques, tangles and dementia. A quantitative study. J Neurol Sci. 1982;56:343&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">7175555</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye L, Morgenstern JL, Lamb JR, Lockhart A. Characterisation of the binding of amyloid imaging tracers to rodent Abeta fibrils and rodent-human Abeta co-polymers. Biochem Biophys Res Commun. 2006;347:669&#x2013;677.</Citation><ArticleIdList><ArticleId IdType="pubmed">16842745</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye L, Morgenstern JL, Gee AD, Hong G, Brown J, Lockhart A. Delineation of positron emission tomography imaging agent binding sites on beta-amyloid peptide fibrils. J Biol Chem. 2005;280:23599&#x2013;23604.</Citation><ArticleIdList><ArticleId IdType="pubmed">15855161</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye L, Velasco A, Fraser G, Beach TG, Sue L, Osredkar T, Libri V, Spillantini MG, Goedert M, Lockhart A. In vitro high affinity alpha-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain. J Neurochem. 2008;105:1428&#x2013;1437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2408655</ArticleId><ArticleId IdType="pubmed">18221373</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19339596</PMID><DateCompleted><Year>2009</Year><Month>04</Month><Day>23</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>13</Issue><PubDate><Year>2009</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>A role for synaptic zinc in activity-dependent Abeta oligomer formation and accumulation at excitatory synapses.</ArticleTitle><Pagination><StartPage>4004</StartPage><EndPage>4015</EndPage><MedlinePgn>4004-15</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.5980-08.2009</ELocationID><Abstract><AbstractText>Soluble amyloid beta oligomers (AbetaOs) interfere with synaptic function and bind with high affinity to synapses, but the mechanism underlying AbetaO synaptic targeting is not known. Here, we show that the accumulation of synthetic or native Alzheimer's disease (AD)-brain oligomers at synapses is regulated by synaptic activity. Electrical or chemical stimulation increased AbetaO synaptic localization and enhanced oligomer formation at synaptic terminals, whereas inhibition with TTX blocked AbetaO synaptic localization and reduced AbetaO synaptic load. The zinc-binding 8-OH-quinoline clioquinol markedly reduced AbetaO synaptic targeting, which was also reduced in brain sections of animals deficient in the synaptic vesicle zinc transporter ZnT3, indicating that vesicular zinc released during neurotransmission is critical for AbetaO synaptic targeting. Oligomers were not internalized in recycled vesicles but remained at the cell surface, where they colocalized with NR2B NMDA receptor subunits. Furthermore, NMDA antagonists blocked AbetaO synaptic targeting, implicating excitatory receptor activity in oligomer formation and accumulation at synapses. In AD brains, oligomers of different size colocalized with synaptic markers in hippocampus and cortex, where oligomer synaptic accumulation correlated with synaptic loss.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Deshpande</LastName><ForeName>Atul</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California, Irvine, Irvine, California 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawai</LastName><ForeName>Hideki</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Metherate</LastName><ForeName>Raju</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Glabe</LastName><ForeName>Charles G</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>Busciglio</LastName><ForeName>Jorge</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 HD038466</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HD38466</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002148">Calmodulin-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D027682">Cation Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018691">Excitatory Amino Acid Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C491177">Slc30a3 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016708">Synaptophysin</NameOfSubstance></Chemical><Chemical><RegistryNumber>3KX376GY7L</RegistryNumber><NameOfSubstance UI="D018698">Glutamic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>4368-28-9</RegistryNumber><NameOfSubstance UI="D013779">Tetrodotoxin</NameOfSubstance></Chemical><Chemical><RegistryNumber>660YQ98I10</RegistryNumber><NameOfSubstance UI="D011189">Potassium Chloride</NameOfSubstance></Chemical><Chemical><RegistryNumber>J41CSQ7QDS</RegistryNumber><NameOfSubstance UI="D015032">Zinc</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002148" MajorTopicYN="N">Calmodulin-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D027682" MajorTopicYN="N">Cation Transport Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018691" MajorTopicYN="N">Excitatory Amino Acid Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018698" MajorTopicYN="N">Glutamic Acid</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D026901" MajorTopicYN="N">Membrane Transport Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011189" MajorTopicYN="N">Potassium Chloride</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016708" MajorTopicYN="N">Synaptophysin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013779" MajorTopicYN="N">Tetrodotoxin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015032" MajorTopicYN="N">Zinc</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>4</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>4</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>4</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19339596</ArticleId><ArticleId IdType="pmc">PMC6665357</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.5980-08.2009</ArticleId><ArticleId IdType="pii">29/13/4004</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adlard PA, Cherny RA, Finkelstein DI, Gautier E, Robb E, Cortes M, Volitakis I, Liu X, Smith JP, Perez K, Laughton K, Li QX, Charman SA, Nicolazzo JA, Wilkins S, Deleva K, Lynch T, Kok G, Ritchie CW, Tanzi RE, et al. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron. 2008;59:43&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">18614028</ArticleId></ArticleIdList></Reference><Reference><Citation>Amatniek JC, Hauser WA, DelCastillo-Castaneda C, Jacobs DM, Marder K, Bell K, Albert M, Brandt J, Stern Y. Incidence and predictors of seizures in patients with Alzheimer's disease. Epilepsia. 2006;47:867&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">16686651</ArticleId></ArticleIdList></Reference><Reference><Citation>Atwood CS, Scarpa RC, Huang X, Moir RD, Jones WD, Fairlie DP, Tanzi RE, Bush AI. Characterization of copper interactions with Alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta1&#x2013;42. J Neurochem. 2000;75:1219&#x2013;1233.</Citation><ArticleIdList><ArticleId IdType="pubmed">10936205</ArticleId></ArticleIdList></Reference><Reference><Citation>Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron. 2005;45:675&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">15748844</ArticleId></ArticleIdList></Reference><Reference><Citation>Billings LM, Green KN, McGaugh JL, LaFerla FM. Learning decreases A beta*56 and tau pathology and ameliorates behavioral decline in 3xTg-AD mice. J Neurosci. 2007;27:751&#x2013;761.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672918</ArticleId><ArticleId IdType="pubmed">17251414</ArticleId></ArticleIdList></Reference><Reference><Citation>Bush AI, Pettingell WH, Jr, Paradis MD, Tanzi RE. Modulation of A beta adhesiveness and secretase site cleavage by zinc. J Biol Chem. 1994a;269:12152&#x2013;12158.</Citation><ArticleIdList><ArticleId IdType="pubmed">8163520</ArticleId></ArticleIdList></Reference><Reference><Citation>Bush AI, Pettingell WH, Multhaup G, d Paradis M, Vonsattel JP, Gusella JF, Beyreuther K, Masters CL, Tanzi RE. Rapid induction of Alzheimer A beta amyloid formation by zinc. Science. 1994b;265:1464&#x2013;1467.</Citation><ArticleIdList><ArticleId IdType="pubmed">8073293</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang L, Bakhos L, Wang Z, Venton DL, Klein WL. Femtomole immunodetection of synthetic and endogenous amyloid-beta oligomers and its application to Alzheimer's disease drug candidate screening. J Mol Neurosci. 2003;20:305&#x2013;313.</Citation><ArticleIdList><ArticleId IdType="pubmed">14501013</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, Kim Y, Huang X, Goldstein LE, Moir RD, Lim JT, Beyreuther K, Zheng H, Tanzi RE, Masters CL, Bush AI. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron. 2001;30:665&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">11430801</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48:913&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci. 2005;8:79&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15608634</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole TB, Wenzel HJ, Kafer KE, Schwartzkroin PA, Palmiter RD. Elimination of zinc from synaptic vesicles in the intact mouse brain by disruption of the ZnT3 gene. Proc Natl Acad Sci U S A. 1999;96:1716&#x2013;1721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15571</ArticleId><ArticleId IdType="pubmed">9990090</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtain CC, Ali F, Volitakis I, Cherny RA, Norton RS, Beyreuther K, Barrow CJ, Masters CL, Bush AI, Barnham KJ. Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J Biol Chem. 2001;276:20466&#x2013;20473.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274207</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshpande A, Mina E, Glabe C, Busciglio J. Different conformations of amyloid &#x3b2; induce neurotoxicity by distinct mechanisms in human cortical neurons. J Neurosci. 2006;26:6011&#x2013;6018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675207</ArticleId><ArticleId IdType="pubmed">16738244</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshpande A, Win KM, Busciglio J. Tau isoform expression and regulation in human cortical neurons. FASEB J. 2008;22:2357&#x2013;2367.</Citation><ArticleIdList><ArticleId IdType="pubmed">18263702</ArticleId></ArticleIdList></Reference><Reference><Citation>Frederickson CJ, Bush AI. Synaptically released zinc: physiological functions and pathological effects. Biometals. 2001;14:353&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">11831465</ArticleId></ArticleIdList></Reference><Reference><Citation>Frederickson CJ, Koh JY, Bush AI. The neurobiology of zinc in health and disease. Nat Rev Neurosci. 2005;6:449&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pubmed">15891778</ArticleId></ArticleIdList></Reference><Reference><Citation>Georganopoulou DG, Chang L, Nam JM, Thaxton CS, Mufson EJ, Klein WL, Mirkin CA. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A. 2005;102:2273&#x2013;2276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC548981</ArticleId><ArticleId IdType="pubmed">15695586</ArticleId></ArticleIdList></Reference><Reference><Citation>Glabe CG. Conformation-dependent antibodies target diseases of protein misfolding. Trends Biochem Sci. 2004;29:542&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450609</ArticleId></ArticleIdList></Reference><Reference><Citation>Glabe CG, Kayed R. Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology. 2006;66:S74&#x2013;S78.</Citation><ArticleIdList><ArticleId IdType="pubmed">16432151</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini MG. A century of Alzheimer's disease. Science. 2006;314:777&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pubmed">17082447</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A. 2003;100:10417&#x2013;10422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC193576</ArticleId><ArticleId IdType="pubmed">12925731</ArticleId></ArticleIdList></Reference><Reference><Citation>Gylys KH, Fein JA, Tan AM, Cole GM. Apolipoprotein E enhances uptake of soluble but not aggregated amyloid-beta protein into synaptic terminals. J Neurochem. 2003;84:1442&#x2013;1451.</Citation><ArticleIdList><ArticleId IdType="pubmed">12614344</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8:101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Head E, Lott IT, Cribbs DH, Cotman CW, Rohn TT. Beta-amyloid deposition and neurofibrillary tangle association with caspase activation in Down syndrome. Neurosci Lett. 2002;330:99&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">12213643</ArticleId></ArticleIdList></Reference><Reference><Citation>Holscher C, Gengler S, Gault VA, Harriott P, Mallot HA. Soluble beta-amyloid[25&#x2013;35] reversibly impairs hippocampal synaptic plasticity and spatial learning. Eur J Pharmacol. 2007;561:85&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">17320856</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang YZ, Pan E, Xiong ZQ, McNamara JO. Zinc-mediated transactivation of TrkB potentiates the hippocampal mossy fiber-CA3 pyramid synapse. Neuron. 2008;57:546&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pubmed">18304484</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes SR, Khorkova O, Goyal S, Knaeblein J, Heroux J, Riedel NG, Sahasrabudhe S. Alpha2-macroglobulin associates with beta-amyloid peptide and prevents fibril formation. Proc Natl Acad Sci U S A. 1998;95:3275&#x2013;3280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19732</ArticleId><ArticleId IdType="pubmed">9501253</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R. APP processing and synaptic function. Neuron. 2003;37:925&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, Glabe CG. Conformation-dependent anti-amyloid oligomer antibodies. Methods Enzymol. 2006;413:326&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">17046404</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300:486&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, Sokolov Y, Edmonds B, McIntire TM, Milton SC, Hall JE, Glabe CG. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem. 2004;279:46363&#x2013;46366.</Citation><ArticleIdList><ArticleId IdType="pubmed">15385542</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, Head E, Sarsoza F, Saing T, Cotman CW, Necula M, Margol L, Wu J, Breydo L, Thompson JL, Rasool S, Gurlo T, Butler P, Glabe CG. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener. 2007;2:18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2100048</ArticleId><ArticleId IdType="pubmed">17897471</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH, Ball MJ, Roher AE. Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem. 1996;271:4077&#x2013;4081.</Citation><ArticleIdList><ArticleId IdType="pubmed">8626743</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EH, Finch CE, Krafft GA, Klein WL. Synaptic targeting by Alzheimer's-related amyloid &#x3b2; oligomers. J Neurosci. 2004;24:10191&#x2013;10200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730194</ArticleId><ArticleId IdType="pubmed">15537891</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, Viola KL, Klein WL. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci. 2007;27:796&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672917</ArticleId><ArticleId IdType="pubmed">17251419</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL. Diffusible, nonfibrillar ligands derived from Abeta1&#x2013;42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A. 1998;95:6448&#x2013;6453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Velasco PT, Chang L, Viola KL, Fernandez S, Lacor PN, Khuon D, Gong Y, Bigio EH, Shaw P, De Felice FG, Krafft GA, Klein WL. Monoclonal antibodies that target pathological assemblies of Abeta. J Neurochem. 2007;100:23&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">17116235</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH. A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006;440:352&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">16541076</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenzo A, Yuan M, Zhang Z, Paganetti PA, Sturchler-Pierrat C, Staufenbiel M, Mautino J, Vigo FS, Sommer B, Yankner BA. Amyloid beta interacts with the amyloid precursor protein: a potential toxic mechanism in Alzheimer's disease. Nat Neurosci. 2000;3:460&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">10769385</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol. 1999;155:853&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866907</ArticleId><ArticleId IdType="pubmed">10487842</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathie A, Sutton GL, Clarke CE, Veale EL. Zinc and copper: pharmacological probes and endogenous modulators of neuronal excitability. Pharmacol Ther. 2006;111:567&#x2013;583.</Citation><ArticleIdList><ArticleId IdType="pubmed">16410023</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol. 1999;46:860&#x2013;866.</Citation><ArticleIdList><ArticleId IdType="pubmed">10589538</ArticleId></ArticleIdList></Reference><Reference><Citation>Mocchegiani E, Bertoni-Freddari C, Marcellini F, Malavolta M. Brain, aging and neurodegeneration: role of zinc ion availability. Prog Neurobiol. 2005;75:367&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pubmed">15927345</ArticleId></ArticleIdList></Reference><Reference><Citation>Moolman DL, Vitolo OV, Vonsattel JP, Shelanski ML. Dendrite and dendritic spine alterations in Alzheimer models. J Neurocytol. 2004;33:377&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pubmed">15475691</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L. High-level neuronal expression of Abeta 1&#x2013;42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Narita M, Holtzman DM, Schwartz AL, Bu G. Alpha2-macroglobulin complexes with and mediates the endocytosis of beta-amyloid peptide via cell surface low-density lipoprotein receptor-related protein. J Neurochem. 1997;69:1904&#x2013;1911.</Citation><ArticleIdList><ArticleId IdType="pubmed">9349534</ArticleId></ArticleIdList></Reference><Reference><Citation>Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA. 2000;283:1571&#x2013;1577.</Citation><ArticleIdList><ArticleId IdType="pubmed">10735393</ArticleId></ArticleIdList></Reference><Reference><Citation>Necula M, Kayed R, Milton S, Glabe CG. Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J Biol Chem. 2007;282:10311&#x2013;10324.</Citation><ArticleIdList><ArticleId IdType="pubmed">17284452</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen HD, Hall CK. Molecular dynamics simulations of spontaneous fibril formation by random-coil peptides. Proc Natl Acad Sci U S A. 2004;101:16180&#x2013;16185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC526199</ArticleId><ArticleId IdType="pubmed">15534217</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitsch RM, Farber SA, Growdon JH, Wurtman RJ. Release of amyloid beta-protein precursor derivatives by electrical depolarization of rat hippocampal slices. Proc Natl Acad Sci U S A. 1993;90:5191&#x2013;5193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46681</ArticleId><ArticleId IdType="pubmed">8506366</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Tran L, Lambert MP, Glabe CG, Klein WL, LaFerla FM. Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem. 2006;281:1599&#x2013;1604.</Citation><ArticleIdList><ArticleId IdType="pubmed">16282321</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, Yu GQ, Kreitzer A, Finkbeiner S, Noebels JL, Mucke L. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron. 2007;55:697&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055171</ArticleId><ArticleId IdType="pubmed">17785178</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelsman A, Hoyo-Vadillo C, Gudasheva TA, Seredenin SB, Ostrovskaya RU, Busciglio J. GVS-111 prevents oxidative damage and apoptosis in normal and Down's syndrome human cortical neurons. Int J Dev Neurosci. 2003;21:117&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">12711349</ArticleId></ArticleIdList></Reference><Reference><Citation>Perin-Dureau F, Rachline J, Neyton J, Paoletti P. Mapping the binding site of the neuroprotectant ifenprodil on NMDA receptors. J Neurosci. 2002;22:5955&#x2013;5965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757916</ArticleId><ArticleId IdType="pubmed">12122058</ArticleId></ArticleIdList></Reference><Reference><Citation>Roselli F, Tirard M, Lu J, Hutzler P, Lamberti P, Livrea P, Morabito M, Almeida OF. Soluble &#x3b2;-amyloid1&#x2013;40 induces NMDA-dependent degradation of postsynaptic density-95 at glutamatergic synapses. J Neurosci. 2005;25:11061&#x2013;11070.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725651</ArticleId><ArticleId IdType="pubmed">16319306</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadowski MJ, Pankiewicz J, Scholtzova H, Mehta PD, Prelli F, Quartermain D, Wisniewski T. Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease. Proc Natl Acad Sci U S A. 2006;103:18787&#x2013;18792.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1654132</ArticleId><ArticleId IdType="pubmed">17116874</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlief L, West T, Craig AM, Holtzman DM, Gitlin JD. Role of the Menkes copper-transporting ATPase in NMDA receptor-mediated neuronal toxicity. Proc Natl Acad Sci U S A. 2006;103:14919&#x2013;14924.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1578502</ArticleId><ArticleId IdType="pubmed">17003121</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlief ML, Craig AM, Gitlin JD. NMDA receptor activation mediates copper homeostasis in hippocampal neurons. J Neurosci. 2005;25:239&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725203</ArticleId><ArticleId IdType="pubmed">15634787</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron. 1991;6:487&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pubmed">1673054</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-&#x3b2; protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007;27:2866&#x2013;2875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672572</ArticleId><ArticleId IdType="pubmed">17360908</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, Greengard P. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci. 2005;8:1051&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">16025111</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires TL, Meyer-Luehmann M, Stern EA, McLean PJ, Skoch J, Nguyen PT, Bacskai BJ, Hyman BT. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci. 2005;25:7278&#x2013;7287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1820616</ArticleId><ArticleId IdType="pubmed">16079410</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol. 2006;572:477&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1779683</ArticleId><ArticleId IdType="pubmed">16469784</ArticleId></ArticleIdList></Reference><Reference><Citation>Trojanowski JQ, Lee VM. The role of tau in Alzheimer's disease. Med Clin North Am. 2002;86:615&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">12168561</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B, Viola KL, Klein WL, Stine WB, Krafft GA, Trommer BL. Soluble oligomers of beta amyloid (1&#x2013;42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res. 2002;924:133&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">11750898</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao WQ, De Felice FG, Fernandez S, Chen H, Lambert MP, Quon MJ, Krafft GA, Klein WL. Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J. 2008;22:246&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">17720802</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19339712</PMID><DateCompleted><Year>2009</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>17</Issue><PubDate><Year>2009</Year><Month>Apr</Month><Day>28</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease.</ArticleTitle><Pagination><StartPage>1487</StartPage><EndPage>1494</EndPage><MedlinePgn>1487-94</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0b013e3181a2e8d0</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine the influence of the APOE genotype on levels of beta-amyloid (Abeta) plaque load and atrophy in patients with Alzheimer disease (AD) in vivo.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Thirty-two patients with moderate AD were divided into carriers and noncarriers of the epsilon4 allele. These groups were matched for age, disease duration, education, and cognitive impairment. In all subjects, [11C]PIB-PET was performed for measurement of cerebral Abeta plaque deposition and cranial MRI for the assessment of gray matter volume by voxel-based morphometry (VBM) and for correction of partial volume effects (PVE) in the PET data. Voxel-based comparisons (SPM5) were performed between patient groups and healthy control populations and completed with multiple regression analyses between imaging data and epsilon4 allele frequency.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Compared to controls, AD-typical patterns of [11C]PIB retention and atrophy were detected in both epsilon4-positive and epsilon4-negative patient groups. In direct comparison, significantly stronger and more extended [11C]PIB uptake was found in epsilon4-positive patients in bilateral temporoparietal and frontal cortex, surviving PVE correction. VBM analysis demonstrated comparable levels of atrophy in both patient groups. Regression analyses revealed a linear association between higher epsilon4 allele frequency and stronger temporoparietal Abeta plaque deposition, independently of other confounds. No major correlation between epsilon4 allele frequency and gray matter decrease was observed.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These results indicate that the epsilon4-positive APOE genotype not only represents a risk factor for Alzheimer disease (AD), but also results in higher levels of Abeta plaque deposition in epsilon4-positive patients with AD compared to age-matched epsilon4-negative patients with similar levels of cognitive impairment and brain atrophy. The potential role of Abeta plaque imaging for patient inclusion and follow-up in anti-amyloid therapy trials is strengthened by these findings.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Drzezga</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Klinikum Rechts der Isar, Technischen Universit&#xe4;t M&#xfc;nchen, Ismaninger Str. 22, D-81675 M&#xfc;nchen/Munich, Germany. a.drzezga@lrz.tum.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grimmer</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Henriksen</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>M&#xfc;hlau</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Perneczky</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Miederer</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Praus</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Sorg</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Wohlschl&#xe4;ger</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Riemenschneider</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Wester</LastName><ForeName>H J</ForeName><Initials>HJ</Initials></Author><Author ValidYN="Y"><LastName>Foerstl</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Schwaiger</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kurz</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>04</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052160">Benzothiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002250">Carbon Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D052160" MajorTopicYN="N">Benzothiazoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002250" MajorTopicYN="N">Carbon Radioisotopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004252" MajorTopicYN="N">DNA Mutational Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005820" MajorTopicYN="N">Genetic Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>4</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>4</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>6</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19339712</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e3181a2e8d0</ArticleId><ArticleId IdType="pii">WNL.0b013e3181a2e8d0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19342064</PMID><DateCompleted><Year>2009</Year><Month>10</Month><Day>08</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-5883</ISSN><JournalIssue CitedMedium="Internet"><Volume>283</Volume><Issue>1-2</Issue><PubDate><Year>2009</Year><Month>Aug</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of the neurological sciences</Title><ISOAbbreviation>J Neurol Sci</ISOAbbreviation></Journal><ArticleTitle>The effect of acetyl-L-carnitine and R-alpha-lipoic acid treatment in ApoE4 mouse as a model of human Alzheimer's disease.</ArticleTitle><Pagination><StartPage>199</StartPage><EndPage>206</EndPage><MedlinePgn>199-206</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jns.2009.03.002</ELocationID><Abstract><AbstractText>We measured age-dependent effects of human ApoE4 on cerebral blood flow (CBF) using ApoE4 transgenic mice compared to age-matched wild-type (WT) mice by use of [(14)C] iodoantipyrene autoradiography. ApoE4 associated factors reduce CBF gradually to create brain hypoperfusion when compared to WT, and the differences in CBF are greatest as animals age from 6-weeks to 12-months. Transmission electron microscopy with colloidal gold immunocytochemistry showed structural damage in young and aged microvessel endothelium of ApoE4 animals extended to the cytoplasm of perivascular cells, perivascular nerve terminals and hippocampal neurons and glial cells. These abnormalities coexist with mitochondrial structural alteration and mitochondrial DNA overproliferation and/or deletion in all brain cellular compartments. Spatial memory and temporal memory tests showed a trend in improving cognitive function in ApoE4 mice fed selective mitochondrial antioxidants acetyl-l-carnitine and R-alpha-lipoic acid. Our findings indicate that ApoE4 genotype-induced mitochondrial changes and associated structural damage may explain age-dependent pathology seen in AD, indicating potential for novel treatment strategies in the near future.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shenk</LastName><ForeName>Justin C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Biology and Electron Microscopy Research Center, University of Texas at San Antonio, San Antonio, TX 78249, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jiankang</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Fischbach</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Kui</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Puchowicz</LastName><ForeName>Michel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Obrenovich</LastName><ForeName>Mark E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Gasimov</LastName><ForeName>Eldar</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Alvarez</LastName><ForeName>Ludis Morales</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Ames</LastName><ForeName>Bruce N</ForeName><Initials>BN</Initials></Author><Author ValidYN="Y"><LastName>Lamanna</LastName><ForeName>Joseph C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Aliev</LastName><ForeName>Gjumrakch</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R25 GM060655</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>GM 60655</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>04</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Neurol Sci</MedlineTA><NlmUniqueID>0375403</NlmUniqueID><ISSNLinking>0022-510X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>6DH1W9VH8Q</RegistryNumber><NameOfSubstance UI="D000108">Acetylcarnitine</NameOfSubstance></Chemical><Chemical><RegistryNumber>73Y7P0K73Y</RegistryNumber><NameOfSubstance UI="D008063">Thioctic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000108" MajorTopicYN="N">Acetylcarnitine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="Y">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000178" MajorTopicYN="Y">diet therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002560" MajorTopicYN="N">Cerebrovascular Circulation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019587" MajorTopicYN="Y">Dietary Supplements</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008063" MajorTopicYN="N">Thioctic Acid</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>4</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>4</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>8</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19342064</ArticleId><ArticleId IdType="mid">NIHMS102544</ArticleId><ArticleId IdType="pmc">PMC2713369</ArticleId><ArticleId IdType="doi">10.1016/j.jns.2009.03.002</ArticleId><ArticleId IdType="pii">S0022-510X(09)00491-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>de la Torre JC. Critically attained threshold of cerebral hypoperfusion: the CATCH hypothesis of Alzheimer&#x2019;s pathogenesis. Neurobiol Aging. 2000;21:331&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">10867218</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Torre JC, Stefano GB. Evidence that Alzheimer&#x2019;s disease is a microvascular disorder: the role of constitutive nitric oxide. Brain Res Brain Res Rev. 2000;34:119&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">11113503</ArticleId></ArticleIdList></Reference><Reference><Citation>Etiene D, Kraft J, Ganju N, Gomez-Isla T, Gemelli B, Hyman BT, et al. Cerebrovascular Pathology Contributes to the Heterogeneity of Alzheimer&#x2019;s Disease. J Alzheimers Dis. 1998;1:119&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">12214008</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalaria RN, Ballard C. Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord. 1999;13 (Suppl 3):S115&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">10609690</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalaria RN. The blood-brain barrier and cerebrovascular pathology in Alzheimer&#x2019;s disease. Ann N Y Acad Sci. 1999;893:113&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">10672233</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240:622&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">3283935</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisgraber KH, Pitas RE, Mahley RW. Lipoproteins, neurobiology, and Alzheimer&#x2019;s disease: structure and function of apolipoprotein E. Curr Opin Struct Biol. 1994;4:507&#x2013;15.</Citation></Reference><Reference><Citation>Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E polymorphism and Alzheimer&#x2019;s disease. Lancet. 1993;342:697&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">8103819</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyles JK, Zoellner CD, Anderson LJ, Kosik LM, Pitas RE, Weisgraber KH, et al. A role for apolipoprotein E, apolipoprotein A&#x2013;I, and low density lipoprotein receptors in cholesterol transport during regeneration and remyelination of the rat sciatic nerve. J Clin Invest. 1989;83:1015&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC303779</ArticleId><ArticleId IdType="pubmed">2493483</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90:9649&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47627</ArticleId><ArticleId IdType="pubmed">8415756</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A. 2000;97:2892&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16026</ArticleId><ArticleId IdType="pubmed">10694577</ArticleId></ArticleIdList></Reference><Reference><Citation>Heeschen C, Jang JJ, Weis M, Pathak A, Kaji S, Hu RS, et al. Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat Med. 2001;7:833&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11433349</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker LC, Parker CA, Pipinski WJ, Callahan MJ, Carroll RT, Gandy SE, et al. Cerebral Lipid Deposition in Aged Apolipoprotein-E-Deficient Mice. American Journal of Pathology. 1997;151:1371&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1858096</ArticleId><ArticleId IdType="pubmed">9358763</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher A, Brandeis R, Chapman S, Pittel Z, Michaelson DM. M1 muscarinic agonist treatment reverses cognitive and cholinergic impairments of apolipoprotein E-deficient mice. J Neurochem. 1998;70:1991&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9572284</ArticleId></ArticleIdList></Reference><Reference><Citation>Genis I, Michaelson DM. Hyperphosphorylation of Tau in Apolipoprotein E-deficient Mice. In: Fe, editor. Progress in Alzheimer&#x2019;s and Parkinson&#x2019;s Diseases. New York: Plenum Press; 1998. pp. 251&#x2013;6.</Citation></Reference><Reference><Citation>Sparks DL. Coronary artery disease, hypertension, ApoE, and cholesterol: a link to Alzheimer&#x2019;s disease? Ann N Y Acad Sci. 1997;826:128&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">9329686</ArticleId></ArticleIdList></Reference><Reference><Citation>Fullerton SM, Shirman GA, Strittmatter WJ, Matthew WD. Impairment of the blood-nerve and blood-brain barriers in apolipoprotein e knockout mice. Exp Neurol. 2001;169:13&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">11312553</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. Jama. 1997;278:1349&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Trogan E, Choudhury RP, Dansky HM, Rong JX, Breslow JL, Fisher EA. Laser capture microdissection analysis of gene expression in macrophages from atherosclerotic lesions of apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A. 2002;99:2234&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122348</ArticleId><ArticleId IdType="pubmed">11842210</ArticleId></ArticleIdList></Reference><Reference><Citation>Bales KR, Verina T, Cummins DJ, Du Y, Dodel RC, Saura J, et al. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A. 1999;96:15233&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24803</ArticleId><ArticleId IdType="pubmed">10611368</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliev G, Smith MA, Turmaine M, Neal ML, Zimina TV, Friedland RP, et al. Atherosclerotic lesions are associated with increased immunoreactivity for inducible nitric oxide synthase and endothelin-1 in thoracic aortic intimal cells of hyperlipidemic Watanabe rabbits. Exp Mol Pathol. 2001;71:40&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">11502096</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliev G, Smith MA, Obrenovich ME, de la Torre JC, Perry G. Role of vascular hypoperfusion-induced oxidative stress and mitochondria failure in the pathogenesis of Azheimer disease. Neurotox Res. 2003;5:491&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pubmed">14715433</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliev G, Smith MA, Seyidov D, Neal ML, Lamb BT, Nunomura A, et al. The role of oxidative stress in the pathophysiology of cerebrovascular lesions in Alzheimer&#x2019;s disease. Brain Pathol. 2002;12:21&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095987</ArticleId><ArticleId IdType="pubmed">11770899</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust WJ, Eberling JL, Reed BR, Mathis CA, Budinger TF. Clinical studies of cerebral blood flow in Alzheimer&#x2019;s disease. Ann N Y Acad Sci. 1997;826:254&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">9329697</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust WJ, Friedland RP, Budinger TF, Koss E, Ober B. Longitudinal studies of regional cerebral metabolism in Alzheimer&#x2019;s disease. Neurology. 1988;38:909&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">3259296</ArticleId></ArticleIdList></Reference><Reference><Citation>Blain JF, Poirier J. Cholesterol homeostasis and the pathophysiology of Alzheimer&#x2019;s disease. Expert Rev Neurother. 2004;4:823&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15853509</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Torre JC. Vascular basis of Alzheimer&#x2019;s pathogenesis. Ann N Y Acad Sci. 2002;977:196&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">12480752</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Torre JC. Alzheimer&#x2019;s disease: how does it start? J Alzheimers Dis. 2002;4:497&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pubmed">12515901</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Torre JC. Alzheimer disease as a vascular disorder: nosological evidence. Stroke. 2002;33:1152&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">11935076</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim GP, Calon F, Morihara T, Yang F, Teter B, Ubeda O, et al. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci. 2005;25:3032&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725084</ArticleId><ArticleId IdType="pubmed">15788759</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliyev A, Chen SG, Seyidova D, Smith MA, Perry G, de la Torre J, et al. Mitochondria DNA deletions in atherosclerotic hypoperfused brain microvessels as a primary target for the development of Alzheimer&#x2019;s disease. J Neurol Sci. 2005;229&#x2013;230:285&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">15760652</ArticleId></ArticleIdList></Reference><Reference><Citation>Meguro K, Blaizot X, Kondoh Y, Le Mestric C, Baron JC, Chavoix C. Neocortical and hippocampal glucose hypometabolism following neurotoxic lesions of the entorhinal and perirhinal cortices in the non-human primate as shown by PET. Implications for Alzheimer&#x2019;s disease. Brain. 1999;122 (Pt 8):1519&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">10430835</ArticleId></ArticleIdList></Reference><Reference><Citation>Beal MF. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol. 1995;38:357&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">7668820</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliev G, Seyidova D, Neal ML, Shi J, Lamb BT, Siedlak SL, et al. Atherosclerotic lesions and mitochondria DNA deletions in brain microvessels as a central target for the development of human AD and AD-like pathology in aged transgenic mice. Ann N Y Acad Sci. 2002;977:45&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">12480733</ArticleId></ArticleIdList></Reference><Reference><Citation>Markesbery WR. Oxidative stress hypothesis in Alzheimer&#x2019;s disease. Free Radic Biol Med. 1997;23:134&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">9165306</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A. 2001;98:3334&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC30654</ArticleId><ArticleId IdType="pubmed">11248079</ArticleId></ArticleIdList></Reference><Reference><Citation>Alves TC, Rays J, Fraguas R, Jr, Wajngarten M, Meneghetti JC, Prando S, et al. Localized cerebral blood flow reductions in patients with heart failure: a study using 99mTc-HMPAO SPECT. J Neuroimaging. 2005;15:150&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">15746227</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliev G, Seyidova D, Lamb BT, Obrenovich ME, Siedlak SL, Vinters HV, et al. Mitochondria and vascular lesions as a central target for the development of Alzheimer&#x2019;s disease and Alzheimer disease-like pathology in transgenic mice. Neurol Res. 2003;25:665&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">14503022</ArticleId></ArticleIdList></Reference><Reference><Citation>Obrenovich ME, Smith MA, Siedlak SL, Chen SG, de la Torre JC, Perry G, et al. Overexpression of GRK2 in Alzheimer disease and in a chronic hypoperfusion rat model is an early marker of brain mitochondrial lesions. Neurotox Res. 2006;10:43&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">17000469</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Head E, Gharib AM, Yuan W, Ingersoll RT, Hagen TM, et al. Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-alpha -lipoic acid. Proc Natl Acad Sci U S A. 2002;99:2356&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122369</ArticleId><ArticleId IdType="pubmed">11854529</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliev G, Liu J, Shenk JC, Fischbach K, Pacheco GJ, Chen SG, et al. Neuronal mitochondrial amelioration by feeding acetyl-L-carnitine and lipoic acid to aged rats. J Cell Mol Med. 2009;13:320&#x2013;333. [Epub ahead of print, Mar 29, 2008]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2790425</ArticleId><ArticleId IdType="pubmed">18373733</ArticleId></ArticleIdList></Reference><Reference><Citation>Puchowicz MA, Radhakrishnan K, Xu K, Magness DL, LaManna JC. Computational study on use of single-point analysis method for quantitating local cerebral blood flow in mice. Adv Exp Med Biol. 2005;566:99&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">16594140</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliev G, Puchowicz M, Xu K, Shenk J, Smith MA, Siedlak SL, et al. ApoE deficiency induces hypoperfusion that initiate age-dependent decreases in cerebral blood flow and microvessels lesions. 8th International Conference on Alzheimer&#x2019;s and Parkinson&#x2019;s disease; 2007; Salzburg, Austria. 2007. p. P545.</Citation></Reference><Reference><Citation>Schenk F, Morris RG. Dissociation between components of spatial memory in rats after recovery from the effects of retrohippocampal lesions. Exp Brain Res. 1985;58:11&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">3987843</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods. 1984;11:47&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">6471907</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Killilea DW, Ames BN. Age-associated mitochondrial oxidative decay: improvement of carnitine acetyltransferase substrate-binding affinity and activity in brain by feeding old rats acetyl-L- carnitine and/or R-alpha -lipoic acid. Proc Natl Acad Sci U S A. 2002;99:1876&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122287</ArticleId><ArticleId IdType="pubmed">11854488</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts S. Isolation of an internal clock. J Exp Psychol Anim Behav Process. 1981;7:242&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">7252428</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, et al. Mitochondrial abnormalities in Alzheimer&#x2019;s disease. J Neurosci. 2001;21:3017&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762571</ArticleId><ArticleId IdType="pubmed">11312286</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliev G, Castellani RJ, Petersen RB, Burnstock G, Perry G, Smith MA. Pathobiology of familial hypercholesterolemic atherosclerosis. J Submicrosc Cytol Pathol. 2004;36:225&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">15906597</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliev G, Smith MA, Obrenovich ME, Perry G. Role of Vascular Hypoperfusion-Induced Oxidative Stress and Mitochondrial Failure in the Pathogenesis of Alzheimer Disease. Neurotox Res. 2003;5:385&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">14715433</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliev G, Smith MA, de la Torre JC, Perry G. Mitochondria as a primary target for vascular hypoperfusion and oxidative stress in Alzheimer&#x2019;s disease. Mitochondrion. 2004;4:649&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">16120422</ArticleId></ArticleIdList></Reference><Reference><Citation>Causes, early detection, treatment, models, prevention, risk factors.  2002 [cited; Available from:  http://www.alz.org/Researchers/RGP/Biological.htm.</Citation></Reference><Reference><Citation>Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A. 2006;103:5644&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1414631</ArticleId><ArticleId IdType="pubmed">16567625</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry G, Nunomura A, Hirai K, Zhu X, Perez M, Avila J, et al. Is oxidative damage the fundamental pathogenic mechanism of Alzheimer&#x2019;s and other neurodegenerative diseases? Free Radic Biol Med. 2002;33:1475&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12446204</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Torre JC, Aliev G. Inhibition of vascular nitric oxide after rat chronic brain hypoperfusion: spatial memory and immunocytochemical changes. J Cereb Blood Flow Metab. 2005;25:663&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">15703700</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliev G, Perry G, Shenk J, Puchowicz M, Xu K, Siedlak SL, et al. The primary pathogenetic role of vascular hypoperfusion, and oxidative stress in Alzheimer disease. Atherosclerosis Supplements. 2007;8:105.</Citation></Reference><Reference><Citation>Aliyev A, Seyidova D, Rzayev N, Obrenovich ME, Lamb BT, Chen SG, et al. Is nitric oxide a key target in the pathogenesis of brain lesions during the development of Alzheimer&#x2019;s disease? Neurol Res. 2004;26:547&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">15265272</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellani R, Hirai K, Aliev G, Drew KL, Nunomura A, Takeda A, et al. Role of mitochondrial dysfunction in Alzheimer&#x2019;s disease. J Neurosci Res. 2002;70:357&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">12391597</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreira PI, Siedlak SL, Wang X, Santos MS, Oliveira CR, Tabaton M, et al. Autophagocytosis of mitochondria is prominent in Alzheimer disease. J Neuropathol Exp Neurol. 2007;66:525&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">17549012</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreira PI, Siedlak SL, Wang X, Santos MS, Oliveira CR, Tabaton M, et al. Increased Autophagic Degradation of Mitochondria in Alzheimer Disease. Autophagy. 2007:3.</Citation><ArticleIdList><ArticleId IdType="pubmed">17786024</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19349228</PMID><DateCompleted><Year>2009</Year><Month>06</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9572</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>4</Issue><PubDate><Year>2009</Year><Month>May</Month><Day>01</Day></PubDate></JournalIssue><Title>NeuroImage</Title><ISOAbbreviation>Neuroimage</ISOAbbreviation></Journal><ArticleTitle>Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI).</ArticleTitle><Pagination><StartPage>1107</StartPage><EndPage>1116</EndPage><MedlinePgn>1107-16</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuroimage.2008.12.072</ELocationID><Abstract><AbstractText>In mostly small single-center studies, Alzheimer's disease (AD) is associated with characteristic and progressive reductions in fluorodeoxyglucose positron emission tomography (PET) measurements of the regional cerebral metabolic rate for glucose (CMRgl). The AD Neuroimaging Initiative (ADNI) is acquiring FDG PET, volumetric magnetic resonance imaging, and other biomarker measurements in a large longitudinal multi-center study of initially mildly affected probable AD (pAD) patients, amnestic mild cognitive impairment (aMCI) patients, who are at increased AD risk, and cognitively normal controls (NC), and we are responsible for analyzing the PET images using statistical parametric mapping (SPM). Here we compare baseline CMRgl measurements from 74 pAD patients and 142 aMCI patients to those from 82 NC, we correlate CMRgl with categorical and continuous measures of clinical disease severity, and we compare apolipoprotein E (APOE) varepsilon4 carriers to non-carriers in each of these subject groups. In comparison with NC, the pAD and aMCI groups each had significantly lower CMRgl bilaterally in posterior cingulate, precuneus, parietotemporal and frontal cortex. Similar reductions were observed when categories of disease severity or lower Mini-Mental State Exam (MMSE) scores were correlated with lower CMRgl. However, when analyses were restricted to the pAD patients, lower MMSE scores were significantly correlated with lower left frontal and temporal CMRgl. These findings from a large, multi-site study support previous single-site findings, supports the characteristic pattern of baseline CMRgl reductions in AD and aMCI patients, as well as preferential anterior CMRgl reductions after the onset of AD dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Langbaum</LastName><ForeName>Jessica B S</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute and Banner Good Samaritan PET Center, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Kewei</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Wendy</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Reschke</LastName><ForeName>Cole</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Bandy</LastName><ForeName>Dan</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Fleisher</LastName><ForeName>Adam S</ForeName><Initials>AS</Initials></Author><Author ValidYN="Y"><LastName>Alexander</LastName><ForeName>Gene E</ForeName><Initials>GE</Initials></Author><Author ValidYN="Y"><LastName>Foster</LastName><ForeName>Norman L</ForeName><Initials>NL</Initials></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials></Author><Author ValidYN="Y"><LastName>Koeppe</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Jagust</LastName><ForeName>William J</ForeName><Initials>WJ</Initials></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><CollectiveName>Alzheimer's Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>01</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuroimage</MedlineTA><NlmUniqueID>9215515</NlmUniqueID><ISSNLinking>1053-8119</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019788" MajorTopicYN="Y">Fluorodeoxyglucose F18</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013223" MajorTopicYN="N">Statistics as Topic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2008</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>12</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>4</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>4</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>6</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>6</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19349228</ArticleId><ArticleId IdType="mid">NIHMS92619</ArticleId><ArticleId IdType="pmc">PMC2886795</ArticleId><ArticleId IdType="doi">10.1016/j.neuroimage.2008.12.072</ArticleId><ArticleId IdType="pii">S1053-8119(09)00003-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET evaluation of cerebral metabolic decline in dementia: A potential outcome measure in Alzheimer&#x2019;s disease treatment studies. Am J Psychiatry. 2002;159:738&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pubmed">11986126</ArticleId></ArticleIdList></Reference><Reference><Citation>Anchisi D, Borroni B, Franceschi M, Kerrouche N, Kalbe E, Beuthien-Beumann B, Cappa S, Lenz O, Ludecke S, Marcone A, Mielke R, Ortelli P, Padovani A, Pelati O, Pupi A, Scarpini E, Weisenbach S, Herholz K, Salmon E, Holthoff V, Sorbi S, Fazio F, Perani D. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol. 2005;62:1728&#x2013;1733.</Citation><ArticleIdList><ArticleId IdType="pubmed">16286547</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnaiz E, Jelic V, Almkvist O, Wahlund LO, Winblad B, Valind S, Nordberg A. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport. 2001;12:851&#x2013;855.</Citation><ArticleIdList><ArticleId IdType="pubmed">11277595</ArticleId></ArticleIdList></Reference><Reference><Citation>Bokde AL, Teipel SJ, Drzezga A, Thissen J, Bartenstein P, Dong W, Leinsinger G, Born C, Schwaiger M, Moeller HJ, Hampel H. Association between cognitive performance and cortical glucose metabolism in patients with mild Alzheimer&#x2019;s disease. Dement Geriatr Cogn Disord. 2005;20:352&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">16192725</ArticleId></ArticleIdList></Reference><Reference><Citation>Chase TN, Foster NL, Fedio P, Brooks R, Mansi L, Di Chiro G. Regional cortical dysfunction in Alzheimer&#x2019;s disease as determined by positron emission tomography. Ann Neurol. 1984;15(Suppl):S170&#x2013;S174.</Citation><ArticleIdList><ArticleId IdType="pubmed">6611118</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xe9;telat G, Desgranges B, Landeau B, M&#xe9;zenge F, Poline JB, de la Sayette V, Viader F, Eustache F, Baron JC. Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer&#x2019;s disease. Brain. 2008;131:60&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">18063588</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xe9;telat G, Eustache F, Viader F, de la Sayette V, P&#xe9;lerin A, M&#xe9;zenge F, Hannequin D, Dupuy B, Baron JC, Desgranges B. FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment. Neurocase. 2005;11:14&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">15804920</ArticleId></ArticleIdList></Reference><Reference><Citation>Choo IH, Lee DY, Youn JC, Jhoo JH, Kim KW, Lee DS, Lee JS, Woo JI. Topographic patterns of brain functional impairment progression according to clinical severity staging in 116 Alzheimer disease patients: FDG-PET study. Alzheimer Dis Assoc Disord. 2007;21:77&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">17545731</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leon MJ, Convit A, Wolf OT, Tarshish CY, DeSanti S, Rusinek H, Tsui W, Kandil E, Scherer AJ, Roche A, Imossi A, Thorn E, Bobinski M, Caraos C, Lesbre P, Schlyer D, Poirier J, Reisberg B, Fowler J. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET) Proc Natl Acad Sci USA. 2001;98:10966&#x2013;10971.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC58582</ArticleId><ArticleId IdType="pubmed">11526211</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leon MJ, Ferris SH, George AE, Reisberg B, Christman DR, Kricheff II, Wolf AP. Computed tomography and positron emission transaxial tomography evaluations of normal aging and Alzheimer&#x2019;s disease. J Cereb Blood Flow Metab. 1983;3:391&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pubmed">6603463</ArticleId></ArticleIdList></Reference><Reference><Citation>De Santi S, de Leon MJ, Rusinek H, Convit A, Tarshish CY, Roche A, Tsui WH, Kandil E, Boppana M, Daisley K, Wang GJ, Schlyer D, Fowler J. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging. 2001;22:529&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11445252</ArticleId></ArticleIdList></Reference><Reference><Citation>De SS, de Leon MJ, Rusinek H, Convit A, Tarshish CY, Roche A, Tsui WH, Kandil E, Boppana M, Daisley K, Wang GJ, Schlyer D, Fowler J. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging. 2001;22:529&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11445252</ArticleId></ArticleIdList></Reference><Reference><Citation>Drzezga A, Grimmer T, Riemenschneider M, Lautenschlager N, Siebner H, Alexopoulus P, Minoshima S, Schwaiger M, Kurz A. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med. 2005;46:1625&#x2013;1632.</Citation><ArticleIdList><ArticleId IdType="pubmed">16204712</ArticleId></ArticleIdList></Reference><Reference><Citation>Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, Schwaiger M, Kurz A. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer&#x2019;s disease: a PET follow-up study. Eur J Nucl Med Mol Imaging. 2003;30:1104&#x2013;1113.</Citation><ArticleIdList><ArticleId IdType="pubmed">12764551</ArticleId></ArticleIdList></Reference><Reference><Citation>Duara R, Grady CL, Haxby JV. Positron emission tomography in Alzheimer&#x2019;s disease. Neurology. 1986:879&#x2013;887.</Citation><ArticleIdList><ArticleId IdType="pubmed">3487046</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster NL, Chase TN, Fedio P, Patronas NJ, Brooks RA, Di Chiro G. Alzheimer&#x2019;s disease: focal cortical changes shown by positron emission tomography. Neurology. 1983;33:961&#x2013;965.</Citation><ArticleIdList><ArticleId IdType="pubmed">6603596</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster NL, Chase TN, Mansi L, Brooks R, Fedio P, Patronas NJ, Di Chiro G. Cortical abnormalities in Alzheimer&#x2019;s disease. Ann Neurol. 1984;16:649&#x2013;654.</Citation><ArticleIdList><ArticleId IdType="pubmed">6335378</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisoni GB, Henneman WJP, Weiner MW, Scheltens P, Vellas B, Reynish E, Hudecova J, Hampel H, Burger K, Blennow K, Waldemar G, Johannsen P, Wahlund LO, Zito G, Rossini PM, Winblad B, Barkhof F. The pilot European Alzheimer&#x2019;s Disease Neuroimaging Initiative of the European Alzheimer&#x2019;s Disease Consortium. Alzheimer&#x2019;s &amp; Dementia. 2008;4:255&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2657833</ArticleId><ArticleId IdType="pubmed">18631976</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg SM, Grabowski T, Gurol ME, Skehan ME, Nandigam RN, Becker JA, Garcia-Alloza M, Prada C, Frosch MP, Rosand J, Viswanathan A, Smith EE, Johnson KA. Detection of isolated cerebrovascular beta-amyloid with Pittsburgh compound B. Ann Neurol. 2008;64:587&#x2013;591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2605158</ArticleId><ArticleId IdType="pubmed">19067370</ArticleId></ArticleIdList></Reference><Reference><Citation>Haxby JV, Grady CL, Koss E, Horwitz B, Heston L, Schapiro M, Friedland RP, Rapoport SI. Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type. Arch Neurol. 1990;47:753&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pubmed">2357155</ArticleId></ArticleIdList></Reference><Reference><Citation>Herholz K, Perani D, Salmon E, Franck G, Fazio F, Heiss WD, Comar D. Comparability of FDG PET studies in probable Alzheimer&#x2019;s disease. The Journal of Nuclear Medicine. 1993;34:1460&#x2013;1466.</Citation><ArticleIdList><ArticleId IdType="pubmed">8355064</ArticleId></ArticleIdList></Reference><Reference><Citation>Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Frolich L, Schonknecht P, Ito K, Mielke R, Kalbe E, Zundorf G, Delbeuck X, Pelati O, Anchisi D, Fazio F, Kerrouche N, Desgranges B, Eustache F, Beuthien-Baumann B, Menzel C, Schroder J, Kato T, Arahata Y, Henze M, Heiss WD. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage. 2002;17:302&#x2013;316.</Citation><ArticleIdList><ArticleId IdType="pubmed">12482085</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman JM, Welsh-Bohmer KA, Hanson M, Crain B, Hulette C, Earl N, Coleman RE. FDG PET imaging in patients with pathologically verified dementia. J Nucl Med. 2000;41:1920&#x2013;1928.</Citation><ArticleIdList><ArticleId IdType="pubmed">11079505</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibanez V, Pietrini P, Alexander GE, Furey ML, Teichberg D, Rajapakse JC, Rapoport SI, Schapiro MB, Horwitz B. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer&#x2019;s disease. Neurology. 1998;50:1585&#x2013;1593.</Citation><ArticleIdList><ArticleId IdType="pubmed">9633698</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust W, Reed B, Mungas D, Ellis W, DeCarli C. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology. 2007;69:871&#x2013;877.</Citation><ArticleIdList><ArticleId IdType="pubmed">17724289</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust WJ, Friedland RP, Budinger TF, Koss E, Ober B. Longitudinal studies of regional cerebral metabolism in Alzheimer&#x2019;s disease. Neurology. 1988;38:909&#x2013;912.</Citation><ArticleIdList><ArticleId IdType="pubmed">3259296</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, Moran EK, Smith EE, Rosand J, Rentz DM, Klunk WE, Mathis CA, Price JC, DeKosky ST, Fischman AJ, Greenberg SM. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol. 2007;62:229&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">17683091</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawano M, Ichimiya A, Ogomori K, Kuwabara Y, Sasaki M, Yoshida T, Tashiro N. Relationship between both IQ and Mini-Mental State Examination and the regional cerebral glucose metabolism in clinically diagnosed Alzheimer&#x2019;s disease: a PET study. Dement Geriatr Cogn Disord. 2001;12:171&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">11173892</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, Ausen B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Langstrom B. Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer EG, Peppard RP, McGeer PL, Tuokko H, Crockett D, Parks R, Akiyama H, Calne DB, Beattie BL, Harrop R. 18Fluorodeoxyglucose positron emission tomography studies in presumed Alzheimer cases, including 13 serial scans. Can J Neurol Sci. 1990;17:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">2311010</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke R, Herholz K, Grond M, Kessler J, Heiss WD. Differences of regional cerebral glucose metabolism between presenile and senile dementia of Alzheimer type. Neurobiol Aging. 1992;13:93&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">1542386</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke R, Schroder R, Fink GR, Kessler J, Herholz K, Heiss WD. Regional cerebral glucose metabolism and postmortem pathology in Alzheimer&#x2019;s disease. Acta Neuropathol. 1996;91:174&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">8787151</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoshima S, Foster NL, Kuhl DE. Posterior cingulate cortex in Alzheimer&#x2019;s disease. Lancet. 1994;344:895.</Citation><ArticleIdList><ArticleId IdType="pubmed">7916431</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoshima S, Foster NL, Sima AA, Frey KA, Albin RL, Kuhl DE. Alzheimer&#x2019;s disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol. 2001;50:358&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pubmed">11558792</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer&#x2019;s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med. 1995;36:1238&#x2013;1248.</Citation><ArticleIdList><ArticleId IdType="pubmed">7790950</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer&#x2019;s disease. Ann Neurol. 1997;42:85&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">9225689</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer&#x2019;s disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging. 2005;32:486&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">15747152</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, De SS, Li J, Tsui WH, Li Y, Boppana M, Laska E, Rusinek H, de Leon MJ. Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol Aging 2007a</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2430185</ArticleId><ArticleId IdType="pubmed">17222480</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, De SS, Li J, Tsui WH, Li Y, Boppana M, Laska E, Rusinek H, de Leon MJ. Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol Aging. 2008a;29:676&#x2013;692.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2430185</ArticleId><ArticleId IdType="pubmed">17222480</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, Perani D, Sorbi S, Herholz K, Nacmias B, Holthoff V, Salmon E, Baron JC, De Cristofaro MT, Padovani A, Borroni B, Franceschi M, Bracco L, Pupi A. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology. 2004;63:2332&#x2013;2340.</Citation><ArticleIdList><ArticleId IdType="pubmed">15623696</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, Tsui WH, De SS, Li J, Rusinek H, Convit A, Li Y, Boppana M, de Leon MJ. Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology. 2005;64:1860&#x2013;1867.</Citation><ArticleIdList><ArticleId IdType="pubmed">15955934</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, Tsui WH, Herholz K, Pupi A, Drzezga A, Lucignani G, Reiman EM, Holthoff V, Kalbe E, Sorbi S, ehl-Schmid J, Perneczky R, Clerici F, Caselli R, Beuthien-Baumann B, Kurz A, Minoshima S, de Leon MJ. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer&#x2019;s disease, and other dementias. The Journal of Nuclear Medicine. 2008b;49:390&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3703818</ArticleId><ArticleId IdType="pubmed">18287270</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, Tsui WH, Pupi A, De SS, Drzezga A, Minoshima S, de Leon MJ. (18)F-FDG PET database of longitudinally confirmed healthy elderly individuals improves detection of mild cognitive impairment and Alzheimer&#x2019;s disease. J Nucl Med. 2007b;48:1129&#x2013;1134.</Citation><ArticleIdList><ArticleId IdType="pubmed">17574982</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust W, Trojanowski JQ, Toga AW, Beckett L. Ways toward an early diagnosis in Alzheimer&#x2019;s disease: The Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI) Alzheimers Dement. 2005;1:55&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1864941</ArticleId><ArticleId IdType="pubmed">17476317</ArticleId></ArticleIdList></Reference><Reference><Citation>Nestor PJ, Fryer TD, Smielewski P, Hodges JR. Limbic hypometabolism in Alzheimer&#x2019;s disease and mild cognitive impairment. Ann Neurol. 2003;54:343&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">12953266</ArticleId></ArticleIdList></Reference><Reference><Citation>Perneczky R, Hartmann J, Grimmer T, Drzezga A, Kurz A. Cerebral metabolic correlates of the clinical dementia rating scale in mild cognitive impairment. J Geriatr Psychiatry Neurol. 2007;20:84&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">17548777</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58:1985&#x2013;1992.</Citation><ArticleIdList><ArticleId IdType="pubmed">11735772</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Langbaum JBS. Brain imaging in the evaluation of putative Alzheimer&#x2019;s disease slowing, risk-reducing and prevention therapies. In: Jagust WJ, D&#x2019;Esposito M, editors. Imaging and the Aging Brain. Oxford University Press; New York: 2008.</Citation></Reference><Reference><Citation>Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J. Declining brain activity in cognitively normal apolipoprotein E &#x3b5;4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer&#x2019;s disease. Proc Natl Acad Sci USA. 2001;98:3334&#x2013;3339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC30654</ArticleId><ArticleId IdType="pubmed">11248079</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, Thibodeau SN, Osborne D. Preclinical evidence of Alzheimer&#x2019;s disease in persons homozygous for the &#x3b5;4 allele for apolipoprotein E. N Engl J Med. 1996;334:752&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">8592548</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, Hardy J. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer&#x2019;s dementia. Proc Natl Acad Sci USA. 2004;101:284&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC314177</ArticleId><ArticleId IdType="pubmed">14688411</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, Hardy J. Correlations between apolipoprotein E &#x3b5;4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci USA. 2005;102:8299&#x2013;8302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1149416</ArticleId><ArticleId IdType="pubmed">15932949</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverman DH, Small GW, Chang CY, Lu CS, Kung De Aburto MA, Chen W, Czernin J, Rapoport SI, Pietrini P, Alexander GE, Schapiro MB, Jagust WJ, Hoffman JM, Welsh-Bohmer KA, Alavi A, Clark CM, Salmon E, de Leon MJ, Mielke R, Cummings JL, Kowell AP, Gambhir SS, Hoh CK, Phelps ME. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA. 2001;286:2120&#x2013;2127.</Citation><ArticleIdList><ArticleId IdType="pubmed">11694153</ArticleId></ArticleIdList></Reference><Reference><Citation>Small GW, Mazziotta JC, Collins MT, Baxter LR, Phelps ME, Mandelkern MA, Kaplan A, La Rue A, Adamson CF, Chang L. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA. 1995;273:942&#x2013;947.</Citation><ArticleIdList><ArticleId IdType="pubmed">7884953</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith GS, de Leon MJ, George AE, Kluger A, Volkow ND, McRae T, Golomb J, Ferris SH, Reisberg B, Ciaravino J. Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer&#x2019;s disease. Pathophysiologic implications. Arch Neurol. 1992;49:1142&#x2013;1150.</Citation><ArticleIdList><ArticleId IdType="pubmed">1444881</ArticleId></ArticleIdList></Reference><Reference><Citation>Talairach J, Tournoux P. Co-Planar Stereotaxic Atlas of the Human Brain. Thieme Medical Publishers; New York: 1988.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19355849</PMID><DateCompleted><Year>2009</Year><Month>06</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-5828</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>2</Issue><PubDate><Year>2009</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Current Alzheimer research</Title><ISOAbbreviation>Curr Alzheimer Res</ISOAbbreviation></Journal><ArticleTitle>Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders.</ArticleTitle><Pagination><StartPage>144</StartPage><EndPage>151</EndPage><MedlinePgn>144-51</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Immunization of patients with Alzheimer's disease (AD) with synthetic amyloid-beta peptide (Abeta(42)) (AN1792) was previously studied in a randomized, double-blind, placebo-controlled phase 2a clinical trial, Study AN1792(QS-21)-201. Treatment was discontinued following reports of encephalitis. One year follow-up revealed that AN1792 antibody responders showed improvements in cognitive measures as assessed by the neuropsychological test battery (NTB) and a decrease in brain volume compared with placebo.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A follow-up study, Study AN1792(QS-21)-251, was conducted to assess the long-term functional, psychometric, neuroimaging, and safety outcomes of patients from the phase 2a study 4.6 years after immunization with AN1792. The results were analyzed by comparing patients originally identified as antibody responders in the AN1792 phase 2a study with placebo-treated patients.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">One hundred and fifty-nine patients/caregivers (30 placebo; 129 AN1792) participated in this follow-up study. Of the 129 AN1792-treated patients, 25 were classified in the phase 2a study as antibody responders (anti-AN1792 titers &gt; or = 1:2,200 at any time after the first injection). Low but detectable, sustained anti-AN1792 titers were found in 17 of 19 samples obtained from patients classified as antibody responders in the phase 2a study. No detectable anti-AN1792 antibodies were found in patients not classified as antibody responders in the phase 2a study. Significantly less decline was observed on the Disability Assessment for Dementia scale among antibody responders than placebo-treated patients (p=0.015) after 4.6 years. Significant differences in favor of responders were also observed on the Dependence Scale (p=0.033). Of the small number of patients who underwent a follow-up MRI, antibody responders showed similar brain volume loss during the follow-up period subsequent to the AN1792 phase 2a study compared with placebo-treated patients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Approximately 4.6 years after immunization with AN1792, patients defined as responders in the phase 2a study maintained low but detectable, sustained anti-AN1792 antibody titers and demonstrated significantly reduced functional decline compared with placebo-treated patients. Brain volume loss in antibody responders was not significantly different from placebo-treated patients approximately 3.6 years from the end of the original study. No further cases of encephalitis were noted. These data support the hypothesis that Abeta immunotherapy may have long-term functional benefits.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vellas</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Geriatrics INSERM U 558, Toulouse University Hospital Center, Toulouse, France. vellas.b@chu-toulouse.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Black</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Thal</LastName><ForeName>Leon J</ForeName><Initials>LJ</Initials></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick C</ForeName><Initials>NC</Initials></Author><Author ValidYN="Y"><LastName>Daniels</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>McLennan</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Tompkins</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Leibman</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Pomfret</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Grundman</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><CollectiveName>AN1792 (QS-21)-251 Study Team</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0401247</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0601846</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0801306</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United Arab Emirates</Country><MedlineTA>Curr Alzheimer Res</MedlineTA><NlmUniqueID>101208441</NlmUniqueID><ISSNLinking>1567-2050</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C437846">AN-1792</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004185" MajorTopicYN="N">Disability Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004306" MajorTopicYN="N">Dose-Response Relationship, Immunologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Brody</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Corey-Bloom</LastName><ForeName>Jody</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boada Rovira</LastName><ForeName>Merc&#xe8;</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dartigues</LastName><ForeName>Jean-Francois</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doody</LastName><ForeName>Rachelle</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dubois</LastName><ForeName>Bruno</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flitman</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frank-Garcia</LastName><ForeName>Ana</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grosz</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hock</LastName><ForeName>Christoph</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jouanny</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kirby</LastName><ForeName>Louis</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Knopman</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laurent</LastName><ForeName>Bernard</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Michel</LastName><ForeName>Bernard</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Molinuevo</LastName><ForeName>Jos&#xe9; Luis</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pasquier</LastName><ForeName>Florence</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pena-Casanova</LastName><ForeName>Jordi</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ribera Casado</LastName><ForeName>Jos&#xe9;</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Richter</LastName><ForeName>Ralph</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rigaud</LastName><ForeName>Anne-Sophie</ForeName><Initials>AS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Touchon</LastName><ForeName>Jacques</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vellas</LastName><ForeName>Bruno</ForeName><Initials>B</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>4</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>4</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>6</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19355849</ArticleId><ArticleId IdType="pmc">PMC2825665</ArticleId><ArticleId IdType="doi">10.2174/156720509787602852</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer&#x2019;s disease. Alzheimer Dement. 2007;3:186&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">19595937</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-&#x3b2; attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">10408445</ArticleId></ArticleIdList></Reference><Reference><Citation>Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell R, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F &#x3b2;-amyloid precursor protein. Nature. 1995;373:523&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">7845465</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey G, Hardy J, et al. A&#x3b2; peptide vaccination prevents memory loss in an animal model of Alzheimer&#x2019;s disease. Nature. 2000;408:982&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pubmed">11140686</ArticleId></ArticleIdList></Reference><Reference><Citation>Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schimdt SD, et al. A&#x3b2; peptide immunization reduces behavioral impairment and plaques in a model of Alzheimer&#x2019;s disease. Nature. 2000;408:979&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pubmed">11140685</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaurin J, Cecal R, Kierstead ME, Tian X, Phinney AL, Manea M, et al. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med. 2002;8:1263&#x2013;1269.</Citation><ArticleIdList><ArticleId IdType="pubmed">12379850</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L, et al. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology. 2005;64:94&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">15642910</ArticleId></ArticleIdList></Reference><Reference><Citation>Orgogozo J-M, Gilman S, Dartigues J-F, Laurent B, Puel M, Kirby LC, et al. Subacute meningoencephalitis in a subset of patients with AD after A&#x3b2;42 immunization. Neurology. 2003;61:46&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">12847155</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilman S, Killer M, Black RS, Jenkins L, Griffith SG, Fox NC, et al. Clinical effects of A&#x3b2; immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64:1563&#x2013;1572.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883316</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, et al. Effects of A&#x3b2; immunization (AN1792) on MRI measures of cerebral volume in Alzheimer&#x2019;s disease. Neurology. 2005;64:1553&#x2013;1562.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883317</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer I, Boada RM, Sanchez Guerra ML, Rossor MN, Griffith SG, Jenkins L, et al. Neuropathology and pathogenesis of encephalitis following amyloid-&#x3b2; immunization in Alzheimer&#x2019;s disease. Brain. 2004;Pathol 14:11&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095815</ArticleId><ArticleId IdType="pubmed">14997933</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, et al. A&#x3b2; vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer&#x2019;s disease. Neurology. 2005;64:129&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">15642916</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll JAR, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer&#x2019;s disease after immunization with amyloid-&#x3b2; peptide: a case report. Nat Med. 2003;9:448&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">12640446</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauthier S, Gelinas I, Gauthier L. Functional disability in Alzheimer&#x2019;s disease. Int Psychogeriatr. 1997;9(suppl 1):163&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">9447439</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y, Albert SM, Sano M, Jacobs DM, Tang MX, Marder K, et al. Assessing patient dependence in Alzheimer&#x2019;s disease. J Gerontol. 1994;49:M216&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pubmed">8056940</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison J, Minassian SL, Jenkins L, Black RS, Koller M, Grundman M. A neuropsychological test battery for use in Alzheimer&#x2019;s disease clinical trials. Arch Neurol. 2007;64:1323&#x2013;1329.</Citation><ArticleIdList><ArticleId IdType="pubmed">17846273</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer&#x2019;s disease. Am J Psychiatry. 1984;141:1356&#x2013;1364.</Citation><ArticleIdList><ArticleId IdType="pubmed">6496779</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19357288</PMID><DateCompleted><Year>2009</Year><Month>05</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>14</Issue><PubDate><Year>2009</Year><Month>Apr</Month><Day>08</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Increased membrane cholesterol might render mature hippocampal neurons more susceptible to beta-amyloid-induced calpain activation and tau toxicity.</ArticleTitle><Pagination><StartPage>4640</StartPage><EndPage>4651</EndPage><MedlinePgn>4640-51</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0862-09.2009</ELocationID><Abstract><AbstractText>A growing body of evidence suggests that beta-amyloid (Abeta), the main component of senile plaques, induces abnormal posttranslational processing of the microtubule-associated protein tau. We have recently described that, in addition to increasing tau phosphorylation, Abeta enhanced calpain activity leading to the generation of a toxic 17 kDa tau fragment in cultured hippocampal neurons. How aging, the greatest Alzheimer's disease (AD) risk factor, might regulate this proteolytic event remains unknown. In this study, we assessed the susceptibility of cultured hippocampal neurons to Abeta-dependent 17 kDa tau production at different developmental stages. Our results revealed that mature neurons were more susceptible to Abeta-induced calpain activation leading to the generation of this fragment than young neurons. In addition, the production of this fragment correlated with a decrease in cell viability in mature hippocampal neurons. Second, we determined whether membrane cholesterol, a suspect player in AD, might mediate these age-dependent differences in Abeta-induced calpain activation. Filipin staining and an Amplex Red cholesterol assay showed that mature neuron membrane cholesterol levels were significantly higher than those detected in young ones. Furthermore, decreasing membrane cholesterol in mature neurons reduced their susceptibility to Abeta-dependent calpain activation, 17 kDa tau production, and cell death, whereas increasing membrane cholesterol in young neurons enhanced these Abeta-mediated cellular processes. Finally, fura-2 calcium imaging indicated that membrane cholesterol alterations might change the vulnerability of cells to Abeta insult by altering calcium influx. Together these data suggested a potential role of cholesterol in linking aging to Abeta-induced tau proteolysis in the context of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nicholson</LastName><ForeName>Alexandra M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, Feinberg School of Medicine, Northwestern University, 303 East Chicago Avenue, Chicago, IL 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferreira</LastName><ForeName>Adriana</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS039080</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS 39080</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008563">Membrane Lipids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D002154">Calpain</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002154" MajorTopicYN="N">Calpain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008563" MajorTopicYN="N">Membrane Lipids</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>4</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>4</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>5</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>10</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19357288</ArticleId><ArticleId IdType="mid">NIHMS107864</ArticleId><ArticleId IdType="pmc">PMC2705291</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0862-09.2009</ArticleId><ArticleId IdType="pii">29/14/4640</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alvarez A, Toro R, C&#xe1;ceres A, Maccioni RB. Inhibition of tau phosphorylating protein kinase cdk5 prevents beta-amyloid-induced neuronal death. FEBS Lett. 1999;459:421&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pubmed">10526177</ArticleId></ArticleIdList></Reference><Reference><Citation>Aras MA, Hartnett KA, Aizenman E. Assessment of cell viability in primary neuronal cultures. Curr Protoc Neurosci. 2008 Chapter 7:Unit 7.18.</Citation><ArticleIdList><ArticleId IdType="pubmed">18633999</ArticleId></ArticleIdList></Reference><Reference><Citation>Arispe N, Doh M. Plasma membrane cholesterol controls the cytotoxicity of Alzheimer's disease AbetaP (1&#x2013;40) and (1&#x2013;42) peptides. FASEB J. 2002;16:1526&#x2013;1536.</Citation><ArticleIdList><ArticleId IdType="pubmed">12374775</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastiaanse EM, Atsma DE, Kuijpers MM, Van der Laarse A. The effect of sarcolemmal cholesterol content on intracellular calcium ion concentration in cultured cardiomyocytes. Arch Biochem Biophys. 1994;313:58&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">8053687</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensadoun A, Weinstein D. Assay of proteins in the presence of interfering materials. Anal Biochem. 1976;70:241&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">1259145</ArticleId></ArticleIdList></Reference><Reference><Citation>Benuck M, Banay-Schwartz M, DeGuzman T, Lajtha A. Changes in brain protease activity in aging. J Neurochem. 1996;67:2019&#x2013;2029.</Citation><ArticleIdList><ArticleId IdType="pubmed">8863509</ArticleId></ArticleIdList></Reference><Reference><Citation>Besshoh S, Chen S, Brown IR, Gurd JW. Developmental changes in the association of NMDA receptors with lipid rafts. J Neurosci Res. 2007;85:1876&#x2013;1883.</Citation><ArticleIdList><ArticleId IdType="pubmed">17492792</ArticleId></ArticleIdList></Reference><Reference><Citation>Bezprozvanny I, Mattson MP. Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci. 2008;31:454&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2566585</ArticleId><ArticleId IdType="pubmed">18675468</ArticleId></ArticleIdList></Reference><Reference><Citation>Black L, Berenbaum MC. Factors affecting the dye exclusion test for cell viability. Exp Cell Res. 1964;35:9&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">14190667</ArticleId></ArticleIdList></Reference><Reference><Citation>Bojarski L, Herms J, Kuznicki J. Calcium dysregulation in Alzheimer's disease. Neurochem Int. 2008;52:621&#x2013;633.</Citation><ArticleIdList><ArticleId IdType="pubmed">18035450</ArticleId></ArticleIdList></Reference><Reference><Citation>Bottenstein JE, Sato GH. Growth of a rat neuroblastoma cell line in serum-free supplemented medium. Proc Natl Acad Sci U S A. 1979;76:514&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC382972</ArticleId><ArticleId IdType="pubmed">284369</ArticleId></ArticleIdList></Reference><Reference><Citation>Brewer GJ, Reichensperger JD, Brinton RD. Prevention of age-related dysregulation of calcium dynamics by estrogen in neurons. Neurobiol Aging. 2006;27:306&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">15961189</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown DA, London E. Structure and origin of ordered lipid domains in biological membranes. J Membr Biol. 1998a;164:103&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pubmed">9662555</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown DA, London E. Functions of lipid rafts in biological membranes. Annu Rev Cell Dev Biol. 1998b;14:111&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">9891780</ArticleId></ArticleIdList></Reference><Reference><Citation>Caroni P. New EMBO members' review: actin cytoskeleton regulation through modulation of PI(4,5)P(2) rafts. EMBO J. 2001;20:4332&#x2013;4336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125564</ArticleId><ArticleId IdType="pubmed">11500359</ArticleId></ArticleIdList></Reference><Reference><Citation>Chamberlain LH, Burgoyne RD, Gould GW. SNARE proteins are highly enriched in lipid rafts in PC12 cells: implications for the spatial control of exocytosis. Proc Natl Acad Sci U S A. 2001;98:5619&#x2013;5624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC33262</ArticleId><ArticleId IdType="pubmed">11331757</ArticleId></ArticleIdList></Reference><Reference><Citation>Christian AE, Haynes MP, Phillips MC, Rothblat GH. Use of cyclodextrins for manipulating cellular cholesterol content. J Lipid Res. 1997;38:2264&#x2013;2272.</Citation><ArticleIdList><ArticleId IdType="pubmed">9392424</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung CW, Song YH, Kim IK, Yoon WJ, Ryu BR, Jo DG, Woo HN, Kwon YK, Kim HH, Gwag BJ, Mook-Jung IH, Jung YK. Proapoptotic effects of tau cleavage product generated by caspase-3. Neurobiol Dis. 2001;8:162&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">11162250</ArticleId></ArticleIdList></Reference><Reference><Citation>Cimino M, Gelosa P, Gianella A, Nobili E, Tremoli E, Sironi L. Statins: multiple mechanisms of action in the ischemic brain. Neuroscientist. 2007;13:208&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">17519364</ArticleId></ArticleIdList></Reference><Reference><Citation>Coolican SA, Hathaway DR. Effect of L-alpha-phosphatidylinositol on a vascular smooth muscle Ca2+-dependent protease. Reduction of the Ca2+ requirement for autolysis. J Biol Chem. 1984;259:11627&#x2013;11630.</Citation><ArticleIdList><ArticleId IdType="pubmed">6090440</ArticleId></ArticleIdList></Reference><Reference><Citation>Crisby M. The role of pleiotropic effects of statins in dementia. Acta Neurol Scand Suppl. 2006;185:115&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">16866920</ArticleId></ArticleIdList></Reference><Reference><Citation>Czogalla A, Sikorski AF. Spectrin and calpain: a &#x2018;target&#x2019; and a &#x2018;sniper&#x2019; in the pathology of neuronal cells. Cell Mol Life Sci. 2005;62:1913&#x2013;1924.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11139101</ArticleId><ArticleId IdType="pubmed">15990959</ArticleId></ArticleIdList></Reference><Reference><Citation>Damke H, Baba T, Warnock DE, Schmid SL. Induction of mutant dynamin specifically blocks endocytic coated vesicle formation. J Cell Biol. 1994;127:915&#x2013;934.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2200053</ArticleId><ArticleId IdType="pubmed">7962076</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckert GP, Wood WG, M&#xfc;ller WE. Statins: drugs for Alzheimer's disease? J Neural Transm. 2005;112:1057&#x2013;1071.</Citation><ArticleIdList><ArticleId IdType="pubmed">15682268</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehehalt R, Keller P, Haass C, Thiele C, Simons K. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol. 2003;160:113&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172747</ArticleId><ArticleId IdType="pubmed">12515826</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Montalv&#xe1;n A, Assfalg-Machleidt I, Pfeiler D, Fritz H, Jochum M, Machleidt W. Mu-calpain binds to lipid bilayers via the exposed hydrophobic surface of its Ca2+-activated conformation. Biol Chem. 2006;387:617&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">16740134</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira A, Lu Q, Orecchio L, Kosik KS. Selective phosphorylation of adult tau isoforms in mature hippocampal neurons exposed to fibrillar A beta. Mol Cell Neurosci. 1997;9:220&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">9245504</ArticleId></ArticleIdList></Reference><Reference><Citation>Fletcher TL, Cameron P, De Camilli P, Banker G. The distribution of synapsin I and synaptophysin in hippocampal neurons developing in culture. J Neurosci. 1991;11:1617&#x2013;1626.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6575396</ArticleId><ArticleId IdType="pubmed">1904480</ArticleId></ArticleIdList></Reference><Reference><Citation>Fletcher TL, De Camilli P, Banker G. Synaptogenesis in hippocampal cultures: evidence indicating that axons and dendrites become competent to form synapses at different stages of neuronal development. J Neurosci. 1994;14:6695&#x2013;6706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577271</ArticleId><ArticleId IdType="pubmed">7965070</ArticleId></ArticleIdList></Reference><Reference><Citation>Foradori CD, Werner SB, Sandau US, Clapp TR, Handa RJ. Activation of the androgen receptor alters the intracellular calcium response to glutamate in primary hippocampal neurons and modulates sarco/endoplasmic reticulum calcium ATPase 2 transcription. Neuroscience. 2007;149:155&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">17870249</ArticleId></ArticleIdList></Reference><Reference><Citation>Galbiati F, Razani B, Lisanti MP. Emerging themes in lipid rafts and caveolae. Cell. 2001;106:403&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pubmed">11525727</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, Lu M, Fu Y, Garcia-Sierra F, LaPointe N, Miller R, Berry RW, Binder LI, Cryns VL. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc Natl Acad Sci U S A. 2003;100:10032&#x2013;10037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC187753</ArticleId><ArticleId IdType="pubmed">12888622</ArticleId></ArticleIdList></Reference><Reference><Citation>Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984;120:885&#x2013;890.</Citation><ArticleIdList><ArticleId IdType="pubmed">6375662</ArticleId></ArticleIdList></Reference><Reference><Citation>Goslin K, Asmussen H, Banker G. Rat hippocampal neurons in low-density culture. In: Banker G, Goslin K, editors. Culturing nerve cells. Ed 2. Cambridge, MA: MIT; 1998. pp. 339&#x2013;357.</Citation></Reference><Reference><Citation>Green KN, Smith IF, Laferla FM. Role of calcium in the pathogenesis of Alzheimer's disease and transgenic models. Subcell Biochem. 2007;45:507&#x2013;521.</Citation><ArticleIdList><ArticleId IdType="pubmed">18193650</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Fu W, Sopher BL, Miller MW, Ware CB, Martin GM, Mattson MP. Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. Nat Med. 1999;5:101&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">9883847</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibrahim M, Upreti RK, Kidwai AM. Calpain from rat intestinal epithelial cells: age-dependent dynamics during cell differentiation. Mol Cell Biochem. 1994;131:49&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">8047065</ArticleId></ArticleIdList></Reference><Reference><Citation>Igbavboa U, Avdulov NA, Schroeder F, Wood WG. Increasing age alters transbilayer fluidity and cholesterol asymmetry in synaptic plasma membranes of mice. J Neurochem. 1996;66:1717&#x2013;1725.</Citation><ArticleIdList><ArticleId IdType="pubmed">8627330</ArticleId></ArticleIdList></Reference><Reference><Citation>Igbavboa U, Eckert GP, Malo TM, Studniski AE, Johnson LN, Yamamoto N, Kobayashi M, Fujita SC, Appel TR, M&#xfc;ller WE, Wood WG, Yanagisawa K. Murine synaptosomal lipid raft protein and lipid composition are altered by expression of human apoE 3 and 4 and by increasing age. J Neurol Sci. 2005;229&#x2013;230:225&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">15760644</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonen E. Roles of lipid rafts in membrane transport. Curr Opin Cell Biol. 2001;13:470&#x2013;477.</Citation><ArticleIdList><ArticleId IdType="pubmed">11454454</ArticleId></ArticleIdList></Reference><Reference><Citation>Imahori K, Hoshi M, Ishiguro K, Sato K, Takahashi M, Shiurba R, Yamaguchi H, Takashima A, Uchida T. Possible role of tau protein kinases in pathogenesis of Alzheimer's disease. Neurobiol Aging. 1998;19:S93&#x2013;S98.</Citation><ArticleIdList><ArticleId IdType="pubmed">9562476</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato-Negishi M, Kawahara M. Neurosteroids block the increase in intracellular calcium level induced by Alzheimer's beta-amyloid protein in long-term cultured rat hippocampal neurons. Neuropsychiatr Dis Treat. 2008;4:209&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2515900</ArticleId><ArticleId IdType="pubmed">18728806</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly BL, Ferreira A. beta-Amyloid-induced dynamin 1 degradation is mediated by N-methyl-D-aspartate receptors in hippocampal neurons. J Biol Chem. 2006;281:28079&#x2013;28089.</Citation><ArticleIdList><ArticleId IdType="pubmed">16864575</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly BL, Ferreira A. Beta-amyloid disrupted synaptic vesicle endocytosis in cultured hippocampal neurons. Neuroscience. 2007;147:60&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1993833</ArticleId><ArticleId IdType="pubmed">17499934</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly BL, Vassar R, Ferreira A. Beta-amyloid-induced dynamin 1 depletion in hippocampal neurons. A potential mechanism for early cognitive decline in Alzheimer disease. J Biol Chem. 2005;280:31746&#x2013;31753.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1364535</ArticleId><ArticleId IdType="pubmed">16002400</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenessey A, Banay-Schwartz M, DeGuzman T, Lajtha A. Calpain II activity and calpastatin content in brain regions of 3- and 24-month-old rats. Neurochem Res. 1990;15:243&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">2366929</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosik KS, Joachim CL, Selkoe DJ. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci U S A. 1986;83:4044&#x2013;4048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC323662</ArticleId><ArticleId IdType="pubmed">2424016</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosik KS, Orecchio LD, Bakalis S, Neve RL. Developmentally regulated expression of specific tau sequences. Neuron. 1989;2:1389&#x2013;1397.</Citation><ArticleIdList><ArticleId IdType="pubmed">2560640</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuller LH. Statins and dementia. Curr Atheroscler Rep. 2007;9:154&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pubmed">17877925</ArticleId></ArticleIdList></Reference><Reference><Citation>Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pubmed">5432063</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang T, Bruns D, Wenzel D, Riedel D, Holroyd P, Thiele C, Jahn R. SNAREs are concentrated in cholesterol-dependent clusters that define docking and fusion sites for exocytosis. EMBO J. 2001;20:2202&#x2013;2213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125434</ArticleId><ArticleId IdType="pubmed">11331586</ArticleId></ArticleIdList></Reference><Reference><Citation>Laux T, Fukami K, Thelen M, Golub T, Frey D, Caroni P. GAP43, MARCKS, and CAP23 modulate PI(4,5)P(2) at plasmalemmal rafts, and regulate cell cortex actin dynamics through a common mechanism. J Cell Biol. 2000;149:1455&#x2013;1472.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2175130</ArticleId><ArticleId IdType="pubmed">10871285</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee VM. Regulation of tau phosphorylation in Alzheimer's disease. Ann N Y Acad Sci. 1996;777:107&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">8624072</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pubmed">14907713</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma H, Hata I, Shih M, Fukiage C, Nakamura Y, Azuma M, Shearer TR. Lp82 is the dominant form of calpain in young mouse lens. Exp Eye Res. 1999;68:447&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pubmed">10192802</ArticleId></ArticleIdList></Reference><Reference><Citation>Manya H, Inomata M, Fujimori T, Dohmae N, Sato Y, Takio K, Nabeshima Y, Endo T. Klotho protein deficiency leads to overactivation of mu-calpain. J Biol Chem. 2002;277:35503&#x2013;35508.</Citation><ArticleIdList><ArticleId IdType="pubmed">12119304</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Lovell MA, Ehmann WD, Markesbery WR. Comparison of the effects of elevated intracellular aluminum and calcium levels on neuronal survival and tau immunoreactivity. Brain Res. 1993;602:21&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">8448655</ArticleId></ArticleIdList></Reference><Reference><Citation>Miida T, Hirayama S, Nakamura Y. Cholesterol-independent effects of statins and new therapeutic targets: ischemic stroke and dementia. J Atheroscler Thromb. 2004;11:253&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">15557707</ArticleId></ArticleIdList></Reference><Reference><Citation>Miida T, Takahashi A, Ikeuchi T. Prevention of stroke and dementia by statin therapy: experimental and clinical evidence of their pleiotropic effects. Pharmacol Ther. 2007;113:378&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pubmed">17113151</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy SN, Miller RJ. Two distinct quisqualate receptors regulate Ca2+ homeostasis in hippocampal neurons in vitro. Mol Pharmacol. 1989;35:671&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pubmed">2566904</ArticleId></ArticleIdList></Reference><Reference><Citation>Novak M, Kabat J, Wischik CM. Molecular characterization of the minimal protease resistant tau unit of the Alzheimer's disease paired helical filament. EMBO J. 1993;12:365&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC413214</ArticleId><ArticleId IdType="pubmed">7679073</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr JD. Statins in the spectrum of neurologic disease. Curr Atheroscler Rep. 2008;10:11&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">18366980</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SY, Ferreira A. The generation of a 17 kDa neurotoxic fragment: an alternative mechanism by which tau mediates &#x3b2;-amyloid-induced neurodegeneration. J Neurosci. 2005;25:5365&#x2013;5375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1352316</ArticleId><ArticleId IdType="pubmed">15930385</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SY, Tournell C, Sinjoanu RC, Ferreira A. Caspase-3- and calpain-mediated tau cleavage are differentially prevented by estrogen and testosterone in beta-amyloid-treated hippocampal neurons. Neuroscience. 2007;144:119&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1955430</ArticleId><ArticleId IdType="pubmed">17055174</ArticleId></ArticleIdList></Reference><Reference><Citation>Pevalova M, Filipcik P, Novak M, Avila J, Iqbal K. Post-translational modifications of tau protein. Bratisl Lek Listy. 2006;107:346&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pubmed">17262986</ArticleId></ArticleIdList></Reference><Reference><Citation>Pontremoli S, Salamino F, Sparatore B, Michetti M, Sacco O, Melloni E. Following association to the membrane, human erythrocyte procalpain is converted and released as fully active calpain. Biochim Biophys Acta. 1985;831:335&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pubmed">2996607</ArticleId></ArticleIdList></Reference><Reference><Citation>Pooler AM, Xi SC, Wurtman RJ. The 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitor pravastatin enhances neurite outgrowth in hippocampal neurons. J Neurochem. 2006;97:716&#x2013;723.</Citation><ArticleIdList><ArticleId IdType="pubmed">16573653</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapoport M, Ferreira A. PD98059 prevents neurite degeneration induced by fibrillar beta-amyloid in mature hippocampal neurons. J Neurochem. 2000;74:125&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">10617113</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A. Tau is essential to beta-amyloid-induced neurotoxicity. Proc Natl Acad Sci U S A. 2002;99:6364&#x2013;6369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122954</ArticleId><ArticleId IdType="pubmed">11959919</ArticleId></ArticleIdList></Reference><Reference><Citation>Resende R, Pereira C, Agostinho P, Vieira AP, Malva JO, Oliveira CR. Susceptibility of hippocampal neurons to Abeta peptide toxicity is associated with perturbation of Ca2+ homeostasis. Brain Res. 2007;1143:11&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">17336275</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science. 2007;316:750&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Saido TC, Shibata M, Takenawa T, Murofushi H, Suzuki K. Positive regulation of mu-calpain action by polyphosphoinositides. J Biol Chem. 1992;267:24585&#x2013;24590.</Citation><ArticleIdList><ArticleId IdType="pubmed">1332961</ArticleId></ArticleIdList></Reference><Reference><Citation>Saido TC, Suzuki H, Yamazaki H, Tanoue K, Suzuki K. In situ capture of mu-calpain activation in platelets. J Biol Chem. 1993;268:7422&#x2013;7426.</Citation><ArticleIdList><ArticleId IdType="pubmed">8463275</ArticleId></ArticleIdList></Reference><Reference><Citation>Sans N, Petralia RS, Wang YX, Blahos J, 2nd, Hell JW, Wenthold RJ. A developmental change in NMDA receptor-associated proteins at hippocampal synapses. J Neurosci. 2000;20:1260&#x2013;1271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6774158</ArticleId><ArticleId IdType="pubmed">10648730</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer's disease. Annu Rev Cell Biol. 1994;10:373&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">7888181</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma DK, Choudhury A, Singh RD, Wheatley CL, Marks DL, Pagano RE. Glycosphingolipids internalized via caveolar-related endocytosis rapidly merge with the clathrin pathway in early endosomes and form microdomains for recycling. J Biol Chem. 2003;278:7564&#x2013;7572.</Citation><ArticleIdList><ArticleId IdType="pubmed">12482757</ArticleId></ArticleIdList></Reference><Reference><Citation>Simons K, Ikonen E. Functional rafts in cell membranes. Nature. 1997;387:569&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">9177342</ArticleId></ArticleIdList></Reference><Reference><Citation>Simons K, Ikonen E. How cells handle cholesterol. Science. 2000;290:1721&#x2013;1726.</Citation><ArticleIdList><ArticleId IdType="pubmed">11099405</ArticleId></ArticleIdList></Reference><Reference><Citation>Simons K, van Meer G. Lipid sorting in epithelial cells. Biochemistry. 1988;27:6197&#x2013;6202.</Citation><ArticleIdList><ArticleId IdType="pubmed">3064805</ArticleId></ArticleIdList></Reference><Reference><Citation>Sponne I, Fifre A, Koziel V, Oster T, Olivier JL, Pillot T. Membrane cholesterol interferes with neuronal apoptosis induced by soluble oligomers but not fibrils of amyloid-beta peptide. FASEB J. 2004;18:836&#x2013;838.</Citation><ArticleIdList><ArticleId IdType="pubmed">15001562</ArticleId></ArticleIdList></Reference><Reference><Citation>Subasinghe S, Unabia S, Barrow CJ, Mok SS, Aguilar MI, Small DH. Cholesterol is necessary both for the toxic effect of Abeta peptides on vascular smooth muscle cells and for Abeta binding to vascular smooth muscle cell membranes. J Neurochem. 2003;84:471&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pubmed">12558967</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun DA, Sombati S, Blair RE, DeLorenzo RJ. Long-lasting alterations in neuronal calcium homeostasis in an in vitro model of stroke-induced epilepsy. Cell Calcium. 2004;35:155&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">14706289</ArticleId></ArticleIdList></Reference><Reference><Citation>Takashima A. GSK-3 is essential in the pathogenesis of Alzheimer's disease. J Alzheimers Dis. 2006;9:309&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">16914869</ArticleId></ArticleIdList></Reference><Reference><Citation>Takashima A, Noguchi K, Sato K, Hoshino T, Imahori K. Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. Proc Natl Acad Sci U S A. 1993;90:7789&#x2013;7793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47228</ArticleId><ArticleId IdType="pubmed">8356085</ArticleId></ArticleIdList></Reference><Reference><Citation>Tompa P, Emori Y, Sorimachi H, Suzuki K, Friedrich P. Domain III of calpain is a Ca2+-regulated phospholipid-binding domain. Biochem Biophys Res Commun. 2001;280:1333&#x2013;1339.</Citation><ArticleIdList><ArticleId IdType="pubmed">11162675</ArticleId></ArticleIdList></Reference><Reference><Citation>Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979;76:4350&#x2013;4354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC411572</ArticleId><ArticleId IdType="pubmed">388439</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai LH, Lee MS, Cruz J. Cdk5, a therapeutic target for Alzheimer's disease? Biochim Biophys Acta. 2004;1697:137&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">15023356</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Bliek AM, Redelmeier TE, Damke H, Tisdale EJ, Meyerowitz EM, Schmid SL. Mutations in human dynamin block an intermediate stage in coated vesicle formation. J Cell Biol. 1993;122:553&#x2013;563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2119674</ArticleId><ArticleId IdType="pubmed">8101525</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaughan CJ. Prevention of stroke and dementia with statins: effects beyond lipid lowering. Am J Cardiol. 2003;91:23B&#x2013;29B.</Citation><ArticleIdList><ArticleId IdType="pubmed">12615295</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Z, Song MS, MacTavish D, Jhamandas JH, Kar S. Role of calpain and caspase in beta-amyloid-induced cell death in rat primary septal cultured neurons. Neuropharmacology. 2008;54:721&#x2013;733.</Citation><ArticleIdList><ArticleId IdType="pubmed">18222494</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolozin B, Manger J, Bryant R, Cordy J, Green RC, McKee A. Re-assessing the relationship between cholesterol, statins and Alzheimer's disease. Acta Neurol Scand Suppl. 2006;185:63&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">16866913</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood JG, Mirra SS, Pollock NJ, Binder LI. Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein tau (tau) Proc Natl Acad Sci U S A. 1986;83:4040&#x2013;4043.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC323661</ArticleId><ArticleId IdType="pubmed">2424015</ArticleId></ArticleIdList></Reference><Reference><Citation>Yakunin AF, Hallenbeck PC. A luminol/iodophenol chemiluminescent detection system for Western immunoblots. Anal Biochem. 1998;258:146&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">9527863</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19358576</PMID><DateCompleted><Year>2009</Year><Month>08</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1520-4995</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>26</Issue><PubDate><Year>2009</Year><Month>Jul</Month><Day>07</Day></PubDate></JournalIssue><Title>Biochemistry</Title><ISOAbbreviation>Biochemistry</ISOAbbreviation></Journal><ArticleTitle>Evidence for novel beta-sheet structures in Iowa mutant beta-amyloid fibrils.</ArticleTitle><Pagination><StartPage>6072</StartPage><EndPage>6084</EndPage><MedlinePgn>6072-84</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/bi9002666</ELocationID><Abstract><AbstractText>Asp23-to-Asn mutation within the coding sequence of beta-amyloid, called the Iowa mutation, is associated with early onset, familial Alzheimer's disease and cerebral amyloid angiopathy, in which patients develop neuritic plaques and massive vascular deposition predominantly of the mutant peptide. We examined the mutant peptide, D23N-Abeta40, by electron microscopy, X-ray diffraction, and solid-state NMR spectroscopy. D23N-Abeta40 forms fibrils considerably faster than the wild-type peptide (k = 3.77 x 10(-3) min(-1) and 1.07 x 10(-4) min(-1) for D23N-Abeta40 and the wild-type peptide WT-Abeta40, respectively) and without a lag phase. Electron microscopy shows that D23N-Abeta40 forms fibrils with multiple morphologies. X-ray fiber diffraction shows a cross-beta pattern, with a sharp reflection at 4.7 A and a broad reflection at 9.4 A, which is notably smaller than the value for WT-Abeta40 fibrils (10.4 A). Solid-state NMR measurements indicate molecular level polymorphism of the fibrils, with only a minority of D23N-Abeta40 fibrils containing the in-register, parallel beta-sheet structure commonly found in WT-Abeta40 fibrils and most other amyloid fibrils. Antiparallel beta-sheet structures in the majority of fibrils are indicated by measurements of intermolecular distances through (13)C-(13)C and (15)N-(13)C dipole-dipole couplings. An intriguing possibility exists that there is a relationship between the aberrant structure of D23N-Abeta40 fibrils and the unusual vasculotropic clinical picture in these patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tycko</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892-0520, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sciarretta</LastName><ForeName>Kimberly L</ForeName><Initials>KL</Initials></Author><Author ValidYN="Y"><LastName>Orgel</LastName><ForeName>Joseph P R O</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Meredith</LastName><ForeName>Stephen C</ForeName><Initials>SC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P41 RR008630</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 HL007237</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL07237</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS042852</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS042852</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>Z01 DK029061</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RR-08630</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biochemistry</MedlineTA><NlmUniqueID>0370623</NlmUniqueID><ISSNLinking>0006-2960</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052160">Benzothiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>2390-54-7</RegistryNumber><NameOfSubstance UI="C009462">thioflavin T</NameOfSubstance></Chemical><Chemical><RegistryNumber>30KYC7MIAI</RegistryNumber><NameOfSubstance UI="D001224">Aspartic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>3KX376GY7L</RegistryNumber><NameOfSubstance UI="D018698">Glutamic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>47E5O17Y3R</RegistryNumber><NameOfSubstance UI="D010649">Phenylalanine</NameOfSubstance></Chemical><Chemical><RegistryNumber>GMW67QNF9C</RegistryNumber><NameOfSubstance UI="D007930">Leucine</NameOfSubstance></Chemical><Chemical><RegistryNumber>K3Z4F929H6</RegistryNumber><NameOfSubstance UI="D008239">Lysine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D028227" MajorTopicYN="N">Amyloid Neuropathies, Familial</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001224" MajorTopicYN="N">Aspartic Acid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D052160" MajorTopicYN="N">Benzothiazoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018698" MajorTopicYN="N">Glutamic Acid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007930" MajorTopicYN="N">Leucine</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008239" MajorTopicYN="N">Lysine</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046529" MajorTopicYN="N">Microscopy, Electron, Transmission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020125" MajorTopicYN="Y">Mutation, Missense</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019906" MajorTopicYN="N">Nuclear Magnetic Resonance, Biomolecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010649" MajorTopicYN="N">Phenylalanine</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017433" MajorTopicYN="N">Protein Structure, Secondary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013050" MajorTopicYN="N">Spectrometry, Fluorescence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014961" MajorTopicYN="N">X-Ray Diffraction</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>4</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>4</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>8</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>7</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19358576</ArticleId><ArticleId IdType="mid">NIHMS153357</ArticleId><ArticleId IdType="pmc">PMC2910621</ArticleId><ArticleId IdType="doi">10.1021/bi9002666</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tycko R. Characterization of amyloid structures at the molecular level by solid state nuclear magnetic resonance spectroscopy. Methods Enzymol. 2006;413:103&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1633711</ArticleId><ArticleId IdType="pubmed">17046393</ArticleId></ArticleIdList></Reference><Reference><Citation>Tycko R. Molecular structure of amyloid fibrils: insights from solid state NMR. Q. Rev. Biophys. 2006;39:1&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">16772049</ArticleId></ArticleIdList></Reference><Reference><Citation>Balbach JJ, Petkova AT, Oyler NA, Antzutkin ON, Gordon DJ, Meredith SC, Tycko R. Supramolecular structure in full-length Alzheimer&#x2019;s &#x3b2;-amyloid fibrils: evidence for a parallel beta-sheet organization from solid-state nuclear magnetic resonance. Biophys. J. 2002;83:1205&#x2013;1216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1302222</ArticleId><ArticleId IdType="pubmed">12124300</ArticleId></ArticleIdList></Reference><Reference><Citation>Benzinger TL, Gregory DM, Burkoth TS, Miller-Auer H, Lynn DG, Botto RE, Meredith SC. Propagating structure of Alzheimer&#x2019;s &#x3b2;-amyloid(10-35) is parallel &#x3b2;-sheet with residues in exact register. Proc. Natl. Acad. Sci. U.S.A. 1998;95:13407&#x2013;13412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24832</ArticleId><ArticleId IdType="pubmed">9811813</ArticleId></ArticleIdList></Reference><Reference><Citation>Antzutkin ON, Balbach JJ, Leapman RD, Rizzo NW, Reed J, Tycko R. Multiple quantum solid-state NMR indicates a parallel, not antiparallel, organization of &#x3b2;-sheets in Alzheimer&#x2019;s &#x3b2;-amyloid fibrils. Proc. Natl. Acad. Sci. U.S.A. 2000;97:13045&#x2013;13050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27175</ArticleId><ArticleId IdType="pubmed">11069287</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkova AT, Leapman RD, Guo ZH, Yau WM, Mattson MP, Tycko R. Self-propagating, molecular-level polymorphism in Alzheimer&#x2019;s &#x3b2;-amyloid fibrils. Science. 2005;307:262&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">15653506</ArticleId></ArticleIdList></Reference><Reference><Citation>Paravastu AK, Leapman RD, Yau WM, Tycko R. Molecular structural basis for polymorphism in Alzheimer&#x2019;s &#x3b2;-amyloid fibrils. Proc. Natl. Acad. Sci. U.S.A. 2008;105:18349&#x2013;18354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2587602</ArticleId><ArticleId IdType="pubmed">19015532</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan JC, Oyler NA, Yau WM, Tycko R. Parallel &#x3b2;-sheets and polar zippers in amyloid fibrils formed by residues 10-39 of the yeast prion protein Ure2p. Biochemistry. 2005;44:10669&#x2013;10680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1380259</ArticleId><ArticleId IdType="pubmed">16060675</ArticleId></ArticleIdList></Reference><Reference><Citation>Shewmaker F, Wickner RB, Tycko R. Amyloid of the prion domain of Sup35p has an in-register parallel &#x3b2;-sheet structure. Proc. Natl. Acad. Sci. U.S.A. 2006;103:19754&#x2013;19759.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1750918</ArticleId><ArticleId IdType="pubmed">17170131</ArticleId></ArticleIdList></Reference><Reference><Citation>T&#xf6;r&#xf6;k M, Milton S, Kayed R, Wu P, McIntire T, Glabe CG, Langen R. Structural and dynamic features of Alzheimer&#x2019;s A&#x3b2; peptide in amyloid fibrils studied by site-directed spin labeling. J. Biol. Chem. 2002;277:40810&#x2013;40805.</Citation><ArticleIdList><ArticleId IdType="pubmed">12181315</ArticleId></ArticleIdList></Reference><Reference><Citation>Der-Sarkissian A, Jao CC, Chen J, Langen R. Structural organization of alpha-synuclein fibrils studied by site-directed spin labeling. J. Biol. Chem. 2003;278:37530&#x2013;37535.</Citation><ArticleIdList><ArticleId IdType="pubmed">12815044</ArticleId></ArticleIdList></Reference><Reference><Citation>Luca S, Yau WM, Leapman R, Tycko R. Peptide conformation and supramolecular organization in amylin fibrils: constraints from solid-state NMR. Biochemistry. 2007;46:13505&#x2013;13522.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2562526</ArticleId><ArticleId IdType="pubmed">17979302</ArticleId></ArticleIdList></Reference><Reference><Citation>Balbach JJ, Ishii Y, Antzutkin ON, Leapman RD, Rizzo NW, Dyda F, Reed J, Tycko R. Amyloid fibril formation by A&#x3b2;16-22, a seven-residue fragment of the Alzheimer&#x2019;s &#x3b2;-amyloid peptide, and structural characterization by solid state NMR. Biochemistry. 2000;39:13748&#x2013;13759.</Citation><ArticleIdList><ArticleId IdType="pubmed">11076514</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkova AT, Buntkowsky G, Dyda F, Leapman RD, Yau WM, Tycko R. Solid state NMR reveals a pH-dependent antiparallel beta-sheet registry in fibrils formed by a &#x3b2;-amyloid peptide. J. Mol. Biol. 2004;335:247&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">14659754</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon DJ, Balbach JJ, Tycko R, Meredith SC. Increasing the amphiphilicity of an amyloidogenic peptide changes the &#x3b2;-sheet structure in the fibrils from antiparallel to parallel. Biophys. J. 2004;86:428&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1303808</ArticleId><ArticleId IdType="pubmed">14695285</ArticleId></ArticleIdList></Reference><Reference><Citation>Lansbury PT, Jr., Costa PR, Griffiths JM, Simon EJ, Auger M, Halverson KJ, Kocisko DA, Hendsch ZS, Ashburn TT, Spencer RG. Structural model for the &#x3b2;-amyloid fibril based on interstrand alignment of an antiparallel-sheet comprising a C-terminal peptide. Nat. Struct. Biol. 1995;2:990&#x2013;998.</Citation><ArticleIdList><ArticleId IdType="pubmed">7583673</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldsbury CS, Wirtz S, M&#xfc;ller SA, Sunderji S, Wicki P, Aebi U, Frey P. Studies on the in vitro assembly of A&#x3b2;1-40: implications for the search for A&#x3b2; fibril formation inhibitors. J. Struct. Biol. 2000;130:217&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">10940227</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkova AT, Ishii Y, Balbach JJ, Antzutkin ON, Leapman RD, Delaglio F, Tycko R. A structural model for Alzheimer&#x2019;s &#x3b2;-amyloid fibrils based on experimental constraints from solid state NMR. Proc. Natl. Acad. Sci. U.S.A. 2002;99:16742&#x2013;16747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC139214</ArticleId><ArticleId IdType="pubmed">12481027</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkova AT, Yau WM, Tycko R. Experimental constraints on quaternary structure in Alzheimer&#x2019;s &#x3b2;-amyloid fibrils. Biochemistry. 2006;45:498&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1435828</ArticleId><ArticleId IdType="pubmed">16401079</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciarretta KL, Gordon DJ, Petkova AT, Tycko R, Meredith SC. A&#x3b2;40-lactam(D23/K28) models a conformation highly favorable for nucleation of amyloid. Biochemistry. 2005;44:6003&#x2013;6014.</Citation><ArticleIdList><ArticleId IdType="pubmed">15835889</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraser PE, Nguyen JT, Inouye H, Surewicz WT, Selkoe DJ, Podlisny MB, Kirschner DA. Fibril formation by primate, rodent, and Dutch-hemorrhagic analogues of Alzheimer&#x2019;s amyloid &#x3b2;-protein. Biochemistry. 1992;31:10716&#x2013;10723.</Citation><ArticleIdList><ArticleId IdType="pubmed">1420187</ArticleId></ArticleIdList></Reference><Reference><Citation>van Nostrand W, Melchor JP, Cho HS, Greenberg SM, Rebeck GW. Pathogenic effects of D23N Iowa mutant amyloid &#x3b2;-protein. J. Biol. Chem. 2001;276:32860&#x2013;32866.</Citation><ArticleIdList><ArticleId IdType="pubmed">11441013</ArticleId></ArticleIdList></Reference><Reference><Citation>Grabowski TJ, Cho HS, Vonsattel JP, Rebeck GW, Greenberg SM. Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy. Ann. Neurol. 2001;49:697&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">11409420</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar-Singh S, Julliams A, Nuydens R, Ceuterick C, Labeur C, Serneels C, Vennekens K, Van Osta P, Geerts H, De Strooper B, Van Broekhoven C. In vitro studies of Flemish, Dutch and wild-type &#x3b2;-amyloid provide evidence for two-staged toxicity. Neurobiol. Dis. 2002;11:330&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">12505425</ArticleId></ArticleIdList></Reference><Reference><Citation>Miravelle L, Tokuda T, Chiarle R, Giaccone G, Bugiani O, Tagliavini F, Frangione B, Ghiso J. Substitutions at codon 22 of Alzheimer&#x2019;s A&#x3b2; peptide induce diverse conformational changes and apoptotic effects in human cerebral endothelial cells. J. Biol. Chem. 2000;275:27110&#x2013;27116.</Citation><ArticleIdList><ArticleId IdType="pubmed">10821838</ArticleId></ArticleIdList></Reference><Reference><Citation>Sian AK, Frears ER, El-Agnaf OMA, Patel BP, Manca MF, Siligardi G, Hussain R, Austen BM. Oligomerization of &#x3b2;-amyloid of the Alzheimer&#x2019;s and Dutch-cerebral-hemorrhage types. Biochem. J. 2000;349:299&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1221151</ArticleId><ArticleId IdType="pubmed">10861242</ArticleId></ArticleIdList></Reference><Reference><Citation>Soto C, Castano EM, Frangione B, Inestrosa NC. The R-helical and &#x3b2;-strand transition in the amino-terminal fragment of amyloid &#x3b2;-peptide modulates amyloid formation. J. Biol. Chem. 1995;270:3063&#x2013;3067.</Citation><ArticleIdList><ArticleId IdType="pubmed">7852387</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis J, van Nostrand WE. Enhanced pathologic properties of Dutch-type mutant amyloid &#x3b2;-protein. Proc. Natl. Acad. Sci. U.S.A. 1996;93:2996&#x2013;3000.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC39749</ArticleId><ArticleId IdType="pubmed">8610157</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Lomakin A, Benedek GB, Condron MM, Teplow DB. Amyloid &#x3b2;-protein fibrillogenesis. J. Biol. Chem. 1997;272:22364&#x2013;22372.</Citation><ArticleIdList><ArticleId IdType="pubmed">9268388</ArticleId></ArticleIdList></Reference><Reference><Citation>Esler WP, Felix AM, Stimson ER, Lachenmann MJ, Ghilardi JR, Lu Y-A, Vinters HV, Mantyh PW, Lee JP, Maggio JE. Activation barriers to structural transition determine deposition rates of Alzheimer&#x2019;s disease A&#x3b2; amyloid. J. Struct. Biol. 2000;130:174&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">10940224</ArticleId></ArticleIdList></Reference><Reference><Citation>Melchor JP, McVoy L, Van Nostrand WE. Charge alterations of E22 enhance the pathogenic properties of Amyoid &#x3b2;-protein. J. Neurochem. 2000;74:2209&#x2013;2212.</Citation><ArticleIdList><ArticleId IdType="pubmed">10800967</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, Stenh C, Luthman J, Teplow DB, Younkin SG, Naslund J, Lannfelt L. The &#x201c;arctic&#x201d; APP mutation (E693G) causes Alzheimer&#x2019;s disease by enhanced A&#x3b2; protofibril formation. Nat. Neurosci. 2001;4:887&#x2013;893.</Citation><ArticleIdList><ArticleId IdType="pubmed">11528419</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomiyama T, Nagata T, Shimada H, Teraoka R, Fukushima A, Kanemitsu H, Takuma H, Kuwano R, Imagawa M, Ataka S, Wada Y, Yoshioka E, Nishizaki T, Watanabe Y, Mori H. A new amyloid &#x3b2; variant favoring oligomerization in Alzheimer&#x2019;s-type dementia. Ann. Neurol. 2008;63:377&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pubmed">18300294</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott D. On optimal and data-based histograms. Biometrika. 1979;66:605&#x2013;610.</Citation></Reference><Reference><Citation>Stubbs G. Developments in fiber diffraction. Curr. Opin. Struct. Biol. 1999;9:615&#x2013;619.</Citation><ArticleIdList><ArticleId IdType="pubmed">10508775</ArticleId></ArticleIdList></Reference><Reference><Citation>Torbet J. Using magnetic orientation to study structure and assembly. Trends Biochem. Sci. 1987;12:327&#x2013;330.</Citation></Reference><Reference><Citation>Bennett AE, Rienstra CM, Auger M, Lakshmi KV, Griffin RG. Heteronuclear decoupling in rotating solids. J. Chem. Phys. 1995;103:6951&#x2013;6958.</Citation></Reference><Reference><Citation>Tycko R. Symmetry-based constant-time homonuclear dipolar recoupling in solid state NMR. J. Chem. Phys. 2007;126:064506-1&#x2013;064506-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17313228</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishii Y, Balbach JJ, Tycko R. Measurement of dipole-coupled lineshapes in a many-spin system by constant-time two-dimensional solid state NMR with high-speed magic-angle spinning. Chem. Phys. 2001;266:231&#x2013;236.</Citation></Reference><Reference><Citation>Gullion T, Schaefer J. Rotational-echo double-resonance NMR. J. Magn. Reson. 1989;81:196&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">22152360</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson RC, Gullion T, Joers JM, Shapiro M, Edwin Villhauer EB, Weber Conformation of [1-13C,15N] acetyl-l-carnitine. Rotational-echo, double-resonance nuclear magnetic resonance spectroscopy. J. Am. Chem. Soc. 1995;117:10546&#x2013;10550.</Citation></Reference><Reference><Citation>Jaroniec CP, Tounge BA, Herzfeld J, Griffin RG. Frequency selective heteronuclear dipolar recoupling in rotating solids: accurate 13C-15N distance measurements in uniformly 13C,15N-labeled peptides. J. Am. Chem. Soc. 2001;123:3507&#x2013;3519.</Citation><ArticleIdList><ArticleId IdType="pubmed">11472123</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkova AT, Tycko R. Sensitivity enhancement in structural measurements by solid state NMR through pulsed spin locking. J. Magn. Reson. 2002;155:293&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">12036340</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett AE, Rienstra CM, Griffiths JM, Zhen W, Lansbury PT, Jr., Griffin RG. Homonuclear radio frequency-driven recoupling in rotating solids. J. Chem. Phys. 1998;108:9463&#x2013;9479.</Citation></Reference><Reference><Citation>Ishii Y. 13C-13C dipolar recoupling under very fast magic angle spinning in solid state nuclear magnetic resonance: applications to distance measurements, spectral assignments, and high-throughput secondary-structure determination. J. Chem. Phys. 2001;114:8473&#x2013;8483.</Citation></Reference><Reference><Citation>Morcombe CR, Gaponenko V, Byrd RA, Zilm KW. 13C CPMAS spectroscopy of deuterated proteins: CP dynamics, line shapes, and T1 relaxation. J. Am. Chem. Soc. 2005;127:397&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">15631490</ArticleId></ArticleIdList></Reference><Reference><Citation>Takegoshi K, Nakamura S, Terao T. 13C-1H dipolar assisted rotational resonance in magic-angle spinning NMR. Chem. Phys. Lett. 2001;344:631&#x2013;637.</Citation></Reference><Reference><Citation>Paravastu AK, Petkova AT, Tycko R. Polymorphic fibril formation by residues 10-40 of the Alzheimer&#x2019;s &#x3b2;-amyloid peptide. Biophys. J. 2006;90:4618&#x2013;4629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1471876</ArticleId><ArticleId IdType="pubmed">16565054</ArticleId></ArticleIdList></Reference><Reference><Citation>Wasmer C, Lange A, Van Melckebeke H, Siemer AB, Riek R, Meier BH. Amyloid fibrils of the HET-s(218-289) prion form a beta solenoid with a triangular hydrophobic core. Science. 2008;319:1523&#x2013;1526.</Citation><ArticleIdList><ArticleId IdType="pubmed">18339938</ArticleId></ArticleIdList></Reference><Reference><Citation>Wishart DS, Bigam CG, Holm A, Hodges RS, Sykes BD. 1H, 13C and 15N random coil NMR chemical shifts of the common amino acids. I. Investigations of nearest-neighbor effects. J. Biomol. NMR. 1995;5:67&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">7881273</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinters HV. Cerebral amyloid angiopathy. A critical review. Stroke. 1987;18:311&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">3551211</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandybur TI. The incidence of cerebral amyloid angiopathy in Alzheimer&#x2019;s disease. Neurology. 1975;25:120&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">46597</ArticleId></ArticleIdList></Reference><Reference><Citation>Joachim CL, Morris JH, Selkoe DJ. Clinically diagnosed Alzheimer&#x2019;s disease: autopsy results in 150 cases. Ann. Neurol. 1988;24:50&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">3415200</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg SM, Rebeck GW, Vonsattel JPG, Gomez-Isla T, Hyman BT. Apolipoprotein E &#x3b5;4 and cerebral hemorrhage associated with amyloid angiopathy. Ann. Neurol. 1995;38:254&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">7654074</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert JJ, Vinters HV. Cerebral amyloid angiopathy: incidence and complications in the aging brain. I. Cerebral hemorrhage. Stroke. 1983;14:915&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">6658995</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19360898</PMID><DateCompleted><Year>2009</Year><Month>09</Month><Day>04</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8249</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>1</Issue><PubDate><Year>2009</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system.</ArticleTitle><Pagination><StartPage>48</StartPage><EndPage>54</EndPage><MedlinePgn>48-54</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ana.21623</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Accumulation of amyloid-beta (Abeta) by overproduction or underclearance in the central nervous system (CNS) is hypothesized to be a necessary event in the pathogenesis of Alzheimer's disease. However, previously, there has not been a method to determine drug effects on Abeta production or clearance in the human CNS. The objective of this study was to determine the effects of a gamma-secretase inhibitor on the production of Abeta in the human CNS.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We utilized a recently developed method of stable-isotope labeling combined with cerebrospinal fluid sampling to directly measure Abeta production during treatment of a gamma-secretase inhibitor, LY450139. We assessed whether this drug could decrease CNS Abeta production in healthy men (age range, 21-50 years) at single oral doses of 100, 140, or 280mg (n = 5 per group).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">LY450139 significantly decreased the production of CNS Abeta in a dose-dependent fashion, with inhibition of Abeta generation of 47, 52, and 84% over a 12-hour period with doses of 100, 140, and 280mg, respectively. There was no difference in Abeta clearance.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Stable isotope labeling of CNS proteins can be utilized to assess the effects of drugs on the production and clearance rates of proteins targeted as potential disease-modifying treatments for Alzheimer's disease and other CNS disorders. Results from this approach can assist in making decisions about drug dosing and frequency in the design of larger and longer clinical trials for diseases such as Alzheimer's disease, and may accelerate effective drug validation. Ann Neurol 2009.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA. batemanr@wustl.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siemers</LastName><ForeName>Eric R</ForeName><Initials>ER</Initials></Author><Author ValidYN="Y"><LastName>Mawuenyega</LastName><ForeName>Kwasi G</ForeName><Initials>KG</Initials></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Guolin</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Browning</LastName><ForeName>Karen R</ForeName><Initials>KR</Initials></Author><Author ValidYN="Y"><LastName>Sigurdson</LastName><ForeName>Wendy C</ForeName><Initials>WC</Initials></Author><Author ValidYN="Y"><LastName>Yarasheski</LastName><ForeName>Kevin E</ForeName><Initials>KE</Initials></Author><Author ValidYN="Y"><LastName>Friedrich</LastName><ForeName>Stuart W</ForeName><Initials>SW</Initials></Author><Author ValidYN="Y"><LastName>Demattos</LastName><ForeName>Ronald B</ForeName><Initials>RB</Initials></Author><Author ValidYN="Y"><LastName>May</LastName><ForeName>Patrick C</ForeName><Initials>PC</Initials></Author><Author ValidYN="Y"><LastName>Paul</LastName><ForeName>Steven M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1UL1 RR024992</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK056341</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>2P60 DK020579-31</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG030946</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>SP30 DK056341-08</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000448</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P60 DK020579</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK020579</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 RR000954</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5P41 RR000954-32</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR024992</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001381">Azepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C484278">N2-((2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-L-alaninamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber><NameOfSubstance UI="D000409">Alanine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Ann Neurol. 2010 Jan;67(1):143-4; author reply 144-5. doi: 10.1002/ana.21929.</RefSource><PMID Version="1">20186950</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001381" MajorTopicYN="N">Azepines</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002851" MajorTopicYN="N">Chromatography, High Pressure Liquid</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053719" MajorTopicYN="N">Tandem Mass Spectrometry</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Conflict of Interest Statement: Drs. Bateman and Holtzman are co-founders of a company (C2N Diagnostics) which has licensed a pending Washington University patent on the technology described in this article. Drs. Siemers, Friedrich, Demattos, May and Paul are employees of Eli Lilly, the sponsor of this study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>4</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>4</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19360898</ArticleId><ArticleId IdType="mid">NIHMS86184</ArticleId><ArticleId IdType="pmc">PMC2730994</ArticleId><ArticleId IdType="doi">10.1002/ana.21623</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003;60:1119&#x2013;1122.</Citation><ArticleIdList><ArticleId IdType="pubmed">12925369</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet. 2006;368:387&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">16876668</ArticleId></ArticleIdList></Reference><Reference><Citation>Skovronsky DM, Lee VMY, Trojanowski JQ. Neurodegenerative diseases: New concepts of pathogenesis and their therapeutic implications. Annual Review of Pathology. 2006;Vol. 1:151&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">18039111</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde TE, Dickson D, Hutton M. Filling the gaps in the A&#x3b2; cascade hypothesis of Alzheimer's disease. Current Alzheimer Research. 2006;3:421&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pubmed">17168641</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron. 2004;44:181&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450169</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid &#x3b2;-peptide. Nature Reviews Molecular Cell Biology. 2007;8:101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Dovey HF, John V, Anderson JP, et al. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem. 2001;76:173&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">11145990</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito J, May P, O'Dell M, et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-&#x3b2; metabolism and half-life. J. Neurosci. 2003;23:8844&#x2013;8853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740389</ArticleId><ArticleId IdType="pubmed">14523085</ArticleId></ArticleIdList></Reference><Reference><Citation>Best JD, Smith DW, Reilly MA, et al. The novel &#x3b3; secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]- 4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse. Journal of Pharmacology and Experimental Therapeutics. 2007;320:552&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pubmed">17099072</ArticleId></ArticleIdList></Reference><Reference><Citation>Imbimbo BP, Del Giudice E, Colavito D, et al. 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl) -cyclopropanecarboxylic acid (CHF5074), a novel &#x3b3;-secretase modulator, reduces brain &#x3b2;-amyloid pathology in a trans genic mouse model of Alzheimer's disease without causing peripheral toxicity. Journal of Pharmacology and Experimental Therapeutics. 2007;323:822&#x2013;830.</Citation><ArticleIdList><ArticleId IdType="pubmed">17895400</ArticleId></ArticleIdList></Reference><Reference><Citation>Siemers ER, Dean RA, Friedrich S, et al. Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. Clinical Neuropharmacology. 2007;30:317&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">18090456</ArticleId></ArticleIdList></Reference><Reference><Citation>Siemers ER, Quinn JF, Kaye J, et al. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology. 2006;66:602&#x2013;604.</Citation><ArticleIdList><ArticleId IdType="pubmed">16505324</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Munsell LY, Morris JC, et al. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med. 2006;12:856&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2983090</ArticleId><ArticleId IdType="pubmed">16799555</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Munsell LY, Chen X, et al. Stable Isotope Labeling Tandem Mass Spectrometry (SILT) to Quantify Protein Production and Clearance Rates. Journal of the American Society for Mass Spectrometry. 2007;18:997&#x2013;1006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2040126</ArticleId><ArticleId IdType="pubmed">17383190</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-{beta} levels: Implications for a diagnostic and therapeutic biomarker. Neurology. 2007;68:666&#x2013;669.</Citation><ArticleIdList><ArticleId IdType="pubmed">17325273</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong GT, Manfra D, Poulet FM, et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem. 2004;279:12876&#x2013;12882.</Citation><ArticleIdList><ArticleId IdType="pubmed">14709552</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T, Wen H, Brayton C, et al. Moderate reduction of &#x3b3;-secretase attenuates amyloid burden and limits mechanism-based liabilities. Journal of Neuroscience. 2007;27:10849&#x2013;10859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672827</ArticleId><ArticleId IdType="pubmed">17913918</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyde LA, McHugh NA, Chen J, et al. Studies to investigate the in vivo therapeutic window of the &#x3b3;-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d] azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 mouse. Journal of Pharmacology and Experimental Therapeutics. 2006;319:1133&#x2013;1143.</Citation><ArticleIdList><ArticleId IdType="pubmed">16946102</ArticleId></ArticleIdList></Reference><Reference><Citation>Siemers E, Skinner M, Dean RA, et al. Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clinical Neuropharmacology. 2005;28:126&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">15965311</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto A, Sudo H, Endo A. Therapeutic effects of ML-236B in primary hypercholesterolemia. Atherosclerosis. 1980;35:259&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">7362699</ArticleId></ArticleIdList></Reference><Reference><Citation>Mabuchi H, Haba T, Tatami R, et al. Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia. N Engl J Med. 1981;305:478&#x2013;482.</Citation><ArticleIdList><ArticleId IdType="pubmed">7254297</ArticleId></ArticleIdList></Reference><Reference><Citation>Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res. 1992;33:1569&#x2013;1582.</Citation><ArticleIdList><ArticleId IdType="pubmed">1464741</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19363289</PMID><DateCompleted><Year>2009</Year><Month>06</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-8238</ISSN><JournalIssue CitedMedium="Internet"><Volume>119</Volume><Issue>5</Issue><PubDate><Year>2009</Year><Month>May</Month></PubDate></JournalIssue><Title>The Journal of clinical investigation</Title><ISOAbbreviation>J Clin Invest</ISOAbbreviation></Journal><ArticleTitle>A zebrafish model of tauopathy allows in vivo imaging of neuronal cell death and drug evaluation.</ArticleTitle><Pagination><StartPage>1382</StartPage><EndPage>1395</EndPage><MedlinePgn>1382-95</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1172/JCI37537</ELocationID><ELocationID EIdType="pii" ValidYN="Y">37537</ELocationID><Abstract><AbstractText>Our aging society is confronted with a dramatic increase of patients suffering from tauopathies, which include Alzheimer disease and certain frontotemporal dementias. These disorders are characterized by typical neuropathological lesions including hyperphosphorylation and subsequent aggregation of TAU protein and neuronal cell death. Currently, no mechanism-based cures are available. We generated fluorescently labeled TAU transgenic zebrafish, which rapidly recapitulated key pathological features of tauopathies, including phosphorylation and conformational changes of human TAU protein, tangle formation, neuronal and behavioral disturbances, and cell death. Due to their optical transparency and small size, zebrafish larvae are well suited for both in vivo imaging and drug development. TAU-induced neuronal cell death was imaged by time-lapse microscopy in vivo. Furthermore, we used this zebrafish model to identify compounds targeting the TAU kinase glycogen synthase kinase 3beta (GSK3beta). We identified a newly developed highly active GSK3beta inhibitor, AR-534, by rational drug design. AR-534 reduced TAU phosphorylation in TAU transgenic zebrafish. This transgenic zebrafish model may become a valuable tool for further studies of the neuropathology of dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Paquet</LastName><ForeName>Dominik</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Deutsches Zentrum f&#xfc;r Neurodegenerative Erkrankungen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhat</LastName><ForeName>Ratan</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Sydow</LastName><ForeName>Astrid</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Mandelkow</LastName><ForeName>Eva-Maria</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><LastName>Berg</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Hellberg</LastName><ForeName>Sven</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>F&#xe4;lting</LastName><ForeName>Johanna</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Distel</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>K&#xf6;ster</LastName><ForeName>Reinhard W</ForeName><Initials>RW</Initials></Author><Author ValidYN="Y"><LastName>Schmid</LastName><ForeName>Bettina</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>04</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Invest</MedlineTA><NlmUniqueID>7802877</NlmUniqueID><ISSNLinking>0021-9738</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008164">Luminescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>134193-27-4</RegistryNumber><NameOfSubstance UI="D050857">Synaptotagmins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C000605506">GSK3B protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D000071679">Glycogen Synthase Kinase 3 beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.26</RegistryNumber><NameOfSubstance UI="D038362">Glycogen Synthase Kinase 3</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030801" MajorTopicYN="N">Animals, Genetically Modified</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015195" MajorTopicYN="N">Drug Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004353" MajorTopicYN="N">Drug Evaluation, Preclinical</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004625" MajorTopicYN="N">Embryo, Nonmammalian</DescriptorName><QualifierName UI="Q000002" MajorTopicYN="N">abnormalities</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004924" MajorTopicYN="N">Escape Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038362" MajorTopicYN="N">Glycogen Synthase Kinase 3</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071679" MajorTopicYN="N">Glycogen Synthase Kinase 3 beta</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007814" MajorTopicYN="N">Larva</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="N">anatomy &amp; histology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008164" MajorTopicYN="N">Luminescent Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016415" MajorTopicYN="N">Sequence Alignment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050857" MajorTopicYN="N">Synaptotagmins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015027" MajorTopicYN="Y">Zebrafish</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000097573" MajorTopicYN="N">Red Fluorescent Protein</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>2</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>4</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>4</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>6</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>4</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19363289</ArticleId><ArticleId IdType="pmc">PMC2673864</ArticleId><ArticleId IdType="doi">10.1172/JCI37537</ArticleId><ArticleId IdType="pii">37537</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer&#x2019;s amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 2007;8:101&#x2013;112. doi: 10.1038/nrm2101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm2101</ArticleId><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosik K.S., Joachim C.L., Selkoe D.J. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1986;83:4044&#x2013;4048. doi: 10.1073/pnas.83.11.4044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.83.11.4044</ArticleId><ArticleId IdType="pmc">PMC323662</ArticleId><ArticleId IdType="pubmed">2424016</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundke-Iqbal I., et al. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. U. S. A. 1986;83:4913&#x2013;4917. doi: 10.1073/pnas.83.13.4913.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.83.13.4913</ArticleId><ArticleId IdType="pmc">PMC323854</ArticleId><ArticleId IdType="pubmed">3088567</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259. doi: 10.1007/BF00308809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00308809</ArticleId><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Santacruz K., et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309:476&#x2013;481. doi: 10.1126/science.1113694.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1113694</ArticleId><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M., et al. Association of missense and 5&#x2032;-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702&#x2013;705. doi: 10.1038/31508.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/31508</ArticleId><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandelkow E.M., Mandelkow E. Tau in Alzheimer&#x2019;s disease. Trends Cell Biol. 1998;8:425&#x2013;427. doi: 10.1016/S0962-8924(98)01368-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0962-8924(98)01368-3</ArticleId><ArticleId IdType="pubmed">9854307</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotz J., Ittner L.M. Animal models of Alzheimer&#x2019;s disease and frontotemporal dementia. Nat. Rev. Neurosci. 2008;9:532&#x2013;544. doi: 10.1038/nrn2420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2420</ArticleId><ArticleId IdType="pubmed">18568014</ArticleId></ArticleIdList></Reference><Reference><Citation>Zon L.I., Peterson R.T. In vivo drug discovery in the zebrafish. Nat. Rev. Drug Discov. 2005;4:35&#x2013;44. doi: 10.1038/nrd1606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd1606</ArticleId><ArticleId IdType="pubmed">15688071</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong J.Y., et al. Functional and developmental analysis of the blood-brain barrier in zebrafish. Brain Res. Bull. 2008;75:619&#x2013;628. doi: 10.1016/j.brainresbull.2007.10.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2007.10.043</ArticleId><ArticleId IdType="pubmed">18355638</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomasiewicz H.G., Flaherty D.B., Soria J.P., Wood J.G. Transgenic zebrafish model of neurodegeneration. J. Neurosci. Res. 2002;70:734&#x2013;745. doi: 10.1002/jnr.10451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.10451</ArticleId><ArticleId IdType="pubmed">12444595</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai Q., Garver J.A., Hukriede N.A., Burton E.A. Generation of a transgenic zebrafish model of tauopathy using a novel promoter element derived from the zebrafish eno2 gene. Nucleic Acids Res. 2007;35:6501&#x2013;6516. doi: 10.1093/nar/gkm608.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkm608</ArticleId><ArticleId IdType="pmc">PMC2095798</ArticleId><ArticleId IdType="pubmed">17897967</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazanetz M.P., Fischer P.M. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat. Rev. Drug Discov. 2007;6:464&#x2013;479. doi: 10.1038/nrd2111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd2111</ArticleId><ArticleId IdType="pubmed">17541419</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhat R., et al. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J. Biol. Chem. 2003;278:45937&#x2013;45945. doi: 10.1074/jbc.M306268200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M306268200</ArticleId><ArticleId IdType="pubmed">12928438</ArticleId></ArticleIdList></Reference><Reference><Citation>Winklhofer K.F., Tatzelt J., Haass C. The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. EMBO J. 2008;27:336&#x2013;349. doi: 10.1038/sj.emboj.7601930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.emboj.7601930</ArticleId><ArticleId IdType="pmc">PMC2234348</ArticleId><ArticleId IdType="pubmed">18216876</ArticleId></ArticleIdList></Reference><Reference><Citation>Urasaki A., Morvan G., Kawakami K. Functional dissection of the Tol2 transposable element identified the minimal cis-sequence and a highly repetitive sequence in the subterminal region essential for transposition. Genetics. 2006;174:639&#x2013;649. doi: 10.1534/genetics.106.060244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1534/genetics.106.060244</ArticleId><ArticleId IdType="pmc">PMC1602067</ArticleId><ArticleId IdType="pubmed">16959904</ArticleId></ArticleIdList></Reference><Reference><Citation>Koster R.W., Fraser S.E. Tracing transgene expression in living zebrafish embryos. Dev. Biol. 2001;233:329&#x2013;346. doi: 10.1006/dbio.2001.0242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/dbio.2001.0242</ArticleId><ArticleId IdType="pubmed">11336499</ArticleId></ArticleIdList></Reference><Reference><Citation>Walhout A.J., et al. GATEWAY recombinational cloning: application to the cloning of large numbers of open reading frames or ORFeomes. Methods Enzymol. 2000;328:575&#x2013;592. doi: 10.1016/S0076-6879(00)28419-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0076-6879(00)28419-X</ArticleId><ArticleId IdType="pubmed">11075367</ArticleId></ArticleIdList></Reference><Reference><Citation>Park H.C., et al. Analysis of upstream elements in the HuC promoter leads to the establishment of transgenic zebrafish with fluorescent neurons. . Dev. Biol. 2000;227:279&#x2013;293. doi: 10.1006/dbio.2000.9898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/dbio.2000.9898</ArticleId><ArticleId IdType="pubmed">11071755</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosik K.S., et al. Epitopes that span the tau molecule are shared with paired helical filaments. Neuron. 1988;1:817&#x2013;825. doi: 10.1016/0896-6273(88)90129-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0896-6273(88)90129-8</ArticleId><ArticleId IdType="pubmed">2483104</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M., et al. Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer&#x2019;s disease: identification of phosphorylation sites in tau protein. Biochem. J. 1994;301:871&#x2013;877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1137067</ArticleId><ArticleId IdType="pubmed">7519852</ArticleId></ArticleIdList></Reference><Reference><Citation>Seubert P., et al. Detection of phosphorylated Ser262 in fetal tau, adult tau, and paired helical filament tau. J. Biol. Chem. 1995;270:18917&#x2013;18922. doi: 10.1074/jbc.270.32.18917.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.270.32.18917</ArticleId><ArticleId IdType="pubmed">7642549</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg S.G., Davies P., Schein J.D., Binder L.I. Hydrofluoric acid-treated tau PHF proteins display the same biochemical properties as normal tau. J. Biol. Chem. 1992;267:564&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pubmed">1370450</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M., et al. Characterization of mAb AP422, a novel phosphorylation-dependent monoclonal antibody against tau protein. FEBS Lett. 1996;384:25&#x2013;30. doi: 10.1016/0014-5793(96)00271-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-5793(96)00271-2</ArticleId><ArticleId IdType="pubmed">8797796</ArticleId></ArticleIdList></Reference><Reference><Citation>Biernat J., et al. The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region. EMBO J. 1992;11:1593&#x2013;1597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC556608</ArticleId><ArticleId IdType="pubmed">1563356</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha G.A., Berenfeld B., Davies P. Sequence requirements for formation of conformational variants of tau similar to those found in Alzheimer&#x2019;s disease. J. Neurosci. Res. 1999;55:713&#x2013;723. doi: 10.1002/(SICI)1097-4547(19990315)55:6&lt;713::AID-JNR6&gt;3.0.CO;2-G.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-4547(19990315)55:6&lt;713::AID-JNR6&gt;3.0.CO;2-G</ArticleId><ArticleId IdType="pubmed">10220112</ArticleId></ArticleIdList></Reference><Reference><Citation>Furutani-Seiki M., et al. Neural degeneration mutants in the zebrafish, Danio rerio. Development. 1996;123:229&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">9007243</ArticleId></ArticleIdList></Reference><Reference><Citation>Thies E., Mandelkow E.M. Missorting of tau in neurons causes degeneration of synapses that can be rescued by the kinase MARK2/Par-1. . J. Neurosci. 2007;27:2896&#x2013;2907. doi: 10.1523/JNEUROSCI.4674-06.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4674-06.2007</ArticleId><ArticleId IdType="pmc">PMC6672561</ArticleId><ArticleId IdType="pubmed">17360912</ArticleId></ArticleIdList></Reference><Reference><Citation>Terwel D., et al. Changed conformation of mutant Tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of Tau-4R/2N transgenic mice. J. Biol. Chem. 2005;280:3963&#x2013;3973. doi: 10.1074/jbc.M409876200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M409876200</ArticleId><ArticleId IdType="pubmed">15509565</ArticleId></ArticleIdList></Reference><Reference><Citation>Trevarrow B., Marks D.L., Kimmel C.B. Organization of hindbrain segments in the zebrafish embryo. Neuron. 1990;4:669&#x2013;679. doi: 10.1016/0896-6273(90)90194-K.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0896-6273(90)90194-K</ArticleId><ArticleId IdType="pubmed">2344406</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox M.A., Sanes J.R. Synaptotagmin I and II are present in distinct subsets of central synapses. . J. Comp. Neurol. 2007;503:280&#x2013;296. doi: 10.1002/cne.21381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.21381</ArticleId><ArticleId IdType="pubmed">17492637</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers P.Z., Eisen J.S., Westerfield M. Development and axonal outgrowth of identified motoneurons in the zebrafish. J. Neurosci. 1986;6:2278&#x2013;2289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6568750</ArticleId><ArticleId IdType="pubmed">3746410</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith D.G., et al. 3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg. Med. Chem. Lett. 2001;11:635&#x2013;639. doi: 10.1016/S0960-894X(00)00721-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0960-894X(00)00721-6</ArticleId><ArticleId IdType="pubmed">11266159</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong M., Chen D.C., Klein P.S., Lee V.M. Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J. Biol. Chem. 1997;272:25326&#x2013;25332. doi: 10.1074/jbc.272.40.25326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.272.40.25326</ArticleId><ArticleId IdType="pubmed">9312151</ArticleId></ArticleIdList></Reference><Reference><Citation>Doble B.W., Woodgett J.R. GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci. 2003;116:1175&#x2013;1186. doi: 10.1242/jcs.00384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.00384</ArticleId><ArticleId IdType="pmc">PMC3006448</ArticleId><ArticleId IdType="pubmed">12615961</ArticleId></ArticleIdList></Reference><Reference><Citation>Stachel S.E., Grunwald D.J., Myers P.Z. Lithium perturbation and goosecoid expression identify a dorsal specification pathway in the pregastrula zebrafish. Development. 1993;117:1261&#x2013;1274.</Citation><ArticleIdList><ArticleId IdType="pubmed">8104775</ArticleId></ArticleIdList></Reference><Reference><Citation>Geling A., Steiner H., Willem M., Bally-Cuif L., Haass C. A gamma-secretase inhibitor blocks Notch signaling in vivo and causes a severe neurogenic phenotype in zebrafish. EMBO Rep. 2002;3:688&#x2013;694. doi: 10.1093/embo-reports/kvf124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/embo-reports/kvf124</ArticleId><ArticleId IdType="pmc">PMC1084181</ArticleId><ArticleId IdType="pubmed">12101103</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerhard G.S., et al. Life spans and senescent phenotypes in two strains of Zebrafish (Danio rerio). Exp. Gerontol. 2002;37:1055&#x2013;1068. doi: 10.1016/S0531-5565(02)00088-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0531-5565(02)00088-8</ArticleId><ArticleId IdType="pubmed">12213556</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts R.C. The lifetime growth and reproduction of selected strains of mice. Heredity. 1961;16:369&#x2013;381. doi: 10.1038/hdy.1961.46.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/hdy.1961.46</ArticleId></ArticleIdList></Reference><Reference><Citation>Koster R.W., Fraser S.E. Direct imaging of in vivo neuronal migration in the developing cerebellum. Curr. Biol. 2001;11:1858&#x2013;1863. doi: 10.1016/S0960-9822(01)00585-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0960-9822(01)00585-1</ArticleId><ArticleId IdType="pubmed">11728308</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullins M.C., Hammerschmidt M., Haffter P., Nusslein-Volhard C. Large-scale mutagenesis in the zebrafish: in search of genes controlling development in a vertebrate. Curr. Biol. 1994;4:189&#x2013;202. doi: 10.1016/S0960-9822(00)00048-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0960-9822(00)00048-8</ArticleId><ArticleId IdType="pubmed">7922324</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimmel C.B., Ballard W.W., Kimmel S.R., Ullmann B., Schilling T.F. Stages of embryonic development of the zebrafish. Dev. Dyn. 1995;203:253&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">8589427</ArticleId></ArticleIdList></Reference><Reference><Citation>Bevis B.J., Glick B.S. Rapidly maturing variants of the Discosoma red fluorescent protein (DsRed). Nat. Biotechnol. 2002;20:83&#x2013;87. doi: 10.1038/nbt0102-83.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt0102-83</ArticleId><ArticleId IdType="pubmed">11753367</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawakami K. Transposon tools and methods in zebrafish. Dev. Dyn. 2005;234:244&#x2013;254. doi: 10.1002/dvdy.20516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dvdy.20516</ArticleId><ArticleId IdType="pubmed">16110506</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xfc;sslein-Volhard, C., and Dahm, R. 2002. Zebrafish: a practical approach. Oxford University Press. Oxford, United Kingdom. 303 pp.</Citation></Reference><Reference><Citation>Mocanu M.M., et al. The potential for beta-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy. J. Neurosci. 2008;28:737&#x2013;748. doi: 10.1523/JNEUROSCI.2824-07.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2824-07.2008</ArticleId><ArticleId IdType="pmc">PMC6670355</ArticleId><ArticleId IdType="pubmed">18199773</ArticleId></ArticleIdList></Reference><Reference><Citation>Cecchelli R., et al. In vitro model for evaluating drug transport across the blood-brain barrier. Adv. Drug Deliv. Rev. 1999;36:165&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">10837714</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19369565</PMID><DateCompleted><Year>2009</Year><Month>05</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>15</Issue><PubDate><Year>2009</Year><Month>Apr</Month><Day>15</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Suppression of amyloid deposition leads to long-term reductions in Alzheimer's pathologies in Tg2576 mice.</ArticleTitle><Pagination><StartPage>4964</StartPage><EndPage>4971</EndPage><MedlinePgn>4964-71</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.4560-08.2009</ELocationID><Abstract><AbstractText>In amyloid precursor protein (APP) models of amyloid deposition, the amount of amyloid deposits increase with mouse age. At a first approximation, the extent of amyloid accumulation may either reflect small excesses of production over clearance that accumulate over time or, alternatively, indicate a steady-state equilibrium at that age, reflecting the instantaneous excess of production over clearance, which increases as the organism ages. To discriminate between these options, we reversibly suppressed amyloid deposition in Tg2576 mice with the anti-Abeta antibody 2H6, starting at 8 months, just before the first histological deposits can be discerned. Six months later, we stopped the suppression and monitored the progression of amyloid accumulation in control APP mice and suppressed APP mice over the next 3 months. The accumulation hypothesis would predict that the rate of amyloid from 14 to 17 months would be similar in the suppressed and control mice, while the equilibrium hypothesis would predict that the increase would be faster in the suppressed group, possibly catching up completely with the control mice. The results strongly support the accumulation hypothesis, with no evidence of the suppressed mice catching up with the control mice as predicted by equilibrium models. If anything, there was a slower rate of increase in the suppressed APP mice than the control mice, suggesting that a slow seeding mechanism likely precedes a rapid fibrillogenesis in determining the extent of amyloid deposition.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Karlnoski</LastName><ForeName>Rachel A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Alzheimer's Research Laboratory, Department of Molecular Pharmacology and Physiology, School of Basic Biomedical Sciences, University of South Florida, Tampa, Florida 33612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenthal</LastName><ForeName>Arnon</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Kobayashi</LastName><ForeName>Dione</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Pons</LastName><ForeName>Jaume</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Alamed</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Mercer</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qingyou</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Gordon</LastName><ForeName>Marcia N</ForeName><Initials>MN</Initials></Author><Author ValidYN="Y"><LastName>Gottschall</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials></Author><Author ValidYN="Y"><LastName>Morgan</LastName><ForeName>David</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG004418</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG018478</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 04418</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 18478</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D029721">Drosophila Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029721" MajorTopicYN="N">Drosophila Proteins</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>4</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>4</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>5</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>10</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19369565</ArticleId><ArticleId IdType="mid">NIHMS109795</ArticleId><ArticleId IdType="pmc">PMC2688812</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4560-08.2009</ArticleId><ArticleId IdType="pii">29/15/4964</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alamed J, Wilcock DM, Diamond DM, Gordon MN, Morgan D. Two-day radial-arm water maze learning and memory task; robust resolution of amyloid-related memory deficits in transgenic mice. Nat Protoc. 2006;1:1671&#x2013;1679.</Citation><ArticleIdList><ArticleId IdType="pubmed">17487150</ArticleId></ArticleIdList></Reference><Reference><Citation>Best JD, Smith DW, Reilly MA, O'Donnell R, Lewis HD, Ellis S, Wilkie N, Rosahl TW, Laroque PA, Boussiquet-Leroux C, Churcher I, Atack JR, Harrison T, Shearman MS. The novel gamma secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1, 1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse. J Pharmacol Exp Ther. 2007;320:552&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pubmed">17099072</ArticleId></ArticleIdList></Reference><Reference><Citation>Caccamo A, Oddo S, Sugarman MC, Akbari Y, LaFerla FM. Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. Neurobiol Aging. 2005;26:645&#x2013;654.</Citation><ArticleIdList><ArticleId IdType="pubmed">15708439</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauhan NB, Siegel GJ, Lichtor T. Effect of age on the duration and extent of amyloid plaque reduction and microglial activation after injection of anti-Abeta antibody into the third ventricle of TgCRND8 mice. J Neurosci Res. 2004;78:732&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">15478192</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, Johnson-Wood K, Lee M, Seubert P, Davis A, Kholodenko D, Motter R, Sherrington R, Perry B, Yao H, Strome R, Lieberburg I, Rommens J, Kim S, Schenk D, Fraser P, St George Hyslop P, Selkoe DJ. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med. 1997;3:67&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">8986743</ArticleId></ArticleIdList></Reference><Reference><Citation>Das P, Murphy MP, Younkin LH, Younkin SG, Golde TE. Reduced effectiveness of Abeta1&#x2013;42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol Aging. 2001;22:721&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pubmed">11705631</ArticleId></ArticleIdList></Reference><Reference><Citation>Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 1995;373:523&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">7845465</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon MN, King DL, Diamond DM, Jantzen PT, Boyett KV, Hope CE, Hatcher JM, DiCarlo G, Gottschall WP, Morgan D, Arendash GW. Correlation between cognitive deficits and Abeta deposits in transgenic APP+PS1 mice. Neurobiol Aging. 2001;22:377&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pubmed">11378242</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon MN, Holcomb LA, Jantzen PT, DiCarlo G, Wilcock D, Boyett KW, Connor K, Melachrino J, O'Callaghan JP, Morgan D. Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Exp Neurol. 2002;173:183&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">11822882</ArticleId></ArticleIdList></Reference><Reference><Citation>Herber DL, Roth LM, Wilson D, Wilson N, Mason JE, Morgan D, Gordon MN. Time-dependent reduction in Abeta levels after intracranial LPS administration in APP transgenic mice. Exp Neurol. 2004;190:245&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">15473997</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, Saad I, Mueller R, Morgan D, Sanders S, Zehr C, O'Campo K, Hardy J, Prada CM, Eckman C, Younkin S, Hsiao K, Duff K. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med. 1998;4:97&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">9427614</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008;372:216&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">18640458</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata N, Takaki Y, Fukami S, Tsubuki S, Saido TC. Region-specific reduction of A beta-degrading endopeptidase, neprilysin, in mouse hippocampus upon aging. J Neurosci Res. 2002;70:493&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">12391610</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43) Neuron. 1994;13:45&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">8043280</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Slunt HH, Gonzales V, Savonenko AV, Wen JC, Jenkins NA, Copeland NG, Younkin LH, Lester HA, Younkin SG, Borchelt DR. Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease. PLoS Med. 2005;2:e355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1283364</ArticleId><ArticleId IdType="pubmed">16279840</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrett JT, Lansbury PT., Jr Seeding &#x201c;one-dimensional crystallization&#x201d; of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell. 1993;73:1055&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">8513491</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrett JT, Berger EP, Lansbury PT., Jr The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry. 1993;32:4693&#x2013;4697.</Citation><ArticleIdList><ArticleId IdType="pubmed">8490014</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, Khan K, Gordon M, Tan H, Games D, Lieberburg I, Schenk D, Seubert P, McConlogue L. Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci U S A. 1997;94:1550&#x2013;1555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19829</ArticleId><ArticleId IdType="pubmed">9037091</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid &#x3b2; protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci. 2001;21:372&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763819</ArticleId><ArticleId IdType="pubmed">11160418</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Onstead L, Randle S, Price R, Smithson L, Zwizinski C, Dickson DW, Golde T, McGowan E. Abeta40 inhibits amyloid deposition in vivo . J Neurosci. 2007;27:627&#x2013;633.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672801</ArticleId><ArticleId IdType="pubmed">17234594</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirschner DA, Inouye H, Duffy LK, Sinclair A, Lind M, Selkoe DJ. Synthetic peptide homologous to beta protein from Alzheimer disease forms amyloid-like fibrils in vitro. Proc Natl Acad Sci U S A. 1987;84:6953&#x2013;6957.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC299203</ArticleId><ArticleId IdType="pubmed">3477820</ArticleId></ArticleIdList></Reference><Reference><Citation>Levites Y, Jansen K, Smithson LA, Dakin R, Holloway VM, Das P, Golde TE. Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid &#x3b2;40, and amyloid &#x3b2;42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice. J Neurosci. 2006;26:11923&#x2013;11928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674861</ArticleId><ArticleId IdType="pubmed">17108166</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Gordon M, Cao C, Ugen KE, Morgan D. Improvement of a low pH antigen-antibody dissociation procedure for ELISA measurement of circulating anti-Abeta antibodies. BMC Neurosci. 2007;8:22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1845169</ArticleId><ArticleId IdType="pubmed">17374155</ArticleId></ArticleIdList></Reference><Reference><Citation>Maggio JE, Stimson ER, Ghilardi JR, Allen CJ, Dahl CE, Whitcomb DC, Vigna SR, Vinters HV, Labenski ME, Mantyh PW. Reversible in vitro growth of Alzheimer disease beta-amyloid plaques by deposition of labeled amyloid peptide. Proc Natl Acad Sci U S A. 1992;89:5462&#x2013;5466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC49312</ArticleId><ArticleId IdType="pubmed">1608956</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann DM, Iwatsubo T, Cairns NJ, Lantos PL, Nochlin D, Sumi SM, Bird TD, Poorkaj P, Hardy J, Hutton M, Prihar G, Crook R, Rossor MN, Haltia M. Amyloid beta protein (Abeta) deposition in chromosome 14-linked Alzheimer's disease: predominance of Abeta42(43) Ann Neurol. 1996;40:149&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">8773595</ArticleId></ArticleIdList></Reference><Reference><Citation>McGowan E, Pickford F, Kim J, Onstead L, Erikson J, Yu C, Skipper L, Murphy MP, Beard J, Das P, Jansen K, Delucia M, Lin WL, Dolios G, Wang R, Eckman CB, Dickson DW, Hutton M, Hardy J, Golde T. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron. 2005;47:191&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1373682</ArticleId><ArticleId IdType="pubmed">16039562</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature. 2008;451:720&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3264491</ArticleId><ArticleId IdType="pubmed">18256671</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron. 2004;43:321&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pubmed">15294141</ArticleId></ArticleIdList></Reference><Reference><Citation>Prior R, D'Urso D, Frank R, Prikulis I, Cleven S, Ihl R, Pavlakovic G. Selective binding of soluble Abeta1&#x2013;40 and Abeta1&#x2013;42 to a subset of senile plaques. Am J Pathol. 1996;148:1749&#x2013;1756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1861649</ArticleId><ArticleId IdType="pubmed">8669461</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001;81:741&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Fu Y, Yasvoina M, Shao P, Hitt B, O'Connor T, Logan S, Maus E, Citron M, Berry R, Binder L, Vassar R. &#x3b2;-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis. J Neurosci. 2007;27:3639&#x2013;3649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672403</ArticleId><ArticleId IdType="pubmed">17409228</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19376973</PMID><DateCompleted><Year>2009</Year><Month>05</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>106</Volume><Issue>18</Issue><PubDate><Year>2009</Year><Month>May</Month><Day>05</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Seeded growth of beta-amyloid fibrils from Alzheimer's brain-derived fibrils produces a distinct fibril structure.</ArticleTitle><Pagination><StartPage>7443</StartPage><EndPage>7448</EndPage><MedlinePgn>7443-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0812033106</ELocationID><Abstract><AbstractText>Studies by solid-state nuclear magnetic resonance (NMR) of amyloid fibrils prepared in vitro from synthetic 40-residue beta-amyloid (Abeta(1-40)) peptides have shown that the molecular structure of Abeta(1-40) fibrils is not uniquely determined by amino acid sequence. Instead, the fibril structure depends on the precise details of growth conditions. The molecular structures of beta-amyloid fibrils that develop in Alzheimer's disease (AD) are therefore uncertain. We demonstrate through thioflavin T fluorescence and electron microscopy that fibrils extracted from brain tissue of deceased AD patients can be used to seed the growth of synthetic Abeta(1-40) fibrils, allowing preparation of fibrils with isotopic labeling and in sufficient quantities for solid-state NMR and other measurements. Because amyloid structures propagate themselves in seeded growth, as shown in previous studies, the molecular structures of brain-seeded synthetic Abeta(1-40) fibrils most likely reflect structures that are present in AD brain. Solid-state (13)C NMR spectra of fibril samples seeded with brain material from two AD patients were found to be nearly identical, indicating the same molecular structures. Spectra of an unseeded control sample indicate greater structural heterogeneity. (13)C chemical shifts and other NMR data indicate that the predominant molecular structure in brain-seeded fibrils differs from the structures of purely synthetic Abeta(1-40) fibrils that have been characterized in detail previously. These results demonstrate a new approach to detailed structural characterization of amyloid fibrils that develop in human tissue, and to investigations of possible correlations between fibril structure and the degree of cognitive impairment and neurodegeneration in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Paravastu</LastName><ForeName>Anant K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-0520, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qahwash</LastName><ForeName>Isam</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Leapman</LastName><ForeName>Richard D</ForeName><Initials>RD</Initials></Author><Author ValidYN="Y"><LastName>Meredith</LastName><ForeName>Stephen C</ForeName><Initials>SC</Initials></Author><Author ValidYN="Y"><LastName>Tycko</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS042852</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS042852</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>04</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046529" MajorTopicYN="N">Microscopy, Electron, Transmission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019906" MajorTopicYN="N">Nuclear Magnetic Resonance, Biomolecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>4</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>4</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>5</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>10</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19376973</ArticleId><ArticleId IdType="pmc">PMC2678625</ArticleId><ArticleId IdType="doi">10.1073/pnas.0812033106</ArticleId><ArticleId IdType="pii">0812033106</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Petkova AT, et al. Self-propagating, molecular-level polymorphism in Alzheimer's &#x3b2;-amyloid fibrils. Science. 2005;307:262&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">15653506</ArticleId></ArticleIdList></Reference><Reference><Citation>Paravastu AK, Petkova AT, Tycko R. Polymorphic fibril formation by residues 10&#x2013;40 of the Alzheimer's &#x3b2;-amyloid peptide. Biophys J. 2006;90:4618&#x2013;4629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1471876</ArticleId><ArticleId IdType="pubmed">16565054</ArticleId></ArticleIdList></Reference><Reference><Citation>Wetzel R, Shivaprasad S, Williams AD. Plasticity of amyloid fibrils. Biochemistry. 2007;46:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2526019</ArticleId><ArticleId IdType="pubmed">17198370</ArticleId></ArticleIdList></Reference><Reference><Citation>Paravastu AK, Leapman RD, Yau W-M, Tycko R. Molecular structural basis for polymorphism in Alzheimer's &#x3b2;-amyloid fibrils. Proc Natl Acad Sci USA. 2008;105:18349&#x2013;18354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2587602</ArticleId><ArticleId IdType="pubmed">19015532</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkova AT, Yau WM, Tycko R. Experimental constraints on quaternary structure in Alzheimer's &#x3b2;-amyloid fibrils. Biochemistry. 2006;45:498&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1435828</ArticleId><ArticleId IdType="pubmed">16401079</ArticleId></ArticleIdList></Reference><Reference><Citation>Wickner R, et al. Prions: Proteins as genes and infectious entities. Genes Dev. 2004;18:470&#x2013;485.</Citation><ArticleIdList><ArticleId IdType="pubmed">15037545</ArticleId></ArticleIdList></Reference><Reference><Citation>Caughey B, Raymond GJ, Bessen RA. Strain-dependent differences in &#x3b2;-sheet conformations of abnormal prion protein. J Biol Chem. 1998;273:32230&#x2013;32235.</Citation><ArticleIdList><ArticleId IdType="pubmed">9822701</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien P, Weissman JS, De Pace AH. Emerging principles of conformation-based prion inheritance. Annu Rev Biochem. 2004;73:617&#x2013;656.</Citation><ArticleIdList><ArticleId IdType="pubmed">15189155</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, et al. Exogenous induction of cerebral &#x3b2;-amyloidogenesis is governed by agent and host. Science. 2006;313:1781&#x2013;1784.</Citation><ArticleIdList><ArticleId IdType="pubmed">16990547</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesne S, et al. A specific amyloid-&#x3b2; protein assembly in the brain impairs memory. Nature. 2006;440:352&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">16541076</ArticleId></ArticleIdList></Reference><Reference><Citation>Roher AE, Kuo YM. In: Methods in Enzymology. Wetzel R, editor. Vol. 309. San Diego: Academic; 1999. pp. 58&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Roher AE, et al. Structural alterations in the peptide backbone of &#x3b2;-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J Biol Chem. 1993;268:3072&#x2013;3083.</Citation><ArticleIdList><ArticleId IdType="pubmed">8428986</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciarretta KL, Gordon DJ, Petkova AT, Tycko R, Meredith SC. A&#x3b2;40-lactam(D23/K28) models a conformation highly favorable for nucleation of amyloid. Biochemistry. 2005;44:6003&#x2013;6014.</Citation><ArticleIdList><ArticleId IdType="pubmed">15835889</ArticleId></ArticleIdList></Reference><Reference><Citation>Qahwash I, et al. Site-specific effects of peptide lipidation on &#x3b2;-amyloid aggregation and cytotoxicity. J Biol Chem. 2007;282:36987&#x2013;36997.</Citation><ArticleIdList><ArticleId IdType="pubmed">17693400</ArticleId></ArticleIdList></Reference><Reference><Citation>Feja B, Durrenberger M, Muller S, Reichelt R, Aebi U. Mass determination by inelastic electron scattering in an energy-filtering transmission electron microscope with slow-scan CCD camera. J Struct Biol. 1997;119:72&#x2013;82.</Citation></Reference><Reference><Citation>Goldsbury C, Frey P, Olivieri V, Aebi U, Muller SA. Multiple assembly pathways underlie amyloid-&#x3b2; fibril polymorphisms. J Mol Biol. 2005;352:282&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">16095615</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishii Y. 13C-13C dipolar recoupling under very fast magic angle spinning in solid state nuclear magnetic resonance: Applications to distance measurements, spectral assignments, and high-throughput secondary-structure determination. J Chem Phys. 2001;114:8473&#x2013;8483.</Citation></Reference><Reference><Citation>Wishart DS, Bigam CG, Holm A, Hodges RS, Sykes BD. 1H, 13C and 15N random coil NMR chemical shifts of the common amino acids. 1. Investigations of nearest-neighbor effects. J Biomol Nucl Magnet Reson. 1995;5:67&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">7881273</ArticleId></ArticleIdList></Reference><Reference><Citation>Morcombe CR, Gaponenko V, Byrd RA, Zilm KW. Diluting abundant spins by isotope edited radio frequency field assisted diffusion. J Am Chem Soc. 2004;126:7196&#x2013;7197.</Citation><ArticleIdList><ArticleId IdType="pubmed">15186155</ArticleId></ArticleIdList></Reference><Reference><Citation>Takegoshi K, Nakamura S, Terao T. 13C-1H dipolar-assisted rotational resonance in magic angle spinning NMR. Chem Phys Lett. 2001;344:631&#x2013;637.</Citation></Reference><Reference><Citation>Jaroniec CP, Tounge BA, Herzfeld J, Griffin RG. Frequency selective heteronuclear dipolar recoupling in rotating solids: Accurate 13C-15N distance measurements in uniformly 13C,15N-labeled peptides. J Am Chem Soc. 2001;123:3507&#x2013;3519.</Citation><ArticleIdList><ArticleId IdType="pubmed">11472123</ArticleId></ArticleIdList></Reference><Reference><Citation>Tycko R. Symmetry-based constant-time homonuclear dipolar recoupling in solid state NMR. J Chem Phys. 2007;126 064506.</Citation><ArticleIdList><ArticleId IdType="pubmed">17313228</ArticleId></ArticleIdList></Reference><Reference><Citation>Balbach JJ, et al. Supramolecular structure in full-length Alzheimer's &#x3b2;-amyloid fibrils: Evidence for a parallel &#x3b2;-sheet organization from solid state nuclear magnetic resonance. Biophys J. 2002;83:1205&#x2013;1216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1302222</ArticleId><ArticleId IdType="pubmed">12124300</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkova AT, et al. A structural model for Alzheimer's &#x3b2;-amyloid fibrils based on experimental constraints from solid state NMR. Proc Natl Acad Sci USA. 2002;99:16742&#x2013;16747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC139214</ArticleId><ArticleId IdType="pubmed">12481027</ArticleId></ArticleIdList></Reference><Reference><Citation>Luhrs T, et al. 3D structure of Alzheimer's amyloid-&#x3b2;(1&#x2013;42) fibrils. Proc Natl Acad Sci USA. 2005;102:17342&#x2013;17347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1297669</ArticleId><ArticleId IdType="pubmed">16293696</ArticleId></ArticleIdList></Reference><Reference><Citation>Esler WP, et al. In vitro growth of Alzheimer's disease &#x3b2;-amyloid plaques displays first-order kinetics. Biochemistry. 1996;35:749&#x2013;757.</Citation><ArticleIdList><ArticleId IdType="pubmed">8547255</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YR, Glabe CG. Distinct early folding and aggregation properties of Alzheimer amyloid-&#x3b2; peptides A&#x3b2;40 and A&#x3b2;42: Stable trimer or tetramer formation by A&#x3b2;42. J Biol Chem. 2006;281:24414&#x2013;24422.</Citation><ArticleIdList><ArticleId IdType="pubmed">16809342</ArticleId></ArticleIdList></Reference><Reference><Citation>Bitan G, et al. Amyloid &#x3b2;-protein (A&#x3b2;) assembly: A&#x3b2;40 and A&#x3b2;42 oligomerize through distinct pathways. Proc Natl Acad Sci USA. 2003;100:330&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC140968</ArticleId><ArticleId IdType="pubmed">12506200</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Soluble oligomers of the amyloid &#x3b2;-protein impair synaptic plasticity and behavior. Behav Brain Res. 2008;192:106&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2601528</ArticleId><ArticleId IdType="pubmed">18359102</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg L, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer disease: Relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol. 1998;55:326&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">9520006</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee AC, et al. Visual association pathology in preclinical Alzheimer disease. J Neuropath Exp Neurol. 2006;65:621&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pubmed">16783172</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Rub U, Orantes M, Braak H. Phases of a &#x3b2;-deposition in the human brain and its relevance for the development of ad. Neurology. 2002;58:1791&#x2013;1800.</Citation><ArticleIdList><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson KPR, et al. Imaging distinct conformational states of amyloid-&#x3b2; fibrils in Alzheimer's disease using novel luminescent probes. ACS Chem Biol. 2007;2:553&#x2013;560.</Citation><ArticleIdList><ArticleId IdType="pubmed">17672509</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigurdson CJ, et al. Prion strain discrimination using luminescent conjugated polymers. Nat Methods. 2007;4:1023&#x2013;1030.</Citation><ArticleIdList><ArticleId IdType="pubmed">18026110</ArticleId></ArticleIdList></Reference><Reference><Citation>Atarashi R, et al. Simplified ultrasensitive prion detection by recombinant PrP conversion with shaking. Nat Methods. 2008;5:211&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">18309304</ArticleId></ArticleIdList></Reference><Reference><Citation>Saa P, Castilla J, Soto C. Ultra-efficient replication of infectious prions by automated protein misfolding cyclic amplification. J Biol Chem. 2006;281:35245&#x2013;35252.</Citation><ArticleIdList><ArticleId IdType="pubmed">16982620</ArticleId></ArticleIdList></Reference><Reference><Citation>Colby DW, et al. Prion detection by an amyloid seeding assay. Proc Natl Acad Sci USA. 2007;104:20915&#x2013;20919.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2409241</ArticleId><ArticleId IdType="pubmed">18096717</ArticleId></ArticleIdList></Reference><Reference><Citation>Luca S, Yau WM, Leapman R, Tycko R. Peptide conformation and supramolecular organization in amylin fibrils: Constraints from solid state NMR. Biochemistry. 2007;46:13505&#x2013;13522.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2562526</ArticleId><ArticleId IdType="pubmed">17979302</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19412541</PMID><DateCompleted><Year>2009</Year><Month>08</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>5</Issue><PubDate><Year>2009</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Cerebrospinal fluid concentration of brain-derived neurotrophic factor and cognitive function in non-demented subjects.</ArticleTitle><Pagination><StartPage>e5424</StartPage><MedlinePgn>e5424</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e5424</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0005424</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Brain-derived neurotrophic factor (BDNF) is an activity-dependent secreted protein that is critical to organization of neuronal networks and synaptic plasticity, especially in the hippocampus. We tested hypothesis that reduced CSF BDNF is associated with age-related cognitive decline.</AbstractText><AbstractText Label="METHODOLOGY/PRINCIPAL FINDINGS, AND CONCLUSIONS/SIGNIFICANCE" NlmCategory="UNASSIGNED">CSF concentration of BDNF, Abeta(42) and total tau were measured in 128 cognitively normal adults (Normals), 21 patients with Alzheimer's disease (AD), and nine patients with Mild Cognitive Impairment. Apolipoprotein E and BDNF SNP rs6265 genotype were determined. Neuropsychological tests were performed at baseline for all subjects and at follow-up visits in 50 Normals. CSF BDNF level was lower in AD patients compared to age-matched Normals (p = 0.02). CSF BDNF concentration decreased with age among Normals and was higher in women than men (both p&lt;0.001). After adjusting for age, gender, education, CSF Abeta(42) and total tau, and APOE and BDNF genotypes, lower CSF BDNF concentration was associated poorer immediate and delayed recall at baseline (both p&lt;0.05) and in follow up of approximately 3 years duration (both p&lt;0.01).</AbstractText><AbstractText Label="CONCLUSIONS/SIGNIFICANCE" NlmCategory="CONCLUSIONS">Reduced CSF BDNF was associated with age-related cognitive decline, suggesting a potential mechanism that may contribute in part to cognitive decline in older individuals.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ge</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, Washington, USA. gli@u.washington.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peskind</LastName><ForeName>Elaine R</ForeName><Initials>ER</Initials></Author><Author ValidYN="Y"><LastName>Millard</LastName><ForeName>Steven P</ForeName><Initials>SP</Initials></Author><Author ValidYN="Y"><LastName>Chi</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Sokal</LastName><ForeName>Izabela</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Chang-En</ForeName><Initials>CE</Initials></Author><Author ValidYN="Y"><LastName>Bekris</LastName><ForeName>Lynn M</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Raskind</LastName><ForeName>Murray A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Galasko</LastName><ForeName>Douglas R</ForeName><Initials>DR</Initials></Author><Author ValidYN="Y"><LastName>Montine</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG023185</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG023185</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50-AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>05</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019208">Brain-Derived Neurotrophic Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019208" MajorTopicYN="N">Brain-Derived Neurotrophic Factor</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>5</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>5</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>8</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19412541</ArticleId><ArticleId IdType="pmc">PMC2671606</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0005424</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hariri AR, Goldberg TE, Mattay VS, Kolachana BS, Callicott JH, et al. Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci. 2003;23:6690&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740735</ArticleId><ArticleId IdType="pubmed">12890761</ArticleId></ArticleIdList></Reference><Reference><Citation>Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 2003;112:257&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">12553913</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyajima F, Ollier W, Mayes A, Jackson A, Thacker N, et al. Brain-derived neurotrophic factor polymorphism Val66Met influences cognitive abilities in the elderly. Genes Brain Behav. 2008;7:411&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17973920</ArticleId></ArticleIdList></Reference><Reference><Citation>Bueller JA, Aftab M, Sen S, Gomez-Hassan D, Burmeister M, et al. BDNF Val66Met allele is associated with reduced hippocampal volume in healthy subjects. Biol Psychiatry. 2006;59:812&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">16442082</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10190820</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Sokal I, Peskind ER, Quinn JF, Jankovic J, et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol. 2008;129:526&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2688655</ArticleId><ArticleId IdType="pubmed">18343778</ArticleId></ArticleIdList></Reference><Reference><Citation>Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 1990;31:545&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">2341813</ArticleId></ArticleIdList></Reference><Reference><Citation>Bekris LM, Millard SP, Galloway NM, Vuletic S, Albers JJ, et al. Multiple SNPs within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels. J Alzheimers Dis. 2008;13:255&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3192652</ArticleId><ArticleId IdType="pubmed">18430993</ArticleId></ArticleIdList></Reference><Reference><Citation>Newcomer JW, Selke G, Melson AK, Gross J, Vogler GP, et al. Dose-dependent cortisol-induced increases in plasma leptin concentration in healthy humans. Arch Gen Psychiatry. 1998;55:995&#x2013;1000.</Citation><ArticleIdList><ArticleId IdType="pubmed">9819068</ArticleId></ArticleIdList></Reference><Reference><Citation>Craft S, Dagogo-Jack SE, Wiethop BV, Murphy C, Nevins RT, et al. Effects of hyperglycemia on memory and hormone levels in dementia of the Alzheimer type: a longitudinal study. Behav Neurosci. 1993;107:926&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">8136068</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D, Stone CP. Manual: Wechsler Memory Scale. New York: Psychological Corporation; 1983.</Citation></Reference><Reference><Citation>Gomez RG, White DA. Using verbal fluency to detect very mild dementia of the Alzheimer type. Arch Clin Neuropsychol. 2006;21:771&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">17011743</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitan RW, D. The Halstead-Reitan neuropsychological test battery. Tucson: Neuropsychology Press; 1985.</Citation></Reference><Reference><Citation>Milliken JK, Edland SD. Mixed effect models of longitudinal Alzheimer's disease data: a cautionary note. Stat Med. 2000;19:1617&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">10844723</ArticleId></ArticleIdList></Reference><Reference><Citation>Corporation I, S-PLUS. 2008, Insightful Corporation: seattle, WA.</Citation></Reference><Reference><Citation>Team R D C, R: A language and environment for statistical computing. 2008, R Foundation for Statistical Computing: Vienna, Austria.</Citation></Reference><Reference><Citation>Li G, Sokal I, Quinn JF, Leverenz JB, Brodey M, et al. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology. 2007;69:631&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17698783</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, et al. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64:343&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210801</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagatsu T, Mogi M, Ichinose H, Togari A. Changes in cytokines and neurotrophins in Parkinson's disease. J Neural Transm Suppl. 2000:277&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">11205147</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Goodlett DR, Quinn JF, Peskind E, Kaye JA, et al. Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J Alzheimers Dis. 2005;7:125&#x2013;33; discussion 73&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">15851850</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasko I, Lederer W, Oberbauer H, Walch T, Kemmler G, et al. Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias. Dement Geriatr Cogn Disord. 2006;21:9&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">16244482</ArticleId></ArticleIdList></Reference><Reference><Citation>Laske C, Stransky E, Leyhe T, Eschweiler GW, Maetzler W, et al. BDNF serum and CSF concentrations in Alzheimer's disease, normal pressure hydrocephalus and healthy controls. J Psychiatr Res. 2007;41:387&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">16554070</ArticleId></ArticleIdList></Reference><Reference><Citation>Laske C, Stransky E, Leyhe T, Eschweiler GW, Wittorf A, et al. Stage-dependent BDNF serum concentrations in Alzheimer's disease. J Neural Transm. 2006;113:1217&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">16362629</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohrabji F, Lewis DK. Estrogen-BDNF interactions: implications for neurodegenerative diseases. Front Neuroendocrinol. 2006;27:404&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1828910</ArticleId><ArticleId IdType="pubmed">17069877</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19414612</PMID><DateCompleted><Year>2009</Year><Month>05</Month><Day>20</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1540-8140</ISSN><JournalIssue CitedMedium="Internet"><Volume>185</Volume><Issue>3</Issue><PubDate><Year>2009</Year><Month>May</Month><Day>04</Day></PubDate></JournalIssue><Title>The Journal of cell biology</Title><ISOAbbreviation>J Cell Biol</ISOAbbreviation></Journal><ArticleTitle>Synaptic activity prompts gamma-secretase-mediated cleavage of EphA4 and dendritic spine formation.</ArticleTitle><Pagination><StartPage>551</StartPage><EndPage>564</EndPage><MedlinePgn>551-64</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1083/jcb.200809151</ELocationID><Abstract><AbstractText>Alzheimer's disease is an age-dependent neurodegenerative disorder that is characterized by a progressive decline in cognitive function. gamma-secretase dysfunction is evident in many cases of early onset familial Alzheimer's disease. However, the mechanism by which gamma-secretase dysfunction results in memory loss and neurodegeneration is not fully understood. Here, we demonstrate that gamma-secretase is localized at synapses and regulates spine formation. We identify EphA4, one of the Ephrin receptor family members, as a substrate of gamma-secretase, and find that EphA4 processing is enhanced by synaptic activity. Moreover, overexpression of EphA4 intracellular domain increases the number of dendritic spines by activating the Rac signaling pathway. These findings reveal a function for EphA4-mediated intracellular signaling in the morphogenesis of dendritic spines and suggest that the processing of EphA4 by gamma-secretase affects the pathogenesis of Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Inoue</LastName><ForeName>Eiji</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>KAN Research Institute, Kobe, Japan. e-inoue@kan.eisai.co.jp</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deguchi-Tawarada</LastName><ForeName>Maki</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Togawa</LastName><ForeName>Aki</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Matsui</LastName><ForeName>Chiyuki</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Arita</LastName><ForeName>Kohei</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Katahira-Tayama</LastName><ForeName>Sayaka</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Toshitaka</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Yamauchi</LastName><ForeName>Emiko</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Oda</LastName><ForeName>Yoshiya</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Takai</LastName><ForeName>Yoshimi</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Cell Biol</MedlineTA><NlmUniqueID>0375356</NlmUniqueID><ISSNLinking>0021-9525</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D036122">Receptor, EphA4</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>YOW8V9698H</RegistryNumber><NameOfSubstance UI="D004121">Dimethyl Sulfoxide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003712" MajorTopicYN="N">Dendrites</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004121" MajorTopicYN="N">Dimethyl Sulfoxide</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036122" MajorTopicYN="N">Receptor, EphA4</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013131" MajorTopicYN="N">Spine</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>5</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>5</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>5</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>11</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19414612</ArticleId><ArticleId IdType="pmc">PMC2700400</ArticleId><ArticleId IdType="doi">10.1083/jcb.200809151</ArticleId><ArticleId IdType="pii">jcb.200809151</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Annaert W.G., Levesque L., Craessaerts K., Dierinck I., Snellings G., Westaway D., St. George-Hyslop P., Cordell B., Fraser P., De Strooper B. 1999. Presenilin 1 controls &#x3b3;-secretase processing of the amyloid precursor protein in pre-Golgi compartments of hippocampal neurons.J. Cell Biol. 147:277&#x2013;294</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2174229</ArticleId><ArticleId IdType="pubmed">10525535</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoto J., Chen L. 2007. Bidirectional ephrin/Eph signaling in synaptic functions.Brain Res. 1184:72&#x2013;80</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2170431</ArticleId><ArticleId IdType="pubmed">17166489</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriagada P.V., Marzloff K., Hyman B.T. 1992. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease.Neurology. 42:1681&#x2013;1688</Citation><ArticleIdList><ArticleId IdType="pubmed">1307688</ArticleId></ArticleIdList></Reference><Reference><Citation>Beher D., Elle C., Underwood J., Davis J.B., Ward R., Karran E., Masters C.L., Beyreuther K., Multhaup G. 1999. Proteolytic fragments of Alzheimer's disease-associated presenilin 1 are present in synaptic organelles and growth cone membranes of rat brain.J. Neurochem. 72:1564&#x2013;1573</Citation><ArticleIdList><ArticleId IdType="pubmed">10098862</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentahir M., Nyabi O., Verhamme J., Tolia A., Horr&#xe9; K., Wiltfang J., Esselmann H., De Strooper B. 2006. Presenilin clinical mutations can affect &#x3b3;-secretase activity by different mechanisms.J. Neurochem. 96:732&#x2013;742</Citation><ArticleIdList><ArticleId IdType="pubmed">16405513</ArticleId></ArticleIdList></Reference><Reference><Citation>Bickel P.E., Scherer P.E., Schnitzer J.E., Oh P., Lisanti M.P., Lodish H.F. 1997. Flotillin and epidermal surface antigen define a new family of caveolae-associated integral membrane proteins.J. Biol. Chem. 272:13793&#x2013;13802</Citation><ArticleIdList><ArticleId IdType="pubmed">9153235</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourgin C., Murai K.K., Richter M., Pasquale E.B. 2007. The EphA4 receptor regulates dendritic spine remodeling by affecting &#x3b2;1-integrin signaling pathways.J. Cell Biol. 178:1295&#x2013;1307</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2064660</ArticleId><ArticleId IdType="pubmed">17875741</ArticleId></ArticleIdList></Reference><Reference><Citation>Derkach V.A., Oh M.C., Guire E.S., Soderling T.R. 2007. Regulatory mechanisms of AMPA receptors in synaptic plasticity.Nat. Rev. Neurosci. 8:101&#x2013;113</Citation><ArticleIdList><ArticleId IdType="pubmed">17237803</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B. 2003. Aph-1, Pen-2, and Nicastrin with Presenilin generate an active &#x3b3;-secretase complex.Neuron. 38:9&#x2013;12</Citation><ArticleIdList><ArticleId IdType="pubmed">12691659</ArticleId></ArticleIdList></Reference><Reference><Citation>Elia L.P., Yamamoto M., Zang K., Reichardt L.F. 2006. p120 catenin regulates dendritic spine and synapse development through Rho-family GTPases and cadherins.Neuron. 51:43&#x2013;56</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2587166</ArticleId><ArticleId IdType="pubmed">16815331</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu W.Y., Chen Y., Sahin M., Zhao X.S., Shi L., Bikoff J.B., Lai K.O., Yung W.H., Fu A.K., Greenberg M.E., Ip N.Y. 2007. Cdk5 regulates EphA4-mediated dendritic spine retraction through an ephexin1-dependent mechanism.Nat. Neurosci. 10:67&#x2013;76</Citation><ArticleIdList><ArticleId IdType="pubmed">17143272</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia R.A., Vasudevan K., Buonanno A. 2000. The neuregulin receptor ErbB-4 interacts with PDZ-containing proteins at neuronal synapses.Proc. Natl. Acad. Sci. USA. 97:3596&#x2013;3601</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16285</ArticleId><ArticleId IdType="pubmed">10725395</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgakopoulos A., Litterst C., Ghersi E., Baki L., Xu C., Serban G., Robakis N.K. 2006. Metalloproteinase/Presenilin1 processing of ephrinB regulates EphB-induced Src phosphorylation and signaling.EMBO J. 25:1242&#x2013;1252</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1422162</ArticleId><ArticleId IdType="pubmed">16511561</ArticleId></ArticleIdList></Reference><Reference><Citation>Haapasalo A., Kim D.Y., Carey B.W., Turunen M.K., Pettingell W.H., Kovacs D.M. 2007. Presenilin/&#x3b3;-secretase-mediated cleavage regulates association of leukocyte-common antigen-related (LAR) receptor tyrosine phosphatase with &#x3b2;-catenin.J. Biol. Chem. 282:9063&#x2013;9072</Citation><ArticleIdList><ArticleId IdType="pubmed">17259169</ArticleId></ArticleIdList></Reference><Reference><Citation>Hering H., Lin C.C., Sheng M. 2003. Lipid rafts in the maintenance of synapses, dendritic spines, and surface AMPA receptor stability.J. Neurosci. 23:3262&#x2013;3271</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742299</ArticleId><ArticleId IdType="pubmed">12716933</ArticleId></ArticleIdList></Reference><Reference><Citation>Herreman A., Hartmann D., Annaert W., Saftig P., Craessaerts K., Serneels L., Umans L., Schrijvers V., Checler F., Vanderstichele H., et al. 1999. Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency.Proc. Natl. Acad. Sci. USA. 96:11872&#x2013;11877</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18379</ArticleId><ArticleId IdType="pubmed">10518543</ArticleId></ArticleIdList></Reference><Reference><Citation>Herreman A., Van Gassen G., Bentahir M., Nyabi O., Craessaerts K., Mueller U., Annaert W., De Strooper B. 2003. &#x3b3;-secretase activity requires the presenilin-dependent trafficking of nicastrin through the Golgi apparatus but not its complex glycosylation.J. Cell Sci. 116:1127&#x2013;1136</Citation><ArticleIdList><ArticleId IdType="pubmed">12584255</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoogenraad C.C., Feliu-Mojer M.I., Spangler S.A., Milstein A.D., Dunah A.W., Hung A.Y., Sheng M. 2007. Liprin &#x3b1;1 degradation by calcium/calmodulin-dependent protein kinase II regulates LAR receptor tyrosine phosphatase distribution and dendrite development.Dev. Cell. 12:587&#x2013;602</Citation><ArticleIdList><ArticleId IdType="pubmed">17419996</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue E., Mochida S., Takagi H., Higa S., Deguchi-Tawarada M., Takao-Rikitsu E., Inoue M., Yao I., Takeuchi K., Kitajima I., et al. 2006. SAD: a presynaptic kinase associated with synaptic vesicles and the active zone cytomatrix that regulates neurotransmitter release.Neuron. 50:261&#x2013;275</Citation><ArticleIdList><ArticleId IdType="pubmed">16630837</ArticleId></ArticleIdList></Reference><Reference><Citation>Isaac J.T., Nicoll R.A., Malenka R.C. 1995. Evidence for silent synapses: implications for the expression of LTP.Neuron. 15:427&#x2013;434</Citation><ArticleIdList><ArticleId IdType="pubmed">7646894</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasato T., Katoh H., Nishimaru H., Ishikawa Y., Inoue H., Saito Y.M., Ando R., Iwama M., Takahashi R., Negishi M., Itohara S. 2007. Rac-GAP &#x3b1;-chimerin regulates motor-circuit formation as a key mediator of EphrinB3/EphA4 forward signaling.Cell. 130:742&#x2013;753</Citation><ArticleIdList><ArticleId IdType="pubmed">17719550</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamal A., Almenar-Queralt A., LeBlanc J.F., Roberts E.A., Goldstein L.S. 2001. Kinesin-mediated axonal transport of a membrane compartment containing &#x3b2;-secretase and presenilin-1 requires APP.Nature. 414:643&#x2013;648</Citation><ArticleIdList><ArticleId IdType="pubmed">11740561</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazee A.M., Johnson E.M. 1998. Alzheimer's disease pathology in non-demented elderly.J. Alzheimers Dis. 1:81&#x2013;89</Citation><ArticleIdList><ArticleId IdType="pubmed">12214005</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim E., Sheng M. 2004. PDZ domain proteins of synapses.Nat. Rev. Neurosci. 5:771&#x2013;781</Citation><ArticleIdList><ArticleId IdType="pubmed">15378037</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopec C.D., Li B., Wei W., Boehm J., Malinow R. 2006. Glutamate receptor exocytosis and spine enlargement during chemically induced long-term potentiation.J. Neurosci. 26:2000&#x2013;2009</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674938</ArticleId><ArticleId IdType="pubmed">16481433</ArticleId></ArticleIdList></Reference><Reference><Citation>Landman N., Kim T.W. 2004. Got RIP? Presenilin-dependent intramembrane proteolysis in growth factor receptor signaling.Cytokine Growth Factor Rev. 15:337&#x2013;351</Citation><ArticleIdList><ArticleId IdType="pubmed">15450250</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Borgne R., Bardin A., Schweisguth F. 2005. The roles of receptor and ligand endocytosis in regulating Notch signaling.Development. 132:1751&#x2013;1762</Citation><ArticleIdList><ArticleId IdType="pubmed">15790962</ArticleId></ArticleIdList></Reference><Reference><Citation>Litterst C., Georgakopoulos A., Shioi J., Ghersi E., Wisniewski T., Wang R., Ludwig A., Robakis N.K. 2007. Ligand binding and calcium influx induce distinct ectodomain/&#x3b3;-secretase-processing pathways of EphB2 receptor.J. Biol. Chem. 282:16155&#x2013;16163</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4005067</ArticleId><ArticleId IdType="pubmed">17428795</ArticleId></ArticleIdList></Reference><Reference><Citation>Machesky L.M., Hall A. 1997. Role of actin polymerization and adhesion to extracellular matrix in Rac- and Rho-induced cytoskeletal reorganization.J. Cell Biol. 138:913&#x2013;926</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2138040</ArticleId><ArticleId IdType="pubmed">9265656</ArticleId></ArticleIdList></Reference><Reference><Citation>Marambaud P., Wen P.H., Dutt A., Shioi J., Takashima A., Siman R., Robakis N.K. 2003. A CBP binding transcriptional repressor produced by the PS1/&#x3f5;-cleavage of N-cadherin is inhibited by PS1 FAD mutations.Cell. 114:635&#x2013;645</Citation><ArticleIdList><ArticleId IdType="pubmed">13678586</ArticleId></ArticleIdList></Reference><Reference><Citation>Maretzky T., Schulte M., Ludwig A., Rose-John S., Blobel C., Hartmann D., Altevogt P., Saftig P., Reiss K. 2005. L1 is sequentially processed by two differently activated metalloproteases and presenilin/&#x3b3;-secretase and regulates neural cell adhesion, cell migration, and neurite outgrowth.Mol. Cell. Biol. 25:9040&#x2013;9053</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1265787</ArticleId><ArticleId IdType="pubmed">16199880</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuzaki M., Ellis-Davies G.C., Nemoto T., Miyashita Y., Iino M., Kasai H. 2001. Dendritic spine geometry is critical for AMPA receptor expression in hippocampal CA1 pyramidal neurons.Nat. Neurosci. 4:1086&#x2013;1092</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4229049</ArticleId><ArticleId IdType="pubmed">11687814</ArticleId></ArticleIdList></Reference><Reference><Citation>Moehlmann T., Winkler E., Xia X., Edbauer D., Murrell J., Capell A., Kaether C., Zheng H., Ghetti B., Haass C., Steiner H. 2002. Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on A&#x3b2; 42 production.Proc. Natl. Acad. Sci. USA. 99:8025&#x2013;8030</Citation><ArticleIdList><ArticleId IdType="pmc">PMC123014</ArticleId><ArticleId IdType="pubmed">12048239</ArticleId></ArticleIdList></Reference><Reference><Citation>Murai K.K., Nguyen L.N., Irie F., Yamaguchi Y., Pasquale E.B. 2003. Control of hippocampal dendritic spine morphology through ephrin-A3/EphA4 signaling.Nat. Neurosci. 6:153&#x2013;160</Citation><ArticleIdList><ArticleId IdType="pubmed">12496762</ArticleId></ArticleIdList></Reference><Reference><Citation>Niwa H., Yamamura K., Miyazaki J. 1991. Efficient selection for high-expression transfectants with a novel eukaryotic vector.Gene. 108:193&#x2013;199</Citation><ArticleIdList><ArticleId IdType="pubmed">1660837</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh M.C., Derkach V.A., Guire E.S., Soderling T.R. 2006. Extrasynaptic membrane trafficking regulated by GluR1 serine 845 phosphorylation primes AMPA receptors for long-term potentiation.J. Biol. Chem. 281:752&#x2013;758</Citation><ArticleIdList><ArticleId IdType="pubmed">16272153</ArticleId></ArticleIdList></Reference><Reference><Citation>Otmakhov N., Khibnik L., Otmakhova N., Carpenter S., Riahi S., Asrican B., Lisman J. 2004. Forskolin-induced LTP in the CA1 hippocampal region is NMDA receptor dependent.J. Neurophysiol. 91:1955&#x2013;1962</Citation><ArticleIdList><ArticleId IdType="pubmed">14702333</ArticleId></ArticleIdList></Reference><Reference><Citation>Penzes P., Cahill M.E., Jones K.A., Srivastava D.P. 2008. Convergent CaMK and RacGEF signals control dendritic structure and function.Trends Cell Biol. 18:405&#x2013;413</Citation><ArticleIdList><ArticleId IdType="pubmed">18701290</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramakers G.J. 2002. Rho proteins, mental retardation and the cellular basis of cognition.Trends Neurosci. 25:191&#x2013;199</Citation><ArticleIdList><ArticleId IdType="pubmed">11998687</ArticleId></ArticleIdList></Reference><Reference><Citation>Rechards M., Xia W., Oorschot V.M., Selkoe D.J., Klumperman J. 2003. Presenilin-1 exists in both pre- and post-Golgi compartments and recycles via COPI-coated membranes.Traffic. 4:553&#x2013;565</Citation><ArticleIdList><ArticleId IdType="pubmed">12839498</ArticleId></ArticleIdList></Reference><Reference><Citation>Rumbaugh G., Adams J.P., Kim J.H., Huganir R.L. 2006. SynGAP regulates synaptic strength and mitogen-activated protein kinases in cultured neurons.Proc. Natl. Acad. Sci. USA. 103:4344&#x2013;4351</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1450173</ArticleId><ArticleId IdType="pubmed">16537406</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura C.A., Choi S.Y., Beglopoulos V., Malkani S., Zhang D., Shankaranarayana Rao B.S., Chattarji S., Kelleher R.J., III, Kandel E.R., Duff K., et al. 2004. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration.Neuron. 42:23&#x2013;36</Citation><ArticleIdList><ArticleId IdType="pubmed">15066262</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff S.W., Price D.A., Schmitt F.A., Mufson E.J. 2006. Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment.Neurobiol. Aging. 27:1372&#x2013;1384</Citation><ArticleIdList><ArticleId IdType="pubmed">16289476</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabata T., Sato T., Kuromitsu J., Oda Y. 2007. Pseudo internal standard approach for label-free quantitative proteomics.Anal. Chem. 79:8440&#x2013;8445</Citation><ArticleIdList><ArticleId IdType="pubmed">17929902</ArticleId></ArticleIdList></Reference><Reference><Citation>Tashiro A., Yuste R. 2004. Regulation of dendritic spine motility and stability by Rac1 and Rho kinase: evidence for two forms of spine motility.Mol. Cell. Neurosci. 26:429&#x2013;440</Citation><ArticleIdList><ArticleId IdType="pubmed">15234347</ArticleId></ArticleIdList></Reference><Reference><Citation>Van de Ven T.J., VanDongen H.M., VanDongen A.M. 2005. The nonkinase phorbol ester receptor &#x3b1;1-chimerin binds the NMDA receptor NR2A subunit and regulates dendritic spine density.J. Neurosci. 25:9488&#x2013;9496</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725706</ArticleId><ArticleId IdType="pubmed">16221859</ArticleId></ArticleIdList></Reference><Reference><Citation>Vetrivel K.S., Cheng H., Lin W., Sakurai T., Li T., Nukina N., Wong P.C., Xu H., Thinakaran G. 2004. Association of &#x3b3;-secretase with lipid rafts in post-Golgi and endosome membranes.J. Biol. Chem. 279:44945&#x2013;44954</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1201506</ArticleId><ArticleId IdType="pubmed">15322084</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh D.M., Selkoe D.J. 2004. Deciphering the molecular basis of memory failure in Alzheimer's disease.Neuron. 44:181&#x2013;193</Citation><ArticleIdList><ArticleId IdType="pubmed">15450169</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Z., Srivastava D.P., Photowala H., Kai L., Cahill M.E., Woolfrey K.M., Shum C.Y., Surmeier D.J., Penzes P. 2007. Kalirin-7 controls activity-dependent structural and functional plasticity of dendritic spines.Neuron. 56:640&#x2013;656</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2118058</ArticleId><ArticleId IdType="pubmed">18031682</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L., Ma Q.L., Calon F., Harris-White M.E., Yang F., Lim G.P., Morihara T., Ubeda O.J., Ambegaokar S., Hansen J.E., et al. 2006. Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease.Nat. Neurosci. 9:234&#x2013;242</Citation><ArticleIdList><ArticleId IdType="pubmed">16415866</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19416837</PMID><DateCompleted><Year>2009</Year><Month>06</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>106</Volume><Issue>19</Issue><PubDate><Year>2009</Year><Month>May</Month><Day>12</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>p75 reduces beta-amyloid-induced sympathetic innervation deficits in an Alzheimer's disease mouse model.</ArticleTitle><Pagination><StartPage>7870</StartPage><EndPage>7875</EndPage><MedlinePgn>7870-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0901533106</ELocationID><Abstract><AbstractText>Beta-amyloid (Abeta) has adverse effects on brain cells, but little is known about its effects on the peripheral nervous system in Alzheimer's disease (AD). Several lines of in vitro evidence suggest that the neurotrophin receptor p75 mediates or exacerbates Abeta-induced neurotoxicity. Here, we show that p75-deficient sympathetic neurons are more sensitive to Abeta-induced neurite growth inhibition. To investigate the role of p75 in the sympathetic nervous system of AD, p75 mutant mice were crossed with a mouse line of AD model. The majority of p75-deficient AD mice died by 3 weeks of age. The lethality is associated with severe defects in sympathetic innervation to multiple organs. When 1 copy of the BACE1 gene encoding a protein essential in Abeta production was deleted in p75-deficient AD mice, sympathetic innervation was significantly restored. These results suggest that p75 is neuroprotective for the sympathetic nervous system in a mouse model of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bengoechea</LastName><ForeName>Tasha G</ForeName><Initials>TG</Initials><AffiliationInfo><Affiliation>Peptide Biology Laboratory, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Zhijiang</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>O'Leary</LastName><ForeName>Debra A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Masliah</LastName><ForeName>Eliezer</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Kuo-Fen</ForeName><Initials>KF</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG10435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS060833</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS060833</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG010435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HD034534</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>04</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020800">Receptor, Nerve Growth Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):20134</RefSource><Note>O'Leary, Deborah [corrected to O'Leary, Debra A]</Note></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020800" MajorTopicYN="N">Receptor, Nerve Growth Factor</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013233" MajorTopicYN="N">Stellate Ganglion</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013546" MajorTopicYN="N">Sweating</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013564" MajorTopicYN="N">Sympathetic Nervous System</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>5</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>5</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>6</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>11</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19416837</ArticleId><ArticleId IdType="pmc">PMC2683130</ArticleId><ArticleId IdType="doi">10.1073/pnas.0901533106</ArticleId><ArticleId IdType="pii">0901533106</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goedert M, Spillantini MG. A century of Alzheimer's disease. Science. 2006;314:777&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pubmed">17082447</ArticleId></ArticleIdList></Reference><Reference><Citation>Borson S, Barnes RF, Veith RC, Halter JB, Raskind MA. Impaired sympathetic nervous system response to cognitive effort in early Alzheimer's disease. J Gerontol. 1989;44:M8&#x2013;M12.</Citation><ArticleIdList><ArticleId IdType="pubmed">2910990</ArticleId></ArticleIdList></Reference><Reference><Citation>Allan LM, et al. Autonomic dysfunction in dementia. J Neurol Neurosurg Psychiatry. 2007;78:671&#x2013;677.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2117678</ArticleId><ArticleId IdType="pubmed">17178816</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Mucke L. 100 years and counting: Prospects for defeating Alzheimer's disease. Science. 2006;314:781&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3544944</ArticleId><ArticleId IdType="pubmed">17082448</ArticleId></ArticleIdList></Reference><Reference><Citation>Barker PA. p75NTR is positively promiscuous: Novel partners and new insights. Neuron. 2004;42:529&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pubmed">15157416</ArticleId></ArticleIdList></Reference><Reference><Citation>Nykjaer A, et al. Sortilin is essential for proNGF-induced neuronal cell death. Nature. 2004;427:843&#x2013;848.</Citation><ArticleIdList><ArticleId IdType="pubmed">14985763</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim YS, et al. p75(NTR) mediates ephrin-A reverse signaling required for axon repulsion and mapping. Neuron. 2008;59:746&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677386</ArticleId><ArticleId IdType="pubmed">18786358</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuner P, Schubenel R, Hertel C. Beta-amyloid binds to p57NTR and activates NFkappaB in human neuroblastoma cells. J Neurosci Res. 1998;54:798&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pubmed">9856863</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaar M, et al. Binding of &#x3b2;-amyloid to the p75 neurotrophin receptor induces apoptosis. J Clin Invest. 1997;100:2333&#x2013;2340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC508430</ArticleId><ArticleId IdType="pubmed">9410912</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaar M, et al. Amyloid beta binds trimers as well as monomers of the 75-kDa neurotrophin receptor and activates receptor signaling. J Biol Chem. 2002;277:7720&#x2013;7725.</Citation><ArticleIdList><ArticleId IdType="pubmed">11756426</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabizadeh S, Bitler CM, Butcher LL, Bredesen DE. Expression of the low-affinity nerve growth factor receptor enhances &#x3b2;-amyloid peptide toxicity. Proc Natl Acad Sci USA. 1994;91:10703&#x2013;10706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC45090</ArticleId><ArticleId IdType="pubmed">7938014</ArticleId></ArticleIdList></Reference><Reference><Citation>Perini G, et al. Role of p75 neurotrophin receptor in the neurotoxicity by beta-amyloid peptides and synergistic effect of inflammatory cytokines. J Exp Med. 2002;195:907&#x2013;918.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2193732</ArticleId><ArticleId IdType="pubmed">11927634</ArticleId></ArticleIdList></Reference><Reference><Citation>Sotthibundhu A, et al. Beta-amyloid(1-42) induces neuronal death through the p75 neurotrophin receptor. J Neurosci. 2008;28:3941&#x2013;3946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670462</ArticleId><ArticleId IdType="pubmed">18400893</ArticleId></ArticleIdList></Reference><Reference><Citation>Troy CM, et al. beta-Amyloid-induced neuronal apoptosis requires c-Jun N-terminal kinase activation. J Neurochem. 2001;77:157&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">11279271</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrington AW, Kim JY, Yoon SO. Activation of Rac GTPase by p75 is necessary for c-jun N-terminal kinase-mediated apoptosis. J Neurosci. 2002;22:156&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757583</ArticleId><ArticleId IdType="pubmed">11756498</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, et al. p75 neurotrophin receptor protects primary cultures of human neurons against extracellular amyloid beta peptide cytotoxicity. J Neurosci. 2003;23:7385&#x2013;7394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740455</ArticleId><ArticleId IdType="pubmed">12917374</ArticleId></ArticleIdList></Reference><Reference><Citation>Roher AE, Ball MJ, Bhave SV, Wakade AR. Beta-amyloid from Alzheimer disease brains inhibits sprouting and survival of sympathetic neurons. Biochem Biophys Res Commun. 1991;174:572&#x2013;579.</Citation><ArticleIdList><ArticleId IdType="pubmed">1993054</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolar M, Scott SA, Crutcher KA. Sympathetic neurite outgrowth is greater on plaque-poor vs. plaque-rich regions of Alzheimer's disease cryostat sections. Brain Res. 1998;787:49&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">9518548</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, et al. Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer's disease. J Neurosci. 1996;16:5795&#x2013;5811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578961</ArticleId><ArticleId IdType="pubmed">8795633</ArticleId></ArticleIdList></Reference><Reference><Citation>Landis SC. Neurotransmitter plasticity in sympathetic neurons and its regulation by environmental factors in vitro and in vivo. In: Bj&#xf6;rklund A, H&#xf6;kfelt T, Owman C, editors. Handbook of Chemical Neuroanatomy: The Peripheral Nervous System. Vol 6. Amsterdam, The Netherlands: Elsevier Science Publishers B.V.; 1988. pp. 65&#x2013;115.</Citation></Reference><Reference><Citation>Lee KF, Bachman K, Landis S, Jaenisch R. Dependence on p75 for innervation of some sympathetic targets. Science. 1994;263:1447&#x2013;1449.</Citation><ArticleIdList><ArticleId IdType="pubmed">8128229</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardini BJ, Lund DD, Schmid PG. Organization of the sympathetic postganglionic innervation of the rat heart. J Auton Nerv Syst. 1989;28:193&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">2628461</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y, et al. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci. 2001;4:231&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">11224535</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno M, et al. BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron. 2004;41:27&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">14715132</ArticleId></ArticleIdList></Reference><Reference><Citation>Laird FM, et al. BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci. 2005;25:11693&#x2013;11709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2564291</ArticleId><ArticleId IdType="pubmed">16354928</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, et al. Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci. 2006;9:1520&#x2013;1525.</Citation><ArticleIdList><ArticleId IdType="pubmed">17099708</ArticleId></ArticleIdList></Reference><Reference><Citation>Willem M, et al. Control of peripheral nerve myelination by the beta-secretase BACE1. Science. 2006;314:664&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pubmed">16990514</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin J, et al. Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. J Neurosci. 2004;24:4692&#x2013;4697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729387</ArticleId><ArticleId IdType="pubmed">15140940</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science. 2007;316:750&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee KF, Davies AM, Jaenisch R. p75-deficient embryonic dorsal root sensory and neonatal sympathetic neurons displayed decreased sensitivity to NGF. Development. 1994;120:1027&#x2013;1033.</Citation><ArticleIdList><ArticleId IdType="pubmed">7600951</ArticleId></ArticleIdList></Reference><Reference><Citation>Brennan C, Rivas-Plata K, Landis SC. The p75 neurotrophin receptor influences NT-3 responsiveness of sympathetic neurons in vivo. Nat Neurosci. 1999;2:699&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">10412058</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan H, Newgreen DF, Young HM. Developmental changes in neurite outgrowth responses of dorsal root and sympathetic ganglia to GDNF, neurturin, and artemin. Dev Dyn. 2003;227:395&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">12815625</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita T, Higuchi H, Tohyama M. The p75 receptor transduces the signal from myelin-associated glycoprotein to Rho. J Cell Biol. 2002;157:565&#x2013;570.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2173856</ArticleId><ArticleId IdType="pubmed">12011108</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong ST, et al. A p75(NTR) and Nogo receptor complex mediates repulsive signaling by myelin-associated glycoprotein. Nat Neurosci. 2002;5:1302&#x2013;1308.</Citation><ArticleIdList><ArticleId IdType="pubmed">12426574</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang KC, Kim JA, Sivasankaran R, Segal R, He Z. P75 interacts with the Nogo receptor as a co-receptor for Nogo, MAG and OMgp. Nature. 2002;420:74&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">12422217</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang T, et al. Small molecule, non-peptide p75 ligands inhibit Abeta-induced neurodegeneration and synaptic impairment. PLoS ONE. 2008;3:e3604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2575383</ArticleId><ArticleId IdType="pubmed">18978948</ArticleId></ArticleIdList></Reference><Reference><Citation>Roux PP, Bhakar AL, Kennedy TE, Barker PA. The p75 neurotrophin receptor activates Akt (protein kinase B) through a phosphatidylinositol 3-kinase-dependent pathway. J Biol Chem. 2001;276:23097&#x2013;23104.</Citation><ArticleIdList><ArticleId IdType="pubmed">11312266</ArticleId></ArticleIdList></Reference><Reference><Citation>Longo FM, Massa SM. Small molecule modulation of p75 neurotrophin receptor functions. CNS Neurol Disord Drug Targets. 2008;7:63&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">18289033</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolaev A, McLaughlin T, O'Leary DD, Tessier-Lavigne M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature. 2009;457:981&#x2013;989.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677572</ArticleId><ArticleId IdType="pubmed">19225519</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee KF, et al. Targeted mutation of the gene encoding the low affinity NGF receptor p75 leads to deficits in the peripheral sensory nervous system. Cell. 1992;69:737&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pubmed">1317267</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentley CA, Lee KF. p75 is important for axon growth and schwann cell migration during development. J Neurosci. 2000;20:7706&#x2013;7715.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772891</ArticleId><ArticleId IdType="pubmed">11027232</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsui-Pierchala BA, Milbrandt J, Johnson EM., Jr NGF utilizes c-Ret via a novel GFL-independent, inter-RTK signaling mechanism to maintain the trophic status of mature sympathetic neurons. Neuron. 2002;33:261&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pubmed">11804573</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19433663</PMID><DateCompleted><Year>2009</Year><Month>09</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3687</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>5</Issue><PubDate><Year>2009</Year><Month>May</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings.</ArticleTitle><Pagination><StartPage>632</StartPage><EndPage>637</EndPage><MedlinePgn>632-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archneurol.2009.59</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Alterations in cerebrospinal fluid (CSF) tau and beta-amyloid peptide 1-42 (Abeta(42)) levels and rates of cerebral glucose metabolism (CMRglu) on fluorodeoxyglucose positron emission tomography (FDG-PET) occur years before clinical symptoms of Alzheimer disease (AD) become manifest, but their relationship remains unclear.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine whether CSF AD biomarker levels and CMRglu in healthy individuals correlate in brain structures affected early in AD.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Cohort study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Alzheimer disease research center.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Twenty individuals without dementia aged 46 to 83 years.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Lumbar CSF sampling and FDG-PET imaging of CMRglu. The CSF Abeta(42), tau, and tau phosphorylated at threonine 181 (ptau(181)) levels were measured using immunobead-based multiplex assays.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Correlations between CMRglu and CSF biomarker levels were analyzed via voxel-based and volume-of-interest approaches.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Voxel-based analyses demonstrated significant negative correlations between CSF tau and ptau(181) levels and CMRglu in the posterior cingulate, precuneus, and parahippocampal regions. In contrast, a limited positive correlation was found between CSF Abeta(42) levels and CMRglu in the inferior temporal cortex. Volume-of-interest analyses confirmed negative associations between CSF tau and ptau(181) levels and CMRglu in the parietal and medial parietal lobes and a positive association between CSF Abeta(42) levels and CMRglu in the parahippocampal gyrus.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In healthy individuals, higher CSF tau and ptau(181) concentrations were associated with more severe hypometabolism in several brain regions affected very early in AD, whereas lower CSF Abeta(42) concentrations were associated with hypometabolism only in the medial temporal lobe. This suggests that early tau and Abeta abnormalities may be associated with subtle synaptic changes in brain regions vulnerable to AD. A longitudinal assessment of CSF and FDG-PET biomarkers is needed to determine whether these changes predict cognitive impairment and incipient AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Petrie</LastName><ForeName>Eric C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Mail Code S-182-GRECC, Veterans Affairs Puget Sound Health Care System, 1660 S Columbian Way, Seattle, WA 98108, USA. eric.petrie@med.va.gov</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cross</LastName><ForeName>Donna J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Galasko</LastName><ForeName>Douglas</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Schellenberg</LastName><ForeName>Gerard D</ForeName><Initials>GD</Initials></Author><Author ValidYN="Y"><LastName>Raskind</LastName><ForeName>Murray A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Peskind</LastName><ForeName>Elaine R</ForeName><Initials>ER</Initials></Author><Author ValidYN="Y"><LastName>Minoshima</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG05136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG023185</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS045254</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 AG023670</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG05131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical><Chemical><RegistryNumber>IY9XDZ35W2</RegistryNumber><NameOfSubstance UI="D005947">Glucose</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002555" MajorTopicYN="N">Cerebrospinal Fluid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="N">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019788" MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>5</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>5</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19433663</ArticleId><ArticleId IdType="mid">NIHMS103533</ArticleId><ArticleId IdType="pmc">PMC2718788</ArticleId><ArticleId IdType="doi">10.1001/archneurol.2009.59</ArticleId><ArticleId IdType="pii">66/5/632</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer&#x2013;related changes. Acta Neuropathol. 1991;82(4):239&#x2013;259. Medline:1759558.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez&#x2013;Isla T, Hollister R, West H et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer&#x2019;s disease. Ann Neurol. 1997;41(1):17&#x2013;24. Medline:9005861.</Citation><ArticleIdList><ArticleId IdType="pubmed">9005861</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer&#x2019;s disease in patients with mild cognitive impairment: a follow&#x2013;up study. Lancet Neurol. 2006;5(3):228&#x2013;234. Medline:16488378.</Citation><ArticleIdList><ArticleId IdType="pubmed">16488378</ArticleId></ArticleIdList></Reference><Reference><Citation>Peskind ER, Li G, Shofer J et al. Age and apolipoprotein E*4 allele effects on cerebrospinal fluid &#x3b2;&#x2013; amyloid 42 in adults with normal cognition. Arch Neurol. 2006;63(7):936&#x2013;939. Medline:16831961.</Citation><ArticleIdList><ArticleId IdType="pubmed">16831961</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadekaro M, Crane AM, Sokoloff L. Differential effects of electrical stimulation of sciatic nerve on metabolic activity in spinal cord and dorsal root ganglion in the rat. Proc Natl Acad Sci U S A. 1985;82(17):6010&#x2013;6013. Medline:3862113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC390684</ArticleId><ArticleId IdType="pubmed">3862113</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Uecker A, Gonzalez&#x2013;Lima F et al. Tracking Alzheimer&#x2019;s disease in transgenic mice using fluorodeoxyglucose autoradiography. Neuroreport. 2000;11(5):987&#x2013;991. Medline:10790869.</Citation><ArticleIdList><ArticleId IdType="pubmed">10790869</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhl DE. Imaging local brain function with emission computed tomography. Radiology. 1984;150(3):625&#x2013;631. Medline:6607481.</Citation><ArticleIdList><ArticleId IdType="pubmed">6607481</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Caselli RJ, Yun LS et al. Preclinical evidence of Alzheimer&#x2019;s disease in persons homozygous for the &#x3b5;4 allele for apolipoprotein E. N Engl J Med. 1996;334(12):752&#x2013;758. Medline:8592548.</Citation><ArticleIdList><ArticleId IdType="pubmed">8592548</ArticleId></ArticleIdList></Reference><Reference><Citation>Small GW, Mazziotta JC, Collins MT et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA. 1995;273(12):942&#x2013;947. Medline:7884953.</Citation><ArticleIdList><ArticleId IdType="pubmed">7884953</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer&#x2019;s disease. Ann Neurol. 1997;42(1):85&#x2013;94. Medline:9225689.</Citation><ArticleIdList><ArticleId IdType="pubmed">9225689</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leon MJ, Convit A, Wolf OT et al. Prediction of cognitive decline in normal elderly subjects with 2 [18F]fluoro 2 deoxy D glucose/positron emission tomography (FDG/PET) Proc Natl Acad Sci U S A. 2001;98(19):10966&#x2013;10971. Medline:11526211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC58582</ArticleId><ArticleId IdType="pubmed">11526211</ArticleId></ArticleIdList></Reference><Reference><Citation>DeCarli C, Atack JR, Ball MJ, et al. Post mortem regional neurofibrillary tangle densities but not senile plaque densities are related to regional cerebral metabolic rates for glucose during life in Alzheimer&#x2019;s disease patients. Neurodegeneration. 1992;1:113&#x2013;121.</Citation></Reference><Reference><Citation>Mielke R, Schroder R, Fink GR, Kessler J, Herholz K, Heiss WD. Regional cerebral glucose metabolism and postmortem pathology in Alzheimer&#x2019;s disease. Acta Neuropathol. 1996;91(2):174&#x2013;179. Medline:8787151.</Citation><ArticleIdList><ArticleId IdType="pubmed">8787151</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoshima S, Cross DJ, Foster NL, Henry TR, Kuhl DE. Discordance between traditional pathologic and energy metabolic changes in very early Alzheimer&#x2019;s disease: pathophysiological implications. Ann N Y Acad Sci. 1999;893:350&#x2013;352. Medline:10672264.</Citation><ArticleIdList><ArticleId IdType="pubmed">10672264</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoshima S, Koeppe RA, Frey KA, Kuhl DE. Anatomic standardization: linear scaling and nonlinear warping of functional brain images. J Nucl Med. 1994;35(9):1528&#x2013;1537. Medline:8071705.</Citation><ArticleIdList><ArticleId IdType="pubmed">8071705</ArticleId></ArticleIdList></Reference><Reference><Citation>Worsley KJ, Marrett S, Neelin P, Evans AC. A unified statistical approach for determining significant signals in location and scale space images of cerebral activation. In: Myers R, Cunningham VJ, Bailey D, Jones T, editors. Quantification of Brain Function Using PET. San Diego, CA: Academic Press; 1996. pp. 327&#x2013;333.</Citation></Reference><Reference><Citation>Minoshima S, Foster NL, Kuhl DE. Posterior cingulate cortex in Alzheimer&#x2019;s disease. Lancet. 1994;344(8926):895. Medline:7916431.</Citation><ArticleIdList><ArticleId IdType="pubmed">7916431</ArticleId></ArticleIdList></Reference><Reference><Citation>Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 1990;31(3):545&#x2013;548. Medline:2341813.</Citation><ArticleIdList><ArticleId IdType="pubmed">2341813</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceravolo R, Borghetti D, Kiferle L et al. CSF phosporylated TAU protein levels correlate with cerebral glucose metabolism assessed with PET in Alzheimer&#x2019;s disease. Brain Res Bull. 2008;76(1&#x2013;2):80&#x2013;84. Medline:18395614.</Citation><ArticleIdList><ArticleId IdType="pubmed">18395614</ArticleId></ArticleIdList></Reference><Reference><Citation>Fellgiebel A, Scheurich A, Bartenstein P, Muller MJ. FDG&#x2013;PET and CSF phospho&#x2013;tau for prediction of cognitive decline in mild cognitive impairment. Psychiatry Res. 2007;155(2):167&#x2013;171. Medline:17531450.</Citation><ArticleIdList><ArticleId IdType="pubmed">17531450</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamura N, Arai H, Higuchi M et al. Cerebrospinal fluid levels of amyloid &#x3b2;&#x2013;peptide1&#x2013;42, but not tau have positive correlation with brain glucose metabolism in humans. Neurosci Lett. 1999;273(3):203&#x2013;207. Medline:10515194.</Citation><ArticleIdList><ArticleId IdType="pubmed">10515194</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, De Santi S, Brys M et al. Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints. Biol Psychiatry. 2008;63(6):609&#x2013;618. Medline:17720148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2386268</ArticleId><ArticleId IdType="pubmed">17720148</ArticleId></ArticleIdList></Reference><Reference><Citation>Galasko D, Chang L, Motter R et al. High cerebrospinal fluid tau and low amyloid &#x3b2;42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol. 1998;55(7):937&#x2013;945. Medline:9678311.</Citation><ArticleIdList><ArticleId IdType="pubmed">9678311</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanai M, Shizuka M, Urakami K et al. Apolipoprotein E4 accelerates dementia and increases cerebrospinal fluid tau levels in Alzheimer&#x2019;s disease. Neurosci Lett. 1999;267(1):65&#x2013;68. Medline:10400250.</Citation><ArticleIdList><ArticleId IdType="pubmed">10400250</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunderland T, Mirza N, Putnam KT et al. Cerebrospinal fluid &#x3b2;&#x2013;amyloid 1&#x2013;42 and tau in control subjects at risk for Alzheimer&#x2019;s disease: the effect of APOE &#x3b5;4 allele. Biol Psychiatry. 2004;56(9):670&#x2013;676. Medline:15522251.</Citation><ArticleIdList><ArticleId IdType="pubmed">15522251</ArticleId></ArticleIdList></Reference><Reference><Citation>Buerger K, Teipel SJ, Zinkowski R et al. Increased levels of CSF phosphorylated tau in apolipoprotein E &#x3b5;4 carriers with mild cognitive impairment. Neurosci Lett. 2005;391(1&#x2013;2):48&#x2013;50. Medline:16165272.</Citation><ArticleIdList><ArticleId IdType="pubmed">16165272</ArticleId></ArticleIdList></Reference><Reference><Citation>Herukka SK, Helisalmi S, Hallikainen M, Tervo S, Soininen H, Pirttila T. CSF A&#x3b2;42, Tau and phosphorylated Tau, APOE &#x3b5;4 allele and MCI type in progressive MCI. Neurobiol Aging. 2007;28(4):507&#x2013;514. Medline:16546302.</Citation><ArticleIdList><ArticleId IdType="pubmed">16546302</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeda S, Sahara N, Saito Y, Murayama S, Ikai A, Takashima A. Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer&#x2019;s disease. Neurosci Res. 2006;54(3):197&#x2013;201. Medline:16406150.</Citation><ArticleIdList><ArticleId IdType="pubmed">16406150</ArticleId></ArticleIdList></Reference><Reference><Citation>Baleydier C, Mauguiere F. Anatomical evidence for medial pulvinar connections with the posterior cingulate cortex, the retrosplenial area, and the posterior parahippocampal gyrus in monkeys. J Comp Neurol. 1985;232(2):219&#x2013;228. Medline:3973091.</Citation><ArticleIdList><ArticleId IdType="pubmed">3973091</ArticleId></ArticleIdList></Reference><Reference><Citation>Leh SE, Chakravarty MM, Ptito A. The connectivity of the human pulvinar: a diffusion tensor imaging tractography study. Int J Biomed Imaging [serial online] 2008 January 02;:1&#x2013;5. Medline:18274667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2233985</ArticleId><ArticleId IdType="pubmed">18274667</ArticleId></ArticleIdList></Reference><Reference><Citation>Karnath HO, Himmelbach M, Rorden C. The subcortical anatomy of human spatial neglect: putamen, caudate nucleus and pulvinar. Brain. 2002;125(pt 2):350&#x2013;360. Medline:11844735.</Citation><ArticleIdList><ArticleId IdType="pubmed">11844735</ArticleId></ArticleIdList></Reference><Reference><Citation>LaBerge D, Buchsbaum MS. Positron emission tomographic measurements of pulvinar activity during an attention task. J Neurosci. 1990;10(2):613&#x2013;619. Medline:2303863.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6570168</ArticleId><ArticleId IdType="pubmed">2303863</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuljis RO. Lesions in the pulvinar in patients with Alzheimer&#x2019;s disease. J Neuropathol Exp Neurol. 1994;53(2):202&#x2013;211. Medline:8120542.</Citation><ArticleIdList><ArticleId IdType="pubmed">8120542</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Mintun MA, Mach RH et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A&#x3b2;42 in humans. Ann Neurol. 2006;59(3):512&#x2013;519. Medline:16372280.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A et al. Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh Compound B. Ann Neurol. 2004;55(3):306&#x2013;319. Medline:14991808.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Buerger K, Ewers M, Pirttila T et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer&#x2019;s disease. Brain. 2006;129(pt 11):3035&#x2013;3041. Medline:17012293.</Citation><ArticleIdList><ArticleId IdType="pubmed">17012293</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelborghs S, Sleegers1 K, Cras P et al. No association of CSF biomarkers with APOE&#x3b5;4, plaque and tangle burden in definite Alzheimer&#x2019;s disease. Brain. 2007;130(pt 9):2320&#x2013;2326. Medline:17586559.</Citation><ArticleIdList><ArticleId IdType="pubmed">17586559</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19458211</PMID><DateCompleted><Year>2009</Year><Month>06</Month><Day>08</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>20</Issue><PubDate><Year>2009</Year><Month>May</Month><Day>20</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Mitochondrial cholesterol loading exacerbates amyloid beta peptide-induced inflammation and neurotoxicity.</ArticleTitle><Pagination><StartPage>6394</StartPage><EndPage>6405</EndPage><MedlinePgn>6394-405</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.4909-08.2009</ELocationID><Abstract><AbstractText>The role of cholesterol in Alzheimer's disease (AD) has been linked to the generation of toxic amyloid beta peptides (Abeta). Using genetic mouse models of cholesterol loading, we examined whether mitochondrial cholesterol regulates Abeta neurotoxicity and AD pathology. Isolated mitochondria from brain or cortical neurons of transgenic mice overexpressing SREBP-2 (sterol regulatory element binding protein 2) or NPC1 (Niemann-Pick type C1) knock-out mice exhibited mitochondrial cholesterol accumulation, mitochondrial glutathione (mGSH) depletion and increased susceptibility to Abeta1-42-induced oxidative stress and release of apoptogenic proteins. Similar findings were observed in pharmacologically GSH-restricted rat brain mitochondria, while selective mGSH depletion sensitized human neuronal and glial cell lines to Abeta1-42-mediated cell death. Intracerebroventricular human Abeta delivery colocalized with mitochondria resulting in oxidative stress, neuroinflammation and neuronal damage that were enhanced in Tg-SREBP-2 mice and prevented upon mGSH recovery by GSH ethyl ester coinfusion, with a similar protection observed by intraperitoneal administration of GSH ethyl ester. Finally, APP/PS1 (amyloid precursor protein/presenilin 1) mice, a transgenic AD mouse model, exhibited mitochondrial cholesterol loading and mGSH depletion. Thus, mitochondrial cholesterol accumulation emerges as a novel pathogenic factor in AD by modulating Abeta toxicity via mGSH regulation; strategies boosting the particular pool of mGSH may be of relevance to slow down disease progression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fern&#xe1;ndez</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cell Death and Proliferation, Institut d'Investigacions Biom&#xe8;diques de Barcelona, Consejo Superior de Investigaciones Cient&#xed;ficas and Unidad de Hepatolog&#xed;a, Hospital Clinic i Provincial, 08036 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Llacuna</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Checa</LastName><ForeName>Jos&#xe9; C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Colell</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AA011999</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AA 11999</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077296">Niemann-Pick C1 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C106831">Npc1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497391">Srebf2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051782">Sterol Regulatory Element Binding Protein 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>7W95D60F4J</RegistryNumber><NameOfSubstance UI="C042431">S-ethyl glutathione</NameOfSubstance></Chemical><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical><Chemical><RegistryNumber>GAN16C9B8O</RegistryNumber><NameOfSubstance UI="D005978">Glutathione</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004622" MajorTopicYN="N">Embryo, Mammalian</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005978" MajorTopicYN="N">Glutathione</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020258" MajorTopicYN="N">Neurotoxicity Syndromes</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077296" MajorTopicYN="N">Niemann-Pick C1 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051782" MajorTopicYN="N">Sterol Regulatory Element Binding Protein 2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>5</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>5</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>6</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>11</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19458211</ArticleId><ArticleId IdType="mid">NIHMS119163</ArticleId><ArticleId IdType="pmc">PMC2740839</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4909-08.2009</ArticleId><ArticleId IdType="pii">29/20/6394</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Anstey KJ, Lipnicki DM, Low LF. Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis. Am J Geriatr Psychiatry. 2008;16:343&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pubmed">18448847</ArticleId></ArticleIdList></Reference><Reference><Citation>Ariga T, McDonald MP, Yu RK. Role of ganglioside metabolism in the pathogenesis of Alzheimer's disease&#x2013;a review. J Lipid Res. 2008;49:1157&#x2013;1175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2386904</ArticleId><ArticleId IdType="pubmed">18334715</ArticleId></ArticleIdList></Reference><Reference><Citation>Atamna H, Boyle K. Amyloid-beta peptide binds with heme to form a peroxidase: relationship to the cytopathologies of Alzheimer's disease. Proc Natl Acad Sci U S A. 2006;103:3381&#x2013;3386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1413946</ArticleId><ArticleId IdType="pubmed">16492752</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandaru VV, Troncoso J, Wheeler D, Pletnikova O, Wang J, Conant K, Haughey NJ. ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer's but not normal brain. Neurobiol Aging. 2007 doi: 10.1016/j.neurobiolaging.2007.07.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2007.07.024</ArticleId><ArticleId IdType="pmc">PMC2758772</ArticleId><ArticleId IdType="pubmed">17888544</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell RD, Deane R, Chow N, Long X, Sagare A, Singh I, Streb JW, Guo H, Rubio A, Van Nostrand W, Miano JM, Zlokovic BV. SRF and myocardin regulate LRP-mediated amyloid-beta clearance in brain vascular cells. Nat Cell Biol. 2009;11:143&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2654279</ArticleId><ArticleId IdType="pubmed">19098903</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyd-Kimball D, Sultana R, Abdul HM, Butterfield DA. Gamma-glutamylcysteine ethyl ester-induced up-regulation of glutathione protects neurons against Abeta(1&#x2013;42)-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease. J Neurosci Res. 2005;79:700&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pubmed">15678514</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardoso SM, Santos S, Swerdlow RH, Oliveira CR. Functional mitochondria are required for amyloid beta-mediated neurotoxicity. FASEB J. 2001;15:1439&#x2013;1441.</Citation><ArticleIdList><ArticleId IdType="pubmed">11387250</ArticleId></ArticleIdList></Reference><Reference><Citation>Casley CS, Canevari L, Land JM, Clark JB, Sharpe MA. Beta-amyloid inhibits integrated mitochondrial respiration and key enzyme activities. J Neurochem. 2002;80:91&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">11796747</ArticleId></ArticleIdList></Reference><Reference><Citation>Caspersen C, Wang N, Yao J, Sosunov A, Chen X, Lustbader JW, Xu HW, Stern D, McKhann G, Yan SD. Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J. 2005;19:2040&#x2013;2041.</Citation><ArticleIdList><ArticleId IdType="pubmed">16210396</ArticleId></ArticleIdList></Reference><Reference><Citation>Colell A, Garc&#xed;a-Ruiz C, Morales A, Ballesta A, Ookhtens M, Rod&#xe9;s J, Kaplowitz N, Fern&#xe1;ndez-Checa JC. Transport of reduced glutathione in hepatic mitochondria and mitoplasts from ethanol-treated rats: effect of membrane physical properties and S-adenosyl-L-methionine. Hepatology. 1997;26:699&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pubmed">9303501</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler RG, Kelly J, Storie K, Pedersen WA, Tammara A, Hatanpaa K, Troncoso JC, Mattson MP. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci U S A. 2004;101:2070&#x2013;2075.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC357053</ArticleId><ArticleId IdType="pubmed">14970312</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, Zlokovic BV. Role of blood brain barrier in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res. 2007;4:191&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">17430246</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, Xu F, Parisi M, LaRue B, Hu HW, Spijkers P, Guo H, Song X, Lenting PJ, Van Nostrand WE, Zlokovic BV. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron. 2004;43:333&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">15294142</ArticleId></ArticleIdList></Reference><Reference><Citation>Devi L, Prabhu BM, Galati DF, Avadhani NG, Anandatheerthavarada HK. Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction. J Neurosci. 2006;26:9057&#x2013;9068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675337</ArticleId><ArticleId IdType="pubmed">16943564</ArticleId></ArticleIdList></Reference><Reference><Citation>Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, Runz H, Kuhl S, Bertsch T, von Bergmann K, Hennerici M, Beyreuther K, Hartmann T. Simvastatin strongly reduces levels of Alzheimer's disease &#x3b2;-amyloid peptides A&#x3b2; 42 and A&#x3b2; 40 in vitro and in vivo. Proc Natl Acad Sci U S A. 2001;98:5856&#x2013;5861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC33303</ArticleId><ArticleId IdType="pubmed">11296263</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Checa JC, Kaplowitz N. Hepatic mitochondrial glutathione: transport and role in disease and toxicity. Toxicol Appl Pharmacol. 2005;204:263&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pubmed">15845418</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Checa JC, Ookhtens M, Kaplowitz N. Effect of chronic ethanol feeding on rat hepatocytic glutathione: compartmentation, efflux and response to incubation with ethanol. J Clin Invest. 1987;80:57&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC442201</ArticleId><ArticleId IdType="pubmed">2885343</ArticleId></ArticleIdList></Reference><Reference><Citation>Frautschy SA, Yang F, Calder&#xf3;n L, Cole GM. Rodent models of Alzheimer's disease: rat A&#x3b2; infusion approaches to amyloid deposits. Neurobiol Aging. 1996;17:311&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pubmed">8744413</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Ruiz C, Colell A, Mar&#xed; M, Morales A, Calvo M, Enrich C, Fern&#xe1;ndez-Checa JC. Defective TNF-alpha-mediated hepatocellular apoptosis and liver damage in acidic sphingomyelinase knockout mice. J Clin Invest. 2003;111:197&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC151862</ArticleId><ArticleId IdType="pubmed">12531875</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimm MO, Grimm HS, P&#xe4;tzold AJ, Zinser EG, Halonen R, Duering M, Tsch&#xe4;pe JA, De Strooper B, M&#xfc;ller U, Shen J, Hartmann T. Regulation of cholesterol and sphingomyelin metabolism by amyloid beta and presenilin. Nat Cell Biol. 2005;7:1118&#x2013;1123.</Citation><ArticleIdList><ArticleId IdType="pubmed">16227967</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8:101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson CA, Frykman S, Farmery MR, Tjernberg LO, Nilsberth C, Pursglove SE, Ito A, Winblad B, Cowburn RF, Thyberg J, Ankarcrona M. Nicastrin, presenilin, APH-1, and PEN-2 form active gamma-secretase complexes in mitochondria. J Biol Chem. 2004;279:51654&#x2013;51660.</Citation><ArticleIdList><ArticleId IdType="pubmed">15456764</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, O'Banion MK. Inflammatory processes in Alzheimer's disease. J Neuroimmunol. 2007;184:69&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">17222916</ArticleId></ArticleIdList></Reference><Reference><Citation>Horton JD, Shimomura I, Brown MS, Hammer RE, Goldstein JL, Shimano H. Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory element-binding protein-2. J Clin Invest. 1998;101:2331&#x2013;2339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC508822</ArticleId><ArticleId IdType="pubmed">9616204</ArticleId></ArticleIdList></Reference><Reference><Citation>Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002;109:1125&#x2013;1131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC150968</ArticleId><ArticleId IdType="pubmed">11994399</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain A, M&#xe5;rtensson J, Stole E, Auld PA, Meister A. Glutathione deficiency leads to mitochondrial damage in brain. Proc Natl Acad Sci U S A. 1991;88:1913&#x2013;1917.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC51136</ArticleId><ArticleId IdType="pubmed">2000395</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalvodova L, Kahya N, Schwille P, Ehehalt R, Verkade P, Drechsel D, Simons K. Lipids as modulators of proteolytic activity of BACE: involvement of cholesterol, glycosphingolipids, and anionic phospholipids in vitro. J Biol Chem. 2005;280:36815&#x2013;36823.</Citation><ArticleIdList><ArticleId IdType="pubmed">16115865</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SJ, Liyanage U, Bickel PE, Xia W, Lansbury PT, Jr, Kosik KS. A detergent-insoluble membrane compartment contains A&#x3b2; in vivo. Nat Med. 1998;4:730&#x2013;734.</Citation><ArticleIdList><ArticleId IdType="pubmed">9623986</ArticleId></ArticleIdList></Reference><Reference><Citation>Leissring MA, Farris W, Wu X, Christodoulou DC, Haigis MC, Guarente L, Selkoe DJ. Alternative translation initiation generates a novel isoform of insulin-degrading enzyme targeted to mitochondria. Biochem J. 2004;383:439&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1133736</ArticleId><ArticleId IdType="pubmed">15285718</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443:787&#x2013;795.</Citation><ArticleIdList><ArticleId IdType="pubmed">17051205</ArticleId></ArticleIdList></Reference><Reference><Citation>Lluis JM, Buricchi F, Chiarugi P, Morales A, Fernandez-Checa JC. Dual role of mitochondrial reactive oxygen species in hypoxia signaling: activation of nuclear factor-{kappa} B via c-SRC and oxidant-dependent cell death. Cancer Res. 2007;67:7368&#x2013;7377.</Citation><ArticleIdList><ArticleId IdType="pubmed">17671207</ArticleId></ArticleIdList></Reference><Reference><Citation>Lustbader JW, Cirilli M, Lin C, Xu HW, Takuma K, Wang N, Caspersen C, Chen X, Pollak S, Chaney M, Trinchese F, Liu S, Gunn-Moore F, Lue LF, Walker DG, Kuppusamy P, Zewier ZL, Arancio O, Stern D, Yan SS, et al. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science. 2004;304:448&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">15087549</ArticleId></ArticleIdList></Reference><Reference><Citation>Manczak M, Anekonda TS, Henson E, Park BS, Quinn J, Reddy PH. Mitochondria are a direct site of A{beta} accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet. 2006;15:1437&#x2013;1449.</Citation><ArticleIdList><ArticleId IdType="pubmed">16551656</ArticleId></ArticleIdList></Reference><Reference><Citation>Mar&#xed; M, Caballero F, Colell A, Morales A, Caballeria J, Fernandez A, Enrich C, Fernandez-Checa JC, Garc&#xed;a-Ruiz C. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab. 2006;4:185&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">16950136</ArticleId></ArticleIdList></Reference><Reference><Citation>Mar&#xed; M, Colell A, Morales A, Caballero F, Moles A, Fern&#xe1;ndez A, Terrones O, Basa&#xf1;ez G, Antonsson B, Garc&#xed;a-Ruiz C, Fern&#xe1;ndez-Checa JC. Mechanism of mitochondrial glutathione-dependent hepatocellular susceptibility to TNF despite NF-kB activation. Gastroenterology. 2008;134:1507&#x2013;1520.</Citation><ArticleIdList><ArticleId IdType="pubmed">18343380</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xe5;rtensson J, Han J, Griffith OW, Meister A. Glutathione ester delays the onset of scurvy in ascorbate-deficient guinea pigs. Proc Natl Acad Sci U S A. 1993;90:317&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC45651</ArticleId><ArticleId IdType="pubmed">8419936</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Mallory M, Hansen L, DeTeresa R, Alford M, Terry R. Synaptic and neuritic alterations during the progression of Alzheimer's disease. Neurosci Lett. 1994;174:67&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">7970158</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP. Pathways towards and away from Alzheimer's disease. Nature. 2004;430:631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091392</ArticleId><ArticleId IdType="pubmed">15295589</ArticleId></ArticleIdList></Reference><Reference><Citation>Montero J, Morales A, Llacuna L, Lluis JM, Terrones O, Basa&#xf1;ez G, Antonsson B, Prieto J, Garc&#xed;a-Ruiz C, Colell A, Fern&#xe1;ndez-Checa JC. Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma. Cancer Res. 2008;68:5246&#x2013;5256.</Citation><ArticleIdList><ArticleId IdType="pubmed">18593925</ArticleId></ArticleIdList></Reference><Reference><Citation>Norman AW, Demel RA, de Kruyff B, van Deenen LL. Studies on the biological properties of polyene antibiotics. Evidence for the direct interaction of filipin with cholesterol. J Biol Chem. 1972;247:1918&#x2013;1929.</Citation><ArticleIdList><ArticleId IdType="pubmed">5012767</ArticleId></ArticleIdList></Reference><Reference><Citation>Notkola IL, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, Kivinen P, Tuomilehto J, Nissinen A. Serum total cholesterol, apolipoprotein E 4 allele, and Alzheimer's disease. Neuroepidemiology. 1998;17:14&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">9549720</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer's disease with plaques and tangles:intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Osenkowski P, Ye W, Wang R, Wolfe MS, Selkoe DJ. Direct and potent regulation of gamma-secretase by its lipid microenvironment. J Biol Chem. 2008;283:22529&#x2013;22540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2504869</ArticleId><ArticleId IdType="pubmed">18539594</ArticleId></ArticleIdList></Reference><Reference><Citation>Parsons RB, Price GC, Farrant JK, Subramaniam D, Adeagbo-Sheikh J, Austen BM. Statins inhibit the dimerization of b-secretase via both isoprenoid and cholesterol-mediated mechanisms. Biochem J. 2006;399:205&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1609905</ArticleId><ArticleId IdType="pubmed">16803455</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul CA, Boegle AK, Maue RA. Before the loss: neuronal dysfunction in Niemann-Pick Type C disease. Biochim Biophys Acta. 2004;1685:63&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">15465427</ArticleId></ArticleIdList></Reference><Reference><Citation>Pirttil&#xe4; T, Soininen H, Mehta PD, Heinonen O, Lehtim&#xe4;ki T, Bogdanovic N, Palj&#xe4;rvi L, Kim KS, Kosunen O, Winblad B, Riekkinen P, Sr, Wisniewski HM. Apolipoprotein E genotype and amyloid load in Alzheimer disease and control brains. Neurobiol Aging. 1997;18:121&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">8983040</ArticleId></ArticleIdList></Reference><Reference><Citation>Puglielli L, Konopka G, Pack-Chung E, MacKenzie Ingano LA, Berezovska O, Hyman BT, Chang TY, Tanzi RE, Kovacs DM. Acyl-coenzyme A:cholesterol acyltransferase modulates the generation of the amyloid b-peptide. Nat Cell Biol. 2001;3:905&#x2013;912.</Citation><ArticleIdList><ArticleId IdType="pubmed">11584272</ArticleId></ArticleIdList></Reference><Reference><Citation>Resende R, Moreira PI, Proen&#xe7;a T, Deshpande A, Busciglio J, Pereira C, Oliveira CR. Brain oxidative stress in a triple-transgenic mouse model of Alzheimer disease. Free Radic Biol Med. 2008;44:2051&#x2013;2057.</Citation><ArticleIdList><ArticleId IdType="pubmed">18423383</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;nknecht P, L&#xfc;tjohann D, Pantel J, Bardenheuer H, Hartmann T, von Bergmann K, Beyreuther K, Schr&#xf6;der J. Cerebrospinal fluid 24S-hydroxycholesterol is increased in patients with Alzheimer's disease compared to healthy controls. Neurosci Lett. 2002;324:83&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">11983301</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Developing preventive therapies for chronic diseases: lessons learned from Alzheimer's disease. Nutr Rev. 2007;65:S239&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">18240556</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008;14:837&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen C, Chen Y, Liu H, Zhang K, Zhang T, Lin A, Jing N. Hydrogen peroxide promotes A&#x3b2; production through JNK-dependent activation of g-secretase. J Biol Chem. 2008;283:17721&#x2013;17730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2427353</ArticleId><ArticleId IdType="pubmed">18436531</ArticleId></ArticleIdList></Reference><Reference><Citation>Soccio RE, Breslow JL. Intracellular cholesterol transport. Arterioscler Thromb Vasc Biol. 2004;24:1150&#x2013;1160.</Citation><ArticleIdList><ArticleId IdType="pubmed">15130918</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE, Moir RD, Wagner SL. Clearance of Alzheimer's Ab peptide: The many roads to perdition. Neuron. 2004;43:605&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">15339642</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor DR, Hooper NM. Role of lipid rafts in the processing of the pathogenic prion and Alzheimer's amyloid-beta proteins. Semin Cell Dev Biol. 2007;18:638&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pubmed">17822928</ArticleId></ArticleIdList></Reference><Reference><Citation>Tietze F. Enzymatic method for quantitative determination of nano-gram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem. 1969;27:502&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pubmed">4388022</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulery PG, Beers J, Mikhailenko I, Tanzi RE, Rebeck GW, Hyman BT, Strickland DK. Modulation of beta-amyloid precursor protein processing by the low density lipoprotein receptor-related protein (LRP). Evidence that LRP contributes to the pathogenesis of Alzheimer's disease. J Biol Chem. 2000;275:7410&#x2013;7415.</Citation><ArticleIdList><ArticleId IdType="pubmed">10702315</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron. 2004;44:181&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450169</ArticleId></ArticleIdList></Reference><Reference><Citation>Webber KM, Stocco DM, Casadesus G, Bowen RL, Atwood CS, Previll LA, Harris PL, Zhu X, Perry G, Smith MA. Steroidogenic acute regulatory protein (StAR): evidence of gonadotropin-induced steroidogenesis in Alzheimer disease. Mol Neurodegener. 2006;1:14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1592538</ArticleId><ArticleId IdType="pubmed">17018137</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000;57:1439&#x2013;1443.</Citation><ArticleIdList><ArticleId IdType="pubmed">11030795</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu W, Gong JS, Ko M, Garver WS, Yanagisawa K, Michikawa M. Altered cholesterol metabolism in Niemann-Pick type C1 mouse brains affects mitochondrial function. J Biol Chem. 2005;280:11731&#x2013;11739.</Citation><ArticleIdList><ArticleId IdType="pubmed">15644330</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeevalk GD, Manzino L, Sonsalla PK, Bernard LP. Characterization of intracellular elevation of glutathione (GSH) with glutathione monoethyl ester and GSH in brain and neuronal cultures: relevance to Parkinson's disease. Exp Neurol. 2007;203:512&#x2013;520.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1839874</ArticleId><ArticleId IdType="pubmed">17049515</ArticleId></ArticleIdList></Reference><Reference><Citation>Zerbinatti CV, Wozniak DF, Cirrito J, Cam JA, Osaka H, Bales KR, Zhuo M, Paul SM, Holtzman DM, Bu G. Increased soluble amyloid-beta peptide and memory deficits in amyloid model mice overexpressing the low-density lipoprotein receptor-related protein. Proc Natl Acad Sci U S A. 2004;101:1075&#x2013;1080.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC327153</ArticleId><ArticleId IdType="pubmed">14732699</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci. 2005;28:202&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">15808355</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19458225</PMID><DateCompleted><Year>2009</Year><Month>06</Month><Day>08</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>20</Issue><PubDate><Year>2009</Year><Month>May</Month><Day>20</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Interruption of beta-catenin signaling reduces neurogenesis in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>6545</StartPage><EndPage>6557</EndPage><MedlinePgn>6545-57</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0421-09.2009</ELocationID><Abstract><AbstractText>The neuronal loss associated with Alzheimer's disease (AD) affects areas of the brain that are vital to cognition. Although recent studies have shown that new neurons can be generated from progenitor cells in the neocortices of healthy adults, the neurogenic potential of the stem/progenitor cells of AD patients is not known. To answer this question, we compared the properties of glial progenitor cells (GPCs) from the cortices of healthy control (HC) and AD subjects. The GPCs from AD brain samples displayed reduced renewal capability and reduced neurogenesis compared with GPCs from HC brains. To investigate the mechanisms underlying this difference, we compared beta-catenin signaling proteins in GPCs from AD versus HC subjects and studied the effect of amyloid beta peptide (Abeta, a hallmark of AD pathology) on GPCs. Interestingly, GPCs from AD patients exhibited elevated levels of glycogen synthase kinase 3beta (GSK-3beta, an enzyme known to phosphorylate beta-catenin), accompanied by an increase in phosphorylated beta-catenin and a decrease in nonphosphorylated beta-catenin compared with HC counterparts. Furthermore. we found that Abeta treatment impaired the ability of GPCs from HC subjects to generate new neurons and caused changes in beta-catenin signaling proteins similar to those observed in GPCs from AD patients. Similar results were observed in GPCs isolated from AD transgenic mice. These results suggest that Abeta-induced interruption of beta-catenin signaling may contribute to the impairment of neurogenesis in AD progenitor cells.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>He</LastName><ForeName>Ping</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Haldeman Laboratory of Molecular and Cellular Neurobiology, Sun Health Research Institute, Sun City, Arizona 85351, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Yong</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG025888</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG025888</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011508">Chondroitin Sulfate Proteoglycans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050505">Mutant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D039842">Neural Cell Adhesion Molecule L1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019081">O Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012794">Sialic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051176">beta Catenin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C103469">polysialyl neural cell adhesion molecule</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C000605506">GSK3B protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D000071679">Glycogen Synthase Kinase 3 beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C000605507">Gsk3b protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.26</RegistryNumber><NameOfSubstance UI="D038362">Glycogen Synthase Kinase 3</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Neurosci. 2009 Oct 7;29(40):12369-71. doi: 10.1523/JNEUROSCI.3502-09.2009.</RefSource><PMID Version="1">19812311</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D053687" MajorTopicYN="N">Adult Stem Cells</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011508" MajorTopicYN="N">Chondroitin Sulfate Proteoglycans</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038362" MajorTopicYN="N">Glycogen Synthase Kinase 3</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071679" MajorTopicYN="N">Glycogen Synthase Kinase 3 beta</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020287" MajorTopicYN="N">In Situ Nick-End Labeling</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050505" MajorTopicYN="N">Mutant Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039842" MajorTopicYN="N">Neural Cell Adhesion Molecule L1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055495" MajorTopicYN="N">Neurogenesis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009457" MajorTopicYN="N">Neuroglia</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019081" MajorTopicYN="N">O Antigens</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012794" MajorTopicYN="N">Sialic Acids</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051176" MajorTopicYN="N">beta Catenin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>5</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>5</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>6</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>11</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19458225</ArticleId><ArticleId IdType="mid">NIHMS119144</ArticleId><ArticleId IdType="pmc">PMC3618977</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0421-09.2009</ArticleId><ArticleId IdType="pii">29/20/6545</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aguirre A, Gallo V. Postnatal neurogenesis and gliogenesis in the olfactory bulb from NG2-expressing progenitors of the subventricular zone. J Neurosci. 2004;24:10530&#x2013;10541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730319</ArticleId><ArticleId IdType="pubmed">15548668</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguirre AA, Chittajallu R, Belachew S, Gallo V. NG2-expressing cells in the subventricular zone are type C-like cells and contribute to interneuron generation in the postnatal hippocampus. J Cell Biol. 2004;165:575&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172347</ArticleId><ArticleId IdType="pubmed">15159421</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez AR, Godoy JA, Mullendorff K, Olivares GH, Bronfman M, Inestrosa NC. Wnt-3a overcomes beta-amyloid toxicity in rat hippocampal neurons. Exp Cell Res. 2004;297:186&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">15194435</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderton BH, Dayanandan R, Killick R, Lovestone S. Does dysregulation of the Notch and wingless/Wnt pathways underlie the pathogenesis of Alzheimer's disease? Mol Med Today. 2000;6:54&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">10652477</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong RC, Dorn HH, Kufta CV, Friedman E, Dubois-Dalcq ME. Pre-oligodendrocytes from adult human CNS. J Neurosci. 1992;12:1538&#x2013;1547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6575800</ArticleId><ArticleId IdType="pubmed">1556607</ArticleId></ArticleIdList></Reference><Reference><Citation>Arsenijevic Y, Villemure JG, Brunet JF, Bloch JJ, D&#xe9;glon N, Kostic C, Zurn A, Aebischer P. Isolation of multipotent neural precursors residing in the cortex of the adult human brain. Exp Neurol. 2001;170:48&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">11421583</ArticleId></ArticleIdList></Reference><Reference><Citation>Behrens J, von Kries JP, K&#xfc;hl M, Bruhn L, Wedlich D, Grosschedl R, Birchmeier W. Functional interaction of beta-catenin with the transcription factor LEF-1. Nature. 1996;382:638&#x2013;642.</Citation><ArticleIdList><ArticleId IdType="pubmed">8757136</ArticleId></ArticleIdList></Reference><Reference><Citation>Belachew S, Chittajallu R, Aguirre AA, Yuan X, Kirby M, Anderson S, Gallo V. Postnatal NG2 proteoglycan-expressing progenitor cells are intrinsically multipotent and generate functional neurons. J Cell Biol. 2003;161:169&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172886</ArticleId><ArticleId IdType="pubmed">12682089</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhardwaj RD, Curtis MA, Spalding KL, Buchholz BA, Fink D, Bj&#xf6;rk-Eriksson T, Nordborg C, Gage FH, Druid H, Eriksson PS, Fris&#xe9;n J. Neocortical neurogenesis in humans is restricted to development. Proc Natl Acad Sci U S A. 2006;103:12564&#x2013;12568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1567918</ArticleId><ArticleId IdType="pubmed">16901981</ArticleId></ArticleIdList></Reference><Reference><Citation>Bondolfi L, Calhoun M, Ermini F, Kuhn HG, Wiederhold KH, Walker L, Staufenbiel M, Jucker M. Amyloid-associated neuron loss and gliogenesis in the neocortex of amyloid precursor protein transgenic mice. J Neurosci. 2002;22:515&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758656</ArticleId><ArticleId IdType="pubmed">11784797</ArticleId></ArticleIdList></Reference><Reference><Citation>Brantjes H, Roose J, van De Wetering M, Clevers H. All Tcf HMG box transcription factors interact with Groucho-related co-repressors. Nucleic Acids Res. 2001;29:1410&#x2013;1419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC31284</ArticleId><ArticleId IdType="pubmed">11266540</ArticleId></ArticleIdList></Reference><Reference><Citation>Bundgaard MJ, Regeur L, Gundersen HJ, Pakkenberg B. Size of neocortical neurons in control subjects and in Alzheimer's disease. J Anat. 2001;198:481&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1468234</ArticleId><ArticleId IdType="pubmed">11327210</ArticleId></ArticleIdList></Reference><Reference><Citation>Busser J, Geldmacher DS, Herrup K. Ectopic cell cycle proteins predict the sites of neuronal cell death in Alzheimer's disease brain. J Neurosci. 1998;18:2801&#x2013;2807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792587</ArticleId><ArticleId IdType="pubmed">9525997</ArticleId></ArticleIdList></Reference><Reference><Citation>Castelo-Branco G, Rawal N, Arenas E. GSK-3beta inhibition/beta-catenin stabilization in ventral midbrain precursors increases differentiation into dopamine neurons. J Cell Sci. 2004;117:5731&#x2013;5737.</Citation><ArticleIdList><ArticleId IdType="pubmed">15522889</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavallo RA, Cox RT, Moline MM, Roose J, Polevoy GA, Clevers H, Peifer M, Bejsovec A. Drosophila Tcf and Groucho interact to repress Wingless signalling activity. Nature. 1998;395:604&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">9783586</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang A, Nishiyama A, Peterson J, Prineas J, Trapp BD. NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions. J Neurosci. 2000;20:6404&#x2013;6412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772992</ArticleId><ArticleId IdType="pubmed">10964946</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G, Fernandez J, Mische S, Courey AJ. A functional interaction between the histone deacetylase Rpd3 and the corepressor groucho in Drosophila development. Genes Dev. 1999;13:2218&#x2013;2230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC316998</ArticleId><ArticleId IdType="pubmed">10485845</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Magavi SS, Macklis JD. Neurogenesis of corticospinal motor neurons extending spinal projections in adult mice. Proc Natl Acad Sci U S A. 2004;101:16357&#x2013;16362.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC528970</ArticleId><ArticleId IdType="pubmed">15534207</ArticleId></ArticleIdList></Reference><Reference><Citation>Chenn A, Walsh CA. Regulation of cerebral cortical size by control of cell cycle exit in neural precursors. Science. 2002;297:365&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130776</ArticleId></ArticleIdList></Reference><Reference><Citation>Chittajallu R, Aguirre A, Gallo V. NG2-positive cells in the mouse white and grey matter display distinct physiological properties. J Physiol. 2004;561:109&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1665337</ArticleId><ArticleId IdType="pubmed">15358811</ArticleId></ArticleIdList></Reference><Reference><Citation>Cicero S, Herrup K. Cyclin-dependent kinase 5 is essential for neuronal cell cycle arrest and differentiation. J Neurosci. 2005;25:9658&#x2013;9668.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725732</ArticleId><ArticleId IdType="pubmed">16237170</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis MA, Penney EB, Pearson AG, van Roon-Mom WM, Butterworth NJ, Dragunow M, Connor B, Faull RL. Increased cell proliferation and neurogenesis in the adult human Huntington's disease brain. Proc Natl Acad Sci U S A. 2003;100:9023&#x2013;9027.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC166431</ArticleId><ArticleId IdType="pubmed">12853570</ArticleId></ArticleIdList></Reference><Reference><Citation>De Ferrari GV, Inestrosa NC. Wnt signaling function in Alzheimer's disease. Brain Res Brain Res Rev. 2000;33:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">10967351</ArticleId></ArticleIdList></Reference><Reference><Citation>De Ferrari GV, Chac&#xf3;n MA, Barr&#xed;a MI, Garrido JL, Godoy JA, Olivares G, Reyes AE, Alvarez A, Bronfman M, Inestrosa NC. Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by beta-amyloid fibrils. Mol Psychiatry. 2003;8:195&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">12610652</ArticleId></ArticleIdList></Reference><Reference><Citation>Dravid G, Ye Z, Hammond H, Chen G, Pyle A, Donovan P, Yu X, Cheng L. Defining the role of Wnt/beta-catenin signaling in the survival, proliferation, and self-renewal of human embryonic stem cells. Stem Cells. 2005;23:1489&#x2013;1501.</Citation><ArticleIdList><ArticleId IdType="pubmed">16002782</ArticleId></ArticleIdList></Reference><Reference><Citation>Eucher JN, Uemura E, Sakaguchi DS, Greenlee MH. Amyloid-beta peptide affects viability but not differentiation of embryonic and adult rat hippocampal progenitor cells. Exp Neurol. 2007;203:486&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pubmed">17112517</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrido JL, Godoy JA, Alvarez A, Bronfman M, Inestrosa NC. Protein kinase C inhibits amyloid beta peptide neurotoxicity by acting on members of the Wnt pathway. FASEB J. 2002;16:1982&#x2013;1984.</Citation><ArticleIdList><ArticleId IdType="pubmed">12397090</ArticleId></ArticleIdList></Reference><Reference><Citation>Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 1992;119:493&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2289665</ArticleId><ArticleId IdType="pubmed">1400587</ArticleId></ArticleIdList></Reference><Reference><Citation>Gogate N, Verma L, Zhou JM, Milward E, Rusten R, O'Connor M, Kufta C, Kim J, Hudson L, Dubois-Dalcq M. Plasticity in the adult human oligodendrocyte lineage. J Neurosci. 1994;14:4571&#x2013;4587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577192</ArticleId><ArticleId IdType="pubmed">7519254</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman SA, Sim F. Neural progenitor cells of the adult brain. Novartis Found Symp. 2005;265:66&#x2013;80. discussion 82&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">16050251</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould E. How widespread is adult neurogenesis in mammals? Nat Rev Neurosci. 2007;8:481&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">17514200</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould E, Tanapat P. Lesion-induced proliferation of neuronal progenitors in the dentate gyrus of the adult rat. Neuroscience. 1997;80:427&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pubmed">9284346</ArticleId></ArticleIdList></Reference><Reference><Citation>Haughey NJ, Liu D, Nath A, Borchard AC, Mattson MP. Disruption of neurogenesis in the subventricular zone of adult mice, and in human cortical neuronal precursor cells in culture, by amyloid beta-peptide: implications for the pathogenesis of Alzheimer's disease. Neuromolecular Med. 2002a;1:125&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">12025858</ArticleId></ArticleIdList></Reference><Reference><Citation>Haughey NJ, Nath A, Chan SL, Borchard AC, Rao MS, Mattson MP. Disruption of neurogenesis by amyloid beta-peptide, and perturbed neural progenitor cell homeostasis, in models of Alzheimer's disease. J Neurochem. 2002b;83:1509&#x2013;1524.</Citation><ArticleIdList><ArticleId IdType="pubmed">12472904</ArticleId></ArticleIdList></Reference><Reference><Citation>He P, Zhong Z, Lindholm K, Berning L, Lee W, Lemere C, Staufenbiel M, Li R, Shen Y. Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer's mice. J Cell Biol. 2007;178:829&#x2013;841.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2064547</ArticleId><ArticleId IdType="pubmed">17724122</ArticleId></ArticleIdList></Reference><Reference><Citation>He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW. Identification of c-MYC as a target of the APC pathway. Science. 1998;281:1509&#x2013;1512.</Citation><ArticleIdList><ArticleId IdType="pubmed">9727977</ArticleId></ArticleIdList></Reference><Reference><Citation>He XC, Zhang J, Tong WG, Tawfik O, Ross J, Scoville DH, Tian Q, Zeng X, He X, Wiedemann LM, Mishina Y, Li L. BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-beta-catenin signaling. Nat Genet. 2004;36:1117&#x2013;1121.</Citation><ArticleIdList><ArticleId IdType="pubmed">15378062</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrup K, Arendt T. Re-expression of cell cycle proteins induces neuronal cell death during Alzheimer's disease. J Alzheimers Dis. 2002;4:243&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pubmed">12226544</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrup K, Neve R, Ackerman SL, Copani A. Divide and die: cell cycle events as triggers of nerve cell death. J Neurosci. 2004;24:9232&#x2013;9239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730083</ArticleId><ArticleId IdType="pubmed">15496657</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirabayashi Y, Gotoh Y. Stage-dependent fate determination of neural precursor cells in mouse forebrain. Neurosci Res. 2005;51:331&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">15740796</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirabayashi Y, Itoh Y, Tabata H, Nakajima K, Akiyama T, Masuyama N, Gotoh Y. The Wnt/beta-catenin pathway directs neuronal differentiation of cortical neural precursor cells. Development. 2004;131:2791&#x2013;2801.</Citation><ArticleIdList><ArticleId IdType="pubmed">15142975</ArticleId></ArticleIdList></Reference><Reference><Citation>Horky LL, Galimi F, Gage FH, Horner PJ. Fate of endogenous stem/progenitor cells following spinal cord injury. J Comp Neurol. 2006;498:525&#x2013;538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2553041</ArticleId><ArticleId IdType="pubmed">16874803</ArticleId></ArticleIdList></Reference><Reference><Citation>Inestrosa N, De Ferrari GV, Garrido JL, Alvarez A, Olivares GH, Barr&#xed;a MI, Bronfman M, Chac&#xf3;n MA. Wnt signaling involvement in beta-amyloid-dependent neurodegeneration. Neurochem Int. 2002;41:341&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">12176076</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang W, Gu W, Br&#xe4;nnstr&#xf6;m T, Rosqvist R, Wester P. Cortical neurogenesis in adult rats after transient middle cerebral artery occlusion. Stroke. 2001;32:1201&#x2013;1207.</Citation><ArticleIdList><ArticleId IdType="pubmed">11340234</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin K, Peel AL, Mao XO, Xie L, Cottrell BA, Henshall DC, Greenberg DA. Increased hippocampal neurogenesis in Alzheimer's disease. Proc Natl Acad Sci U S A. 2004;101:343&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC314187</ArticleId><ArticleId IdType="pubmed">14660786</ArticleId></ArticleIdList></Reference><Reference><Citation>Koketsu D, Furuichi Y, Maeda M, Matsuoka N, Miyamoto Y, Hisatsune T. Increased number of new neurons in the olfactory bulb and hippocampus of adult non-human primates after focal ischemia. Exp Neurol. 2006;199:92&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">16712840</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolligs FT, Hu G, Dang CV, Fearon ER. Neoplastic transformation of RK3E by mutant beta-catenin requires deregulation of Tcf/Lef transcription but not activation of c-myc expression. Mol Cell Biol. 1999;19:5696&#x2013;5706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC84421</ArticleId><ArticleId IdType="pubmed">10409758</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondo T, Raff M. Oligodendrocyte precursor cells reprogrammed to become multipotential CNS stem cells. Science. 2000;289:1754&#x2013;1757.</Citation><ArticleIdList><ArticleId IdType="pubmed">10976069</ArticleId></ArticleIdList></Reference><Reference><Citation>Konishi Y, Lindholm K, Yang LB, Li R, Shen Y. Isolation of living neurons from human elderly brains using the immunomagnetic sorting DNA-linker system. Am J Pathol. 2002;161:1567&#x2013;1576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850778</ArticleId><ArticleId IdType="pubmed">12414505</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HY, Kl&#xe9;ber M, Hari L, Brault V, Suter U, Taketo MM, Kemler R, Sommer L. Instructive role of Wnt/beta-catenin in sensory fate specification in neural crest stem cells. Science. 2004;303:1020&#x2013;1023.</Citation><ArticleIdList><ArticleId IdType="pubmed">14716020</ArticleId></ArticleIdList></Reference><Reference><Citation>Lie DC, Colamarino SA, Song HJ, D&#xe9;sir&#xe9; L, Mira H, Consiglio A, Lein ES, Jessberger S, Lansford H, Dearie AR, Gage FH. Wnt signalling regulates adult hippocampal neurogenesis. Nature. 2005;437:1370&#x2013;1375.</Citation><ArticleIdList><ArticleId IdType="pubmed">16251967</ArticleId></ArticleIdList></Reference><Reference><Citation>Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004;20:781&#x2013;810.</Citation><ArticleIdList><ArticleId IdType="pubmed">15473860</ArticleId></ArticleIdList></Reference><Reference><Citation>Magavi SS, Leavitt BR, Macklis JD. Induction of neurogenesis in the neocortex of adult mice. Nature. 2000;405:951&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">10879536</ArticleId></ArticleIdList></Reference><Reference><Citation>Millet P, Lages CS, Ha&#xef;k S, Nowak E, Allemand I, Granotier C, Boussin FD. Amyloid-beta peptide triggers Fas-independent apoptosis and differentiation of neural progenitor cells. Neurobiol Dis. 2005;19:57&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">15837561</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet. 2004;5:691&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pubmed">15372092</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunes MC, Roy NS, Keyoung HM, Goodman RR, McKhann G, 2nd, Jiang L, Kang J, Nedergaard M, Goldman SA. Identification and isolation of multipotential neural progenitor cells from the subcortical white matter of the adult human brain. Nat Med. 2003;9:439&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pubmed">12627226</ArticleId></ArticleIdList></Reference><Reference><Citation>Nusse R. WNT targets. Repression and activation. Trends Genet. 1999;15:1&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">10087922</ArticleId></ArticleIdList></Reference><Reference><Citation>Otero JJ, Fu W, Kan L, Cuadra AE, Kessler JA. Beta-catenin signaling is required for neural differentiation of embryonic stem cells. Development. 2004;131:3545&#x2013;3557.</Citation><ArticleIdList><ArticleId IdType="pubmed">15262888</ArticleId></ArticleIdList></Reference><Reference><Citation>Othman M, Klueber K, Lu C, Winstead W, Roisen F. Immunomagnetic separation of adult human olfactory neural progenitors. Biotech Histochem. 2005;80:177&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">16720518</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer TD, Schwartz PH, Taupin P, Kaspar B, Stein SA, Gage FH. Cell culture. Progenitor cells from human brain after death. Nature. 2001;411:42&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">11333968</ArticleId></ArticleIdList></Reference><Reference><Citation>Parent JM. Injury-induced neurogenesis in the adult mammalian brain. Neuroscientist. 2003;9:261&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pubmed">12934709</ArticleId></ArticleIdList></Reference><Reference><Citation>Pei JJ, Braak E, Braak H, Grundke-Iqbal I, Iqbal K, Winblad B, Cowburn RF. Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol. 1999;58:1010&#x2013;1019.</Citation><ArticleIdList><ArticleId IdType="pubmed">10499443</ArticleId></ArticleIdList></Reference><Reference><Citation>Pincus DW, Harrison-Restelli C, Barry J, Goodman RR, Fraser RA, Nedergaard M, Goldman SA. In vitro neurogenesis by adult human epileptic temporal neocortex. Clin Neurosurg. 1997;44:17&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">10079997</ArticleId></ArticleIdList></Reference><Reference><Citation>Probst A, Langui D, Ulrich J. Alzheimer's disease: a description of the structural lesions. Brain Pathol. 1991;1:229&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">1727015</ArticleId></ArticleIdList></Reference><Reference><Citation>Regeur L, Jensen GB, Pakkenberg H, Evans SM, Pakkenberg B. No global neocortical nerve cell loss in brains from patients with senile dementia of Alzheimer's type. Neurobiol Aging. 1994;15:347&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">7936059</ArticleId></ArticleIdList></Reference><Reference><Citation>Reya T, Duncan AW, Ailles L, Domen J, Scherer DC, Willert K, Hintz L, Nusse R, Weissman IL. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature. 2003;423:409&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">12717450</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivers LE, Young KM, Rizzi M, Jamen F, Psachoulia K, Wade A, Kessaris N, Richardson WD. PDGFRA/NG2 glia generate myelinating oligodendrocytes and piriform projection neurons in adult mice. Nat Neurosci. 2008;11:1392&#x2013;1401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3842596</ArticleId><ArticleId IdType="pubmed">18849983</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy NS, Wang S, Harrison-Restelli C, Benraiss A, Fraser RA, Gravel M, Braun PE, Goldman SA. Identification, isolation, and promoter-defined separation of mitotic oligodendrocyte progenitor cells from the adult human subcortical white matter. J Neurosci. 1999;19:9986&#x2013;9995.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782951</ArticleId><ArticleId IdType="pubmed">10559406</ArticleId></ArticleIdList></Reference><Reference><Citation>Salins P, Shawesh S, He Y, Dibrov A, Kashour T, Arthur G, Amara F. Lovastatin protects human neurons against Abeta-induced toxicity and causes activation of beta-catenin-TCF/LEF signaling. Neurosci Lett. 2007;412:211&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">17234346</ArticleId></ArticleIdList></Reference><Reference><Citation>Scolding N, Franklin R, Stevens S, Heldin CH, Compston A, Newcombe J. Oligodendrocyte progenitors are present in the normal adult human CNS and in the lesions of multiple sclerosis. Brain. 1998;121:2221&#x2013;2228.</Citation><ArticleIdList><ArticleId IdType="pubmed">9874475</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature. 1999;399:A23&#x2013;A31.</Citation><ArticleIdList><ArticleId IdType="pubmed">10392577</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Aging, amyloid, and Alzheimer's disease: a perspective in honor of Carl Cotman. Neurochem Res. 2003;28:1705&#x2013;1713.</Citation><ArticleIdList><ArticleId IdType="pubmed">14584824</ArticleId></ArticleIdList></Reference><Reference><Citation>Spalding KL, Bhardwaj RD, Buchholz BA, Druid H, Fris&#xe9;n J. Retrospective birth dating of cells in humans. Cell. 2005;122:133&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">16009139</ArticleId></ArticleIdList></Reference><Reference><Citation>Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol. 1996;6:1664&#x2013;1668.</Citation><ArticleIdList><ArticleId IdType="pubmed">8994831</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugaya K. Possible use of autologous stem cell therapies for Alzheimer's disease. Curr Alzheimer Res. 2005;2:367&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">15974902</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugaya K, Alvarez A, Marutle A, Kwak YD, Choumkina E. Stem cell strategies for Alzheimer's disease therapy. Panminerva Med. 2006;48:87&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">16953146</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell. 2005;120:545&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">15734686</ArticleId></ArticleIdList></Reference><Reference><Citation>Teo JL, Ma H, Nguyen C, Lam C, Kahn M. Specific inhibition of CBP/beta-catenin interaction rescues defects in neuronal differentiation caused by a presenilin-1 mutation. Proc Natl Acad Sci U S A. 2005;102:12171&#x2013;12176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1189325</ArticleId><ArticleId IdType="pubmed">16093313</ArticleId></ArticleIdList></Reference><Reference><Citation>Valenta T, Lukas J, Korinek V. HMG box transcription factor TCF-4's interaction with CtBP1 controls the expression of the Wnt target Axin2/Conductin in human embryonic kidney cells. Nucleic Acids Res. 2003;31:2369&#x2013;2380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC154232</ArticleId><ArticleId IdType="pubmed">12711682</ArticleId></ArticleIdList></Reference><Reference><Citation>Willert K, Brown JD, Danenberg E, Duncan AW, Weissman IL, Reya T, Yates JR, 3rd, Nusse R. Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature. 2003;423:448&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">12717451</ArticleId></ArticleIdList></Reference><Reference><Citation>Windrem MS, Roy NS, Wang J, Nunes M, Benraiss A, Goodman R, McKhann GM, 2nd, Goldman SA. Progenitor cells derived from the adult human subcortical white matter disperse and differentiate as oligodendrocytes within demyelinated lesions of the rat brain. J Neurosci Res. 2002;69:966&#x2013;975.</Citation><ArticleIdList><ArticleId IdType="pubmed">12205690</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolswijk G. Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells. J Neurosci. 1998;18:601&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792542</ArticleId><ArticleId IdType="pubmed">9425002</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright AP, Fitzgerald JJ, Colello RJ. Rapid purification of glial cells using immunomagnetic separation. J Neurosci Methods. 1997;74:37&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">9210573</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Q, Combs C, Cannady SB, Geldmacher DS, Herrup K. Beta-amyloid activated microglia induce cell cycling and cell death in cultured cortical neurons. Neurobiol Aging. 2000;21:797&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pubmed">11124423</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Herrup K. Cell division in the CNS: protective response or lethal event in post-mitotic neurons? Biochim Biophys Acta. 2007;1772:457&#x2013;466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2785903</ArticleId><ArticleId IdType="pubmed">17158035</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Geldmacher DS, Herrup K. DNA replication precedes neuronal cell death in Alzheimer's disease. J Neurosci. 2001;21:2661&#x2013;2668.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762514</ArticleId><ArticleId IdType="pubmed">11306619</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Mufson EJ, Herrup K. Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer's disease. J Neurosci. 2003;23:2557&#x2013;2563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742098</ArticleId><ArticleId IdType="pubmed">12684440</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Varvel NH, Lamb BT, Herrup K. Ectopic cell cycle events link human Alzheimer's disease and amyloid precursor protein transgenic mouse models. J Neurosci. 2006;26:775&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675370</ArticleId><ArticleId IdType="pubmed">16421297</ArticleId></ArticleIdList></Reference><Reference><Citation>Zechner D, Fujita Y, H&#xfc;lsken J, M&#xfc;ller T, Walther I, Taketo MM, Crenshaw EB, 3rd, Birchmeier W, Birchmeier C. beta-Catenin signals regulate cell growth and the balance between progenitor cell expansion and differentiation in the nervous system. Dev Biol. 2003;258:406&#x2013;418.</Citation><ArticleIdList><ArticleId IdType="pubmed">12798297</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng G, Apte U, Cieply B, Singh S, Monga SP. siRNA-mediated beta-catenin knockdown in human hepatoma cells results in decreased growth and survival. Neoplasia. 2007;9:951&#x2013;959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2077886</ArticleId><ArticleId IdType="pubmed">18030363</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Cicero SA, Wang L, Romito-Digiacomo RR, Yang Y, Herrup K. Nuclear localization of Cdk5 is a key determinant in the postmitotic state of neurons. Proc Natl Acad Sci U S A. 2008;105:8772&#x2013;8777.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2438417</ArticleId><ArticleId IdType="pubmed">18550843</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang SC, Wernig M, Duncan ID, Br&#xfc;stle O, Thomson JA. In vitro differentiation of transplantable neural precursors from human embryonic stem cells. Nat Biotechnol. 2001;19:1129&#x2013;1133.</Citation><ArticleIdList><ArticleId IdType="pubmed">11731781</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Hartmann H, Do VM, Abramowski D, Sturchler-Pierrat C, Staufenbiel M, Sommer B, van de Wetering M, Clevers H, Saftig P, De Strooper B, He X, Yankner BA. Destabilization of beta-catenin by mutations in presenilin-1 potentiates neuronal apoptosis. Nature. 1998;395:698&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pubmed">9790190</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Zhang L, Wang A, Song B, Gong K, Zhang L, Hu M, Zhang X, Zhao N, Gong Y. The association of GSK3 beta with E2F1 facilitates nerve growth factor-induced neural cell differentiation. J Biol Chem. 2008;283:14506&#x2013;14515.</Citation><ArticleIdList><ArticleId IdType="pubmed">18367454</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19470201</PMID><DateCompleted><Year>2009</Year><Month>09</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>03</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1041-6102</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>4</Issue><PubDate><Year>2009</Year><Month>Aug</Month></PubDate></JournalIssue><Title>International psychogeriatrics</Title><ISOAbbreviation>Int Psychogeriatr</ISOAbbreviation></Journal><ArticleTitle>The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>672</StartPage><EndPage>687</EndPage><MedlinePgn>672-87</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1017/S1041610209009405</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The Australian Imaging, Biomarkers and Lifestyle (AIBL) flagship study of aging aimed to recruit 1000 individuals aged over 60 to assist with prospective research into Alzheimer's disease (AD). This paper describes the recruitment of the cohort and gives information about the study methodology, baseline demography, diagnoses, medical comorbidities, medication use, and cognitive function of the participants.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Volunteers underwent a screening interview, had comprehensive cognitive testing, gave 80 ml of blood, and completed health and lifestyle questionnaires. One quarter of the sample also underwent amyloid PET brain imaging with Pittsburgh compound B (PiB PET) and MRI brain imaging, and a subgroup of 10% had ActiGraph activity monitoring and body composition scanning.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 1166 volunteers were recruited, 54 of whom were excluded from further study due to comorbid disorders which could affect cognition or because of withdrawal of consent. Participants with AD (211) had neuropsychological profiles which were consistent with AD, and were more impaired than participants with mild cognitive impairment (133) or healthy controls (768), who performed within expected norms for age on neuropsychological testing. PiB PET scans were performed on 287 participants, 100 had DEXA scans and 91 participated in ActiGraph monitoring.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The participants comprising the AIBL cohort represent a group of highly motivated and well-characterized individuals who represent a unique resource for the study of AD. They will be reassessed at 18-month intervals in order to determine the predictive utility of various biomarkers, cognitive parameters and lifestyle factors as indicators of AD, and as predictors of future cognitive decline.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ellis</LastName><ForeName>Kathryn A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Academic Unit for Psychiatry of Old Age, Department of Psychiatry, The University of Melbourne, St. Vincent's Aged Psychiatry Service, St George's Hospital, Victoria, Australia. kellis@unimelb.edu.au</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bush</LastName><ForeName>Ashley I</ForeName><Initials>AI</Initials></Author><Author ValidYN="Y"><LastName>Darby</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>De Fazio</LastName><ForeName>Daniela</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Foster</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Hudson</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Lautenschlager</LastName><ForeName>Nicola T</ForeName><Initials>NT</Initials></Author><Author ValidYN="Y"><LastName>Lenzo</LastName><ForeName>Nat</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Martins</LastName><ForeName>Ralph N</ForeName><Initials>RN</Initials></Author><Author ValidYN="Y"><LastName>Maruff</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>Colin</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Milner</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Pike</LastName><ForeName>Kerryn</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Savage</LastName><ForeName>Greg</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Szoeke</LastName><ForeName>Cassandra</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Taddei</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Villemagne</LastName><ForeName>Victor</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Woodward</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Ames</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><CollectiveName>AIBL Research Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>05</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int Psychogeriatr</MedlineTA><NlmUniqueID>9007918</NlmUniqueID><ISSNLinking>1041-6102</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001315" MajorTopicYN="N" Type="Geographic">Australia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008019" MajorTopicYN="Y">Life Style</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="Y">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="Y">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008403" MajorTopicYN="N">Mass Screening</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="Y">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018579" MajorTopicYN="Y">Patient Selection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="Y">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Acosta</LastName><ForeName>Oscar</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ames</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ames</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Agarwal</LastName><ForeName>Manoj</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bahar-Fuchs</LastName><ForeName>Alex</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baxendale</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bechta-Metti</LastName><ForeName>Kiara</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bevage</LastName><ForeName>Carlita</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bevage</LastName><ForeName>Lindsay</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bourgeat</LastName><ForeName>Pierrick</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>Belinda</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bush</LastName><ForeName>Ashley</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clarnette</LastName><ForeName>Roger</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cowie</LastName><ForeName>Tiffiany</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crowley</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Currie</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Darby</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Fazio</LastName><ForeName>Daniela</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ellis</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dickinson</LastName><ForeName>Kerryn</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farrow</LastName><ForeName>Maree</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Faux</LastName><ForeName>Noel</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foster</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fripp</LastName><ForeName>Jurgen</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fowler</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gupta</LastName><ForeName>Veer</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hudson</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jones</LastName><ForeName>Gareth</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khoo</LastName><ForeName>Jane</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Killedar</LastName><ForeName>Asawari</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rembach</LastName><ForeName>Alan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rimajova</LastName><ForeName>Miroslava</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robins</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ronsisvalle</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rumble</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodrigues</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rowe</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salvado</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sach</LastName><ForeName>Jack</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Samuel</LastName><ForeName>Mathew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Savage</LastName><ForeName>Greg</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sittironnarit</LastName><ForeName>Gobhathai</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Szoeke</LastName><ForeName>Cassandra</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taddei</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taddei</LastName><ForeName>Tania</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trivedi</LastName><ForeName>Darsha</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trounson</LastName><ForeName>Brett</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsikkos</LastName><ForeName>Marinos</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villemagne</LastName><ForeName>Victor</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walker</LastName><ForeName>Stacey</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ward</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Woodward</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yastrubetskaya</LastName><ForeName>Olga</ForeName><Initials>O</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>5</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>5</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19470201</ArticleId><ArticleId IdType="doi">10.1017/S1041610209009405</ArticleId><ArticleId IdType="pii">S1041-6102(24)02568-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19474305</PMID><DateCompleted><Year>2009</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>21</Issue><PubDate><Year>2009</Year><Month>May</Month><Day>27</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice.</ArticleTitle><Pagination><StartPage>6771</StartPage><EndPage>6779</EndPage><MedlinePgn>6771-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0887-09.2009</ELocationID><Abstract><AbstractText>To investigate the role of human apolipoprotein E (apoE) on Abeta deposition in vivo, we crossed PDAPP mice lacking mouse Apoe to targeted replacement mice expressing human apoE (PDAPP/TRE2, PDAPP/TRE3, or PDAPP/TRE4). We then measured the levels of apoE protein and Abeta peptides in plasma, CSF, and brain homogenates in these mice at different ages. We also quantified the amount of brain Abeta and amyloid burden in 18-month-old mice. In young PDAPP/TRE4 mice that were analyzed at an age before brain Abeta deposition, we observed a significant decrease in the levels of apoE in CSF and brain when compared with age-matched mice expressing either human E2 or E3. The brain levels of Abeta42 in PDAPP/TRE4 mice were substantially elevated even at this very early time point. In older PDAPP/TRE4 mice, the levels of insoluble apoE protein increased in parallel to the dramatic rise in brain Abeta burden, and the majority of apoE was associated with Abeta. In TRE4 only mice, we also observed a significant decrease in the level of apoE in brain homogenates. Since the relative level of apoE mRNA was equivalent in PDAPP/TRE and TRE only mice, it appears that post-translational mechanisms influence the levels of apoE protein in brain (E4 &lt; E3 &lt;&lt; E2), resulting in early and dramatic apoE isoform-dependent effects on brain Abeta levels (E4 &gt;&gt; E3 &gt; E2) that increase with age. Therapeutic strategies aimed at increasing the soluble levels of apoE protein, regardless of isoform, may effectively prevent and (or) treat Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bales</LastName><ForeName>Kelly R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Neuroscience Discovery Research, Eli Lilly and Company, Indianapolis, Indiana 46285, USA. Kelly.Bales@Pfizer.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Feng</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Su</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Suizhen</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Koger</LastName><ForeName>Deanna</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>DeLong</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Hansen</LastName><ForeName>Jeffrey C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Patrick M</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><LastName>Paul</LastName><ForeName>Steven M</ForeName><Initials>SM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>5</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>5</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>6</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>11</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19474305</ArticleId><ArticleId IdType="pmc">PMC6665579</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0887-09.2009</ArticleId><ArticleId IdType="pii">29/21/6771</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ, Piccardo P, Ghetti B, Paul SM. Lack of apolipoprotein E dramatically reduces amyloid &#x3b2;-peptide deposition. Nat Genet. 1997;17:263&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">9354781</ArticleId></ArticleIdList></Reference><Reference><Citation>Bales KR, Verina T, Cummins DJ, Du Y, Dodel RC, Saura J, Fishman CE, DeLong CA, Piccardo P, Petegnief V, Ghetti B, Paul SM. Apolipoprotein E is essential for amyloid deposition in the APP V717F transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 1999;96:15233&#x2013;15238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24803</ArticleId><ArticleId IdType="pubmed">10611368</ArticleId></ArticleIdList></Reference><Reference><Citation>Beffert U, Cohn JS, Petit-Turcotte C, Tremblay M, Aumont N, Ramassamy C, Davignon J, Poirier J. Apolipoprotein E and beta-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype dependent. Brain Res. 1999;843:87&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">10528114</ArticleId></ArticleIdList></Reference><Reference><Citation>Boschert U, Merlo-Pich E, Higgins G, Roses AD, Catsicas S. Apolipoprotein E expression by neurons surviving excitotoxic stress. Neurobiol Dis. 1999;6:508&#x2013;514.</Citation><ArticleIdList><ArticleId IdType="pubmed">10600406</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyles JK, Pitas RE, Wilson E, Mahley RW, Taylor JM. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmylinating glia of the peripheral nervous system. J Clin Invest. 1985;76:1501&#x2013;1513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC424114</ArticleId><ArticleId IdType="pubmed">3932467</ArticleId></ArticleIdList></Reference><Reference><Citation>Burt TD, Agan BK, Marconi VC, He W, Kulkarni H, Mold JE, Cavrois M, Huang Y, Mahley RW, Dolan MJ, McCune JM, Ahuja SK. Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE &#x3b5;4/&#x3b5;4 genotype accelerates HIV disease progression. Proc Natl Acad Sci U S A. 2008;105:8718&#x2013;8723.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2438419</ArticleId><ArticleId IdType="pubmed">18562290</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC, Jr, Rimmler JB, Locke PA, Conneally PM, Schmader KE. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994;7:180&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">7920638</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, Holtzman DM, Zlokovic BV. ApoE isoform-specific disruption of amyloid &#x3b2; peptide clearance from mouse brain. J Clin Invest. 2008;118:4002&#x2013;4013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2582453</ArticleId><ArticleId IdType="pubmed">19033669</ArticleId></ArticleIdList></Reference><Reference><Citation>Deary IJ, Whiteman MC, Pattie A, Starr JM, Hayward C, Wright AF, Carothers A, Whalley LJ. Cognitive change and APOE &#x3b5;4 allele. Nature. 2002;418:932.</Citation><ArticleIdList><ArticleId IdType="pubmed">12198535</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB. Apolipoprotein E dose-dependent modulation of &#x3b2;-amyloid deposition in a transgenic mouse model of Alzheimer's disease. J Mol Neurosci. 2004;23:255&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pubmed">15181254</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB, Brendza RP, Heuser JE, Kierson M, Cirrito JR, Fryer J, Sullivan PM, Fagan AM, Han X, Holtzman DM. Purification and characterization of astrocyte-secreted apolipoprotein E and J-containing lipoproteins from wild-type and human apoE transgenic mice. Neurochem Int. 2001;39:415&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pubmed">11578777</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Watson M, Parsadanian M, Bales KR, Paul SM, Holtzman DM. Human and murine ApoE markedly alters A&#x3b2; metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol Dis. 2002;9:305&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">11950276</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278:1349&#x2013;1356.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Fryer JD, Simmons K, Parsadanian M, Bales KR, Paul SM, Sullivan PM, Holtzman DM. Human apolipoprotein E4 alters the amyloid-&#x3b2;40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J Neurosci. 2005;25:2803&#x2013;2810.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725147</ArticleId><ArticleId IdType="pubmed">15772340</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasty AH, Plummer MR, Weisgraber KH, Linton MF, Fazio S, Swift LL. The recycling of apolipoprotein E in macrophages: influence of HDL and apolipoprotein A-I. J Lipid Res. 2005;46:1433&#x2013;1439.</Citation><ArticleIdList><ArticleId IdType="pubmed">15805547</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsch-Reinshagen V, Maia LF, Burgess BL, Blain JF, Naus KE, McIsaac SA, Parkinson PF, Chan JY, Tansley GH, Hayden MR, Poirier J, Van Nostrand W, Wellington CL. The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. J Biol Chem. 2005;280:43243&#x2013;43256.</Citation><ArticleIdList><ArticleId IdType="pubmed">16207707</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Fagan AM. Potential role of apoE in structural plasticity in the nervous system: implications for diseases of the central nervous system. Trends Cardiovasc Med. 1998;6:250&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">14987560</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Bales KR, Wu S, Bhat P, Parsadanian M, Fagan AM, Chang LK, Sun Y, Paul SM. Expression of human apolipoprotein E reduces amyloid-&#x3b2; deposition in a mouse model of Alzheimer's disease. J Clin Invest. 1999;103:R15&#x2013;R21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC408154</ArticleId><ArticleId IdType="pubmed">10079115</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D, Paul SM. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2000;97:2892&#x2013;2897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16026</ArticleId><ArticleId IdType="pubmed">10694577</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry MC, Deng A, Lleo A, Berezovska O, Von Arnim CA, Martin-Rehrmann M, Manelli A, LaDu MJ, Hyman BT, Rebeck GW. Apolipoprotein E modulates &#x3b3;-secretase cleavage of the amyloid precursor protein. J Neurochem. 2004;90:1132&#x2013;1143.</Citation><ArticleIdList><ArticleId IdType="pubmed">15312168</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tontonoz P, Landreth GE. ApoE promotes the proteolytic degradation of A&#x3b2;. Neuron. 2008;58:681&#x2013;693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2493297</ArticleId><ArticleId IdType="pubmed">18549781</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, Khan K, Gordon M, Tan H, Games D, Lieberburg I, Schenk D, Seubert P, McConlogue L. Amyloid precursor protein processing and Abeta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci U S A. 1997;94:1550&#x2013;1555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19829</ArticleId><ArticleId IdType="pubmed">9037091</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch S, Donarski N, Goetze K, Kreckel M, Stuerenburg HJ, Buhmann C, Beisiegel U. Characterization of four lipoprotein classes in human cerebrospinal fluid. J Lipid Res. 2001;42:1143&#x2013;1151.</Citation><ArticleIdList><ArticleId IdType="pubmed">11441143</ArticleId></ArticleIdList></Reference><Reference><Citation>LaDu MJ, Gilligan SM, Lukens JR, Cabana VG, Reardon CA, Van Eldik LJ, Holtzman DM. Nascent astrocyte particles differ from lipoproteins in CSF. J Neurochem. 1998;70:2070&#x2013;2081.</Citation><ArticleIdList><ArticleId IdType="pubmed">9572293</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Zerbinatti CV, Zhang J, Hoe HS, Wang B, Cole SL, Herz J, Muglia L, Bu G. Amyloid precursor protein upregulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neuron. 2007;56:66&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2045076</ArticleId><ArticleId IdType="pubmed">17920016</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley RW, Rall SC., Jr Apolipoprotien E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet. 2000;1:507&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pubmed">11701639</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci U S A. 2006;103:5644&#x2013;5651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1414631</ArticleId><ArticleId IdType="pubmed">16567625</ArticleId></ArticleIdList></Reference><Reference><Citation>Marmillot P, Rao MN, Liu QH, Lakshman MR. Desialylation of human apolipoprotein E decreases its binding to human high-density lipoprotein and its ability to deliver esterified cholesterol to the liver. Metabolism. 1999;48:1184&#x2013;1192.</Citation><ArticleIdList><ArticleId IdType="pubmed">10484062</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer MR, Tschanz JT, Norton MC, Welsh-Bohmer KA, Steffens DC, Wyse BW, Breitner JC. APOE genotype predicts when-not whether-one is predisposed to develop Alzheimer disease. Nat Genet. 1998;19:321&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pubmed">9697689</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RM, Federoff HJ. Isoform-specific effects of ApoE on HSV immediate early gene expression and establishment of latency. Neurobiol Aging. 2008;29:71&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">17101197</ArticleId></ArticleIdList></Reference><Reference><Citation>Morikawa M, Fryer JD, Sullivan PM, Christopher EA, Wahrle SE, DeMattos RB, O'Dell MA, Fagan AM, Lashuel HA, Walz T, Asai K, Holtzman DM. Production and characterization of astrocyte-derived human apolipoprotein E isoforms from immortalized astrocytes and their interactions with amyloid-&#x3b2;. Neurobiol Dis. 2005;19:66&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">15837562</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy Z, Esiri MM, Jobst KA, Johnston C, Litchfield S, Sim E, Smith AD. Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. Neuroscience. 1995;69:757&#x2013;761.</Citation><ArticleIdList><ArticleId IdType="pubmed">8596645</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll JA, Roberts GW, Graham DI. Amyloid &#x3b2;-protein, APOE genotype and head injury. Ann N Y Acad Sci. 1996;777:271&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pubmed">8624097</ArticleId></ArticleIdList></Reference><Reference><Citation>Poirier J. Apolipoprotein E represents a potent gene-based therapeutic target for the treatment of sporadic Alzheimer's disease. Alzheimer's and Dementia. 2008;4:S91&#x2013;S98.</Citation><ArticleIdList><ArticleId IdType="pubmed">18632009</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramaswamy G, Xu Q, Huang Y, Weisgraber KH. Effect of domain interaction on Apolipoprotein E levels in mouse brain. J Neurosci. 2005;25:10658&#x2013;10663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725862</ArticleId><ArticleId IdType="pubmed">16291938</ArticleId></ArticleIdList></Reference><Reference><Citation>Rees D, Sloane T, Jessup W, Dean RT, Kritharides L. Apolipoprotein A-I stimulates secretion of apolipoprotein E by foam macrophages. J Biol Chem. 1999;274:27925&#x2013;27933.</Citation><ArticleIdList><ArticleId IdType="pubmed">10488140</ArticleId></ArticleIdList></Reference><Reference><Citation>Riddell DR, Zhou H, Atchison K, Warwick HK, Atkinson PJ, Jefferson J, Xu L, Aschmies S, Kirksey Y, Hu Y, Wagner E, Parratt A, Xu J, Li Z, Zaleska MM, Jacobsen JS, Pangalos MN, Reinhart PH. Impact of apolipoprotein E (ApoE) polymorphism on brain apoE levels. J Neurosci. 2008;28:11445&#x2013;11453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671315</ArticleId><ArticleId IdType="pubmed">18987181</ArticleId></ArticleIdList></Reference><Reference><Citation>Royston MC, Mann D, Pickering-Brown S, Owen F, Perry R, Raghavan R, Khin-Nu C, Tyrer S, Day K, Crook R. Apolipoprotein E &#x3b5;2 allele promotes longevity and protects patients with Down's syndrome from dementia. Neuroreport. 1994;5:2583&#x2013;2585.</Citation><ArticleIdList><ArticleId IdType="pubmed">7696609</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ. Association of apolipoprotein allele &#x3b5;4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993;43:1467&#x2013;1472.</Citation><ArticleIdList><ArticleId IdType="pubmed">8350998</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD. Increased amyloid &#x3b2;-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90:9649&#x2013;9653.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47627</ArticleId><ArticleId IdType="pubmed">8415756</ArticleId></ArticleIdList></Reference><Reference><Citation>Slooter AJ, Tang MX, van Duijn CM, Stern Y, Ott A, Bell K, Breteler MM, Van Broeckhoven C, Tatemichi TK, Tycko B, Hofman A, Mayeux R. Apolipoprotein E &#x3b5;4 and the risk of dementia with stroke: a population-based investigation. JAMA. 1997;277:818&#x2013;821.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052712</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan PM, Mezdour H, Aratani Y, Knouff C, Najib J, Reddick RL, Quarfordt SH, Maeda N. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia. J Biol Chem. 1997;272:17972&#x2013;17980.</Citation><ArticleIdList><ArticleId IdType="pubmed">9218423</ArticleId></ArticleIdList></Reference><Reference><Citation>Teasdale GM, Nicoll JA, Murray G, Fiddes M. Association of apolipoprotein E polymorphism with outcome after head injury. Lancet. 1997;350:1069&#x2013;1071.</Citation><ArticleIdList><ArticleId IdType="pubmed">10213549</ArticleId></ArticleIdList></Reference><Reference><Citation>Utermann G, Langenbeck U, Beisiegel U, Weber W. Genetics of the apolipoprotein E system in man. Am J Hum Genet. 1980;32:339&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1686062</ArticleId><ArticleId IdType="pubmed">7386461</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle SE, Jiang H, Parsadanian M, Legleiter J, Han X, Fryer JD, Kowalewski T, Holtzman DM. ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J Biol Chem. 2004;279:40987&#x2013;40993.</Citation><ArticleIdList><ArticleId IdType="pubmed">15269217</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle SE, Jiang H, Parsadanian M, Hartman RE, Bales KR, Paul SM, Holtzman DM. Deletion of Abca1 increases A&#x3b2; deposition in the PDAPP transgenic mouse model of Alzheimer disease. J Biol Chem. 2005;280:43236&#x2013;43242.</Citation><ArticleIdList><ArticleId IdType="pubmed">16207708</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A, Jain S, Hirsch-Reinshagen V, Wellington CL, Bales KR, Paul SM, Holtzman DM. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest. 2008;118:671&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2200302</ArticleId><ArticleId IdType="pubmed">18202749</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker LC, Pahnke J, Madauss M, Vogelgesang S, Pahnke A, Herbst EW, Stausske D, Walther R, Kessler C, Warzok RW. Apolipoprotein E4 promotes the early deposition of A&#x3b2;42 and then A&#x3b2;40 in the elderly. Acta Neuropathol. 2000;100:36&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">10912918</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisgraber KH. Apolipoprotein E: structure-function relationships. Adv Protein Chem. 1994;45:249&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pubmed">8154371</ArticleId></ArticleIdList></Reference><Reference><Citation>Weller RO, Massey A, Newman TA, Hutchings M, Kuo YM, Roher AE. Cerebral amyloid angiopathy: amyloid beta accumulation in putative interstitial fluid drainage pathways in Alzheimer's disease. Am J Pathol. 1998;153:725&#x2013;733.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1853019</ArticleId><ArticleId IdType="pubmed">9736023</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye S, Huang Y, M&#xfc;llendorff K, Dong L, Giedt G, Meng EC, Cohen FE, Kuntz ID, Weisgraber KH, Mahley RW. Apolipoprotein (apo) E4 enhances amyloid &#x3b2; peptide production in cultured neuronal cells: ApoE structure as a potential therapeutic target. Proc Natl Acad Sci U S A. 2005;102:18700&#x2013;18705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1311738</ArticleId><ArticleId IdType="pubmed">16344478</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19475670</PMID><DateCompleted><Year>2009</Year><Month>06</Month><Day>26</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8249</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>5</Issue><PubDate><Year>2009</Year><Month>May</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>Amyloid imaging in mild cognitive impairment subtypes.</ArticleTitle><Pagination><StartPage>557</StartPage><EndPage>568</EndPage><MedlinePgn>557-68</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ana.21598</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We utilized the amyloid imaging ligand Pittsburgh Compound B (PiB) to determine the presence of Alzheimer's disease (AD) pathology in different mild cognitive impairment (MCI) subtypes and to relate increased PiB binding to other markers of early AD and longitudinal outcome.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Twenty-six patients with MCI (13 single-domain amnestic-MCI [a-MCI], 6 multidomain a-MCI, and 7 nonamnestic MCI) underwent PiB imaging. Twenty-three had clinical follow-up (21.2 +/- 16.0 [standard deviation] months) subsequent to their PiB scan.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Using cutoffs established from a control cohort, we found that 14 (54%) patients had increased levels of PiB retention and were considered "amyloid-positive." All subtypes were associated with a significant proportion of amyloid-positive patients (6/13 single-domain a-MCI, 5/6 multidomain a-MCI, 3/7 nonamnestic MCI). There were no obvious differences in the distribution of PiB retention in the nonamnestic MCI group. Predictors of conversion to clinical AD in a-MCI, including poorer episodic memory, and medial temporal atrophy, were found in the amyloid-positive relative to amyloid-negative a-MCI patients. Longitudinal follow-up demonstrated 5 of 13 amyloid-positive patients, but 0 of 10 amyloid-negative patients, converted to clinical AD. Further, 3 of 10 amyloid-negative patients "reverted to normal."</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">These data support the notion that amyloid-positive patients are likely to have early AD, and that the use of amyloid imaging may have an important role in determining which patients are likely to benefit from disease-specific therapies. In addition, our data are consistent with longitudinal studies that suggest a significant percentage of all MCI subtypes will develop AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wolk</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, University of Pittsburgh, Pittsburgh, PA 19104, USA. david.wolk@uphs.upenn.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Julie C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Saxton</LastName><ForeName>Judy A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Snitz</LastName><ForeName>Beth E</ForeName><Initials>BE</Initials></Author><Author ValidYN="Y"><LastName>James</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials></Author><Author ValidYN="Y"><LastName>Aizenstein</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Ann D</ForeName><Initials>AD</Initials></Author><Author ValidYN="Y"><LastName>Weissfeld</LastName><ForeName>Lisa A</ForeName><Initials>LA</Initials></Author><Author ValidYN="Y"><LastName>Mathis</LastName><ForeName>Chester A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Klunk</LastName><ForeName>William E</ForeName><Initials>WE</Initials></Author><Author ValidYN="Y"><LastName>De-Kosky</LastName><ForeName>Steven T</ForeName><Initials>ST</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG 020226</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG 028018</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG018402</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG 005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH070729</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG025516</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG 018402</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG020226</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG 020098</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 MH001976</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH 070729</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K02 AG 001039</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K02 AG 027998</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG 025204</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG020098</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG025516</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K02 AG001039</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG 025516</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG028018</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG025204</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Ann Neurol. 2009 Jul;66(1):123</RefSource><Note>DeKoskym, Steven T [corrected to De-Kosky, Steven T]</Note></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="Y">Cognition Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>5</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>5</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>6</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>2</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19475670</ArticleId><ArticleId IdType="mid">NIHMS86162</ArticleId><ArticleId IdType="pmc">PMC2828870</ArticleId><ArticleId IdType="doi">10.1002/ana.21598</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Petersen RC. Mild cognitive impairment as a diagnostic entity. Journal of Internal Medicine. 2004;256:183&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">15324362</ArticleId></ArticleIdList></Reference><Reference><Citation>Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004;256:240&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">15324367</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol. 2001;58:397&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">11255443</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment. Clinical characterization and outcome. Archives of Neurology. 1999;56:303&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">10190820</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman H, Scheltens P, Scarpini E, et al. Behavioral symptoms in mild cognitive impairment. Neurology. 2004;62:1199&#x2013;1201.</Citation><ArticleIdList><ArticleId IdType="pubmed">15079026</ArticleId></ArticleIdList></Reference><Reference><Citation>Daly E, Zaitchik D, Copeland M, et al. Predicting conversion to Alzheimer disease using standardized clinical information. Arch Neurol. 2000;57:675&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pubmed">10815133</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal LJ, Ferris SH, Kirby L, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology. 2005;30:1204&#x2013;1215.</Citation><ArticleIdList><ArticleId IdType="pubmed">15742005</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky ST, Ikonomovic MD, Styren SD, et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol. 2002;51:145&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pubmed">11835370</ArticleId></ArticleIdList></Reference><Reference><Citation>Markesbery WR, Schmitt FA, Kryscio RJ, et al. Neuropathologic substrate of mild cognitive impairment. Archives of Neurology. 2006;63:38&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">16401735</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Parisi JE, Dickson DW, et al. Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol. 2006;63:665&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pubmed">16682536</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell TW, Mufson EJ, Schneider JA, et al. Parahippocampal tau pathology in healthy aging, mild cognitive impairment, and early alzheimer&#x2019;s disease. Annals of Neurology. 2002;51:182&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">11835374</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser PJ, Kester A, Jolles J, Verhey F. Ten-year risk of dementia in subjects with mild cognitive impairment. Neurology. 2006;67:1201&#x2013;1207.</Citation><ArticleIdList><ArticleId IdType="pubmed">17030753</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganguli M, Dodge HH, Shen C, DeKosky ST. Mild cognitive impairment, amnestic type: an epidemiologic study. Neurology. 2004;63:115&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pubmed">15249620</ArticleId></ArticleIdList></Reference><Reference><Citation>Larrieu S, Letenneur L, Orgogozo JM, et al. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology. 2002;59:1594&#x2013;1599.</Citation><ArticleIdList><ArticleId IdType="pubmed">12451203</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie K, Artero S, Touchon J. Classification criteria for mild cognitive impairment: a population-based validation study. Neurology. 2001;56:37&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">11148233</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, Parisi JE, Dickson DW, et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol. 2006;63:674&#x2013;681.</Citation><ArticleIdList><ArticleId IdType="pubmed">16682537</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser PJ, Scheltens P, Verhey FR. Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer&#x2019;s disease? J Neurol Neurosurg Psychiatry. 2005;76:1348&#x2013;1354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1739362</ArticleId><ArticleId IdType="pubmed">16170074</ArticleId></ArticleIdList></Reference><Reference><Citation>Tierney MC, Black SE, Szalai JP, et al. Recognition memory and verbal fluency differentiate probable Alzheimer disease from subcortical ischemic vascular dementia. Archives of Neurology. 2001;58:1654&#x2013;1659.</Citation><ArticleIdList><ArticleId IdType="pubmed">11594925</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, Sowell BB, Taylor C, et al. Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology. 2007;68:1588&#x2013;1595.</Citation><ArticleIdList><ArticleId IdType="pubmed">17287448</ArticleId></ArticleIdList></Reference><Reference><Citation>de Toledo-Morrell L, Stoub TR, Bulgakova M, et al. MRI-derived entorhinal volume is a good predictor of conversion from MCI to AD. Neurobiology of Aging. 2004;25:1197&#x2013;1203.</Citation><ArticleIdList><ArticleId IdType="pubmed">15312965</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Petersen RC, Xu YC, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology. 1999;52:1397&#x2013;1403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730146</ArticleId><ArticleId IdType="pubmed">10227624</ArticleId></ArticleIdList></Reference><Reference><Citation>Drzezga A, Grimmer T, Riemenschneider M, et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med. 2005;46:1625&#x2013;1632.</Citation><ArticleIdList><ArticleId IdType="pubmed">16204712</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, Perani D, Sorbi S, et al. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology. 2004;63:2332&#x2013;2340.</Citation><ArticleIdList><ArticleId IdType="pubmed">15623696</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Zetterberg H, Buchhave P, et al. Association between CSF biomarkers and incipient Alzheimer&#x2019;s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5:228&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">16488378</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal NT, Wilson RS, Beck TL, et al. The apolipoprotein E epsilon4 allele and incident Alzheimer&#x2019;s disease in persons with mild cognitive impairment. Neurocase. 2005;11:3&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15804918</ArticleId></ArticleIdList></Reference><Reference><Citation>Busse A, Hensel A, Guhne U, et al. Mild cognitive impairment: long-term course of four clinical subtypes. Neurology. 2006;67:2176&#x2013;2185.</Citation><ArticleIdList><ArticleId IdType="pubmed">17190940</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer P, Jungwirth S, Zehetmayer S, et al. Conversion from subtypes of mild cognitive impairment to Alzheimer dementia. Neurology. 2007;68:288&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">17242334</ArticleId></ArticleIdList></Reference><Reference><Citation>Rountree SD, Waring SC, Chan WC, et al. Importance of subtle amnestic and nonamnestic deficits in mild cognitive impairment: prognosis and conversion to dementia. Dement Geriatr Cogn Disord. 2007;24:476&#x2013;482.</Citation><ArticleIdList><ArticleId IdType="pubmed">17992015</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Kuller LH, Becker JT, et al. Incidence of dementia in mild cognitive impairment in the cardiovascular health study cognition study. Arch Neurol. 2007;64:416&#x2013;420.</Citation><ArticleIdList><ArticleId IdType="pubmed">17353386</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Small GW, Kepe V, Ercoli LM, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med. 2006;355:2652&#x2013;2663.</Citation><ArticleIdList><ArticleId IdType="pubmed">17182990</ArticleId></ArticleIdList></Reference><Reference><Citation>Verhoeff NP, Wilson AA, Takeshita S, et al. In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry. 2004;12:584&#x2013;595.</Citation><ArticleIdList><ArticleId IdType="pubmed">15545326</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer&#x2019;s disease. Brain. 2008</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2408940</ArticleId><ArticleId IdType="pubmed">18339640</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathologica. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791&#x2013;1800.</Citation><ArticleIdList><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference><Reference><Citation>Engler H, Forsberg A, Almkvist O, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer&#x2019;s disease. Brain. 2006;129:2856&#x2013;2866.</Citation><ArticleIdList><ArticleId IdType="pubmed">16854944</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemppainen NM, Aalto S, Wilson IA, et al. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology. 2007;68:1603&#x2013;1606.</Citation><ArticleIdList><ArticleId IdType="pubmed">17485647</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2007</Citation><ArticleIdList><ArticleId IdType="pubmed">17499392</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Ng S, Ackermann U, et al. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007;68:1718&#x2013;1725.</Citation><ArticleIdList><ArticleId IdType="pubmed">17502554</ArticleId></ArticleIdList></Reference><Reference><Citation>Pike KE, Savage G, Villemagne VL, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer&#x2019;s disease. Brain. 2007;130:2837&#x2013;2844.</Citation><ArticleIdList><ArticleId IdType="pubmed">17928318</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr., Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer&#x2019;s disease and amnestic mild cognitive impairment. Brain. 2008;131:665&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730157</ArticleId><ArticleId IdType="pubmed">18263627</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JC, Klunk WE, Lopresti BJ, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005;25:1528&#x2013;1547.</Citation><ArticleIdList><ArticleId IdType="pubmed">15944649</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopresti BJ, Klunk WE, Mathis CA, et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med. 2005;46:1959&#x2013;1972.</Citation><ArticleIdList><ArticleId IdType="pubmed">16330558</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Becker JT, Klunk W, et al. Research evaluation and diagnosis of probable Alzheimer&#x2019;s disease over the last two decades: I. Neurology. 2000;55:1854&#x2013;1862.</Citation><ArticleIdList><ArticleId IdType="pubmed">11134385</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauthier S, Reisberg B, Zaudig M, et al. Mild cognitive impairment. Lancet. 2006;367:1262&#x2013;1270.</Citation><ArticleIdList><ArticleId IdType="pubmed">16631882</ArticleId></ArticleIdList></Reference><Reference><Citation>Aizenstein HJ, Nebes RD, Saxton JA, et al. Amyloid deposition is frequent and often not associated with significant cognitive impairment in the elderly. Archives of Neurology. 2008</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2636844</ArticleId><ArticleId IdType="pubmed">19001171</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Price JC, Mathis CA, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci. 2007;27:6174&#x2013;6184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3265970</ArticleId><ArticleId IdType="pubmed">17553989</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner J, Friston KJ. Unified segmentation. Neuroimage. 2005;26:839&#x2013;851.</Citation><ArticleIdList><ArticleId IdType="pubmed">15955494</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu M, Carmichael O, Lopez-Garcia P, et al. Quantitative comparison of AIR, SPM, and the fully deformable model for atlas-based segmentation of functional and structural MR images. Hum Brain Mapp. 2006;27:747&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2886594</ArticleId><ArticleId IdType="pubmed">16463385</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreescu C, Butters MA, Begley A, et al. Gray Matter Changes in Late Life Depression-a Structural MRI Analysis. Neuropsychopharmacology. 2007</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2872084</ArticleId><ArticleId IdType="pubmed">18075490</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmichael OT, Aizenstein HA, Davis SW, et al. Atlas-based hippocampus segmentation in Alzheimer&#x2019;s disease and mild cognitive impairment. Neuroimage. 2005;27:979&#x2013;990.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2862692</ArticleId><ArticleId IdType="pubmed">15990339</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15:273&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">11771995</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Brady M, Smith S. Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. IEEE Trans Med Imaging. 2001;20:45&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">11293691</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson CC. New, faster, image-based scatter correction for 3D-PET. IEEE Transactions of Nuclear Science. 2000;47:1587&#x2013;1594.</Citation></Reference><Reference><Citation>Morris JC, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer&#x2019;s disease. Neurology. 1989;39:1159&#x2013;1165.</Citation><ArticleIdList><ArticleId IdType="pubmed">2771064</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxton JA, Becker JT, Wisniewski S. The ROCF and dementia. In: Knight JA, editor. The handbook of Rey-Osterrieth complex figure usage: clinical and research applications. Psychological Assessment Resources Inc.; Lutz: 2003. pp. 569&#x2013;582.</Citation></Reference><Reference><Citation>Saxton J, Ratcliff G, Newman A, et al. Cognitive test performance and presence of subclinical cardiovascular disease in the cardiovascular health study. Neuroepidemiology. 2000;19:312&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">11060505</ArticleId></ArticleIdList></Reference><Reference><Citation>Spreen O, Strauss E. A compendium of neuropsychological tests: Administration, norms, and commentatory. 2nd ed Oxford University Press; New York: 1998.</Citation></Reference><Reference><Citation>Ivnik RJ, Malec JF, Smith GE, et al. Neuropsychological tests&#x2019; normsabove age 55: COWAT, BNT, MAE Token, WRAT-R Reading, AMNART, STROOP, TMT, and JLO. Clinical Neuropsychologist. 1996;10:262&#x2013;278.</Citation></Reference><Reference><Citation>Alladi S, Xuereb J, Bak T, et al. Focal cortical presentations of Alzheimer&#x2019;s disease. Brain. 2007;130:2636&#x2013;2645.</Citation><ArticleIdList><ArticleId IdType="pubmed">17898010</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings BJ, Pike CJ, Shankle R, Cotman CW. Beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer&#x2019;s disease. Neurobiol Aging. 1996;17:921&#x2013;933.</Citation><ArticleIdList><ArticleId IdType="pubmed">9363804</ArticleId></ArticleIdList></Reference><Reference><Citation>Prohovnik I, Perl DP, Davis KL, et al. Dissociation of neuropathology from severity of dementia in late-onset Alzheimer disease. Neurology. 2006;66:49&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">16401845</ArticleId></ArticleIdList></Reference><Reference><Citation>Naslund J, Haroutunian V, Mohs R, et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. Jama. 2000;283:1571&#x2013;1577.</Citation><ArticleIdList><ArticleId IdType="pubmed">10735393</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer&#x2019;s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer&#x2019;s disease. Neurology. 1992;42:631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">1549228</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer&#x2019;s disease: correlation with cognitive severity. Ann Neurol. 1990;27:457&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">2360787</ArticleId></ArticleIdList></Reference><Reference><Citation>Edison P, Archer HA, Hinz R, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology. 2007;68:501&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pubmed">17065593</ArticleId></ArticleIdList></Reference><Reference><Citation>Killiany RJ, Hyman BT, Gomez-Isla T, et al. MRI measures of entorhinal cortex vs hippocampus in preclinical AD. Neurology. 2002;58:1188&#x2013;1196.</Citation><ArticleIdList><ArticleId IdType="pubmed">11971085</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Albert ML. Amnestic MCI or prodromal Alzheimer&#x2019;s disease? Lancet Neurol. 2004;3:246&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">15039037</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19515914</PMID><DateCompleted><Year>2009</Year><Month>06</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>23</Issue><PubDate><Year>2009</Year><Month>Jun</Month><Day>10</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Interaction of reelin with amyloid precursor protein promotes neurite outgrowth.</ArticleTitle><Pagination><StartPage>7459</StartPage><EndPage>7473</EndPage><MedlinePgn>7459-73</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.4872-08.2009</ELocationID><Abstract><AbstractText>The processing of amyloid precursor protein (APP) to Abeta is an important event in the pathogenesis of Alzheimer's disease, but the physiological function of APP is not well understood. Our previous work has shown that APP processing and Abeta production are regulated by the extracellular matrix protein Reelin. In the present study, we examined whether Reelin interacts with APP, and the functional consequences of that interaction in vitro. Using coimmunoprecipitation, we found that Reelin interacted with APP through the central domain of Reelin (repeats 3-6) and the E1 extracellular domain of APP. Reelin increased cell surface levels of APP and decreased endocytosis of APP in hippocampal neurons in vitro. In vivo, Reelin levels were increased in brains of APP knock-out mice and decreased in APP-overexpressing mice. RNA interference knockdown of APP decreased neurite outgrowth in vitro and prevented Reelin from increasing neurite outgrowth. Knock-out of APP or Reelin decreased dendritic arborization in cortical neurons in vivo, and APP overexpression increased dendritic arborization. APP and Reelin have previously been shown to promote neurite outgrowth through interactions with integrins. We confirmed that APP interacted with alpha3beta1 integrin, and alpha3beta1 integrin altered APP trafficking and processing. Addition of an alpha3beta1 integrin antibody prevented APP and Reelin-induced neurite outgrowth. These findings demonstrate that Reelin interacts with APP, potentially having important effects on neurite development.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hoe</LastName><ForeName>Hyang-Sook</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Georgetown University Medical Center, Washington, DC 20057-1464, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Kea Joo</ForeName><Initials>KJ</Initials></Author><Author ValidYN="Y"><LastName>Carney</LastName><ForeName>Rosalind S E</ForeName><Initials>RS</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jiyeon</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Markova</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Ji-Yun</ForeName><Initials>JY</Initials></Author><Author ValidYN="Y"><LastName>Howell</LastName><ForeName>Brian W</ForeName><Initials>BW</Initials></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials></Author><Author ValidYN="Y"><LastName>Pak</LastName><ForeName>Daniel T S</ForeName><Initials>DT</Initials></Author><Author ValidYN="Y"><LastName>Bu</LastName><ForeName>Guojun</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Rebeck</LastName><ForeName>G William</ForeName><Initials>GW</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG035355</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG032330</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R29 AG014473</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG012406</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS048085</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027924</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG030128</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG014473</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG014473</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03 AG030060</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03 AG032330</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545487">APP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015816">Cell Adhesion Molecules, Neuronal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016326">Extracellular Matrix Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D039201">Integrin alpha3beta1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019012">Integrin beta1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058255">Protease Nexins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000091042">Reelin Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000717129">Reln protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="C000717127">RELN protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="C000717128">Reln protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="D012697">Serine Endopeptidases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019556" MajorTopicYN="N">COS Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015816" MajorTopicYN="N">Cell Adhesion Molecules, Neuronal</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003712" MajorTopicYN="N">Dendrites</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016326" MajorTopicYN="N">Extracellular Matrix Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039201" MajorTopicYN="N">Integrin alpha3beta1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019012" MajorTopicYN="N">Integrin beta1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008818" MajorTopicYN="N">Mice, Neurologic Mutants</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016501" MajorTopicYN="N">Neurites</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058255" MajorTopicYN="N">Protease Nexins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011956" MajorTopicYN="N">Receptors, Cell Surface</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000091042" MajorTopicYN="N">Reelin Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012697" MajorTopicYN="N">Serine Endopeptidases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>6</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>6</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>6</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>12</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19515914</ArticleId><ArticleId IdType="mid">NIHMS124494</ArticleId><ArticleId IdType="pmc">PMC2759694</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4872-08.2009</ArticleId><ArticleId IdType="pii">29/23/7459</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alvarez VA, Ridenour DA, Sabatini BL. Retraction of synapses and dendritic spines induced by off-target effects of RNA interference. J Neurosci. 2006;26:7820&#x2013;7825.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674211</ArticleId><ArticleId IdType="pubmed">16870727</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrade N, Komnenovic V, Blake SM, Jossin Y, Howell B, Goffinet A, Schneider WJ, Nimpf J. ApoER2/VLDL receptor and Dab1 in the rostral migratory stream function in postnatal neuronal migration independently of Reelin. Proc Natl Acad Sci U S A. 2007;104:8508&#x2013;8513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1895980</ArticleId><ArticleId IdType="pubmed">17494763</ArticleId></ArticleIdList></Reference><Reference><Citation>Andressen C, Arnhold S, Puschmann M, Bloch W, Hescheler J, F&#xe4;ssler R, Addicks K. Beta1 integrin deficiency impairs migration and differentiation of mouse embryonic stem cell derived neurons. Neurosci Lett. 1998;251:165&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">9726369</ArticleId></ArticleIdList></Reference><Reference><Citation>Beffert U, Weeber EJ, Durudas A, Qiu S, Masiulis I, Sweatt JD, Li WP, Adelmann G, Frotscher M, Hammer RE, Herz J. Modulation of synaptic plasticity and memory by Reelin involves differential splicing of the lipoprotein receptor Apoer2. Neuron. 2005;47:567&#x2013;579.</Citation><ArticleIdList><ArticleId IdType="pubmed">16102539</ArticleId></ArticleIdList></Reference><Reference><Citation>Botella-L&#xf3;pez A, Burgaya F, Gav&#xed;n R, Garc&#xed;a-Ayll&#xf3;n MS, G&#xf3;mez-Tortosa E, Pe&#xf1;a-Casanova J, Ure&#xf1;a JM, Del R&#xed;o JA, Blesa R, Soriano E, S&#xe1;ez-Valero J. Reelin expression and glycosylation patterns are altered in Alzheimer's disease. Proc Natl Acad Sci U S A. 2006;103:5573&#x2013;5578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1414634</ArticleId><ArticleId IdType="pubmed">16567613</ArticleId></ArticleIdList></Reference><Reference><Citation>Brich J, Shie FS, Howell BW, Li R, Tus K, Wakeland EK, Jin LW, Mumby M, Churchill G, Herz J, Cooper JA. Genetic modulation of tau phosphorylation in the mouse. J Neurosci. 2003;23:187&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742161</ArticleId><ArticleId IdType="pubmed">12514215</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai X, F&#xf6;rster E, Zhao S, Bock HH, Frotscher M. Reelin stabilizes the actin cytoskeleton of neuronal processes by inducing n-cofilin phosphorylation at serine3. J Neurosci. 2009;29:288&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6664910</ArticleId><ArticleId IdType="pubmed">19129405</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan CS, Weeber EJ, Zong L, Fuchs E, Sweatt JD, Davis RL. &#x3b2;1-integrins are required for hippocampal AMPA receptor-dependent synaptic transmission, synaptic plasticity, and working memory. J Neurosci. 2006;26:223&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2408376</ArticleId><ArticleId IdType="pubmed">16399691</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen K, Ochalski PG, Tran TS, Sahir N, Schubert M, Pramatarova A, Howell BW. Interaction between Dab1 and CrkII is promoted by Reelin signaling. J Cell Sci. 2004;117:4527&#x2013;4536.</Citation><ArticleIdList><ArticleId IdType="pubmed">15316068</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin J, Massaro CM, Palop JJ, Thwin MT, Yu GQ, Bien-Ly N, Bender A, Mucke L. Reelin depletion in the entorhinal cortex of human amyloid precursor protein transgenic mice and humans with Alzheimer's disease. J Neurosci. 2007;27:2727&#x2013;2733.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672562</ArticleId><ArticleId IdType="pubmed">17360894</ArticleId></ArticleIdList></Reference><Reference><Citation>DeFreitas MF, Yoshida CK, Frazier WA, Mendrick DL, Kypta RM, Reichardt LF. Identification of integrin alpha 3 beta 1 as a neuronal thrombospondin receptor mediating neurite outgrowth. Neuron. 1995;15:333&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pubmed">7544141</ArticleId></ArticleIdList></Reference><Reference><Citation>Demali KA, Jue AL, Burridge K. IpaA targets beta1 integrins and rho to promote actin cytoskeleton rearrangements necessary for Shigella entry. J Biol Chem. 2006;281:39534&#x2013;39541.</Citation><ArticleIdList><ArticleId IdType="pubmed">17060328</ArticleId></ArticleIdList></Reference><Reference><Citation>Dulabon L, Olson EC, Taglienti MG, Eisenhuth S, McGrath B, Walsh CA, Kreidberg JA, Anton ES. Reelin binds alpha3beta1 integrin and inhibits neuronal migration. Neuron. 2000;27:33&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">10939329</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotthardt M, Trommsdorff M, Nevitt MF, Shelton J, Richardson JA, Stockinger W, Nimpf J, Herz J. Interactions of the low density lipoprotein receptor gene family with cytosolic adaptor and scaffold proteins suggest diverse biological functions in cellular communication and signal transduction. J Biol Chem. 2000;275:25616&#x2013;25624.</Citation><ArticleIdList><ArticleId IdType="pubmed">10827173</ArticleId></ArticleIdList></Reference><Reference><Citation>Herms J, Anliker B, Heber S, Ring S, Fuhrmann M, Kretzschmar H, Sisodia S, M&#xfc;ller U. Cortical dysplasia resembling human type 2 lissencephaly in mice lacking all three APP family members. EMBO J. 2004;23:4106&#x2013;4115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC524337</ArticleId><ArticleId IdType="pubmed">15385965</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiesberger T, Trommsdorff M, Howell BW, Goffinet A, Mumby MC, Cooper JA, Herz J. Direct binding of Reelin to VLDL receptor and ApoE receptor 2 induces tyrosine phosphorylation of disabled-1 and modulates tau phosphorylation. Neuron. 1999;24:481&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">10571241</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho A, S&#xfc;dhof TC. Binding of F-spondin to amyloid-beta precursor protein: a candidate amyloid-beta precursor protein ligand that modulates amyloid-beta precursor protein cleavage. Proc Natl Acad Sci U S A. 2004;101:2548&#x2013;2553.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC356987</ArticleId><ArticleId IdType="pubmed">14983046</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoareau C, Borrell V, Soriano E, Krebs MO, Prochiantz A, Allinquant B. Amyloid precursor protein cytoplasmic domain antagonizes reelin neurite outgrowth inhibition of hippocampal neurons. Neurobiol Aging. 2008;29:542&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pubmed">17169463</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoe HS, Wessner D, Beffert U, Becker AG, Matsuoka Y, Rebeck GW. F-spondin interaction with the apolipoprotein E receptor ApoEr2 affects processing of amyloid precursor protein. Mol Cell Biol. 2005;25:9259&#x2013;9268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1265841</ArticleId><ArticleId IdType="pubmed">16227578</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoe HS, Tran TS, Matsuoka Y, Howell BW, Rebeck GW. DAB1 and Reelin effects on amyloid precursor protein and ApoE receptor 2 trafficking and processing. J Biol Chem. 2006;281:35176&#x2013;35185.</Citation><ArticleIdList><ArticleId IdType="pubmed">16951405</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoe HS, Cooper MJ, Burns MP, Lewis PA, van der Brug M, Chakraborty G, Cartagena CM, Pak DT, Cookson MR, Rebeck GW. The metalloprotease inhibitor TIMP-3 regulates amyloid precursor protein and apolipoprotein E receptor proteolysis. J Neurosci. 2007;27:10895&#x2013;10905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672812</ArticleId><ArticleId IdType="pubmed">17913923</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoogenraad CC, Milstein AD, Ethell IM, Henkemeyer M, Sheng M. GRIP1 controls dendrite morphogenesis by regulating EphB receptor trafficking. Nat Neurosci. 2005;8:906&#x2013;915.</Citation><ArticleIdList><ArticleId IdType="pubmed">15965473</ArticleId></ArticleIdList></Reference><Reference><Citation>Horikoshi Y, Sakaguchi G, Becker AG, Gray AJ, Duff K, Aisen PS, Yamaguchi H, Maeda M, Kinoshita N, Matsuoka Y. Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variant. Biochem Biophys Res Commun. 2004;319:733&#x2013;737.</Citation><ArticleIdList><ArticleId IdType="pubmed">15184044</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao KK, Borchelt DR, Olson K, Johannsdottir R, Kitt C, Yunis W, Xu S, Eckman C, Younkin S, Price D, Iadecola C, Clark HB, Carlson G. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron. 1995;15:1203&#x2013;1218.</Citation><ArticleIdList><ArticleId IdType="pubmed">7576662</ArticleId></ArticleIdList></Reference><Reference><Citation>Jossin Y, Bar I, Ignatova N, Tissir F, De Rouvroit CL, Goffinet AM. The reelin signaling pathway: some recent developments. Cereb Cortex. 2003;13:627&#x2013;633.</Citation><ArticleIdList><ArticleId IdType="pubmed">12764038</ArticleId></ArticleIdList></Reference><Reference><Citation>Kram&#xe1;r EA, Bernard JA, Gall CM, Lynch G. Alpha3 integrin receptors contribute to the consolidation of long-term potentiation. Neuroscience. 2002;110:29&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">11882370</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyssen M, Ayaz D, H&#xe9;bert SS, Reeve S, De Strooper B, Hassan BA. Amyloid precursor protein promotes post-developmental neurite arborization in the Drosophila brain. EMBO J. 2005;24:2944&#x2013;2955.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1187942</ArticleId><ArticleId IdType="pubmed">16052209</ArticleId></ArticleIdList></Reference><Reference><Citation>Mechai N, Wenzel M, Koch M, Lucka L, Horstkorte R, Reutter W, Danker K. The cytoplasmic tail of the alpha3 integrin subunit promotes neurite outgrowth in PC12 cells. J Neurosci Res. 2005;82:753&#x2013;761.</Citation><ArticleIdList><ArticleId IdType="pubmed">16267829</ArticleId></ArticleIdList></Reference><Reference><Citation>Miettinen R, Riedel A, Kalesnykas G, Kettunen HP, Puoliv&#xe4;li J, Soininen H, Arendt T. Reelin-immunoreactivity in the hippocampal formation of 9-month-old wildtype mouse: effects of APP/PS1 genotype and ovariectomy. J Chem Neuroanat. 2005;30:105&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">16081247</ArticleId></ArticleIdList></Reference><Reference><Citation>Milward EA, Papadopoulos R, Fuller SJ, Moir RD, Small D, Beyreuther K, Masters CL. The amyloid protein precursor of Alzheimer's disease is a mediator of the effects of nerve growth factor on neurite outgrowth. Neuron. 1992;9:129&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">1632967</ArticleId></ArticleIdList></Reference><Reference><Citation>Motoi Y, Itaya M, Mori H, Mizuno Y, Iwasaki T, Hattori H, Haga S, Ikeda K. Apolipoprotein E receptor 2 is involved in neuritic plaque formation in APP sw mice. Neurosci Lett. 2004;368:144&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">15351437</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu S, Renfro A, Quattrocchi CC, Sheldon M, D'Arcangelo G. Reelin promotes hippocampal dendrite development through the VLDLR/ApoER2-Dab1 pathway. Neuron. 2004;41:71&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">14715136</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu S, Yabut O, D'Arcangelo G. The Reelin signaling pathways promotes dendritic spine development in hippocampal neurons. J Neurosci. 2008;28:10339&#x2013;10348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2572775</ArticleId><ArticleId IdType="pubmed">18842893</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohsawa I, Takamura C, Kohsaka S. The amino-terminal region of amyloid precursor protein is responsible for neurite outgrowth in rat neocortical explant culture. Biochem Biophys Res Commun. 1997;236:59&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">9223426</ArticleId></ArticleIdList></Reference><Reference><Citation>Osterfield M, Egelund R, Young LM, Flanagan JG. Interaction of amyloid precursor protein with contactins and NgCAM in the retinotectal system. Development. 2008;135:1189&#x2013;1199.</Citation><ArticleIdList><ArticleId IdType="pubmed">18272596</ArticleId></ArticleIdList></Reference><Reference><Citation>Pak DT, Yang S, Rudolph-Correia S, Kim E, Sheng M. Regulation of denritic spine morphology by SPAR, a PSD-95-associated RapGAP. Neuron. 2001;31:289&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">11502259</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez RG, Zheng H, Van der Ploeg LH, Koo EH. The &#x3b2;-amyloid precursor protein of Alzheimer's disease enhances neuron viability and modulates neuronal polarity. J Neurosci. 1997;17:9407&#x2013;9414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573428</ArticleId><ArticleId IdType="pubmed">9390996</ArticleId></ArticleIdList></Reference><Reference><Citation>Pramatarova A, Ochalski PG, Lee CH, Howell BW. Mouse disabled 1 regulates the nuclear position of neurons in a Drosophila eye model. Mol Cell Biol. 2006;26:1510&#x2013;1517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1367204</ArticleId><ArticleId IdType="pubmed">16449660</ArticleId></ArticleIdList></Reference><Reference><Citation>Pramatarova A, Chen K, Howell BW. A genetic interaction between the APP and Dab1 genes influences brain development. Mol Cell Neurosci. 2008;37:178&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2272583</ArticleId><ArticleId IdType="pubmed">18029196</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu S, Weeber EJ. Reelin signaling facilitates maturation of CA1 glutamatergic synapses. J Neurophysiol. 2007;97:2312&#x2013;2321.</Citation><ArticleIdList><ArticleId IdType="pubmed">17229826</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu S, Zhao LF, Korwek KM, Weeber EJ. Differential reelin-induced enhancement of NMDA and AMPA receptor activity in the adult hippocampus. J Neurosci. 2006;26:12943&#x2013;12955.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674964</ArticleId><ArticleId IdType="pubmed">17167084</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu WQ, Ferreira A, Miller C, Koo EH, Selkoe DJ. Cell-surface &#x3b2;-amyloid precursor protein stimulates neurite outgrowth of hippocampal neurons in an isoform-dependent manner. J Neurosci. 1995;15:2157&#x2013;2167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578166</ArticleId><ArticleId IdType="pubmed">7891158</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu Z, Strickland DK, Hyman BT, Rebeck GW. &#x3b1;2-Macroglobulin exposure reduces calcium responses to N-methyl-d-aspartate via low density lipoprotein receptor-related protein in cultured hippocampal neurons. J Biol Chem. 2002;277:14458&#x2013;14466.</Citation><ArticleIdList><ArticleId IdType="pubmed">11839752</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabo SL, Ikin AF, Buxbaum JD, Greengard P. The amyloid precursor protein and its regulatory protein, FE65, in growth cones and synapses in vitro and in vivo. J Neurosci. 2003;23:5407&#x2013;5415.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741254</ArticleId><ArticleId IdType="pubmed">12843239</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmid RS, Jo R, Shelton S, Kreidberg JA, Anton ES. Reelin, integrin and DAB1 interactions during embryonic cerebral cortical development. Cereb Cortex. 2005;15:1632&#x2013;1636.</Citation><ArticleIdList><ArticleId IdType="pubmed">15703255</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001;81:741&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Siemes C, Quast T, Kummer C, Wehner S, Kirfel G, M&#xfc;ller U, Herzog V. Keratinocytes from APP/APLP2-deficient mice are impaired in proliferation, adhesion and migration in vitro. Exp Cell Res. 2006;312:1939&#x2013;1949.</Citation><ArticleIdList><ArticleId IdType="pubmed">16584729</ArticleId></ArticleIdList></Reference><Reference><Citation>Small DH, Clarris HL, Williamson TG, Reed G, Key B, Mok SS, Beyreuther K, Masters CL, Nurcombe V. Neurite-outgrowth regulating functions of the amyloid protein precursor of Alzheimer's disease. J Alzheimers Dis. 1999;1:275&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">12214125</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei L, Wang L, Carson JA, Agan JE, Imanaka-Yoshida K, Schwartz RJ. beta1 integrin and organized actin filaments facilitate cardiomyocyte-specific RhoA-dependent activation of the skeletal alpha-actin promoter. FASEB J. 2001;15:785&#x2013;796.</Citation><ArticleIdList><ArticleId IdType="pubmed">11259397</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirths O, Multhaup G, Czech C, Blanchard V, Tremp G, Pradier L, Beyreuther K, Bayer TA. Reelin in plaques of beta-amyloid precursor protein and presenilin-1 double-transgenic mice. Neurosci Lett. 2001;316:145&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">11744223</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamazaki T, Koo EH, Selkoe DJ. Cell surface amyloid &#x3b2;-protein precursor colocalizes with &#x3b2;1 integrins at substrate contact sites in neural cells. J Neurosci. 1997;17:1004&#x2013;1010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573178</ArticleId><ArticleId IdType="pubmed">8994055</ArticleId></ArticleIdList></Reference><Reference><Citation>Young-Pearse TL, Bai J, Chang R, Zheng JB, LoTurco JJ, Selkoe DJ. A critical function for &#x3b2;-amyloid precursor protein in neuronal migration revealed by in utero RNA interference. J Neurosci. 2007;27:14459&#x2013;14469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673432</ArticleId><ArticleId IdType="pubmed">18160654</ArticleId></ArticleIdList></Reference><Reference><Citation>Young-Pearse TL, Chen AC, Chang R, Marquez C, Selkoe DJ. Secreted APP regulates the function of full-length APP in neurite outgrowth through interaction with integrin beta1. Neural Dev. 2008;3:15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2442059</ArticleId><ArticleId IdType="pubmed">18573216</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H, Jiang M, Trumbauer ME, Hopkins R, Sirinathsinghji DJ, Stevens KA, Conner MW, Slunt HH, Sisodia SS, Chen HY, Van der Ploeg LH. Mice deficient for the amyloid precursor protein gene. Ann N Y Acad Sci. 1996;777:421&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pubmed">8624124</ArticleId></ArticleIdList></Reference><Reference><Citation>Zisman S, Marom K, Avraham O, Rinsky-Halivni L, Gai U, Kligun G, Tzarfaty-Majar V, Suzuki T, Klar A. Proteolysis and membrane capture of F-spondin generates combinatorial guidance cues from a single molecule. J Cell Biol. 2007;178:1237&#x2013;1249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2064656</ArticleId><ArticleId IdType="pubmed">17875744</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>